Secukinumab/PsA CAIN457F2366

AMNOG Dossier Sensitivity Analysis

Date: 22.08.2020

Document Status: Final

Author: Monika Schwager, Winicker Norimed GmbH

Table of Contents

Tables

Patient Disposition and Baseline Characteristics

1.1 Patient Disposition and Compliance (RAN, FAS)

	Treatment Groups		
Disposition/Reason	**SEC (N=66) n (%)**	**ADA (N=62) n (%)**	**Total (N=128) n (%)**
Randomized (RAN)	**66 (100.0)**	**62 (100.0)**	**128 (100.0)**
Full Analysis Set (FAS)	**66 (100.0)**	**62 (100.0)**	**128 (100.0)**
Study discontinuation (RAN)	**4 (6.1)**	**14 (22.6)**	**18 (14.1)**
Reasons for study discontinuation during Treatment Period			
Adverse event	0 (0.0)	2 (3.2)	2 (1.6)
Death	0 (0.0)	0 (0.0)	0 (0.0)
Lack of efficacy	1 (1.5)	4 (6.5)	5 (3.9)
No longer requires treatment	0 (0.0)	0 (0.0)	0 (0.0)
New therapy for study indication	0 (0.0)	0 (0.0)	0 (0.0)
Non-compliance with study treatment	0 (0.0)	0 (0.0)	0 (0.0)
Pregnancy	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviation	0 (0.0)	0 (0.0)	0 (0.0)
Study terminated by sponsor	0 (0.0)	0 (0.0)	0 (0.0)
Lost to follow-up	1 (1.5)	2 (3.2)	3 (2.3)
Technical problems	0 (0.0)	0 (0.0)	0 (0.0)
Physician decision	1 (1.5)	0 (0.0)	1 (0.8)
Subject/guardian decision	1 (1.5)	6 (9.7)	7 (5.5)
Study drug			
Received study drug	66 (100.0)	62 (100.0)	128 (100.0)
Did not receive study drug	0 (0.0)	0 (0.0)	0 (0.0)
Completed treatment period on double-blind study drug	62 (93.9)	47 (75.8)	109 (85.2)
Prematurely discontinued double-blind study drug during treatment period	4 (6.1)	15 (24.2)	19 (14.8)
Primary reason for premature discontinuation of double-blind study drug			
Adverse event	0 (0.0)	2 (3.2)	2 (1.6)
Death	0 (0.0)	0 (0.0)	0 (0.0)
Lack of efficacy	1 (1.5)	6 (9.7)	7 (5.5)
No longer requires treatment	0 (0.0)	0 (0.0)	0 (0.0)
New therapy for study indication	0 (0.0)	0 (0.0)	0 (0.0)

Disposition/Reason	SEC (N=66) n (%)	ADA (N=62) n (%)	Total (N=128) n (%)
Treatment Groups			
Non-compliance with study treatment	0 (0.0)	0 (0.0)	0 (0.0)
Pregnancy	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviation	0 (0.0)	0 (0.0)	0 (0.0)
Study terminated by sponsor	0 (0.0)	0 (0.0)	0 (0.0)
Lost to follow-up	0 (0.0)	2 (3.2)	2 (1.6)
Technical problems	0 (0.0)	0 (0.0)	0 (0.0)
Physician decision	1 (1.5)	0 (0.0)	1 (0.8)
Subject/guardian decision	2 (3.0)	5 (8.1)	7 (5.5)
Subjects who received rescue medication before week 52	**6 (9.1)**	**4 (6.5)**	**10 (7.8)**
Patients who received cDMARDs (e.g. MTX) including apremilast	2 (3.0)	2 (3.2)	4 (3.1)
Subject with at least one protocol deviation	**17 (25.8)**	**17 (27.4)**	**34 (26.6)**
Key procedures not performed	0 (0.0)	0 (0.0)	0 (0.0)
Other deviation	9 (13.6)	8 (12.9)	17 (13.3)
Prohibited concomitant medication	7 (10.6)	9 (14.5)	16 (12.5)
Selection criteria not met	2 (3.0)	3 (4.8)	5 (3.9)
Subject not withdrawn as per protocol	0 (0.0)	0 (0.0)	0 (0.0)
Treatment deviation	0 (0.0)	0 (0.0)	0 (0.0)

1.2 Length of Treatment Phase (FAS)

Treatment phase (FAS)	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Mean ± SD (in days)	375.3 ± 30.4	334.6 ± 101.0	355.6 ± 76.1
Median (in days)	376.5	372.0	374.0
Range (in days)	204 - 454	18 - 456	18 - 456

1.2 Length of Treatment Phase (FAS)

1.3 Characterization of Study Population, Demographic Characteristics (FAS)

	Treatment Groups		
Patient characteristics	SEC (N=66)	ADA (N=62)	Total (N=128)
Age (years)			
Mean ± SD	48.1 ± 11.9	46.6 ± 11.9	47.4 ± 11.9
Median	50.0	50.5	50.0
Range	21.0 - 73.0	20.0 - 69.0	20.0 - 73.0
Age group (years), n (%)			
< 65	62 (93.9)	59 (95.2)	121 (94.5)
65 - 74	4 (6.1)	3 (4.8)	7 (5.5)
Sex, n (%)			
Male	42 (63.6)	33 (53.2)	75 (58.6)
Female	24 (36.4)	29 (46.8)	53 (41.4)
Weight (kg)			
Mean ± SD	85.1 ± 18.7	84.4 ± 17.3	84.8 ± 18.0
Median	85.8	84.5	85.0
Range	51.0 - 153.0	45.0 - 122.9	45.0 - 153.0
Height (cm)			
Mean ± SD	172.0 ± 9.2	170.0 ± 9.2	171.1 ± 9.2
Median	173.0	170.5	171.0
Range	153.0 - 190.0	152.4 - 196.0	152.4 - 196.0
BMI (kg/m²)			
Mean ± SD	28.8 ± 6.1	29.2 ± 5.5	29.0 ± 5.8
Median	28.2	28.5	28.3
Range	18.9 - 51.4	18.0 - 41.9	18.0 - 51.4
Current smoker	**19 (28.8)**	**16 (25.8)**	**35 (27.3)**
Race, n (%)			
Asian	2 (3.0)	6 (9.7)	8 (6.3)
American Indian or Alaska Native	0 (0.0)	1 (1.6)	1 (0.8)
Black or African American	0 (0.0)	1 (1.6)	1 (0.8)
White	64 (97.0)	53 (85.5)	117 (91.4)
Other	0 (0.0)	1 (1.6)	1 (0.8)
Ethnicity, n (%)			
Hispanic or Latino	6 (9.1)	4 (6.5)	10 (7.8)
Not Hispanic or Latino	58 (87.9)	56 (90.3)	114 (89.1)
Not reported	1 (1.5)	1 (1.6)	2 (1.6)
Unknown	1 (1.5)	1 (1.6)	2 (1.6)
Region, n (%)			

Patient characteristics	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
America	0 (0.0)	4 (6.5)	4 (3.1)
Asia	4 (6.1)	6 (9.7)	10 (7.8)
Australia	1 (1.5)	0 (0.0)	1 (0.8)
Europe	61 (92.4)	52 (83.9)	113 (88.3)

1.4 PsA Disease History and Baseline Characteristics (FAS)

	Treatment Groups		
	SEC **(N=66)**	**ADA** **(N=62)**	**Total** **(N=128)**
Time since first PsA diagnosis (years)			
Mean ± SD	5.9 ± 9.3	6.6 ± 8.2	6.2 ± 8.8
Median	2.1	4.1	2.7
Range	0.0 - 50.9	0.0 - 34.5	0.0 - 50.9
CASPAR score at baseline, n (%)			
3	8 (12.1)	13 (21.0)	21 (16.4)
4	30 (45.5)	28 (45.2)	58 (45.3)
5	22 (33.3)	15 (24.2)	37 (28.9)
6	6 (9.1)	6 (9.7)	12 (9.4)
Enthesitis at baseline, n (%)	**32 (48.5)**	**40 (64.5)**	**72 (56.3)**
Dactylitis at baseline, n (%)	**17 (25.8)**	**16 (25.8)**	**33 (25.8)**
Concomitant medication, n (%)			
Corticosteroid use at baseline	5 (7.6)	4 (6.5)	9 (7.0)
Methotrexate use at baseline	0 (0.0)	0 (0.0)	0 (0.0)
Sulfasalazine use at baseline	0 (0.0)	0 (0.0)	0 (0.0)
Prior Medication, n (%)			
DMARDs documented as prior treatments**	66 (100.0)	62 (100.0)	128 (100.0)
Discontinued due to lack of tolerability	14 (21.2)	14 (22.6)	28 (21.9)
Discontinued due to lack of efficacy	66 (100.0)	62 (100.0)	128 (100.0)
MTX documented as prior treatments**	59 (89.4)	57 (91.9)	116 (90.6)
Discontinued due to lack of tolerability	9 (13.6)	12 (19.4)	21 (16.4)
Discontinued due to lack of efficacy	54 (81.8)	52 (83.9)	106 (82.8)
TNFalpha-Antagonists documented as prior treatments**	0 (0.0)	0 (0.0)	0 (0.0)
Discontinued due to lack of tolerability	0 (0.0)	0 (0.0)	0 (0.0)
Discontinued due to lack of efficacy	0 (0.0)	0 (0.0)	0 (0.0)

* Based on documented protocol deviations from inclusion criterion 9 and documented prior treatments
** Based on documented prior treatments
Medications classified as cDMARDs: AZATHIOPRINE, CHLOROQUINE, CICLOSPORIN, GOLD PREPARATIONS, HYDROXYCHLOROQUINE, LEFLUNOMIDE, MESALAZINE, METHOTREXATE, SODIUM AUROTHIOMALATE, SULFASALAZINE, TRUXOFOL
Medications classified as bDMARDs: DENOSUMAB, INFLIXIMAB, TOCILIZUMAB
Medications classified as DMARDs: cDMARDs, bDMARDs, APREMILAST, TOFACITINIB

1.5 Concomitant Medication (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
DMARDs, n (%)	2 (3.0)	2 (3.2)	4 (3.1)
Median; range of application time (weeks)	3.1; 0.1 - 6.1	2.9; 0.1 - 5.7	2.9; 0.1 - 6.1
cDMARDs, n (%)	2 (3.0)	2 (3.2)	4 (3.1)
Median; range of application time (weeks)	3.1; 0.1 - 6.1	2.9; 0.1 - 5.7	2.9; 0.1 - 6.1
Methotrexate, n (%)	2 (3.0)	2 (3.2)	4 (3.1)
Median; range of application time (weeks)	3.1; 0.1 - 6.1	2.9; 0.1 - 5.7	2.9; 0.1 - 6.1
bDMARDs, n (%)	0 (0.0)	0 (0.0)	0 (0.0)
Median; range of application time (weeks)	-; - - -	-; - - -	-; - - -
NSAIDs, n (%)	46 (69.7)	44 (71.0)	90 (70.3)
Median; range of application time (weeks)	53.4; 23.0 - 64.9	52.1; 2.6 - 57.1	53.0; 2.6 - 64.9
Psoriasis medication, n (%)	5 (7.6)	5 (8.1)	10 (7.8)
Median; range of application time (weeks)	17.0; 0.1 - 53.9	17.3; 0.1 - 56.1	17.1; 0.1 - 56.1
Intraarticular corticosteroids, n (%)	1 (1.5)	1 (1.6)	2 (1.6)
Median; range of application time (weeks)	4.1; 4.1 - 4.1	19.1; 19.1 - 19.1	11.6; 4.1 - 19.1
Systemic corticosteroids, n (%)	5 (7.6)	7 (11.3)	12 (9.4)
Median; range of application time (weeks)	54.7; 49.6 - 56.1	26.6; 3.1 - 65.1	53.0; 3.1 - 65.1
Patients who experienced any dose change of systemic corticosteroids during study period, n (%)	2 (3.0)	4 (6.5)	6 (4.7)

Medications classified as cDMARDs: AZATHIOPRINE, CHLOROQUINE, CICLOSPORIN, GOLD PREPARATIONS, HYDROXYCHLOROQUINE, LEFLUNOMIDE, MESALAZINE, METHOTREXATE, SODIUM AUROTHIOMALATE, SULFASALAZINE, TRUXOFOL
Medications classified as bDMARDs: DENOSUMAB, INFLIXIMAB, TOCILIZUMAB
Medications classified as DMARDs: cDMARDs, bDMARDs, APREMILAST, TOFACITINIB
Medication classified as Psoriasis medication: Acitretin, Alpicort A, Apremilast, Belosalic, Betadermic, Betamethason, Betzee S, Calpsor C, Ciclosporin, Clobetasol, Clobetasonbutyrat, Clotrason, Daivobet, Desonid, Desoximetason, Dexamethason, Diflucortolonvalerat, Dimethylfumarat, Diprospan, Dithranol, Fluocinolonacetonid, Fluticasonpropionat, Hydrocortison, Methotrexat, Methylprednisolonaceponat, Mometason, Phototherapie, Prdenicarbat, Propysalic NF, Travocort, Triamcinolon, Truxofol, Ulobetasol, Velosalic, Xamiol

1.6 Definition of Subpopulation (FAS)

		Treatment Groups		
BSA	**PASI**	**SEC** **(N=426)** **(N'=281)**	**ADA** **(N=427)** **(N'=260)**	**Total** **(N=853)** **(N'=541)**
<u>Patients with Moderate / Severe Psoriasis</u>				
$\leq 10\%$	< 10	214	198	412
$\leq 10\%$	**≥ 10**	**5**	**2**	**7**
> 10%	**< 10**	**15**	**22**	**37**
> 10%	**≥ 10**	**46**	**38**	**84**
BSA > 10% and/or PASI ≥ 10	**PASI ≥ 10**	**66**	**62**	**128**
N in the column headers refers to the total population, N' to the population of subjects who discontinued prior DMARD due to lack of efficacy. The table is based on N', the population of subjects who discontinued prior DMARD due to lack of efficacy.				

1.7 Number of Subjects in Subgroups (FAS)

Subgrouping Factor	Subgroup	Treatment Groups		
		SEC (N=66)	ADA (N=62)	Total (N=128)
Age	< 65 years	62	59	121
	>= 65 years	4	3	7
Gender	Male	42	33	75
	Female	24	29	53
Disease Severity	PASDAS <= 3.2	0	0	0
	3.2 < PASDAS < 5.4	16	13	29
	PASDAS >= 5.4	50	49	99
Disease Severity	PASDAS < 5.4	16	13	29
	PASDAS >= 5.4	50	49	99
Region	America	0	4	4
	Asia	4	6	10
	Australia	1	0	1
	Europe	61	52	113
Moderate/Severe PSO Def. 1	No	0	0	0
	Yes	66	62	128
Moderate/Severe PSO Def. 2	No	28	32	60
	Yes	38	30	68
Lymphocyte Count at BL	<= Median	40	29	69
	> Median	26	33	59
Enthesitis at BL According to LEI	No	34	22	56
	Yes	32	40	72
HLA-DQA1*05	Non-carrier	29	25	54
	Carrier	22	19	41
	Missing	15	18	33
Lead Candidate Variant rs10555659	Non-carrier	28	19	47
	Carrier	22	19	41
	Missing	16	24	40
Lead Candidate Variant rs111937633	Non-carrier	19	21	40
	Carrier	30	23	53
	Missing	17	18	35
Lead Candidate Variant rs11726476	Non-carrier	25	32	57
	Carrier	26	12	38
	Missing	15	18	33
Lead Candidate Variant rs10609046	Non-carrier	38	33	71

Subgrouping Factor	Subgroup	Treatment Groups		
		SEC (N=66)	ADA (N=62)	Total (N=128)
	Carrier	12	9	21
	Missing	16	20	36
Lead Candidate Variant rs8007401	Non-carrier	36	34	70
	Carrier	13	10	23
	Missing	17	18	35
Lead Candidate Variant rs7349145	Non-carrier	42	36	78
	Carrier	9	5	14
	Missing	15	21	36
Lead Candidate Allele Score	Low score	11	22	33
	High score	40	22	62
	Missing	15	18	33
Linkage Variant rs10891185	Non-carrier	31	23	54
	Carrier	20	21	41
	Missing	15	18	33
Linkage Variant rs12065362	Non-carrier	19	20	39
	Carrier	32	24	56
	Missing	15	18	33
Linkage Variant rs11721988	Non-carrier	25	32	57
	Carrier	26	12	38
	Missing	15	18	33
Linkage Variant rs7787032	Non-carrier	39	35	74
	Carrier	11	9	20
	Missing	16	18	34
Presence of Antibodies	Not present	65	56	121
	Present	0	3	3
	Missing	1	3	4

Efficacy and safety subgroup analysis is displayed for all subgrouping factors with at least 10 patients in each subgroup.

Efficacy Analysis

2.1 All-Cause Mortality (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
All-cause Mortality Week 52, N' n (%)	66 0 (0.0)	62 0 (0.0)	N.E.	N.E.	N.E.

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with Wald CI) from logistic regression model with predictors treatment and weight, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) without adjustment.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

3.0 BSA (Percent) - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	66 (100.0)	59 (95.2)	125 (97.7)
Week 4 Returns	66 (100.0)	59 (95.2)	125 (97.7)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	57 (91.9)	121 (94.5)
Week 16 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 24 Returns	64 (97.0)	53 (85.5)	117 (91.4)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	49 (79.0)	112 (87.5)

3.1 BSA (Percent) - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	61		
Baseline Mean (SD)	22.15 (12.56)	23.08 (15.06)		
Week 52 Mean (SD)	2.41 (4.49)	4.88 (8.05)		
Week 52 Adjusted Mean Change (SE)	-19.71 (0.75)	-16.76 (0.82)	-2.95 [-5.15; -0.74]	0.009

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

3.2 BSA (Percent) - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.994				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	23.02 (12.76)	25.15 (16.41)		
Week 52 Mean (SD)	2.43 (5.00)	3.96 (6.64)		
Week 52 Adjusted Mean Change (SE)	-19.85 (0.94)	-18.39 (1.12)	-1.46 [-4.35; 1.43]	0.319
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	20.63 (12.31)	20.72 (13.24)		
Week 52 Mean (SD)	2.39 (3.54)	5.91 (9.45)		
Week 52 Adjusted Mean Change (SE)	-19.47 (1.24)	-14.93 (1.19)	-4.54 [-7.95; -1.14]	0.009

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

3.3 BSA (Percent) - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.936				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	17.56 (8.28)	17.00 (7.00)		
Week 52 Mean (SD)	1.13 (2.36)	5.22 (7.01)		
Week 52 Adjusted Mean Change (SE)	-20.25 (1.53)	-15.97 (1.85)	-4.28 [-9.00; 0.43]	0.075
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	23.62 (13.39)	24.69 (16.22)		
Week 52 Mean (SD)	2.85 (4.96)	4.80 (8.35)		
Week 52 Adjusted Mean Change (SE)	-19.53 (0.87)	-16.92 (0.92)	-2.62 [-5.11; -0.12]	0.040

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

3.4 BSA (Percent) - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.345				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	15.00 (5.96)	14.41 (4.03)		
Week 52 Mean (SD)	1.12 (1.95)	3.43 (4.93)		
Week 52 Adjusted Mean Change (SE)	-19.76 (1.23)	-16.59 (1.25)	-3.16 [-6.44; 0.12]	0.059
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	27.42 (13.56)	32.33 (16.97)		
Week 52 Mean (SD)	3.32 (5.48)	6.15 (9.97)		
Week 52 Adjusted Mean Change (SE)	-19.69 (1.03)	-16.86 (1.24)	-2.83 [-5.88; 0.22]	0.068

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

3.5 BSA (Percent) - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.812				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	24.18 (14.03)	21.69 (12.98)		
Week 52 Mean (SD)	2.84 (5.16)	2.67 (3.85)		
Week 52 Adjusted Mean Change (SE)	-19.59 (0.96)	-18.11 (1.20)	-1.48 [-4.53; 1.58]	0.340
> Median, N	**26**	**33**		
N'	26	32		
Baseline Mean (SD)	19.04 (9.29)	24.30 (16.78)		
Week 52 Mean (SD)	1.76 (3.21)	6.54 (9.88)		
Week 52 Adjusted Mean Change (SE)	-19.91 (1.19)	-15.72 (1.10)	-4.18 [-7.40; -0.96]	0.011

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

3.6 BSA (Percent) - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.962				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	19.50 (8.86)	23.14 (13.15)		
Week 52 Mean (SD)	1.56 (3.54)	6.11 (10.18)		
Week 52 Adjusted Mean Change (SE)	-20.22 (1.06)	-16.40 (1.35)	-3.82 [-7.23; -0.42]	0.028
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	24.97 (15.21)	23.05 (16.17)		
Week 52 Mean (SD)	3.29 (5.22)	4.10 (6.43)		
Week 52 Adjusted Mean Change (SE)	-19.17 (1.08)	-17.01 (1.04)	-2.16 [-5.13; 0.81]	0.153

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

3.7 BSA (Percent) - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.552				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	21.14 (9.69)	19.88 (11.53)		
Week 52 Mean (SD)	2.14 (3.42)	5.09 (9.51)		
Week 52 Adjusted Mean Change (SE)	-19.69 (1.21)	-16.73 (1.33)	-2.96 [-6.53; 0.61]	0.103
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	23.18 (13.43)	24.05 (16.26)		
Week 52 Mean (SD)	2.35 (4.39)	3.69 (5.78)		
Week 52 Adjusted Mean Change (SE)	-19.33 (1.41)	-16.41 (1.56)	-2.92 [-7.10; 1.25]	0.167

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

3.8 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.295				
Non-carrier, N	28	19		
N'	28	19		
Baseline Mean (SD)	23.61 (9.84)	22.37 (12.49)		
Week 52 Mean (SD)	1.78 (3.00)	4.36 (11.38)		
Week 52 Adjusted Mean Change (SE)	-19.65 (1.24)	-16.25 (1.61)	-3.39 [-7.40; 0.62]	0.096
Carrier, N	22	19		
N'	22	19		
Baseline Mean (SD)	18.18 (9.41)	19.37 (13.43)		
Week 52 Mean (SD)	2.90 (4.77)	5.72 (6.06)		
Week 52 Adjusted Mean Change (SE)	-17.38 (1.40)	-14.10 (1.50)	-3.28 [-7.34; 0.78]	0.112

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

3.9 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.989				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	19.95 (10.23)	25.81 (15.62)		
Week 52 Mean (SD)	2.00 (3.37)	4.75 (10.91)		
Week 52 Adjusted Mean Change (SE)	-19.86 (1.47)	-15.90 (1.52)	-3.96 [-8.18; 0.26]	0.065
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	23.80 (12.19)	17.91 (10.82)		
Week 52 Mean (SD)	2.25 (4.14)	4.32 (5.48)		
Week 52 Adjusted Mean Change (SE)	-19.99 (1.19)	-17.41 (1.36)	-2.58 [-6.21; 1.04]	0.160

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

3.10 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.911				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	20.44 (9.24)	22.66 (14.85)		
Week 52 Mean (SD)	1.65 (2.85)	3.79 (5.07)		
Week 52 Adjusted Mean Change (SE)	-19.78 (1.28)	-17.51 (1.15)	-2.27 [-5.70; 1.16]	0.192
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	23.54 (13.11)	19.08 (10.41)		
Week 52 Mean (SD)	2.76 (4.51)	6.50 (13.62)		
Week 52 Adjusted Mean Change (SE)	-19.35 (1.25)	-13.99 (1.94)	-5.37 [-9.97; -0.76]	0.023

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

3.11 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.774				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	22.63 (11.91)	23.61 (15.14)		
Week 52 Mean (SD)	2.89 (4.27)	4.93 (9.17)		
Week 52 Adjusted Mean Change (SE)	-18.96 (1.07)	-16.17 (1.19)	-2.78 [-5.95; 0.38]	0.084
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	19.00 (9.18)	16.44 (4.45)		
Week 52 Mean (SD)	0.50 (0.80)	3.67 (4.97)		
Week 52 Adjusted Mean Change (SE)	-21.04 (1.88)	-17.72 (2.17)	-3.32 [-8.99; 2.34]	0.246

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

3.12 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.197				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	21.56 (10.87)	23.62 (14.89)		
Week 52 Mean (SD)	2.55 (4.27)	5.36 (9.15)		
Week 52 Adjusted Mean Change (SE)	-19.12 (1.09)	-15.77 (1.17)	-3.35 [-6.53; -0.18]	0.039
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	23.23 (13.32)	15.10 (5.38)		
Week 52 Mean (SD)	1.77 (2.65)	2.10 (2.96)		
Week 52 Adjusted Mean Change (SE)	-20.24 (1.79)	-19.17 (2.07)	-1.07 [-6.53; 4.40]	0.699

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

3.13 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.696				
Non-carrier, N	42	36		
N'	42	36		
Baseline Mean (SD)	22.21 (12.02)	20.67 (10.96)		
Week 52 Mean (SD)	2.64 (4.08)	4.67 (8.66)		
Week 52 Adjusted Mean Change (SE)	-18.43 (1.01)	-15.33 (1.12)	-3.10 [-6.11; -0.10]	0.043
Carrier, N	9	5		
N'	9	5		
Baseline Mean (SD)	21.11 (8.16)	14.00 (2.55)		
Week 52 Mean (SD)	0.44 (1.33)	5.20 (7.16)		
Week 52 Adjusted Mean Change (SE)	-20.54 (2.14)	-14.76 (2.90)	-5.78 [-12.93; 1.38]	0.112

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

3.14 BSA (Percent) - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.626				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	20.09 (9.98)	28.00 (16.67)		
Week 52 Mean (SD)	2.00 (3.37)	4.19 (10.60)		
Week 52 Adjusted Mean Change (SE)	-18.86 (1.97)	-16.83 (1.54)	-2.03 [-7.03; 2.96]	0.421
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	22.55 (11.79)	15.36 (5.09)		
Week 52 Mean (SD)	2.29 (3.96)	4.73 (5.89)		
Week 52 Adjusted Mean Change (SE)	-19.72 (1.02)	-16.44 (1.42)	-3.28 [-6.78; 0.21]	0.065

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

3.15 BSA (Percent) - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.135				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	24.77 (11.68)	21.35 (11.74)		
Week 52 Mean (SD)	1.90 (3.09)	3.56 (10.09)		
Week 52 Adjusted Mean Change (SE)	-20.34 (1.15)	-17.62 (1.41)	-2.72 [-6.34; 0.89]	0.138
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	17.75 (9.67)	22.05 (15.97)		
Week 52 Mean (SD)	2.78 (4.83)	5.35 (5.88)		
Week 52 Adjusted Mean Change (SE)	-18.32 (1.45)	-15.67 (1.39)	-2.64 [-6.64; 1.35]	0.192

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

3.16 BSA (Percent) - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.902				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	19.95 (10.23)	26.25 (15.89)		
Week 52 Mean (SD)	2.00 (3.37)	5.07 (11.22)		
Week 52 Adjusted Mean Change (SE)	-19.75 (1.48)	-15.31 (1.57)	-4.43 [-8.75; -0.12]	0.044
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	23.25 (11.99)	17.88 (10.58)		
Week 52 Mean (SD)	2.38 (4.13)	4.13 (5.43)		
Week 52 Adjusted Mean Change (SE)	-19.41 (1.16)	-17.53 (1.34)	-1.89 [-5.44; 1.66]	0.294

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

3.17 BSA (Percent) - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.911				
Non-carrier, N	25	32		
N'	25	32		
Baseline Mean (SD)	20.44 (9.24)	22.66 (14.85)		
Week 52 Mean (SD)	1.65 (2.85)	3.79 (5.07)		
Week 52 Adjusted Mean Change (SE)	-19.78 (1.28)	-17.51 (1.15)	-2.27 [-5.70; 1.16]	0.192
Carrier, N	26	12		
N'	26	12		
Baseline Mean (SD)	23.54 (13.11)	19.08 (10.41)		
Week 52 Mean (SD)	2.76 (4.51)	6.50 (13.62)		
Week 52 Adjusted Mean Change (SE)	-19.35 (1.25)	-13.99 (1.94)	-5.37 [-9.97; -0.76]	0.023

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

3.18 BSA (Percent) - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.623				
Non-carrier, N	39	35		
N'	39	35		
Baseline Mean (SD)	22.95 (11.92)	23.43 (14.71)		
Week 52 Mean (SD)	2.81 (4.23)	5.07 (9.05)		
Week 52 Adjusted Mean Change (SE)	-18.96 (1.05)	-15.92 (1.14)	-3.04 [-6.11; 0.03]	0.052
Carrier, N	11	9		
N'	11	9		
Baseline Mean (SD)	18.09 (9.05)	14.89 (5.71)		
Week 52 Mean (SD)	0.36 (0.67)	2.67 (3.24)		
Week 52 Adjusted Mean Change (SE)	-21.05 (1.95)	-18.57 (2.17)	-2.48 [-8.22; 3.26]	0.393

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

4.0 C-Reactive Protein (hsCRP) (mg/L) - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	**ADA (N=62)**	**Total (N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	65 (98.5)	59 (95.2)	124 (96.9)
Week 4 Returns	64 (97.0)	58 (93.5)	122 (95.3)
Week 8 Returns	64 (97.0)	58 (93.5)	122 (95.3)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	63 (95.5)	54 (87.1)	117 (91.4)
Week 20 Returns	64 (97.0)	54 (87.1)	118 (92.2)
Week 24 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 28 Returns	62 (93.9)	49 (79.0)	111 (86.7)
Week 32 Returns	62 (93.9)	50 (80.6)	112 (87.5)
Week 36 Returns	61 (92.4)	49 (79.0)	110 (85.9)
Week 40 Returns	63 (95.5)	48 (77.4)	111 (86.7)
Week 44 Returns	63 (95.5)	47 (75.8)	110 (85.9)
Week 48 Returns	59 (89.4)	45 (72.6)	104 (81.3)
Week 52 Returns	62 (93.9)	47 (75.8)	109 (85.2)

4.0 C-Reactive Protein (hsCRP) (mg/L) - Return Rates (FAS)

4.1 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	61		
Baseline Mean (SD)	12.27 (25.25)	13.57 (28.00)		
Week 52 Mean (SD)	5.96 (10.41)	4.56 (5.93)		
Week 52 Adjusted Mean Change (SE)	-5.45 (1.07)	-4.84 (1.19)	-0.60 [-3.78; 2.57]	0.708

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

4.2 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.004				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	8.98 (11.39)	10.88 (12.88)		
Week 52 Mean (SD)	4.95 (10.30)	2.94 (3.16)		
Week 52 Adjusted Mean Change (SE)	-5.44 (1.29)	-8.02 (1.60)	2.58 [-1.49; 6.65]	0.212
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	18.03 (38.95)	16.63 (38.73)		
Week 52 Mean (SD)	7.67 (10.61)	6.24 (7.57)		
Week 52 Adjusted Mean Change (SE)	-5.45 (1.71)	-1.56 (1.67)	-3.89 [-8.65; 0.87]	0.108

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

4.3 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.344				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	3.29 (3.28)	3.15 (3.21)		
Week 52 Mean (SD)	6.08 (14.12)	4.33 (5.69)		
Week 52 Adjusted Mean Change (SE)	-2.35 (2.16)	-3.89 (2.81)	1.54 [-5.42; 8.50]	0.662
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	15.15 (28.42)	16.34 (30.93)		
Week 52 Mean (SD)	5.92 (8.98)	4.61 (6.05)		
Week 52 Adjusted Mean Change (SE)	-6.54 (1.25)	-4.85 (1.33)	-1.68 [-5.30; 1.94]	0.359

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

4.4 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.797				
Moderate/Severe Psoriasis (Def D): No, N	28	32		
N'	28	32		
Baseline Mean (SD)	6.74 (10.97)	9.78 (15.08)		
Week 52 Mean (SD)	6.92 (12.50)	5.68 (7.41)		
Week 52 Adjusted Mean Change (SE)	-2.71 (1.64)	-3.29 (1.70)	0.58 [-4.08; 5.24]	0.806
Moderate/Severe Psoriasis (Def D): Yes, N	38	30		
N'	38	29		
Baseline Mean (SD)	16.35 (31.50)	17.62 (37.06)		
Week 52 Mean (SD)	5.26 (8.73)	3.57 (4.15)		
Week 52 Adjusted Mean Change (SE)	-7.48 (1.41)	-6.04 (1.65)	-1.43 [-5.73; 2.86]	0.509

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

4.5 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.047				
≤ Median, N	40	29		
N'	40	29		
Baseline Mean (SD)	14.75 (31.47)	16.73 (37.95)		
Week 52 Mean (SD)	5.13 (8.72)	4.55 (7.47)		
Week 52 Adjusted Mean Change (SE)	-7.01 (1.36)	-4.18 (1.81)	-2.83 [-7.32; 1.66]	0.214
> Median, N	26	33		
N'	26	32		
Baseline Mean (SD)	8.47 (9.42)	10.80 (14.76)		
Week 52 Mean (SD)	7.27 (12.74)	4.56 (4.76)		
Week 52 Adjusted Mean Change (SE)	-3.03 (1.69)	-5.47 (1.57)	2.44 [-2.12; 6.99]	0.291

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

4.6 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.591				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	8.09 (9.46)	10.81 (15.61)		
Week 52 Mean (SD)	4.96 (10.46)	6.38 (7.86)		
Week 52 Adjusted Mean Change (SE)	-5.34 (1.50)	-4.34 (1.92)	-1.00 [-5.81; 3.82]	0.683
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	16.71 (34.68)	15.09 (32.99)		
Week 52 Mean (SD)	6.96 (10.44)	3.32 (3.84)		
Week 52 Adjusted Mean Change (SE)	-5.56 (1.53)	-5.29 (1.53)	-0.26 [-4.56; 4.03]	0.903

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

4.7 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.657				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	10.14 (13.83)	10.32 (13.77)		
Week 52 Mean (SD)	5.29 (8.40)	6.32 (7.87)		
Week 52 Adjusted Mean Change (SE)	-6.48 (1.33)	-6.08 (1.48)	-0.40 [-4.35; 3.55]	0.840
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	18.14 (40.26)	10.36 (15.03)		
Week 52 Mean (SD)	6.14 (9.88)	3.71 (4.19)		
Week 52 Adjusted Mean Change (SE)	-6.38 (1.55)	-5.57 (1.71)	-0.81 [-5.43; 3.81]	0.728

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

4.8 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.208				
Non-carrier, N	**28**	**19**		
N'	28	19		
Baseline Mean (SD)	11.41 (20.03)	10.38 (16.18)		
Week 52 Mean (SD)	3.29 (3.58)	3.64 (3.64)		
Week 52 Adjusted Mean Change (SE)	-8.77 (1.36)	-5.40 (1.77)	-3.38 [-7.82; 1.07]	0.135
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	16.95 (37.04)	10.21 (11.09)		
Week 52 Mean (SD)	9.22 (12.81)	6.23 (8.06)		
Week 52 Adjusted Mean Change (SE)	-3.68 (1.57)	-6.08 (1.68)	2.40 [-2.18; 6.98]	0.300

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

4.9 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.658				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	20.51 (39.16)	12.98 (17.30)		
Week 52 Mean (SD)	7.48 (11.75)	3.70 (3.75)		
Week 52 Adjusted Mean Change (SE)	-6.37 (1.58)	-6.64 (1.58)	0.28 [-4.17; 4.72]	0.902
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	9.47 (19.44)	7.93 (10.34)		
Week 52 Mean (SD)	4.55 (6.48)	6.33 (8.04)		
Week 52 Adjusted Mean Change (SE)	-7.14 (1.26)	-5.23 (1.45)	-1.91 [-5.72; 1.90]	0.323

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

4.10 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.598				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	11.30 (20.94)	7.92 (10.85)		
Week 52 Mean (SD)	2.99 (2.85)	5.59 (7.40)		
Week 52 Adjusted Mean Change (SE)	-7.94 (1.36)	-5.94 (1.24)	-2.00 [-5.65; 1.64]	0.278
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	15.79 (34.30)	16.78 (19.73)		
Week 52 Mean (SD)	8.20 (11.80)	4.03 (3.56)		
Week 52 Adjusted Mean Change (SE)	-5.00 (1.34)	-5.72 (2.04)	0.72 [-4.13; 5.56]	0.769
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

4.11 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.079				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	10.16 (18.15)	9.40 (14.24)		
Week 52 Mean (SD)	4.80 (6.12)	4.62 (5.05)		
Week 52 Adjusted Mean Change (SE)	-6.57 (1.15)	-5.80 (1.29)	-0.77 [-4.21; 2.67]	0.658
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	23.03 (48.81)	15.47 (14.78)		
Week 52 Mean (SD)	8.43 (14.53)	7.20 (10.14)		
Week 52 Adjusted Mean Change (SE)	-5.38 (2.06)	-5.34 (2.33)	-0.04 [-6.19; 6.10]	0.989

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

4.12 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.520				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	17.35 (33.06)	12.06 (15.56)		
Week 52 Mean (SD)	5.91 (10.32)	5.88 (7.38)		
Week 52 Adjusted Mean Change (SE)	-6.86 (1.19)	-5.65 (1.26)	-1.21 [-4.67; 2.25]	0.488
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	3.81 (3.51)	4.48 (4.52)		
Week 52 Mean (SD)	3.86 (3.80)	3.27 (3.12)		
Week 52 Adjusted Mean Change (SE)	-6.50 (1.97)	-6.67 (2.21)	0.18 [-5.67; 6.02]	0.953

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

4.13 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.728				
Non-carrier, N	**42**	**36**		
N'	42	36		
Baseline Mean (SD)	11.86 (27.52)	9.81 (14.00)		
Week 52 Mean (SD)	6.44 (9.78)	5.15 (6.59)		
Week 52 Adjusted Mean Change (SE)	-5.25 (1.10)	-5.12 (1.22)	-0.13 [-3.39; 3.14]	0.939
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	21.64 (32.49)	12.84 (20.07)		
Week 52 Mean (SD)	2.33 (2.01)	2.43 (2.49)		
Week 52 Adjusted Mean Change (SE)	-11.55 (2.36)	-9.97 (3.39)	-1.58 [-9.80; 6.63]	0.703
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

4.14 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.446				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	12.81 (13.01)	10.51 (15.68)		
Week 52 Mean (SD)	4.23 (4.63)	4.10 (4.93)		
Week 52 Adjusted Mean Change (SE)	-6.16 (2.15)	-6.00 (1.61)	-0.16 [-5.50; 5.18]	0.952
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	13.80 (31.42)	10.16 (12.83)		
Week 52 Mean (SD)	6.04 (9.83)	6.01 (7.62)		
Week 52 Adjusted Mean Change (SE)	-6.50 (1.12)	-5.57 (1.52)	-0.93 [-4.68; 2.83]	0.625

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

4.15 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.166				
Non-carrier, N	31	23		
N'	31	23		
Baseline Mean (SD)	15.87 (34.52)	10.96 (16.95)		
Week 52 Mean (SD)	4.59 (8.20)	3.52 (3.52)		
Week 52 Adjusted Mean Change (SE)	-8.37 (1.23)	-6.09 (1.52)	-2.28 [-6.18; 1.62]	0.248
Carrier, N	20	21		
N'	20	21		
Baseline Mean (SD)	10.05 (14.59)	9.65 (10.68)		
Week 52 Mean (SD)	7.53 (10.16)	6.62 (8.22)		
Week 52 Adjusted Mean Change (SE)	-3.39 (1.56)	-5.38 (1.50)	1.99 [-2.30; 6.29]	0.359

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

4.16 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.520				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	20.51 (39.16)	13.46 (17.60)		
Week 52 Mean (SD)	7.48 (11.75)	3.89 (3.80)		
Week 52 Adjusted Mean Change (SE)	-6.33 (1.64)	-6.39 (1.68)	0.06 [-4.61; 4.73]	0.981
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	9.48 (18.96)	7.73 (10.16)		
Week 52 Mean (SD)	4.41 (6.40)	6.06 (7.93)		
Week 52 Adjusted Mean Change (SE)	-6.55 (1.27)	-5.39 (1.47)	-1.16 [-5.01; 2.70]	0.552

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

4.17 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.598				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	11.30 (20.94)	7.92 (10.85)		
Week 52 Mean (SD)	2.99 (2.85)	5.59 (7.40)		
Week 52 Adjusted Mean Change (SE)	-7.94 (1.36)	-5.94 (1.24)	-2.00 [-5.65; 1.64]	0.278
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	15.79 (34.30)	16.78 (19.73)		
Week 52 Mean (SD)	8.20 (11.80)	4.03 (3.56)		
Week 52 Adjusted Mean Change (SE)	-5.00 (1.34)	-5.72 (2.04)	0.72 [-4.13; 5.56]	0.769

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

4.18 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.572				
Non-carrier, N	39	35		
N'	39	35		
Baseline Mean (SD)	10.68 (18.21)	9.13 (13.87)		
Week 52 Mean (SD)	4.70 (6.06)	4.59 (4.94)		
Week 52 Adjusted Mean Change (SE)	-6.73 (1.13)	-5.81 (1.25)	-0.92 [-4.26; 2.42]	0.585
Carrier, N	11	9		
N'	11	9		
Baseline Mean (SD)	23.46 (51.16)	15.04 (15.10)		
Week 52 Mean (SD)	9.12 (15.04)	6.88 (10.18)		
Week 52 Adjusted Mean Change (SE)	-4.75 (2.13)	-5.52 (2.32)	0.77 [-5.46; 7.00]	0.807

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

5.0 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	66 (100.0)	61 (98.4)	127 (99.2)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 8 Returns	66 (100.0)	59 (95.2)	125 (97.7)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	64 (97.0)	56 (90.3)	120 (93.8)
Week 20 Returns	64 (97.0)	54 (87.1)	118 (92.2)
Week 24 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 28 Returns	62 (93.9)	48 (77.4)	110 (85.9)
Week 32 Returns	62 (93.9)	50 (80.6)	112 (87.5)
Week 36 Returns	61 (92.4)	50 (80.6)	111 (86.7)
Week 40 Returns	63 (95.5)	48 (77.4)	111 (86.7)
Week 44 Returns	63 (95.5)	47 (75.8)	110 (85.9)
Week 48 Returns	60 (90.9)	46 (74.2)	106 (82.8)
Week 52 Returns	62 (93.9)	47 (75.8)	109 (85.2)

5.1 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	61		
Baseline Mean (SD)	23.18 (18.12)	26.92 (19.00)		
Week 52 Mean (SD)	13.26 (12.26)	13.74 (13.07)		
Week 52 Adjusted Mean Change (SE)	-9.95 (1.56)	-10.11 (1.69)	0.16 [-4.42; 4.73]	0.946

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

5.2 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.037				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	18.10 (15.43)	23.09 (17.11)		
Week 52 Mean (SD)	9.44 (8.64)	8.83 (7.77)		
Week 52 Adjusted Mean Change (SE)	-11.09 (1.96)	-14.93 (2.26)	3.84 [-2.07; 9.74]	0.201
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	32.08 (19.33)	31.28 (20.38)		
Week 52 Mean (SD)	19.74 (14.77)	18.87 (15.49)		
Week 52 Adjusted Mean Change (SE)	-8.07 (2.56)	-4.40 (2.41)	-3.67 [-10.54; 3.19]	0.292

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

5.3 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.574				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	10.44 (7.88)	15.08 (16.84)		
Week 52 Mean (SD)	11.00 (10.28)	17.00 (17.07)		
Week 52 Adjusted Mean Change (SE)	-6.39 (3.28)	-3.49 (3.82)	-2.90 [-12.64; 6.84]	0.557
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	27.26 (18.62)	30.06 (18.44)		
Week 52 Mean (SD)	14.04 (12.89)	13.08 (12.26)		
Week 52 Adjusted Mean Change (SE)	-11.05 (1.80)	-11.55 (1.90)	0.50 [-4.64; 5.65]	0.847

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

5.4 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.640				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	20.82 (14.82)	27.22 (17.72)		
Week 52 Mean (SD)	15.88 (12.15)	14.45 (15.94)		
Week 52 Adjusted Mean Change (SE)	-7.28 (2.41)	-10.47 (2.39)	3.19 [-3.55; 9.93]	0.350
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	24.92 (20.23)	26.60 (20.59)		
Week 52 Mean (SD)	11.36 (12.16)	13.12 (10.20)		
Week 52 Adjusted Mean Change (SE)	-11.89 (2.05)	-9.98 (2.40)	-1.91 [-8.15; 4.33]	0.545

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

5.5 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.976				
≤ Median, N	40	29		
N'	40	29		
Baseline Mean (SD)	20.33 (17.60)	28.86 (22.51)		
Week 52 Mean (SD)	9.32 (7.39)	10.00 (8.14)		
Week 52 Adjusted Mean Change (SE)	-12.13 (1.96)	-12.31 (2.44)	0.19 [-6.06; 6.43]	0.953
> Median, N	26	33		
N'	26	32		
Baseline Mean (SD)	27.58 (18.36)	25.21 (15.45)		
Week 52 Mean (SD)	19.50 (15.64)	16.29 (15.17)		
Week 52 Adjusted Mean Change (SE)	-6.75 (2.42)	-8.26 (2.23)	1.51 [-4.99; 8.02]	0.646

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

5.6 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.489				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	18.91 (13.38)	26.36 (16.76)		
Week 52 Mean (SD)	11.10 (7.92)	14.84 (16.34)		
Week 52 Adjusted Mean Change (SE)	-10.98 (2.24)	-10.33 (2.81)	-0.65 [-7.78; 6.47]	0.856
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	27.72 (21.37)	27.23 (20.33)		
Week 52 Mean (SD)	15.42 (15.28)	13.00 (10.56)		
Week 52 Adjusted Mean Change (SE)	-8.90 (2.27)	-10.26 (2.16)	1.36 [-4.82; 7.54]	0.664

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

5.7 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.288				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	23.34 (18.98)	21.72 (15.91)		
Week 52 Mean (SD)	13.93 (12.94)	15.55 (14.53)		
Week 52 Adjusted Mean Change (SE)	-9.15 (2.26)	-9.21 (2.51)	0.06 [-6.66; 6.78]	0.985
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	24.73 (19.46)	25.00 (15.90)		
Week 52 Mean (SD)	11.95 (8.02)	10.25 (12.97)		
Week 52 Adjusted Mean Change (SE)	-9.88 (2.61)	-11.71 (2.90)	1.84 [-5.91; 9.58]	0.639

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

5.8 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.305				
Non-carrier, N	28	19		
N'	28	19		
Baseline Mean (SD)	20.82 (19.11)	18.53 (10.93)		
Week 52 Mean (SD)	11.67 (12.85)	10.71 (6.59)		
Week 52 Adjusted Mean Change (SE)	-11.11 (2.28)	-10.92 (2.97)	-0.18 [-7.59; 7.22]	0.961
Carrier, N	22	19		
N'	22	19		
Baseline Mean (SD)	28.64 (18.52)	27.47 (16.30)		
Week 52 Mean (SD)	15.68 (7.54)	15.41 (18.16)		
Week 52 Adjusted Mean Change (SE)	-7.26 (2.61)	-8.75 (2.79)	1.49 [-6.06; 9.04]	0.695

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

5.9 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.205				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	27.37 (18.86)	22.76 (16.81)		
Week 52 Mean (SD)	17.58 (14.16)	11.94 (9.99)		
Week 52 Adjusted Mean Change (SE)	-6.96 (2.68)	-10.04 (2.70)	3.09 [-4.49; 10.66]	0.420
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	20.77 (16.55)	23.48 (15.20)		
Week 52 Mean (SD)	10.33 (7.08)	14.20 (16.62)		
Week 52 Adjusted Mean Change (SE)	-11.92 (2.16)	-10.03 (2.48)	-1.89 [-8.43; 4.65]	0.567

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

5.10 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.432				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	23.52 (21.56)	23.03 (16.74)		
Week 52 Mean (SD)	12.00 (13.03)	13.15 (12.48)		
Week 52 Adjusted Mean Change (SE)	-9.31 (2.46)	-10.66 (2.23)	1.35 [-5.25; 7.95]	0.686
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	24.35 (16.61)	23.42 (13.65)		
Week 52 Mean (SD)	14.13 (8.93)	13.30 (17.93)		
Week 52 Adjusted Mean Change (SE)	-9.57 (2.42)	-8.78 (3.71)	-0.79 [-9.59; 8.01]	0.858

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

5.11 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.369				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	24.47 (20.31)	22.76 (16.01)		
Week 52 Mean (SD)	13.38 (12.08)	14.04 (15.80)		
Week 52 Adjusted Mean Change (SE)	-9.14 (2.02)	-9.76 (2.25)	0.62 [-5.40; 6.64]	0.838
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	22.25 (15.84)	24.56 (16.50)		
Week 52 Mean (SD)	12.83 (8.28)	12.67 (8.94)		
Week 52 Adjusted Mean Change (SE)	-9.72 (3.57)	-11.14 (4.09)	1.42 [-9.37; 12.20]	0.794

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

5.12 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.212				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	26.44 (21.41)	22.06 (15.68)		
Week 52 Mean (SD)	12.97 (12.10)	15.27 (15.54)		
Week 52 Adjusted Mean Change (SE)	-10.12 (2.02)	-7.90 (2.15)	-2.22 [-8.11; 3.66]	0.454
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	15.69 (7.92)	26.80 (16.52)		
Week 52 Mean (SD)	10.58 (5.12)	7.80 (6.21)		
Week 52 Adjusted Mean Change (SE)	-9.21 (3.38)	-16.29 (3.79)	7.08 [-3.09; 17.24]	0.170

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

5.13 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.374				
Non-carrier, N	42	36		
N'	42	36		
Baseline Mean (SD)	24.52 (19.18)	22.19 (16.04)		
Week 52 Mean (SD)	14.50 (11.36)	13.30 (14.30)		
Week 52 Adjusted Mean Change (SE)	-7.94 (1.85)	-9.29 (2.05)	1.34 [-4.15; 6.84]	0.629
Carrier, N	9	5		
N'	9	5		
Baseline Mean (SD)	21.22 (19.06)	25.80 (15.16)		
Week 52 Mean (SD)	7.11 (7.49)	11.33 (9.45)		
Week 52 Adjusted Mean Change (SE)	-15.31 (3.94)	-12.71 (5.64)	-2.60 [-16.28; 11.08]	0.707

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

5.14 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.404				
Low score, N	11	22		
N'	11	22		
Baseline Mean (SD)	30.00 (26.81)	20.59 (15.60)		
Week 52 Mean (SD)	18.60 (19.14)	12.63 (10.44)		
Week 52 Adjusted Mean Change (SE)	-2.73 (3.67)	-9.55 (2.75)	6.83 [-2.32; 15.98]	0.142
High score, N	40	22		
N'	40	22		
Baseline Mean (SD)	22.28 (16.30)	25.68 (15.95)		
Week 52 Mean (SD)	11.59 (7.34)	13.65 (16.45)		
Week 52 Adjusted Mean Change (SE)	-11.28 (1.91)	-10.73 (2.58)	-0.55 [-6.94; 5.84]	0.865

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

5.15 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.871				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	21.00 (19.14)	20.35 (15.41)		
Week 52 Mean (SD)	12.00 (12.81)	9.65 (6.79)		
Week 52 Adjusted Mean Change (SE)	-11.01 (2.17)	-13.23 (2.68)	2.22 [-4.61; 9.05]	0.520
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	28.50 (18.35)	26.19 (16.04)		
Week 52 Mean (SD)	15.00 (6.93)	16.37 (17.71)		
Week 52 Adjusted Mean Change (SE)	-6.93 (2.75)	-7.31 (2.66)	0.38 [-7.19; 7.95]	0.921

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

5.16 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.422				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	27.37 (18.86)	23.45 (16.94)		
Week 52 Mean (SD)	17.58 (14.16)	12.20 (10.28)		
Week 52 Adjusted Mean Change (SE)	-7.35 (2.81)	-9.90 (2.90)	2.56 [-5.46; 10.58]	0.528
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	21.91 (19.10)	22.88 (15.15)		
Week 52 Mean (SD)	10.04 (7.12)	13.90 (16.25)		
Week 52 Adjusted Mean Change (SE)	-10.76 (2.19)	-10.22 (2.54)	-0.53 [-7.19; 6.13]	0.874

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

5.17 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.432				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	23.52 (21.56)	23.03 (16.74)		
Week 52 Mean (SD)	12.00 (13.03)	13.15 (12.48)		
Week 52 Adjusted Mean Change (SE)	-9.31 (2.46)	-10.66 (2.23)	1.35 [-5.25; 7.95]	0.686
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	24.35 (16.61)	23.42 (13.65)		
Week 52 Mean (SD)	14.13 (8.93)	13.30 (17.93)		
Week 52 Adjusted Mean Change (SE)	-9.57 (2.42)	-8.78 (3.71)	-0.79 [-9.59; 8.01]	0.858

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

5.18 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.128				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	24.46 (20.04)	22.49 (15.69)		
Week 52 Mean (SD)	13.17 (11.97)	14.33 (15.58)		
Week 52 Adjusted Mean Change (SE)	-9.14 (1.98)	-9.09 (2.17)	-0.05 [-5.90; 5.79]	0.986
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	20.64 (15.55)	25.67 (16.94)		
Week 52 Mean (SD)	13.09 (8.63)	9.78 (6.51)		
Week 52 Adjusted Mean Change (SE)	-8.85 (3.70)	-14.26 (4.07)	5.41 [-5.52; 16.34]	0.328

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

6.0 HAQ-DI - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	66 (100.0)	61 (98.4)	127 (99.2)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	64 (97.0)	56 (90.3)	120 (93.8)
Week 20 Returns	64 (97.0)	54 (87.1)	118 (92.2)
Week 24 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 28 Returns	62 (93.9)	49 (79.0)	111 (86.7)
Week 32 Returns	62 (93.9)	49 (79.0)	111 (86.7)
Week 36 Returns	61 (92.4)	50 (80.6)	111 (86.7)
Week 40 Returns	63 (95.5)	48 (77.4)	111 (86.7)
Week 44 Returns	63 (95.5)	47 (75.8)	110 (85.9)
Week 48 Returns	60 (90.9)	46 (74.2)	106 (82.8)
Week 52 Returns	62 (93.9)	46 (74.2)	108 (84.4)

6.1 HAQ-DI - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N'	66	61		
Baseline Mean (SD)	1.27 (0.64)	1.31 (0.71)		
Week 52 Mean (SD)	0.66 (0.64)	0.68 (0.63)		
Week 2 Adjusted Mean Change (SE)	-0.20 (0.04)	-0.29 (0.04)		
Week 4 Adjusted Mean Change (SE)	-0.30 (0.05)	-0.33 (0.05)		
Week 8 Adjusted Mean Change (SE)	-0.35 (0.05)	-0.35 (0.05)		
Week 12 Adjusted Mean Change (SE)	-0.44 (0.06)	-0.43 (0.06)		
Week 16 Adjusted Mean Change (SE)	-0.45 (0.06)	-0.45 (0.06)		
Week 20 Adjusted Mean Change (SE)	-0.48 (0.06)	-0.46 (0.07)		
Week 24 Adjusted Mean Change (SE)	-0.51 (0.06)	-0.49 (0.07)		
Week 28 Adjusted Mean Change (SE)	-0.53 (0.06)	-0.48 (0.07)		
Week 32 Adjusted Mean Change (SE)	-0.54 (0.06)	-0.50 (0.07)		
Week 36 Adjusted Mean Change (SE)	-0.55 (0.06)	-0.54 (0.06)		
Week 40 Adjusted Mean Change (SE)	-0.54 (0.06)	-0.54 (0.07)		
Week 44 Adjusted Mean Change (SE)	-0.56 (0.06)	-0.60 (0.07)		
Week 48 Adjusted Mean Change (SE)	-0.57 (0.06)	-0.57 (0.07)		
Week 52 Adjusted Mean Change (SE)	-0.60 (0.06)	-0.59 (0.07)	-0.01 [-0.20; 0.17]	0.886

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

6.2 HAQ-DI - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.223				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	1.15 (0.64)	1.00 (0.69)		
Week 52 Mean (SD)	0.53 (0.63)	0.39 (0.51)		
Week 2 Adjusted Mean Change (SE)	-0.26 (0.05)	-0.37 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.37 (0.06)	-0.44 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.40 (0.06)	-0.46 (0.07)		
Week 12 Adjusted Mean Change (SE)	-0.51 (0.08)	-0.60 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.53 (0.08)	-0.57 (0.09)		
Week 20 Adjusted Mean Change (SE)	-0.56 (0.08)	-0.64 (0.09)		
Week 24 Adjusted Mean Change (SE)	-0.60 (0.08)	-0.69 (0.09)		
Week 28 Adjusted Mean Change (SE)	-0.56 (0.08)	-0.70 (0.09)		
Week 32 Adjusted Mean Change (SE)	-0.59 (0.08)	-0.69 (0.09)		
Week 36 Adjusted Mean Change (SE)	-0.57 (0.07)	-0.71 (0.09)		
Week 40 Adjusted Mean Change (SE)	-0.57 (0.08)	-0.71 (0.09)		
Week 44 Adjusted Mean Change (SE)	-0.62 (0.08)	-0.79 (0.09)		
Week 48 Adjusted Mean Change (SE)	-0.62 (0.08)	-0.71 (0.10)		
Week 52 Adjusted Mean Change (SE)	-0.64 (0.08)	-0.74 (0.10)	0.09 [-0.15; 0.33]	0.446
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	1.47 (0.60)	1.66 (0.57)		
Week 52 Mean (SD)	0.88 (0.61)	1.01 (0.58)		
Week 2 Adjusted Mean Change (SE)	-0.09 (0.07)	-0.21 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.16 (0.08)	-0.21 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.26 (0.08)	-0.22 (0.08)		
Week 12 Adjusted Mean Change (SE)	-0.33 (0.10)	-0.25 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.30 (0.10)	-0.33 (0.10)		
Week 20 Adjusted Mean Change (SE)	-0.35 (0.10)	-0.26 (0.10)		
Week 24 Adjusted Mean Change (SE)	-0.34 (0.10)	-0.27 (0.10)		
Week 28 Adjusted Mean Change (SE)	-0.50 (0.10)	-0.24 (0.10)		
Week 32 Adjusted Mean Change (SE)	-0.46 (0.10)	-0.28 (0.10)		
Week 36 Adjusted Mean Change (SE)	-0.52 (0.10)	-0.34 (0.09)		
Week 40 Adjusted Mean Change (SE)	-0.48 (0.10)	-0.33 (0.10)		
Week 44 Adjusted Mean Change (SE)	-0.44 (0.10)	-0.39 (0.10)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.50 (0.11)	-0.42 (0.10)		
Week 52 Adjusted Mean Change (SE)	-0.53 (0.10)	-0.42 (0.10)	-0.11 [-0.40; 0.17]	0.434

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

6.3 HAQ-DI - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.673				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	0.67 (0.43)	0.46 (0.58)		
Week 52 Mean (SD)	0.29 (0.47)	0.44 (0.46)		
Week 2 Adjusted Mean Change (SE)	-0.29 (0.09)	-0.33 (0.10)		
Week 4 Adjusted Mean Change (SE)	-0.43 (0.10)	-0.41 (0.12)		
Week 8 Adjusted Mean Change (SE)	-0.31 (0.11)	-0.34 (0.13)		
Week 12 Adjusted Mean Change (SE)	-0.47 (0.14)	-0.51 (0.15)		
Week 16 Adjusted Mean Change (SE)	-0.55 (0.13)	-0.52 (0.15)		
Week 20 Adjusted Mean Change (SE)	-0.51 (0.14)	-0.49 (0.16)		
Week 24 Adjusted Mean Change (SE)	-0.51 (0.14)	-0.37 (0.16)		
Week 28 Adjusted Mean Change (SE)	-0.58 (0.14)	-0.57 (0.17)		
Week 32 Adjusted Mean Change (SE)	-0.56 (0.14)	-0.56 (0.16)		
Week 36 Adjusted Mean Change (SE)	-0.55 (0.13)	-0.51 (0.15)		
Week 40 Adjusted Mean Change (SE)	-0.56 (0.14)	-0.54 (0.16)		
Week 44 Adjusted Mean Change (SE)	-0.61 (0.14)	-0.38 (0.17)		
Week 48 Adjusted Mean Change (SE)	-0.62 (0.14)	-0.42 (0.17)		
Week 52 Adjusted Mean Change (SE)	-0.61 (0.14)	-0.42 (0.17)	-0.18 [-0.58; 0.22]	0.364
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	1.46 (0.58)	1.53 (0.56)		
Week 52 Mean (SD)	0.79 (0.64)	0.74 (0.65)		
Week 2 Adjusted Mean Change (SE)	-0.17 (0.05)	-0.28 (0.05)		
Week 4 Adjusted Mean Change (SE)	-0.25 (0.06)	-0.30 (0.06)		
Week 8 Adjusted Mean Change (SE)	-0.36 (0.06)	-0.35 (0.06)		
Week 12 Adjusted Mean Change (SE)	-0.43 (0.07)	-0.41 (0.08)		
Week 16 Adjusted Mean Change (SE)	-0.41 (0.07)	-0.43 (0.08)		
Week 20 Adjusted Mean Change (SE)	-0.47 (0.07)	-0.45 (0.08)		
Week 24 Adjusted Mean Change (SE)	-0.50 (0.07)	-0.52 (0.08)		
Week 28 Adjusted Mean Change (SE)	-0.52 (0.08)	-0.46 (0.08)		
Week 32 Adjusted Mean Change (SE)	-0.53 (0.07)	-0.48 (0.08)		
Week 36 Adjusted Mean Change (SE)	-0.55 (0.07)	-0.54 (0.07)		
Week 40 Adjusted Mean Change (SE)	-0.53 (0.07)	-0.54 (0.08)		
Week 44 Adjusted Mean Change (SE)	-0.53 (0.07)	-0.66 (0.08)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.55 (0.08)	-0.61 (0.08)		
Week 52 Adjusted Mean Change (SE)	-0.60 (0.07)	-0.63 (0.08)	0.03 [-0.18; 0.24]	0.781

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

6.4 HAQ-DI - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.671				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	1.30 (0.65)	1.33 (0.73)		
Week 52 Mean (SD)	0.81 (0.61)	0.71 (0.66)		
Week 2 Adjusted Mean Change (SE)	-0.20 (0.06)	-0.27 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.32 (0.07)	-0.28 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.35 (0.08)	-0.31 (0.07)		
Week 12 Adjusted Mean Change (SE)	-0.39 (0.09)	-0.40 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.36 (0.09)	-0.46 (0.09)		
Week 20 Adjusted Mean Change (SE)	-0.40 (0.10)	-0.46 (0.09)		
Week 24 Adjusted Mean Change (SE)	-0.45 (0.10)	-0.49 (0.09)		
Week 28 Adjusted Mean Change (SE)	-0.53 (0.10)	-0.51 (0.10)		
Week 32 Adjusted Mean Change (SE)	-0.47 (0.10)	-0.55 (0.09)		
Week 36 Adjusted Mean Change (SE)	-0.54 (0.09)	-0.53 (0.09)		
Week 40 Adjusted Mean Change (SE)	-0.51 (0.10)	-0.54 (0.09)		
Week 44 Adjusted Mean Change (SE)	-0.48 (0.10)	-0.58 (0.10)		
Week 48 Adjusted Mean Change (SE)	-0.50 (0.10)	-0.58 (0.10)		
Week 52 Adjusted Mean Change (SE)	-0.51 (0.10)	-0.60 (0.10)	0.09 [-0.18; 0.36]	0.506
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	1.24 (0.64)	1.28 (0.71)		
Week 52 Mean (SD)	0.55 (0.64)	0.66 (0.60)		
Week 2 Adjusted Mean Change (SE)	-0.19 (0.05)	-0.32 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.28 (0.06)	-0.38 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.34 (0.07)	-0.39 (0.08)		
Week 12 Adjusted Mean Change (SE)	-0.48 (0.08)	-0.47 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.51 (0.08)	-0.44 (0.09)		
Week 20 Adjusted Mean Change (SE)	-0.54 (0.08)	-0.47 (0.10)		
Week 24 Adjusted Mean Change (SE)	-0.55 (0.08)	-0.50 (0.10)		
Week 28 Adjusted Mean Change (SE)	-0.54 (0.08)	-0.46 (0.10)		
Week 32 Adjusted Mean Change (SE)	-0.59 (0.08)	-0.45 (0.10)		
Week 36 Adjusted Mean Change (SE)	-0.55 (0.08)	-0.54 (0.09)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 40 Adjusted Mean Change (SE)	-0.56 (0.08)	-0.53 (0.10)		
Week 44 Adjusted Mean Change (SE)	-0.61 (0.09)	-0.61 (0.10)		
Week 48 Adjusted Mean Change (SE)	-0.62 (0.09)	-0.57 (0.10)		
Week 52 Adjusted Mean Change (SE)	-0.67 (0.08)	-0.58 (0.10)	-0.09 [-0.35; 0.16]	0.478

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

6.5 HAQ-DI - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.230				
≤ Median, N	40	29		
N'	40	29		
Baseline Mean (SD)	1.26 (0.56)	1.23 (0.76)		
Week 52 Mean (SD)	0.60 (0.62)	0.67 (0.62)		
Week 2 Adjusted Mean Change (SE)	-0.24 (0.05)	-0.31 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.35 (0.06)	-0.32 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.35 (0.07)	-0.40 (0.08)		
Week 12 Adjusted Mean Change (SE)	-0.49 (0.08)	-0.48 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.49 (0.08)	-0.44 (0.09)		
Week 20 Adjusted Mean Change (SE)	-0.53 (0.08)	-0.50 (0.10)		
Week 24 Adjusted Mean Change (SE)	-0.56 (0.08)	-0.45 (0.10)		
Week 28 Adjusted Mean Change (SE)	-0.59 (0.08)	-0.48 (0.10)		
Week 32 Adjusted Mean Change (SE)	-0.61 (0.08)	-0.45 (0.10)		
Week 36 Adjusted Mean Change (SE)	-0.58 (0.08)	-0.51 (0.09)		
Week 40 Adjusted Mean Change (SE)	-0.61 (0.08)	-0.46 (0.10)		
Week 44 Adjusted Mean Change (SE)	-0.64 (0.08)	-0.47 (0.10)		
Week 48 Adjusted Mean Change (SE)	-0.65 (0.08)	-0.51 (0.10)		
Week 52 Adjusted Mean Change (SE)	-0.66 (0.08)	-0.50 (0.10)	-0.17 [-0.42; 0.09]	0.207
> Median, N	26	33		
N'	26	32		
Baseline Mean (SD)	1.27 (0.77)	1.38 (0.68)		
Week 52 Mean (SD)	0.76 (0.68)	0.69 (0.64)		
Week 2 Adjusted Mean Change (SE)	-0.13 (0.07)	-0.28 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.22 (0.08)	-0.34 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.33 (0.08)	-0.30 (0.07)		
Week 12 Adjusted Mean Change (SE)	-0.37 (0.10)	-0.39 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.38 (0.10)	-0.47 (0.09)		
Week 20 Adjusted Mean Change (SE)	-0.40 (0.10)	-0.43 (0.09)		
Week 24 Adjusted Mean Change (SE)	-0.42 (0.10)	-0.52 (0.09)		
Week 28 Adjusted Mean Change (SE)	-0.45 (0.10)	-0.48 (0.10)		
Week 32 Adjusted Mean Change (SE)	-0.43 (0.10)	-0.53 (0.09)		
Week 36 Adjusted Mean Change (SE)	-0.50 (0.09)	-0.56 (0.09)		
Week 40 Adjusted Mean Change (SE)	-0.43 (0.10)	-0.60 (0.09)		
Week 44 Adjusted Mean Change (SE)	-0.42 (0.10)	-0.71 (0.10)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.45 (0.10)	-0.63 (0.09)		
Week 52 Adjusted Mean Change (SE)	-0.51 (0.10)	-0.66 (0.09)	0.15 [-0.12; 0.43]	0.266

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

6.6 HAQ-DI - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.299				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	1.14 (0.71)	1.30 (0.73)		
Week 52 Mean (SD)	0.57 (0.63)	0.65 (0.58)		
Week 2 Adjusted Mean Change (SE)	-0.22 (0.06)	-0.35 (0.07)		
Week 4 Adjusted Mean Change (SE)	-0.34 (0.07)	-0.44 (0.08)		
Week 8 Adjusted Mean Change (SE)	-0.34 (0.07)	-0.52 (0.09)		
Week 12 Adjusted Mean Change (SE)	-0.48 (0.08)	-0.63 (0.11)		
Week 16 Adjusted Mean Change (SE)	-0.44 (0.08)	-0.64 (0.11)		
Week 20 Adjusted Mean Change (SE)	-0.48 (0.09)	-0.63 (0.11)		
Week 24 Adjusted Mean Change (SE)	-0.49 (0.09)	-0.56 (0.11)		
Week 28 Adjusted Mean Change (SE)	-0.53 (0.09)	-0.56 (0.11)		
Week 32 Adjusted Mean Change (SE)	-0.54 (0.09)	-0.56 (0.11)		
Week 36 Adjusted Mean Change (SE)	-0.54 (0.08)	-0.66 (0.10)		
Week 40 Adjusted Mean Change (SE)	-0.53 (0.09)	-0.62 (0.11)		
Week 44 Adjusted Mean Change (SE)	-0.55 (0.09)	-0.65 (0.12)		
Week 48 Adjusted Mean Change (SE)	-0.58 (0.09)	-0.65 (0.11)		
Week 52 Adjusted Mean Change (SE)	-0.61 (0.09)	-0.70 (0.11)	0.09 [-0.19; 0.38]	0.524
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	1.40 (0.54)	1.31 (0.71)		
Week 52 Mean (SD)	0.75 (0.65)	0.71 (0.66)		
Week 2 Adjusted Mean Change (SE)	-0.17 (0.06)	-0.26 (0.05)		
Week 4 Adjusted Mean Change (SE)	-0.25 (0.07)	-0.27 (0.06)		
Week 8 Adjusted Mean Change (SE)	-0.35 (0.07)	-0.26 (0.06)		
Week 12 Adjusted Mean Change (SE)	-0.40 (0.09)	-0.33 (0.08)		
Week 16 Adjusted Mean Change (SE)	-0.45 (0.09)	-0.35 (0.08)		
Week 20 Adjusted Mean Change (SE)	-0.48 (0.09)	-0.37 (0.08)		
Week 24 Adjusted Mean Change (SE)	-0.52 (0.09)	-0.46 (0.08)		
Week 28 Adjusted Mean Change (SE)	-0.54 (0.09)	-0.45 (0.09)		
Week 32 Adjusted Mean Change (SE)	-0.54 (0.09)	-0.46 (0.08)		
Week 36 Adjusted Mean Change (SE)	-0.56 (0.08)	-0.47 (0.08)		
Week 40 Adjusted Mean Change (SE)	-0.55 (0.09)	-0.50 (0.08)		
Week 44 Adjusted Mean Change (SE)	-0.56 (0.09)	-0.59 (0.09)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.57 (0.09)	-0.54 (0.09)		
Week 52 Adjusted Mean Change (SE)	-0.60 (0.09)	-0.53 (0.09)	-0.07 [-0.32; 0.18]	0.566

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

6.7 HAQ-DI - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.252				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	1.47 (0.62)	1.29 (0.68)		
Week 52 Mean (SD)	0.85 (0.72)	0.62 (0.58)		
Week 2 Adjusted Mean Change (SE)	-0.21 (0.06)	-0.38 (0.07)		
Week 4 Adjusted Mean Change (SE)	-0.27 (0.08)	-0.50 (0.08)		
Week 8 Adjusted Mean Change (SE)	-0.37 (0.08)	-0.52 (0.08)		
Week 12 Adjusted Mean Change (SE)	-0.47 (0.10)	-0.61 (0.10)		
Week 16 Adjusted Mean Change (SE)	-0.46 (0.09)	-0.58 (0.10)		
Week 20 Adjusted Mean Change (SE)	-0.57 (0.09)	-0.62 (0.10)		
Week 24 Adjusted Mean Change (SE)	-0.55 (0.09)	-0.67 (0.10)		
Week 28 Adjusted Mean Change (SE)	-0.60 (0.10)	-0.60 (0.10)		
Week 32 Adjusted Mean Change (SE)	-0.58 (0.10)	-0.64 (0.10)		
Week 36 Adjusted Mean Change (SE)	-0.60 (0.09)	-0.72 (0.10)		
Week 40 Adjusted Mean Change (SE)	-0.58 (0.09)	-0.71 (0.10)		
Week 44 Adjusted Mean Change (SE)	-0.57 (0.10)	-0.82 (0.11)		
Week 48 Adjusted Mean Change (SE)	-0.59 (0.10)	-0.72 (0.10)		
Week 52 Adjusted Mean Change (SE)	-0.55 (0.10)	-0.79 (0.10)	0.24 [-0.04; 0.52]	0.097
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	1.12 (0.55)	1.28 (0.77)		
Week 52 Mean (SD)	0.55 (0.50)	0.71 (0.71)		
Week 2 Adjusted Mean Change (SE)	-0.16 (0.07)	-0.23 (0.08)		
Week 4 Adjusted Mean Change (SE)	-0.29 (0.09)	-0.26 (0.10)		
Week 8 Adjusted Mean Change (SE)	-0.30 (0.09)	-0.19 (0.10)		
Week 12 Adjusted Mean Change (SE)	-0.47 (0.11)	-0.32 (0.12)		
Week 16 Adjusted Mean Change (SE)	-0.42 (0.10)	-0.46 (0.11)		
Week 20 Adjusted Mean Change (SE)	-0.40 (0.11)	-0.43 (0.11)		
Week 24 Adjusted Mean Change (SE)	-0.43 (0.11)	-0.42 (0.12)		
Week 28 Adjusted Mean Change (SE)	-0.50 (0.11)	-0.47 (0.12)		
Week 32 Adjusted Mean Change (SE)	-0.54 (0.11)	-0.46 (0.12)		
Week 36 Adjusted Mean Change (SE)	-0.49 (0.10)	-0.48 (0.11)		
Week 40 Adjusted Mean Change (SE)	-0.52 (0.11)	-0.45 (0.12)		
Week 44 Adjusted Mean Change (SE)	-0.59 (0.11)	-0.40 (0.12)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 48 Adjusted Mean Change (SE)	-0.60 (0.11)	-0.42 (0.12)		
Week 52 Adjusted Mean Change (SE)	-0.62 (0.11)	-0.46 (0.12)	-0.17 [-0.49; 0.16]	0.315

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

6.8 HAQ-DI - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.461				
Non-carrier, N	28	19		
N'	28	19		
Baseline Mean (SD)	1.30 (0.58)	1.30 (0.65)		
Week 52 Mean (SD)	0.71 (0.66)	0.73 (0.56)		
Week 2 Adjusted Mean Change (SE)	-0.21 (0.07)	-0.23 (0.08)		
Week 4 Adjusted Mean Change (SE)	-0.33 (0.08)	-0.28 (0.10)		
Week 8 Adjusted Mean Change (SE)	-0.38 (0.08)	-0.31 (0.10)		
Week 12 Adjusted Mean Change (SE)	-0.53 (0.10)	-0.46 (0.13)		
Week 16 Adjusted Mean Change (SE)	-0.53 (0.09)	-0.46 (0.12)		
Week 20 Adjusted Mean Change (SE)	-0.59 (0.10)	-0.54 (0.12)		
Week 24 Adjusted Mean Change (SE)	-0.53 (0.10)	-0.56 (0.13)		
Week 28 Adjusted Mean Change (SE)	-0.56 (0.10)	-0.56 (0.13)		
Week 32 Adjusted Mean Change (SE)	-0.59 (0.10)	-0.56 (0.13)		
Week 36 Adjusted Mean Change (SE)	-0.53 (0.09)	-0.61 (0.12)		
Week 40 Adjusted Mean Change (SE)	-0.56 (0.10)	-0.56 (0.12)		
Week 44 Adjusted Mean Change (SE)	-0.62 (0.10)	-0.63 (0.13)		
Week 48 Adjusted Mean Change (SE)	-0.63 (0.10)	-0.53 (0.13)		
Week 52 Adjusted Mean Change (SE)	-0.60 (0.10)	-0.65 (0.13)	0.04 [-0.29; 0.38]	0.797
Carrier, N	22	19		
N'	22	19		
Baseline Mean (SD)	1.38 (0.64)	1.29 (0.74)		
Week 52 Mean (SD)	0.76 (0.65)	0.63 (0.71)		
Week 2 Adjusted Mean Change (SE)	-0.16 (0.08)	-0.40 (0.08)		
Week 4 Adjusted Mean Change (SE)	-0.23 (0.09)	-0.46 (0.10)		
Week 8 Adjusted Mean Change (SE)	-0.30 (0.09)	-0.38 (0.10)		
Week 12 Adjusted Mean Change (SE)	-0.41 (0.12)	-0.46 (0.12)		
Week 16 Adjusted Mean Change (SE)	-0.33 (0.10)	-0.62 (0.11)		
Week 20 Adjusted Mean Change (SE)	-0.40 (0.11)	-0.60 (0.12)		
Week 24 Adjusted Mean Change (SE)	-0.47 (0.11)	-0.58 (0.12)		
Week 28 Adjusted Mean Change (SE)	-0.56 (0.11)	-0.55 (0.12)		
Week 32 Adjusted Mean Change (SE)	-0.53 (0.11)	-0.55 (0.12)		
Week 36 Adjusted Mean Change (SE)	-0.59 (0.11)	-0.66 (0.11)		
Week 40 Adjusted Mean Change (SE)	-0.55 (0.11)	-0.62 (0.12)		
Week 44 Adjusted Mean Change (SE)	-0.54 (0.12)	-0.69 (0.13)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.56 (0.11)	-0.63 (0.12)		
Week 52 Adjusted Mean Change (SE)	-0.58 (0.12)	-0.69 (0.13)	0.11 [-0.23; 0.45]	0.523

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

6.9 HAQ-DI - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.731				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	1.41 (0.63)	1.29 (0.74)		
Week 52 Mean (SD)	0.82 (0.69)	0.71 (0.70)		
Week 2 Adjusted Mean Change (SE)	-0.19 (0.08)	-0.31 (0.08)		
Week 4 Adjusted Mean Change (SE)	-0.28 (0.10)	-0.35 (0.09)		
Week 8 Adjusted Mean Change (SE)	-0.34 (0.10)	-0.43 (0.10)		
Week 12 Adjusted Mean Change (SE)	-0.49 (0.12)	-0.56 (0.12)		
Week 16 Adjusted Mean Change (SE)	-0.40 (0.11)	-0.49 (0.11)		
Week 20 Adjusted Mean Change (SE)	-0.43 (0.12)	-0.53 (0.11)		
Week 24 Adjusted Mean Change (SE)	-0.45 (0.12)	-0.50 (0.12)		
Week 28 Adjusted Mean Change (SE)	-0.65 (0.12)	-0.46 (0.12)		
Week 32 Adjusted Mean Change (SE)	-0.56 (0.12)	-0.43 (0.12)		
Week 36 Adjusted Mean Change (SE)	-0.57 (0.11)	-0.59 (0.11)		
Week 40 Adjusted Mean Change (SE)	-0.53 (0.12)	-0.51 (0.11)		
Week 44 Adjusted Mean Change (SE)	-0.56 (0.12)	-0.56 (0.12)		
Week 48 Adjusted Mean Change (SE)	-0.54 (0.12)	-0.54 (0.12)		
Week 52 Adjusted Mean Change (SE)	-0.56 (0.12)	-0.59 (0.12)	0.03 [-0.31; 0.37]	0.841
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	1.28 (0.59)	1.28 (0.71)		
Week 52 Mean (SD)	0.68 (0.62)	0.63 (0.60)		
Week 2 Adjusted Mean Change (SE)	-0.17 (0.06)	-0.33 (0.07)		
Week 4 Adjusted Mean Change (SE)	-0.27 (0.08)	-0.44 (0.09)		
Week 8 Adjusted Mean Change (SE)	-0.33 (0.08)	-0.34 (0.09)		
Week 12 Adjusted Mean Change (SE)	-0.44 (0.10)	-0.44 (0.11)		
Week 16 Adjusted Mean Change (SE)	-0.46 (0.09)	-0.55 (0.10)		
Week 20 Adjusted Mean Change (SE)	-0.53 (0.09)	-0.55 (0.11)		
Week 24 Adjusted Mean Change (SE)	-0.52 (0.09)	-0.62 (0.11)		
Week 28 Adjusted Mean Change (SE)	-0.53 (0.09)	-0.62 (0.11)		
Week 32 Adjusted Mean Change (SE)	-0.57 (0.09)	-0.67 (0.11)		
Week 36 Adjusted Mean Change (SE)	-0.55 (0.09)	-0.65 (0.10)		
Week 40 Adjusted Mean Change (SE)	-0.57 (0.09)	-0.68 (0.11)		
Week 44 Adjusted Mean Change (SE)	-0.59 (0.10)	-0.71 (0.11)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.63 (0.10)	-0.64 (0.11)		
Week 52 Adjusted Mean Change (SE)	-0.60 (0.10)	-0.70 (0.11)	0.10 [-0.19; 0.40]	0.482

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

6.10 HAQ-DI - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.068				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	1.35 (0.52)	1.25 (0.71)		
Week 52 Mean (SD)	0.74 (0.73)	0.79 (0.64)		
Week 2 Adjusted Mean Change (SE)	-0.20 (0.07)	-0.26 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.35 (0.08)	-0.35 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.38 (0.09)	-0.38 (0.08)		
Week 12 Adjusted Mean Change (SE)	-0.50 (0.11)	-0.47 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.52 (0.09)	-0.44 (0.08)		
Week 20 Adjusted Mean Change (SE)	-0.60 (0.10)	-0.50 (0.09)		
Week 24 Adjusted Mean Change (SE)	-0.56 (0.10)	-0.47 (0.09)		
Week 28 Adjusted Mean Change (SE)	-0.56 (0.10)	-0.45 (0.09)		
Week 32 Adjusted Mean Change (SE)	-0.60 (0.10)	-0.46 (0.09)		
Week 36 Adjusted Mean Change (SE)	-0.56 (0.10)	-0.55 (0.09)		
Week 40 Adjusted Mean Change (SE)	-0.57 (0.10)	-0.51 (0.09)		
Week 44 Adjusted Mean Change (SE)	-0.63 (0.10)	-0.54 (0.09)		
Week 48 Adjusted Mean Change (SE)	-0.64 (0.10)	-0.50 (0.09)		
Week 52 Adjusted Mean Change (SE)	-0.61 (0.10)	-0.56 (0.09)	-0.04 [-0.32; 0.23]	0.752
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	1.30 (0.69)	1.40 (0.74)		
Week 52 Mean (SD)	0.70 (0.57)	0.29 (0.47)		
Week 2 Adjusted Mean Change (SE)	-0.17 (0.07)	-0.47 (0.10)		
Week 4 Adjusted Mean Change (SE)	-0.22 (0.08)	-0.51 (0.12)		
Week 8 Adjusted Mean Change (SE)	-0.30 (0.09)	-0.38 (0.13)		
Week 12 Adjusted Mean Change (SE)	-0.44 (0.10)	-0.54 (0.16)		
Week 16 Adjusted Mean Change (SE)	-0.37 (0.09)	-0.77 (0.14)		
Week 20 Adjusted Mean Change (SE)	-0.40 (0.10)	-0.67 (0.15)		
Week 24 Adjusted Mean Change (SE)	-0.44 (0.10)	-0.80 (0.15)		
Week 28 Adjusted Mean Change (SE)	-0.56 (0.10)	-0.78 (0.15)		
Week 32 Adjusted Mean Change (SE)	-0.52 (0.10)	-0.81 (0.15)		
Week 36 Adjusted Mean Change (SE)	-0.54 (0.09)	-0.81 (0.14)		
Week 40 Adjusted Mean Change (SE)	-0.53 (0.10)	-0.83 (0.15)		
Week 44 Adjusted Mean Change (SE)	-0.52 (0.10)	-0.93 (0.16)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.55 (0.10)	-0.84 (0.15)		
Week 52 Adjusted Mean Change (SE)	-0.56 (0.10)	-0.89 (0.16)	0.33 [-0.04; 0.70]	0.078

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

6.11 HAQ-DI - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.546				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	1.32 (0.63)	1.23 (0.72)		
Week 52 Mean (SD)	0.77 (0.62)	0.61 (0.58)		
Week 2 Adjusted Mean Change (SE)	-0.20 (0.05)	-0.28 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.28 (0.06)	-0.37 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.31 (0.07)	-0.36 (0.08)		
Week 12 Adjusted Mean Change (SE)	-0.43 (0.08)	-0.48 (0.08)		
Week 16 Adjusted Mean Change (SE)	-0.42 (0.08)	-0.50 (0.09)		
Week 20 Adjusted Mean Change (SE)	-0.47 (0.08)	-0.53 (0.09)		
Week 24 Adjusted Mean Change (SE)	-0.50 (0.08)	-0.58 (0.09)		
Week 28 Adjusted Mean Change (SE)	-0.50 (0.08)	-0.57 (0.09)		
Week 32 Adjusted Mean Change (SE)	-0.55 (0.08)	-0.62 (0.09)		
Week 36 Adjusted Mean Change (SE)	-0.53 (0.07)	-0.68 (0.08)		
Week 40 Adjusted Mean Change (SE)	-0.55 (0.08)	-0.63 (0.09)		
Week 44 Adjusted Mean Change (SE)	-0.55 (0.08)	-0.69 (0.09)		
Week 48 Adjusted Mean Change (SE)	-0.58 (0.08)	-0.59 (0.09)		
Week 52 Adjusted Mean Change (SE)	-0.53 (0.08)	-0.65 (0.09)	0.12 [-0.13; 0.37]	0.355
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	1.32 (0.58)	1.32 (0.71)		
Week 52 Mean (SD)	0.63 (0.74)	0.51 (0.56)		
Week 2 Adjusted Mean Change (SE)	-0.11 (0.10)	-0.56 (0.11)		
Week 4 Adjusted Mean Change (SE)	-0.23 (0.12)	-0.64 (0.13)		
Week 8 Adjusted Mean Change (SE)	-0.39 (0.12)	-0.57 (0.14)		
Week 12 Adjusted Mean Change (SE)	-0.53 (0.14)	-0.80 (0.16)		
Week 16 Adjusted Mean Change (SE)	-0.51 (0.14)	-0.68 (0.16)		
Week 20 Adjusted Mean Change (SE)	-0.55 (0.14)	-0.79 (0.16)		
Week 24 Adjusted Mean Change (SE)	-0.46 (0.14)	-0.74 (0.16)		
Week 28 Adjusted Mean Change (SE)	-0.65 (0.14)	-0.67 (0.16)		
Week 32 Adjusted Mean Change (SE)	-0.54 (0.14)	-0.61 (0.16)		
Week 36 Adjusted Mean Change (SE)	-0.59 (0.13)	-0.69 (0.15)		
Week 40 Adjusted Mean Change (SE)	-0.53 (0.14)	-0.72 (0.16)		
Week 44 Adjusted Mean Change (SE)	-0.62 (0.15)	-0.72 (0.17)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.61 (0.15)	-0.81 (0.17)		
Week 52 Adjusted Mean Change (SE)	-0.66 (0.15)	-0.79 (0.17)	0.13 [-0.32; 0.57]	0.577

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

6.12 HAQ-DI - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.608				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	1.32 (0.58)	1.21 (0.75)		
Week 52 Mean (SD)	0.74 (0.67)	0.61 (0.62)		
Week 2 Adjusted Mean Change (SE)	-0.16 (0.06)	-0.35 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.24 (0.07)	-0.47 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.36 (0.07)	-0.45 (0.07)		
Week 12 Adjusted Mean Change (SE)	-0.49 (0.08)	-0.55 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.45 (0.08)	-0.54 (0.08)		
Week 20 Adjusted Mean Change (SE)	-0.51 (0.08)	-0.56 (0.09)		
Week 24 Adjusted Mean Change (SE)	-0.48 (0.08)	-0.55 (0.09)		
Week 28 Adjusted Mean Change (SE)	-0.53 (0.08)	-0.58 (0.09)		
Week 32 Adjusted Mean Change (SE)	-0.53 (0.08)	-0.58 (0.09)		
Week 36 Adjusted Mean Change (SE)	-0.53 (0.08)	-0.67 (0.08)		
Week 40 Adjusted Mean Change (SE)	-0.53 (0.08)	-0.60 (0.09)		
Week 44 Adjusted Mean Change (SE)	-0.55 (0.09)	-0.65 (0.09)		
Week 48 Adjusted Mean Change (SE)	-0.58 (0.09)	-0.61 (0.09)		
Week 52 Adjusted Mean Change (SE)	-0.58 (0.09)	-0.64 (0.09)	0.06 [-0.19; 0.32]	0.630
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	1.21 (0.62)	1.54 (0.50)		
Week 52 Mean (SD)	0.66 (0.57)	0.79 (0.70)		
Week 2 Adjusted Mean Change (SE)	-0.19 (0.10)	-0.21 (0.11)		
Week 4 Adjusted Mean Change (SE)	-0.37 (0.11)	-0.15 (0.13)		
Week 8 Adjusted Mean Change (SE)	-0.24 (0.12)	-0.13 (0.13)		
Week 12 Adjusted Mean Change (SE)	-0.32 (0.14)	-0.26 (0.16)		
Week 16 Adjusted Mean Change (SE)	-0.33 (0.13)	-0.44 (0.15)		
Week 20 Adjusted Mean Change (SE)	-0.38 (0.14)	-0.45 (0.16)		
Week 24 Adjusted Mean Change (SE)	-0.47 (0.14)	-0.55 (0.16)		
Week 28 Adjusted Mean Change (SE)	-0.52 (0.14)	-0.37 (0.16)		
Week 32 Adjusted Mean Change (SE)	-0.51 (0.14)	-0.45 (0.16)		
Week 36 Adjusted Mean Change (SE)	-0.51 (0.13)	-0.44 (0.15)		
Week 40 Adjusted Mean Change (SE)	-0.48 (0.14)	-0.57 (0.16)		
Week 44 Adjusted Mean Change (SE)	-0.58 (0.15)	-0.58 (0.17)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.52 (0.14)	-0.47 (0.17)		
Week 52 Adjusted Mean Change (SE)	-0.49 (0.14)	-0.63 (0.17)	0.14 [-0.30; 0.58]	0.523

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

6.13 HAQ-DI - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.575				
Non-carrier, N	**42**	**36**		
N'	42	36		
Baseline Mean (SD)	1.29 (0.62)	1.36 (0.69)		
Week 52 Mean (SD)	0.69 (0.64)	0.70 (0.66)		
Week 2 Adjusted Mean Change (SE)	-0.20 (0.05)	-0.35 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.30 (0.06)	-0.41 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.35 (0.07)	-0.36 (0.07)		
Week 12 Adjusted Mean Change (SE)	-0.47 (0.08)	-0.47 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.43 (0.07)	-0.51 (0.08)		
Week 20 Adjusted Mean Change (SE)	-0.49 (0.08)	-0.56 (0.08)		
Week 24 Adjusted Mean Change (SE)	-0.50 (0.08)	-0.59 (0.09)		
Week 28 Adjusted Mean Change (SE)	-0.55 (0.08)	-0.53 (0.09)		
Week 32 Adjusted Mean Change (SE)	-0.56 (0.08)	-0.54 (0.09)		
Week 36 Adjusted Mean Change (SE)	-0.55 (0.07)	-0.62 (0.08)		
Week 40 Adjusted Mean Change (SE)	-0.56 (0.08)	-0.59 (0.09)		
Week 44 Adjusted Mean Change (SE)	-0.58 (0.08)	-0.65 (0.09)		
Week 48 Adjusted Mean Change (SE)	-0.60 (0.08)	-0.59 (0.09)		
Week 52 Adjusted Mean Change (SE)	-0.60 (0.08)	-0.66 (0.09)	0.06 [-0.18; 0.31]	0.600
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	1.47 (0.57)	0.83 (0.77)		
Week 52 Mean (SD)	0.86 (0.70)	0.50 (0.33)		
Week 2 Adjusted Mean Change (SE)	-0.13 (0.12)	-0.10 (0.16)		
Week 4 Adjusted Mean Change (SE)	-0.23 (0.14)	-0.13 (0.19)		
Week 8 Adjusted Mean Change (SE)	-0.30 (0.14)	-0.23 (0.19)		
Week 12 Adjusted Mean Change (SE)	-0.49 (0.17)	-0.33 (0.24)		
Week 16 Adjusted Mean Change (SE)	-0.49 (0.16)	-0.41 (0.22)		
Week 20 Adjusted Mean Change (SE)	-0.56 (0.17)	-0.32 (0.23)		
Week 24 Adjusted Mean Change (SE)	-0.50 (0.17)	-0.28 (0.23)		
Week 28 Adjusted Mean Change (SE)	-0.58 (0.17)	-0.46 (0.23)		
Week 32 Adjusted Mean Change (SE)	-0.54 (0.17)	-0.49 (0.24)		
Week 36 Adjusted Mean Change (SE)	-0.59 (0.16)	-0.50 (0.22)		
Week 40 Adjusted Mean Change (SE)	-0.53 (0.17)	-0.56 (0.23)		
Week 44 Adjusted Mean Change (SE)	-0.59 (0.18)	-0.50 (0.25)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.59 (0.18)	-0.52 (0.24)		
Week 52 Adjusted Mean Change (SE)	-0.53 (0.18)	-0.47 (0.25)	-0.07 [-0.68; 0.54]	0.822

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

6.14 HAQ-DI - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.358				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	1.26 (0.76)	1.22 (0.75)		
Week 52 Mean (SD)	0.74 (0.82)	0.81 (0.67)		
Week 2 Adjusted Mean Change (SE)	-0.31 (0.10)	-0.22 (0.07)		
Week 4 Adjusted Mean Change (SE)	-0.33 (0.13)	-0.32 (0.09)		
Week 8 Adjusted Mean Change (SE)	-0.35 (0.13)	-0.38 (0.09)		
Week 12 Adjusted Mean Change (SE)	-0.53 (0.16)	-0.49 (0.11)		
Week 16 Adjusted Mean Change (SE)	-0.48 (0.15)	-0.39 (0.11)		
Week 20 Adjusted Mean Change (SE)	-0.53 (0.15)	-0.47 (0.11)		
Week 24 Adjusted Mean Change (SE)	-0.50 (0.15)	-0.44 (0.11)		
Week 28 Adjusted Mean Change (SE)	-0.52 (0.15)	-0.46 (0.11)		
Week 32 Adjusted Mean Change (SE)	-0.52 (0.15)	-0.45 (0.11)		
Week 36 Adjusted Mean Change (SE)	-0.49 (0.14)	-0.57 (0.11)		
Week 40 Adjusted Mean Change (SE)	-0.50 (0.15)	-0.45 (0.11)		
Week 44 Adjusted Mean Change (SE)	-0.48 (0.16)	-0.48 (0.12)		
Week 48 Adjusted Mean Change (SE)	-0.49 (0.16)	-0.42 (0.12)		
Week 52 Adjusted Mean Change (SE)	-0.52 (0.16)	-0.50 (0.12)	-0.02 [-0.42; 0.37]	0.901
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	1.34 (0.57)	1.35 (0.68)		
Week 52 Mean (SD)	0.72 (0.60)	0.55 (0.60)		
Week 2 Adjusted Mean Change (SE)	-0.15 (0.05)	-0.41 (0.07)		
Week 4 Adjusted Mean Change (SE)	-0.27 (0.07)	-0.48 (0.09)		
Week 8 Adjusted Mean Change (SE)	-0.33 (0.07)	-0.39 (0.09)		
Week 12 Adjusted Mean Change (SE)	-0.45 (0.08)	-0.49 (0.11)		
Week 16 Adjusted Mean Change (SE)	-0.43 (0.08)	-0.66 (0.10)		
Week 20 Adjusted Mean Change (SE)	-0.49 (0.08)	-0.62 (0.11)		
Week 24 Adjusted Mean Change (SE)	-0.50 (0.08)	-0.68 (0.11)		
Week 28 Adjusted Mean Change (SE)	-0.57 (0.08)	-0.62 (0.11)		
Week 32 Adjusted Mean Change (SE)	-0.57 (0.08)	-0.66 (0.11)		
Week 36 Adjusted Mean Change (SE)	-0.57 (0.08)	-0.68 (0.10)		
Week 40 Adjusted Mean Change (SE)	-0.56 (0.08)	-0.73 (0.11)		
Week 44 Adjusted Mean Change (SE)	-0.60 (0.08)	-0.78 (0.11)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 48 Adjusted Mean Change (SE)	-0.62 (0.08)	-0.74 (0.11)		
Week 52 Adjusted Mean Change (SE)	-0.60 (0.08)	-0.78 (0.11)	0.18 [-0.09; 0.46]	0.189

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

6.15 HAQ-DI - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.662				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	1.28 (0.58)	1.30 (0.68)		
Week 52 Mean (SD)	0.74 (0.66)	0.70 (0.57)		
Week 2 Adjusted Mean Change (SE)	-0.21 (0.06)	-0.26 (0.07)		
Week 4 Adjusted Mean Change (SE)	-0.32 (0.07)	-0.32 (0.09)		
Week 8 Adjusted Mean Change (SE)	-0.35 (0.08)	-0.35 (0.09)		
Week 12 Adjusted Mean Change (SE)	-0.50 (0.09)	-0.49 (0.11)		
Week 16 Adjusted Mean Change (SE)	-0.49 (0.09)	-0.45 (0.10)		
Week 20 Adjusted Mean Change (SE)	-0.52 (0.09)	-0.52 (0.11)		
Week 24 Adjusted Mean Change (SE)	-0.49 (0.09)	-0.56 (0.11)		
Week 28 Adjusted Mean Change (SE)	-0.55 (0.09)	-0.54 (0.11)		
Week 32 Adjusted Mean Change (SE)	-0.57 (0.09)	-0.56 (0.11)		
Week 36 Adjusted Mean Change (SE)	-0.52 (0.09)	-0.60 (0.10)		
Week 40 Adjusted Mean Change (SE)	-0.54 (0.09)	-0.59 (0.11)		
Week 44 Adjusted Mean Change (SE)	-0.59 (0.10)	-0.62 (0.12)		
Week 48 Adjusted Mean Change (SE)	-0.60 (0.09)	-0.57 (0.11)		
Week 52 Adjusted Mean Change (SE)	-0.56 (0.09)	-0.64 (0.11)	0.08 [-0.22; 0.37]	0.607
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	1.38 (0.67)	1.27 (0.76)		
Week 52 Mean (SD)	0.69 (0.64)	0.63 (0.70)		
Week 2 Adjusted Mean Change (SE)	-0.16 (0.08)	-0.38 (0.08)		
Week 4 Adjusted Mean Change (SE)	-0.22 (0.09)	-0.48 (0.09)		
Week 8 Adjusted Mean Change (SE)	-0.32 (0.10)	-0.42 (0.09)		
Week 12 Adjusted Mean Change (SE)	-0.42 (0.12)	-0.49 (0.11)		
Week 16 Adjusted Mean Change (SE)	-0.36 (0.11)	-0.61 (0.10)		
Week 20 Adjusted Mean Change (SE)	-0.47 (0.11)	-0.57 (0.11)		
Week 24 Adjusted Mean Change (SE)	-0.51 (0.11)	-0.57 (0.11)		
Week 28 Adjusted Mean Change (SE)	-0.56 (0.12)	-0.55 (0.11)		
Week 32 Adjusted Mean Change (SE)	-0.54 (0.12)	-0.56 (0.11)		
Week 36 Adjusted Mean Change (SE)	-0.60 (0.11)	-0.65 (0.10)		
Week 40 Adjusted Mean Change (SE)	-0.57 (0.11)	-0.61 (0.11)		
Week 44 Adjusted Mean Change (SE)	-0.56 (0.12)	-0.67 (0.12)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.58 (0.12)	-0.61 (0.11)		
Week 52 Adjusted Mean Change (SE)	-0.62 (0.12)	-0.67 (0.11)	0.05 [-0.28; 0.38]	0.765

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

6.16 HAQ-DI - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.962				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	1.41 (0.63)	1.30 (0.75)		
Week 52 Mean (SD)	0.82 (0.69)	0.70 (0.72)		
Week 2 Adjusted Mean Change (SE)	-0.19 (0.08)	-0.37 (0.08)		
Week 4 Adjusted Mean Change (SE)	-0.28 (0.10)	-0.41 (0.09)		
Week 8 Adjusted Mean Change (SE)	-0.34 (0.10)	-0.47 (0.10)		
Week 12 Adjusted Mean Change (SE)	-0.49 (0.12)	-0.60 (0.12)		
Week 16 Adjusted Mean Change (SE)	-0.40 (0.11)	-0.53 (0.11)		
Week 20 Adjusted Mean Change (SE)	-0.43 (0.11)	-0.59 (0.11)		
Week 24 Adjusted Mean Change (SE)	-0.45 (0.12)	-0.56 (0.12)		
Week 28 Adjusted Mean Change (SE)	-0.64 (0.12)	-0.48 (0.12)		
Week 32 Adjusted Mean Change (SE)	-0.55 (0.12)	-0.43 (0.12)		
Week 36 Adjusted Mean Change (SE)	-0.57 (0.11)	-0.61 (0.11)		
Week 40 Adjusted Mean Change (SE)	-0.53 (0.11)	-0.51 (0.12)		
Week 44 Adjusted Mean Change (SE)	-0.56 (0.12)	-0.57 (0.13)		
Week 48 Adjusted Mean Change (SE)	-0.53 (0.12)	-0.55 (0.12)		
Week 52 Adjusted Mean Change (SE)	-0.56 (0.12)	-0.60 (0.12)	0.04 [-0.30; 0.38]	0.817
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	1.27 (0.60)	1.28 (0.69)		
Week 52 Mean (SD)	0.65 (0.62)	0.64 (0.59)		
Week 2 Adjusted Mean Change (SE)	-0.19 (0.06)	-0.27 (0.07)		
Week 4 Adjusted Mean Change (SE)	-0.29 (0.07)	-0.39 (0.09)		
Week 8 Adjusted Mean Change (SE)	-0.34 (0.08)	-0.31 (0.09)		
Week 12 Adjusted Mean Change (SE)	-0.46 (0.09)	-0.41 (0.11)		
Week 16 Adjusted Mean Change (SE)	-0.47 (0.09)	-0.52 (0.10)		
Week 20 Adjusted Mean Change (SE)	-0.54 (0.09)	-0.50 (0.10)		
Week 24 Adjusted Mean Change (SE)	-0.53 (0.09)	-0.55 (0.10)		
Week 28 Adjusted Mean Change (SE)	-0.51 (0.09)	-0.58 (0.11)		
Week 32 Adjusted Mean Change (SE)	-0.56 (0.09)	-0.64 (0.11)		
Week 36 Adjusted Mean Change (SE)	-0.55 (0.09)	-0.63 (0.10)		
Week 40 Adjusted Mean Change (SE)	-0.57 (0.09)	-0.66 (0.10)		
Week 44 Adjusted Mean Change (SE)	-0.59 (0.09)	-0.69 (0.11)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.63 (0.09)	-0.62 (0.11)		
Week 52 Adjusted Mean Change (SE)	-0.60 (0.09)	-0.68 (0.11)	0.08 [-0.20; 0.37]	0.554

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

6.17 HAQ-DI - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.068				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	1.35 (0.52)	1.25 (0.71)		
Week 52 Mean (SD)	0.74 (0.73)	0.79 (0.64)		
Week 2 Adjusted Mean Change (SE)	-0.20 (0.07)	-0.26 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.35 (0.08)	-0.35 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.38 (0.09)	-0.38 (0.08)		
Week 12 Adjusted Mean Change (SE)	-0.50 (0.11)	-0.47 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.52 (0.09)	-0.44 (0.08)		
Week 20 Adjusted Mean Change (SE)	-0.60 (0.10)	-0.50 (0.09)		
Week 24 Adjusted Mean Change (SE)	-0.56 (0.10)	-0.47 (0.09)		
Week 28 Adjusted Mean Change (SE)	-0.56 (0.10)	-0.45 (0.09)		
Week 32 Adjusted Mean Change (SE)	-0.60 (0.10)	-0.46 (0.09)		
Week 36 Adjusted Mean Change (SE)	-0.56 (0.10)	-0.55 (0.09)		
Week 40 Adjusted Mean Change (SE)	-0.57 (0.10)	-0.51 (0.09)		
Week 44 Adjusted Mean Change (SE)	-0.63 (0.10)	-0.54 (0.09)		
Week 48 Adjusted Mean Change (SE)	-0.64 (0.10)	-0.50 (0.09)		
Week 52 Adjusted Mean Change (SE)	-0.61 (0.10)	-0.56 (0.09)	-0.04 [-0.32; 0.23]	0.752
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	1.30 (0.69)	1.40 (0.74)		
Week 52 Mean (SD)	0.70 (0.57)	0.29 (0.47)		
Week 2 Adjusted Mean Change (SE)	-0.17 (0.07)	-0.47 (0.10)		
Week 4 Adjusted Mean Change (SE)	-0.22 (0.08)	-0.51 (0.12)		
Week 8 Adjusted Mean Change (SE)	-0.30 (0.09)	-0.38 (0.13)		
Week 12 Adjusted Mean Change (SE)	-0.44 (0.10)	-0.54 (0.16)		
Week 16 Adjusted Mean Change (SE)	-0.37 (0.09)	-0.77 (0.14)		
Week 20 Adjusted Mean Change (SE)	-0.40 (0.10)	-0.67 (0.15)		
Week 24 Adjusted Mean Change (SE)	-0.44 (0.10)	-0.80 (0.15)		
Week 28 Adjusted Mean Change (SE)	-0.56 (0.10)	-0.78 (0.15)		
Week 32 Adjusted Mean Change (SE)	-0.52 (0.10)	-0.81 (0.15)		
Week 36 Adjusted Mean Change (SE)	-0.54 (0.09)	-0.81 (0.14)		
Week 40 Adjusted Mean Change (SE)	-0.53 (0.10)	-0.83 (0.15)		
Week 44 Adjusted Mean Change (SE)	-0.52 (0.10)	-0.93 (0.16)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.55 (0.10)	-0.84 (0.15)		
Week 52 Adjusted Mean Change (SE)	-0.56 (0.10)	-0.89 (0.16)	0.33 [-0.04; 0.70]	0.078

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

6.18 HAQ-DI - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.849				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	1.32 (0.62)	1.27 (0.72)		
Week 52 Mean (SD)	0.75 (0.62)	0.67 (0.61)		
Week 2 Adjusted Mean Change (SE)	-0.21 (0.06)	-0.28 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.30 (0.07)	-0.36 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.32 (0.07)	-0.35 (0.07)		
Week 12 Adjusted Mean Change (SE)	-0.45 (0.08)	-0.46 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.42 (0.08)	-0.50 (0.08)		
Week 20 Adjusted Mean Change (SE)	-0.48 (0.08)	-0.50 (0.09)		
Week 24 Adjusted Mean Change (SE)	-0.51 (0.08)	-0.54 (0.09)		
Week 28 Adjusted Mean Change (SE)	-0.52 (0.08)	-0.53 (0.09)		
Week 32 Adjusted Mean Change (SE)	-0.56 (0.08)	-0.56 (0.09)		
Week 36 Adjusted Mean Change (SE)	-0.54 (0.08)	-0.64 (0.08)		
Week 40 Adjusted Mean Change (SE)	-0.56 (0.08)	-0.58 (0.09)		
Week 44 Adjusted Mean Change (SE)	-0.56 (0.09)	-0.64 (0.09)		
Week 48 Adjusted Mean Change (SE)	-0.58 (0.08)	-0.56 (0.09)		
Week 52 Adjusted Mean Change (SE)	-0.55 (0.08)	-0.64 (0.09)	0.09 [-0.16; 0.33]	0.491
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	1.30 (0.61)	1.35 (0.73)		
Week 52 Mean (SD)	0.59 (0.77)	0.64 (0.75)		
Week 2 Adjusted Mean Change (SE)	-0.15 (0.10)	-0.47 (0.11)		
Week 4 Adjusted Mean Change (SE)	-0.28 (0.13)	-0.53 (0.14)		
Week 8 Adjusted Mean Change (SE)	-0.35 (0.13)	-0.48 (0.14)		
Week 12 Adjusted Mean Change (SE)	-0.49 (0.16)	-0.59 (0.17)		
Week 16 Adjusted Mean Change (SE)	-0.53 (0.15)	-0.63 (0.16)		
Week 20 Adjusted Mean Change (SE)	-0.55 (0.15)	-0.69 (0.17)		
Week 24 Adjusted Mean Change (SE)	-0.48 (0.15)	-0.62 (0.17)		
Week 28 Adjusted Mean Change (SE)	-0.70 (0.15)	-0.59 (0.17)		
Week 32 Adjusted Mean Change (SE)	-0.56 (0.16)	-0.54 (0.17)		
Week 36 Adjusted Mean Change (SE)	-0.65 (0.14)	-0.58 (0.16)		
Week 40 Adjusted Mean Change (SE)	-0.56 (0.15)	-0.66 (0.17)		
Week 44 Adjusted Mean Change (SE)	-0.65 (0.16)	-0.64 (0.18)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.63 (0.16)	-0.72 (0.18)		
Week 52 Adjusted Mean Change (SE)	-0.69 (0.16)	-0.69 (0.17)	0.00 [-0.46; 0.46]	0.999

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

7.1 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	62 40.62 (61.55)	46 39.63 (63.92)	0.91 [0.42; 1.95] 0.806	0.96 [0.73; 1.27] 0.788	-0.024 [-0.195; 0.148] 0.786

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.
RR and RD calculated directly without adjustment.

All results are combined over MI:
n and % are averages of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

7.2 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
HAQ-DI Response (≥ 0.3) Week 52	p=0.658				
Male (N)	**42**	**33**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	39 25.62 (61.00)	24 20.21 (61.24)	1.04 [0.39; 2.82] 0.933	1.00 [0.69; 1.45] 0.985	-0.002 [-0.230; 0.225] 0.983
Female (N)	**24**	**29**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	23 15.00 (62.50)	22 19.42 (66.97)	0.73 [0.22; 2.46] 0.614	0.93 [0.62; 1.41] 0.747	-0.045 [-0.310; 0.221] 0.742

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

7.3 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
HAQ-DI Response (≥ 0.3) Week 52	p=0.027				
PASDAS < 5.4 (N)	**16**	**13**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	16 9.00 (56.25)	8 3.00 (23.08)	5.16 [0.93; 28.69] 0.061	2.44 [0.83; 7.20] 0.107	0.332 [-0.002; 0.666] 0.052
PASDAS ≥ 5.4 (N)	**50**	**49**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	46 31.62 (63.24)	38 36.63 (74.76)	0.57 [0.22; 1.44] 0.234	0.85 [0.64; 1.11] 0.235	-0.115 [-0.302; 0.072] 0.227

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) HAQ-DI Response (>= 0.3), all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

7.4 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
HAQ-DI Response (≥ 0.3) Week 52	p=0.678				
Moderate/Severe Psoriasis (Def D): No (N)	**28**	**32**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	26 15.77 (56.32)	22 19.52 (61.00)	0.74 [0.24; 2.26] 0.602	0.92 [0.59; 1.44] 0.726	-0.047 [-0.304; 0.211] 0.722
Moderate/Severe Psoriasis (Def D): Yes (N)	**38**	**30**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	36 24.85 (65.39)	24 20.11 (67.03)	1.03 [0.36; 3.00] 0.954	0.98 [0.69; 1.38] 0.891	-0.016 [-0.247; 0.214] 0.889

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

7.5 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
HAQ-DI Response (≥ 0.3) Week 52	p=0.831				
≤ Median (N)	**40**	**29**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	38 23.70 (59.25)	19 18.73 (64.59)	0.85 [0.29; 2.52] 0.774	0.92 [0.62; 1.36] 0.669	-0.053 [-0.295; 0.188] 0.665
> Median (N)	**26**	**33**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	24 16.92 (65.08)	27 20.90 (63.33)	1.01 [0.33; 3.13] 0.982	1.03 [0.69; 1.52] 0.890	0.017 [-0.234; 0.269] 0.892

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

7.6 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
HAQ-DI Response (≥ 0.3) Week 52	p=0.182				
Enthesitis: No (N)	**34**	**22**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	31 20.69 (60.85)	18 16.88 (76.73)	0.43 [0.12; 1.52] 0.190	0.79 [0.55; 1.14] 0.208	-0.159 [-0.403; 0.086] 0.204
Enthesitis: Yes (N)	**32**	**40**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	31 19.93 (62.28)	28 22.75 (56.88)	1.30 [0.47; 3.58] 0.616	1.10 [0.74; 1.62] 0.647	0.054 [-0.179; 0.287] 0.650

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

7.7 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
HAQ-DI Response (≥ 0.3) Week 52	p=0.896				
Non-carrier (N)	**29**	**25**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	27 19.92 (68.69)	19 19.00 (76.00)	0.66 [0.18; 2.42] 0.533	0.90 [0.65; 1.26] 0.549	-0.073 [-0.312; 0.165] 0.548
Carrier (N)	**22**	**19**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	20 10.70 (48.64)	16 10.54 (55.47)	0.75 [0.19; 2.90] 0.676	0.88 [0.48; 1.62] 0.677	-0.068 [-0.385; 0.248] 0.672

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

7.8 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
HAQ-DI Response (≥ 0.3) Week 52	p=0.947				
Non-carrier (N)	**28**	**19**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	27 17.77 (63.46)	13 13.30 (70.00)	0.79 [0.20; 3.10] 0.730	0.91 [0.60; 1.38] 0.649	-0.065 [-0.345; 0.215] 0.647
Carrier (N)	**22**	**19**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	19 12.85 (58.41)	17 12.24 (64.42)	0.74 [0.19; 2.87] 0.658	0.91 [0.55; 1.49] 0.698	-0.060 [-0.363; 0.243] 0.697

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

7.9 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
HAQ-DI Response (≥ 0.3) Week 52	p=0.306				
Non-carrier (N)	**19**	**21**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	19 12.00 (63.16)	15 12.54 (59.71)	1.18 [0.29; 4.79] 0.812	1.06 [0.64; 1.76] 0.823	0.034 [-0.275; 0.344] 0.827
Carrier (N)	**30**	**23**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	27 16.69 (55.63)	20 17.00 (73.91)	0.45 [0.13; 1.54] 0.202	0.75 [0.50; 1.13] 0.170	-0.183 [-0.438; 0.072] 0.160

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

7.10 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
HAQ-DI Response (≥ 0.3) Week 52	p=0.207				
Non-carrier (N)	**25**	**32**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	23 15.93 (63.72)	26 19.24 (60.13)	1.02 [0.32; 3.28] 0.970	1.06 [0.70; 1.60] 0.782	0.036 [-0.219; 0.291] 0.783
Carrier (N)	**26**	**12**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	24 14.69 (56.50)	9 10.30 (85.83)	0.21 [0.03; 1.81] 0.157	0.66 [0.43; 1.01] 0.057	-0.293 [-0.584; -0.003] 0.048

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

7.11 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
HAQ-DI Response (≥ 0.3) Week 52	p=0.242				
Non-carrier (N)	**38**	**33**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	34 21.62 (56.89)	24 21.54 (65.27)	0.77 [0.27; 2.21] 0.633	0.87 [0.60; 1.28] 0.481	-0.084 [-0.316; 0.148] 0.479
Carrier (N)	**12**	**9**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	12 8.00 (66.67)	9 8.00 (88.89)	0.15 [0.01; 1.89] 0.143	0.75 [0.47; 1.19] 0.222	-0.222 [-0.559; 0.114] 0.196

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) HAQ-DI Response (>= 0.3), all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

7.12 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
HAQ-DI Response (≥ 0.3) Week 52	p=0.303				
Non-carrier (N)	**36**	**34**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	33 22.70 (63.06)	25 21.54 (63.35)	0.88 [0.31; 2.50] 0.809	1.00 [0.69; 1.44] 0.981	-0.003 [-0.234; 0.228] 0.980
Carrier (N)	**13**	**10**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	12 5.92 (45.54)	10 8.00 (80.00)	0.27 [0.04; 2.00] 0.198	0.57 [0.29; 1.12] 0.103	-0.345 [-0.714; 0.025] 0.067

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

7.13 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) by Lead Candidate Variant rs7349145 (FAS)

| | Treatment Groups | | Comparison | | |
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
HAQ-DI Response (≥ 0.3) Week 52	p=0.180				
Non-carrier (N)	**42**	**36**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	38 25.62 (61.00)	29 25.54 (70.94)	0.65 [0.23; 1.85] 0.416	0.86 [0.62; 1.19] 0.367	-0.099 [-0.314; 0.115] 0.363
Carrier (N)	**9**	**5**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	9 5.00 (55.56)	3 1.00 (20.00)	4.35 [0.33; 57.77] 0.265	2.78 [0.44; 17.63] 0.279	0.356 [-0.122; 0.833] 0.145

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) HAQ-DI Response (>= 0.3), all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

7.14 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
HAQ-DI Response (≥ 0.3) Week 52	p=0.361				
Low score (N)	**11**	**22**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	10 6.93 (63.00)	15 12.54 (57.00)	1.18 [0.24; 5.82] 0.835	1.11 [0.61; 2.01] 0.740	0.060 [-0.301; 0.421] 0.744
High score (N)	**40**	**22**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	37 23.69 (59.23)	20 17.00 (77.27)	0.46 [0.13; 1.59] 0.222	0.77 [0.54; 1.08] 0.131	-0.180 [-0.414; 0.053] 0.130

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

7.15 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
HAQ-DI Response (≥ 0.3) Week 52	p=0.675				
Non-carrier (N)	**31**	**23**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	30 17.77 (57.32)	16 16.30 (70.87)	0.60 [0.17; 2.10] 0.420	0.81 [0.54; 1.22] 0.311	-0.135 [-0.396; 0.125] 0.308
Carrier (N)	**20**	**21**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	17 12.85 (64.25)	19 13.24 (63.05)	0.89 [0.23; 3.43] 0.860	1.02 [0.64; 1.63] 0.938	0.012 [-0.288; 0.312] 0.937

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

7.16 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
HAQ-DI Response (≥ 0.3) Week 52	p=0.519				
Non-carrier (N)	**19**	**20**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	19 12.00 (63.16)	14 12.54 (62.70)	1.04 [0.25; 4.36] 0.958	1.01 [0.61; 1.66] 0.972	0.005 [-0.307; 0.316] 0.977
Carrier (N)	**32**	**24**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	28 18.62 (58.19)	21 17.00 (70.83)	0.56 [0.17; 1.85] 0.344	0.82 [0.55; 1.22] 0.329	-0.126 [-0.379; 0.126] 0.326

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

7.17 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
HAQ-DI Response (≥ 0.3) Week 52	p=0.207				
Non-carrier (N)	**25**	**32**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	23 15.93 (63.72)	26 19.24 (60.13)	1.02 [0.32; 3.28] 0.970	1.06 [0.70; 1.60] 0.782	0.036 [-0.219; 0.291] 0.783
Carrier (N)	**26**	**12**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	24 14.69 (56.50)	9 10.30 (85.83)	0.21 [0.03; 1.81] 0.157	0.66 [0.43; 1.01] 0.057	-0.293 [-0.584; -0.003] 0.048

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

7.18 HAQ-DI Response (≥ 0.3) / HAQ-DI Response (≥ 0.35) by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
HAQ-DI Response (≥ 0.3) Week 52	p=0.447				
Non-carrier (N)	**39**	**35**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	35 22.62 (58.00)	26 22.54 (64.40)	0.84 [0.30; 2.32] 0.733	0.90 [0.62; 1.31] 0.582	-0.064 [-0.291; 0.163] 0.580
Carrier (N)	**11**	**9**			
HAQ-DI Response (≥ 0.3) Week 52, N' n (%)	11 7.00 (63.64)	9 7.00 (77.78)	0.34 [0.04; 2.80] 0.313	0.82 [0.46; 1.44] 0.488	-0.141 [-0.535; 0.252] 0.481

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) HAQ-DI Response (>= 0.3), all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

Note: HAQ-DI Response (≥ 0.3) is identical to HAQ-DI Response (≥ 0.35) as HAQ-DI can take only a limited number of values.

8.0 LDI Leeds Dactylitis Index - Return Rates (FAS)

	Treatment Groups		
	SEC **(N=66)**	**ADA** **(N=62)**	**Total** **(N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	65 (98.5)	61 (98.4)	126 (98.4)
Week 4 Returns	66 (100.0)	59 (95.2)	125 (97.7)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	55 (88.7)	120 (93.8)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	49 (79.0)	112 (87.5)

8.1 LDI Leeds Dactylitis Index - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	61		
Baseline Mean (SD)	18.94 (59.07)	19.45 (64.90)		
Week 52 Mean (SD)	0.33 (2.61)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-19.96 (2.82)	-19.09 (3.14)	-0.87 [-9.16; 7.42]	0.837

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: compound symmetry (cs)

8.1 LDI Leeds Dactylitis Index - Change from Baseline (FAS)

8.2 LDI Leeds Dactylitis Index - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.806				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	20.58 (64.59)	7.44 (15.61)		
Week 52 Mean (SD)	0.52 (3.28)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-19.93 (3.57)	-19.50 (4.34)	-0.43 [-11.45; 10.60]	0.940
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	16.07 (49.11)	33.11 (92.38)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-20.02 (4.72)	-18.63 (4.64)	-1.39 [-14.37; 11.60]	0.834

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

8.3 LDI Leeds Dactylitis Index - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.475				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	1.27 (5.09)	1.54 (5.55)		
Week 52 Mean (SD)	1.30 (5.18)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-18.83 (5.71)	-18.46 (7.27)	-0.37 [-18.42; 17.69]	0.968
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	24.59 (66.98)	24.20 (72.35)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-20.34 (3.28)	-19.43 (3.52)	-0.91 [-10.35; 8.52]	0.849

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

8.3 LDI Leeds Dactylitis Index - Change from Baseline by Disease Severity (FAS)

8.4 LDI Leeds Dactylitis Index - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.517				
Moderate/Severe Psoriasis (Def D): No, N	28	32		
N'	28	32		
Baseline Mean (SD)	7.05 (18.11)	21.02 (65.67)		
Week 52 Mean (SD)	0.80 (4.07)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-19.92 (4.42)	-17.91 (4.55)	-2.01 [-14.49; 10.46]	0.751
Moderate/Severe Psoriasis (Def D): Yes, N	38	30		
N'	38	29		
Baseline Mean (SD)	27.69 (75.53)	17.77 (65.14)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-20.03 (3.72)	-19.92 (4.38)	-0.11 [-11.40; 11.18]	0.985

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

8.5 LDI Leeds Dactylitis Index - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.641				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	26.42 (73.59)	17.32 (65.91)		
Week 52 Mean (SD)	0.55 (3.36)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-19.91 (3.65)	-19.26 (4.75)	-0.66 [-12.42; 11.11]	0.913
> Median, N	**26**	**33**		
N'	26	32		
Baseline Mean (SD)	7.43 (19.95)	21.31 (64.96)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-20.05 (4.52)	-19.38 (4.22)	-0.67 [-12.83; 11.49]	0.914

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

8.6 LDI Leeds Dactylitis Index - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.530				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	7.70 (19.10)	27.91 (82.14)		
Week 52 Mean (SD)	0.65 (3.66)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-19.85 (4.00)	-19.20 (5.15)	-0.65 [-13.48; 12.17]	0.920
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	30.87 (81.51)	14.79 (53.78)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-20.04 (4.08)	-18.95 (4.02)	-1.09 [-12.33; 10.14]	0.848

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

8.7 LDI Leeds Dactylitis Index - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.497				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	5.96 (18.84)	23.95 (73.13)		
Week 52 Mean (SD)	0.74 (3.92)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-12.49 (2.25)	-13.03 (2.54)	0.54 [-6.16; 7.25]	0.873
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	15.75 (42.85)	5.41 (13.55)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-13.27 (2.64)	-13.08 (2.95)	-0.20 [-7.98; 7.58]	0.960

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

8.7 LDI Leeds Dactylitis Index - Change from Baseline by HLA-DQA1*05 (FAS)

8.8 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.672				
Non-carrier, N	28	19		
N'	28	19		
Baseline Mean (SD)	8.05 (19.08)	18.46 (75.12)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-13.94 (2.36)	-13.64 (3.23)	-0.30 [-8.18; 7.58]	0.941
Carrier, N	22	19		
N'	22	19		
Baseline Mean (SD)	13.37 (43.32)	16.02 (41.81)		
Week 52 Mean (SD)	1.04 (4.64)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-12.64 (2.72)	-13.66 (2.88)	1.02 [-6.75; 8.79]	0.797

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

8.9 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.176				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	18.65 (47.97)	2.98 (9.81)		
Week 52 Mean (SD)	1.09 (4.76)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-12.33 (2.76)	-13.23 (2.96)	0.90 [-7.07; 8.86]	0.825
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	5.50 (14.44)	27.78 (75.89)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-13.54 (2.27)	-13.36 (2.59)	-0.19 [-7.01; 6.63]	0.957

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

8.10 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.849				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	7.63 (18.61)	4.03 (11.56)		
Week 52 Mean (SD)	0.90 (4.32)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-12.24 (2.48)	-13.04 (2.25)	0.80 [-5.77; 7.36]	0.812
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	12.65 (40.52)	47.72 (102.05)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-13.40 (2.39)	-13.22 (3.96)	-0.18 [-9.28; 8.93]	0.970

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

8.11 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.543				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	8.05 (19.75)	19.26 (64.21)		
Week 52 Mean (SD)	0.59 (3.50)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-13.02 (2.03)	-13.30 (2.31)	0.28 [-5.79; 6.35]	0.928
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	16.18 (56.06)	7.33 (15.44)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-13.31 (3.50)	-13.36 (4.02)	0.05 [-10.41; 10.50]	0.993

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

8.12 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.390				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	13.54 (36.79)	10.41 (32.55)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-13.62 (2.07)	-13.29 (2.24)	-0.33 [-6.32; 5.66]	0.915
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	2.46 (8.86)	34.74 (103.19)		
Week 52 Mean (SD)	1.59 (5.75)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-11.90 (3.34)	-13.19 (3.85)	1.29 [-8.81; 11.39]	0.802

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

8.13 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.891				
Non-carrier, N	**42**	**36**		
N'	42	36		
Baseline Mean (SD)	8.59 (32.44)	15.34 (61.43)		
Week 52 Mean (SD)	0.53 (3.32)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-12.32 (1.93)	-12.57 (2.19)	0.26 [-5.49; 6.00]	0.930
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	17.63 (27.27)	13.19 (20.41)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-12.55 (4.04)	-12.62 (5.41)	0.07 [-13.17; 13.32]	0.991

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

8.14 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.029				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	8.39 (22.21)	2.86 (9.62)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-13.69 (3.65)	-13.00 (2.87)	-0.70 [-9.79; 8.40]	0.880
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	10.68 (33.86)	29.03 (77.42)		
Week 52 Mean (SD)	0.55 (3.36)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-12.69 (1.88)	-13.05 (2.52)	0.37 [-5.82; 6.56]	0.907

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

8.15 LDI Leeds Dactylitis Index - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.943				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	13.54 (38.15)	17.27 (68.54)		
Week 52 Mean (SD)	0.69 (3.79)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-12.66 (2.18)	-13.06 (2.79)	0.40 [-6.56; 7.36]	0.910
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	4.99 (16.43)	14.49 (39.96)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-13.16 (2.81)	-13.14 (2.67)	-0.02 [-7.63; 7.59]	0.996

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

8.16 LDI Leeds Dactylitis Index - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.176				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	18.65 (47.97)	3.13 (10.04)		
Week 52 Mean (SD)	1.09 (4.76)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-12.07 (2.73)	-12.94 (3.03)	0.88 [-7.14; 8.89]	0.830
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	5.16 (14.03)	26.62 (74.43)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-13.27 (2.20)	-13.10 (2.50)	-0.17 [-6.77; 6.43]	0.960

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

8.17 LDI Leeds Dactylitis Index - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC **(N=66)**	**ADA** **(N=62)**	**Mean Difference** **[95% CI]**	**p-value**
Interaction test: p=0.849				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	7.63 (18.61)	4.03 (11.56)		
Week 52 Mean (SD)	0.90 (4.32)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-12.24 (2.48)	-13.04 (2.25)	0.80 [-5.77; 7.36]	0.812
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	12.65 (40.52)	47.72 (102.05)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-13.40 (2.39)	-13.22 (3.96)	-0.18 [-9.28; 8.93]	0.970

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

8.18 LDI Leeds Dactylitis Index - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.480				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	8.34 (19.57)	18.16 (62.45)		
Week 52 Mean (SD)	0.58 (3.46)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-12.97 (1.99)	-13.23 (2.21)	0.25 [-5.60; 6.11]	0.932
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	17.65 (58.55)	7.33 (15.44)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-13.24 (3.62)	-13.29 (3.99)	0.05 [-10.52; 10.62]	0.993

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

9.0 LDI Dactylitis Count - Return Rates (FAS)

	Treatment Groups		
	SEC **(N=66)**	**ADA** **(N=62)**	**Total** **(N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	65 (98.5)	61 (98.4)	126 (98.4)
Week 4 Returns	66 (100.0)	59 (95.2)	125 (97.7)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	55 (88.7)	120 (93.8)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	49 (79.0)	112 (87.5)

9.1 LDI Dactylitis Count - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N'	66	61		
Baseline Mean (SD)	1.20 (2.45)	1.21 (2.66)		
Week 52 Mean (SD)	0.05 (0.28)	0.04 (0.29)		
Week 52 Adjusted Mean Change (SE)	-1.21 (0.03)	-1.20 (0.04)	-0.01 [-0.11; 0.09]	0.828

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

9.2 LDI Dactylitis Count - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.225				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	1.17 (2.38)	1.24 (2.33)		
Week 52 Mean (SD)	0.08 (0.35)	0.08 (0.39)		
Week 52 Adjusted Mean Change (SE)	-1.19 (0.04)	-1.18 (0.05)	-0.01 [-0.15; 0.12]	0.871
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	1.25 (2.63)	1.17 (3.04)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.24 (0.06)	-1.22 (0.06)	-0.02 [-0.18; 0.14]	0.779

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

9.3 LDI Dactylitis Count - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.992				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	0.25 (0.77)	0.46 (1.13)		
Week 52 Mean (SD)	0.06 (0.25)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.17 (0.07)	-1.15 (0.09)	-0.03 [-0.25; 0.19]	0.798
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	1.50 (2.72)	1.41 (2.91)		
Week 52 Mean (SD)	0.04 (0.29)	0.05 (0.32)		
Week 52 Adjusted Mean Change (SE)	-1.22 (0.04)	-1.21 (0.04)	-0.01 [-0.12; 0.11]	0.886

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

9.4 LDI Dactylitis Count - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.098				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	0.61 (1.23)	1.31 (2.80)		
Week 52 Mean (SD)	0.04 (0.20)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.21 (0.05)	-1.23 (0.05)	0.02 [-0.13; 0.17]	0.799
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	1.63 (3.00)	1.10 (2.55)		
Week 52 Mean (SD)	0.05 (0.33)	0.08 (0.39)		
Week 52 Adjusted Mean Change (SE)	-1.21 (0.05)	-1.17 (0.05)	-0.04 [-0.18; 0.10]	0.564

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

9.5 LDI Dactylitis Count - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.281				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	1.43 (2.70)	1.00 (2.28)		
Week 52 Mean (SD)	0.08 (0.36)	0.10 (0.44)		
Week 52 Adjusted Mean Change (SE)	-1.19 (0.04)	-1.13 (0.06)	-0.06 [-0.20; 0.08]	0.432
> Median, N	**26**	**33**		
N'	26	32		
Baseline Mean (SD)	0.85 (2.01)	1.39 (2.98)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.25 (0.05)	-1.26 (0.05)	0.01 [-0.14; 0.16]	0.872

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

9.6 LDI Dactylitis Count - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.488				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	0.68 (1.59)	1.32 (2.71)		
Week 52 Mean (SD)	0.09 (0.39)	0.11 (0.46)		
Week 52 Adjusted Mean Change (SE)	-1.16 (0.05)	-1.13 (0.06)	-0.02 [-0.18; 0.13]	0.751
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	1.75 (3.05)	1.15 (2.67)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.26 (0.05)	-1.24 (0.05)	-0.02 [-0.16; 0.11]	0.740

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

9.7 LDI Dactylitis Count - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.221				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	0.72 (1.98)	1.48 (3.07)		
Week 52 Mean (SD)	0.04 (0.19)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.05 (0.15)	-1.08 (0.16)	0.03 [-0.40; 0.47]	0.884
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	1.32 (2.46)	0.74 (1.66)		
Week 52 Mean (SD)	0.10 (0.45)	0.13 (0.50)		
Week 52 Adjusted Mean Change (SE)	-1.01 (0.17)	-0.97 (0.19)	-0.04 [-0.55; 0.47]	0.870

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

9.8 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.162				
Non-carrier, N	**28**	**19**		
N'	28	19		
Baseline Mean (SD)	0.89 (1.87)	1.16 (3.22)		
Week 52 Mean (SD)	0.07 (0.38)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.07 (0.15)	-1.08 (0.21)	0.01 [-0.49; 0.52]	0.961
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	1.14 (2.62)	1.32 (2.11)		
Week 52 Mean (SD)	0.05 (0.22)	0.11 (0.47)		
Week 52 Adjusted Mean Change (SE)	-1.09 (0.18)	-1.04 (0.19)	-0.05 [-0.55; 0.46]	0.851

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

9.9 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.791				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	1.42 (2.61)	0.48 (1.40)		
Week 52 Mean (SD)	0.16 (0.50)	0.13 (0.50)		
Week 52 Adjusted Mean Change (SE)	-0.97 (0.18)	-0.98 (0.19)	0.00 [-0.52; 0.52]	0.993
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	0.77 (1.96)	1.78 (3.19)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.11 (0.15)	-1.13 (0.17)	0.02 [-0.42; 0.46]	0.930

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

9.10 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.813				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	0.96 (2.15)	0.78 (1.95)		
Week 52 Mean (SD)	0.04 (0.21)	0.07 (0.38)		
Week 52 Adjusted Mean Change (SE)	-1.04 (0.16)	-1.00 (0.15)	-0.04 [-0.47; 0.39]	0.854
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	1.00 (2.28)	2.17 (3.66)		
Week 52 Mean (SD)	0.08 (0.40)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.03 (0.16)	-1.14 (0.25)	0.11 [-0.47; 0.69]	0.702

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

9.11 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.981				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	0.95 (2.05)	1.30 (2.86)		
Week 52 Mean (SD)	0.03 (0.17)	0.07 (0.38)		
Week 52 Adjusted Mean Change (SE)	-1.06 (0.13)	-0.99 (0.15)	-0.07 [-0.45; 0.31]	0.715
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	0.67 (2.31)	0.89 (1.45)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.01 (0.22)	-1.05 (0.26)	0.03 [-0.63; 0.70]	0.919

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

9.12 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.680				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	1.00 (2.10)	1.03 (2.10)		
Week 52 Mean (SD)	0.06 (0.35)	0.07 (0.38)		
Week 52 Adjusted Mean Change (SE)	-1.00 (0.05)	-0.99 (0.05)	-0.01 [-0.15; 0.14]	0.922
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	0.62 (2.22)	1.60 (3.86)		
Week 52 Mean (SD)	0.08 (0.28)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.97 (0.08)	-1.06 (0.10)	0.09 [-0.17; 0.34]	0.499

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

9.13 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.796				
Non-carrier, N	**42**	**36**		
N'	42	36		
Baseline Mean (SD)	0.95 (2.31)	0.94 (2.60)		
Week 52 Mean (SD)	0.08 (0.35)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.97 (0.11)	-1.02 (0.13)	0.05 [-0.29; 0.38]	0.783
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	1.11 (1.69)	1.80 (2.05)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.02 (0.24)	-1.04 (0.32)	0.02 [-0.75; 0.80]	0.951

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

9.14 LDI Dactylitis Count - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.503				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	1.45 (2.54)	0.73 (2.10)		
Week 52 Mean (SD)	0.20 (0.63)	0.13 (0.50)		
Week 52 Adjusted Mean Change (SE)	-0.93 (0.24)	-0.96 (0.19)	0.03 [-0.58; 0.63]	0.932
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	0.85 (2.11)	1.59 (2.94)		
Week 52 Mean (SD)	0.03 (0.16)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.06 (0.13)	-1.09 (0.17)	0.03 [-0.38; 0.44]	0.894

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

9.15 LDI Dactylitis Count - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.252				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	1.06 (2.21)	1.13 (3.00)		
Week 52 Mean (SD)	0.10 (0.40)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.01 (0.14)	-1.04 (0.18)	0.03 [-0.42; 0.48]	0.886
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	0.85 (2.23)	1.19 (2.04)		
Week 52 Mean (SD)	0.00 (0.00)	0.10 (0.45)		
Week 52 Adjusted Mean Change (SE)	-1.07 (0.18)	-1.01 (0.17)	-0.07 [-0.56; 0.42]	0.785

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

9.16 LDI Dactylitis Count - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.745				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	1.42 (2.61)	0.50 (1.43)		
Week 52 Mean (SD)	0.16 (0.50)	0.13 (0.52)		
Week 52 Adjusted Mean Change (SE)	-0.95 (0.18)	-0.95 (0.20)	-0.00 [-0.53; 0.52]	0.989
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	0.72 (1.90)	1.71 (3.14)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.08 (0.14)	-1.10 (0.16)	0.02 [-0.41; 0.45]	0.917

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

9.17 LDI Dactylitis Count - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.813				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	0.96 (2.15)	0.78 (1.95)		
Week 52 Mean (SD)	0.04 (0.21)	0.07 (0.38)		
Week 52 Adjusted Mean Change (SE)	-1.04 (0.16)	-1.00 (0.15)	-0.04 [-0.47; 0.39]	0.854
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	1.00 (2.28)	2.17 (3.66)		
Week 52 Mean (SD)	0.08 (0.40)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.03 (0.16)	-1.14 (0.25)	0.11 [-0.47; 0.69]	0.702

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

9.18 LDI Dactylitis Count - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.794				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	1.08 (2.18)	1.23 (2.79)		
Week 52 Mean (SD)	0.08 (0.37)	0.07 (0.37)		
Week 52 Adjusted Mean Change (SE)	-1.05 (0.13)	-1.04 (0.14)	-0.01 [-0.39; 0.37]	0.957
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	0.73 (2.41)	0.89 (1.45)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.05 (0.24)	-1.09 (0.26)	0.03 [-0.66; 0.72]	0.924

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

10.1 LDI Presence of Dactylitis (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
LDI Presence of Dactylitis Week 52, N' n (%)	63 2.08 (3.15)	49 2.57 (4.15)	0.68 [0.07; 6.64] 0.743	0.84 [0.10; 7.23] 0.876	-0.010 [-0.086; 0.066] 0.798

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.
RR and RD calculated directly without adjustment.

All results are combined over MI:
n and % are averages of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

10.2 LDI Presence of Dactylitis by Gender (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

10.2 LDI Presence of Dactylitis by Gender (FAS)

10.3 LDI Presence of Dactylitis by Disease Severity (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

10.4 LDI Presence of Dactylitis by Moderate/Severe PSO D (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

10.4 LDI Presence of Dactylitis by Moderate/Severe PSO D (FAS)

10.5 LDI Presence of Dactylitis by Lymphocyte Count at BL (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

10.6 LDI Presence of Dactylitis by Enthesitis at BL According to LEI (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

10.6 LDI Presence of Dactylitis by Enthesitis at BL According to LEI (FAS)

10.7 LDI Presence of Dactylitis by HLA-DQA1*05 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

10.8 LDI Presence of Dactylitis by Lead Candidate Variant rs10555659 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

10.8 LDI Presence of Dactylitis by Lead Candidate Variant rs10555659 (FAS)

10.9 LDI Presence of Dactylitis by Lead Candidate Variant rs111937633 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

10.9 LDI Presence of Dactylitis by Lead Candidate Variant rs111937633 (FAS)

10.10 LDI Presence of Dactylitis by Lead Candidate Variant rs11726476 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

10.10 LDI Presence of Dactylitis by Lead Candidate Variant rs11726476 (FAS)

10.11 LDI Presence of Dactylitis by Lead Candidate Variant rs10609046 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

10.11 LDI Presence of Dactylitis by Lead Candidate Variant rs10609046 (FAS)

10.12 LDI Presence of Dactylitis by Lead Candidate Variant rs8007401 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

10.12 LDI Presence of Dactylitis by Lead Candidate Variant rs8007401 (FAS)

10.13 LDI Presence of Dactylitis by Lead Candidate Variant rs7349145 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

10.13 LDI Presence of Dactylitis by Lead Candidate Variant rs7349145 (FAS)

10.14 LDI Presence of Dactylitis by Lead Candidate Allele Score (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

10.15 LDI Presence of Dactylitis by Linkage Variant rs10891185 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

10.16 LDI Presence of Dactylitis by Linkage Variant rs12065362 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

10.17 LDI Presence of Dactylitis by Linkage Variant rs11721988 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

10.18 LDI Presence of Dactylitis by Linkage Variant rs7787032 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

10.18 LDI Presence of Dactylitis by Linkage Variant rs7787032 (FAS)

11.0 LEI Leeds Enthesitis Index - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	65 (98.5)	61 (98.4)	126 (98.4)
Week 4 Returns	66 (100.0)	59 (95.2)	125 (97.7)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	55 (88.7)	120 (93.8)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	49 (79.0)	112 (87.5)

11.0 LEI Leeds Enthesitis Index - Return Rates (FAS)

11.1 LEI Leeds Enthesitis Index - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	61		
Baseline Mean (SD)	1.29 (1.61)	1.84 (1.87)		
Week 52 Mean (SD)	0.57 (1.13)	0.31 (0.68)		
Week 52 Adjusted Mean Change (SE)	-0.91 (0.11)	-1.18 (0.13)	0.26 [-0.08; 0.61]	0.126

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

11.2 LEI Leeds Enthesitis Index - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.960				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	1.05 (1.51)	1.67 (1.63)		
Week 52 Mean (SD)	0.43 (0.87)	0.35 (0.63)		
Week 52 Adjusted Mean Change (SE)	-1.04 (0.14)	-1.16 (0.17)	0.12 [-0.33; 0.57]	0.591
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	1.71 (1.71)	2.03 (2.11)		
Week 52 Mean (SD)	0.83 (1.47)	0.26 (0.75)		
Week 52 Adjusted Mean Change (SE)	-0.70 (0.19)	-1.19 (0.18)	0.49 [-0.03; 1.01]	0.063

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

11.3 LEI Leeds Enthesitis Index - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.951				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	0.31 (0.79)	0.77 (0.93)		
Week 52 Mean (SD)	0.06 (0.25)	0.11 (0.33)		
Week 52 Adjusted Mean Change (SE)	-1.28 (0.23)	-1.19 (0.29)	-0.09 [-0.82; 0.63]	0.797
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	1.60 (1.68)	2.12 (1.95)		
Week 52 Mean (SD)	0.74 (1.26)	0.35 (0.74)		
Week 52 Adjusted Mean Change (SE)	-0.80 (0.13)	-1.17 (0.14)	0.37 [-0.01; 0.75]	0.054

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

11.4 LEI Leeds Enthesitis Index - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.135				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	1.11 (1.52)	2.00 (2.02)		
Week 52 Mean (SD)	0.38 (0.75)	0.35 (0.78)		
Week 52 Adjusted Mean Change (SE)	-1.06 (0.18)	-1.09 (0.18)	0.04 [-0.47; 0.54]	0.882
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	1.42 (1.67)	1.67 (1.71)		
Week 52 Mean (SD)	0.70 (1.33)	0.27 (0.60)		
Week 52 Adjusted Mean Change (SE)	-0.81 (0.15)	-1.27 (0.18)	0.45 [-0.01; 0.91]	0.053

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

11.5 LEI Leeds Enthesitis Index - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.106				
≤ Median, N	40	29		
N'	40	29		
Baseline Mean (SD)	1.38 (1.55)	1.24 (1.41)		
Week 52 Mean (SD)	0.37 (0.67)	0.19 (0.51)		
Week 52 Adjusted Mean Change (SE)	-1.13 (0.14)	-1.04 (0.19)	-0.09 [-0.55; 0.37]	0.698
> Median, N	26	33		
N'	26	32		
Baseline Mean (SD)	1.15 (1.71)	2.36 (2.07)		
Week 52 Mean (SD)	0.88 (1.56)	0.39 (0.79)		
Week 52 Adjusted Mean Change (SE)	-0.58 (0.18)	-1.32 (0.17)	0.74 [0.25; 1.24]	0.004

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

11.6 LEI Leeds Enthesitis Index - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.929				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Mean (SD)	0.31 (0.86)	0.21 (0.54)		
Week 52 Adjusted Mean Change (SE)	-0.84 (0.20)	-0.94 (0.24)	0.10 [-0.41; 0.61]	0.700
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	2.66 (1.29)	2.85 (1.58)		
Week 52 Mean (SD)	0.84 (1.32)	0.37 (0.76)		
Week 52 Adjusted Mean Change (SE)	-0.96 (0.19)	-1.34 (0.19)	0.38 [-0.08; 0.83]	0.101

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

11.7 LEI Leeds Enthesitis Index - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.537				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	1.41 (1.76)	2.04 (2.03)		
Week 52 Mean (SD)	0.86 (1.48)	0.18 (0.50)		
Week 52 Adjusted Mean Change (SE)	-0.61 (0.18)	-1.36 (0.20)	0.74 [0.21; 1.27]	0.007
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	0.82 (1.14)	1.47 (1.71)		
Week 52 Mean (SD)	0.35 (0.67)	0.50 (0.89)		
Week 52 Adjusted Mean Change (SE)	-0.93 (0.21)	-0.90 (0.23)	-0.03 [-0.65; 0.60]	0.935

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

11.8 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.814				
Non-carrier, N	**28**	**19**		
N'	28	19		
Baseline Mean (SD)	1.21 (1.66)	1.84 (1.86)		
Week 52 Mean (SD)	0.63 (1.21)	0.14 (0.36)		
Week 52 Adjusted Mean Change (SE)	-0.79 (0.19)	-1.30 (0.25)	0.51 [-0.12; 1.14]	0.113
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	1.09 (1.44)	1.95 (2.09)		
Week 52 Mean (SD)	0.70 (1.30)	0.56 (0.92)		
Week 52 Adjusted Mean Change (SE)	-0.70 (0.22)	-1.03 (0.23)	0.33 [-0.31; 0.97]	0.308

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

11.9 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.902				
Non-carrier, N	19	21		
N'	19	21		
Baseline Mean (SD)	1.42 (1.89)	1.62 (2.01)		
Week 52 Mean (SD)	0.74 (1.37)	0.31 (0.70)		
Week 52 Adjusted Mean Change (SE)	-0.75 (0.22)	-1.09 (0.23)	0.34 [-0.30; 0.98]	0.296
Carrier, N	30	23		
N'	30	23		
Baseline Mean (SD)	0.97 (1.27)	1.96 (1.82)		
Week 52 Mean (SD)	0.61 (1.17)	0.32 (0.72)		
Week 52 Adjusted Mean Change (SE)	-0.74 (0.18)	-1.22 (0.21)	0.48 [-0.08; 1.04]	0.091

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

11.10 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.209				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	1.28 (1.72)	1.94 (1.95)		
Week 52 Mean (SD)	0.70 (1.29)	0.39 (0.79)		
Week 52 Adjusted Mean Change (SE)	-0.69 (0.20)	-1.13 (0.18)	0.44 [-0.09; 0.97]	0.106
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	1.04 (1.37)	1.42 (1.78)		
Week 52 Mean (SD)	0.60 (1.19)	0.10 (0.32)		
Week 52 Adjusted Mean Change (SE)	-0.80 (0.19)	-1.26 (0.30)	0.46 [-0.24; 1.16]	0.197

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

11.11 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.320				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	1.11 (1.39)	1.94 (1.87)		
Week 52 Mean (SD)	0.63 (1.17)	0.26 (0.59)		
Week 52 Adjusted Mean Change (SE)	-0.78 (0.16)	-1.21 (0.18)	0.43 [-0.06; 0.91]	0.086
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	1.42 (2.02)	1.11 (1.76)		
Week 52 Mean (SD)	0.67 (1.50)	0.22 (0.44)		
Week 52 Adjusted Mean Change (SE)	-0.69 (0.28)	-1.16 (0.32)	0.47 [-0.38; 1.31]	0.276

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

11.12 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.550				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	1.19 (1.58)	1.53 (1.73)		
Week 52 Mean (SD)	0.73 (1.28)	0.25 (0.59)		
Week 52 Adjusted Mean Change (SE)	-0.66 (0.17)	-1.18 (0.18)	0.52 [0.03; 1.00]	0.037
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	1.08 (1.55)	2.70 (2.26)		
Week 52 Mean (SD)	0.54 (1.20)	0.50 (0.97)		
Week 52 Adjusted Mean Change (SE)	-0.89 (0.27)	-1.14 (0.32)	0.25 [-0.59; 1.09]	0.554

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

11.13 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.289				
Non-carrier, N	42	36		
N'	42	36		
Baseline Mean (SD)	1.26 (1.62)	1.81 (2.05)		
Week 52 Mean (SD)	0.72 (1.32)	0.30 (0.70)		
Week 52 Adjusted Mean Change (SE)	-0.71 (0.15)	-1.18 (0.17)	0.48 [0.02; 0.93]	0.040
Carrier, N	9	5		
N'	9	5		
Baseline Mean (SD)	0.67 (1.00)	2.00 (0.71)		
Week 52 Mean (SD)	0.33 (0.71)	0.20 (0.45)		
Week 52 Adjusted Mean Change (SE)	-0.90 (0.32)	-1.38 (0.43)	0.48 [-0.59; 1.55]	0.376

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

11.14 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.996				
Low score, N	11	22		
N'	11	22		
Baseline Mean (SD)	1.27 (1.79)	1.68 (1.78)		
Week 52 Mean (SD)	0.80 (1.14)	0.31 (0.70)		
Week 52 Adjusted Mean Change (SE)	-0.58 (0.30)	-1.14 (0.23)	0.56 [-0.19; 1.31]	0.142
High score, N	40	22		
N'	40	22		
Baseline Mean (SD)	1.13 (1.49)	1.91 (2.04)		
Week 52 Mean (SD)	0.61 (1.26)	0.32 (0.72)		
Week 52 Adjusted Mean Change (SE)	-0.79 (0.16)	-1.20 (0.21)	0.41 [-0.10; 0.93]	0.115

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

11.15 LEI Leeds Enthesitis Index - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.550				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	1.19 (1.60)	1.70 (1.79)		
Week 52 Mean (SD)	0.60 (1.16)	0.11 (0.32)		
Week 52 Adjusted Mean Change (SE)	-0.83 (0.17)	-1.28 (0.22)	0.46 [-0.10; 1.01]	0.106
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	1.10 (1.48)	1.90 (2.05)		
Week 52 Mean (SD)	0.72 (1.36)	0.50 (0.89)		
Week 52 Adjusted Mean Change (SE)	-0.61 (0.22)	-1.07 (0.21)	0.46 [-0.16; 1.08]	0.141

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

11.16 LEI Leeds Enthesitis Index - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.874				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	1.42 (1.89)	1.60 (2.06)		
Week 52 Mean (SD)	0.74 (1.37)	0.33 (0.72)		
Week 52 Adjusted Mean Change (SE)	-0.75 (0.22)	-1.06 (0.24)	0.31 [-0.34; 0.95]	0.347
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	1.00 (1.30)	1.96 (1.78)		
Week 52 Mean (SD)	0.59 (1.15)	0.30 (0.70)		
Week 52 Adjusted Mean Change (SE)	-0.73 (0.18)	-1.24 (0.20)	0.51 [-0.03; 1.05]	0.066

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

11.17 LEI Leeds Enthesitis Index - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.209				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	1.28 (1.72)	1.94 (1.95)		
Week 52 Mean (SD)	0.70 (1.29)	0.39 (0.79)		
Week 52 Adjusted Mean Change (SE)	-0.69 (0.20)	-1.13 (0.18)	0.44 [-0.09; 0.97]	0.106
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	1.04 (1.37)	1.42 (1.78)		
Week 52 Mean (SD)	0.60 (1.19)	0.10 (0.32)		
Week 52 Adjusted Mean Change (SE)	-0.80 (0.19)	-1.26 (0.30)	0.46 [-0.24; 1.16]	0.197

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

11.18 LEI Leeds Enthesitis Index - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.098				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	1.08 (1.38)	1.83 (1.87)		
Week 52 Mean (SD)	0.64 (1.15)	0.28 (0.59)		
Week 52 Adjusted Mean Change (SE)	-0.74 (0.15)	-1.12 (0.16)	0.38 [-0.05; 0.81]	0.086
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	1.00 (1.48)	1.67 (2.12)		
Week 52 Mean (SD)	0.27 (0.65)	0.44 (1.01)		
Week 52 Adjusted Mean Change (SE)	-0.98 (0.27)	-0.98 (0.29)	0.01 [-0.78; 0.80]	0.984

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

12.1 LEI Presence of Enthesitis (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
LEI Presence of Enthesitis Week 52, N' n (%)	63 18.23 (27.62)	49 17.03 (27.47)	0.99 [0.43; 2.31] 0.987	1.01 [0.55; 1.84] 0.977	0.002 [-0.163; 0.166] 0.985

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.
RR and RD calculated directly without adjustment.

All results are combined over MI:
n and % are averages of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

12.2 LEI Presence of Enthesitis by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
LEI Presence of Enthesitis Week 52	p=0.399				
Male (N)	**42**	**33**			
LEI Presence of Enthesitis Week 52, N' n (%)	40 10.99 (26.17)	26 10.23 (31.00)	0.74 [0.25; 2.23] 0.596	0.85 [0.39; 1.82] 0.674	-0.048 [-0.267; 0.171] 0.665
Female (N)	**24**	**29**			
LEI Presence of Enthesitis Week 52, N' n (%)	23 7.24 (30.17)	23 6.80 (23.45)	1.57 [0.41; 5.99] 0.512	1.30 [0.50; 3.40] 0.594	0.067 [-0.185; 0.319] 0.602

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

12.3 LEI Presence of Enthesitis by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
LEI Presence of Enthesitis Week 52	p=0.258				
PASDAS < 5.4 (N)	**16**	**13**			
LEI Presence of Enthesitis Week 52, N' n (%)	16 1.00 (6.25)	9 2.68 (20.62)	0.24 [0.02; 3.73] 0.307	0.33 [0.03; 3.46] 0.352	-0.144 [-0.430; 0.142] 0.325
PASDAS ≥ 5.4 (N)	**50**	**49**			
LEI Presence of Enthesitis Week 52, N' n (%)	47 17.23 (34.46)	40 14.35 (29.29)	1.27 [0.51; 3.18] 0.610	1.18 [0.64; 2.18] 0.596	0.052 [-0.140; 0.244] 0.597

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

12.4 LEI Presence of Enthesitis by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction test					
LEI Presence of Enthesitis Week 52	p=0.271				
Moderate/Severe Psoriasis (Def D): No (N)	**28**	**32**			
LEI Presence of Enthesitis Week 52, N' n (%)	26 6.48 (23.14)	23 10.81 (33.78)	0.61 [0.17; 2.12] 0.435	0.69 [0.28; 1.66] 0.405	-0.106 [-0.348; 0.135] 0.388
Moderate/Severe Psoriasis (Def D): Yes (N)	**38**	**30**			
LEI Presence of Enthesitis Week 52, N' n (%)	37 11.75 (30.92)	26 6.22 (20.73)	1.61 [0.48; 5.37] 0.443	1.51 [0.61; 3.72] 0.375	0.102 [-0.114; 0.318] 0.356

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

12.5 LEI Presence of Enthesitis by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
LEI Presence of Enthesitis Week 52	p=0.973				
≤ Median (N)	**40**	**29**			
LEI Presence of Enthesitis Week 52, N' n (%)	38 10.99 (27.48)	21 7.62 (26.28)	0.99 [0.29; 3.35] 0.990	1.06 [0.44; 2.53] 0.898	0.012 [-0.217; 0.241] 0.918
> Median (N)	**26**	**33**			
LEI Presence of Enthesitis Week 52, N' n (%)	25 7.24 (27.85)	28 9.41 (28.52)	1.02 [0.31; 3.41] 0.972	0.98 [0.42; 2.30] 0.961	-0.007 [-0.246; 0.232] 0.956

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

12.6 LEI Presence of Enthesitis by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
LEI Presence of Enthesitis Week 52	p=0.654				
Enthesitis: No (N)	**34**	**22**			
LEI Presence of Enthesitis Week 52, N' n (%)	32 5.48 (16.12)	19 3.95 (17.95)	0.89 [0.18; 4.34] 0.885	0.91 [0.25; 3.28] 0.889	-0.018 [-0.236; 0.199] 0.868
Enthesitis: Yes (N)	**32**	**40**			
LEI Presence of Enthesitis Week 52, N' n (%)	31 12.75 (39.84)	30 13.08 (32.70)	1.37 [0.48; 3.95] 0.557	1.22 [0.64; 2.35] 0.545	0.071 [-0.162; 0.305] 0.549

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

12.7 LEI Presence of Enthesitis by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
LEI Presence of Enthesitis Week 52	p=0.269				
Non-carrier (N)	**29**	**25**			
LEI Presence of Enthesitis Week 52, N' n (%)	28 9.24 (31.86)	22 4.53 (18.12)	2.21 [0.53; 9.19] 0.274	1.79 [0.61; 5.24] 0.291	0.137 [-0.100; 0.375] 0.257
Carrier (N)	**22**	**19**			
LEI Presence of Enthesitis Week 52, N' n (%)	20 5.99 (27.23)	16 6.34 (33.37)	0.71 [0.17; 3.01] 0.638	0.82 [0.30; 2.19] 0.688	-0.061 [-0.357; 0.235] 0.684

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

12.8 LEI Presence of Enthesitis by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
LEI Presence of Enthesitis Week 52	p=0.759				
Non-carrier (N)	**28**	**19**			
LEI Presence of Enthesitis Week 52, N' n (%)	27 8.24 (29.43)	14 4.56 (24.00)	1.28 [0.28; 5.86] 0.751	1.25 [0.41; 3.80] 0.688	0.054 [-0.222; 0.330] 0.700
Carrier (N)	**22**	**19**			
LEI Presence of Enthesitis Week 52, N' n (%)	20 6.99 (31.77)	18 6.31 (33.21)	0.93 [0.23; 3.77] 0.915	0.95 [0.38; 2.40] 0.922	-0.014 [-0.312; 0.283] 0.925

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

12.9 LEI Presence of Enthesitis by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
LEI Presence of Enthesitis Week 52	p=0.991				
Non-carrier (N)	**19**	**21**			
LEI Presence of Enthesitis Week 52, N' n (%)	19 6.00 (31.58)	16 5.63 (26.81)	1.26 [0.28; 5.75] 0.761	1.20 [0.42; 3.40] 0.736	0.048 [-0.248; 0.344] 0.752
Carrier (N)	**30**	**23**			
LEI Presence of Enthesitis Week 52, N' n (%)	28 8.48 (28.27)	22 5.24 (22.78)	1.25 [0.33; 4.70] 0.741	1.24 [0.47; 3.27] 0.661	0.055 [-0.186; 0.296] 0.656

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

12.10 LEI Presence of Enthesitis by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
LEI Presence of Enthesitis Week 52	p=0.832				
Non-carrier (N)	**25**	**32**			
LEI Presence of Enthesitis Week 52, N' n (%)	23 7.99 (31.96)	28 8.84 (27.63)	1.35 [0.38; 4.80] 0.638	1.16 [0.49; 2.73] 0.734	0.043 [-0.210; 0.296] 0.737
Carrier (N)	**26**	**12**			
LEI Presence of Enthesitis Week 52, N' n (%)	25 7.24 (27.85)	10 2.03 (16.92)	1.75 [0.24; 12.69] 0.580	1.72 [0.35; 8.45] 0.507	0.109 [-0.180; 0.399] 0.459

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

12.11 LEI Presence of Enthesitis by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
LEI Presence of Enthesitis Week 52	p=0.869				
Non-carrier (N)	**38**	**33**			
LEI Presence of Enthesitis Week 52, N' n (%)	35 11.23 (29.55)	27 7.87 (23.85)	1.21 [0.37; 3.99] 0.748	1.25 [0.53; 2.93] 0.610	0.057 [-0.163; 0.277] 0.611
Carrier (N)	**12**	**9**			
LEI Presence of Enthesitis Week 52, N' n (%)	12 3.00 (25.00)	9 2.00 (22.22)	1.49 [0.18; 12.27] 0.710	1.13 [0.23; 5.39] 0.883	0.028 [-0.338; 0.394] 0.882

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) LEI Presence of Enthesitis, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

12.12 LEI Presence of Enthesitis by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
LEI Presence of Enthesitis Week 52	p=0.209				
Non-carrier (N)	**36**	**34**			
LEI Presence of Enthesitis Week 52, N' n (%)	33 12.23 (33.97)	28 7.87 (23.15)	1.94 [0.59; 6.33] 0.272	1.48 [0.64; 3.40] 0.356	0.108 [-0.116; 0.332] 0.343
Carrier (N)	**13**	**10**			
LEI Presence of Enthesitis Week 52, N' n (%)	13 3.00 (23.08)	10 3.00 (30.00)	0.41 [0.05; 3.24] 0.401	0.77 [0.20; 3.03] 0.708	-0.069 [-0.434; 0.296] 0.710

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) LEI Presence of Enthesitis, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

12.13 LEI Presence of Enthesitis by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
LEI Presence of Enthesitis Week 52	p=0.959				
Non-carrier (N)	**42**	**36**			
LEI Presence of Enthesitis Week 52, N' n (%)	39 13.23 (31.50)	30 8.87 (24.64)	1.35 [0.45; 4.09] 0.591	1.29 [0.59; 2.81] 0.528	0.069 [-0.143; 0.280] 0.525
Carrier (N)	**9**	**5**			
LEI Presence of Enthesitis Week 52, N' n (%)	9 2.00 (22.22)	5 1.00 (20.00)	1.25 [0.08; 18.81] 0.870	1.11 [0.13; 9.42] 0.923	0.022 [-0.421; 0.466] 0.922

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) LEI Presence of Enthesitis, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

12.14 LEI Presence of Enthesitis by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
LEI Presence of Enthesitis Week 52	p=0.461				
Low score (N)	**11**	**22**			
LEI Presence of Enthesitis Week 52, N' n (%)	10 4.75 (43.18)	16 5.87 (26.68)	2.36 [0.43; 12.90] 0.323	1.64 [0.56; 4.81] 0.367	0.165 [-0.203; 0.533] 0.379
High score (N)	**40**	**22**			
LEI Presence of Enthesitis Week 52, N' n (%)	38 10.48 (26.20)	22 5.00 (22.73)	1.06 [0.30; 3.77] 0.930	1.15 [0.45; 2.94] 0.768	0.035 [-0.189; 0.258] 0.761

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

12.15 LEI Presence of Enthesitis by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
LEI Presence of Enthesitis Week 52	p=0.739				
Non-carrier (N)	**31**	**23**			
LEI Presence of Enthesitis Week 52, N' n (%)	30 9.24 (29.81)	18 4.56 (19.83)	1.59 [0.37; 6.87] 0.538	1.54 [0.51; 4.65] 0.445	0.100 [-0.145; 0.345] 0.425
Carrier (N)	**20**	**21**			
LEI Presence of Enthesitis Week 52, N' n (%)	18 5.99 (29.95)	20 6.31 (30.05)	1.12 [0.27; 4.66] 0.876	0.99 [0.37; 2.64] 0.989	-0.001 [-0.292; 0.290] 0.995

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

12.16 LEI Presence of Enthesitis by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
LEI Presence of Enthesitis Week 52	p=0.848				
Non-carrier (N)	**19**	**20**			
LEI Presence of Enthesitis Week 52, N' n (%)	19 6.00 (31.58)	15 5.63 (28.15)	1.17 [0.26; 5.32] 0.842	1.14 [0.40; 3.22] 0.805	0.034 [-0.268; 0.337] 0.824
Carrier (N)	**32**	**24**			
LEI Presence of Enthesitis Week 52, N' n (%)	29 9.23 (28.84)	23 5.24 (21.83)	1.42 [0.38; 5.22] 0.600	1.32 [0.50; 3.46] 0.571	0.070 [-0.165; 0.305] 0.559

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

12.17 LEI Presence of Enthesitis by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
LEI Presence of Enthesitis Week 52	p=0.832				
Non-carrier (N)	**25**	**32**			
LEI Presence of Enthesitis Week 52, N' n (%)	23 7.99 (31.96)	28 8.84 (27.63)	1.35 [0.38; 4.80] 0.638	1.16 [0.49; 2.73] 0.734	0.043 [-0.210; 0.296] 0.737
Carrier (N)	**26**	**12**			
LEI Presence of Enthesitis Week 52, N' n (%)	25 7.24 (27.85)	10 2.03 (16.92)	1.75 [0.24; 12.69] 0.580	1.72 [0.35; 8.45] 0.507	0.109 [-0.180; 0.399] 0.459

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

12.18 LEI Presence of Enthesitis by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
LEI Presence of Enthesitis Week 52	p=0.876				
Non-carrier (N)	**39**	**35**			
LEI Presence of Enthesitis Week 52, N' n (%)	36 12.23 (31.36)	29 8.87 (25.34)	1.22 [0.39; 3.82] 0.729	1.24 [0.56; 2.75] 0.588	0.060 [-0.158; 0.278] 0.589
Carrier (N)	**11**	**9**			
LEI Presence of Enthesitis Week 52, N' n (%)	11 2.00 (18.18)	9 2.00 (22.22)	1.00 [0.10; 9.60] 0.999	0.82 [0.14; 4.71] 0.822	-0.040 [-0.395; 0.314] 0.823

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) LEI Presence of Enthesitis, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

13.0 PASI Score - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	66 (100.0)	59 (95.2)	125 (97.7)
Week 4 Returns	66 (100.0)	59 (95.2)	125 (97.7)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	57 (91.9)	121 (94.5)
Week 16 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 24 Returns	64 (97.0)	53 (85.5)	117 (91.4)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	49 (79.0)	112 (87.5)

13.1 PASI Score - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N'	66	61		
Baseline Mean (SD)	14.57 (8.14)	14.64 (9.39)		
Week 52 Mean (SD)	1.46 (2.78)	2.92 (4.69)		
Week 52 Adjusted Mean Change (SE)	-12.92 (0.47)	-11.04 (0.52)	-1.88 [-3.27; -0.49]	0.008

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

13.2 PASI Score - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.789				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	15.57 (6.98)	16.06 (9.13)		
Week 52 Mean (SD)	1.41 (2.34)	2.73 (3.65)		
Week 52 Adjusted Mean Change (SE)	-13.13 (0.59)	-11.67 (0.71)	-1.47 [-3.30; 0.37]	0.116
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	12.81 (9.76)	13.02 (9.58)		
Week 52 Mean (SD)	1.54 (3.48)	3.13 (5.72)		
Week 52 Adjusted Mean Change (SE)	-12.56 (0.78)	-10.28 (0.76)	-2.28 [-4.43; -0.13]	0.038

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

13.3 PASI Score - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.599				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	12.05 (4.46)	10.91 (5.66)		
Week 52 Mean (SD)	1.06 (1.42)	3.00 (3.33)		
Week 52 Adjusted Mean Change (SE)	-13.27 (0.95)	-10.63 (1.19)	-2.64 [-5.64; 0.35]	0.083
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	15.37 (8.89)	15.62 (9.97)		
Week 52 Mean (SD)	1.60 (3.11)	2.90 (4.98)		
Week 52 Adjusted Mean Change (SE)	-12.82 (0.54)	-11.12 (0.58)	-1.70 [-3.27; -0.12]	0.035

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

13.4 PASI Score - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.986				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	8.54 (2.87)	8.36 (2.32)		
Week 52 Mean (SD)	0.66 (1.01)	1.97 (2.71)		
Week 52 Adjusted Mean Change (SE)	-13.32 (0.80)	-11.32 (0.81)	-1.99 [-4.04; 0.05]	0.056
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	19.00 (7.91)	21.33 (9.48)		
Week 52 Mean (SD)	2.03 (3.44)	3.76 (5.85)		
Week 52 Adjusted Mean Change (SE)	-12.62 (0.66)	-10.83 (0.80)	-1.79 [-3.69; 0.11]	0.064

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

13.5 PASI Score - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.500				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	15.92 (8.94)	13.38 (7.57)		
Week 52 Mean (SD)	1.48 (2.38)	1.83 (2.19)		
Week 52 Adjusted Mean Change (SE)	-13.00 (0.60)	-11.53 (0.77)	-1.48 [-3.42; 0.46]	0.134
> Median, N	**26**	**33**		
N'	26	32		
Baseline Mean (SD)	12.48 (6.33)	15.74 (10.75)		
Week 52 Mean (SD)	1.44 (3.36)	3.74 (5.83)		
Week 52 Adjusted Mean Change (SE)	-12.83 (0.74)	-10.70 (0.70)	-2.13 [-4.16; -0.10]	0.040

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

13.6 PASI Score - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.550				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	12.54 (5.55)	13.90 (8.56)		
Week 52 Mean (SD)	0.80 (1.20)	3.36 (5.94)		
Week 52 Adjusted Mean Change (SE)	-13.60 (0.66)	-11.02 (0.84)	-2.58 [-4.70; -0.46]	0.017
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	16.72 (9.84)	15.04 (9.91)		
Week 52 Mean (SD)	2.15 (3.68)	2.64 (3.79)		
Week 52 Adjusted Mean Change (SE)	-12.22 (0.68)	-11.08 (0.66)	-1.14 [-3.00; 0.73]	0.230

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

13.7 PASI Score - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.939				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	13.69 (6.12)	14.06 (9.85)		
Week 52 Mean (SD)	1.44 (3.21)	2.75 (5.87)		
Week 52 Adjusted Mean Change (SE)	-12.95 (0.77)	-11.71 (0.86)	-1.24 [-3.54; 1.05]	0.286
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	14.79 (9.23)	15.20 (9.44)		
Week 52 Mean (SD)	1.20 (2.17)	3.23 (3.88)		
Week 52 Adjusted Mean Change (SE)	-12.86 (0.90)	-10.41 (1.01)	-2.45 [-5.14; 0.23]	0.073

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

13.8 PASI Score - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.803				
Non-carrier, N	**28**	**19**		
N'	28	19		
Baseline Mean (SD)	15.19 (5.75)	13.76 (8.45)		
Week 52 Mean (SD)	1.40 (3.31)	2.91 (7.08)		
Week 52 Adjusted Mean Change (SE)	-12.53 (0.80)	-10.35 (1.04)	-2.18 [-4.77; 0.42]	0.099
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	11.40 (5.89)	13.72 (7.52)		
Week 52 Mean (SD)	1.29 (2.10)	3.77 (3.85)		
Week 52 Adjusted Mean Change (SE)	-11.56 (0.91)	-9.69 (0.97)	-1.87 [-4.50; 0.76]	0.160

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

13.9 PASI Score - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.663				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	12.87 (6.14)	16.89 (9.01)		
Week 52 Mean (SD)	1.44 (3.51)	3.20 (6.56)		
Week 52 Adjusted Mean Change (SE)	-12.98 (0.92)	-10.68 (0.96)	-2.30 [-4.97; 0.37]	0.091
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	14.96 (8.54)	12.42 (9.78)		
Week 52 Mean (SD)	1.18 (2.27)	2.77 (3.81)		
Week 52 Adjusted Mean Change (SE)	-13.30 (0.74)	-11.56 (0.85)	-1.74 [-3.99; 0.52]	0.129

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

13.10 PASI Score - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.702				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	14.13 (5.53)	15.89 (10.32)		
Week 52 Mean (SD)	1.24 (3.18)	2.38 (2.64)		
Week 52 Adjusted Mean Change (SE)	-12.70 (0.82)	-11.95 (0.75)	-0.75 [-2.96; 1.46]	0.502
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	14.20 (9.21)	11.00 (6.29)		
Week 52 Mean (SD)	1.43 (2.46)	4.55 (9.00)		
Week 52 Adjusted Mean Change (SE)	-13.11 (0.80)	-9.02 (1.25)	-4.09 [-7.05; -1.14]	0.007

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

13.11 PASI Score - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.652				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	14.45 (8.04)	15.61 (10.55)		
Week 52 Mean (SD)	1.72 (3.20)	3.30 (5.77)		
Week 52 Adjusted Mean Change (SE)	-12.46 (0.68)	-10.76 (0.77)	-1.70 [-3.74; 0.34]	0.102
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	12.63 (5.80)	10.90 (5.04)		
Week 52 Mean (SD)	0.34 (0.41)	1.70 (2.18)		
Week 52 Adjusted Mean Change (SE)	-13.74 (1.20)	-12.44 (1.39)	-1.30 [-4.93; 2.32]	0.477

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

13.12 PASI Score - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.184				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	14.37 (6.33)	16.03 (10.32)		
Week 52 Mean (SD)	1.57 (3.28)	3.36 (5.68)		
Week 52 Adjusted Mean Change (SE)	-12.60 (0.71)	-10.88 (0.77)	-1.72 [-3.80; 0.36]	0.104
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	13.63 (10.56)	9.53 (3.46)		
Week 52 Mean (SD)	0.95 (1.22)	1.79 (2.62)		
Week 52 Adjusted Mean Change (SE)	-13.54 (1.16)	-12.27 (1.35)	-1.27 [-4.80; 2.27]	0.479

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

13.13 PASI Score - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.295				
Non-carrier, N	**42**	**36**		
N'	42	36		
Baseline Mean (SD)	14.18 (7.86)	13.58 (7.54)		
Week 52 Mean (SD)	1.57 (3.05)	2.95 (5.49)		
Week 52 Adjusted Mean Change (SE)	-12.05 (0.66)	-10.40 (0.74)	-1.65 [-3.61; 0.31]	0.098
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	14.11 (6.30)	10.46 (2.98)		
Week 52 Mean (SD)	0.33 (0.66)	3.60 (4.17)		
Week 52 Adjusted Mean Change (SE)	-13.43 (1.40)	-9.82 (1.88)	-3.62 [-8.28; 1.04]	0.126

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

13.14 PASI Score - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.865				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	14.25 (6.39)	18.68 (11.34)		
Week 52 Mean (SD)	2.16 (4.75)	3.08 (6.53)		
Week 52 Adjusted Mean Change (SE)	-11.33 (1.27)	-10.97 (1.02)	-0.36 [-3.60; 2.87]	0.825
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	14.15 (7.91)	10.43 (4.86)		
Week 52 Mean (SD)	1.12 (2.06)	2.85 (3.86)		
Week 52 Adjusted Mean Change (SE)	-13.32 (0.66)	-11.27 (0.91)	-2.05 [-4.28; 0.18]	0.071

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

13.15 PASI Score - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.648				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	16.08 (7.86)	13.30 (8.10)		
Week 52 Mean (SD)	1.43 (3.19)	2.31 (6.30)		
Week 52 Adjusted Mean Change (SE)	-13.23 (0.75)	-11.61 (0.92)	-1.62 [-3.98; 0.74]	0.176
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	11.20 (6.10)	15.93 (11.01)		
Week 52 Mean (SD)	1.19 (2.08)	3.53 (3.72)		
Week 52 Adjusted Mean Change (SE)	-12.37 (0.95)	-10.77 (0.91)	-1.60 [-4.23; 1.03]	0.229

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

13.16 PASI Score - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.901				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	12.87 (6.14)	17.23 (9.11)		
Week 52 Mean (SD)	1.44 (3.51)	3.41 (6.73)		
Week 52 Adjusted Mean Change (SE)	-12.99 (0.95)	-10.38 (1.03)	-2.62 [-5.43; 0.20]	0.068
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	14.94 (8.28)	12.33 (9.58)		
Week 52 Mean (SD)	1.28 (2.29)	2.65 (3.77)		
Week 52 Adjusted Mean Change (SE)	-12.88 (0.75)	-11.72 (0.87)	-1.17 [-3.45; 1.11]	0.312

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

13.17 PASI Score - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.702				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	14.13 (5.53)	15.89 (10.32)		
Week 52 Mean (SD)	1.24 (3.18)	2.38 (2.64)		
Week 52 Adjusted Mean Change (SE)	-12.70 (0.82)	-11.95 (0.75)	-0.75 [-2.96; 1.46]	0.502
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	14.20 (9.21)	11.00 (6.29)		
Week 52 Mean (SD)	1.43 (2.46)	4.55 (9.00)		
Week 52 Adjusted Mean Change (SE)	-13.11 (0.80)	-9.02 (1.25)	-4.09 [-7.05; -1.14]	0.007

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

13.18 PASI Score - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.830				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	14.64 (8.02)	15.69 (10.24)		
Week 52 Mean (SD)	1.67 (3.17)	3.26 (5.61)		
Week 52 Adjusted Mean Change (SE)	-12.52 (0.68)	-10.82 (0.75)	-1.70 [-3.71; 0.31]	0.096
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	11.99 (5.63)	10.14 (4.49)		
Week 52 Mean (SD)	0.27 (0.35)	1.97 (2.76)		
Week 52 Adjusted Mean Change (SE)	-13.82 (1.27)	-12.17 (1.41)	-1.65 [-5.38; 2.08]	0.382

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

14.1 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI75 Response Week 52, N' n (%)	63 58.23 (88.23)	49 40.88 (65.94)	4.43 [1.62; 12.12] 0.004	1.34 [1.08; 1.66] 0.008	0.223 [0.072; 0.374] 0.004
PASI90 Response Week 52, N' n (%)	63 46.98 (71.18)	49 25.79 (41.60)	3.69 [1.70; 8.00] <.001	1.71 [1.21; 2.42] 0.002	0.296 [0.127; 0.465] <.001
PASI100 Response Week 52, N' n (%)	63 24.31 (36.83)	49 13.35 (21.53)	2.24 [0.99; 5.08] 0.054	1.71 [0.96; 3.05] 0.069	0.153 [-0.004; 0.310] 0.056
PASI Absolute ≤ 3 Week 52, N' n (%)	63 56.82 (86.09)	49 39.63 (63.92)	3.82 [1.50; 9.76] 0.005	1.35 [1.08; 1.69] 0.009	0.222 [0.068; 0.376] 0.005

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.
RR and RD calculated directly without adjustment.

All results are combined over MI:
n and % are averages of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

14.2 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASI75 Response Week 52	p=0.816				
PASI90 Response Week 52	p=0.778				
PASI100 Response Week 52	p=0.171				
PASI Absolute ≤ 3 Week 52	p=0.417				
Male (N)	**42**	**33**			
PASI75 Response Week 52, N' n (%)	40 38.05 (90.60)	26 23.73 (71.91)	4.68 [1.13; 19.39] 0.034	1.26 [0.98; 1.62] 0.072	0.187 [-0.002; 0.375] 0.052
PASI90 Response Week 52, N' n (%)	40 29.95 (71.31)	26 15.04 (45.58)	3.26 [1.19; 8.98] 0.022	1.57 [1.01; 2.43] 0.044	0.257 [0.033; 0.482] 0.025
PASI100 Response Week 52, N' n (%)	40 16.31 (38.83)	26 5.23 (15.85)	3.84 [1.18; 12.49] 0.025	2.46 [1.01; 6.00] 0.048	0.230 [0.034; 0.426] 0.022
PASI Absolute ≤ 3 Week 52, N' n (%)	40 35.04 (83.43)	26 22.06 (66.85)	2.78 [0.87; 8.93] 0.086	1.25 [0.93; 1.67] 0.134	0.166 [-0.039; 0.371] 0.113
Female (N)	**24**	**29**			
PASI75 Response Week 52, N' n (%)	23 20.18 (84.08)	23 17.15 (59.14)	3.68 [0.86; 15.79] 0.080	1.42 [0.98; 2.07] 0.063	0.249 [0.006; 0.493] 0.045
PASI90 Response Week 52, N' n (%)	23 17.03 (70.96)	23 10.75 (37.07)	4.09 [1.22; 13.69] 0.022	1.92 [1.10; 3.35] 0.022	0.339 [0.081; 0.597] 0.010
PASI100 Response Week 52, N' n (%)	23 8.00 (33.33)	23 8.12 (28.00)	1.17 [0.35; 3.96] 0.801	1.19 [0.53; 2.70] 0.674	0.053 [-0.197; 0.304] 0.676
PASI Absolute ≤ 3 Week 52, N' n (%)	23 21.78 (90.75)	23 17.57 (60.59)	6.46 [1.20; 34.81] 0.030	1.50 [1.07; 2.11] 0.020	0.302 [0.078; 0.526] 0.008

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

14.3 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASI75 Response Week 52	p=0.175				
PASI90 Response Week 52	p=0.680				
PASI100 Response Week 52	p=0.625				
PASI Absolute ≤ 3 Week 52	p=0.619				
PASDAS < 5.4 (N)	**16**	**13**			
PASI75 Response Week 52, N' n (%)	16 15.00 (93.75)	9 6.74 (51.85)	20.67 [1.60; 267.67] 0.020	1.82 [1.01; 3.27] 0.045	0.419 [0.103; 0.735] 0.009
PASI90 Response Week 52, N' n (%)	16 11.00 (68.75)	9 6.04 (46.46)	2.74 [0.55; 13.59] 0.218	1.48 [0.74; 2.97] 0.264	0.223 [-0.138; 0.584] 0.226
PASI100 Response Week 52, N' n (%)	16 6.00 (37.50)	9 2.19 (16.85)	3.43 [0.51; 22.90] 0.203	2.26 [0.55; 9.29] 0.260	0.207 [-0.111; 0.524] 0.203
PASI Absolute ≤ 3 Week 52, N' n (%)	16 14.00 (87.50)	9 7.53 (57.92)	5.99 [0.79; 45.40] 0.083	1.52 [0.88; 2.63] 0.134	0.296 [-0.039; 0.630] 0.083
PASDAS ≥ 5.4 (N)	**50**	**49**			
PASI75 Response Week 52, N' n (%)	47 43.23 (86.46)	40 34.14 (69.67)	3.07 [1.02; 9.24] 0.046	1.24 [0.99; 1.56] 0.064	0.168 [-0.001; 0.337] 0.052
PASI90 Response Week 52, N' n (%)	47 35.98 (71.96)	40 19.75 (40.31)	4.01 [1.67; 9.66] 0.002	1.79 [1.20; 2.66] 0.004	0.317 [0.126; 0.507] 0.001
PASI100 Response Week 52, N' n (%)	47 18.31 (36.62)	40 11.16 (22.78)	2.03 [0.81; 5.05] 0.129	1.61 [0.85; 3.04] 0.144	0.138 [-0.041; 0.318] 0.130
PASI Absolute ≤ 3 Week 52, N' n (%)	47 42.82 (85.64)	40 32.10 (65.51)	3.37 [1.18; 9.64] 0.024	1.31 [1.02; 1.67] 0.032	0.201 [0.029; 0.374] 0.022

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

14.4 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASI75 Response Week 52	p=0.467				
PASI90 Response Week 52	p=0.298				
PASI100 Response Week 52	p=0.389				
PASI Absolute ≤ 3 Week 52	p=0.296				
Moderate/Severe Psoriasis (Def D): No (N)	**28**	**32**			
PASI75 Response Week 52, N' n (%)	26 25.18 (89.93)	23 19.19 (59.97)	6.65 [1.32; 33.64] 0.022	1.50 [1.06; 2.13] 0.021	0.300 [0.076; 0.523] 0.009
PASI90 Response Week 52, N' n (%)	26 20.98 (74.93)	23 11.08 (34.63)	5.74 [1.76; 18.75] 0.004	2.17 [1.25; 3.76] 0.006	0.403 [0.165; 0.641] <.001
PASI100 Response Week 52, N' n (%)	26 10.31 (36.82)	23 8.13 (25.41)	1.59 [0.50; 5.08] 0.438	1.45 [0.67; 3.15] 0.350	0.114 [-0.123; 0.351] 0.345
PASI Absolute ≤ 3 Week 52, N' (%)	26 26.78 (95.64)	23 21.94 (68.56)	11.85 [1.25; 112.18] 0.031	1.40 [1.06; 1.84] 0.018	0.271 [0.074; 0.468] 0.007
Moderate/Severe Psoriasis (Def D): Yes (N)	**38**	**30**			
PASI75 Response Week 52, N' n (%)	37 33.05 (86.97)	26 21.69 (72.30)	3.08 [0.82; 11.51] 0.095	1.20 [0.92; 1.57] 0.168	0.147 [-0.052; 0.346] 0.149
PASI90 Response Week 52, N' n (%)	37 26.00 (68.42)	26 14.71 (49.03)	2.51 [0.89; 7.03] 0.080	1.40 [0.90; 2.16] 0.133	0.194 [-0.043; 0.431] 0.109
PASI100 Response Week 52, N' n (%)	37 14.00 (36.84)	26 5.22 (17.40)	3.32 [0.99; 11.12] 0.051	2.12 [0.86; 5.22] 0.101	0.194 [-0.012; 0.401] 0.065
PASI Absolute ≤ 3 Week 52, N' n (%)	37 30.04 (79.05)	26 17.69 (58.97)	3.14 [1.01; 9.77] 0.048	1.34 [0.94; 1.91] 0.100	0.201 [-0.023; 0.425] 0.078

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

14.5 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASI75 Response Week 52	p=0.484				
PASI90 Response Week 52	p=0.788				
PASI100 Response Week 52	p=0.808				
PASI Absolute ≤ 3 Week 52	p=0.412				
≤ Median (N)	**40**	**29**			
PASI75 Response Week 52, N' n (%)	38 35.05 (87.63)	21 21.67 (74.72)	2.91 [0.71; 11.91] 0.138	1.17 [0.90; 1.53] 0.235	0.129 [-0.075; 0.333] 0.215
PASI90 Response Week 52, N' n (%)	38 26.95 (67.38)	21 11.56 (39.86)	3.54 [1.22; 10.27] 0.020	1.69 [1.01; 2.85] 0.047	0.275 [0.038; 0.513] 0.023
PASI100 Response Week 52, N' n (%)	38 13.31 (33.28)	21 6.20 (21.38)	2.11 [0.66; 6.76] 0.210	1.56 [0.67; 3.61] 0.300	0.119 [-0.093; 0.331] 0.272
PASI Absolute ≤ 3 Week 52, N' n (%)	38 33.04 (82.60)	21 19.15 (66.03)	2.82 [0.83; 9.57] 0.096	1.25 [0.91; 1.72] 0.165	0.166 [-0.055; 0.386] 0.141
> Median (N)	**26**	**33**			
PASI75 Response Week 52, N' n (%)	25 23.18 (89.15)	28 19.21 (58.21)	6.10 [1.31; 28.34] 0.021	1.53 [1.10; 2.14] 0.013	0.309 [0.093; 0.526] 0.005
PASI90 Response Week 52, N' n (%)	25 20.03 (77.04)	28 14.23 (43.12)	4.40 [1.35; 14.34] 0.014	1.79 [1.13; 2.84] 0.013	0.339 [0.100; 0.578] 0.005
PASI100 Response Week 52, N' n (%)	25 11.00 (42.31)	28 7.15 (21.67)	2.59 [0.80; 8.36] 0.112	1.96 [0.88; 4.33] 0.099	0.206 [-0.031; 0.444] 0.088
PASI Absolute ≤ 3 Week 52, N' n (%)	25 23.78 (91.46)	28 20.48 (62.06)	6.64 [1.28; 34.52] 0.024	1.48 [1.08; 2.01] 0.014	0.294 [0.085; 0.503] 0.006

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

14.6 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASI75 Response Week 52	p=0.927				
PASI90 Response Week 52	p=0.211				
PASI100 Response Week 52	p=0.039				
PASI Absolute ≤ 3 Week 52	p=0.394				
Enthesitis: No (N)	**34**	**22**			
PASI75 Response Week 52, N' n (%)	32 31.18 (91.71)	19 16.34 (74.27)	4.38 [0.75; 25.38] 0.100	1.24 [0.93; 1.65] 0.149	0.174 [-0.046; 0.394] 0.121
PASI90 Response Week 52, N' n (%)	32 24.98 (73.47)	19 6.53 (29.68)	6.85 [1.98; 23.69] 0.002	2.48 [1.24; 4.99] 0.011	0.438 [0.191; 0.685] <.001
PASI100 Response Week 52, N' n (%)	32 15.31 (45.03)	19 2.12 (9.64)	8.08 [1.57; 41.69] 0.013	4.72 [1.20; 18.58] 0.027	0.354 [0.142; 0.566] 0.001
PASI Absolute ≤ 3 Week 52, N' n (%)	32 30.78 (90.53)	19 13.96 (63.45)	6.05 [1.28; 28.53] 0.023	1.43 [1.00; 2.04] 0.049	0.271 [0.036; 0.506] 0.024
Enthesitis: Yes (N)	**32**	**40**			
PASI75 Response Week 52, N' n (%)	31 27.05 (84.53)	30 24.54 (61.35)	3.96 [1.13; 13.89] 0.032	1.38 [1.02; 1.87] 0.038	0.232 [0.026; 0.437] 0.027
PASI90 Response Week 52, N' n (%)	31 22.00 (68.75)	30 19.26 (48.15)	2.48 [0.90; 6.82] 0.079	1.43 [0.95; 2.16] 0.089	0.206 [-0.023; 0.435] 0.077
PASI100 Response Week 52, N' n (%)	31 9.00 (28.13)	30 11.23 (28.08)	1.03 [0.35; 2.99] 0.961	1.00 [0.47; 2.12] 0.995	0.000 [-0.210; 0.211] 0.996
PASI Absolute ≤ 3 Week 52, N' n (%)	31 26.04 (81.38)	30 25.67 (64.18)	2.61 [0.81; 8.49] 0.110	1.27 [0.94; 1.72] 0.120	0.172 [-0.038; 0.382] 0.108

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

14.7 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASI75 Response Week 52	p=0.375				
PASI90 Response Week 52	p=0.900				
PASI100 Response Week 52	p=0.244				
PASI Absolute ≤ 3 Week 52	p=0.619				
Non-carrier (N)	**29**	**25**			
PASI75 Response Week 52, N' n (%)	28 25.18 (86.83)	22 19.55 (78.20)	2.12 [0.42; 10.75] 0.365	1.11 [0.86; 1.44] 0.430	0.086 [-0.124; 0.297] 0.422
PASI90 Response Week 52, N' n (%)	28 22.03 (75.97)	22 12.98 (51.92)	3.14 [0.94; 10.52] 0.064	1.46 [0.95; 2.26] 0.086	0.240 [-0.012; 0.493] 0.062
PASI100 Response Week 52, N' n (%)	28 11.00 (37.93)	22 8.19 (32.76)	1.26 [0.39; 4.07] 0.697	1.16 [0.56; 2.42] 0.694	0.052 [-0.205; 0.309] 0.693
PASI Absolute ≤ 3 Week 52, N' n (%)	28 25.78 (88.90)	22 19.25 (77.00)	2.79 [0.54; 14.56] 0.223	1.15 [0.89; 1.50] 0.277	0.119 [-0.089; 0.327] 0.261
Carrier (N)	**22**	**19**			
PASI75 Response Week 52, N' n (%)	20 19.05 (86.59)	16 10.97 (57.74)	6.05 [1.12; 32.75] 0.037	1.50 [0.97; 2.33] 0.069	0.289 [0.014; 0.563] 0.039
PASI90 Response Week 52, N' n (%)	20 14.95 (67.95)	16 7.46 (39.26)	3.53 [0.93; 13.44] 0.065	1.73 [0.91; 3.31] 0.095	0.287 [-0.012; 0.586] 0.060
PASI100 Response Week 52, N' n (%)	20 9.31 (42.32)	16 3.12 (16.42)	3.99 [0.85; 18.70] 0.080	2.59 [0.82; 8.17] 0.106	0.259 [-0.012; 0.530] 0.061
PASI Absolute ≤ 3 Week 52, N' n (%)	20 18.04 (82.00)	16 10.01 (52.68)	4.91 [1.07; 22.62] 0.041	1.56 [0.96; 2.53] 0.072	0.293 [0.011; 0.576] 0.042

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

14.8 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASI75 Response Week 52	p=0.437				
PASI90 Response Week 52	p=0.980				
PASI100 Response Week 52	p=0.130				
PASI Absolute ≤ 3 Week 52	p=0.984				
Non-carrier (N)	**28**	**19**			
PASI75 Response Week 52, N' n (%)	27 26.00 (92.86)	14 13.32 (70.11)	7.51 [1.10; 51.28] 0.040	1.33 [0.95; 1.86] 0.100	0.228 [-0.015; 0.470] 0.066
PASI90 Response Week 52, N' n (%)	27 22.95 (81.96)	14 10.41 (54.79)	4.33 [1.06; 17.66] 0.041	1.50 [0.94; 2.38] 0.087	0.272 [-0.002; 0.545] 0.052
PASI100 Response Week 52, N' n (%)	27 11.31 (40.39)	14 7.31 (38.47)	1.16 [0.33; 4.10] 0.819	1.05 [0.50; 2.22] 0.895	0.019 [-0.273; 0.311] 0.897
PASI Absolute ≤ 3 Week 52, N' (%)	27 25.00 (89.29)	14 13.20 (69.47)	4.50 [0.83; 24.51] 0.082	1.29 [0.91; 1.82] 0.153	0.198 [-0.051; 0.448] 0.119
Carrier (N)	**22**	**19**			
PASI75 Response Week 52, N' n (%)	20 17.23 (78.32)	18 11.20 (58.95)	2.88 [0.63; 13.20] 0.174	1.33 [0.85; 2.07] 0.209	0.194 [-0.092; 0.480] 0.184
PASI90 Response Week 52, N' n (%)	20 13.03 (59.23)	18 5.03 (26.47)	4.22 [1.08; 16.57] 0.039	2.24 [0.98; 5.13] 0.057	0.328 [0.041; 0.614] 0.025
PASI100 Response Week 52, N' n (%)	20 9.00 (40.91)	18 2.00 (10.53)	6.01 [1.08; 33.45] 0.040	3.89 [0.95; 15.82] 0.058	0.304 [0.056; 0.551] 0.016
PASI Absolute ≤ 3 Week 52, N' n (%)	20 17.82 (81.00)	18 10.06 (52.95)	4.40 [0.96; 20.18] 0.057	1.53 [0.95; 2.46] 0.079	0.281 [-0.001; 0.562] 0.051

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) PASI100 Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

14.9 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASI75 Response Week 52	p=0.872				
PASI90 Response Week 52	p=0.672				
PASI100 Response Week 52	p=0.845				
PASI Absolute ≤ 3 Week 52	p=0.816				
Non-carrier (N)	**19**	**21**			
PASI75 Response Week 52, N' n (%)	19 17.00 (89.47)	16 14.53 (69.19)	5.20 [0.70; 38.48] 0.106	1.30 [0.91; 1.84] 0.147	0.203 [-0.053; 0.459] 0.120
PASI90 Response Week 52, N' n (%)	19 15.00 (78.95)	16 9.54 (45.43)	5.21 [1.18; 23.04] 0.030	1.74 [1.02; 2.98] 0.043	0.335 [0.049; 0.621] 0.022
PASI100 Response Week 52, N' n (%)	19 8.00 (42.11)	16 5.12 (24.38)	2.43 [0.59; 10.03] 0.220	1.73 [0.68; 4.38] 0.247	0.177 [-0.112; 0.467] 0.230
PASI Absolute ≤ 3 Week 52, N' n (%)	19 17.00 (89.47)	16 13.30 (63.33)	6.81 [0.97; 47.84] 0.054	1.42 [0.97; 2.07] 0.074	0.261 [0.003; 0.520] 0.048
Carrier (N)	**30**	**23**			
PASI75 Response Week 52, N' n (%)	28 26.18 (87.27)	22 15.99 (69.52)	4.24 [0.87; 20.62] 0.074	1.26 [0.93; 1.70] 0.144	0.177 [-0.047; 0.402] 0.121
PASI90 Response Week 52, N' n (%)	28 21.98 (73.27)	22 10.90 (47.39)	3.45 [1.04; 11.53] 0.044	1.55 [0.95; 2.52] 0.079	0.259 [-0.002; 0.519] 0.052
PASI100 Response Week 52, N' n (%)	28 12.31 (41.03)	22 6.19 (26.91)	2.02 [0.59; 6.88] 0.264	1.53 [0.68; 3.44] 0.308	0.141 [-0.116; 0.398] 0.282
PASI Absolute ≤ 3 Week 52, N' n (%)	28 26.78 (89.27)	22 15.96 (69.39)	5.08 [0.99; 25.93] 0.051	1.29 [0.95; 1.74] 0.102	0.199 [-0.022; 0.420] 0.078

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale
with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters,
subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of
imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

14.10 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction test					
PASI75 Response Week 52	p=0.792				
PASI90 Response Week 52	p=0.894				
PASI100 Response Week 52	p=0.985				
PASI Absolute ≤ 3 Week 52	p=0.617				
Non-carrier (N)	**25**	**32**			
PASI75 Response Week 52, N' n (%)	23 21.23 (84.92)	28 21.75 (67.97)	2.78 [0.61; 12.59] 0.184	1.25 [0.93; 1.69] 0.146	0.170 [-0.052; 0.391] 0.134
PASI90 Response Week 52, N' n (%)	23 19.03 (76.12)	28 15.01 (46.91)	3.59 [1.09; 11.85] 0.036	1.62 [1.05; 2.51] 0.029	0.292 [0.049; 0.535] 0.018
PASI100 Response Week 52, N' n (%)	23 9.00 (36.00)	28 7.19 (22.47)	1.77 [0.53; 5.96] 0.353	1.60 [0.70; 3.70] 0.268	0.135 [-0.103; 0.374] 0.266
PASI Absolute ≤ 3 Week 52, N' n (%)	23 21.82 (87.28)	28 20.31 (63.47)	4.25 [0.92; 19.65] 0.064	1.38 [1.01; 1.88] 0.045	0.238 [0.021; 0.456] 0.032
Carrier (N)	**26**	**12**			
PASI75 Response Week 52, N' n (%)	25 23.00 (88.46)	10 8.77 (73.08)	3.85 [0.56; 26.24] 0.169	1.21 [0.82; 1.79] 0.334	0.154 [-0.138; 0.445] 0.301
PASI90 Response Week 52, N' n (%)	25 17.95 (69.04)	10 5.43 (45.25)	3.15 [0.71; 13.95] 0.130	1.53 [0.76; 3.09] 0.233	0.238 [-0.104; 0.580] 0.173
PASI100 Response Week 52, N' n (%)	25 11.31 (43.50)	10 4.12 (34.33)	1.74 [0.39; 7.84] 0.469	1.27 [0.51; 3.17] 0.609	0.092 [-0.244; 0.427] 0.592
PASI Absolute ≤ 3 Week 52, N' n (%)	25 22.00 (84.62)	10 8.95 (74.58)	2.34 [0.38; 14.39] 0.360	1.14 [0.77; 1.67] 0.516	0.100 [-0.192; 0.393] 0.502

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

14.11 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASI75 Response Week 52	N.E.				
PASI90 Response Week 52	N.E.				
PASI100 Response Week 52	p=0.517				
PASI Absolute ≤ 3 Week 52	N.E.				
Non-carrier (N)	**38**	**33**			
PASI75 Response Week 52, N' n (%)	35 31.23 (82.18)	27 22.52 (68.24)	2.82 [0.79; 10.05] 0.109	1.21 [0.90; 1.61] 0.208	0.139 [-0.070; 0.349] 0.192
PASI90 Response Week 52, N' n (%)	35 23.98 (63.11)	27 15.44 (46.79)	2.09 [0.78; 5.59] 0.143	1.35 [0.86; 2.11] 0.189	0.163 [-0.070; 0.396] 0.170
PASI100 Response Week 52, N' n (%)	35 14.31 (37.66)	27 7.31 (22.15)	2.41 [0.80; 7.30] 0.120	1.70 [0.78; 3.70] 0.179	0.155 [-0.058; 0.368] 0.154
PASI Absolute ≤ 3 Week 52, N' n (%)	35 30.82 (81.11)	27 21.26 (64.42)	2.95 [0.89; 9.85] 0.078	1.26 [0.93; 1.71] 0.141	0.167 [-0.045; 0.379] 0.123
Carrier (N)	**12**	**9**			
PASI75 Response Week 52, N' n (%)	12 12.00 (100.00)	9 7.00 (77.78)	N.E.	1.29 [0.91; 1.82] 0.158	0.222 [-0.049; 0.494] 0.109
PASI90 Response Week 52, N' n (%)	12 12.00 (100.00)	9 4.00 (44.44)	N.E.	2.25 [1.08; 4.67] 0.030	0.556 [0.231; 0.880] <.001
PASI100 Response Week 52, N' n (%)	12 5.00 (41.67)	9 3.00 (33.33)	1.17 [0.18; 7.61] 0.868	1.25 [0.40; 3.91] 0.701	0.083 [-0.332; 0.499] 0.694
PASI Absolute ≤ 3 Week 52, N' n (%)	12 12.00 (100.00)	9 7.00 (77.78)	N.E.	1.29 [0.91; 1.82] 0.158	0.222 [-0.049; 0.494] 0.109

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) PASI75 Response, PASI90 Response, PASI100 Response, PASI Absolute <= 3, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

14.12 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASI75 Response Week 52	p=0.983				
PASI90 Response Week 52	p=0.954				
PASI100 Response Week 52	p=0.124				
PASI Absolute ≤ 3 Week 52	p=0.255				
Non-carrier (N)	**36**	**34**			
PASI75 Response Week 52, N' n (%)	33 31.23 (86.75)	28 22.52 (66.24)	3.27 [0.89; 12.06] 0.075	1.31 [0.98; 1.75] 0.064	0.205 [0.002; 0.408] 0.048
PASI90 Response Week 52, N' n (%)	33 25.98 (72.17)	28 15.44 (45.41)	3.04 [1.09; 8.51] 0.034	1.59 [1.03; 2.45] 0.035	0.268 [0.041; 0.494] 0.021
PASI100 Response Week 52, N' n (%)	33 14.31 (39.75)	28 6.31 (18.56)	2.81 [0.90; 8.78] 0.075	2.15 [0.93; 4.93] 0.072	0.212 [0.001; 0.422] 0.049
PASI Absolute ≤ 3 Week 52, N' n (%)	33 29.82 (82.83)	28 22.26 (65.47)	2.45 [0.73; 8.18] 0.145	1.27 [0.94; 1.70] 0.119	0.174 [-0.035; 0.382] 0.102
Carrier (N)	**13**	**10**			
PASI75 Response Week 52, N' n (%)	13 11.00 (84.62)	10 8.00 (80.00)	3.17 [0.26; 38.13] 0.362	1.06 [0.72; 1.56] 0.776	0.046 [-0.270; 0.362] 0.775
PASI90 Response Week 52, N' n (%)	13 9.00 (69.23)	10 5.00 (50.00)	3.23 [0.52; 20.00] 0.207	1.38 [0.68; 2.84] 0.374	0.192 [-0.206; 0.591] 0.345
PASI100 Response Week 52, N' n (%)	13 4.00 (30.77)	10 5.00 (50.00)	0.54 [0.09; 3.16] 0.492	0.62 [0.22; 1.71] 0.353	-0.192 [-0.591; 0.206] 0.345
PASI Absolute ≤ 3 Week 52, N' n (%)	13 12.00 (92.31)	10 7.00 (70.00)	15.06 [0.82; 275.90] 0.068	1.32 [0.85; 2.04] 0.213	0.223 [-0.096; 0.542] 0.170

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) PASI75 Response, PASI90 Response, PASI100 Response, PASI Absolute <= 3, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

14.13 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASI75 Response Week 52	N.E.				
PASI90 Response Week 52	p=0.373				
PASI100 Response Week 52	p=0.668				
PASI Absolute ≤ 3 Week 52	N.E.				
Non-carrier (N)	**42**	**36**			
PASI75 Response Week 52, N' n (%)	39 35.23 (83.88)	30 24.52 (68.11)	3.08 [0.90; 10.61] 0.074	1.23 [0.94; 1.62] 0.133	0.158 [-0.039; 0.355] 0.116
PASI90 Response Week 52, N' n (%)	39 28.98 (69.00)	30 16.44 (45.67)	2.95 [1.11; 7.87] 0.030	1.51 [0.99; 2.30] 0.053	0.233 [0.015; 0.452] 0.036
PASI100 Response Week 52, N' n (%)	39 14.31 (34.07)	30 9.31 (25.86)	1.57 [0.56; 4.40] 0.390	1.32 [0.65; 2.68] 0.444	0.082 [-0.124; 0.288] 0.435
PASI Absolute ≤ 3 Week 52, N' n (%)	39 34.82 (82.90)	30 24.26 (67.39)	2.79 [0.86; 9.00] 0.087	1.23 [0.93; 1.62] 0.139	0.155 [-0.042; 0.352] 0.122
Carrier (N)	**9**	**5**			
PASI75 Response Week 52, N' n (%)	9 9.00 (100.00)	5 3.00 (60.00)	N.E.	1.67 [0.81; 3.41] 0.162	0.400 [-0.029; 0.829] 0.068
PASI90 Response Week 52, N' n (%)	9 8.00 (88.89)	5 2.00 (40.00)	11.16 [0.71; 175.08] 0.086	2.22 [0.74; 6.66] 0.154	0.489 [0.013; 0.965] 0.044
PASI100 Response Week 52, N' n (%)	9 6.00 (66.67)	5 2.00 (40.00)	2.72 [0.28; 26.57] 0.390	1.67 [0.52; 5.36] 0.392	0.267 [-0.262; 0.795] 0.323
PASI Absolute ≤ 3 Week 52, N' n (%)	9 9.00 (100.00)	5 3.00 (60.00)	N.E.	1.67 [0.81; 3.41] 0.162	0.400 [-0.029; 0.829] 0.068

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) PASI75 Response, PASI90 Response, PASI100 Response, PASI Absolute <= 3, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

14.14 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASI75 Response Week 52	p=0.408				
PASI90 Response Week 52	p=0.221				
PASI100 Response Week 52	p=0.394				
PASI Absolute ≤ 3 Week 52	p=0.225				
Low score (N)	**11**	**22**			
PASI75 Response Week 52, N' n (%)	10 9.05 (82.27)	16 15.52 (70.55)	1.79 [0.24; 13.23] 0.567	1.17 [0.78; 1.76] 0.457	0.117 [-0.194; 0.428] 0.460
PASI90 Response Week 52, N' n (%)	10 7.00 (63.64)	16 11.44 (52.00)	1.55 [0.33; 7.23] 0.579	1.23 [0.66; 2.26] 0.515	0.116 [-0.241; 0.474] 0.524
PASI100 Response Week 52, N' n (%)	10 5.00 (45.45)	16 4.31 (19.59)	3.48 [0.67; 18.16] 0.140	2.34 [0.78; 6.98] 0.129	0.259 [-0.082; 0.600] 0.137
PASI Absolute ≤ 3 Week 52, N' n (%)	10 8.04 (73.09)	16 14.26 (64.82)	1.36 [0.24; 7.58] 0.725	1.13 [0.69; 1.84] 0.627	0.083 [-0.257; 0.422] 0.633
High score (N)	**40**	**22**			
PASI75 Response Week 52, N' n (%)	38 35.18 (87.95)	22 15.00 (68.18)	5.20 [1.16; 23.37] 0.031	1.29 [0.95; 1.76] 0.106	0.198 [-0.022; 0.418] 0.078
PASI90 Response Week 52, N' n (%)	38 29.98 (74.95)	22 9.00 (40.91)	5.20 [1.62; 16.71] 0.006	1.83 [1.07; 3.12] 0.026	0.340 [0.095; 0.586] 0.007
PASI100 Response Week 52, N' n (%)	38 15.31 (38.28)	22 7.00 (31.82)	1.46 [0.47; 4.53] 0.517	1.20 [0.58; 2.49] 0.621	0.065 [-0.183; 0.312] 0.609
PASI Absolute ≤ 3 Week 52, N' n (%)	38 35.78 (89.45)	22 15.00 (68.18)	5.68 [1.25; 25.81] 0.024	1.31 [0.97; 1.78] 0.082	0.213 [-0.005; 0.430] 0.055

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

14.15 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASI75 Response Week 52	p=0.532				
PASI90 Response Week 52	p=0.771				
PASI100 Response Week 52	p=0.111				
PASI Absolute ≤ 3 Week 52	p=0.871				
Non-carrier (N)	**31**	**23**			
PASI75 Response Week 52, N' n (%)	30 28.00 (90.32)	18 17.32 (75.30)	4.82 [0.83; 28.13] 0.080	1.20 [0.91; 1.59] 0.198	0.150 [-0.066; 0.367] 0.174
PASI90 Response Week 52, N' n (%)	30 24.95 (80.48)	18 13.41 (58.30)	3.64 [0.98; 13.48] 0.053	1.38 [0.93; 2.06] 0.113	0.222 [-0.030; 0.473] 0.084
PASI100 Response Week 52, N' n (%)	30 12.31 (39.71)	18 9.31 (40.48)	1.07 [0.33; 3.44] 0.909	0.98 [0.50; 1.93] 0.957	-0.008 [-0.278; 0.262] 0.956
PASI Absolute ≤ 3 Week 52, N' n (%)	30 27.00 (87.10)	18 17.20 (74.78)	3.06 [0.63; 14.90] 0.167	1.17 [0.87; 1.56] 0.297	0.123 [-0.100; 0.346] 0.279
Carrier (N)	**20**	**21**			
PASI75 Response Week 52, N' n (%)	18 16.23 (81.15)	20 13.20 (62.86)	2.29 [0.49; 10.77] 0.292	1.29 [0.87; 1.92] 0.210	0.183 [-0.091; 0.457] 0.191
PASI90 Response Week 52, N' n (%)	18 12.03 (60.15)	20 7.03 (33.48)	2.77 [0.75; 10.20] 0.127	1.80 [0.89; 3.63] 0.102	0.267 [-0.029; 0.562] 0.077
PASI100 Response Week 52, N' n (%)	18 8.00 (40.00)	20 2.00 (9.52)	5.85 [1.04; 33.05] 0.046	4.20 [1.01; 17.43] 0.048	0.305 [0.056; 0.553] 0.016
PASI Absolute ≤ 3 Week 52, N' n (%)	18 16.82 (84.10)	20 12.06 (57.43)	3.67 [0.77; 17.58] 0.103	1.46 [0.96; 2.23] 0.075	0.267 [-0.002; 0.536] 0.052

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) PASI100 Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

14.16 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASI75 Response Week 52	p=0.602				
PASI90 Response Week 52	p=0.348				
PASI100 Response Week 52	p=0.444				
PASI Absolute ≤ 3 Week 52	p=0.385				
Non-carrier (N)	**19**	**20**			
PASI75 Response Week 52, N' n (%)	19 17.00 (89.47)	15 13.53 (67.65)	5.33 [0.75; 37.81] 0.094	1.33 [0.92; 1.92] 0.134	0.218 [-0.045; 0.481] 0.104
PASI90 Response Week 52, N' n (%)	19 15.00 (78.95)	15 8.54 (42.70)	5.75 [1.29; 25.57] 0.022	1.85 [1.04; 3.30] 0.036	0.362 [0.073; 0.652] 0.014
PASI100 Response Week 52, N' n (%)	19 8.00 (42.11)	15 4.12 (20.60)	3.09 [0.70; 13.64] 0.136	2.05 [0.74; 5.69] 0.169	0.215 [-0.071; 0.501] 0.140
PASI Absolute ≤ 3 Week 52, N' n (%)	19 17.00 (89.47)	15 12.30 (61.50)	6.79 [1.03; 44.92] 0.047	1.46 [0.97; 2.18] 0.066	0.280 [0.014; 0.545] 0.039
Carrier (N)	**32**	**24**			
PASI75 Response Week 52, N' n (%)	29 27.23 (85.09)	23 16.99 (70.79)	2.83 [0.68; 11.76] 0.153	1.20 [0.89; 1.62] 0.225	0.143 [-0.078; 0.364] 0.205
PASI90 Response Week 52, N' n (%)	29 21.98 (68.69)	23 11.90 (49.58)	2.35 [0.76; 7.29] 0.137	1.39 [0.87; 2.22] 0.174	0.191 [-0.067; 0.450] 0.148
PASI100 Response Week 52, N' n (%)	29 12.31 (38.47)	23 7.19 (29.96)	1.48 [0.46; 4.78] 0.516	1.28 [0.60; 2.76] 0.521	0.085 [-0.168; 0.338] 0.510
PASI Absolute ≤ 3 Week 52, N' n (%)	29 26.82 (83.81)	23 16.96 (70.67)	2.45 [0.62; 9.63] 0.201	1.19 [0.88; 1.60] 0.269	0.131 [-0.093; 0.356] 0.252

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

14.17 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASI75 Response Week 52	p=0.792				
PASI90 Response Week 52	p=0.894				
PASI100 Response Week 52	p=0.985				
PASI Absolute ≤ 3 Week 52	p=0.617				
Non-carrier (N)	**25**	**32**			
PASI75 Response Week 52, N' n (%)	23 21.23 (84.92)	28 21.75 (67.97)	2.78 [0.61; 12.59] 0.184	1.25 [0.93; 1.69] 0.146	0.170 [-0.052; 0.391] 0.134
PASI90 Response Week 52, N' n (%)	23 19.03 (76.12)	28 15.01 (46.91)	3.59 [1.09; 11.85] 0.036	1.62 [1.05; 2.51] 0.029	0.292 [0.049; 0.535] 0.018
PASI100 Response Week 52, N' n (%)	23 9.00 (36.00)	28 7.19 (22.47)	1.77 [0.53; 5.96] 0.353	1.60 [0.70; 3.70] 0.268	0.135 [-0.103; 0.374] 0.266
PASI Absolute ≤ 3 Week 52, N' n (%)	23 21.82 (87.28)	28 20.31 (63.47)	4.25 [0.92; 19.65] 0.064	1.38 [1.01; 1.88] 0.045	0.238 [0.021; 0.456] 0.032
Carrier (N)	**26**	**12**			
PASI75 Response Week 52, N' n (%)	25 23.00 (88.46)	10 8.77 (73.08)	3.85 [0.56; 26.24] 0.169	1.21 [0.82; 1.79] 0.334	0.154 [-0.138; 0.445] 0.301
PASI90 Response Week 52, N' n (%)	25 17.95 (69.04)	10 5.43 (45.25)	3.15 [0.71; 13.95] 0.130	1.53 [0.76; 3.09] 0.233	0.238 [-0.104; 0.580] 0.173
PASI100 Response Week 52, N' n (%)	25 11.31 (43.50)	10 4.12 (34.33)	1.74 [0.39; 7.84] 0.469	1.27 [0.51; 3.17] 0.609	0.092 [-0.244; 0.427] 0.592
PASI Absolute ≤ 3 Week 52, N' n (%)	25 22.00 (84.62)	10 8.95 (74.58)	2.34 [0.38; 14.39] 0.360	1.14 [0.77; 1.67] 0.516	0.100 [-0.192; 0.393] 0.502

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

14.18 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASI75 Response Week 52	N.E.				
PASI90 Response Week 52	N.E.				
PASI100 Response Week 52	p=0.656				
PASI Absolute ≤ 3 Week 52	N.E.				
Non-carrier (N)	**39**	**35**			
PASI75 Response Week 52, N' n (%)	36 32.23 (82.64)	29 23.52 (67.20)	3.08 [0.88; 10.75] 0.078	1.23 [0.92; 1.64] 0.155	0.154 [-0.050; 0.359] 0.139
PASI90 Response Week 52, N' n (%)	36 24.98 (64.05)	29 16.44 (46.97)	2.16 [0.82; 5.66] 0.119	1.36 [0.89; 2.10] 0.159	0.171 [-0.057; 0.398] 0.141
PASI100 Response Week 52, N' n (%)	36 15.31 (39.26)	29 8.31 (23.74)	2.33 [0.80; 6.74] 0.119	1.66 [0.80; 3.42] 0.173	0.155 [-0.057; 0.367] 0.151
PASI Absolute ≤ 3 Week 52, N' n (%)	36 31.82 (81.59)	29 22.26 (63.60)	3.17 [0.97; 10.40] 0.057	1.28 [0.95; 1.74] 0.105	0.180 [-0.027; 0.386] 0.088
Carrier (N)	**11**	**9**			
PASI75 Response Week 52, N' n (%)	11 11.00 (100.00)	9 7.00 (77.78)	N.E.	1.29 [0.91; 1.82] 0.158	0.222 [-0.049; 0.494] 0.109
PASI90 Response Week 52, N' n (%)	11 11.00 (100.00)	9 4.00 (44.44)	N.E.	2.25 [1.08; 4.67] 0.030	0.556 [0.231; 0.880] <.001
PASI100 Response Week 52, N' n (%)	11 5.00 (45.45)	9 3.00 (33.33)	1.42 [0.21; 9.47] 0.718	1.36 [0.44; 4.21] 0.590	0.121 [-0.305; 0.547] 0.577
PASI Absolute ≤ 3 Week 52, N' n (%)	11 11.00 (100.00)	9 7.00 (77.78)	N.E.	1.29 [0.91; 1.82] 0.158	0.222 [-0.049; 0.494] 0.109

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) PASI75 Response, PASI90 Response, PASI100 Response, PASI Absolute <= 3, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

15.0 Patient's Assessment of PsA Pain (VAS) - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	**ADA (N=62)**	**Total (N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	66 (100.0)	61 (98.4)	127 (99.2)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	64 (97.0)	56 (90.3)	120 (93.8)
Week 20 Returns	64 (97.0)	54 (87.1)	118 (92.2)
Week 24 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 28 Returns	62 (93.9)	49 (79.0)	111 (86.7)
Week 32 Returns	62 (93.9)	49 (79.0)	111 (86.7)
Week 36 Returns	61 (92.4)	50 (80.6)	111 (86.7)
Week 40 Returns	63 (95.5)	48 (77.4)	111 (86.7)
Week 44 Returns	63 (95.5)	47 (75.8)	110 (85.9)
Week 48 Returns	60 (90.9)	46 (74.2)	106 (82.8)
Week 52 Returns	62 (93.9)	46 (74.2)	108 (84.4)

15.1 Patient's Assessment of PsA Pain (VAS) - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	61		
Baseline Mean (SD)	57.74 (24.51)	57.13 (25.69)		
Week 52 Mean (SD)	25.85 (22.82)	27.96 (23.91)		
Week 2 Adjusted Mean Change (SE)	-11.62 (2.47)	-11.75 (2.57)		
Week 4 Adjusted Mean Change (SE)	-18.59 (2.49)	-15.37 (2.60)		
Week 8 Adjusted Mean Change (SE)	-19.96 (2.62)	-19.17 (2.74)		
Week 12 Adjusted Mean Change (SE)	-21.94 (2.71)	-18.84 (2.83)		
Week 16 Adjusted Mean Change (SE)	-25.07 (2.72)	-22.72 (2.87)		
Week 20 Adjusted Mean Change (SE)	-25.57 (2.89)	-19.85 (3.07)		
Week 24 Adjusted Mean Change (SE)	-24.09 (2.73)	-22.29 (2.91)		
Week 28 Adjusted Mean Change (SE)	-26.69 (2.49)	-22.44 (2.68)		
Week 32 Adjusted Mean Change (SE)	-29.46 (2.68)	-27.49 (2.92)		
Week 36 Adjusted Mean Change (SE)	-29.19 (2.51)	-26.91 (2.73)		
Week 40 Adjusted Mean Change (SE)	-27.46 (2.64)	-25.68 (2.88)		
Week 44 Adjusted Mean Change (SE)	-28.78 (2.76)	-26.54 (3.01)		
Week 48 Adjusted Mean Change (SE)	-28.25 (2.83)	-26.22 (3.10)		
Week 52 Adjusted Mean Change (SE)	-30.95 (2.76)	-27.51 (3.05)	-3.44 [-11.57; 4.70]	0.405

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

15.2 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.431				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	57.62 (23.50)	51.67 (22.75)		
Week 52 Mean (SD)	23.97 (22.98)	21.00 (22.60)		
Week 2 Adjusted Mean Change (SE)	-13.35 (3.12)	-15.82 (3.58)		
Week 4 Adjusted Mean Change (SE)	-19.91 (3.13)	-18.97 (3.60)		
Week 8 Adjusted Mean Change (SE)	-23.27 (3.26)	-23.42 (3.75)		
Week 12 Adjusted Mean Change (SE)	-25.80 (3.32)	-24.23 (3.80)		
Week 16 Adjusted Mean Change (SE)	-26.93 (3.39)	-27.21 (3.89)		
Week 20 Adjusted Mean Change (SE)	-28.53 (3.62)	-23.77 (4.19)		
Week 24 Adjusted Mean Change (SE)	-26.14 (3.32)	-30.37 (3.91)		
Week 28 Adjusted Mean Change (SE)	-29.19 (3.04)	-28.63 (3.60)		
Week 32 Adjusted Mean Change (SE)	-31.66 (3.38)	-31.84 (4.04)		
Week 36 Adjusted Mean Change (SE)	-29.39 (3.18)	-30.37 (3.77)		
Week 40 Adjusted Mean Change (SE)	-28.80 (3.32)	-29.80 (3.97)		
Week 44 Adjusted Mean Change (SE)	-31.92 (3.40)	-32.48 (4.04)		
Week 48 Adjusted Mean Change (SE)	-28.92 (3.54)	-31.44 (4.23)		
Week 52 Adjusted Mean Change (SE)	-32.45 (3.43)	-33.61 (4.15)	1.16 [-9.48; 11.80]	0.829
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	57.96 (26.70)	63.34 (27.77)		
Week 52 Mean (SD)	29.04 (22.70)	35.55 (23.44)		
Week 2 Adjusted Mean Change (SE)	-8.59 (4.13)	-7.25 (3.77)		
Week 4 Adjusted Mean Change (SE)	-16.27 (4.15)	-11.37 (3.82)		
Week 8 Adjusted Mean Change (SE)	-14.15 (4.32)	-14.42 (3.99)		
Week 12 Adjusted Mean Change (SE)	-15.13 (4.41)	-12.76 (4.08)		
Week 16 Adjusted Mean Change (SE)	-21.71 (4.46)	-17.57 (4.21)		
Week 20 Adjusted Mean Change (SE)	-20.37 (4.81)	-15.65 (4.54)		
Week 24 Adjusted Mean Change (SE)	-20.57 (4.41)	-13.17 (4.15)		
Week 28 Adjusted Mean Change (SE)	-22.30 (4.10)	-15.38 (3.90)		
Week 32 Adjusted Mean Change (SE)	-25.56 (4.44)	-22.53 (4.28)		
Week 36 Adjusted Mean Change (SE)	-28.71 (4.17)	-23.00 (4.02)		
Week 40 Adjusted Mean Change (SE)	-25.05 (4.35)	-21.02 (4.24)		
Week 44 Adjusted Mean Change (SE)	-23.20 (4.49)	-19.55 (4.40)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-26.81 (4.64)	-20.24 (4.57)		
Week 52 Adjusted Mean Change (SE)	-28.24 (4.51)	-20.51 (4.42)	-7.73 [-20.19; 4.73]	0.222

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

15.3 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.474				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	40.25 (20.23)	30.38 (26.04)		
Week 52 Mean (SD)	17.38 (21.51)	26.13 (26.87)		
Week 2 Adjusted Mean Change (SE)	-13.57 (5.23)	-15.96 (6.00)		
Week 4 Adjusted Mean Change (SE)	-18.70 (5.28)	-15.70 (6.06)		
Week 8 Adjusted Mean Change (SE)	-16.28 (5.53)	-21.71 (6.35)		
Week 12 Adjusted Mean Change (SE)	-20.17 (5.79)	-18.22 (6.58)		
Week 16 Adjusted Mean Change (SE)	-27.66 (5.73)	-18.14 (6.58)		
Week 20 Adjusted Mean Change (SE)	-28.10 (6.20)	-17.56 (7.20)		
Week 24 Adjusted Mean Change (SE)	-23.81 (5.84)	-21.94 (6.95)		
Week 28 Adjusted Mean Change (SE)	-31.60 (5.24)	-23.90 (6.33)		
Week 32 Adjusted Mean Change (SE)	-32.57 (5.69)	-25.56 (7.01)		
Week 36 Adjusted Mean Change (SE)	-28.75 (5.29)	-25.48 (6.64)		
Week 40 Adjusted Mean Change (SE)	-28.81 (5.60)	-19.52 (7.16)		
Week 44 Adjusted Mean Change (SE)	-35.17 (5.71)	-18.78 (7.08)		
Week 48 Adjusted Mean Change (SE)	-31.86 (5.89)	-12.96 (7.50)		
Week 52 Adjusted Mean Change (SE)	-34.76 (5.77)	-23.60 (7.43)	-11.16 [-28.95; 6.63]	0.217
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	63.34 (23.23)	64.22 (20.59)		
Week 52 Mean (SD)	28.80 (22.75)	28.34 (23.61)		
Week 2 Adjusted Mean Change (SE)	-10.96 (2.90)	-10.61 (2.97)		
Week 4 Adjusted Mean Change (SE)	-18.55 (2.93)	-15.29 (3.01)		
Week 8 Adjusted Mean Change (SE)	-21.14 (3.07)	-18.47 (3.16)		
Week 12 Adjusted Mean Change (SE)	-22.48 (3.19)	-19.03 (3.29)		
Week 16 Adjusted Mean Change (SE)	-24.23 (3.19)	-24.08 (3.32)		
Week 20 Adjusted Mean Change (SE)	-24.80 (3.38)	-20.53 (3.54)		
Week 24 Adjusted Mean Change (SE)	-24.13 (3.21)	-22.39 (3.36)		
Week 28 Adjusted Mean Change (SE)	-25.07 (2.91)	-22.10 (3.08)		
Week 32 Adjusted Mean Change (SE)	-28.45 (3.15)	-28.06 (3.36)		
Week 36 Adjusted Mean Change (SE)	-29.42 (2.97)	-27.27 (3.13)		
Week 40 Adjusted Mean Change (SE)	-26.98 (3.10)	-27.13 (3.28)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 44 Adjusted Mean Change (SE)	-26.63 (3.18)	-28.59 (3.38)		
Week 48 Adjusted Mean Change (SE)	-27.03 (3.28)	-29.13 (3.48)		
Week 52 Adjusted Mean Change (SE)	-29.69 (3.23)	-28.56 (3.45)	-1.13 [-10.36; 8.10]	0.809

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

15.4 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.274				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	55.86 (24.87)	57.56 (26.08)		
Week 52 Mean (SD)	28.38 (19.63)	25.77 (22.13)		
Week 2 Adjusted Mean Change (SE)	-12.60 (3.77)	-15.97 (3.53)		
Week 4 Adjusted Mean Change (SE)	-19.02 (3.83)	-17.97 (3.62)		
Week 8 Adjusted Mean Change (SE)	-17.00 (4.04)	-19.04 (3.82)		
Week 12 Adjusted Mean Change (SE)	-19.04 (4.16)	-18.92 (3.95)		
Week 16 Adjusted Mean Change (SE)	-21.05 (4.16)	-19.68 (3.99)		
Week 20 Adjusted Mean Change (SE)	-22.47 (4.47)	-22.38 (4.30)		
Week 24 Adjusted Mean Change (SE)	-22.58 (4.22)	-23.63 (4.10)		
Week 28 Adjusted Mean Change (SE)	-25.10 (3.87)	-23.20 (3.80)		
Week 32 Adjusted Mean Change (SE)	-26.33 (4.10)	-31.18 (4.08)		
Week 36 Adjusted Mean Change (SE)	-27.64 (3.88)	-28.83 (3.87)		
Week 40 Adjusted Mean Change (SE)	-22.78 (4.06)	-25.72 (4.08)		
Week 44 Adjusted Mean Change (SE)	-26.72 (4.29)	-26.36 (4.31)		
Week 48 Adjusted Mean Change (SE)	-23.21 (4.34)	-26.94 (4.39)		
Week 52 Adjusted Mean Change (SE)	-28.75 (4.28)	-30.95 (4.36)	2.19 [-9.90; 14.29]	0.720
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	59.13 (24.48)	56.67 (25.69)		
Week 52 Mean (SD)	24.03 (24.99)	29.96 (25.74)		
Week 2 Adjusted Mean Change (SE)	-10.90 (3.24)	-7.10 (3.71)		
Week 4 Adjusted Mean Change (SE)	-18.27 (3.29)	-12.50 (3.77)		
Week 8 Adjusted Mean Change (SE)	-22.15 (3.47)	-19.22 (3.97)		
Week 12 Adjusted Mean Change (SE)	-24.09 (3.61)	-18.71 (4.12)		
Week 16 Adjusted Mean Change (SE)	-28.04 (3.60)	-25.92 (4.14)		
Week 20 Adjusted Mean Change (SE)	-27.92 (3.81)	-17.21 (4.41)		
Week 24 Adjusted Mean Change (SE)	-25.18 (3.62)	-20.82 (4.21)		
Week 28 Adjusted Mean Change (SE)	-27.96 (3.29)	-21.55 (3.86)		
Week 32 Adjusted Mean Change (SE)	-31.68 (3.53)	-23.84 (4.17)		
Week 36 Adjusted Mean Change (SE)	-30.25 (3.32)	-24.89 (3.88)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 40 Adjusted Mean Change (SE)	-30.92 (3.48)	-25.56 (4.09)		
Week 44 Adjusted Mean Change (SE)	-30.30 (3.66)	-26.39 (4.31)		
Week 48 Adjusted Mean Change (SE)	-31.99 (3.72)	-25.51 (4.38)		
Week 52 Adjusted Mean Change (SE)	-32.52 (3.64)	-24.24 (4.32)	-8.28 [-19.48; 2.92]	0.146

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

15.5 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.769				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	58.05 (23.93)	56.14 (28.95)		
Week 52 Mean (SD)	24.84 (22.28)	26.32 (24.37)		
Week 2 Adjusted Mean Change (SE)	-11.12 (3.18)	-14.15 (3.74)		
Week 4 Adjusted Mean Change (SE)	-17.64 (3.22)	-16.24 (3.78)		
Week 8 Adjusted Mean Change (SE)	-20.14 (3.38)	-21.05 (3.98)		
Week 12 Adjusted Mean Change (SE)	-21.29 (3.51)	-21.97 (4.09)		
Week 16 Adjusted Mean Change (SE)	-25.07 (3.53)	-25.39 (4.20)		
Week 20 Adjusted Mean Change (SE)	-24.88 (3.70)	-24.38 (4.43)		
Week 24 Adjusted Mean Change (SE)	-24.55 (3.51)	-27.51 (4.21)		
Week 28 Adjusted Mean Change (SE)	-26.36 (3.18)	-23.38 (3.92)		
Week 32 Adjusted Mean Change (SE)	-29.00 (3.50)	-25.23 (4.31)		
Week 36 Adjusted Mean Change (SE)	-29.25 (3.28)	-26.88 (4.05)		
Week 40 Adjusted Mean Change (SE)	-29.52 (3.44)	-23.11 (4.29)		
Week 44 Adjusted Mean Change (SE)	-30.47 (3.57)	-25.68 (4.43)		
Week 48 Adjusted Mean Change (SE)	-29.22 (3.69)	-26.77 (4.66)		
Week 52 Adjusted Mean Change (SE)	-32.43 (3.58)	-28.01 (4.59)	-4.42 [-15.95; 7.10]	0.449
> Median, N	**26**	**33**		
N'	26	32		
Baseline Mean (SD)	57.27 (25.85)	58.00 (22.87)		
Week 52 Mean (SD)	27.46 (24.07)	29.11 (23.97)		
Week 2 Adjusted Mean Change (SE)	-12.38 (3.95)	-9.58 (3.56)		
Week 4 Adjusted Mean Change (SE)	-20.04 (3.99)	-14.61 (3.63)		
Week 8 Adjusted Mean Change (SE)	-19.68 (4.19)	-17.45 (3.83)		
Week 12 Adjusted Mean Change (SE)	-22.89 (4.32)	-15.93 (3.97)		
Week 16 Adjusted Mean Change (SE)	-25.07 (4.35)	-20.27 (3.99)		
Week 20 Adjusted Mean Change (SE)	-26.63 (4.60)	-15.66 (4.25)		
Week 24 Adjusted Mean Change (SE)	-23.39 (4.30)	-17.52 (4.01)		
Week 28 Adjusted Mean Change (SE)	-27.26 (4.05)	-21.54 (3.73)		
Week 32 Adjusted Mean Change (SE)	-30.06 (4.26)	-29.30 (4.03)		
Week 36 Adjusted Mean Change (SE)	-29.03 (3.99)	-26.83 (3.76)		
Week 40 Adjusted Mean Change (SE)	-24.49 (4.23)	-27.39 (3.98)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 44 Adjusted Mean Change (SE)	-26.26 (4.41)	-27.06 (4.16)		
Week 48 Adjusted Mean Change (SE)	-26.80 (4.52)	-25.69 (4.25)		
Week 52 Adjusted Mean Change (SE)	-28.74 (4.43)	-26.90 (4.16)	-1.84 [-13.88; 10.19]	0.763

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

15.6 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.545				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	52.82 (25.08)	53.59 (31.46)		
Week 52 Mean (SD)	22.06 (21.30)	24.94 (26.28)		
Week 2 Adjusted Mean Change (SE)	-13.84 (3.42)	-19.46 (4.24)		
Week 4 Adjusted Mean Change (SE)	-19.86 (3.49)	-19.57 (4.39)		
Week 8 Adjusted Mean Change (SE)	-20.14 (3.66)	-25.19 (4.62)		
Week 12 Adjusted Mean Change (SE)	-24.76 (3.76)	-24.45 (4.78)		
Week 16 Adjusted Mean Change (SE)	-24.69 (3.78)	-28.25 (4.83)		
Week 20 Adjusted Mean Change (SE)	-25.67 (4.08)	-24.19 (5.12)		
Week 24 Adjusted Mean Change (SE)	-24.84 (3.84)	-25.05 (4.83)		
Week 28 Adjusted Mean Change (SE)	-26.21 (3.50)	-25.18 (4.46)		
Week 32 Adjusted Mean Change (SE)	-30.14 (3.78)	-25.26 (4.85)		
Week 36 Adjusted Mean Change (SE)	-28.50 (3.55)	-29.02 (4.53)		
Week 40 Adjusted Mean Change (SE)	-25.90 (3.72)	-26.85 (4.75)		
Week 44 Adjusted Mean Change (SE)	-29.57 (3.90)	-28.12 (5.01)		
Week 48 Adjusted Mean Change (SE)	-27.37 (4.00)	-26.31 (5.12)		
Week 52 Adjusted Mean Change (SE)	-32.94 (3.90)	-29.68 (5.01)	-3.26 [-15.77; 9.26]	0.607
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	62.97 (23.14)	59.08 (22.10)		
Week 52 Mean (SD)	29.65 (24.00)	29.89 (22.53)		
Week 2 Adjusted Mean Change (SE)	-9.25 (3.54)	-7.40 (3.18)		
Week 4 Adjusted Mean Change (SE)	-17.23 (3.61)	-12.98 (3.25)		
Week 8 Adjusted Mean Change (SE)	-19.77 (3.79)	-15.81 (3.41)		
Week 12 Adjusted Mean Change (SE)	-18.91 (3.89)	-15.84 (3.49)		
Week 16 Adjusted Mean Change (SE)	-25.54 (3.95)	-19.58 (3.57)		
Week 20 Adjusted Mean Change (SE)	-25.53 (4.19)	-17.58 (3.88)		
Week 24 Adjusted Mean Change (SE)	-23.33 (3.97)	-20.85 (3.71)		
Week 28 Adjusted Mean Change (SE)	-27.25 (3.62)	-21.05 (3.41)		
Week 32 Adjusted Mean Change (SE)	-28.65 (3.89)	-28.96 (3.70)		
Week 36 Adjusted Mean Change (SE)	-29.90 (3.66)	-25.86 (3.48)		
Week 40 Adjusted Mean Change (SE)	-29.06 (3.82)	-25.23 (3.67)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-28.04 (4.01)	-25.77 (3.83)		
Week 48 Adjusted Mean Change (SE)	-29.16 (4.09)	-26.41 (3.94)		
Week 52 Adjusted Mean Change (SE)	-29.02 (3.98)	-26.25 (3.88)	-2.78 [-13.74; 8.18]	0.617

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

15.7 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.827				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	63.66 (22.73)	55.76 (25.51)		
Week 52 Mean (SD)	28.48 (23.12)	24.42 (20.43)		
Week 2 Adjusted Mean Change (SE)	-11.36 (3.75)	-13.14 (4.00)		
Week 4 Adjusted Mean Change (SE)	-20.38 (3.75)	-22.03 (4.00)		
Week 8 Adjusted Mean Change (SE)	-20.54 (4.11)	-22.66 (4.38)		
Week 12 Adjusted Mean Change (SE)	-25.47 (3.99)	-25.91 (4.27)		
Week 16 Adjusted Mean Change (SE)	-27.51 (3.95)	-29.64 (4.25)		
Week 20 Adjusted Mean Change (SE)	-30.02 (4.35)	-25.49 (4.73)		
Week 24 Adjusted Mean Change (SE)	-28.84 (4.17)	-24.33 (4.53)		
Week 28 Adjusted Mean Change (SE)	-31.24 (3.62)	-23.38 (3.96)		
Week 32 Adjusted Mean Change (SE)	-33.42 (3.75)	-29.28 (4.12)		
Week 36 Adjusted Mean Change (SE)	-32.18 (3.61)	-30.10 (3.92)		
Week 40 Adjusted Mean Change (SE)	-30.16 (3.88)	-28.14 (4.24)		
Week 44 Adjusted Mean Change (SE)	-31.03 (4.12)	-30.64 (4.51)		
Week 48 Adjusted Mean Change (SE)	-30.25 (4.28)	-30.43 (4.66)		
Week 52 Adjusted Mean Change (SE)	-29.86 (4.15)	-30.73 (4.61)	0.87 [-11.46; 13.19]	0.889
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	53.55 (25.21)	53.95 (28.37)		
Week 52 Mean (SD)	23.95 (23.57)	29.63 (27.33)		
Week 2 Adjusted Mean Change (SE)	-13.31 (4.27)	-6.95 (4.59)		
Week 4 Adjusted Mean Change (SE)	-17.05 (4.27)	-7.87 (4.67)		
Week 8 Adjusted Mean Change (SE)	-18.18 (4.68)	-14.98 (5.13)		
Week 12 Adjusted Mean Change (SE)	-19.45 (4.57)	-16.08 (4.99)		
Week 16 Adjusted Mean Change (SE)	-21.77 (4.51)	-23.03 (4.97)		
Week 20 Adjusted Mean Change (SE)	-17.60 (5.00)	-21.83 (5.42)		
Week 24 Adjusted Mean Change (SE)	-22.24 (4.71)	-22.19 (5.26)		
Week 28 Adjusted Mean Change (SE)	-20.32 (4.13)	-25.07 (4.64)		
Week 32 Adjusted Mean Change (SE)	-29.17 (4.35)	-24.34 (4.83)		
Week 36 Adjusted Mean Change (SE)	-26.71 (4.15)	-24.17 (4.60)		
Week 40 Adjusted Mean Change (SE)	-25.53 (4.46)	-26.28 (5.03)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-27.64 (4.74)	-20.26 (5.32)		
Week 48 Adjusted Mean Change (SE)	-24.88 (4.95)	-20.68 (5.59)		
Week 52 Adjusted Mean Change (SE)	-31.84 (4.79)	-24.37 (5.34)	-7.46 [-21.65; 6.72]	0.299

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

15.8 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC **(N=66)**	**ADA** **(N=62)**	**Mean Difference** **[95% CI]**	**p-value**
Interaction test: p=0.192				
Non-carrier, N	**28**	**19**		
N'	28	19		
Baseline Mean (SD)	58.86 (23.62)	62.84 (19.45)		
Week 52 Mean (SD)	27.70 (24.28)	32.62 (23.35)		
Week 2 Adjusted Mean Change (SE)	-12.69 (3.80)	-4.81 (4.64)		
Week 4 Adjusted Mean Change (SE)	-21.35 (3.89)	-13.49 (4.82)		
Week 8 Adjusted Mean Change (SE)	-21.40 (4.22)	-16.12 (5.23)		
Week 12 Adjusted Mean Change (SE)	-25.16 (4.19)	-23.59 (5.21)		
Week 16 Adjusted Mean Change (SE)	-28.51 (3.96)	-21.48 (4.95)		
Week 20 Adjusted Mean Change (SE)	-26.86 (4.52)	-16.79 (5.72)		
Week 24 Adjusted Mean Change (SE)	-26.48 (4.25)	-20.00 (5.46)		
Week 28 Adjusted Mean Change (SE)	-29.33 (3.75)	-25.80 (4.89)		
Week 32 Adjusted Mean Change (SE)	-32.95 (3.89)	-26.09 (5.05)		
Week 36 Adjusted Mean Change (SE)	-30.27 (3.72)	-23.65 (4.79)		
Week 40 Adjusted Mean Change (SE)	-28.39 (3.99)	-20.34 (5.18)		
Week 44 Adjusted Mean Change (SE)	-32.30 (4.22)	-19.19 (5.56)		
Week 48 Adjusted Mean Change (SE)	-29.02 (4.51)	-24.21 (5.89)		
Week 52 Adjusted Mean Change (SE)	-30.51 (4.28)	-24.27 (5.71)	-6.24 [-20.43; 7.95]	0.384
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	62.23 (22.99)	49.63 (28.73)		
Week 52 Mean (SD)	26.21 (22.02)	24.12 (24.09)		
Week 2 Adjusted Mean Change (SE)	-12.33 (4.30)	-15.51 (4.68)		
Week 4 Adjusted Mean Change (SE)	-17.14 (4.41)	-17.15 (4.79)		
Week 8 Adjusted Mean Change (SE)	-18.27 (4.78)	-22.93 (5.19)		
Week 12 Adjusted Mean Change (SE)	-21.99 (4.77)	-22.12 (5.18)		
Week 16 Adjusted Mean Change (SE)	-21.68 (4.49)	-31.54 (4.94)		
Week 20 Adjusted Mean Change (SE)	-23.64 (5.13)	-33.68 (5.59)		
Week 24 Adjusted Mean Change (SE)	-26.41 (4.78)	-28.49 (5.27)		
Week 28 Adjusted Mean Change (SE)	-24.42 (4.32)	-25.76 (4.74)		
Week 32 Adjusted Mean Change (SE)	-30.85 (4.39)	-29.09 (4.88)		
Week 36 Adjusted Mean Change (SE)	-30.52 (4.20)	-33.37 (4.59)		
Week 40 Adjusted Mean Change (SE)	-29.26 (4.48)	-33.97 (4.97)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-27.56 (4.79)	-33.23 (5.27)		
Week 48 Adjusted Mean Change (SE)	-27.69 (5.09)	-27.78 (5.60)		
Week 52 Adjusted Mean Change (SE)	-32.36 (4.90)	-32.43 (5.34)	0.07 [-14.41; 14.56]	0.992

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

15.9 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.399				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	61.84 (25.50)	57.24 (29.29)		
Week 52 Mean (SD)	31.95 (23.17)	30.13 (27.32)		
Week 2 Adjusted Mean Change (SE)	-12.50 (4.67)	-10.38 (4.42)		
Week 4 Adjusted Mean Change (SE)	-18.42 (4.76)	-18.66 (4.57)		
Week 8 Adjusted Mean Change (SE)	-12.22 (4.95)	-25.53 (4.76)		
Week 12 Adjusted Mean Change (SE)	-19.56 (4.90)	-28.54 (4.77)		
Week 16 Adjusted Mean Change (SE)	-21.33 (4.87)	-27.40 (4.80)		
Week 20 Adjusted Mean Change (SE)	-21.06 (5.51)	-21.79 (5.35)		
Week 24 Adjusted Mean Change (SE)	-23.15 (5.21)	-25.29 (5.13)		
Week 28 Adjusted Mean Change (SE)	-25.45 (4.69)	-25.63 (4.61)		
Week 32 Adjusted Mean Change (SE)	-29.69 (4.67)	-27.13 (4.69)		
Week 36 Adjusted Mean Change (SE)	-29.06 (4.47)	-29.30 (4.48)		
Week 40 Adjusted Mean Change (SE)	-25.69 (4.79)	-27.44 (4.83)		
Week 44 Adjusted Mean Change (SE)	-26.33 (5.15)	-26.48 (5.23)		
Week 48 Adjusted Mean Change (SE)	-25.83 (5.31)	-28.01 (5.40)		
Week 52 Adjusted Mean Change (SE)	-27.15 (5.08)	-23.73 (5.23)	-3.42 [-17.90; 11.07]	0.640
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	57.37 (22.98)	52.91 (24.09)		
Week 52 Mean (SD)	23.19 (23.23)	24.30 (20.79)		
Week 2 Adjusted Mean Change (SE)	-11.20 (3.70)	-10.39 (4.24)		
Week 4 Adjusted Mean Change (SE)	-18.23 (3.77)	-13.72 (4.32)		
Week 8 Adjusted Mean Change (SE)	-23.43 (3.92)	-13.95 (4.49)		
Week 12 Adjusted Mean Change (SE)	-24.55 (3.90)	-15.98 (4.45)		
Week 16 Adjusted Mean Change (SE)	-26.45 (3.88)	-26.22 (4.46)		
Week 20 Adjusted Mean Change (SE)	-27.30 (4.35)	-25.71 (5.00)		
Week 24 Adjusted Mean Change (SE)	-27.31 (4.08)	-21.88 (4.75)		
Week 28 Adjusted Mean Change (SE)	-27.56 (3.62)	-23.03 (4.25)		
Week 32 Adjusted Mean Change (SE)	-32.80 (3.74)	-26.94 (4.33)		
Week 36 Adjusted Mean Change (SE)	-29.70 (3.59)	-26.34 (4.11)		
Week 40 Adjusted Mean Change (SE)	-29.53 (3.82)	-27.15 (4.42)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 44 Adjusted Mean Change (SE)	-31.29 (4.12)	-26.10 (4.75)		
Week 48 Adjusted Mean Change (SE)	-28.84 (4.29)	-25.18 (4.94)		
Week 52 Adjusted Mean Change (SE)	-32.45 (4.10)	-31.38 (4.72)	-1.06 [-13.48; 11.35]	0.865

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

15.10 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

| | Treatment Groups | | Comparison | |
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.102				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	61.52 (23.78)	51.81 (26.95)		
Week 52 Mean (SD)	26.30 (25.65)	31.12 (25.22)		
Week 2 Adjusted Mean Change (SE)	-13.38 (3.99)	-8.03 (3.53)		
Week 4 Adjusted Mean Change (SE)	-20.79 (4.13)	-15.89 (3.65)		
Week 8 Adjusted Mean Change (SE)	-18.33 (4.36)	-16.17 (3.86)		
Week 12 Adjusted Mean Change (SE)	-21.62 (4.32)	-18.96 (3.81)		
Week 16 Adjusted Mean Change (SE)	-24.00 (4.25)	-23.79 (3.76)		
Week 20 Adjusted Mean Change (SE)	-25.80 (4.57)	-18.39 (4.11)		
Week 24 Adjusted Mean Change (SE)	-27.98 (4.32)	-18.71 (3.93)		
Week 28 Adjusted Mean Change (SE)	-27.88 (3.80)	-19.31 (3.49)		
Week 32 Adjusted Mean Change (SE)	-33.93 (4.04)	-24.90 (3.70)		
Week 36 Adjusted Mean Change (SE)	-30.03 (3.92)	-26.68 (3.53)		
Week 40 Adjusted Mean Change (SE)	-30.48 (4.16)	-26.23 (3.81)		
Week 44 Adjusted Mean Change (SE)	-33.42 (4.46)	-24.38 (4.04)		
Week 48 Adjusted Mean Change (SE)	-28.76 (4.63)	-24.15 (4.22)		
Week 52 Adjusted Mean Change (SE)	-32.64 (4.43)	-25.62 (4.04)	-7.02 [-18.98; 4.95]	0.247
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	57.15 (24.73)	63.42 (24.21)		
Week 52 Mean (SD)	26.79 (21.07)	14.33 (12.10)		
Week 2 Adjusted Mean Change (SE)	-11.15 (3.90)	-16.86 (5.75)		
Week 4 Adjusted Mean Change (SE)	-17.11 (4.03)	-16.24 (6.11)		
Week 8 Adjusted Mean Change (SE)	-20.69 (4.26)	-28.38 (6.47)		
Week 12 Adjusted Mean Change (SE)	-24.17 (4.19)	-29.66 (6.40)		
Week 16 Adjusted Mean Change (SE)	-25.89 (4.10)	-35.32 (6.37)		
Week 20 Adjusted Mean Change (SE)	-23.67 (4.51)	-39.11 (6.79)		
Week 24 Adjusted Mean Change (SE)	-24.19 (4.25)	-36.37 (6.44)		
Week 28 Adjusted Mean Change (SE)	-25.29 (3.77)	-37.15 (5.72)		
Week 32 Adjusted Mean Change (SE)	-29.39 (3.96)	-32.89 (5.99)		
Week 36 Adjusted Mean Change (SE)	-29.35 (3.82)	-30.00 (5.85)		
Week 40 Adjusted Mean Change (SE)	-25.87 (4.10)	-29.79 (6.31)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-25.95 (4.35)	-31.93 (6.78)		
Week 48 Adjusted Mean Change (SE)	-27.00 (4.51)	-33.08 (6.95)		
Week 52 Adjusted Mean Change (SE)	-28.76 (4.34)	-35.16 (6.77)	6.40 [-9.58; 22.38]	0.428

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

15.11 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.271				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	59.32 (24.09)	52.12 (24.81)		
Week 52 Mean (SD)	27.65 (22.31)	24.04 (20.03)		
Week 2 Adjusted Mean Change (SE)	-11.67 (3.20)	-11.09 (3.43)		
Week 4 Adjusted Mean Change (SE)	-19.15 (3.26)	-17.76 (3.53)		
Week 8 Adjusted Mean Change (SE)	-20.92 (3.47)	-19.10 (3.77)		
Week 12 Adjusted Mean Change (SE)	-22.78 (3.38)	-22.20 (3.65)		
Week 16 Adjusted Mean Change (SE)	-24.13 (3.36)	-27.03 (3.66)		
Week 20 Adjusted Mean Change (SE)	-25.47 (3.67)	-22.12 (4.04)		
Week 24 Adjusted Mean Change (SE)	-27.97 (3.53)	-22.98 (3.93)		
Week 28 Adjusted Mean Change (SE)	-25.37 (3.16)	-25.32 (3.49)		
Week 32 Adjusted Mean Change (SE)	-31.99 (3.20)	-30.99 (3.56)		
Week 36 Adjusted Mean Change (SE)	-30.32 (3.11)	-29.05 (3.45)		
Week 40 Adjusted Mean Change (SE)	-27.70 (3.27)	-26.45 (3.69)		
Week 44 Adjusted Mean Change (SE)	-29.18 (3.57)	-25.29 (4.01)		
Week 48 Adjusted Mean Change (SE)	-26.40 (3.67)	-26.49 (4.09)		
Week 52 Adjusted Mean Change (SE)	-29.62 (3.51)	-28.80 (3.99)	-0.82 [-11.42; 9.78]	0.878
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	59.17 (26.32)	58.67 (31.47)		
Week 52 Mean (SD)	25.25 (26.53)	21.89 (20.08)		
Week 2 Adjusted Mean Change (SE)	-9.59 (5.72)	-13.27 (6.54)		
Week 4 Adjusted Mean Change (SE)	-13.60 (5.81)	-15.94 (6.65)		
Week 8 Adjusted Mean Change (SE)	-11.00 (6.19)	-26.21 (7.09)		
Week 12 Adjusted Mean Change (SE)	-18.56 (6.00)	-28.53 (7.01)		
Week 16 Adjusted Mean Change (SE)	-23.45 (5.94)	-33.57 (6.95)		
Week 20 Adjusted Mean Change (SE)	-18.11 (6.62)	-37.76 (7.48)		
Week 24 Adjusted Mean Change (SE)	-16.42 (6.26)	-30.64 (7.17)		
Week 28 Adjusted Mean Change (SE)	-25.92 (5.67)	-26.42 (6.69)		
Week 32 Adjusted Mean Change (SE)	-27.13 (5.65)	-21.92 (6.46)		
Week 36 Adjusted Mean Change (SE)	-25.74 (5.48)	-29.57 (6.27)		
Week 40 Adjusted Mean Change (SE)	-25.55 (5.80)	-36.32 (6.63)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 44 Adjusted Mean Change (SE)	-27.02 (6.31)	-35.38 (7.23)		
Week 48 Adjusted Mean Change (SE)	-28.13 (6.41)	-35.07 (7.44)		
Week 52 Adjusted Mean Change (SE)	-29.25 (6.13)	-34.52 (7.02)	5.27 [-13.23; 23.76]	0.573

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

15.12 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.892				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	60.31 (24.21)	53.68 (28.86)		
Week 52 Mean (SD)	28.39 (24.90)	25.80 (23.44)		
Week 2 Adjusted Mean Change (SE)	-11.61 (3.38)	-11.22 (3.48)		
Week 4 Adjusted Mean Change (SE)	-19.76 (3.38)	-17.17 (3.50)		
Week 8 Adjusted Mean Change (SE)	-19.67 (3.69)	-21.88 (3.83)		
Week 12 Adjusted Mean Change (SE)	-26.81 (3.50)	-22.90 (3.66)		
Week 16 Adjusted Mean Change (SE)	-27.23 (3.48)	-30.03 (3.66)		
Week 20 Adjusted Mean Change (SE)	-24.81 (4.00)	-24.96 (4.18)		
Week 24 Adjusted Mean Change (SE)	-25.88 (3.75)	-23.94 (3.99)		
Week 28 Adjusted Mean Change (SE)	-25.90 (3.36)	-24.49 (3.57)		
Week 32 Adjusted Mean Change (SE)	-31.96 (3.39)	-27.44 (3.61)		
Week 36 Adjusted Mean Change (SE)	-29.82 (3.20)	-29.07 (3.41)		
Week 40 Adjusted Mean Change (SE)	-29.41 (3.42)	-26.61 (3.67)		
Week 44 Adjusted Mean Change (SE)	-29.41 (3.67)	-27.72 (3.92)		
Week 48 Adjusted Mean Change (SE)	-26.97 (3.88)	-26.44 (4.14)		
Week 52 Adjusted Mean Change (SE)	-29.58 (3.73)	-28.29 (4.04)	-1.29 [-12.25; 9.67]	0.815
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	53.46 (24.64)	59.40 (16.29)		
Week 52 Mean (SD)	23.25 (19.17)	29.30 (25.14)		
Week 2 Adjusted Mean Change (SE)	-10.51 (5.61)	-6.54 (6.43)		
Week 4 Adjusted Mean Change (SE)	-11.92 (5.60)	-11.09 (6.42)		
Week 8 Adjusted Mean Change (SE)	-18.07 (6.13)	-9.82 (7.01)		
Week 12 Adjusted Mean Change (SE)	-9.75 (5.81)	-16.37 (6.66)		
Week 16 Adjusted Mean Change (SE)	-16.12 (5.72)	-15.63 (6.55)		
Week 20 Adjusted Mean Change (SE)	-21.38 (6.67)	-19.71 (7.65)		
Week 24 Adjusted Mean Change (SE)	-23.15 (6.19)	-20.43 (7.09)		
Week 28 Adjusted Mean Change (SE)	-27.69 (5.57)	-21.58 (6.53)		
Week 32 Adjusted Mean Change (SE)	-27.68 (5.59)	-25.14 (6.61)		
Week 36 Adjusted Mean Change (SE)	-24.87 (5.35)	-21.69 (6.04)		
Week 40 Adjusted Mean Change (SE)	-22.65 (5.63)	-27.02 (6.46)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 44 Adjusted Mean Change (SE)	-29.15 (6.02)	-20.82 (6.95)		
Week 48 Adjusted Mean Change (SE)	-26.85 (6.37)	-25.30 (7.42)		
Week 52 Adjusted Mean Change (SE)	-29.27 (6.14)	-25.66 (6.96)	-3.61 [-22.12; 14.90]	0.699

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

15.13 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.765				
Non-carrier, N	**42**	**36**		
N'	42	36		
Baseline Mean (SD)	57.83 (25.63)	56.86 (26.83)		
Week 52 Mean (SD)	25.32 (22.97)	27.79 (25.05)		
Week 2 Adjusted Mean Change (SE)	-14.48 (3.06)	-9.54 (3.30)		
Week 4 Adjusted Mean Change (SE)	-20.43 (3.09)	-15.32 (3.37)		
Week 8 Adjusted Mean Change (SE)	-20.98 (3.36)	-19.76 (3.66)		
Week 12 Adjusted Mean Change (SE)	-23.93 (3.27)	-23.05 (3.57)		
Week 16 Adjusted Mean Change (SE)	-25.80 (3.12)	-25.76 (3.43)		
Week 20 Adjusted Mean Change (SE)	-25.18 (3.70)	-22.91 (4.06)		
Week 24 Adjusted Mean Change (SE)	-25.82 (3.38)	-22.06 (3.76)		
Week 28 Adjusted Mean Change (SE)	-27.95 (3.00)	-24.82 (3.37)		
Week 32 Adjusted Mean Change (SE)	-32.17 (3.09)	-24.40 (3.47)		
Week 36 Adjusted Mean Change (SE)	-30.05 (3.01)	-25.90 (3.35)		
Week 40 Adjusted Mean Change (SE)	-28.78 (3.21)	-26.00 (3.60)		
Week 44 Adjusted Mean Change (SE)	-30.00 (3.48)	-24.68 (3.90)		
Week 48 Adjusted Mean Change (SE)	-29.74 (3.57)	-24.93 (4.03)		
Week 52 Adjusted Mean Change (SE)	-31.34 (3.48)	-27.02 (3.91)	-4.32 [-14.72; 6.08]	0.411
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	66.11 (14.39)	36.40 (21.24)		
Week 52 Mean (SD)	31.78 (24.67)	26.33 (12.50)		
Week 2 Adjusted Mean Change (SE)	-1.06 (6.65)	-9.91 (9.01)		
Week 4 Adjusted Mean Change (SE)	-11.73 (6.73)	-14.58 (9.12)		
Week 8 Adjusted Mean Change (SE)	-12.20 (7.32)	-6.38 (9.91)		
Week 12 Adjusted Mean Change (SE)	-18.62 (7.09)	-8.70 (9.61)		
Week 16 Adjusted Mean Change (SE)	-20.62 (6.75)	-13.69 (9.14)		
Week 20 Adjusted Mean Change (SE)	-22.28 (8.00)	-19.05 (10.83)		
Week 24 Adjusted Mean Change (SE)	-25.38 (7.32)	-25.52 (9.91)		
Week 28 Adjusted Mean Change (SE)	-20.18 (6.44)	-17.78 (8.72)		
Week 32 Adjusted Mean Change (SE)	-26.89 (6.66)	-28.62 (9.02)		
Week 36 Adjusted Mean Change (SE)	-27.46 (6.48)	-29.55 (8.78)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 40 Adjusted Mean Change (SE)	-24.55 (6.94)	-25.90 (9.58)		
Week 44 Adjusted Mean Change (SE)	-26.78 (7.50)	-25.99 (10.39)		
Week 48 Adjusted Mean Change (SE)	-18.23 (7.76)	-27.55 (10.39)		
Week 52 Adjusted Mean Change (SE)	-26.26 (7.43)	-21.23 (10.74)	-5.03 [-31.26; 21.20]	0.704

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

15.14 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.572				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	61.00 (28.39)	57.64 (27.96)		
Week 52 Mean (SD)	33.20 (26.22)	32.47 (24.76)		
Week 2 Adjusted Mean Change (SE)	-21.23 (5.94)	-7.56 (4.20)		
Week 4 Adjusted Mean Change (SE)	-25.73 (6.16)	-16.63 (4.42)		
Week 8 Adjusted Mean Change (SE)	-20.56 (6.66)	-20.17 (4.78)		
Week 12 Adjusted Mean Change (SE)	-26.62 (6.49)	-24.29 (4.68)		
Week 16 Adjusted Mean Change (SE)	-26.19 (6.49)	-25.95 (4.69)		
Week 20 Adjusted Mean Change (SE)	-21.25 (7.02)	-17.16 (5.14)		
Week 24 Adjusted Mean Change (SE)	-27.76 (6.73)	-18.19 (4.99)		
Week 28 Adjusted Mean Change (SE)	-24.89 (5.93)	-23.36 (4.50)		
Week 32 Adjusted Mean Change (SE)	-30.89 (6.08)	-27.63 (4.64)		
Week 36 Adjusted Mean Change (SE)	-27.48 (5.87)	-26.36 (4.41)		
Week 40 Adjusted Mean Change (SE)	-27.08 (6.18)	-21.93 (4.73)		
Week 44 Adjusted Mean Change (SE)	-25.43 (6.72)	-22.29 (5.11)		
Week 48 Adjusted Mean Change (SE)	-24.32 (7.05)	-23.72 (5.31)		
Week 52 Adjusted Mean Change (SE)	-25.79 (6.66)	-23.72 (5.13)	-2.07 [-18.77; 14.63]	0.806
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	58.83 (23.20)	52.32 (25.26)		
Week 52 Mean (SD)	24.76 (22.33)	22.55 (22.39)		
Week 2 Adjusted Mean Change (SE)	-9.71 (3.11)	-13.37 (4.22)		
Week 4 Adjusted Mean Change (SE)	-17.04 (3.23)	-15.63 (4.38)		
Week 8 Adjusted Mean Change (SE)	-19.21 (3.49)	-18.77 (4.73)		
Week 12 Adjusted Mean Change (SE)	-21.87 (3.41)	-19.29 (4.64)		
Week 16 Adjusted Mean Change (SE)	-24.68 (3.36)	-27.82 (4.57)		
Week 20 Adjusted Mean Change (SE)	-25.73 (3.71)	-30.48 (5.02)		
Week 24 Adjusted Mean Change (SE)	-25.55 (3.46)	-28.13 (4.69)		
Week 28 Adjusted Mean Change (SE)	-26.96 (3.17)	-24.80 (4.33)		
Week 32 Adjusted Mean Change (SE)	-31.79 (3.22)	-26.94 (4.35)		
Week 36 Adjusted Mean Change (SE)	-30.40 (3.08)	-29.04 (4.13)		
Week 40 Adjusted Mean Change (SE)	-28.40 (3.26)	-31.92 (4.41)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 44 Adjusted Mean Change (SE)	-30.64 (3.51)	-29.94 (4.74)		
Week 48 Adjusted Mean Change (SE)	-28.84 (3.64)	-29.07 (4.94)		
Week 52 Adjusted Mean Change (SE)	-31.95 (3.48)	-32.09 (4.70)	0.13 [-11.50; 11.77]	0.982

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

15.15 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.385				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	55.87 (24.85)	60.22 (21.27)		
Week 52 Mean (SD)	27.77 (24.54)	30.38 (23.89)		
Week 2 Adjusted Mean Change (SE)	-12.72 (3.57)	-6.08 (4.14)		
Week 4 Adjusted Mean Change (SE)	-19.29 (3.68)	-13.35 (4.34)		
Week 8 Adjusted Mean Change (SE)	-18.67 (3.95)	-16.85 (4.66)		
Week 12 Adjusted Mean Change (SE)	-22.47 (3.88)	-23.37 (4.59)		
Week 16 Adjusted Mean Change (SE)	-25.92 (3.76)	-20.97 (4.45)		
Week 20 Adjusted Mean Change (SE)	-24.96 (4.17)	-16.51 (5.00)		
Week 24 Adjusted Mean Change (SE)	-24.68 (4.01)	-21.80 (4.86)		
Week 28 Adjusted Mean Change (SE)	-28.00 (3.57)	-24.86 (4.40)		
Week 32 Adjusted Mean Change (SE)	-31.25 (3.62)	-23.94 (4.42)		
Week 36 Adjusted Mean Change (SE)	-29.02 (3.46)	-22.94 (4.20)		
Week 40 Adjusted Mean Change (SE)	-26.66 (3.70)	-22.68 (4.53)		
Week 44 Adjusted Mean Change (SE)	-29.52 (3.95)	-20.43 (4.88)		
Week 48 Adjusted Mean Change (SE)	-27.68 (4.16)	-25.94 (5.12)		
Week 52 Adjusted Mean Change (SE)	-29.16 (3.96)	-25.20 (4.97)	-3.95 [-16.60; 8.70]	0.537
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	64.60 (22.52)	49.24 (30.70)		
Week 52 Mean (SD)	24.41 (21.07)	23.79 (23.60)		
Week 2 Adjusted Mean Change (SE)	-11.26 (4.49)	-15.35 (4.37)		
Week 4 Adjusted Mean Change (SE)	-18.23 (4.63)	-19.14 (4.52)		
Week 8 Adjusted Mean Change (SE)	-20.74 (4.97)	-22.26 (4.84)		
Week 12 Adjusted Mean Change (SE)	-23.65 (4.92)	-20.00 (4.79)		
Week 16 Adjusted Mean Change (SE)	-23.37 (4.73)	-33.47 (4.67)		
Week 20 Adjusted Mean Change (SE)	-24.20 (5.27)	-32.22 (5.12)		
Week 24 Adjusted Mean Change (SE)	-27.86 (5.01)	-25.30 (4.94)		
Week 28 Adjusted Mean Change (SE)	-23.77 (4.61)	-23.22 (4.49)		
Week 32 Adjusted Mean Change (SE)	-31.73 (4.55)	-30.59 (4.51)		
Week 36 Adjusted Mean Change (SE)	-30.78 (4.34)	-32.72 (4.25)		
Week 40 Adjusted Mean Change (SE)	-30.19 (4.62)	-32.24 (4.59)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 44 Adjusted Mean Change (SE)	-29.31 (4.99)	-32.51 (4.90)		
Week 48 Adjusted Mean Change (SE)	-28.02 (5.22)	-27.59 (5.13)		
Week 52 Adjusted Mean Change (SE)	-32.89 (5.05)	-31.35 (4.91)	-1.54 [-15.66; 12.58]	0.829

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

15.16 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.327				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	61.84 (25.50)	56.65 (29.92)		
Week 52 Mean (SD)	31.95 (23.17)	30.43 (28.33)		
Week 2 Adjusted Mean Change (SE)	-12.58 (4.65)	-11.98 (4.51)		
Week 4 Adjusted Mean Change (SE)	-18.51 (4.71)	-20.09 (4.64)		
Week 8 Adjusted Mean Change (SE)	-12.26 (4.90)	-26.21 (4.84)		
Week 12 Adjusted Mean Change (SE)	-19.68 (4.82)	-29.96 (4.81)		
Week 16 Adjusted Mean Change (SE)	-21.48 (4.83)	-29.82 (4.89)		
Week 20 Adjusted Mean Change (SE)	-21.24 (5.48)	-23.73 (5.46)		
Week 24 Adjusted Mean Change (SE)	-23.20 (5.14)	-26.47 (5.21)		
Week 28 Adjusted Mean Change (SE)	-25.46 (4.63)	-26.77 (4.68)		
Week 32 Adjusted Mean Change (SE)	-29.76 (4.60)	-25.37 (4.76)		
Week 36 Adjusted Mean Change (SE)	-29.14 (4.43)	-28.69 (4.56)		
Week 40 Adjusted Mean Change (SE)	-25.70 (4.74)	-27.38 (4.93)		
Week 44 Adjusted Mean Change (SE)	-26.37 (5.11)	-26.44 (5.31)		
Week 48 Adjusted Mean Change (SE)	-25.85 (5.26)	-26.14 (5.51)		
Week 52 Adjusted Mean Change (SE)	-27.21 (5.02)	-22.90 (5.32)	-4.30 [-18.84; 10.23]	0.558
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	57.78 (23.55)	53.58 (23.79)		
Week 52 Mean (SD)	22.89 (22.85)	24.38 (20.27)		
Week 2 Adjusted Mean Change (SE)	-12.00 (3.56)	-9.18 (4.13)		
Week 4 Adjusted Mean Change (SE)	-19.16 (3.61)	-12.86 (4.18)		
Week 8 Adjusted Mean Change (SE)	-23.79 (3.76)	-14.01 (4.35)		
Week 12 Adjusted Mean Change (SE)	-24.83 (3.71)	-15.47 (4.28)		
Week 16 Adjusted Mean Change (SE)	-27.06 (3.74)	-24.42 (4.32)		
Week 20 Adjusted Mean Change (SE)	-26.86 (4.18)	-24.02 (4.86)		
Week 24 Adjusted Mean Change (SE)	-27.56 (3.90)	-21.15 (4.58)		
Week 28 Adjusted Mean Change (SE)	-27.29 (3.46)	-22.34 (4.10)		
Week 32 Adjusted Mean Change (SE)	-32.51 (3.57)	-28.26 (4.17)		
Week 36 Adjusted Mean Change (SE)	-29.92 (3.45)	-26.96 (3.97)		
Week 40 Adjusted Mean Change (SE)	-29.57 (3.67)	-27.20 (4.28)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 44 Adjusted Mean Change (SE)	-31.44 (3.97)	-26.17 (4.62)		
Week 48 Adjusted Mean Change (SE)	-28.92 (4.13)	-26.82 (4.78)		
Week 52 Adjusted Mean Change (SE)	-32.94 (3.94)	-31.71 (4.55)	-1.23 [-13.19; 10.73]	0.838

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

15.17 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.102				
Non-carrier, N	25	32		
N'	25	32		
Baseline Mean (SD)	61.52 (23.78)	51.81 (26.95)		
Week 52 Mean (SD)	26.30 (25.65)	31.12 (25.22)		
Week 2 Adjusted Mean Change (SE)	-13.38 (3.99)	-8.03 (3.53)		
Week 4 Adjusted Mean Change (SE)	-20.79 (4.13)	-15.89 (3.65)		
Week 8 Adjusted Mean Change (SE)	-18.33 (4.36)	-16.17 (3.86)		
Week 12 Adjusted Mean Change (SE)	-21.62 (4.32)	-18.96 (3.81)		
Week 16 Adjusted Mean Change (SE)	-24.00 (4.25)	-23.79 (3.76)		
Week 20 Adjusted Mean Change (SE)	-25.80 (4.57)	-18.39 (4.11)		
Week 24 Adjusted Mean Change (SE)	-27.98 (4.32)	-18.71 (3.93)		
Week 28 Adjusted Mean Change (SE)	-27.88 (3.80)	-19.31 (3.49)		
Week 32 Adjusted Mean Change (SE)	-33.93 (4.04)	-24.90 (3.70)		
Week 36 Adjusted Mean Change (SE)	-30.03 (3.92)	-26.68 (3.53)		
Week 40 Adjusted Mean Change (SE)	-30.48 (4.16)	-26.23 (3.81)		
Week 44 Adjusted Mean Change (SE)	-33.42 (4.46)	-24.38 (4.04)		
Week 48 Adjusted Mean Change (SE)	-28.76 (4.63)	-24.15 (4.22)		
Week 52 Adjusted Mean Change (SE)	-32.64 (4.43)	-25.62 (4.04)	-7.02 [-18.98; 4.95]	0.247
Carrier, N	26	12		
N'	26	12		
Baseline Mean (SD)	57.15 (24.73)	63.42 (24.21)		
Week 52 Mean (SD)	26.79 (21.07)	14.33 (12.10)		
Week 2 Adjusted Mean Change (SE)	-11.15 (3.90)	-16.86 (5.75)		
Week 4 Adjusted Mean Change (SE)	-17.11 (4.03)	-16.24 (6.11)		
Week 8 Adjusted Mean Change (SE)	-20.69 (4.26)	-28.38 (6.47)		
Week 12 Adjusted Mean Change (SE)	-24.17 (4.19)	-29.66 (6.40)		
Week 16 Adjusted Mean Change (SE)	-25.89 (4.10)	-35.32 (6.37)		
Week 20 Adjusted Mean Change (SE)	-23.67 (4.51)	-39.11 (6.79)		
Week 24 Adjusted Mean Change (SE)	-24.19 (4.25)	-36.37 (6.44)		
Week 28 Adjusted Mean Change (SE)	-25.29 (3.77)	-37.15 (5.72)		
Week 32 Adjusted Mean Change (SE)	-29.39 (3.96)	-32.89 (5.99)		
Week 36 Adjusted Mean Change (SE)	-29.35 (3.82)	-30.00 (5.85)		
Week 40 Adjusted Mean Change (SE)	-25.87 (4.10)	-29.79 (6.31)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-25.95 (4.35)	-31.93 (6.78)		
Week 48 Adjusted Mean Change (SE)	-27.00 (4.51)	-33.08 (6.95)		
Week 52 Adjusted Mean Change (SE)	-28.76 (4.34)	-35.16 (6.77)	6.40 [-9.58; 22.38]	0.428

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

15.18 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.350				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	59.33 (23.77)	52.60 (25.72)		
Week 52 Mean (SD)	27.00 (22.31)	27.81 (23.58)		
Week 2 Adjusted Mean Change (SE)	-12.62 (3.26)	-9.57 (3.43)		
Week 4 Adjusted Mean Change (SE)	-20.16 (3.29)	-16.83 (3.50)		
Week 8 Adjusted Mean Change (SE)	-21.64 (3.53)	-18.61 (3.76)		
Week 12 Adjusted Mean Change (SE)	-23.77 (3.50)	-20.95 (3.73)		
Week 16 Adjusted Mean Change (SE)	-24.99 (3.44)	-25.68 (3.68)		
Week 20 Adjusted Mean Change (SE)	-26.33 (3.79)	-21.14 (4.09)		
Week 24 Adjusted Mean Change (SE)	-28.58 (3.51)	-20.64 (3.82)		
Week 28 Adjusted Mean Change (SE)	-26.18 (3.25)	-23.67 (3.54)		
Week 32 Adjusted Mean Change (SE)	-32.49 (3.28)	-28.89 (3.58)		
Week 36 Adjusted Mean Change (SE)	-30.59 (3.15)	-27.97 (3.42)		
Week 40 Adjusted Mean Change (SE)	-28.47 (3.35)	-24.85 (3.69)		
Week 44 Adjusted Mean Change (SE)	-29.76 (3.60)	-23.88 (3.96)		
Week 48 Adjusted Mean Change (SE)	-27.14 (3.75)	-24.66 (4.09)		
Week 52 Adjusted Mean Change (SE)	-30.44 (3.61)	-25.65 (4.00)	-4.80 [-15.53; 5.93]	0.377
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	55.64 (24.45)	64.22 (28.89)		
Week 52 Mean (SD)	23.82 (27.33)	23.89 (24.89)		
Week 2 Adjusted Mean Change (SE)	-9.69 (6.15)	-12.34 (6.77)		
Week 4 Adjusted Mean Change (SE)	-11.86 (6.21)	-11.75 (6.85)		
Week 8 Adjusted Mean Change (SE)	-11.42 (6.66)	-20.70 (7.35)		
Week 12 Adjusted Mean Change (SE)	-17.92 (6.57)	-23.08 (7.25)		
Week 16 Adjusted Mean Change (SE)	-22.21 (6.43)	-29.32 (7.22)		
Week 20 Adjusted Mean Change (SE)	-18.35 (7.21)	-32.34 (7.86)		
Week 24 Adjusted Mean Change (SE)	-17.44 (6.58)	-31.97 (7.26)		
Week 28 Adjusted Mean Change (SE)	-26.18 (6.16)	-23.54 (6.98)		
Week 32 Adjusted Mean Change (SE)	-26.39 (6.13)	-19.20 (6.87)		
Week 36 Adjusted Mean Change (SE)	-26.10 (5.87)	-25.37 (6.47)		
Week 40 Adjusted Mean Change (SE)	-25.83 (6.28)	-33.51 (6.92)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 44 Adjusted Mean Change (SE)	-27.33 (6.72)	-32.96 (7.49)		
Week 48 Adjusted Mean Change (SE)	-28.46 (6.94)	-31.56 (7.86)		
Week 52 Adjusted Mean Change (SE)	-29.89 (6.67)	-34.48 (7.36)	4.59 [-15.15; 24.32]	0.645

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

16.0 Patient's Global Assessment of PsA Disease Activity (VAS) - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	66 (100.0)	61 (98.4)	127 (99.2)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	64 (97.0)	56 (90.3)	120 (93.8)
Week 20 Returns	64 (97.0)	54 (87.1)	118 (92.2)
Week 24 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 28 Returns	62 (93.9)	49 (79.0)	111 (86.7)
Week 32 Returns	62 (93.9)	49 (79.0)	111 (86.7)
Week 36 Returns	61 (92.4)	50 (80.6)	111 (86.7)
Week 40 Returns	63 (95.5)	48 (77.4)	111 (86.7)
Week 44 Returns	63 (95.5)	47 (75.8)	110 (85.9)
Week 48 Returns	60 (90.9)	46 (74.2)	106 (82.8)
Week 52 Returns	62 (93.9)	46 (74.2)	108 (84.4)

16.1 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	61		
Baseline Mean (SD)	64.23 (21.70)	64.11 (20.74)		
Week 52 Mean (SD)	28.37 (22.21)	28.78 (25.06)		
Week 2 Adjusted Mean Change (SE)	-17.60 (2.33)	-16.03 (2.43)		
Week 4 Adjusted Mean Change (SE)	-22.46 (2.50)	-20.11 (2.61)		
Week 8 Adjusted Mean Change (SE)	-27.05 (2.54)	-24.82 (2.65)		
Week 12 Adjusted Mean Change (SE)	-27.13 (2.68)	-24.68 (2.80)		
Week 16 Adjusted Mean Change (SE)	-30.54 (2.53)	-25.99 (2.67)		
Week 20 Adjusted Mean Change (SE)	-30.74 (2.69)	-26.32 (2.86)		
Week 24 Adjusted Mean Change (SE)	-28.65 (2.70)	-25.79 (2.87)		
Week 28 Adjusted Mean Change (SE)	-31.51 (2.59)	-29.49 (2.80)		
Week 32 Adjusted Mean Change (SE)	-33.70 (2.65)	-27.53 (2.85)		
Week 36 Adjusted Mean Change (SE)	-35.14 (2.63)	-31.12 (2.86)		
Week 40 Adjusted Mean Change (SE)	-34.05 (2.65)	-30.51 (2.89)		
Week 44 Adjusted Mean Change (SE)	-34.55 (2.87)	-33.42 (3.16)		
Week 48 Adjusted Mean Change (SE)	-34.48 (2.75)	-34.80 (3.02)		
Week 52 Adjusted Mean Change (SE)	-35.51 (2.95)	-31.92 (3.25)	-3.59 [-12.28; 5.11]	0.416

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

16.2 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.126				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	63.02 (20.27)	60.67 (21.97)		
Week 52 Mean (SD)	27.26 (21.59)	19.88 (20.97)		
Week 2 Adjusted Mean Change (SE)	-17.50 (2.94)	-20.00 (3.37)		
Week 4 Adjusted Mean Change (SE)	-23.43 (3.13)	-24.90 (3.59)		
Week 8 Adjusted Mean Change (SE)	-28.12 (3.17)	-29.58 (3.63)		
Week 12 Adjusted Mean Change (SE)	-28.66 (3.33)	-30.33 (3.80)		
Week 16 Adjusted Mean Change (SE)	-32.97 (3.12)	-31.93 (3.57)		
Week 20 Adjusted Mean Change (SE)	-32.76 (3.37)	-30.17 (3.89)		
Week 24 Adjusted Mean Change (SE)	-30.17 (3.30)	-33.32 (3.84)		
Week 28 Adjusted Mean Change (SE)	-32.49 (3.16)	-36.95 (3.74)		
Week 32 Adjusted Mean Change (SE)	-33.39 (3.24)	-35.58 (3.80)		
Week 36 Adjusted Mean Change (SE)	-35.25 (3.31)	-35.72 (3.91)		
Week 40 Adjusted Mean Change (SE)	-35.54 (3.24)	-37.88 (3.86)		
Week 44 Adjusted Mean Change (SE)	-36.06 (3.56)	-39.61 (4.24)		
Week 48 Adjusted Mean Change (SE)	-36.23 (3.43)	-39.88 (4.08)		
Week 52 Adjusted Mean Change (SE)	-35.92 (3.65)	-39.34 (4.41)	3.41 [-7.89; 14.72]	0.551
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	66.33 (24.31)	68.03 (18.85)		
Week 52 Mean (SD)	30.26 (23.58)	38.50 (25.96)		
Week 2 Adjusted Mean Change (SE)	-17.80 (3.90)	-11.62 (3.54)		
Week 4 Adjusted Mean Change (SE)	-20.77 (4.15)	-14.75 (3.81)		
Week 8 Adjusted Mean Change (SE)	-25.20 (4.20)	-19.49 (3.86)		
Week 12 Adjusted Mean Change (SE)	-24.50 (4.43)	-18.35 (4.07)		
Week 16 Adjusted Mean Change (SE)	-26.33 (4.11)	-19.13 (3.85)		
Week 20 Adjusted Mean Change (SE)	-27.25 (4.48)	-22.32 (4.22)		
Week 24 Adjusted Mean Change (SE)	-25.95 (4.38)	-17.33 (4.09)		
Week 28 Adjusted Mean Change (SE)	-29.68 (4.25)	-21.16 (4.03)		
Week 32 Adjusted Mean Change (SE)	-34.16 (4.28)	-18.68 (4.05)		
Week 36 Adjusted Mean Change (SE)	-34.82 (4.34)	-26.04 (4.19)		
Week 40 Adjusted Mean Change (SE)	-31.49 (4.26)	-22.41 (4.14)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-31.95 (4.70)	-26.63 (4.62)		
Week 48 Adjusted Mean Change (SE)	-31.46 (4.50)	-29.41 (4.42)		
Week 52 Adjusted Mean Change (SE)	-34.76 (4.80)	-23.77 (4.69)	-10.98 [-24.23; 2.26]	0.103

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

16.3 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.689				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	45.38 (17.21)	42.38 (26.01)		
Week 52 Mean (SD)	18.88 (17.02)	30.75 (31.79)		
Week 2 Adjusted Mean Change (SE)	-22.35 (5.00)	-26.06 (5.58)		
Week 4 Adjusted Mean Change (SE)	-27.92 (5.31)	-33.30 (5.92)		
Week 8 Adjusted Mean Change (SE)	-29.19 (5.40)	-38.27 (6.02)		
Week 12 Adjusted Mean Change (SE)	-28.57 (5.89)	-26.18 (6.50)		
Week 16 Adjusted Mean Change (SE)	-36.34 (5.45)	-32.29 (6.08)		
Week 20 Adjusted Mean Change (SE)	-35.97 (5.92)	-28.02 (6.66)		
Week 24 Adjusted Mean Change (SE)	-29.63 (5.94)	-27.00 (6.75)		
Week 28 Adjusted Mean Change (SE)	-39.73 (5.58)	-31.86 (6.57)		
Week 32 Adjusted Mean Change (SE)	-37.84 (5.78)	-30.53 (6.74)		
Week 36 Adjusted Mean Change (SE)	-37.74 (5.70)	-30.26 (6.92)		
Week 40 Adjusted Mean Change (SE)	-41.01 (5.72)	-32.17 (7.03)		
Week 44 Adjusted Mean Change (SE)	-43.28 (6.16)	-30.25 (7.47)		
Week 48 Adjusted Mean Change (SE)	-44.71 (5.89)	-33.10 (7.23)		
Week 52 Adjusted Mean Change (SE)	-44.18 (6.30)	-28.43 (7.77)	-15.75 [-34.42; 2.93]	0.098
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	70.26 (19.51)	69.88 (14.69)		
Week 52 Mean (SD)	31.67 (22.99)	28.37 (23.90)		
Week 2 Adjusted Mean Change (SE)	-16.07 (2.71)	-13.30 (2.77)		
Week 4 Adjusted Mean Change (SE)	-20.69 (2.88)	-16.50 (2.95)		
Week 8 Adjusted Mean Change (SE)	-26.35 (2.93)	-21.14 (3.00)		
Week 12 Adjusted Mean Change (SE)	-26.62 (3.17)	-24.33 (3.26)		
Week 16 Adjusted Mean Change (SE)	-28.63 (2.97)	-24.25 (3.08)		
Week 20 Adjusted Mean Change (SE)	-29.19 (3.16)	-25.84 (3.29)		
Week 24 Adjusted Mean Change (SE)	-28.21 (3.19)	-25.42 (3.32)		
Week 28 Adjusted Mean Change (SE)	-28.86 (3.03)	-28.81 (3.19)		
Week 32 Adjusted Mean Change (SE)	-32.38 (3.13)	-26.65 (3.28)		
Week 36 Adjusted Mean Change (SE)	-34.40 (3.12)	-31.17 (3.27)		
Week 40 Adjusted Mean Change (SE)	-31.79 (3.10)	-30.17 (3.27)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 44 Adjusted Mean Change (SE)	-31.68 (3.36)	-34.05 (3.56)		
Week 48 Adjusted Mean Change (SE)	-31.15 (3.21)	-35.08 (3.39)		
Week 52 Adjusted Mean Change (SE)	-32.64 (3.45)	-32.70 (3.66)	0.06 [-9.71; 9.82]	0.991

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

16.4 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.462				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	60.79 (21.45)	63.22 (21.88)		
Week 52 Mean (SD)	28.96 (19.41)	26.95 (21.92)		
Week 2 Adjusted Mean Change (SE)	-18.02 (3.56)	-20.84 (3.33)		
Week 4 Adjusted Mean Change (SE)	-20.74 (3.84)	-23.78 (3.62)		
Week 8 Adjusted Mean Change (SE)	-25.52 (3.92)	-26.91 (3.70)		
Week 12 Adjusted Mean Change (SE)	-25.08 (4.13)	-22.97 (3.90)		
Week 16 Adjusted Mean Change (SE)	-25.48 (3.87)	-25.25 (3.70)		
Week 20 Adjusted Mean Change (SE)	-26.44 (4.15)	-28.72 (3.99)		
Week 24 Adjusted Mean Change (SE)	-26.65 (4.19)	-24.33 (4.04)		
Week 28 Adjusted Mean Change (SE)	-28.26 (4.03)	-28.46 (3.95)		
Week 32 Adjusted Mean Change (SE)	-30.49 (4.10)	-27.10 (4.00)		
Week 36 Adjusted Mean Change (SE)	-32.04 (4.08)	-28.73 (4.07)		
Week 40 Adjusted Mean Change (SE)	-30.50 (4.11)	-29.03 (4.11)		
Week 44 Adjusted Mean Change (SE)	-32.76 (4.50)	-32.11 (4.54)		
Week 48 Adjusted Mean Change (SE)	-30.98 (4.26)	-32.15 (4.30)		
Week 52 Adjusted Mean Change (SE)	-35.56 (4.63)	-33.30 (4.68)	-2.26 [-15.28; 10.77]	0.732
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	66.76 (21.82)	65.07 (19.78)		
Week 52 Mean (SD)	27.94 (24.29)	30.46 (28.00)		
Week 2 Adjusted Mean Change (SE)	-17.29 (3.06)	-10.72 (3.50)		
Week 4 Adjusted Mean Change (SE)	-23.72 (3.30)	-16.07 (3.77)		
Week 8 Adjusted Mean Change (SE)	-28.18 (3.36)	-22.47 (3.85)		
Week 12 Adjusted Mean Change (SE)	-28.67 (3.57)	-26.56 (4.07)		
Week 16 Adjusted Mean Change (SE)	-34.38 (3.34)	-26.78 (3.84)		
Week 20 Adjusted Mean Change (SE)	-33.79 (3.53)	-23.82 (4.08)		
Week 24 Adjusted Mean Change (SE)	-30.14 (3.59)	-27.32 (4.15)		
Week 28 Adjusted Mean Change (SE)	-33.89 (3.42)	-30.54 (4.02)		
Week 32 Adjusted Mean Change (SE)	-36.07 (3.53)	-27.86 (4.11)		
Week 36 Adjusted Mean Change (SE)	-37.42 (3.49)	-33.29 (4.08)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 40 Adjusted Mean Change (SE)	-36.67 (3.51)	-31.76 (4.12)		
Week 44 Adjusted Mean Change (SE)	-35.91 (3.82)	-34.49 (4.51)		
Week 48 Adjusted Mean Change (SE)	-37.10 (3.65)	-37.27 (4.29)		
Week 52 Adjusted Mean Change (SE)	-35.54 (3.94)	-30.51 (4.67)	-5.03 [-17.12; 7.05]	0.411

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

16.5 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.880				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	65.88 (21.45)	60.17 (22.68)		
Week 52 Mean (SD)	27.95 (21.85)	23.42 (20.52)		
Week 2 Adjusted Mean Change (SE)	-20.12 (3.00)	-17.42 (3.54)		
Week 4 Adjusted Mean Change (SE)	-23.42 (3.24)	-20.55 (3.82)		
Week 8 Adjusted Mean Change (SE)	-27.76 (3.27)	-27.57 (3.86)		
Week 12 Adjusted Mean Change (SE)	-26.00 (3.49)	-24.60 (4.08)		
Week 16 Adjusted Mean Change (SE)	-31.01 (3.28)	-28.82 (3.92)		
Week 20 Adjusted Mean Change (SE)	-31.14 (3.46)	-29.14 (4.16)		
Week 24 Adjusted Mean Change (SE)	-30.98 (3.49)	-27.31 (4.20)		
Week 28 Adjusted Mean Change (SE)	-31.31 (3.34)	-31.35 (4.12)		
Week 32 Adjusted Mean Change (SE)	-34.07 (3.47)	-28.16 (4.22)		
Week 36 Adjusted Mean Change (SE)	-35.92 (3.44)	-27.14 (4.26)		
Week 40 Adjusted Mean Change (SE)	-35.87 (3.44)	-29.89 (4.32)		
Week 44 Adjusted Mean Change (SE)	-36.04 (3.73)	-32.80 (4.70)		
Week 48 Adjusted Mean Change (SE)	-37.27 (3.55)	-32.97 (4.50)		
Week 52 Adjusted Mean Change (SE)	-35.96 (3.82)	-34.95 (4.90)	-1.02 [-13.34; 11.31]	0.871
> Median, N	**26**	**33**		
N'	26	32		
Baseline Mean (SD)	61.69 (22.25)	67.58 (18.53)		
Week 52 Mean (SD)	29.04 (23.21)	32.56 (27.56)		
Week 2 Adjusted Mean Change (SE)	-13.72 (3.73)	-14.76 (3.37)		
Week 4 Adjusted Mean Change (SE)	-20.97 (4.02)	-19.73 (3.66)		
Week 8 Adjusted Mean Change (SE)	-25.96 (4.06)	-22.28 (3.71)		
Week 12 Adjusted Mean Change (SE)	-28.77 (4.29)	-24.78 (3.95)		
Week 16 Adjusted Mean Change (SE)	-29.81 (4.04)	-23.43 (3.72)		
Week 20 Adjusted Mean Change (SE)	-29.99 (4.30)	-23.69 (4.00)		
Week 24 Adjusted Mean Change (SE)	-25.26 (4.29)	-24.36 (4.00)		
Week 28 Adjusted Mean Change (SE)	-32.08 (4.21)	-27.81 (3.92)		
Week 32 Adjusted Mean Change (SE)	-33.16 (4.26)	-26.86 (4.00)		
Week 36 Adjusted Mean Change (SE)	-33.93 (4.20)	-34.10 (3.97)		
Week 40 Adjusted Mean Change (SE)	-31.27 (4.23)	-30.78 (4.00)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-32.25 (4.61)	-33.69 (4.38)		
Week 48 Adjusted Mean Change (SE)	-30.40 (4.36)	-35.86 (4.12)		
Week 52 Adjusted Mean Change (SE)	-34.86 (4.75)	-29.61 (4.47)	-5.25 [-18.21; 7.72]	0.425

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

16.6 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.626				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	60.21 (24.42)	62.77 (24.16)		
Week 52 Mean (SD)	24.58 (19.67)	25.22 (23.83)		
Week 2 Adjusted Mean Change (SE)	-18.15 (3.27)	-20.87 (4.06)		
Week 4 Adjusted Mean Change (SE)	-21.96 (3.53)	-22.74 (4.42)		
Week 8 Adjusted Mean Change (SE)	-24.51 (3.53)	-30.17 (4.44)		
Week 12 Adjusted Mean Change (SE)	-28.89 (3.76)	-28.42 (4.76)		
Week 16 Adjusted Mean Change (SE)	-30.75 (3.52)	-32.15 (4.47)		
Week 20 Adjusted Mean Change (SE)	-32.66 (3.79)	-29.69 (4.75)		
Week 24 Adjusted Mean Change (SE)	-28.74 (3.80)	-27.54 (4.78)		
Week 28 Adjusted Mean Change (SE)	-31.56 (3.63)	-32.50 (4.64)		
Week 32 Adjusted Mean Change (SE)	-34.09 (3.74)	-30.34 (4.78)		
Week 36 Adjusted Mean Change (SE)	-34.52 (3.71)	-34.22 (4.75)		
Week 40 Adjusted Mean Change (SE)	-36.46 (3.71)	-30.28 (4.75)		
Week 44 Adjusted Mean Change (SE)	-36.82 (4.04)	-32.90 (5.19)		
Week 48 Adjusted Mean Change (SE)	-34.89 (3.88)	-34.93 (4.97)		
Week 52 Adjusted Mean Change (SE)	-38.86 (4.14)	-37.11 (5.32)	-1.75 [-15.06; 11.56]	0.795
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	68.50 (17.78)	64.85 (18.89)		
Week 52 Mean (SD)	32.16 (24.20)	31.07 (25.98)		
Week 2 Adjusted Mean Change (SE)	-17.02 (3.38)	-13.29 (3.04)		
Week 4 Adjusted Mean Change (SE)	-23.00 (3.64)	-18.60 (3.28)		
Week 8 Adjusted Mean Change (SE)	-29.76 (3.64)	-21.85 (3.29)		
Week 12 Adjusted Mean Change (SE)	-25.26 (3.88)	-22.64 (3.48)		
Week 16 Adjusted Mean Change (SE)	-30.31 (3.65)	-22.58 (3.31)		
Week 20 Adjusted Mean Change (SE)	-28.80 (3.87)	-24.56 (3.61)		
Week 24 Adjusted Mean Change (SE)	-28.57 (3.92)	-25.00 (3.64)		
Week 28 Adjusted Mean Change (SE)	-31.47 (3.75)	-27.98 (3.54)		
Week 32 Adjusted Mean Change (SE)	-33.27 (3.85)	-26.10 (3.60)		
Week 36 Adjusted Mean Change (SE)	-35.72 (3.83)	-29.28 (3.64)		
Week 40 Adjusted Mean Change (SE)	-31.54 (3.80)	-31.12 (3.65)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 44 Adjusted Mean Change (SE)	-32.24 (4.13)	-34.21 (3.98)		
Week 48 Adjusted Mean Change (SE)	-34.01 (3.96)	-35.06 (3.82)		
Week 52 Adjusted Mean Change (SE)	-32.16 (4.22)	-28.77 (4.10)	-3.39 [-15.01; 8.23]	0.564

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

16.7 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.535				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	68.03 (20.82)	64.24 (20.70)		
Week 52 Mean (SD)	32.52 (24.36)	25.42 (19.93)		
Week 2 Adjusted Mean Change (SE)	-16.03 (3.27)	-17.49 (3.51)		
Week 4 Adjusted Mean Change (SE)	-20.93 (3.92)	-23.81 (4.21)		
Week 8 Adjusted Mean Change (SE)	-25.23 (3.91)	-26.99 (4.19)		
Week 12 Adjusted Mean Change (SE)	-29.57 (3.90)	-31.31 (4.21)		
Week 16 Adjusted Mean Change (SE)	-29.59 (3.72)	-30.33 (4.02)		
Week 20 Adjusted Mean Change (SE)	-32.97 (3.97)	-29.07 (4.35)		
Week 24 Adjusted Mean Change (SE)	-29.88 (4.12)	-28.66 (4.48)		
Week 28 Adjusted Mean Change (SE)	-32.40 (3.96)	-31.83 (4.36)		
Week 32 Adjusted Mean Change (SE)	-35.33 (3.78)	-32.81 (4.15)		
Week 36 Adjusted Mean Change (SE)	-35.43 (3.98)	-37.14 (4.35)		
Week 40 Adjusted Mean Change (SE)	-33.24 (3.95)	-34.39 (4.35)		
Week 44 Adjusted Mean Change (SE)	-34.52 (4.48)	-37.95 (4.95)		
Week 48 Adjusted Mean Change (SE)	-31.74 (4.24)	-38.13 (4.66)		
Week 52 Adjusted Mean Change (SE)	-32.70 (4.45)	-37.14 (4.98)	4.43 [-8.82; 17.68]	0.508
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	61.95 (23.13)	62.79 (24.69)		
Week 52 Mean (SD)	26.05 (20.92)	35.31 (31.82)		
Week 2 Adjusted Mean Change (SE)	-17.73 (3.75)	-14.93 (4.03)		
Week 4 Adjusted Mean Change (SE)	-22.46 (4.49)	-14.85 (4.90)		
Week 8 Adjusted Mean Change (SE)	-25.77 (4.47)	-25.83 (4.89)		
Week 12 Adjusted Mean Change (SE)	-23.22 (4.51)	-21.67 (4.91)		
Week 16 Adjusted Mean Change (SE)	-26.18 (4.27)	-28.66 (4.71)		
Week 20 Adjusted Mean Change (SE)	-28.63 (4.60)	-29.18 (5.00)		
Week 24 Adjusted Mean Change (SE)	-26.57 (4.71)	-26.91 (5.23)		
Week 28 Adjusted Mean Change (SE)	-27.16 (4.55)	-29.93 (5.13)		
Week 32 Adjusted Mean Change (SE)	-33.48 (4.37)	-24.18 (4.86)		
Week 36 Adjusted Mean Change (SE)	-34.43 (4.59)	-30.50 (5.12)		
Week 40 Adjusted Mean Change (SE)	-36.09 (4.57)	-29.68 (5.13)		

	Treatment Groups		Comparison	
	SEC **(N=66)**	**ADA** **(N=62)**	**Mean Difference** **[95% CI]**	**p-value**
Week 44 Adjusted Mean Change (SE)	-35.15 (5.19)	-29.48 (5.83)		
Week 48 Adjusted Mean Change (SE)	-36.48 (4.92)	-32.35 (5.55)		
Week 52 Adjusted Mean Change (SE)	-37.17 (5.13)	-27.20 (5.72)	-9.98 [-25.21; 5.26]	0.196

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

16.8 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.092				
Non-carrier, N	**28**	**19**		
N'	28	19		
Baseline Mean (SD)	65.96 (22.59)	65.74 (17.47)		
Week 52 Mean (SD)	31.00 (24.35)	34.92 (27.93)		
Week 2 Adjusted Mean Change (SE)	-19.22 (3.14)	-9.95 (3.81)		
Week 4 Adjusted Mean Change (SE)	-24.36 (3.85)	-16.72 (4.74)		
Week 8 Adjusted Mean Change (SE)	-26.46 (3.88)	-19.64 (4.79)		
Week 12 Adjusted Mean Change (SE)	-28.64 (3.99)	-23.72 (4.96)		
Week 16 Adjusted Mean Change (SE)	-30.27 (3.63)	-22.48 (4.52)		
Week 20 Adjusted Mean Change (SE)	-33.12 (4.04)	-23.36 (5.14)		
Week 24 Adjusted Mean Change (SE)	-28.77 (4.08)	-23.02 (5.19)		
Week 28 Adjusted Mean Change (SE)	-31.41 (3.97)	-32.86 (5.17)		
Week 32 Adjusted Mean Change (SE)	-35.23 (3.88)	-25.12 (4.98)		
Week 36 Adjusted Mean Change (SE)	-35.90 (4.06)	-29.12 (5.27)		
Week 40 Adjusted Mean Change (SE)	-35.73 (3.98)	-24.86 (5.18)		
Week 44 Adjusted Mean Change (SE)	-35.19 (4.59)	-27.34 (6.07)		
Week 48 Adjusted Mean Change (SE)	-34.31 (4.38)	-30.82 (5.70)		
Week 52 Adjusted Mean Change (SE)	-32.84 (4.63)	-27.09 (6.14)	-5.75 [-21.04; 9.54]	0.456
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	63.18 (20.49)	62.21 (23.82)		
Week 52 Mean (SD)	29.21 (21.42)	28.18 (25.52)		
Week 2 Adjusted Mean Change (SE)	-11.74 (3.54)	-20.46 (3.81)		
Week 4 Adjusted Mean Change (SE)	-16.26 (4.34)	-20.50 (4.68)		
Week 8 Adjusted Mean Change (SE)	-22.45 (4.37)	-30.02 (4.71)		
Week 12 Adjusted Mean Change (SE)	-22.66 (4.54)	-27.13 (4.89)		
Week 16 Adjusted Mean Change (SE)	-23.67 (4.10)	-36.18 (4.45)		
Week 20 Adjusted Mean Change (SE)	-27.39 (4.57)	-33.58 (4.92)		
Week 24 Adjusted Mean Change (SE)	-25.76 (4.59)	-32.83 (4.99)		
Week 28 Adjusted Mean Change (SE)	-26.38 (4.53)	-30.94 (4.95)		
Week 32 Adjusted Mean Change (SE)	-31.55 (4.37)	-31.21 (4.78)		
Week 36 Adjusted Mean Change (SE)	-32.26 (4.58)	-36.09 (4.97)		
Week 40 Adjusted Mean Change (SE)	-30.87 (4.46)	-35.86 (4.89)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-32.54 (5.18)	-40.09 (5.65)		
Week 48 Adjusted Mean Change (SE)	-30.97 (4.91)	-38.49 (5.35)		
Week 52 Adjusted Mean Change (SE)	-35.85 (5.29)	-35.91 (5.71)	0.06 [-15.41; 15.52]	0.994

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

16.9 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.265				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	60.47 (24.78)	66.43 (23.17)		
Week 52 Mean (SD)	34.00 (22.91)	31.73 (29.78)		
Week 2 Adjusted Mean Change (SE)	-17.80 (4.11)	-17.31 (3.89)		
Week 4 Adjusted Mean Change (SE)	-17.79 (4.91)	-22.71 (4.71)		
Week 8 Adjusted Mean Change (SE)	-19.26 (4.77)	-28.69 (4.58)		
Week 12 Adjusted Mean Change (SE)	-25.02 (4.89)	-31.34 (4.76)		
Week 16 Adjusted Mean Change (SE)	-21.93 (4.55)	-31.26 (4.45)		
Week 20 Adjusted Mean Change (SE)	-25.67 (4.90)	-27.99 (4.79)		
Week 24 Adjusted Mean Change (SE)	-21.50 (5.08)	-30.00 (4.98)		
Week 28 Adjusted Mean Change (SE)	-27.73 (5.05)	-34.76 (5.01)		
Week 32 Adjusted Mean Change (SE)	-32.00 (4.76)	-29.63 (4.74)		
Week 36 Adjusted Mean Change (SE)	-32.42 (4.93)	-35.57 (4.97)		
Week 40 Adjusted Mean Change (SE)	-31.83 (4.95)	-30.68 (4.98)		
Week 44 Adjusted Mean Change (SE)	-31.20 (5.59)	-35.86 (5.69)		
Week 48 Adjusted Mean Change (SE)	-27.17 (5.21)	-37.98 (5.30)		
Week 52 Adjusted Mean Change (SE)	-30.95 (5.58)	-30.05 (5.73)	-0.90 [-16.84; 15.04]	0.911
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	69.77 (18.82)	61.04 (21.55)		
Week 52 Mean (SD)	27.22 (23.32)	28.60 (23.71)		
Week 2 Adjusted Mean Change (SE)	-16.58 (3.28)	-15.95 (3.73)		
Week 4 Adjusted Mean Change (SE)	-23.72 (3.92)	-18.14 (4.47)		
Week 8 Adjusted Mean Change (SE)	-28.86 (3.80)	-25.02 (4.33)		
Week 12 Adjusted Mean Change (SE)	-29.79 (3.92)	-24.30 (4.45)		
Week 16 Adjusted Mean Change (SE)	-32.07 (3.64)	-28.63 (4.15)		
Week 20 Adjusted Mean Change (SE)	-35.19 (3.91)	-30.66 (4.46)		
Week 24 Adjusted Mean Change (SE)	-32.91 (4.03)	-26.77 (4.63)		
Week 28 Adjusted Mean Change (SE)	-32.35 (3.97)	-28.37 (4.61)		
Week 32 Adjusted Mean Change (SE)	-36.33 (3.82)	-29.07 (4.39)		
Week 36 Adjusted Mean Change (SE)	-37.03 (3.98)	-33.90 (4.54)		
Week 40 Adjusted Mean Change (SE)	-36.62 (3.98)	-34.44 (4.56)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-37.30 (4.50)	-33.87 (5.16)		
Week 48 Adjusted Mean Change (SE)	-37.97 (4.22)	-34.41 (4.84)		
Week 52 Adjusted Mean Change (SE)	-37.26 (4.52)	-35.61 (5.19)	-1.65 [-15.39; 12.08]	0.812

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

16.10 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.263				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	67.48 (17.91)	63.41 (22.57)		
Week 52 Mean (SD)	29.26 (25.48)	34.62 (27.86)		
Week 2 Adjusted Mean Change (SE)	-16.24 (3.53)	-15.67 (3.11)		
Week 4 Adjusted Mean Change (SE)	-21.89 (4.26)	-21.14 (3.76)		
Week 8 Adjusted Mean Change (SE)	-26.29 (4.16)	-23.83 (3.66)		
Week 12 Adjusted Mean Change (SE)	-28.60 (4.25)	-24.20 (3.74)		
Week 16 Adjusted Mean Change (SE)	-24.05 (3.94)	-27.11 (3.47)		
Week 20 Adjusted Mean Change (SE)	-32.88 (4.17)	-25.24 (3.73)		
Week 24 Adjusted Mean Change (SE)	-28.24 (4.38)	-25.01 (3.93)		
Week 28 Adjusted Mean Change (SE)	-31.49 (4.18)	-26.63 (3.82)		
Week 32 Adjusted Mean Change (SE)	-35.33 (4.06)	-25.74 (3.66)		
Week 36 Adjusted Mean Change (SE)	-34.70 (4.34)	-33.55 (3.89)		
Week 40 Adjusted Mean Change (SE)	-33.89 (4.28)	-31.56 (3.88)		
Week 44 Adjusted Mean Change (SE)	-35.18 (4.88)	-33.06 (4.42)		
Week 48 Adjusted Mean Change (SE)	-35.47 (4.62)	-34.60 (4.18)		
Week 52 Adjusted Mean Change (SE)	-36.76 (4.86)	-30.26 (4.43)	-6.50 [-19.56; 6.57]	0.326
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	63.42 (25.24)	64.17 (22.33)		
Week 52 Mean (SD)	30.25 (20.79)	16.44 (14.05)		
Week 2 Adjusted Mean Change (SE)	-17.26 (3.46)	-18.29 (5.07)		
Week 4 Adjusted Mean Change (SE)	-21.31 (4.17)	-16.65 (6.27)		
Week 8 Adjusted Mean Change (SE)	-24.67 (4.07)	-34.05 (6.14)		
Week 12 Adjusted Mean Change (SE)	-25.24 (4.13)	-35.86 (6.29)		
Week 16 Adjusted Mean Change (SE)	-31.62 (3.83)	-36.54 (5.88)		
Week 20 Adjusted Mean Change (SE)	-29.18 (4.13)	-40.01 (6.22)		
Week 24 Adjusted Mean Change (SE)	-28.57 (4.31)	-36.11 (6.53)		
Week 28 Adjusted Mean Change (SE)	-28.70 (4.13)	-43.06 (6.28)		
Week 32 Adjusted Mean Change (SE)	-33.74 (3.97)	-38.73 (6.03)		
Week 36 Adjusted Mean Change (SE)	-35.23 (4.23)	-36.37 (6.51)		
Week 40 Adjusted Mean Change (SE)	-34.83 (4.22)	-34.15 (6.50)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 44 Adjusted Mean Change (SE)	-34.39 (4.78)	-37.82 (7.46)		
Week 48 Adjusted Mean Change (SE)	-32.01 (4.53)	-39.08 (6.98)		
Week 52 Adjusted Mean Change (SE)	-32.50 (4.77)	-39.64 (7.44)	7.15 [-10.41; 24.70]	0.421

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

16.11 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.635				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	68.53 (20.99)	62.27 (21.37)		
Week 52 Mean (SD)	31.88 (22.15)	28.83 (24.82)		
Week 2 Adjusted Mean Change (SE)	-16.54 (2.86)	-16.96 (3.03)		
Week 4 Adjusted Mean Change (SE)	-21.40 (3.38)	-24.81 (3.61)		
Week 8 Adjusted Mean Change (SE)	-25.97 (3.39)	-27.21 (3.63)		
Week 12 Adjusted Mean Change (SE)	-25.30 (3.36)	-29.57 (3.60)		
Week 16 Adjusted Mean Change (SE)	-27.65 (3.22)	-28.81 (3.47)		
Week 20 Adjusted Mean Change (SE)	-31.68 (3.47)	-28.84 (3.79)		
Week 24 Adjusted Mean Change (SE)	-30.68 (3.53)	-29.48 (3.85)		
Week 28 Adjusted Mean Change (SE)	-30.68 (3.37)	-33.14 (3.71)		
Week 32 Adjusted Mean Change (SE)	-34.08 (3.22)	-32.40 (3.54)		
Week 36 Adjusted Mean Change (SE)	-34.59 (3.36)	-37.09 (3.70)		
Week 40 Adjusted Mean Change (SE)	-33.80 (3.34)	-33.22 (3.72)		
Week 44 Adjusted Mean Change (SE)	-34.71 (3.94)	-33.81 (4.39)		
Week 48 Adjusted Mean Change (SE)	-32.57 (3.67)	-36.38 (4.05)		
Week 52 Adjusted Mean Change (SE)	-32.68 (3.89)	-32.34 (4.37)	-0.35 [-12.01; 11.32]	0.953
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	58.00 (22.64)	62.89 (25.53)		
Week 52 Mean (SD)	25.50 (25.67)	21.33 (19.01)		
Week 2 Adjusted Mean Change (SE)	-16.56 (5.12)	-19.51 (5.80)		
Week 4 Adjusted Mean Change (SE)	-20.03 (6.03)	-9.59 (6.85)		
Week 8 Adjusted Mean Change (SE)	-21.98 (6.04)	-30.59 (6.87)		
Week 12 Adjusted Mean Change (SE)	-28.97 (5.97)	-28.14 (6.93)		
Week 16 Adjusted Mean Change (SE)	-26.93 (5.72)	-39.46 (6.58)		
Week 20 Adjusted Mean Change (SE)	-27.06 (6.24)	-35.48 (7.02)		
Week 24 Adjusted Mean Change (SE)	-18.76 (6.28)	-29.70 (7.14)		
Week 28 Adjusted Mean Change (SE)	-26.39 (6.02)	-33.82 (7.00)		
Week 32 Adjusted Mean Change (SE)	-33.54 (5.73)	-28.28 (6.51)		
Week 36 Adjusted Mean Change (SE)	-34.21 (5.91)	-36.20 (6.72)		
Week 40 Adjusted Mean Change (SE)	-33.52 (5.94)	-39.17 (6.75)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-32.85 (6.97)	-43.43 (7.94)		
Week 48 Adjusted Mean Change (SE)	-34.54 (6.45)	-44.03 (7.41)		
Week 52 Adjusted Mean Change (SE)	-37.42 (6.84)	-42.79 (7.79)	5.37 [-15.19; 25.92]	0.605

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

16.12 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.715				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	65.67 (21.21)	62.85 (24.41)		
Week 52 Mean (SD)	31.61 (25.11)	27.80 (24.22)		
Week 2 Adjusted Mean Change (SE)	-15.00 (2.92)	-16.78 (3.01)		
Week 4 Adjusted Mean Change (SE)	-21.77 (3.52)	-21.84 (3.65)		
Week 8 Adjusted Mean Change (SE)	-25.95 (3.47)	-28.10 (3.61)		
Week 12 Adjusted Mean Change (SE)	-29.16 (3.50)	-29.30 (3.67)		
Week 16 Adjusted Mean Change (SE)	-30.93 (3.29)	-31.50 (3.44)		
Week 20 Adjusted Mean Change (SE)	-31.22 (3.59)	-28.99 (3.76)		
Week 24 Adjusted Mean Change (SE)	-28.86 (3.72)	-27.75 (3.94)		
Week 28 Adjusted Mean Change (SE)	-29.00 (3.60)	-32.42 (3.84)		
Week 32 Adjusted Mean Change (SE)	-34.65 (3.43)	-29.92 (3.64)		
Week 36 Adjusted Mean Change (SE)	-35.47 (3.55)	-35.89 (3.80)		
Week 40 Adjusted Mean Change (SE)	-34.40 (3.55)	-33.37 (3.82)		
Week 44 Adjusted Mean Change (SE)	-34.22 (4.01)	-34.46 (4.30)		
Week 48 Adjusted Mean Change (SE)	-32.79 (3.80)	-36.63 (4.06)		
Week 52 Adjusted Mean Change (SE)	-33.08 (4.07)	-34.17 (4.42)	1.09 [-10.85; 13.02]	0.857
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	62.00 (24.53)	66.20 (13.01)		
Week 52 Mean (SD)	27.00 (16.91)	35.30 (31.10)		
Week 2 Adjusted Mean Change (SE)	-17.56 (4.87)	-13.80 (5.58)		
Week 4 Adjusted Mean Change (SE)	-18.13 (5.86)	-12.66 (6.71)		
Week 8 Adjusted Mean Change (SE)	-21.54 (5.78)	-19.59 (6.62)		
Week 12 Adjusted Mean Change (SE)	-18.36 (5.83)	-18.74 (6.68)		
Week 16 Adjusted Mean Change (SE)	-20.89 (5.44)	-21.92 (6.24)		
Week 20 Adjusted Mean Change (SE)	-28.86 (6.01)	-28.68 (6.90)		
Week 24 Adjusted Mean Change (SE)	-24.56 (6.18)	-26.58 (7.07)		
Week 28 Adjusted Mean Change (SE)	-31.73 (5.99)	-25.24 (7.01)		
Week 32 Adjusted Mean Change (SE)	-31.52 (5.70)	-25.55 (6.64)		
Week 36 Adjusted Mean Change (SE)	-29.58 (5.96)	-28.01 (6.71)		
Week 40 Adjusted Mean Change (SE)	-30.88 (5.88)	-27.94 (6.74)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-35.27 (6.61)	-32.07 (7.61)		
Week 48 Adjusted Mean Change (SE)	-34.86 (6.28)	-31.34 (7.27)		
Week 52 Adjusted Mean Change (SE)	-34.50 (6.74)	-27.62 (7.64)	-6.88 [-27.18; 13.42]	0.502

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

16.13 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.842				
Non-carrier, N	**42**	**36**		
N'	42	36		
Baseline Mean (SD)	63.71 (23.49)	65.58 (20.56)		
Week 52 Mean (SD)	29.84 (23.17)	29.48 (26.25)		
Week 2 Adjusted Mean Change (SE)	-18.47 (2.72)	-15.49 (2.93)		
Week 4 Adjusted Mean Change (SE)	-24.00 (3.12)	-19.29 (3.39)		
Week 8 Adjusted Mean Change (SE)	-27.52 (3.21)	-26.39 (3.49)		
Week 12 Adjusted Mean Change (SE)	-28.67 (3.20)	-27.00 (3.50)		
Week 16 Adjusted Mean Change (SE)	-29.88 (3.05)	-29.82 (3.34)		
Week 20 Adjusted Mean Change (SE)	-31.74 (3.33)	-30.09 (3.67)		
Week 24 Adjusted Mean Change (SE)	-29.08 (3.36)	-28.61 (3.72)		
Week 28 Adjusted Mean Change (SE)	-31.87 (3.25)	-31.86 (3.67)		
Week 32 Adjusted Mean Change (SE)	-35.00 (3.16)	-29.82 (3.53)		
Week 36 Adjusted Mean Change (SE)	-35.52 (3.34)	-33.45 (3.73)		
Week 40 Adjusted Mean Change (SE)	-35.06 (3.30)	-30.52 (3.70)		
Week 44 Adjusted Mean Change (SE)	-35.10 (3.80)	-33.29 (4.28)		
Week 48 Adjusted Mean Change (SE)	-34.18 (3.59)	-35.09 (4.04)		
Week 52 Adjusted Mean Change (SE)	-34.56 (3.79)	-33.55 (4.26)	-1.01 [-12.37; 10.34]	0.859
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	73.33 (8.14)	53.00 (28.90)		
Week 52 Mean (SD)	29.44 (23.37)	38.67 (29.94)		
Week 2 Adjusted Mean Change (SE)	-9.72 (5.91)	-19.21 (7.93)		
Week 4 Adjusted Mean Change (SE)	-11.65 (6.79)	-21.36 (9.11)		
Week 8 Adjusted Mean Change (SE)	-17.08 (6.98)	-22.29 (9.36)		
Week 12 Adjusted Mean Change (SE)	-19.27 (6.94)	-14.32 (9.31)		
Week 16 Adjusted Mean Change (SE)	-21.02 (6.59)	-25.81 (8.84)		
Week 20 Adjusted Mean Change (SE)	-31.16 (7.20)	-17.09 (9.66)		
Week 24 Adjusted Mean Change (SE)	-26.14 (7.29)	-24.86 (9.78)		
Week 28 Adjusted Mean Change (SE)	-23.82 (7.00)	-26.32 (9.39)		
Week 32 Adjusted Mean Change (SE)	-32.31 (6.86)	-20.24 (9.20)		
Week 36 Adjusted Mean Change (SE)	-33.69 (7.19)	-31.45 (9.65)		
Week 40 Adjusted Mean Change (SE)	-31.88 (7.15)	-34.90 (9.70)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-34.23 (8.19)	-41.14 (11.19)		
Week 48 Adjusted Mean Change (SE)	-31.67 (7.80)	-39.80 (10.38)		
Week 52 Adjusted Mean Change (SE)	-35.28 (8.14)	-23.26 (11.66)	-12.01 [-40.46; 16.44]	0.404

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

16.14 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.950				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	60.73 (25.91)	64.91 (22.75)		
Week 52 Mean (SD)	40.80 (28.42)	35.00 (28.90)		
Week 2 Adjusted Mean Change (SE)	-18.18 (5.28)	-14.06 (3.73)		
Week 4 Adjusted Mean Change (SE)	-22.58 (6.38)	-23.68 (4.56)		
Week 8 Adjusted Mean Change (SE)	-25.46 (6.31)	-24.15 (4.53)		
Week 12 Adjusted Mean Change (SE)	-23.89 (6.44)	-29.66 (4.64)		
Week 16 Adjusted Mean Change (SE)	-28.44 (6.06)	-26.05 (4.38)		
Week 20 Adjusted Mean Change (SE)	-27.09 (6.42)	-26.12 (4.73)		
Week 24 Adjusted Mean Change (SE)	-30.60 (6.72)	-24.65 (4.93)		
Week 28 Adjusted Mean Change (SE)	-27.23 (6.49)	-31.86 (4.92)		
Week 32 Adjusted Mean Change (SE)	-31.51 (6.19)	-27.29 (4.64)		
Week 36 Adjusted Mean Change (SE)	-29.53 (6.48)	-33.78 (4.90)		
Week 40 Adjusted Mean Change (SE)	-30.58 (6.40)	-28.81 (4.88)		
Week 44 Adjusted Mean Change (SE)	-27.08 (7.24)	-28.87 (5.54)		
Week 48 Adjusted Mean Change (SE)	-24.02 (6.92)	-32.82 (5.22)		
Week 52 Adjusted Mean Change (SE)	-23.81 (7.23)	-27.62 (5.55)	3.81 [-14.31; 21.93]	0.677
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	66.70 (20.76)	62.32 (22.19)		
Week 52 Mean (SD)	26.78 (20.70)	26.15 (23.87)		
Week 2 Adjusted Mean Change (SE)	-16.36 (2.77)	-18.73 (3.74)		
Week 4 Adjusted Mean Change (SE)	-21.32 (3.35)	-16.65 (4.52)		
Week 8 Adjusted Mean Change (SE)	-25.46 (3.31)	-28.80 (4.47)		
Week 12 Adjusted Mean Change (SE)	-27.71 (3.39)	-24.61 (4.60)		
Week 16 Adjusted Mean Change (SE)	-28.09 (3.15)	-32.89 (4.27)		
Week 20 Adjusted Mean Change (SE)	-32.38 (3.40)	-32.21 (4.58)		
Week 24 Adjusted Mean Change (SE)	-27.91 (3.48)	-31.12 (4.70)		
Week 28 Adjusted Mean Change (SE)	-30.89 (3.44)	-30.04 (4.68)		
Week 32 Adjusted Mean Change (SE)	-35.31 (3.26)	-30.74 (4.40)		
Week 36 Adjusted Mean Change (SE)	-36.54 (3.40)	-34.88 (4.55)		
Week 40 Adjusted Mean Change (SE)	-35.47 (3.37)	-35.24 (4.55)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-36.90 (3.79)	-39.04 (5.10)		
Week 48 Adjusted Mean Change (SE)	-36.24 (3.60)	-38.50 (4.86)		
Week 52 Adjusted Mean Change (SE)	-37.59 (3.78)	-37.12 (5.10)	-0.47 [-13.10; 12.17]	0.942

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

16.15 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.172				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	65.45 (23.19)	66.39 (16.67)		
Week 52 Mean (SD)	31.53 (24.26)	31.69 (27.05)		
Week 2 Adjusted Mean Change (SE)	-20.51 (3.06)	-12.08 (3.55)		
Week 4 Adjusted Mean Change (SE)	-24.19 (3.78)	-16.54 (4.44)		
Week 8 Adjusted Mean Change (SE)	-26.02 (3.73)	-22.45 (4.38)		
Week 12 Adjusted Mean Change (SE)	-28.90 (3.81)	-24.56 (4.50)		
Week 16 Adjusted Mean Change (SE)	-29.65 (3.52)	-24.40 (4.17)		
Week 20 Adjusted Mean Change (SE)	-32.74 (3.81)	-24.42 (4.58)		
Week 24 Adjusted Mean Change (SE)	-28.05 (3.95)	-24.59 (4.75)		
Week 28 Adjusted Mean Change (SE)	-31.97 (3.86)	-31.68 (4.73)		
Week 32 Adjusted Mean Change (SE)	-35.19 (3.68)	-26.75 (4.46)		
Week 36 Adjusted Mean Change (SE)	-36.01 (3.83)	-30.97 (4.68)		
Week 40 Adjusted Mean Change (SE)	-35.94 (3.78)	-27.36 (4.63)		
Week 44 Adjusted Mean Change (SE)	-34.47 (4.33)	-29.70 (5.35)		
Week 48 Adjusted Mean Change (SE)	-34.06 (4.14)	-33.13 (5.09)		
Week 52 Adjusted Mean Change (SE)	-32.75 (4.33)	-30.10 (5.43)	-2.66 [-16.46; 11.14]	0.703
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	65.35 (20.13)	60.57 (27.20)		
Week 52 Mean (SD)	26.65 (20.78)	28.47 (25.95)		
Week 2 Adjusted Mean Change (SE)	-10.95 (3.81)	-21.11 (3.72)		
Week 4 Adjusted Mean Change (SE)	-17.56 (4.70)	-23.87 (4.60)		
Week 8 Adjusted Mean Change (SE)	-24.60 (4.64)	-30.88 (4.54)		
Week 12 Adjusted Mean Change (SE)	-23.66 (4.78)	-30.03 (4.68)		
Week 16 Adjusted Mean Change (SE)	-25.74 (4.39)	-35.21 (4.33)		
Week 20 Adjusted Mean Change (SE)	-28.81 (4.76)	-34.41 (4.65)		
Week 24 Adjusted Mean Change (SE)	-28.89 (4.90)	-31.69 (4.84)		
Week 28 Adjusted Mean Change (SE)	-27.10 (4.87)	-30.32 (4.81)		
Week 32 Adjusted Mean Change (SE)	-33.30 (4.58)	-31.76 (4.54)		
Week 36 Adjusted Mean Change (SE)	-33.34 (4.78)	-37.97 (4.69)		
Week 40 Adjusted Mean Change (SE)	-31.86 (4.68)	-37.58 (4.65)		

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-35.26 (5.40)	-39.24 (5.33)		
Week 48 Adjusted Mean Change (SE)	-33.05 (5.14)	-38.72 (5.07)		
Week 52 Adjusted Mean Change (SE)	-37.84 (5.47)	-35.75 (5.34)	-2.09 [-17.30; 13.12]	0.785

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

16.16 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.253				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	60.47 (24.78)	65.05 (22.87)		
Week 52 Mean (SD)	34.00 (22.91)	32.21 (30.84)		
Week 2 Adjusted Mean Change (SE)	-17.58 (4.05)	-17.85 (3.93)		
Week 4 Adjusted Mean Change (SE)	-17.48 (4.86)	-22.55 (4.78)		
Week 8 Adjusted Mean Change (SE)	-18.94 (4.73)	-29.41 (4.66)		
Week 12 Adjusted Mean Change (SE)	-24.80 (4.87)	-31.58 (4.87)		
Week 16 Adjusted Mean Change (SE)	-21.59 (4.49)	-32.56 (4.52)		
Week 20 Adjusted Mean Change (SE)	-25.33 (4.90)	-29.54 (4.92)		
Week 24 Adjusted Mean Change (SE)	-21.26 (5.02)	-30.82 (5.05)		
Week 28 Adjusted Mean Change (SE)	-27.39 (5.00)	-33.59 (5.10)		
Week 32 Adjusted Mean Change (SE)	-31.70 (4.71)	-29.86 (4.81)		
Week 36 Adjusted Mean Change (SE)	-32.09 (4.90)	-33.83 (5.08)		
Week 40 Adjusted Mean Change (SE)	-31.54 (4.89)	-29.23 (5.06)		
Week 44 Adjusted Mean Change (SE)	-30.88 (5.53)	-34.30 (5.77)		
Week 48 Adjusted Mean Change (SE)	-26.85 (5.17)	-35.95 (5.40)		
Week 52 Adjusted Mean Change (SE)	-30.57 (5.52)	-28.57 (5.84)	-2.00 [-17.98; 13.99]	0.804
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	68.34 (19.71)	62.42 (22.13)		
Week 52 Mean (SD)	26.89 (22.95)	28.43 (23.12)		
Week 2 Adjusted Mean Change (SE)	-16.28 (3.12)	-15.16 (3.59)		
Week 4 Adjusted Mean Change (SE)	-24.05 (3.75)	-17.94 (4.31)		
Week 8 Adjusted Mean Change (SE)	-29.37 (3.65)	-24.06 (4.20)		
Week 12 Adjusted Mean Change (SE)	-28.12 (3.77)	-23.86 (4.32)		
Week 16 Adjusted Mean Change (SE)	-32.05 (3.49)	-27.15 (4.01)		
Week 20 Adjusted Mean Change (SE)	-34.70 (3.77)	-28.89 (4.35)		
Week 24 Adjusted Mean Change (SE)	-32.59 (3.84)	-25.68 (4.46)		
Week 28 Adjusted Mean Change (SE)	-31.93 (3.79)	-28.91 (4.45)		
Week 32 Adjusted Mean Change (SE)	-36.15 (3.65)	-28.49 (4.24)		
Week 36 Adjusted Mean Change (SE)	-36.70 (3.84)	-34.59 (4.40)		
Week 40 Adjusted Mean Change (SE)	-36.07 (3.80)	-34.57 (4.40)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 44 Adjusted Mean Change (SE)	-37.00 (4.32)	-34.24 (5.00)		
Week 48 Adjusted Mean Change (SE)	-37.95 (4.06)	-35.36 (4.68)		
Week 52 Adjusted Mean Change (SE)	-36.99 (4.34)	-35.71 (5.01)	-1.28 [-14.48; 11.91]	0.847

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

16.17 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.263				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	67.48 (17.91)	63.41 (22.57)		
Week 52 Mean (SD)	29.26 (25.48)	34.62 (27.86)		
Week 2 Adjusted Mean Change (SE)	-16.24 (3.53)	-15.67 (3.11)		
Week 4 Adjusted Mean Change (SE)	-21.89 (4.26)	-21.14 (3.76)		
Week 8 Adjusted Mean Change (SE)	-26.29 (4.16)	-23.83 (3.66)		
Week 12 Adjusted Mean Change (SE)	-28.60 (4.25)	-24.20 (3.74)		
Week 16 Adjusted Mean Change (SE)	-24.05 (3.94)	-27.11 (3.47)		
Week 20 Adjusted Mean Change (SE)	-32.88 (4.17)	-25.24 (3.73)		
Week 24 Adjusted Mean Change (SE)	-28.24 (4.38)	-25.01 (3.93)		
Week 28 Adjusted Mean Change (SE)	-31.49 (4.18)	-26.63 (3.82)		
Week 32 Adjusted Mean Change (SE)	-35.33 (4.06)	-25.74 (3.66)		
Week 36 Adjusted Mean Change (SE)	-34.70 (4.34)	-33.55 (3.89)		
Week 40 Adjusted Mean Change (SE)	-33.89 (4.28)	-31.56 (3.88)		
Week 44 Adjusted Mean Change (SE)	-35.18 (4.88)	-33.06 (4.42)		
Week 48 Adjusted Mean Change (SE)	-35.47 (4.62)	-34.60 (4.18)		
Week 52 Adjusted Mean Change (SE)	-36.76 (4.86)	-30.26 (4.43)	-6.50 [-19.56; 6.57]	0.326
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	63.42 (25.24)	64.17 (22.33)		
Week 52 Mean (SD)	30.25 (20.79)	16.44 (14.05)		
Week 2 Adjusted Mean Change (SE)	-17.26 (3.46)	-18.29 (5.07)		
Week 4 Adjusted Mean Change (SE)	-21.31 (4.17)	-16.65 (6.27)		
Week 8 Adjusted Mean Change (SE)	-24.67 (4.07)	-34.05 (6.14)		
Week 12 Adjusted Mean Change (SE)	-25.24 (4.13)	-35.86 (6.29)		
Week 16 Adjusted Mean Change (SE)	-31.62 (3.83)	-36.54 (5.88)		
Week 20 Adjusted Mean Change (SE)	-29.18 (4.13)	-40.01 (6.22)		
Week 24 Adjusted Mean Change (SE)	-28.57 (4.31)	-36.11 (6.53)		
Week 28 Adjusted Mean Change (SE)	-28.70 (4.13)	-43.06 (6.28)		
Week 32 Adjusted Mean Change (SE)	-33.74 (3.97)	-38.73 (6.03)		
Week 36 Adjusted Mean Change (SE)	-35.23 (4.23)	-36.37 (6.51)		
Week 40 Adjusted Mean Change (SE)	-34.83 (4.22)	-34.15 (6.50)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 44 Adjusted Mean Change (SE)	-34.39 (4.78)	-37.82 (7.46)		
Week 48 Adjusted Mean Change (SE)	-32.01 (4.53)	-39.08 (6.98)		
Week 52 Adjusted Mean Change (SE)	-32.50 (4.77)	-39.64 (7.44)	7.15 [-10.41; 24.70]	0.421

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

16.18 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.703				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	67.69 (21.36)	63.34 (21.51)		
Week 52 Mean (SD)	31.23 (22.16)	31.96 (26.41)		
Week 2 Adjusted Mean Change (SE)	-16.70 (2.83)	-15.81 (2.96)		
Week 4 Adjusted Mean Change (SE)	-21.97 (3.35)	-22.59 (3.53)		
Week 8 Adjusted Mean Change (SE)	-26.41 (3.36)	-25.89 (3.55)		
Week 12 Adjusted Mean Change (SE)	-26.10 (3.45)	-27.92 (3.66)		
Week 16 Adjusted Mean Change (SE)	-28.28 (3.25)	-27.85 (3.45)		
Week 20 Adjusted Mean Change (SE)	-32.04 (3.41)	-26.74 (3.66)		
Week 24 Adjusted Mean Change (SE)	-31.32 (3.51)	-27.31 (3.77)		
Week 28 Adjusted Mean Change (SE)	-31.23 (3.50)	-31.66 (3.80)		
Week 32 Adjusted Mean Change (SE)	-34.58 (3.36)	-30.37 (3.63)		
Week 36 Adjusted Mean Change (SE)	-35.01 (3.49)	-35.69 (3.78)		
Week 40 Adjusted Mean Change (SE)	-34.44 (3.49)	-30.64 (3.80)		
Week 44 Adjusted Mean Change (SE)	-35.02 (3.96)	-32.66 (4.32)		
Week 48 Adjusted Mean Change (SE)	-33.02 (3.78)	-35.03 (4.10)		
Week 52 Adjusted Mean Change (SE)	-33.34 (3.98)	-29.97 (4.37)	-3.37 [-15.12; 8.38]	0.570
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	55.36 (21.73)	64.67 (26.32)		
Week 52 Mean (SD)	24.18 (26.49)	24.11 (25.81)		
Week 2 Adjusted Mean Change (SE)	-14.35 (5.39)	-17.64 (5.83)		
Week 4 Adjusted Mean Change (SE)	-16.54 (6.37)	-9.27 (6.91)		
Week 8 Adjusted Mean Change (SE)	-18.85 (6.39)	-27.47 (6.93)		
Week 12 Adjusted Mean Change (SE)	-26.18 (6.54)	-23.12 (7.10)		
Week 16 Adjusted Mean Change (SE)	-26.13 (6.16)	-35.52 (6.76)		
Week 20 Adjusted Mean Change (SE)	-28.50 (6.54)	-37.48 (7.01)		
Week 24 Adjusted Mean Change (SE)	-20.46 (6.66)	-29.57 (7.23)		
Week 28 Adjusted Mean Change (SE)	-25.77 (6.67)	-27.37 (7.41)		
Week 32 Adjusted Mean Change (SE)	-32.83 (6.37)	-23.69 (6.98)		
Week 36 Adjusted Mean Change (SE)	-33.61 (6.57)	-28.68 (7.13)		
Week 40 Adjusted Mean Change (SE)	-33.46 (6.60)	-36.24 (7.16)		

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Week 44 Adjusted Mean Change (SE)	-33.43 (7.45)	-39.00 (8.18)		
Week 48 Adjusted Mean Change (SE)	-35.18 (7.09)	-36.92 (7.86)		
Week 52 Adjusted Mean Change (SE)	-38.14 (7.45)	-39.98 (8.10)	1.84 [-20.03; 23.71]	0.868

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

17.0 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	66 (100.0)	61 (98.4)	127 (99.2)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	57 (91.9)	122 (95.3)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	48 (77.4)	111 (86.7)

17.1 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N'	66	61		
Baseline Mean (SD)	68.98 (19.71)	70.37 (20.08)		
Week 52 Mean (SD)	30.16 (23.69)	31.17 (25.37)		
Week 2 Adjusted Mean Change (SE)	-19.40 (2.27)	-17.66 (2.36)		
Week 4 Adjusted Mean Change (SE)	-27.75 (2.58)	-23.66 (2.70)		
Week 8 Adjusted Mean Change (SE)	-31.12 (2.56)	-28.22 (2.67)		
Week 12 Adjusted Mean Change (SE)	-31.65 (2.68)	-29.70 (2.79)		
Week 16 Adjusted Mean Change (SE)	-35.34 (2.58)	-29.80 (2.72)		
Week 24 Adjusted Mean Change (SE)	-34.19 (2.55)	-32.65 (2.74)		
Week 32 Adjusted Mean Change (SE)	-37.64 (2.51)	-34.54 (2.68)		
Week 40 Adjusted Mean Change (SE)	-37.65 (2.70)	-36.31 (2.98)		
Week 52 Adjusted Mean Change (SE)	-39.74 (3.02)	-36.72 (3.35)	-3.02 [-11.97; 5.93]	0.505

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

17.2 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.209				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	69.69 (16.60)	66.97 (19.49)		
Week 52 Mean (SD)	29.78 (24.09)	25.62 (24.85)		
Week 2 Adjusted Mean Change (SE)	-21.25 (2.85)	-21.35 (3.26)		
Week 4 Adjusted Mean Change (SE)	-31.46 (3.17)	-29.83 (3.63)		
Week 8 Adjusted Mean Change (SE)	-32.48 (3.18)	-33.80 (3.64)		
Week 12 Adjusted Mean Change (SE)	-34.40 (3.30)	-34.33 (3.77)		
Week 16 Adjusted Mean Change (SE)	-38.34 (3.14)	-36.75 (3.58)		
Week 24 Adjusted Mean Change (SE)	-36.01 (3.10)	-39.50 (3.63)		
Week 32 Adjusted Mean Change (SE)	-38.10 (3.12)	-38.99 (3.64)		
Week 40 Adjusted Mean Change (SE)	-37.97 (3.30)	-43.89 (3.93)		
Week 52 Adjusted Mean Change (SE)	-40.24 (3.75)	-42.94 (4.49)	2.70 [-8.87; 14.27]	0.645
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	67.75 (24.59)	74.24 (20.37)		
Week 52 Mean (SD)	30.83 (23.49)	37.73 (24.96)		
Week 2 Adjusted Mean Change (SE)	-16.21 (3.79)	-13.56 (3.44)		
Week 4 Adjusted Mean Change (SE)	-21.32 (4.20)	-16.69 (3.86)		
Week 8 Adjusted Mean Change (SE)	-28.81 (4.21)	-21.90 (3.88)		
Week 12 Adjusted Mean Change (SE)	-26.87 (4.39)	-24.57 (4.04)		
Week 16 Adjusted Mean Change (SE)	-30.19 (4.14)	-21.56 (3.89)		
Week 24 Adjusted Mean Change (SE)	-31.01 (4.14)	-24.78 (3.92)		
Week 32 Adjusted Mean Change (SE)	-36.95 (4.15)	-29.39 (3.88)		
Week 40 Adjusted Mean Change (SE)	-37.09 (4.34)	-27.47 (4.27)		
Week 52 Adjusted Mean Change (SE)	-38.89 (4.95)	-29.61 (4.86)	-9.28 [-23.03; 4.46]	0.184

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

17.3 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.969				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	53.88 (19.60)	49.23 (22.77)		
Week 52 Mean (SD)	21.75 (19.97)	34.44 (30.15)		
Week 2 Adjusted Mean Change (SE)	-27.42 (4.79)	-25.01 (5.40)		
Week 4 Adjusted Mean Change (SE)	-34.00 (5.50)	-31.25 (6.20)		
Week 8 Adjusted Mean Change (SE)	-30.44 (5.44)	-38.08 (6.13)		
Week 12 Adjusted Mean Change (SE)	-36.16 (5.75)	-33.58 (6.44)		
Week 16 Adjusted Mean Change (SE)	-40.90 (5.49)	-37.34 (6.19)		
Week 24 Adjusted Mean Change (SE)	-39.11 (5.46)	-38.85 (6.32)		
Week 32 Adjusted Mean Change (SE)	-45.27 (5.30)	-40.81 (6.25)		
Week 40 Adjusted Mean Change (SE)	-43.09 (5.79)	-41.24 (7.05)		
Week 52 Adjusted Mean Change (SE)	-46.44 (6.37)	-34.01 (7.84)	-12.43 [-31.44; 6.57]	0.198
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	73.82 (17.31)	75.98 (15.15)		
Week 52 Mean (SD)	33.02 (24.35)	30.41 (24.53)		
Week 2 Adjusted Mean Change (SE)	-16.92 (2.60)	-15.56 (2.70)		
Week 4 Adjusted Mean Change (SE)	-25.83 (2.99)	-21.50 (3.12)		
Week 8 Adjusted Mean Change (SE)	-31.40 (2.96)	-25.44 (3.08)		
Week 12 Adjusted Mean Change (SE)	-30.23 (3.11)	-28.62 (3.25)		
Week 16 Adjusted Mean Change (SE)	-33.65 (2.99)	-27.62 (3.14)		
Week 24 Adjusted Mean Change (SE)	-32.67 (2.95)	-30.85 (3.15)		
Week 32 Adjusted Mean Change (SE)	-35.25 (2.89)	-32.80 (3.05)		
Week 40 Adjusted Mean Change (SE)	-35.95 (3.14)	-34.78 (3.39)		
Week 52 Adjusted Mean Change (SE)	-37.56 (3.50)	-37.10 (3.78)	-0.45 [-10.48; 9.57]	0.929

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

17.4 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.354				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	63.71 (19.15)	68.25 (20.75)		
Week 52 Mean (SD)	30.46 (21.00)	29.43 (24.55)		
Week 2 Adjusted Mean Change (SE)	-17.84 (3.51)	-20.82 (3.26)		
Week 4 Adjusted Mean Change (SE)	-26.75 (4.03)	-25.33 (3.77)		
Week 8 Adjusted Mean Change (SE)	-28.22 (3.98)	-29.55 (3.73)		
Week 12 Adjusted Mean Change (SE)	-27.45 (4.12)	-27.83 (3.87)		
Week 16 Adjusted Mean Change (SE)	-28.88 (3.95)	-28.44 (3.75)		
Week 24 Adjusted Mean Change (SE)	-30.55 (3.96)	-34.10 (3.79)		
Week 32 Adjusted Mean Change (SE)	-35.23 (3.90)	-36.05 (3.73)		
Week 40 Adjusted Mean Change (SE)	-36.09 (4.26)	-33.43 (4.25)		
Week 52 Adjusted Mean Change (SE)	-39.34 (4.77)	-37.62 (4.76)	-1.72 [-15.03; 11.59]	0.799
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	72.87 (19.45)	72.63 (19.42)		
Week 52 Mean (SD)	29.95 (25.69)	32.76 (26.51)		
Week 2 Adjusted Mean Change (SE)	-20.55 (3.00)	-14.17 (3.43)		
Week 4 Adjusted Mean Change (SE)	-28.48 (3.44)	-21.81 (3.94)		
Week 8 Adjusted Mean Change (SE)	-33.25 (3.40)	-26.74 (3.89)		
Week 12 Adjusted Mean Change (SE)	-34.67 (3.54)	-31.74 (4.05)		
Week 16 Adjusted Mean Change (SE)	-40.12 (3.38)	-31.23 (3.88)		
Week 24 Adjusted Mean Change (SE)	-36.84 (3.37)	-30.99 (3.97)		
Week 32 Adjusted Mean Change (SE)	-39.40 (3.32)	-32.81 (3.87)		
Week 40 Adjusted Mean Change (SE)	-38.83 (3.62)	-38.34 (4.27)		
Week 52 Adjusted Mean Change (SE)	-40.14 (4.02)	-35.38 (4.78)	-4.76 [-17.08; 7.56]	0.446

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

17.5 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.995				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	72.93 (19.87)	68.21 (22.26)		
Week 52 Mean (SD)	27.66 (21.76)	28.57 (22.92)		
Week 2 Adjusted Mean Change (SE)	-23.08 (2.90)	-19.09 (3.39)		
Week 4 Adjusted Mean Change (SE)	-30.37 (3.33)	-25.48 (3.90)		
Week 8 Adjusted Mean Change (SE)	-30.54 (3.30)	-32.30 (3.86)		
Week 12 Adjusted Mean Change (SE)	-32.11 (3.48)	-31.21 (4.05)		
Week 16 Adjusted Mean Change (SE)	-36.42 (3.33)	-34.14 (3.92)		
Week 24 Adjusted Mean Change (SE)	-35.78 (3.26)	-37.43 (3.95)		
Week 32 Adjusted Mean Change (SE)	-37.86 (3.27)	-35.85 (3.91)		
Week 40 Adjusted Mean Change (SE)	-40.16 (3.52)	-35.19 (4.38)		
Week 52 Adjusted Mean Change (SE)	-42.41 (3.93)	-37.56 (4.96)	-4.85 [-17.39; 7.69]	0.445
> Median, N	**26**	**33**		
N'	26	32		
Baseline Mean (SD)	62.92 (18.20)	72.27 (18.08)		
Week 52 Mean (SD)	33.96 (26.35)	33.19 (27.39)		
Week 2 Adjusted Mean Change (SE)	-13.68 (3.62)	-16.41 (3.24)		
Week 4 Adjusted Mean Change (SE)	-23.68 (4.16)	-22.02 (3.76)		
Week 8 Adjusted Mean Change (SE)	-32.04 (4.12)	-24.40 (3.72)		
Week 12 Adjusted Mean Change (SE)	-30.91 (4.32)	-28.39 (3.92)		
Week 16 Adjusted Mean Change (SE)	-33.70 (4.14)	-25.81 (3.77)		
Week 24 Adjusted Mean Change (SE)	-31.69 (4.09)	-28.29 (3.76)		
Week 32 Adjusted Mean Change (SE)	-37.25 (4.05)	-33.34 (3.72)		
Week 40 Adjusted Mean Change (SE)	-33.78 (4.36)	-36.95 (4.07)		
Week 52 Adjusted Mean Change (SE)	-35.59 (4.90)	-35.85 (4.56)	0.26 [-13.09; 13.61]	0.969

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

17.6 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.471				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	65.76 (20.38)	68.77 (24.34)		
Week 52 Mean (SD)	28.53 (24.14)	28.89 (26.76)		
Week 2 Adjusted Mean Change (SE)	-19.87 (3.19)	-21.79 (3.95)		
Week 4 Adjusted Mean Change (SE)	-28.03 (3.64)	-27.71 (4.56)		
Week 8 Adjusted Mean Change (SE)	-29.50 (3.58)	-33.05 (4.50)		
Week 12 Adjusted Mean Change (SE)	-33.05 (3.77)	-32.15 (4.76)		
Week 16 Adjusted Mean Change (SE)	-35.28 (3.59)	-36.82 (4.56)		
Week 24 Adjusted Mean Change (SE)	-34.59 (3.59)	-34.58 (4.54)		
Week 32 Adjusted Mean Change (SE)	-39.02 (3.52)	-38.50 (4.42)		
Week 40 Adjusted Mean Change (SE)	-38.99 (3.80)	-37.75 (4.85)		
Week 52 Adjusted Mean Change (SE)	-41.50 (4.27)	-40.20 (5.48)	-1.30 [-15.04; 12.44]	0.852
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	72.41 (18.69)	71.25 (17.59)		
Week 52 Mean (SD)	31.84 (23.48)	32.53 (24.87)		
Week 2 Adjusted Mean Change (SE)	-18.91 (3.28)	-15.32 (2.97)		
Week 4 Adjusted Mean Change (SE)	-27.46 (3.74)	-21.40 (3.38)		
Week 8 Adjusted Mean Change (SE)	-32.85 (3.68)	-25.54 (3.33)		
Week 12 Adjusted Mean Change (SE)	-30.22 (3.87)	-28.17 (3.49)		
Week 16 Adjusted Mean Change (SE)	-35.45 (3.70)	-25.95 (3.36)		
Week 24 Adjusted Mean Change (SE)	-33.78 (3.68)	-31.69 (3.46)		
Week 32 Adjusted Mean Change (SE)	-36.21 (3.60)	-32.40 (3.37)		
Week 40 Adjusted Mean Change (SE)	-36.31 (3.87)	-35.86 (3.76)		
Week 52 Adjusted Mean Change (SE)	-37.94 (4.35)	-34.91 (4.22)	-3.03 [-14.99; 8.93]	0.617

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

17.7 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.272				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	74.45 (17.10)	71.00 (18.13)		
Week 52 Mean (SD)	34.39 (25.71)	25.57 (20.21)		
Week 2 Adjusted Mean Change (SE)	-18.07 (3.34)	-20.61 (3.57)		
Week 4 Adjusted Mean Change (SE)	-26.74 (4.05)	-29.60 (4.34)		
Week 8 Adjusted Mean Change (SE)	-32.00 (3.91)	-32.90 (4.18)		
Week 12 Adjusted Mean Change (SE)	-33.76 (3.94)	-36.71 (4.24)		
Week 16 Adjusted Mean Change (SE)	-37.01 (3.88)	-34.01 (4.19)		
Week 24 Adjusted Mean Change (SE)	-35.54 (3.89)	-35.42 (4.27)		
Week 32 Adjusted Mean Change (SE)	-40.15 (3.59)	-37.92 (3.92)		
Week 40 Adjusted Mean Change (SE)	-39.20 (4.11)	-40.26 (4.52)		
Week 52 Adjusted Mean Change (SE)	-37.72 (4.51)	-43.63 (5.00)	5.91 [-7.44; 19.25]	0.381
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	66.45 (23.23)	68.16 (24.19)		
Week 52 Mean (SD)	27.90 (21.75)	40.94 (32.24)		
Week 2 Adjusted Mean Change (SE)	-21.61 (3.82)	-10.90 (4.10)		
Week 4 Adjusted Mean Change (SE)	-25.33 (4.65)	-16.05 (5.07)		
Week 8 Adjusted Mean Change (SE)	-29.33 (4.48)	-25.23 (4.89)		
Week 12 Adjusted Mean Change (SE)	-29.80 (4.54)	-25.97 (4.94)		
Week 16 Adjusted Mean Change (SE)	-30.88 (4.47)	-29.62 (4.87)		
Week 24 Adjusted Mean Change (SE)	-33.03 (4.48)	-29.94 (4.95)		
Week 32 Adjusted Mean Change (SE)	-37.57 (4.21)	-31.44 (4.57)		
Week 40 Adjusted Mean Change (SE)	-39.38 (4.75)	-32.08 (5.37)		
Week 52 Adjusted Mean Change (SE)	-41.20 (5.25)	-26.95 (5.82)	-14.25 [-29.75; 1.25]	0.071

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

17.8 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.064				
Non-carrier, N	**28**	**19**		
N'	28	19		
Baseline Mean (SD)	73.21 (20.58)	67.42 (16.58)		
Week 52 Mean (SD)	32.19 (24.94)	34.08 (28.26)		
Week 2 Adjusted Mean Change (SE)	-22.08 (3.22)	-10.49 (3.90)		
Week 4 Adjusted Mean Change (SE)	-28.20 (4.07)	-18.34 (5.02)		
Week 8 Adjusted Mean Change (SE)	-31.93 (3.97)	-24.06 (4.91)		
Week 12 Adjusted Mean Change (SE)	-35.35 (4.03)	-29.39 (4.98)		
Week 16 Adjusted Mean Change (SE)	-36.25 (3.86)	-25.58 (4.81)		
Week 24 Adjusted Mean Change (SE)	-36.02 (3.87)	-27.92 (4.92)		
Week 32 Adjusted Mean Change (SE)	-40.87 (3.72)	-31.79 (4.72)		
Week 40 Adjusted Mean Change (SE)	-41.19 (4.07)	-27.22 (5.28)		
Week 52 Adjusted Mean Change (SE)	-38.24 (4.83)	-32.98 (6.35)	-5.26 [-21.17; 10.65]	0.513
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	66.86 (18.93)	71.84 (20.55)		
Week 52 Mean (SD)	32.35 (23.42)	33.11 (27.91)		
Week 2 Adjusted Mean Change (SE)	-13.94 (3.63)	-19.41 (3.90)		
Week 4 Adjusted Mean Change (SE)	-21.00 (4.59)	-25.44 (4.92)		
Week 8 Adjusted Mean Change (SE)	-27.33 (4.48)	-32.17 (4.81)		
Week 12 Adjusted Mean Change (SE)	-25.65 (4.57)	-31.34 (4.90)		
Week 16 Adjusted Mean Change (SE)	-30.13 (4.37)	-35.84 (4.69)		
Week 24 Adjusted Mean Change (SE)	-30.27 (4.38)	-37.80 (4.77)		
Week 32 Adjusted Mean Change (SE)	-34.18 (4.22)	-35.66 (4.53)		
Week 40 Adjusted Mean Change (SE)	-34.54 (4.56)	-43.59 (5.01)		
Week 52 Adjusted Mean Change (SE)	-38.88 (5.48)	-36.96 (5.89)	-1.91 [-17.95; 14.12]	0.813

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

17.9 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.111				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	62.11 (23.43)	72.10 (21.60)		
Week 52 Mean (SD)	35.11 (24.77)	30.07 (28.41)		
Week 2 Adjusted Mean Change (SE)	-17.72 (4.28)	-16.70 (4.00)		
Week 4 Adjusted Mean Change (SE)	-21.11 (5.15)	-26.63 (4.89)		
Week 8 Adjusted Mean Change (SE)	-23.88 (4.83)	-34.36 (4.59)		
Week 12 Adjusted Mean Change (SE)	-27.67 (4.99)	-36.40 (4.78)		
Week 16 Adjusted Mean Change (SE)	-27.88 (4.86)	-33.85 (4.66)		
Week 24 Adjusted Mean Change (SE)	-25.69 (4.81)	-35.44 (4.72)		
Week 32 Adjusted Mean Change (SE)	-33.90 (4.52)	-35.76 (4.42)		
Week 40 Adjusted Mean Change (SE)	-35.65 (5.23)	-37.31 (5.20)		
Week 52 Adjusted Mean Change (SE)	-33.91 (5.81)	-36.10 (5.91)	2.19 [-14.36; 18.74]	0.793
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	76.53 (15.90)	67.65 (20.17)		
Week 52 Mean (SD)	29.32 (24.27)	33.68 (26.26)		
Week 2 Adjusted Mean Change (SE)	-20.05 (3.39)	-16.10 (3.83)		
Week 4 Adjusted Mean Change (SE)	-28.13 (4.09)	-21.29 (4.61)		
Week 8 Adjusted Mean Change (SE)	-35.27 (3.83)	-25.30 (4.33)		
Week 12 Adjusted Mean Change (SE)	-34.55 (3.97)	-28.35 (4.47)		
Week 16 Adjusted Mean Change (SE)	-38.17 (3.86)	-30.50 (4.37)		
Week 24 Adjusted Mean Change (SE)	-39.38 (3.80)	-31.13 (4.33)		
Week 32 Adjusted Mean Change (SE)	-42.39 (3.64)	-34.46 (4.08)		
Week 40 Adjusted Mean Change (SE)	-41.80 (4.17)	-36.11 (4.76)		
Week 52 Adjusted Mean Change (SE)	-42.88 (4.67)	-36.17 (5.27)	-6.71 [-20.77; 7.36]	0.346

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

17.10 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.682				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	75.72 (19.88)	69.97 (21.98)		
Week 52 Mean (SD)	31.00 (27.26)	34.64 (27.43)		
Week 2 Adjusted Mean Change (SE)	-17.64 (3.67)	-16.84 (3.21)		
Week 4 Adjusted Mean Change (SE)	-27.38 (4.47)	-25.13 (3.91)		
Week 8 Adjusted Mean Change (SE)	-31.61 (4.26)	-29.49 (3.73)		
Week 12 Adjusted Mean Change (SE)	-31.85 (4.33)	-30.36 (3.79)		
Week 16 Adjusted Mean Change (SE)	-32.30 (4.21)	-30.58 (3.68)		
Week 24 Adjusted Mean Change (SE)	-36.94 (4.15)	-30.33 (3.72)		
Week 32 Adjusted Mean Change (SE)	-40.04 (3.93)	-33.71 (3.48)		
Week 40 Adjusted Mean Change (SE)	-39.79 (4.50)	-36.96 (4.07)		
Week 52 Adjusted Mean Change (SE)	-40.69 (5.06)	-36.15 (4.54)	-4.54 [-18.03; 8.95]	0.505
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	66.46 (19.74)	69.25 (17.88)		
Week 52 Mean (SD)	32.32 (21.36)	24.67 (24.76)		
Week 2 Adjusted Mean Change (SE)	-21.47 (3.59)	-15.32 (5.25)		
Week 4 Adjusted Mean Change (SE)	-24.92 (4.37)	-20.10 (6.56)		
Week 8 Adjusted Mean Change (SE)	-30.12 (4.17)	-29.99 (6.27)		
Week 12 Adjusted Mean Change (SE)	-32.29 (4.21)	-37.18 (6.35)		
Week 16 Adjusted Mean Change (SE)	-36.27 (4.10)	-36.92 (6.27)		
Week 24 Adjusted Mean Change (SE)	-31.97 (4.07)	-40.45 (6.14)		
Week 32 Adjusted Mean Change (SE)	-38.16 (3.82)	-39.23 (5.74)		
Week 40 Adjusted Mean Change (SE)	-38.79 (4.43)	-35.79 (6.77)		
Week 52 Adjusted Mean Change (SE)	-37.80 (4.94)	-36.80 (7.67)	-1.01 [-19.09; 17.07]	0.912

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

17.11 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.538				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	73.92 (17.39)	67.36 (20.45)		
Week 52 Mean (SD)	33.91 (22.86)	31.69 (24.82)		
Week 2 Adjusted Mean Change (SE)	-18.49 (2.97)	-16.42 (3.15)		
Week 4 Adjusted Mean Change (SE)	-26.90 (3.57)	-27.29 (3.83)		
Week 8 Adjusted Mean Change (SE)	-31.06 (3.42)	-30.24 (3.68)		
Week 12 Adjusted Mean Change (SE)	-30.06 (3.34)	-34.40 (3.57)		
Week 16 Adjusted Mean Change (SE)	-33.44 (3.37)	-31.54 (3.64)		
Week 24 Adjusted Mean Change (SE)	-35.92 (3.26)	-32.78 (3.58)		
Week 32 Adjusted Mean Change (SE)	-38.65 (3.15)	-36.97 (3.42)		
Week 40 Adjusted Mean Change (SE)	-38.15 (3.44)	-35.81 (3.82)		
Week 52 Adjusted Mean Change (SE)	-37.56 (3.89)	-35.60 (4.35)	-1.95 [-13.61; 9.70]	0.740
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	63.42 (26.49)	72.33 (20.22)		
Week 52 Mean (SD)	27.42 (27.72)	20.67 (17.21)		
Week 2 Adjusted Mean Change (SE)	-21.04 (5.32)	-21.06 (6.01)		
Week 4 Adjusted Mean Change (SE)	-20.11 (6.38)	-15.25 (7.25)		
Week 8 Adjusted Mean Change (SE)	-27.25 (6.12)	-32.62 (6.95)		
Week 12 Adjusted Mean Change (SE)	-34.32 (5.95)	-33.57 (6.85)		
Week 16 Adjusted Mean Change (SE)	-33.79 (6.02)	-40.17 (6.91)		
Week 24 Adjusted Mean Change (SE)	-26.23 (5.89)	-41.63 (6.72)		
Week 32 Adjusted Mean Change (SE)	-37.58 (5.58)	-35.29 (6.31)		
Week 40 Adjusted Mean Change (SE)	-39.32 (6.11)	-49.30 (6.94)		
Week 52 Adjusted Mean Change (SE)	-40.60 (6.85)	-49.29 (7.79)	8.69 [-11.95; 29.34]	0.405

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

17.12 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.793				
Non-carrier, N	36	34		
N'	36	34		
Baseline Mean (SD)	71.97 (18.48)	69.09 (22.48)		
Week 52 Mean (SD)	34.00 (25.75)	32.19 (26.39)		
Week 2 Adjusted Mean Change (SE)	-17.71 (3.05)	-16.56 (3.14)		
Week 4 Adjusted Mean Change (SE)	-26.48 (3.66)	-26.78 (3.80)		
Week 8 Adjusted Mean Change (SE)	-32.22 (3.49)	-31.18 (3.63)		
Week 12 Adjusted Mean Change (SE)	-34.66 (3.54)	-33.64 (3.70)		
Week 16 Adjusted Mean Change (SE)	-37.92 (3.44)	-34.07 (3.59)		
Week 24 Adjusted Mean Change (SE)	-34.88 (3.54)	-33.13 (3.76)		
Week 32 Adjusted Mean Change (SE)	-38.39 (3.28)	-34.71 (3.46)		
Week 40 Adjusted Mean Change (SE)	-39.07 (3.76)	-37.97 (4.04)		
Week 52 Adjusted Mean Change (SE)	-36.94 (4.18)	-35.81 (4.49)	-1.13 [-13.34; 11.08]	0.855
Carrier, N	13	10		
N'	13	10		
Baseline Mean (SD)	66.85 (25.41)	72.10 (13.97)		
Week 52 Mean (SD)	28.46 (20.38)	32.30 (29.42)		
Week 2 Adjusted Mean Change (SE)	-22.48 (5.08)	-15.42 (5.83)		
Week 4 Adjusted Mean Change (SE)	-24.64 (6.10)	-13.50 (6.98)		
Week 8 Adjusted Mean Change (SE)	-26.95 (5.82)	-23.75 (6.66)		
Week 12 Adjusted Mean Change (SE)	-24.02 (5.91)	-26.33 (6.76)		
Week 16 Adjusted Mean Change (SE)	-25.34 (5.71)	-25.34 (6.54)		
Week 24 Adjusted Mean Change (SE)	-31.82 (5.87)	-31.68 (6.72)		
Week 32 Adjusted Mean Change (SE)	-38.84 (5.43)	-35.26 (6.22)		
Week 40 Adjusted Mean Change (SE)	-38.29 (6.24)	-31.13 (7.22)		
Week 52 Adjusted Mean Change (SE)	-41.65 (6.87)	-36.98 (7.85)	-4.67 [-25.45; 16.12]	0.656

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

17.13 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

| | Treatment Groups | | Comparison | |
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.703				
Non-carrier, N	**42**	**36**		
N'	42	36		
Baseline Mean (SD)	68.64 (21.29)	70.19 (20.50)		
Week 52 Mean (SD)	31.79 (24.39)	31.86 (28.53)		
Week 2 Adjusted Mean Change (SE)	-21.00 (2.81)	-15.40 (3.03)		
Week 4 Adjusted Mean Change (SE)	-29.02 (3.33)	-23.26 (3.62)		
Week 8 Adjusted Mean Change (SE)	-32.61 (3.24)	-28.92 (3.52)		
Week 12 Adjusted Mean Change (SE)	-32.67 (3.28)	-31.27 (3.57)		
Week 16 Adjusted Mean Change (SE)	-35.42 (3.22)	-32.10 (3.52)		
Week 24 Adjusted Mean Change (SE)	-35.07 (3.17)	-32.75 (3.52)		
Week 32 Adjusted Mean Change (SE)	-39.44 (3.02)	-33.73 (3.32)		
Week 40 Adjusted Mean Change (SE)	-39.33 (3.45)	-35.08 (3.89)		
Week 52 Adjusted Mean Change (SE)	-38.92 (3.89)	-36.81 (4.36)	-2.11 [-13.73; 9.51]	0.719
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	82.00 (7.21)	68.40 (28.18)		
Week 52 Mean (SD)	31.22 (24.27)	39.80 (21.46)		
Week 2 Adjusted Mean Change (SE)	-13.55 (6.16)	-14.76 (8.13)		
Week 4 Adjusted Mean Change (SE)	-13.16 (7.30)	-23.00 (9.63)		
Week 8 Adjusted Mean Change (SE)	-23.15 (7.10)	-28.30 (9.37)		
Week 12 Adjusted Mean Change (SE)	-29.68 (7.16)	-23.99 (9.45)		
Week 16 Adjusted Mean Change (SE)	-30.18 (7.04)	-27.73 (9.28)		
Week 24 Adjusted Mean Change (SE)	-31.96 (6.93)	-34.66 (9.14)		
Week 32 Adjusted Mean Change (SE)	-37.37 (6.54)	-35.72 (8.63)		
Week 40 Adjusted Mean Change (SE)	-39.36 (7.53)	-42.47 (9.93)		
Week 52 Adjusted Mean Change (SE)	-40.53 (8.40)	-30.22 (11.08)	-10.31 [-38.02; 17.39]	0.461

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

17.14 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.984				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	69.64 (19.67)	68.95 (21.04)		
Week 52 Mean (SD)	41.80 (29.02)	33.67 (28.22)		
Week 2 Adjusted Mean Change (SE)	-19.59 (5.47)	-14.90 (3.88)		
Week 4 Adjusted Mean Change (SE)	-31.41 (6.61)	-27.25 (4.75)		
Week 8 Adjusted Mean Change (SE)	-28.98 (6.36)	-30.01 (4.58)		
Week 12 Adjusted Mean Change (SE)	-34.04 (6.44)	-35.49 (4.64)		
Week 16 Adjusted Mean Change (SE)	-33.84 (6.38)	-31.06 (4.58)		
Week 24 Adjusted Mean Change (SE)	-36.88 (6.25)	-28.23 (4.67)		
Week 32 Adjusted Mean Change (SE)	-33.75 (5.80)	-33.84 (4.34)		
Week 40 Adjusted Mean Change (SE)	-34.79 (6.59)	-30.93 (5.04)		
Week 52 Adjusted Mean Change (SE)	-28.53 (7.46)	-33.74 (5.73)	5.21 [-13.48; 23.91]	0.581
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	71.38 (20.52)	70.59 (20.90)		
Week 52 Mean (SD)	29.03 (22.33)	31.23 (26.46)		
Week 2 Adjusted Mean Change (SE)	-19.60 (2.87)	-17.95 (3.88)		
Week 4 Adjusted Mean Change (SE)	-24.65 (3.47)	-20.65 (4.68)		
Week 8 Adjusted Mean Change (SE)	-31.35 (3.33)	-29.28 (4.51)		
Week 12 Adjusted Mean Change (SE)	-31.49 (3.39)	-28.80 (4.59)		
Week 16 Adjusted Mean Change (SE)	-34.50 (3.31)	-33.29 (4.50)		
Week 24 Adjusted Mean Change (SE)	-33.71 (3.29)	-37.21 (4.46)		
Week 32 Adjusted Mean Change (SE)	-40.63 (3.08)	-36.25 (4.11)		
Week 40 Adjusted Mean Change (SE)	-40.59 (3.47)	-41.63 (4.70)		
Week 52 Adjusted Mean Change (SE)	-42.18 (3.90)	-38.72 (5.21)	-3.46 [-16.38; 9.47]	0.596

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

17.15 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.125				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	72.58 (20.99)	70.00 (17.85)		
Week 52 Mean (SD)	32.50 (24.77)	32.41 (27.03)		
Week 2 Adjusted Mean Change (SE)	-24.01 (3.18)	-13.52 (3.68)		
Week 4 Adjusted Mean Change (SE)	-29.04 (3.94)	-19.63 (4.62)		
Week 8 Adjusted Mean Change (SE)	-31.56 (3.78)	-26.23 (4.43)		
Week 12 Adjusted Mean Change (SE)	-34.60 (3.83)	-30.16 (4.50)		
Week 16 Adjusted Mean Change (SE)	-35.72 (3.73)	-28.42 (4.42)		
Week 24 Adjusted Mean Change (SE)	-35.17 (3.74)	-29.57 (4.50)		
Week 32 Adjusted Mean Change (SE)	-40.58 (3.48)	-33.31 (4.17)		
Week 40 Adjusted Mean Change (SE)	-40.97 (3.89)	-29.95 (4.75)		
Week 52 Adjusted Mean Change (SE)	-38.64 (4.48)	-35.20 (5.53)	-3.44 [-17.58; 10.71]	0.630
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	68.55 (19.06)	69.52 (23.97)		
Week 52 Mean (SD)	30.33 (23.60)	32.05 (27.35)		
Week 2 Adjusted Mean Change (SE)	-12.79 (3.96)	-19.56 (3.85)		
Week 4 Adjusted Mean Change (SE)	-21.61 (4.90)	-28.34 (4.77)		
Week 8 Adjusted Mean Change (SE)	-29.74 (4.70)	-33.23 (4.57)		
Week 12 Adjusted Mean Change (SE)	-28.00 (4.80)	-34.09 (4.67)		
Week 16 Adjusted Mean Change (SE)	-32.29 (4.67)	-36.14 (4.54)		
Week 24 Adjusted Mean Change (SE)	-33.50 (4.68)	-36.79 (4.60)		
Week 32 Adjusted Mean Change (SE)	-36.56 (4.37)	-37.17 (4.24)		
Week 40 Adjusted Mean Change (SE)	-36.59 (4.81)	-43.96 (4.79)		
Week 52 Adjusted Mean Change (SE)	-40.59 (5.61)	-38.10 (5.46)	-2.49 [-18.06; 13.07]	0.751

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

17.16 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.082				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	62.11 (23.43)	71.20 (21.76)		
Week 52 Mean (SD)	35.11 (24.77)	30.29 (29.47)		
Week 2 Adjusted Mean Change (SE)	-17.70 (4.25)	-17.88 (4.06)		
Week 4 Adjusted Mean Change (SE)	-21.16 (5.12)	-26.81 (4.98)		
Week 8 Adjusted Mean Change (SE)	-24.05 (4.77)	-35.49 (4.64)		
Week 12 Adjusted Mean Change (SE)	-27.75 (4.91)	-37.33 (4.82)		
Week 16 Adjusted Mean Change (SE)	-27.93 (4.78)	-35.81 (4.70)		
Week 24 Adjusted Mean Change (SE)	-25.74 (4.74)	-36.85 (4.76)		
Week 32 Adjusted Mean Change (SE)	-33.94 (4.47)	-35.82 (4.48)		
Week 40 Adjusted Mean Change (SE)	-35.76 (5.17)	-36.46 (5.29)		
Week 52 Adjusted Mean Change (SE)	-34.00 (5.76)	-35.11 (6.02)	1.11 [-15.49; 17.71]	0.895
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	76.28 (16.11)	68.58 (20.25)		
Week 52 Mean (SD)	29.45 (23.84)	33.39 (25.70)		
Week 2 Adjusted Mean Change (SE)	-20.74 (3.26)	-15.18 (3.72)		
Week 4 Adjusted Mean Change (SE)	-29.10 (3.93)	-21.39 (4.48)		
Week 8 Adjusted Mean Change (SE)	-34.93 (3.66)	-24.84 (4.17)		
Week 12 Adjusted Mean Change (SE)	-34.62 (3.79)	-27.95 (4.30)		
Week 16 Adjusted Mean Change (SE)	-38.26 (3.68)	-29.13 (4.20)		
Week 24 Adjusted Mean Change (SE)	-39.57 (3.62)	-30.30 (4.16)		
Week 32 Adjusted Mean Change (SE)	-42.08 (3.48)	-34.44 (3.95)		
Week 40 Adjusted Mean Change (SE)	-41.21 (4.00)	-36.75 (4.60)		
Week 52 Adjusted Mean Change (SE)	-42.25 (4.50)	-36.79 (5.10)	-5.45 [-19.00; 8.09]	0.426

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

17.17 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.682				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	75.72 (19.88)	69.97 (21.98)		
Week 52 Mean (SD)	31.00 (27.26)	34.64 (27.43)		
Week 2 Adjusted Mean Change (SE)	-17.64 (3.67)	-16.84 (3.21)		
Week 4 Adjusted Mean Change (SE)	-27.38 (4.47)	-25.13 (3.91)		
Week 8 Adjusted Mean Change (SE)	-31.61 (4.26)	-29.49 (3.73)		
Week 12 Adjusted Mean Change (SE)	-31.85 (4.33)	-30.36 (3.79)		
Week 16 Adjusted Mean Change (SE)	-32.30 (4.21)	-30.58 (3.68)		
Week 24 Adjusted Mean Change (SE)	-36.94 (4.15)	-30.33 (3.72)		
Week 32 Adjusted Mean Change (SE)	-40.04 (3.93)	-33.71 (3.48)		
Week 40 Adjusted Mean Change (SE)	-39.79 (4.50)	-36.96 (4.07)		
Week 52 Adjusted Mean Change (SE)	-40.69 (5.06)	-36.15 (4.54)	-4.54 [-18.03; 8.95]	0.505
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	66.46 (19.74)	69.25 (17.88)		
Week 52 Mean (SD)	32.32 (21.36)	24.67 (24.76)		
Week 2 Adjusted Mean Change (SE)	-21.47 (3.59)	-15.32 (5.25)		
Week 4 Adjusted Mean Change (SE)	-24.92 (4.37)	-20.10 (6.56)		
Week 8 Adjusted Mean Change (SE)	-30.12 (4.17)	-29.99 (6.27)		
Week 12 Adjusted Mean Change (SE)	-32.29 (4.21)	-37.18 (6.35)		
Week 16 Adjusted Mean Change (SE)	-36.27 (4.10)	-36.92 (6.27)		
Week 24 Adjusted Mean Change (SE)	-31.97 (4.07)	-40.45 (6.14)		
Week 32 Adjusted Mean Change (SE)	-38.16 (3.82)	-39.23 (5.74)		
Week 40 Adjusted Mean Change (SE)	-38.79 (4.43)	-35.79 (6.77)		
Week 52 Adjusted Mean Change (SE)	-37.80 (4.94)	-36.80 (7.67)	-1.01 [-19.09; 17.07]	0.912

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

17.18 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.562				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	73.33 (17.54)	68.80 (20.78)		
Week 52 Mean (SD)	33.11 (23.04)	34.46 (26.39)		
Week 2 Adjusted Mean Change (SE)	-19.03 (2.95)	-15.25 (3.09)		
Week 4 Adjusted Mean Change (SE)	-27.83 (3.54)	-25.86 (3.74)		
Week 8 Adjusted Mean Change (SE)	-31.88 (3.37)	-28.88 (3.56)		
Week 12 Adjusted Mean Change (SE)	-31.27 (3.48)	-32.49 (3.69)		
Week 16 Adjusted Mean Change (SE)	-34.43 (3.38)	-30.38 (3.58)		
Week 24 Adjusted Mean Change (SE)	-36.69 (3.34)	-31.93 (3.61)		
Week 32 Adjusted Mean Change (SE)	-39.29 (3.18)	-35.87 (3.40)		
Week 40 Adjusted Mean Change (SE)	-39.03 (3.60)	-35.04 (3.92)		
Week 52 Adjusted Mean Change (SE)	-38.63 (4.04)	-33.54 (4.42)	-5.10 [-17.02; 6.83]	0.398
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	61.55 (26.94)	73.56 (21.38)		
Week 52 Mean (SD)	26.09 (28.67)	25.22 (28.54)		
Week 2 Adjusted Mean Change (SE)	-20.82 (5.63)	-20.36 (6.09)		
Week 4 Adjusted Mean Change (SE)	-19.95 (6.75)	-15.56 (7.32)		
Week 8 Adjusted Mean Change (SE)	-23.94 (6.41)	-31.64 (6.95)		
Week 12 Adjusted Mean Change (SE)	-32.63 (6.60)	-30.31 (7.17)		
Week 16 Adjusted Mean Change (SE)	-32.31 (6.43)	-38.87 (7.05)		
Week 24 Adjusted Mean Change (SE)	-27.12 (6.41)	-36.77 (6.89)		
Week 32 Adjusted Mean Change (SE)	-37.00 (6.00)	-32.20 (6.49)		
Week 40 Adjusted Mean Change (SE)	-40.02 (6.81)	-42.44 (7.49)		
Week 52 Adjusted Mean Change (SE)	-41.39 (7.59)	-45.34 (8.25)	3.95 [-18.40; 26.30]	0.726

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

18.0 Physician's Global Assessment of PsA Disease Activity (VAS) - Return Rates (FAS)

	Treatment Groups		
	SEC **(N=66)**	**ADA** **(N=62)**	**Total** **(N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 4 Returns	66 (100.0)	59 (95.2)	125 (97.7)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	58 (93.5)	122 (95.3)
Week 16 Returns	63 (95.5)	54 (87.1)	117 (91.4)
Week 20 Returns	63 (95.5)	54 (87.1)	117 (91.4)
Week 24 Returns	64 (97.0)	54 (87.1)	118 (92.2)
Week 28 Returns	61 (92.4)	46 (74.2)	107 (83.6)
Week 32 Returns	61 (92.4)	48 (77.4)	109 (85.2)
Week 36 Returns	61 (92.4)	49 (79.0)	110 (85.9)
Week 40 Returns	63 (95.5)	47 (75.8)	110 (85.9)
Week 44 Returns	62 (93.9)	47 (75.8)	109 (85.2)
Week 48 Returns	60 (90.9)	46 (74.2)	106 (82.8)
Week 52 Returns	62 (93.9)	47 (75.8)	109 (85.2)

18.1 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N'	66	61		
Baseline Mean (SD)	65.42 (14.82)	64.61 (13.46)		
Week 52 Mean (SD)	16.24 (15.49)	15.87 (14.04)		
Week 52 Adjusted Mean Change (SE)	-48.41 (1.91)	-48.46 (2.12)	0.04 [-5.61; 5.70]	0.988

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

18.2 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.571				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	60.93 (14.86)	63.00 (13.95)		
Week 52 Mean (SD)	12.92 (11.44)	12.00 (9.95)		
Week 52 Adjusted Mean Change (SE)	-51.92 (2.36)	-52.64 (2.83)	0.72 [-6.52; 7.96]	0.844
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	73.29 (11.18)	66.45 (12.87)		
Week 52 Mean (SD)	21.87 (19.67)	19.91 (16.58)		
Week 52 Adjusted Mean Change (SE)	-42.26 (3.16)	-43.86 (2.98)	1.60 [-6.91; 10.11]	0.710

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

18.3 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.670				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	56.00 (17.37)	52.92 (12.82)		
Week 52 Mean (SD)	11.63 (11.70)	18.13 (16.35)		
Week 52 Adjusted Mean Change (SE)	-53.59 (3.93)	-46.38 (5.03)	-7.21 [-19.54; 5.12]	0.249
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	68.44 (12.67)	67.71 (11.93)		
Week 52 Mean (SD)	17.85 (16.42)	15.41 (13.71)		
Week 52 Adjusted Mean Change (SE)	-46.64 (2.23)	-48.74 (2.36)	2.10 [-4.29; 8.48]	0.517

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

18.4 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.470				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	66.79 (15.37)	60.19 (12.24)		
Week 52 Mean (SD)	18.73 (14.05)	16.05 (16.04)		
Week 52 Adjusted Mean Change (SE)	-46.86 (2.96)	-47.74 (3.08)	0.88 [-7.62; 9.39]	0.838
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	64.42 (14.52)	69.33 (13.28)		
Week 52 Mean (SD)	14.44 (16.41)	15.72 (12.34)		
Week 52 Adjusted Mean Change (SE)	-49.56 (2.51)	-49.31 (3.01)	-0.25 [-8.02; 7.52]	0.950

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

18.5 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.259				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	66.43 (15.72)	64.45 (14.95)		
Week 52 Mean (SD)	14.34 (13.51)	13.05 (9.79)		
Week 52 Adjusted Mean Change (SE)	-51.05 (2.43)	-50.91 (3.19)	-0.14 [-8.07; 7.80]	0.973
> Median, N	**26**	**33**		
N'	26	32		
Baseline Mean (SD)	63.88 (13.47)	64.76 (12.24)		
Week 52 Mean (SD)	19.25 (18.10)	17.79 (16.19)		
Week 52 Adjusted Mean Change (SE)	-44.40 (3.01)	-46.63 (2.80)	2.23 [-5.92; 10.38]	0.589

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

18.6 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.893				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	63.74 (14.61)	64.32 (14.49)		
Week 52 Mean (SD)	15.42 (15.26)	16.58 (15.95)		
Week 52 Adjusted Mean Change (SE)	-48.70 (2.71)	-48.31 (3.48)	-0.39 [-9.11; 8.33]	0.929
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	67.22 (15.05)	64.78 (13.05)		
Week 52 Mean (SD)	17.06 (15.94)	15.39 (12.86)		
Week 52 Adjusted Mean Change (SE)	-48.07 (2.76)	-48.68 (2.73)	0.61 [-7.08; 8.30]	0.875

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

18.7 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.933				
Non-carrier, N	29	25		
N'	29	25		
Baseline Mean (SD)	64.97 (13.32)	64.44 (13.64)		
Week 52 Mean (SD)	17.48 (18.62)	14.40 (12.64)		
Week 52 Adjusted Mean Change (SE)	-46.61 (3.09)	-52.16 (3.45)	5.55 [-3.65; 14.75]	0.233
Carrier, N	22	19		
N'	22	19		
Baseline Mean (SD)	69.55 (14.40)	63.95 (13.36)		
Week 52 Mean (SD)	15.75 (13.58)	17.50 (18.15)		
Week 52 Adjusted Mean Change (SE)	-51.27 (3.63)	-47.14 (4.02)	-4.13 [-14.95; 6.69]	0.450

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

18.8 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.216				
Non-carrier, N	**28**	**19**		
N'	28	19		
Baseline Mean (SD)	64.46 (15.06)	60.95 (12.19)		
Week 52 Mean (SD)	12.15 (11.65)	12.50 (11.06)		
Week 52 Adjusted Mean Change (SE)	-52.94 (3.13)	-51.10 (4.17)	-1.84 [-12.19; 8.52]	0.725
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	69.73 (12.06)	64.53 (12.96)		
Week 52 Mean (SD)	23.58 (20.46)	19.06 (19.09)		
Week 52 Adjusted Mean Change (SE)	-40.56 (3.66)	-47.77 (3.85)	7.21 [-3.38; 17.80]	0.180

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

18.9 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.432				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	69.68 (14.58)	67.05 (12.71)		
Week 52 Mean (SD)	17.58 (13.28)	15.13 (14.23)		
Week 52 Adjusted Mean Change (SE)	-48.71 (3.85)	-49.14 (3.95)	0.44 [-10.47; 11.34]	0.937
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	65.00 (13.75)	61.65 (13.70)		
Week 52 Mean (SD)	16.78 (18.69)	16.30 (16.25)		
Week 52 Adjusted Mean Change (SE)	-47.37 (3.10)	-50.37 (3.60)	3.00 [-6.42; 12.42]	0.528

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

18.10 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.609				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	64.76 (15.32)	65.00 (14.29)		
Week 52 Mean (SD)	12.65 (12.73)	17.88 (16.44)		
Week 52 Adjusted Mean Change (SE)	-53.22 (3.27)	-48.36 (2.98)	-4.86 [-13.65; 3.93]	0.275
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	69.04 (12.20)	62.17 (10.79)		
Week 52 Mean (SD)	20.67 (18.92)	10.30 (9.96)		
Week 52 Adjusted Mean Change (SE)	-43.99 (3.24)	-54.10 (4.98)	10.11 [-1.79; 22.01]	0.095

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

18.11 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.986				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	67.34 (12.59)	65.21 (13.75)		
Week 52 Mean (SD)	17.47 (17.34)	15.00 (13.16)		
Week 52 Adjusted Mean Change (SE)	-48.21 (2.66)	-50.89 (2.98)	2.68 [-5.27; 10.63]	0.504
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	67.17 (17.56)	60.67 (13.60)		
Week 52 Mean (SD)	15.25 (15.20)	14.56 (13.67)		
Week 52 Adjusted Mean Change (SE)	-49.58 (4.61)	-50.65 (5.32)	1.07 [-12.93; 15.06]	0.880

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

18.12 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.623				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	68.06 (12.26)	65.06 (13.37)		
Week 52 Mean (SD)	17.09 (17.20)	14.04 (13.80)		
Week 52 Adjusted Mean Change (SE)	-49.09 (2.79)	-51.79 (3.00)	2.71 [-5.44; 10.85]	0.511
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	61.69 (17.15)	61.40 (13.64)		
Week 52 Mean (SD)	17.83 (15.76)	20.30 (18.31)		
Week 52 Adjusted Mean Change (SE)	-43.73 (4.57)	-43.39 (5.19)	-0.35 [-14.05; 13.36]	0.960

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

18.13 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.904				
Non-carrier, N	**42**	**36**		
N'	42	36		
Baseline Mean (SD)	67.10 (14.31)	64.78 (12.88)		
Week 52 Mean (SD)	17.66 (16.62)	16.87 (16.25)		
Week 52 Adjusted Mean Change (SE)	-47.53 (2.62)	-48.34 (2.92)	0.81 [-7.00; 8.63]	0.836
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	66.22 (12.14)	57.80 (14.01)		
Week 52 Mean (SD)	12.89 (16.48)	13.00 (7.00)		
Week 52 Adjusted Mean Change (SE)	-52.18 (5.52)	-56.80 (8.17)	4.61 [-15.01; 24.23]	0.642
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

18.14 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.766				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	66.73 (10.85)	65.77 (14.41)		
Week 52 Mean (SD)	10.60 (11.41)	14.31 (10.67)		
Week 52 Adjusted Mean Change (SE)	-55.81 (5.02)	-50.48 (3.85)	-5.33 [-17.89; 7.23]	0.402
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	67.00 (14.68)	62.68 (12.38)		
Week 52 Mean (SD)	18.41 (17.40)	16.95 (18.20)		
Week 52 Adjusted Mean Change (SE)	-46.47 (2.62)	-49.24 (3.54)	2.78 [-6.01; 11.57]	0.532

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

18.15 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.202				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	64.00 (15.20)	61.83 (12.22)		
Week 52 Mean (SD)	12.97 (11.52)	12.53 (10.78)		
Week 52 Adjusted Mean Change (SE)	-53.15 (2.87)	-52.28 (3.63)	-0.87 [-10.01; 8.28]	0.851
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	71.50 (10.19)	66.86 (14.34)		
Week 52 Mean (SD)	23.41 (21.68)	18.68 (18.05)		
Week 52 Adjusted Mean Change (SE)	-40.71 (3.73)	-48.39 (3.52)	7.68 [-2.47; 17.83]	0.136

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

18.16 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.498				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	69.68 (14.58)	67.20 (13.02)		
Week 52 Mean (SD)	17.58 (13.28)	15.80 (14.46)		
Week 52 Adjusted Mean Change (SE)	-48.77 (3.83)	-48.52 (4.04)	-0.24 [-11.26; 10.77]	0.965
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	65.31 (13.36)	61.75 (13.40)		
Week 52 Mean (SD)	16.18 (18.62)	15.76 (16.02)		
Week 52 Adjusted Mean Change (SE)	-48.34 (3.01)	-50.97 (3.50)	2.63 [-6.53; 11.78]	0.570

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

18.17 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.609				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	64.76 (15.32)	65.00 (14.29)		
Week 52 Mean (SD)	12.65 (12.73)	17.88 (16.44)		
Week 52 Adjusted Mean Change (SE)	-53.22 (3.27)	-48.36 (2.98)	-4.86 [-13.65; 3.93]	0.275
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	69.04 (12.20)	62.17 (10.79)		
Week 52 Mean (SD)	20.67 (18.92)	10.30 (9.96)		
Week 52 Adjusted Mean Change (SE)	-43.99 (3.24)	-54.10 (4.98)	10.11 [-1.79; 22.01]	0.095

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

18.18 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.856				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	66.87 (12.77)	65.34 (13.40)		
Week 52 Mean (SD)	17.26 (17.13)	15.63 (14.40)		
Week 52 Adjusted Mean Change (SE)	-47.99 (2.72)	-50.13 (2.99)	2.14 [-5.90; 10.18]	0.598
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	66.00 (17.92)	59.89 (13.06)		
Week 52 Mean (SD)	14.45 (15.68)	16.22 (18.26)		
Week 52 Adjusted Mean Change (SE)	-49.96 (5.00)	-48.51 (5.54)	-1.45 [-16.28; 13.38]	0.846

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

19.0 SJC28 - Return Rates (FAS)

	Treatment Groups		
	SEC **(N=66)**	**ADA** **(N=62)**	**Total** **(N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	65 (98.5)	61 (98.4)	126 (98.4)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 20 Returns	64 (97.0)	54 (87.1)	118 (92.2)
Week 24 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 28 Returns	60 (90.9)	47 (75.8)	107 (83.6)
Week 32 Returns	62 (93.9)	49 (79.0)	111 (86.7)
Week 36 Returns	60 (90.9)	50 (80.6)	110 (85.9)
Week 40 Returns	63 (95.5)	48 (77.4)	111 (86.7)
Week 44 Returns	62 (93.9)	47 (75.8)	109 (85.2)
Week 48 Returns	60 (90.9)	46 (74.2)	106 (82.8)
Week 52 Returns	62 (93.9)	47 (75.8)	109 (85.2)

19.1 SJC28 - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N'	66	61		
Baseline Mean (SD)	5.59 (3.64)	5.31 (4.20)		
Week 52 Mean (SD)	0.45 (1.07)	0.94 (1.80)		
Week 52 Adjusted Mean Change (SE)	-4.98 (0.16)	-4.53 (0.19)	-0.45 [-0.94; 0.04]	0.073

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

19.2 SJC28 - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.945				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	5.69 (3.87)	4.21 (3.19)		
Week 52 Mean (SD)	0.36 (0.84)	0.50 (1.10)		
Week 52 Adjusted Mean Change (SE)	-5.11 (0.21)	-4.82 (0.26)	-0.29 [-0.94; 0.36]	0.372
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	5.42 (3.26)	6.55 (4.88)		
Week 52 Mean (SD)	0.61 (1.37)	1.39 (2.25)		
Week 52 Adjusted Mean Change (SE)	-4.75 (0.27)	-4.21 (0.27)	-0.54 [-1.29; 0.21]	0.156

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

19.3 SJC28 - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.452				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	4.38 (2.90)	4.31 (3.97)		
Week 52 Mean (SD)	0.13 (0.34)	0.38 (0.74)		
Week 52 Adjusted Mean Change (SE)	-5.20 (0.33)	-4.84 (0.44)	-0.36 [-1.44; 0.73]	0.514
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	5.98 (3.79)	5.57 (4.26)		
Week 52 Mean (SD)	0.57 (1.20)	1.05 (1.93)		
Week 52 Adjusted Mean Change (SE)	-4.91 (0.19)	-4.47 (0.21)	-0.44 [-0.99; 0.11]	0.118

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

19.4 SJC28 - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.772				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	5.43 (3.75)	6.22 (4.74)		
Week 52 Mean (SD)	0.38 (0.85)	1.23 (2.31)		
Week 52 Adjusted Mean Change (SE)	-5.00 (0.26)	-4.53 (0.28)	-0.48 [-1.22; 0.27]	0.210
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	5.71 (3.60)	4.33 (3.35)		
Week 52 Mean (SD)	0.50 (1.21)	0.68 (1.18)		
Week 52 Adjusted Mean Change (SE)	-4.96 (0.22)	-4.56 (0.26)	-0.40 [-1.08; 0.27]	0.242

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

19.5 SJC28 - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.144				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	5.80 (3.84)	3.86 (3.63)		
Week 52 Mean (SD)	0.47 (0.86)	0.79 (1.81)		
Week 52 Adjusted Mean Change (SE)	-5.14 (0.36)	-4.30 (0.49)	-0.83 [-2.02; 0.36]	0.170
> Median, N	**26**	**33**		
N'	26	32		
Baseline Mean (SD)	5.27 (3.35)	6.58 (4.31)		
Week 52 Mean (SD)	0.42 (1.35)	1.04 (1.82)		
Week 52 Adjusted Mean Change (SE)	-4.98 (0.45)	-4.46 (0.42)	-0.52 [-1.73; 0.69]	0.401

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

19.6 SJC28 - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.789				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	4.65 (3.50)	3.09 (2.72)		
Week 52 Mean (SD)	0.29 (0.64)	0.47 (1.02)		
Week 52 Adjusted Mean Change (SE)	-4.96 (0.23)	-4.74 (0.31)	-0.22 [-0.97; 0.53]	0.560
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	6.59 (3.56)	6.53 (4.40)		
Week 52 Mean (SD)	0.61 (1.36)	1.25 (2.14)		
Week 52 Adjusted Mean Change (SE)	-5.00 (0.24)	-4.40 (0.25)	-0.60 [-1.26; 0.06]	0.075

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

19.7 SJC28 - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.966				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	5.38 (2.94)	5.52 (4.57)		
Week 52 Mean (SD)	0.63 (1.45)	0.75 (1.48)		
Week 52 Adjusted Mean Change (SE)	-4.64 (0.26)	-4.64 (0.30)	-0.01 [-0.79; 0.78]	0.989
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	5.73 (4.18)	5.00 (4.24)		
Week 52 Mean (SD)	0.45 (0.76)	1.13 (2.00)		
Week 52 Adjusted Mean Change (SE)	-5.00 (0.30)	-4.27 (0.34)	-0.73 [-1.63; 0.17]	0.109

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

19.8 SJC28 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.350				
Non-carrier, N	**28**	**19**		
N'	28	19		
Baseline Mean (SD)	6.39 (4.03)	5.74 (4.33)		
Week 52 Mean (SD)	0.48 (0.85)	0.50 (0.85)		
Week 52 Adjusted Mean Change (SE)	-5.25 (0.27)	-4.98 (0.36)	-0.27 [-1.17; 0.62]	0.545
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	4.55 (2.42)	5.68 (4.84)		
Week 52 Mean (SD)	0.68 (1.60)	1.47 (2.27)		
Week 52 Adjusted Mean Change (SE)	-4.62 (0.31)	-4.27 (0.33)	-0.35 [-1.27; 0.56]	0.447

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

19.9 SJC28 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.811				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	5.89 (3.40)	4.57 (4.04)		
Week 52 Mean (SD)	0.68 (1.25)	1.25 (1.84)		
Week 52 Adjusted Mean Change (SE)	-4.81 (0.31)	-4.01 (0.33)	-0.79 [-1.70; 0.12]	0.086
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	5.37 (3.70)	5.96 (4.68)		
Week 52 Mean (SD)	0.48 (1.19)	0.65 (1.60)		
Week 52 Adjusted Mean Change (SE)	-4.79 (0.26)	-4.88 (0.30)	0.09 [-0.70; 0.87]	0.830

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

19.10 SJC28 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.086				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	4.72 (3.21)	5.00 (4.21)		
Week 52 Mean (SD)	0.30 (0.70)	1.15 (1.95)		
Week 52 Adjusted Mean Change (SE)	-4.96 (0.27)	-4.21 (0.25)	-0.75 [-1.49; -0.01]	0.046
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	6.31 (3.64)	6.08 (4.94)		
Week 52 Mean (SD)	0.79 (1.50)	0.30 (0.48)		
Week 52 Adjusted Mean Change (SE)	-4.65 (0.27)	-5.25 (0.41)	0.60 [-0.38; 1.57]	0.227

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

19.11 SJC28 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.414				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	5.05 (3.53)	5.67 (4.47)		
Week 52 Mean (SD)	0.50 (1.16)	0.92 (1.55)		
Week 52 Adjusted Mean Change (SE)	-4.77 (0.21)	-4.46 (0.23)	-0.31 [-0.94; 0.31]	0.318
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	6.75 (3.19)	3.22 (2.28)		
Week 52 Mean (SD)	0.50 (1.17)	0.33 (0.71)		
Week 52 Adjusted Mean Change (SE)	-4.87 (0.36)	-4.75 (0.41)	-0.11 [-1.22; 0.99]	0.837

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

19.12 SJC28 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.834				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	5.86 (3.60)	4.18 (3.25)		
Week 52 Mean (SD)	0.64 (1.39)	0.46 (1.03)		
Week 52 Adjusted Mean Change (SE)	-4.85 (0.24)	-4.81 (0.27)	-0.04 [-0.75; 0.67]	0.910
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	5.00 (3.14)	9.10 (5.70)		
Week 52 Mean (SD)	0.42 (0.51)	2.10 (2.51)		
Week 52 Adjusted Mean Change (SE)	-4.72 (0.39)	-3.67 (0.47)	-1.05 [-2.28; 0.18]	0.092

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

19.13 SJC28 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.829				
Non-carrier, N	**42**	**36**		
N'	42	36		
Baseline Mean (SD)	5.81 (3.49)	5.00 (4.45)		
Week 52 Mean (SD)	0.61 (1.31)	0.87 (1.76)		
Week 52 Adjusted Mean Change (SE)	-4.77 (0.21)	-4.43 (0.24)	-0.34 [-0.98; 0.30]	0.292
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	4.22 (3.38)	6.80 (3.77)		
Week 52 Mean (SD)	0.33 (0.50)	0.67 (1.15)		
Week 52 Adjusted Mean Change (SE)	-4.83 (0.45)	-5.20 (0.70)	0.37 [-1.30; 2.04]	0.664

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

19.14 SJC28 - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.950				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	6.18 (3.22)	4.32 (3.36)		
Week 52 Mean (SD)	0.70 (1.25)	0.81 (1.33)		
Week 52 Adjusted Mean Change (SE)	-4.86 (0.43)	-4.35 (0.33)	-0.51 [-1.60; 0.57]	0.347
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	5.35 (3.58)	6.27 (5.12)		
Week 52 Mean (SD)	0.51 (1.19)	1.00 (2.00)		
Week 52 Adjusted Mean Change (SE)	-4.78 (0.22)	-4.59 (0.30)	-0.20 [-0.95; 0.55]	0.602

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

19.15 SJC28 - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.227				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	6.26 (3.88)	5.17 (4.13)		
Week 52 Mean (SD)	0.47 (0.82)	0.41 (0.80)		
Week 52 Adjusted Mean Change (SE)	-5.07 (0.24)	-4.84 (0.31)	-0.23 [-1.01; 0.56]	0.570
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	4.40 (2.48)	5.43 (4.76)		
Week 52 Mean (SD)	0.71 (1.69)	1.37 (2.17)		
Week 52 Adjusted Mean Change (SE)	-4.36 (0.31)	-4.13 (0.30)	-0.24 [-1.10; 0.63]	0.587

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

19.16 SJC28 - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.967				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	5.89 (3.40)	4.45 (4.11)		
Week 52 Mean (SD)	0.68 (1.25)	1.33 (1.88)		
Week 52 Adjusted Mean Change (SE)	-4.79 (0.31)	-3.90 (0.34)	-0.89 [-1.80; 0.02]	0.054
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	5.31 (3.59)	6.00 (4.58)		
Week 52 Mean (SD)	0.46 (1.17)	0.62 (1.56)		
Week 52 Adjusted Mean Change (SE)	-4.80 (0.25)	-4.90 (0.29)	0.10 [-0.65; 0.85]	0.794

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

19.17 SJC28 - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.086				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	4.72 (3.21)	5.00 (4.21)		
Week 52 Mean (SD)	0.30 (0.70)	1.15 (1.95)		
Week 52 Adjusted Mean Change (SE)	-4.96 (0.27)	-4.21 (0.25)	-0.75 [-1.49; -0.01]	0.046
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	6.31 (3.64)	6.08 (4.94)		
Week 52 Mean (SD)	0.79 (1.50)	0.30 (0.48)		
Week 52 Adjusted Mean Change (SE)	-4.65 (0.27)	-5.25 (0.41)	0.60 [-0.38; 1.57]	0.227

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

19.18 SJC28 - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.279				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	5.15 (3.54)	5.49 (4.40)		
Week 52 Mean (SD)	0.57 (1.22)	0.93 (1.52)		
Week 52 Adjusted Mean Change (SE)	-4.72 (0.23)	-4.53 (0.25)	-0.19 [-0.86; 0.48]	0.576
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	6.82 (3.34)	4.56 (4.53)		
Week 52 Mean (SD)	0.55 (1.21)	0.89 (2.32)		
Week 52 Adjusted Mean Change (SE)	-4.98 (0.42)	-4.36 (0.45)	-0.62 [-1.85; 0.61]	0.318

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

20.0 SJC66 - Return Rates (FAS)

	Treatment Groups		
	SEC **(N=66)**	**ADA** **(N=62)**	**Total** **(N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	65 (98.5)	61 (98.4)	126 (98.4)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 20 Returns	64 (97.0)	54 (87.1)	118 (92.2)
Week 24 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 28 Returns	60 (90.9)	47 (75.8)	107 (83.6)
Week 32 Returns	62 (93.9)	49 (79.0)	111 (86.7)
Week 36 Returns	60 (90.9)	50 (80.6)	110 (85.9)
Week 40 Returns	63 (95.5)	48 (77.4)	111 (86.7)
Week 44 Returns	62 (93.9)	47 (75.8)	109 (85.2)
Week 48 Returns	60 (90.9)	46 (74.2)	106 (82.8)
Week 52 Returns	62 (93.9)	47 (75.8)	109 (85.2)

20.1 SJC66 - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N'	66	61		
Baseline Mean (SD)	8.67 (5.19)	9.32 (6.00)		
Week 52 Mean (SD)	0.69 (1.61)	1.43 (2.93)		
Week 52 Adjusted Mean Change (SE)	-8.02 (0.28)	-7.58 (0.31)	-0.44 [-1.28; 0.39]	0.297

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

20.2 SJC66 - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.925				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	8.81 (5.80)	8.36 (5.50)		
Week 52 Mean (SD)	0.44 (0.97)	1.13 (2.36)		
Week 52 Adjusted Mean Change (SE)	-8.28 (0.36)	-7.68 (0.43)	-0.60 [-1.71; 0.51]	0.290
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	8.42 (4.02)	10.41 (6.44)		
Week 52 Mean (SD)	1.13 (2.28)	1.74 (3.45)		
Week 52 Adjusted Mean Change (SE)	-7.58 (0.47)	-7.45 (0.46)	-0.13 [-1.43; 1.17]	0.843

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

20.3 SJC66 - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.162				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	6.25 (3.82)	7.62 (5.17)		
Week 52 Mean (SD)	0.19 (0.54)	0.63 (0.92)		
Week 52 Adjusted Mean Change (SE)	-8.36 (0.58)	-7.90 (0.74)	-0.46 [-2.30; 1.38]	0.623
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	9.44 (5.36)	9.78 (6.17)		
Week 52 Mean (SD)	0.87 (1.81)	1.59 (3.18)		
Week 52 Adjusted Mean Change (SE)	-7.90 (0.33)	-7.50 (0.35)	-0.40 [-1.35; 0.55]	0.408

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

20.4 SJC66 - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.778				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	8.79 (5.34)	10.44 (6.62)		
Week 52 Mean (SD)	0.69 (1.26)	1.82 (3.74)		
Week 52 Adjusted Mean Change (SE)	-8.14 (0.44)	-7.51 (0.46)	-0.63 [-1.89; 0.64]	0.331
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	8.58 (5.16)	8.13 (5.10)		
Week 52 Mean (SD)	0.69 (1.83)	1.08 (2.00)		
Week 52 Adjusted Mean Change (SE)	-7.94 (0.38)	-7.66 (0.45)	-0.28 [-1.44; 0.87]	0.630

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

20.5 SJC66 - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.342				
≤ Median, N	40	29		
N'	40	29		
Baseline Mean (SD)	8.83 (5.90)	8.17 (5.46)		
Week 52 Mean (SD)	0.63 (1.13)	1.16 (2.34)		
Week 52 Adjusted Mean Change (SE)	-8.23 (0.36)	-7.78 (0.48)	-0.46 [-1.64; 0.73]	0.447
> Median, N	26	33		
N'	26	32		
Baseline Mean (SD)	8.42 (3.95)	10.33 (6.34)		
Week 52 Mean (SD)	0.79 (2.19)	1.61 (3.30)		
Week 52 Adjusted Mean Change (SE)	-7.71 (0.45)	-7.36 (0.42)	-0.34 [-1.57; 0.88]	0.582

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

20.6 SJC66 - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.403				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	7.76 (5.24)	7.27 (5.20)		
Week 52 Mean (SD)	0.42 (0.85)	0.79 (1.87)		
Week 52 Adjusted Mean Change (SE)	-8.05 (0.40)	-8.00 (0.52)	-0.05 [-1.32; 1.23]	0.942
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	9.63 (5.05)	10.45 (6.17)		
Week 52 Mean (SD)	0.97 (2.09)	1.86 (3.44)		
Week 52 Adjusted Mean Change (SE)	-8.00 (0.40)	-7.32 (0.41)	-0.68 [-1.81; 0.44]	0.232

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

20.7 SJC66 - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.671				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	8.03 (3.73)	9.60 (7.01)		
Week 52 Mean (SD)	1.04 (2.21)	0.90 (1.83)		
Week 52 Adjusted Mean Change (SE)	-7.42 (0.47)	-7.98 (0.53)	0.56 [-0.86; 1.97]	0.437
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	9.18 (6.67)	9.68 (6.21)		
Week 52 Mean (SD)	0.55 (0.89)	2.38 (4.19)		
Week 52 Adjusted Mean Change (SE)	-8.43 (0.55)	-6.82 (0.61)	-1.61 [-3.25; 0.03]	0.054

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

20.8 SJC66 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.459				
Non-carrier, N	**28**	**19**		
N'	28	19		
Baseline Mean (SD)	9.61 (6.38)	9.89 (6.85)		
Week 52 Mean (SD)	0.74 (1.23)	0.50 (0.85)		
Week 52 Adjusted Mean Change (SE)	-8.56 (0.50)	-8.62 (0.66)	0.06 [-1.60; 1.72]	0.940
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	7.27 (2.81)	10.74 (6.85)		
Week 52 Mean (SD)	1.00 (2.40)	2.71 (4.27)		
Week 52 Adjusted Mean Change (SE)	-7.50 (0.59)	-6.89 (0.63)	-0.61 [-2.34; 1.12]	0.485

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

20.9 SJC66 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC **(N=66)**	**ADA** **(N=62)**	**Mean Difference** **[95% CI]**	**p-value**
Interaction test: p=0.900				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	9.26 (4.43)	8.81 (6.05)		
Week 52 Mean (SD)	1.00 (1.56)	1.81 (2.61)		
Week 52 Adjusted Mean Change (SE)	-8.03 (0.59)	-7.00 (0.61)	-1.03 [-2.72; 0.67]	0.231
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	8.33 (5.70)	10.39 (7.11)		
Week 52 Mean (SD)	0.74 (1.95)	1.35 (3.57)		
Week 52 Adjusted Mean Change (SE)	-7.85 (0.48)	-8.00 (0.56)	0.16 [-1.32; 1.64]	0.834

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

20.10 SJC66 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.024				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	7.44 (3.74)	8.59 (6.05)		
Week 52 Mean (SD)	0.39 (0.89)	2.00 (3.61)		
Week 52 Adjusted Mean Change (SE)	-8.23 (0.51)	-6.86 (0.46)	-1.38 [-2.73; -0.02]	0.046
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	9.58 (6.15)	12.42 (7.45)		
Week 52 Mean (SD)	1.25 (2.27)	0.40 (0.52)		
Week 52 Adjusted Mean Change (SE)	-7.47 (0.49)	-9.27 (0.78)	1.80 [-0.03; 3.63]	0.054

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

20.11 SJC66 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.184				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	8.24 (5.47)	10.45 (6.87)		
Week 52 Mean (SD)	0.82 (1.93)	1.48 (2.49)		
Week 52 Adjusted Mean Change (SE)	-7.79 (0.33)	-7.39 (0.38)	-0.40 [-1.41; 0.61]	0.432
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	8.75 (3.79)	6.11 (3.89)		
Week 52 Mean (SD)	0.67 (1.23)	0.44 (0.73)		
Week 52 Adjusted Mean Change (SE)	-8.10 (0.57)	-8.07 (0.66)	-0.03 [-1.76; 1.71]	0.975

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

20.12 SJC66 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.999				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	9.42 (5.57)	8.44 (5.33)		
Week 52 Mean (SD)	1.00 (2.06)	0.85 (1.93)		
Week 52 Adjusted Mean Change (SE)	-8.02 (0.44)	-8.00 (0.47)	-0.02 [-1.30; 1.26]	0.973
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	6.38 (3.62)	13.70 (8.97)		
Week 52 Mean (SD)	0.50 (0.67)	3.40 (4.79)		
Week 52 Adjusted Mean Change (SE)	-7.51 (0.73)	-6.06 (0.85)	-1.45 [-3.74; 0.84]	0.212

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

20.13 SJC66 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.580				
Non-carrier, N	**42**	**36**		
N'	42	36		
Baseline Mean (SD)	8.55 (5.40)	9.22 (6.65)		
Week 52 Mean (SD)	0.95 (1.94)	1.30 (3.04)		
Week 52 Adjusted Mean Change (SE)	-7.66 (0.40)	-7.57 (0.45)	-0.09 [-1.29; 1.11]	0.880
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	8.44 (4.25)	11.40 (5.03)		
Week 52 Mean (SD)	0.33 (0.50)	2.33 (4.04)		
Week 52 Adjusted Mean Change (SE)	-8.45 (0.85)	-6.96 (1.25)	-1.50 [-4.50; 1.51]	0.325

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

20.14 SJC66 - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.648				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	9.45 (4.93)	8.14 (5.32)		
Week 52 Mean (SD)	1.10 (1.79)	1.38 (2.39)		
Week 52 Adjusted Mean Change (SE)	-7.96 (0.80)	-7.22 (0.61)	-0.74 [-2.73; 1.26]	0.464
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	8.28 (5.28)	11.14 (7.50)		
Week 52 Mean (SD)	0.76 (1.79)	1.70 (3.70)		
Week 52 Adjusted Mean Change (SE)	-7.83 (0.42)	-7.68 (0.57)	-0.15 [-1.56; 1.27]	0.839

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

20.15 SJC66 - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.240				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	9.32 (6.14)	9.17 (6.55)		
Week 52 Mean (SD)	0.70 (1.18)	0.41 (0.80)		
Week 52 Adjusted Mean Change (SE)	-8.28 (0.46)	-8.30 (0.57)	0.01 [-1.43; 1.46]	0.985
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	7.30 (2.89)	10.14 (6.78)		
Week 52 Mean (SD)	1.06 (2.54)	2.58 (4.05)		
Week 52 Adjusted Mean Change (SE)	-7.15 (0.58)	-6.65 (0.56)	-0.51 [-2.13; 1.12]	0.536

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

20.16 SJC66 - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.752				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	9.26 (4.43)	8.75 (6.21)		
Week 52 Mean (SD)	1.00 (1.56)	1.93 (2.66)		
Week 52 Adjusted Mean Change (SE)	-7.95 (0.58)	-6.82 (0.62)	-1.14 [-2.83; 0.56]	0.186
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	8.09 (5.60)	10.38 (6.96)		
Week 52 Mean (SD)	0.71 (1.92)	1.29 (3.49)		
Week 52 Adjusted Mean Change (SE)	-7.79 (0.47)	-7.97 (0.54)	0.18 [-1.25; 1.61]	0.802

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

20.17 SJC66 - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.024				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	7.44 (3.74)	8.59 (6.05)		
Week 52 Mean (SD)	0.39 (0.89)	2.00 (3.61)		
Week 52 Adjusted Mean Change (SE)	-8.23 (0.51)	-6.86 (0.46)	-1.38 [-2.73; -0.02]	0.046
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	9.58 (6.15)	12.42 (7.45)		
Week 52 Mean (SD)	1.25 (2.27)	0.40 (0.52)		
Week 52 Adjusted Mean Change (SE)	-7.47 (0.49)	-9.27 (0.78)	1.80 [-0.03; 3.63]	0.054

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

20.18 SJC66 - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.230				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	8.46 (5.58)	10.11 (6.81)		
Week 52 Mean (SD)	0.89 (1.94)	1.44 (2.41)		
Week 52 Adjusted Mean Change (SE)	-7.76 (0.42)	-7.66 (0.46)	-0.10 [-1.35; 1.15]	0.873
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	9.00 (3.87)	7.78 (5.67)		
Week 52 Mean (SD)	0.64 (1.29)	1.89 (4.94)		
Week 52 Adjusted Mean Change (SE)	-8.32 (0.77)	-6.89 (0.85)	-1.43 [-3.72; 0.85]	0.217

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

21.0 SJC76 - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	65 (98.5)	61 (98.4)	126 (98.4)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 20 Returns	64 (97.0)	54 (87.1)	118 (92.2)
Week 24 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 28 Returns	60 (90.9)	47 (75.8)	107 (83.6)
Week 32 Returns	62 (93.9)	49 (79.0)	111 (86.7)
Week 36 Returns	60 (90.9)	50 (80.6)	110 (85.9)
Week 40 Returns	63 (95.5)	48 (77.4)	111 (86.7)
Week 44 Returns	62 (93.9)	47 (75.8)	109 (85.2)
Week 48 Returns	60 (90.9)	46 (74.2)	106 (82.8)
Week 52 Returns	62 (93.9)	47 (75.8)	109 (85.2)

21.1 SJC76 - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N'	66	61		
Baseline Mean (SD)	9.05 (5.60)	10.26 (6.75)		
Week 52 Mean (SD)	0.71 (1.64)	1.51 (3.08)		
Week 52 Adjusted Mean Change (SE)	-8.57 (0.30)	-8.16 (0.33)	-0.41 [-1.28; 0.47]	0.357

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

21.2 SJC76 - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.952				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	9.14 (6.29)	9.52 (6.59)		
Week 52 Mean (SD)	0.44 (0.97)	1.13 (2.36)		
Week 52 Adjusted Mean Change (SE)	-8.83 (0.37)	-8.39 (0.45)	-0.44 [-1.59; 0.72]	0.455
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	8.88 (4.27)	11.10 (6.95)		
Week 52 Mean (SD)	1.17 (2.35)	1.91 (3.69)		
Week 52 Adjusted Mean Change (SE)	-8.13 (0.49)	-7.88 (0.48)	-0.25 [-1.60; 1.10]	0.713

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

21.3 SJC76 - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.205				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	6.50 (4.12)	8.15 (5.11)		
Week 52 Mean (SD)	0.19 (0.54)	0.63 (0.92)		
Week 52 Adjusted Mean Change (SE)	-8.95 (0.61)	-8.47 (0.76)	-0.48 [-2.40; 1.44]	0.622
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	9.86 (5.80)	10.82 (7.06)		
Week 52 Mean (SD)	0.89 (1.85)	1.69 (3.33)		
Week 52 Adjusted Mean Change (SE)	-8.44 (0.34)	-8.08 (0.37)	-0.36 [-1.36; 0.64]	0.475

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

21.4 SJC76 - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.641				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	9.43 (6.06)	11.19 (7.15)		
Week 52 Mean (SD)	0.73 (1.37)	1.91 (3.96)		
Week 52 Adjusted Mean Change (SE)	-8.71 (0.46)	-8.01 (0.48)	-0.69 [-2.02; 0.63]	0.301
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	8.76 (5.30)	9.27 (6.26)		
Week 52 Mean (SD)	0.69 (1.83)	1.16 (2.03)		
Week 52 Adjusted Mean Change (SE)	-8.48 (0.39)	-8.32 (0.47)	-0.16 [-1.37; 1.04]	0.789

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

21.5 SJC76 - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.506				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	9.25 (6.41)	9.14 (5.95)		
Week 52 Mean (SD)	0.66 (1.21)	1.16 (2.34)		
Week 52 Adjusted Mean Change (SE)	-8.78 (0.38)	-8.52 (0.49)	-0.26 [-1.49; 0.97]	0.674
> Median, N	**26**	**33**		
N'	26	32		
Baseline Mean (SD)	8.73 (4.17)	11.24 (7.33)		
Week 52 Mean (SD)	0.79 (2.19)	1.75 (3.51)		
Week 52 Adjusted Mean Change (SE)	-8.27 (0.47)	-7.82 (0.44)	-0.44 [-1.72; 0.84]	0.495

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

21.6 SJC76 - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.453				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	8.15 (5.94)	8.41 (6.34)		
Week 52 Mean (SD)	0.42 (0.85)	0.89 (1.94)		
Week 52 Adjusted Mean Change (SE)	-8.62 (0.42)	-8.57 (0.54)	-0.05 [-1.38; 1.28]	0.940
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	10.00 (5.14)	11.28 (6.83)		
Week 52 Mean (SD)	1.00 (2.14)	1.93 (3.63)		
Week 52 Adjusted Mean Change (SE)	-8.53 (0.42)	-7.92 (0.43)	-0.62 [-1.80; 0.56]	0.301

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

21.7 SJC76 - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.755				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	8.45 (4.03)	10.48 (7.92)		
Week 52 Mean (SD)	1.07 (2.27)	1.05 (2.04)		
Week 52 Adjusted Mean Change (SE)	-8.01 (0.50)	-8.51 (0.55)	0.50 [-0.98; 1.98]	0.504
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	9.64 (7.35)	10.95 (7.13)		
Week 52 Mean (SD)	0.55 (0.89)	2.44 (4.40)		
Week 52 Adjusted Mean Change (SE)	-9.04 (0.58)	-7.50 (0.64)	-1.54 [-3.26; 0.18]	0.078

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

21.8 SJC76 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.446				
Non-carrier, N	**28**	**19**		
N'	28	19		
Baseline Mean (SD)	10.21 (7.05)	10.68 (7.37)		
Week 52 Mean (SD)	0.78 (1.34)	0.64 (1.08)		
Week 52 Adjusted Mean Change (SE)	-9.15 (0.53)	-9.13 (0.69)	-0.02 [-1.74; 1.70]	0.984
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	7.50 (2.82)	12.11 (8.17)		
Week 52 Mean (SD)	1.00 (2.40)	2.82 (4.50)		
Week 52 Adjusted Mean Change (SE)	-8.12 (0.61)	-7.48 (0.66)	-0.64 [-2.46; 1.17]	0.482

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

21.9 SJC76 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.962				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	9.89 (4.78)	9.81 (6.92)		
Week 52 Mean (SD)	1.05 (1.68)	2.00 (2.73)		
Week 52 Adjusted Mean Change (SE)	-8.62 (0.62)	-7.55 (0.63)	-1.08 [-2.83; 0.68]	0.225
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	8.67 (6.26)	11.48 (8.08)		
Week 52 Mean (SD)	0.74 (1.95)	1.40 (3.78)		
Week 52 Adjusted Mean Change (SE)	-8.46 (0.50)	-8.67 (0.58)	0.21 [-1.33; 1.76]	0.785

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

21.10 SJC76 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.034				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	7.72 (3.87)	9.56 (7.16)		
Week 52 Mean (SD)	0.39 (0.89)	2.08 (3.80)		
Week 52 Adjusted Mean Change (SE)	-8.86 (0.54)	-7.52 (0.48)	-1.35 [-2.78; 0.09]	0.065
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	10.15 (6.85)	13.67 (7.90)		
Week 52 Mean (SD)	1.29 (2.33)	0.60 (0.97)		
Week 52 Adjusted Mean Change (SE)	-8.04 (0.52)	-9.69 (0.82)	1.66 [-0.27; 3.58]	0.091

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

21.11 SJC76 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.149				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	8.79 (6.08)	11.67 (7.92)		
Week 52 Mean (SD)	0.85 (1.99)	1.60 (2.58)		
Week 52 Adjusted Mean Change (SE)	-8.84 (0.72)	-7.85 (0.82)	-0.99 [-3.15; 1.17]	0.369
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	8.75 (3.79)	6.78 (4.27)		
Week 52 Mean (SD)	0.67 (1.23)	0.44 (0.73)		
Week 52 Adjusted Mean Change (SE)	-8.59 (1.25)	-8.89 (1.44)	0.30 [-3.41; 4.02]	0.873

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

21.12 SJC76 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.770				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	9.94 (6.16)	9.53 (6.42)		
Week 52 Mean (SD)	1.03 (2.11)	0.92 (1.98)		
Week 52 Adjusted Mean Change (SE)	-8.62 (0.46)	-8.64 (0.49)	0.03 [-1.31; 1.36]	0.969
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	6.46 (3.60)	14.60 (9.81)		
Week 52 Mean (SD)	0.50 (0.67)	3.60 (5.13)		
Week 52 Adjusted Mean Change (SE)	-8.08 (0.77)	-6.50 (0.89)	-1.58 [-3.98; 0.81]	0.192

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

21.13 SJC76 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.669				
Non-carrier, N	**42**	**36**		
N'	42	36		
Baseline Mean (SD)	9.00 (5.93)	10.03 (7.45)		
Week 52 Mean (SD)	0.97 (1.99)	1.43 (3.27)		
Week 52 Adjusted Mean Change (SE)	-8.19 (0.42)	-8.01 (0.47)	-0.18 [-1.44; 1.08]	0.777
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	8.78 (4.52)	13.20 (6.06)		
Week 52 Mean (SD)	0.33 (0.50)	2.33 (4.04)		
Week 52 Adjusted Mean Change (SE)	-9.01 (0.89)	-7.69 (1.31)	-1.33 [-4.48; 1.83]	0.406

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

21.14 SJC76 - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.765				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	10.45 (5.43)	9.00 (6.16)		
Week 52 Mean (SD)	1.20 (1.99)	1.50 (2.42)		
Week 52 Adjusted Mean Change (SE)	-8.54 (0.83)	-7.81 (0.63)	-0.73 [-2.81; 1.34]	0.485
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	8.55 (5.73)	12.36 (8.46)		
Week 52 Mean (SD)	0.76 (1.79)	1.80 (3.96)		
Week 52 Adjusted Mean Change (SE)	-8.42 (0.44)	-8.30 (0.60)	-0.12 [-1.61; 1.37]	0.870

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

21.15 SJC76 - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.245				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	9.87 (6.79)	9.96 (7.13)		
Week 52 Mean (SD)	0.73 (1.28)	0.53 (1.01)		
Week 52 Adjusted Mean Change (SE)	-8.87 (0.48)	-8.86 (0.59)	-0.01 [-1.52; 1.51]	0.992
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	7.55 (2.89)	11.48 (8.00)		
Week 52 Mean (SD)	1.06 (2.54)	2.68 (4.27)		
Week 52 Adjusted Mean Change (SE)	-7.77 (0.61)	-7.25 (0.59)	-0.52 [-2.23; 1.20]	0.551

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

21.16 SJC76 - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.840				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	9.89 (4.78)	9.80 (7.10)		
Week 52 Mean (SD)	1.05 (1.68)	2.13 (2.77)		
Week 52 Adjusted Mean Change (SE)	-8.54 (0.61)	-7.35 (0.64)	-1.19 [-2.95; 0.57]	0.182
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	8.41 (6.14)	11.42 (7.91)		
Week 52 Mean (SD)	0.71 (1.92)	1.33 (3.69)		
Week 52 Adjusted Mean Change (SE)	-8.39 (0.49)	-8.63 (0.56)	0.23 [-1.26; 1.73]	0.757

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

21.17 SJC76 - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.034				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	7.72 (3.87)	9.56 (7.16)		
Week 52 Mean (SD)	0.39 (0.89)	2.08 (3.80)		
Week 52 Adjusted Mean Change (SE)	-8.86 (0.54)	-7.52 (0.48)	-1.35 [-2.78; 0.09]	0.065
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	10.15 (6.85)	13.67 (7.90)		
Week 52 Mean (SD)	1.29 (2.33)	0.60 (0.97)		
Week 52 Adjusted Mean Change (SE)	-8.04 (0.52)	-9.69 (0.82)	1.66 [-0.27; 3.58]	0.091

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

21.18 SJC76 - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.241				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	9.03 (6.18)	11.26 (7.87)		
Week 52 Mean (SD)	0.91 (1.99)	1.56 (2.50)		
Week 52 Adjusted Mean Change (SE)	-8.39 (0.43)	-8.28 (0.48)	-0.11 [-1.40; 1.19]	0.869
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	9.00 (3.87)	8.44 (5.73)		
Week 52 Mean (SD)	0.64 (1.29)	2.00 (5.27)		
Week 52 Adjusted Mean Change (SE)	-8.86 (0.80)	-7.45 (0.88)	-1.42 [-3.78; 0.94]	0.236

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

22.0 SPARCC Enthesitis Index - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	66 (100.0)	61 (98.4)	127 (99.2)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	56 (90.3)	121 (94.5)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	49 (79.0)	112 (87.5)

22.1 SPARCC Enthesitis Index - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	61		
Baseline Mean (SD)	3.14 (3.56)	4.08 (4.26)		
Week 52 Mean (SD)	1.08 (2.43)	0.73 (2.01)		
Week 52 Adjusted Mean Change (SE)	-2.41 (0.24)	-2.78 (0.27)	0.37 [-0.35; 1.09]	0.307

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

22.2 SPARCC Enthesitis Index - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.585				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	2.29 (2.73)	3.42 (3.76)		
Week 52 Mean (SD)	0.63 (1.61)	0.54 (1.63)		
Week 52 Adjusted Mean Change (SE)	-2.70 (0.31)	-2.93 (0.36)	0.24 [-0.71; 1.18]	0.619
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	4.63 (4.35)	4.83 (4.73)		
Week 52 Mean (SD)	1.87 (3.31)	0.96 (2.38)		
Week 52 Adjusted Mean Change (SE)	-1.94 (0.40)	-2.59 (0.39)	0.65 [-0.45; 1.75]	0.243

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

22.3 SPARCC Enthesitis Index - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.735				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	1.56 (2.37)	1.31 (1.11)		
Week 52 Mean (SD)	0.50 (1.51)	0.11 (0.33)		
Week 52 Adjusted Mean Change (SE)	-2.51 (0.50)	-2.76 (0.61)	0.25 [-1.29; 1.79]	0.749
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	3.64 (3.75)	4.82 (4.49)		
Week 52 Mean (SD)	1.28 (2.65)	0.88 (2.20)		
Week 52 Adjusted Mean Change (SE)	-2.38 (0.28)	-2.78 (0.30)	0.41 [-0.41; 1.22]	0.330

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

22.4 SPARCC Enthesitis Index - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.658				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	2.64 (2.96)	4.41 (4.33)		
Week 52 Mean (SD)	0.85 (1.67)	0.78 (2.30)		
Week 52 Adjusted Mean Change (SE)	-2.54 (0.38)	-2.71 (0.38)	0.16 [-0.91; 1.23]	0.761
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	3.50 (3.94)	3.73 (4.23)		
Week 52 Mean (SD)	1.24 (2.85)	0.69 (1.76)		
Week 52 Adjusted Mean Change (SE)	-2.33 (0.32)	-2.90 (0.38)	0.57 [-0.41; 1.55]	0.252

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

22.5 SPARCC Enthesitis Index - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.454				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	3.35 (3.17)	3.38 (3.60)		
Week 52 Mean (SD)	0.68 (1.44)	0.38 (0.80)		
Week 52 Adjusted Mean Change (SE)	-2.88 (0.31)	-2.65 (0.39)	-0.23 [-1.21; 0.75]	0.637
> Median, N	**26**	**33**		
N'	26	32		
Baseline Mean (SD)	2.81 (4.13)	4.70 (4.74)		
Week 52 Mean (SD)	1.68 (3.38)	1.00 (2.55)		
Week 52 Adjusted Mean Change (SE)	-1.69 (0.38)	-2.90 (0.36)	1.21 [0.17; 2.25]	0.023

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

22.6 SPARCC Enthesitis Index - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.525				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	0.74 (1.58)	1.14 (1.36)		
Week 52 Mean (SD)	0.56 (1.76)	0.32 (0.82)		
Week 52 Adjusted Mean Change (SE)	-2.12 (0.38)	-2.53 (0.46)	0.41 [-0.68; 1.51]	0.455
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	5.69 (3.30)	5.70 (4.46)		
Week 52 Mean (SD)	1.61 (2.89)	1.00 (2.46)		
Week 52 Adjusted Mean Change (SE)	-2.68 (0.37)	-2.98 (0.36)	0.30 [-0.65; 1.26]	0.531

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

22.7 SPARCC Enthesitis Index - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.195				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	3.55 (4.06)	4.76 (4.54)		
Week 52 Mean (SD)	1.96 (3.38)	0.82 (1.87)		
Week 52 Adjusted Mean Change (SE)	-1.75 (0.38)	-3.19 (0.43)	1.45 [0.31; 2.59]	0.013
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	2.45 (2.92)	3.37 (4.19)		
Week 52 Mean (SD)	0.45 (0.69)	1.00 (2.73)		
Week 52 Adjusted Mean Change (SE)	-2.84 (0.45)	-2.61 (0.49)	-0.22 [-1.55; 1.10]	0.737

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

22.8 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.996				
Non-carrier, N	**28**	**19**		
N'	28	19		
Baseline Mean (SD)	3.43 (3.97)	3.79 (3.92)		
Week 52 Mean (SD)	1.11 (2.49)	0.29 (0.47)		
Week 52 Adjusted Mean Change (SE)	-2.54 (0.40)	-3.29 (0.53)	0.75 [-0.59; 2.08]	0.268
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	2.68 (3.26)	4.74 (5.19)		
Week 52 Mean (SD)	1.70 (3.06)	1.67 (3.09)		
Week 52 Adjusted Mean Change (SE)	-1.79 (0.47)	-2.45 (0.50)	0.66 [-0.71; 2.03]	0.339

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

22.9 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.144				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	3.84 (4.43)	4.29 (5.15)		
Week 52 Mean (SD)	1.74 (3.05)	1.13 (2.13)		
Week 52 Adjusted Mean Change (SE)	-2.07 (0.48)	-2.77 (0.50)	0.69 [-0.69; 2.08]	0.322
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	2.60 (3.04)	4.04 (3.70)		
Week 52 Mean (SD)	1.11 (2.51)	0.73 (2.35)		
Week 52 Adjusted Mean Change (SE)	-2.27 (0.40)	-3.02 (0.45)	0.76 [-0.43; 1.95]	0.210

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

22.10 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.748				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	3.52 (3.91)	4.50 (4.91)		
Week 52 Mean (SD)	1.26 (2.68)	1.14 (2.56)		
Week 52 Adjusted Mean Change (SE)	-2.36 (0.42)	-2.81 (0.39)	0.45 [-0.69; 1.59]	0.433
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	2.65 (3.35)	3.25 (2.53)		
Week 52 Mean (SD)	1.40 (2.78)	0.20 (0.42)		
Week 52 Adjusted Mean Change (SE)	-2.07 (0.42)	-3.31 (0.64)	1.25 [-0.26; 2.76]	0.104

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

22.11 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.479				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	2.82 (3.17)	4.27 (4.48)		
Week 52 Mean (SD)	1.40 (2.74)	0.63 (1.64)		
Week 52 Adjusted Mean Change (SE)	-2.17 (0.33)	-3.18 (0.37)	1.01 [0.01; 2.00]	0.048
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	4.17 (4.84)	3.11 (3.37)		
Week 52 Mean (SD)	1.17 (2.86)	0.67 (1.12)		
Week 52 Adjusted Mean Change (SE)	-2.37 (0.58)	-2.78 (0.66)	0.41 [-1.33; 2.15]	0.639

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

22.12 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.426				
Non-carrier, N	36	34		
N'	36	34		
Baseline Mean (SD)	3.14 (3.83)	3.68 (4.07)		
Week 52 Mean (SD)	1.36 (2.86)	0.71 (1.70)		
Week 52 Adjusted Mean Change (SE)	-2.22 (0.36)	-3.03 (0.38)	0.81 [-0.24; 1.85]	0.130
Carrier, N	13	10		
N'	13	10		
Baseline Mean (SD)	3.23 (3.32)	5.80 (5.27)		
Week 52 Mean (SD)	1.46 (2.57)	1.40 (3.41)		
Week 52 Adjusted Mean Change (SE)	-2.20 (0.59)	-2.71 (0.68)	0.51 [-1.29; 2.30]	0.576

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

22.13 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.804				
Non-carrier, N	42	36		
N'	42	36		
Baseline Mean (SD)	3.24 (3.78)	4.36 (4.69)		
Week 52 Mean (SD)	1.56 (2.95)	1.03 (2.48)		
Week 52 Adjusted Mean Change (SE)	-2.11 (0.33)	-2.92 (0.37)	0.81 [-0.19; 1.81]	0.112
Carrier, N	9	5		
N'	9	5		
Baseline Mean (SD)	2.33 (2.83)	3.60 (3.65)		
Week 52 Mean (SD)	0.33 (0.71)	0.20 (0.45)		
Week 52 Adjusted Mean Change (SE)	-2.80 (0.71)	-3.44 (0.94)	0.64 [-1.70; 2.99]	0.586

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

22.14 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.387				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	2.64 (3.67)	3.82 (4.40)		
Week 52 Mean (SD)	1.40 (2.72)	0.94 (2.08)		
Week 52 Adjusted Mean Change (SE)	-2.04 (0.65)	-2.85 (0.49)	0.81 [-0.82; 2.43]	0.327
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	3.20 (3.65)	4.50 (4.47)		
Week 52 Mean (SD)	1.32 (2.74)	0.86 (2.40)		
Week 52 Adjusted Mean Change (SE)	-2.26 (0.34)	-2.95 (0.45)	0.69 [-0.43; 1.81]	0.222

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

22.15 SPARCC Enthesitis Index - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.412				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	3.39 (3.83)	3.91 (3.81)		
Week 52 Mean (SD)	1.20 (2.54)	0.22 (0.43)		
Week 52 Adjusted Mean Change (SE)	-2.49 (0.37)	-3.37 (0.46)	0.89 [-0.29; 2.06]	0.137
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	2.60 (3.32)	4.43 (5.05)		
Week 52 Mean (SD)	1.56 (3.03)	1.50 (2.96)		
Week 52 Adjusted Mean Change (SE)	-1.73 (0.47)	-2.50 (0.46)	0.77 [-0.54; 2.09]	0.247

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

22.16 SPARCC Enthesitis Index - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.185				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	3.84 (4.43)	4.40 (5.26)		
Week 52 Mean (SD)	1.74 (3.05)	1.13 (2.20)		
Week 52 Adjusted Mean Change (SE)	-2.06 (0.48)	-2.77 (0.51)	0.71 [-0.69; 2.10]	0.318
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	2.63 (3.03)	3.96 (3.64)		
Week 52 Mean (SD)	1.07 (2.48)	0.74 (2.30)		
Week 52 Adjusted Mean Change (SE)	-2.28 (0.38)	-2.99 (0.43)	0.71 [-0.44; 1.86]	0.224

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

22.17 SPARCC Enthesitis Index - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.748				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	3.52 (3.91)	4.50 (4.91)		
Week 52 Mean (SD)	1.26 (2.68)	1.14 (2.56)		
Week 52 Adjusted Mean Change (SE)	-2.36 (0.42)	-2.81 (0.39)	0.45 [-0.69; 1.59]	0.433
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	2.65 (3.35)	3.25 (2.53)		
Week 52 Mean (SD)	1.40 (2.78)	0.20 (0.42)		
Week 52 Adjusted Mean Change (SE)	-2.07 (0.42)	-3.31 (0.64)	1.25 [-0.26; 2.76]	0.104

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

22.18 SPARCC Enthesitis Index - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.074				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	2.74 (3.16)	4.09 (4.42)		
Week 52 Mean (SD)	1.39 (2.70)	0.69 (1.65)		
Week 52 Adjusted Mean Change (SE)	-2.08 (0.33)	-3.00 (0.36)	0.92 [-0.05; 1.89]	0.064
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	3.09 (3.24)	4.44 (4.59)		
Week 52 Mean (SD)	0.36 (0.67)	1.56 (3.61)		
Week 52 Adjusted Mean Change (SE)	-2.78 (0.60)	-2.16 (0.66)	-0.62 [-2.40; 1.16]	0.490

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

23.1 SPARCC Resolution of Enthesitis (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
SPARCC Resolution of Enthesitis Week 52, N' n (%)	63 44.64 (67.64)	49 42.22 (68.10)	0.98 [0.46; 2.12] 0.969	0.99 [0.78; 1.27] 0.959	-0.005 [-0.171; 0.162] 0.957

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.
RR and RD calculated directly without adjustment.

All results are combined over MI:
n and % are averages of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

23.2 SPARCC Resolution of Enthesitis by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SPARCC Resolution of Enthesitis Week 52	p=0.856				
Male (N)	**42**	**33**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	40 30.73 (73.17)	26 24.49 (74.21)	0.97 [0.32; 2.93] 0.958	0.99 [0.74; 1.31] 0.927	-0.010 [-0.221; 0.200] 0.923
Female (N)	**24**	**29**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	23 13.91 (57.96)	23 17.73 (61.14)	0.84 [0.26; 2.65] 0.761	0.95 [0.60; 1.51] 0.824	-0.032 [-0.305; 0.242] 0.820

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

23.3 SPARCC Resolution of Enthesitis by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SPARCC Resolution of Enthesitis Week 52	p=0.986				
PASDAS < 5.4 (N)	**16**	**13**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	16 13.00 (81.25)	9 10.59 (81.46)	0.93 [0.10; 8.44] 0.949	1.00 [0.68; 1.48] 0.997	-0.002 [-0.315; 0.310] 0.989
PASDAS ≥ 5.4 (N)	**50**	**49**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	47 31.64 (63.28)	40 31.63 (64.55)	0.95 [0.41; 2.23] 0.906	0.98 [0.72; 1.33] 0.900	-0.013 [-0.208; 0.182] 0.898

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

23.4 SPARCC Resolution of Enthesitis by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SPARCC Resolution of Enthesitis Week 52	p=0.459				
Moderate/Severe Psoriasis (Def D): No (N)	**28**	**32**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	26 18.44 (65.86)	23 19.19 (59.97)	1.26 [0.42; 3.81] 0.677	1.10 [0.73; 1.65] 0.649	0.059 [-0.195; 0.313] 0.650
Moderate/Severe Psoriasis (Def D): Yes (N)	**38**	**30**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	37 26.20 (68.95)	26 23.03 (76.77)	0.69 [0.22; 2.17] 0.523	0.90 [0.66; 1.21] 0.487	-0.078 [-0.297; 0.141] 0.484

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

23.5 SPARCC Resolution of Enthesitis by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SPARCC Resolution of Enthesitis Week 52	p=0.655				
≤ Median (N)	**40**	**29**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	38 26.73 (66.83)	21 18.42 (63.52)	1.20 [0.42; 3.43] 0.738	1.05 [0.73; 1.52] 0.782	0.033 [-0.204; 0.270] 0.784
> Median (N)	**26**	**33**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	25 17.91 (68.88)	28 23.80 (72.12)	0.83 [0.26; 2.68] 0.760	0.96 [0.68; 1.35] 0.797	-0.032 [-0.274; 0.209] 0.793

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

23.6 SPARCC Resolution of Enthesitis by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SPARCC Resolution of Enthesitis Week 52	p=0.607				
Enthesitis: No (N)	**34**	**22**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	32 28.44 (83.65)	19 18.07 (82.14)	1.09 [0.24; 5.06] 0.910	1.02 [0.78; 1.32] 0.888	0.015 [-0.200; 0.230] 0.890
Enthesitis: Yes (N)	**32**	**40**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	31 16.20 (50.63)	30 24.15 (60.38)	0.67 [0.25; 1.80] 0.431	0.84 [0.54; 1.30] 0.431	-0.097 [-0.335; 0.140] 0.421

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

23.7 SPARCC Resolution of Enthesitis by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SPARCC Resolution of Enthesitis Week 52	p=0.846				
Non-carrier (N)	**29**	**25**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	28 17.91 (61.76)	22 17.44 (69.76)	0.70 [0.21; 2.27] 0.551	0.89 [0.60; 1.32] 0.550	-0.080 [-0.340; 0.180] 0.546
Carrier (N)	**22**	**19**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	20 13.73 (62.41)	16 12.67 (66.68)	0.84 [0.22; 3.21] 0.793	0.94 [0.58; 1.50] 0.785	-0.043 [-0.347; 0.262] 0.783

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

23.8 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SPARCC Resolution of Enthesitis Week 52	p=0.701				
Non-carrier (N)	**28**	**19**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	27 18.53 (66.18)	14 12.34 (64.95)	1.07 [0.29; 3.95] 0.915	1.02 [0.65; 1.60] 0.927	0.012 [-0.278; 0.303] 0.934
Carrier (N)	**22**	**19**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	20 12.11 (55.05)	18 11.77 (61.95)	0.75 [0.21; 2.70] 0.660	0.89 [0.52; 1.51] 0.660	-0.069 [-0.376; 0.238] 0.659

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

23.9 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SPARCC Resolution of Enthesitis Week 52	p=0.622				
Non-carrier (N)	**19**	**21**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	19 11.00 (57.89)	16 12.59 (59.95)	0.92 [0.25; 3.45] 0.905	0.97 [0.56; 1.66] 0.906	-0.021 [-0.337; 0.295] 0.898
Carrier (N)	**30**	**23**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	28 19.44 (64.80)	22 17.52 (76.17)	0.58 [0.17; 2.04] 0.399	0.85 [0.59; 1.22] 0.376	-0.114 [-0.363; 0.136] 0.372

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

23.10 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SPARCC Resolution of Enthesitis Week 52	p=0.386				
Non-carrier (N)	**25**	**32**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	23 17.11 (68.44)	28 21.21 (66.28)	1.08 [0.34; 3.44] 0.896	1.03 [0.71; 1.50] 0.865	0.022 [-0.231; 0.274] 0.867
Carrier (N)	**26**	**12**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	25 14.53 (55.88)	10 8.90 (74.17)	0.45 [0.09; 2.22] 0.326	0.75 [0.46; 1.24] 0.266	-0.183 [-0.507; 0.142] 0.270

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

23.11 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SPARCC Resolution of Enthesitis Week 52	p=0.804				
Non-carrier (N)	**38**	**33**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	35 23.64 (62.21)	27 23.11 (70.03)	0.72 [0.25; 2.05] 0.539	0.89 [0.63; 1.26] 0.505	-0.078 [-0.306; 0.150] 0.501
Carrier (N)	**12**	**9**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	12 8.00 (66.67)	9 6.00 (66.67)	0.94 [0.15; 6.00] 0.952	1.00 [0.54; 1.84] 1.000	0.000 [-0.407; 0.407] 1.000

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) SPARCC Resolution of Enthesitis, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

23.12 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SPARCC Resolution of Enthesitis Week 52	p=0.805				
Non-carrier (N)	**36**	**34**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	33 22.64 (62.89)	28 24.11 (70.91)	0.67 [0.24; 1.93] 0.462	0.89 [0.63; 1.25] 0.494	-0.080 [-0.308; 0.147] 0.490
Carrier (N)	**13**	**10**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	13 7.00 (53.85)	10 6.00 (60.00)	0.87 [0.16; 4.76] 0.871	0.90 [0.44; 1.83] 0.766	-0.062 [-0.469; 0.345] 0.767

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) SPARCC Resolution of Enthesitis, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

23.13 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SPARCC Resolution of Enthesitis Week 52	p=0.899				
Non-carrier (N)	**42**	**36**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	39 24.64 (58.67)	30 24.11 (66.97)	0.71 [0.27; 1.86] 0.482	0.88 [0.62; 1.25] 0.465	-0.083 [-0.304; 0.138] 0.461
Carrier (N)	**9**	**5**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	9 7.00 (77.78)	5 4.00 (80.00)	0.85 [0.06; 12.67] 0.908	0.97 [0.56; 1.70] 0.922	-0.022 [-0.466; 0.421] 0.922

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) SPARCC Resolution of Enthesitis, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

23.14 SPARCC Resolution of Enthesitis by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SPARCC Resolution of Enthesitis Week 52	p=0.594				
Low score (N)	**11**	**22**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	10 7.20 (65.45)	16 14.11 (64.14)	1.04 [0.21; 5.17] 0.961	1.02 [0.58; 1.79] 0.940	0.013 [-0.347; 0.374] 0.943
High score (N)	**40**	**22**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	38 24.44 (61.10)	22 16.00 (72.73)	0.61 [0.19; 1.91] 0.394	0.84 [0.59; 1.20] 0.341	-0.116 [-0.358; 0.125] 0.345

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

23.15 SPARCC Resolution of Enthesitis by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SPARCC Resolution of Enthesitis Week 52	p=0.760				
Non-carrier (N)	**31**	**23**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	30 20.53 (66.23)	18 16.34 (71.04)	0.83 [0.24; 2.87] 0.766	0.93 [0.64; 1.36] 0.721	-0.048 [-0.308; 0.211] 0.716
Carrier (N)	**20**	**21**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	18 11.11 (55.55)	20 13.77 (65.57)	0.63 [0.17; 2.28] 0.477	0.85 [0.51; 1.41] 0.523	-0.100 [-0.403; 0.203] 0.517

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

23.16 SPARCC Resolution of Enthesitis by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SPARCC Resolution of Enthesitis Week 52	p=0.839				
Non-carrier (N)	**19**	**20**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	19 11.00 (57.89)	15 12.59 (62.95)	0.81 [0.21; 3.13] 0.764	0.92 [0.54; 1.57] 0.764	-0.051 [-0.369; 0.268] 0.756
Carrier (N)	**32**	**24**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	29 20.64 (64.50)	23 17.52 (73.00)	0.67 [0.21; 2.21] 0.516	0.88 [0.61; 1.27] 0.503	-0.085 [-0.333; 0.163] 0.502

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

23.17 SPARCC Resolution of Enthesitis by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SPARCC Resolution of Enthesitis Week 52	p=0.386				
Non-carrier (N)	**25**	**32**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	23 17.11 (68.44)	28 21.21 (66.28)	1.08 [0.34; 3.44] 0.896	1.03 [0.71; 1.50] 0.865	0.022 [-0.231; 0.274] 0.867
Carrier (N)	**26**	**12**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	25 14.53 (55.88)	10 8.90 (74.17)	0.45 [0.09; 2.22] 0.326	0.75 [0.46; 1.24] 0.266	-0.183 [-0.507; 0.142] 0.270

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

23.18 SPARCC Resolution of Enthesitis by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SPARCC Resolution of Enthesitis Week 52	p=0.621				
Non-carrier (N)	**39**	**35**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	36 23.64 (60.62)	29 24.11 (68.89)	0.72 [0.26; 1.96] 0.515	0.88 [0.62; 1.25] 0.474	-0.083 [-0.307; 0.142] 0.470
Carrier (N)	**11**	**9**			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	11 8.00 (72.73)	9 6.00 (66.67)	1.24 [0.18; 8.60] 0.826	1.09 [0.61; 1.96] 0.771	0.061 [-0.345; 0.466] 0.769

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) SPARCC Resolution of Enthesitis, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

24.0 TJC28 - Return Rates (FAS)

	Treatment Groups		
	SEC **(N=66)**	**ADA** **(N=62)**	**Total** **(N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	65 (98.5)	61 (98.4)	126 (98.4)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 20 Returns	64 (97.0)	54 (87.1)	118 (92.2)
Week 24 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 28 Returns	60 (90.9)	47 (75.8)	107 (83.6)
Week 32 Returns	62 (93.9)	49 (79.0)	111 (86.7)
Week 36 Returns	60 (90.9)	50 (80.6)	110 (85.9)
Week 40 Returns	63 (95.5)	48 (77.4)	111 (86.7)
Week 44 Returns	62 (93.9)	47 (75.8)	109 (85.2)
Week 48 Returns	60 (90.9)	46 (74.2)	106 (82.8)
Week 52 Returns	62 (93.9)	47 (75.8)	109 (85.2)

24.1 TJC28 - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	61		
Baseline Mean (SD)	9.21 (5.56)	8.84 (6.18)		
Week 52 Mean (SD)	1.92 (3.35)	2.11 (2.97)		
Week 52 Adjusted Mean Change (SE)	-7.17 (0.37)	-6.98 (0.41)	-0.19 [-1.28; 0.90]	0.730

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

24.2 TJC28 - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.562				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	8.71 (5.47)	7.76 (5.67)		
Week 52 Mean (SD)	0.97 (1.39)	0.79 (1.18)		
Week 52 Adjusted Mean Change (SE)	-8.04 (0.42)	-8.07 (0.53)	0.02 [-1.31; 1.36]	0.973
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	10.08 (5.73)	10.07 (6.60)		
Week 52 Mean (SD)	3.52 (4.86)	3.48 (3.62)		
Week 52 Adjusted Mean Change (SE)	-5.65 (0.56)	-5.83 (0.55)	0.18 [-1.35; 1.72]	0.813

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

24.3 TJC28 - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.315				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	7.25 (3.80)	4.77 (3.75)		
Week 52 Mean (SD)	0.69 (1.30)	2.13 (2.59)		
Week 52 Adjusted Mean Change (SE)	-8.05 (0.73)	-5.97 (0.99)	-2.08 [-4.48; 0.33]	0.090
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	9.84 (5.91)	9.92 (6.27)		
Week 52 Mean (SD)	2.35 (3.74)	2.10 (3.07)		
Week 52 Adjusted Mean Change (SE)	-6.88 (0.42)	-7.20 (0.46)	0.32 [-0.90; 1.55]	0.602

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

24.4 TJC28 - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.330				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	9.32 (5.23)	9.41 (6.69)		
Week 52 Mean (SD)	2.04 (3.53)	3.05 (3.86)		
Week 52 Adjusted Mean Change (SE)	-7.13 (0.57)	-6.51 (0.60)	-0.61 [-2.26; 1.03]	0.463
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	9.13 (5.86)	8.23 (5.63)		
Week 52 Mean (SD)	1.83 (3.27)	1.28 (1.51)		
Week 52 Adjusted Mean Change (SE)	-7.19 (0.49)	-7.45 (0.58)	0.26 [-1.24; 1.76]	0.733

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

24.5 TJC28 - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.223				
≤ Median, N	40	29		
N'	40	29		
Baseline Mean (SD)	9.10 (5.61)	7.52 (5.93)		
Week 52 Mean (SD)	1.63 (3.09)	1.74 (2.38)		
Week 52 Adjusted Mean Change (SE)	-7.56 (0.47)	-6.96 (0.64)	-0.60 [-2.17; 0.97]	0.450
> Median, N	26	33		
N'	26	32		
Baseline Mean (SD)	9.38 (5.59)	10.00 (6.24)		
Week 52 Mean (SD)	2.38 (3.76)	2.36 (3.32)		
Week 52 Adjusted Mean Change (SE)	-6.59 (0.59)	-6.97 (0.55)	0.38 [-1.21; 1.97]	0.635

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

24.6 TJC28 - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.770				
Enthesitis: No, N	34	22		
N'	34	22		
Baseline Mean (SD)	7.50 (5.17)	4.86 (3.27)		
Week 52 Mean (SD)	1.71 (3.34)	1.42 (2.12)		
Week 52 Adjusted Mean Change (SE)	-6.87 (0.53)	-6.93 (0.69)	0.06 [-1.61; 1.74]	0.939
Enthesitis: Yes, N	32	40		
N'	32	39		
Baseline Mean (SD)	11.03 (5.46)	11.03 (6.33)		
Week 52 Mean (SD)	2.13 (3.41)	2.57 (3.38)		
Week 52 Adjusted Mean Change (SE)	-7.49 (0.53)	-7.01 (0.55)	-0.48 [-1.95; 0.99]	0.521

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

24.7 TJC28 - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.695				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	9.97 (5.63)	9.08 (5.32)		
Week 52 Mean (SD)	2.52 (3.59)	1.70 (1.81)		
Week 52 Adjusted Mean Change (SE)	-6.58 (0.60)	-7.24 (0.67)	0.66 [-1.13; 2.45]	0.465
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	9.14 (5.71)	7.32 (6.28)		
Week 52 Mean (SD)	2.35 (3.92)	2.38 (3.95)		
Week 52 Adjusted Mean Change (SE)	-6.79 (0.69)	-6.37 (0.78)	-0.42 [-2.48; 1.64]	0.687

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

24.8 TJC28 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.813				
Non-carrier, N	28	19		
N'	28	19		
Baseline Mean (SD)	10.11 (6.40)	8.84 (4.88)		
Week 52 Mean (SD)	1.89 (2.64)	1.21 (1.19)		
Week 52 Adjusted Mean Change (SE)	-7.57 (0.61)	-7.87 (0.82)	0.29 [-1.75; 2.33]	0.776
Carrier, N	22	19		
N'	22	19		
Baseline Mean (SD)	9.23 (4.55)	8.32 (6.39)		
Week 52 Mean (SD)	3.37 (4.81)	2.94 (3.96)		
Week 52 Adjusted Mean Change (SE)	-5.85 (0.71)	-6.34 (0.76)	0.49 [-1.59; 2.56]	0.641

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

24.9 TJC28 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.089				
Non-carrier, N	19	21		
N'	19	21		
Baseline Mean (SD)	10.21 (6.60)	8.00 (5.48)		
Week 52 Mean (SD)	2.53 (2.99)	1.75 (1.91)		
Week 52 Adjusted Mean Change (SE)	-6.78 (0.74)	-7.02 (0.78)	0.24 [-1.90; 2.38]	0.823
Carrier, N	30	23		
N'	30	23		
Baseline Mean (SD)	9.03 (4.99)	8.61 (6.10)		
Week 52 Mean (SD)	2.48 (4.21)	2.20 (3.58)		
Week 52 Adjusted Mean Change (SE)	-6.22 (0.61)	-6.65 (0.70)	0.42 [-1.41; 2.26]	0.648

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

24.10 TJC28 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.414				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	9.16 (6.62)	8.94 (6.04)		
Week 52 Mean (SD)	1.83 (2.90)	2.46 (3.28)		
Week 52 Adjusted Mean Change (SE)	-7.38 (0.64)	-6.57 (0.59)	-0.81 [-2.55; 0.92]	0.355
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	10.04 (4.56)	6.67 (4.74)		
Week 52 Mean (SD)	3.04 (4.30)	0.80 (1.14)		
Week 52 Adjusted Mean Change (SE)	-6.02 (0.63)	-7.73 (0.98)	1.72 [-0.62; 4.05]	0.148

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

24.11 TJC28 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.504				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	9.11 (5.48)	8.64 (5.46)		
Week 52 Mean (SD)	2.62 (4.24)	1.72 (2.01)		
Week 52 Adjusted Mean Change (SE)	-6.38 (0.50)	-7.17 (0.57)	0.79 [-0.72; 2.30]	0.302
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	11.33 (6.21)	5.11 (2.76)		
Week 52 Mean (SD)	2.00 (1.65)	1.56 (1.81)		
Week 52 Adjusted Mean Change (SE)	-7.05 (0.88)	-6.67 (1.02)	-0.38 [-3.11; 2.35]	0.783

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

24.12 TJC28 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC **(N=66)**	**ADA** **(N=62)**	**Mean Difference** **[95% CI]**	**p-value**
Interaction test: p=0.801				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	10.28 (5.59)	7.56 (5.10)		
Week 52 Mean (SD)	2.48 (3.27)	1.42 (2.06)		
Week 52 Adjusted Mean Change (SE)	-6.89 (0.54)	-7.18 (0.59)	0.28 [-1.33; 1.89]	0.727
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	7.69 (4.31)	10.90 (7.29)		
Week 52 Mean (SD)	2.58 (5.04)	3.50 (4.25)		
Week 52 Adjusted Mean Change (SE)	-5.63 (0.89)	-5.72 (1.00)	0.08 [-2.59; 2.76]	0.950

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

24.13 TJC28 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.919				
Non-carrier, N	**42**	**36**		
N'	42	36		
Baseline Mean (SD)	10.05 (5.22)	8.17 (5.80)		
Week 52 Mean (SD)	2.61 (4.03)	2.17 (3.13)		
Week 52 Adjusted Mean Change (SE)	-6.72 (0.51)	-6.79 (0.57)	0.07 [-1.47; 1.60]	0.930
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	7.56 (7.25)	10.40 (5.94)		
Week 52 Mean (SD)	1.78 (1.64)	2.00 (1.73)		
Week 52 Adjusted Mean Change (SE)	-6.88 (1.07)	-7.02 (1.65)	0.14 [-3.78; 4.07]	0.942

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

24.14 TJC28 - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.660				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	10.45 (5.59)	7.86 (5.09)		
Week 52 Mean (SD)	2.00 (3.97)	1.31 (1.45)		
Week 52 Adjusted Mean Change (SE)	-7.68 (0.98)	-7.59 (0.75)	-0.08 [-2.54; 2.38]	0.946
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	9.38 (5.68)	8.77 (6.44)		
Week 52 Mean (SD)	2.57 (3.66)	2.55 (3.66)		
Week 52 Adjusted Mean Change (SE)	-6.39 (0.51)	-6.29 (0.68)	-0.10 [-1.79; 1.60]	0.908

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

24.15 TJC28 - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.699				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	9.97 (6.23)	8.78 (5.27)		
Week 52 Mean (SD)	1.97 (2.58)	1.24 (1.09)		
Week 52 Adjusted Mean Change (SE)	-7.33 (0.56)	-7.46 (0.71)	0.13 [-1.68; 1.94]	0.888
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	9.05 (4.64)	7.81 (6.34)		
Week 52 Mean (SD)	3.29 (5.10)	2.68 (3.82)		
Week 52 Adjusted Mean Change (SE)	-5.54 (0.72)	-6.26 (0.69)	0.72 [-1.27; 2.71]	0.472

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

24.16 TJC28 - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.090				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	10.21 (6.60)	7.95 (5.61)		
Week 52 Mean (SD)	2.53 (2.99)	1.87 (1.92)		
Week 52 Adjusted Mean Change (SE)	-6.80 (0.75)	-6.91 (0.80)	0.11 [-2.09; 2.30]	0.924
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	9.25 (5.04)	8.63 (5.97)		
Week 52 Mean (SD)	2.39 (4.16)	2.10 (3.52)		
Week 52 Adjusted Mean Change (SE)	-6.49 (0.60)	-6.80 (0.69)	0.32 [-1.49; 2.13]	0.728

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

24.16 TJC28 - Change from Baseline by Linkage Variant rs12065362 (FAS)

24.17 TJC28 - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.414				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	9.16 (6.62)	8.94 (6.04)		
Week 52 Mean (SD)	1.83 (2.90)	2.46 (3.28)		
Week 52 Adjusted Mean Change (SE)	-7.38 (0.64)	-6.57 (0.59)	-0.81 [-2.55; 0.92]	0.355
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	10.04 (4.56)	6.67 (4.74)		
Week 52 Mean (SD)	3.04 (4.30)	0.80 (1.14)		
Week 52 Adjusted Mean Change (SE)	-6.02 (0.63)	-7.73 (0.98)	1.72 [-0.62; 4.05]	0.148

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

24.18 TJC28 - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.504				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	9.08 (5.41)	8.54 (5.33)		
Week 52 Mean (SD)	2.60 (4.18)	1.78 (2.06)		
Week 52 Adjusted Mean Change (SE)	-6.28 (0.52)	-6.99 (0.57)	0.71 [-0.82; 2.24]	0.360
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	9.91 (3.96)	7.44 (7.49)		
Week 52 Mean (SD)	1.82 (1.60)	2.67 (4.80)		
Week 52 Adjusted Mean Change (SE)	-7.05 (0.94)	-5.77 (1.04)	-1.28 [-4.08; 1.52]	0.366

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

25.0 TJC68 - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	65 (98.5)	61 (98.4)	126 (98.4)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 20 Returns	64 (97.0)	54 (87.1)	118 (92.2)
Week 24 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 28 Returns	60 (90.9)	47 (75.8)	107 (83.6)
Week 32 Returns	62 (93.9)	49 (79.0)	111 (86.7)
Week 36 Returns	60 (90.9)	50 (80.6)	110 (85.9)
Week 40 Returns	63 (95.5)	48 (77.4)	111 (86.7)
Week 44 Returns	62 (93.9)	47 (75.8)	109 (85.2)
Week 48 Returns	60 (90.9)	46 (74.2)	106 (82.8)
Week 52 Returns	62 (93.9)	47 (75.8)	109 (85.2)

25.1 TJC68 - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	61		
Baseline Mean (SD)	16.56 (9.68)	17.52 (10.91)		
Week 52 Mean (SD)	3.31 (5.00)	3.53 (5.38)		
Week 52 Adjusted Mean Change (SE)	-13.18 (0.64)	-13.16 (0.72)	-0.02 [-1.93; 1.88]	0.981

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

25.2 TJC68 - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.830				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	16.33 (9.06)	15.73 (8.93)		
Week 52 Mean (SD)	2.00 (2.73)	2.00 (3.16)		
Week 52 Adjusted Mean Change (SE)	-14.30 (0.77)	-14.25 (0.94)	-0.06 [-2.46; 2.35]	0.963
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	16.96 (10.87)	19.55 (12.66)		
Week 52 Mean (SD)	5.52 (6.94)	5.13 (6.69)		
Week 52 Adjusted Mean Change (SE)	-11.25 (1.01)	-12.02 (1.00)	0.76 [-2.04; 3.57]	0.591

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

25.3 TJC68 - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.943				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	13.00 (8.35)	12.31 (6.68)		
Week 52 Mean (SD)	2.00 (3.50)	4.00 (5.29)		
Week 52 Adjusted Mean Change (SE)	-14.09 (1.31)	-11.48 (1.68)	-2.61 [-6.79; 1.58]	0.220
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	17.70 (9.87)	18.90 (11.44)		
Week 52 Mean (SD)	3.76 (5.38)	3.44 (5.46)		
Week 52 Adjusted Mean Change (SE)	-12.87 (0.75)	-13.48 (0.80)	0.61 [-1.56; 2.78]	0.580

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

25.4 TJC68 - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.394				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	17.36 (9.01)	18.88 (11.67)		
Week 52 Mean (SD)	3.65 (4.10)	5.05 (7.05)		
Week 52 Adjusted Mean Change (SE)	-13.43 (1.01)	-12.16 (1.05)	-1.28 [-4.16; 1.61]	0.383
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	15.97 (10.23)	16.07 (10.03)		
Week 52 Mean (SD)	3.06 (5.60)	2.20 (2.81)		
Week 52 Adjusted Mean Change (SE)	-12.96 (0.86)	-14.06 (1.02)	1.10 [-1.54; 3.73]	0.412

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

25.5 TJC68 - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.241				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	16.65 (10.27)	16.07 (12.08)		
Week 52 Mean (SD)	2.82 (3.68)	2.63 (3.55)		
Week 52 Adjusted Mean Change (SE)	-14.00 (0.83)	-13.41 (1.09)	-0.58 [-3.28; 2.11]	0.669
> Median, N	**26**	**33**		
N'	26	32		
Baseline Mean (SD)	16.42 (8.89)	18.79 (9.78)		
Week 52 Mean (SD)	4.08 (6.59)	4.14 (6.32)		
Week 52 Adjusted Mean Change (SE)	-11.93 (1.03)	-12.91 (0.96)	0.98 [-1.80; 3.77]	0.486

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

25.6 TJC68 - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.305				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	13.97 (7.57)	11.41 (5.18)		
Week 52 Mean (SD)	2.65 (4.03)	2.37 (3.86)		
Week 52 Adjusted Mean Change (SE)	-13.08 (0.92)	-13.64 (1.19)	0.56 [-2.35; 3.46]	0.705
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	19.31 (10.97)	20.88 (11.80)		
Week 52 Mean (SD)	3.97 (5.80)	4.32 (6.14)		
Week 52 Adjusted Mean Change (SE)	-13.31 (0.92)	-12.87 (0.94)	-0.44 [-3.00; 2.12]	0.736

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

25.7 TJC68 - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.188				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	18.41 (9.98)	17.80 (11.49)		
Week 52 Mean (SD)	4.70 (6.38)	2.40 (3.08)		
Week 52 Adjusted Mean Change (SE)	-12.00 (1.10)	-14.09 (1.23)	2.09 [-1.19; 5.37]	0.209
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	15.55 (9.19)	16.53 (10.86)		
Week 52 Mean (SD)	3.15 (3.98)	4.81 (7.94)		
Week 52 Adjusted Mean Change (SE)	-13.56 (1.29)	-11.75 (1.42)	-1.80 [-5.61; 2.00]	0.349

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

25.8 TJC68 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.504				
Non-carrier, N	**28**	**19**		
N'	28	19		
Baseline Mean (SD)	19.54 (11.46)	16.37 (7.79)		
Week 52 Mean (SD)	3.15 (4.14)	1.64 (1.91)		
Week 52 Adjusted Mean Change (SE)	-14.86 (1.12)	-14.55 (1.48)	-0.31 [-4.01; 3.39]	0.868
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	14.64 (5.85)	18.95 (12.86)		
Week 52 Mean (SD)	5.42 (6.99)	5.59 (7.85)		
Week 52 Adjusted Mean Change (SE)	-10.47 (1.31)	-12.38 (1.38)	1.91 [-1.91; 5.72]	0.323

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

25.9 TJC68 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.264				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	20.00 (11.41)	16.00 (9.63)		
Week 52 Mean (SD)	4.63 (4.97)	2.75 (3.30)		
Week 52 Adjusted Mean Change (SE)	-13.18 (1.46)	-12.78 (1.49)	-0.40 [-4.56; 3.77]	0.850
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	15.43 (8.17)	18.39 (12.42)		
Week 52 Mean (SD)	3.78 (5.94)	4.05 (7.26)		
Week 52 Adjusted Mean Change (SE)	-12.12 (1.19)	-13.12 (1.35)	1.00 [-2.59; 4.58]	0.582

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

25.10 TJC68 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.317				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	16.92 (10.04)	17.72 (12.19)		
Week 52 Mean (SD)	3.39 (4.81)	4.46 (6.56)		
Week 52 Adjusted Mean Change (SE)	-13.63 (1.20)	-12.26 (1.09)	-1.37 [-4.60; 1.86]	0.401
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	17.42 (9.47)	16.00 (7.84)		
Week 52 Mean (SD)	4.67 (6.11)	0.90 (1.10)		
Week 52 Adjusted Mean Change (SE)	-11.75 (1.18)	-15.14 (1.82)	3.38 [-0.92; 7.68]	0.122

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

25.11 TJC68 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.219				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	16.50 (8.84)	17.97 (10.65)		
Week 52 Mean (SD)	4.26 (6.21)	3.20 (4.36)		
Week 52 Adjusted Mean Change (SE)	-11.99 (0.93)	-12.90 (1.05)	0.91 [-1.88; 3.71]	0.517
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	19.08 (12.46)	11.00 (4.66)		
Week 52 Mean (SD)	3.58 (3.12)	1.78 (1.99)		
Week 52 Adjusted Mean Change (SE)	-13.31 (1.62)	-14.11 (1.89)	0.79 [-4.19; 5.78]	0.752

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

25.12 TJC68 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.713				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	18.50 (10.15)	16.59 (10.11)		
Week 52 Mean (SD)	4.15 (5.62)	2.54 (3.99)		
Week 52 Adjusted Mean Change (SE)	-13.33 (1.02)	-13.61 (1.11)	0.28 [-2.72; 3.28]	0.853
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	13.85 (8.12)	19.50 (14.43)		
Week 52 Mean (SD)	4.25 (5.69)	5.90 (8.81)		
Week 52 Adjusted Mean Change (SE)	-10.18 (1.70)	-11.45 (1.91)	1.27 [-3.83; 6.38]	0.622

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

25.13 TJC68 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.915				
Non-carrier, N	**42**	**36**		
N'	42	36		
Baseline Mean (SD)	17.45 (10.01)	17.08 (10.76)		
Week 52 Mean (SD)	4.42 (5.96)	3.57 (6.09)		
Week 52 Adjusted Mean Change (SE)	-12.57 (0.95)	-13.29 (1.05)	0.72 [-2.10; 3.54]	0.612
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	15.89 (8.22)	22.80 (15.09)		
Week 52 Mean (SD)	2.44 (2.35)	5.33 (5.86)		
Week 52 Adjusted Mean Change (SE)	-14.47 (2.00)	-11.79 (2.99)	-2.68 [-9.84; 4.48]	0.459

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

25.14 TJC68 - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.636				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	20.00 (9.01)	15.55 (8.80)		
Week 52 Mean (SD)	3.30 (5.74)	2.50 (3.29)		
Week 52 Adjusted Mean Change (SE)	-14.24 (1.84)	-13.47 (1.40)	-0.78 [-5.38; 3.82]	0.738
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	16.40 (9.79)	18.95 (13.01)		
Week 52 Mean (SD)	4.24 (5.49)	4.25 (7.22)		
Week 52 Adjusted Mean Change (SE)	-12.20 (0.95)	-12.79 (1.29)	0.59 [-2.60; 3.77]	0.716

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

25.15 TJC68 - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.773				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	19.13 (11.27)	16.78 (9.62)		
Week 52 Mean (SD)	3.50 (4.33)	1.59 (1.73)		
Week 52 Adjusted Mean Change (SE)	-14.22 (1.04)	-13.96 (1.30)	-0.26 [-3.59; 3.06]	0.874
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	14.15 (5.40)	17.76 (12.77)		
Week 52 Mean (SD)	5.00 (7.16)	5.16 (7.51)		
Week 52 Adjusted Mean Change (SE)	-10.04 (1.35)	-12.26 (1.28)	2.21 [-1.49; 5.92]	0.238

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

25.16 TJC68 - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.299				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	20.00 (11.41)	16.05 (9.88)		
Week 52 Mean (SD)	4.63 (4.97)	2.87 (3.38)		
Week 52 Adjusted Mean Change (SE)	-13.16 (1.45)	-12.55 (1.52)	-0.61 [-4.80; 3.58]	0.773
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	15.50 (8.20)	18.25 (12.17)		
Week 52 Mean (SD)	3.64 (5.88)	3.90 (7.11)		
Week 52 Adjusted Mean Change (SE)	-12.11 (1.15)	-13.23 (1.31)	1.12 [-2.36; 4.59]	0.525

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

25.17 TJC68 - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC **(N=66)**	**ADA** **(N=62)**	**Mean Difference** **[95% CI]**	**p-value**
Interaction test: p=0.317				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	16.92 (10.04)	17.72 (12.19)		
Week 52 Mean (SD)	3.39 (4.81)	4.46 (6.56)		
Week 52 Adjusted Mean Change (SE)	-13.63 (1.20)	-12.26 (1.09)	-1.37 [-4.60; 1.86]	0.401
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	17.42 (9.47)	16.00 (7.84)		
Week 52 Mean (SD)	4.67 (6.11)	0.90 (1.10)		
Week 52 Adjusted Mean Change (SE)	-11.75 (1.18)	-15.14 (1.82)	3.38 [-0.92; 7.68]	0.122

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

25.18 TJC68 - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.694				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	16.59 (8.74)	17.57 (10.53)		
Week 52 Mean (SD)	4.20 (6.13)	3.19 (4.27)		
Week 52 Adjusted Mean Change (SE)	-11.78 (0.99)	-12.79 (1.09)	1.02 [-1.92; 3.95]	0.493
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	16.18 (7.72)	16.00 (13.80)		
Week 52 Mean (SD)	2.91 (2.17)	4.33 (9.33)		
Week 52 Adjusted Mean Change (SE)	-13.53 (1.83)	-12.16 (2.01)	-1.37 [-6.76; 4.02]	0.615

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

26.0 TJC78 - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	65 (98.5)	61 (98.4)	126 (98.4)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 20 Returns	64 (97.0)	54 (87.1)	118 (92.2)
Week 24 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 28 Returns	60 (90.9)	47 (75.8)	107 (83.6)
Week 32 Returns	62 (93.9)	49 (79.0)	111 (86.7)
Week 36 Returns	60 (90.9)	50 (80.6)	110 (85.9)
Week 40 Returns	63 (95.5)	48 (77.4)	111 (86.7)
Week 44 Returns	62 (93.9)	47 (75.8)	109 (85.2)
Week 48 Returns	60 (90.9)	46 (74.2)	106 (82.8)
Week 52 Returns	62 (93.9)	47 (75.8)	109 (85.2)

26.1 TJC78 - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N'	66	61		
Baseline Mean (SD)	17.33 (10.34)	19.03 (11.97)		
Week 52 Mean (SD)	3.39 (5.07)	3.74 (5.70)		
Week 52 Adjusted Mean Change (SE)	-14.12 (0.68)	-14.10 (0.75)	-0.02 [-2.02; 1.98]	0.985

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

26.2 TJC78 - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.726				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	17.12 (9.46)	17.24 (10.42)		
Week 52 Mean (SD)	2.13 (3.01)	2.17 (3.27)		
Week 52 Adjusted Mean Change (SE)	-15.19 (0.81)	-15.28 (0.99)	0.09 [-2.42; 2.61]	0.941
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	17.71 (11.92)	21.07 (13.41)		
Week 52 Mean (SD)	5.52 (6.94)	5.39 (7.17)		
Week 52 Adjusted Mean Change (SE)	-12.30 (1.06)	-12.84 (1.04)	0.54 [-2.40; 3.49]	0.717

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

26.3 TJC78 - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.931				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	13.63 (8.68)	13.23 (6.91)		
Week 52 Mean (SD)	2.13 (3.93)	4.00 (5.29)		
Week 52 Adjusted Mean Change (SE)	-14.99 (1.37)	-12.59 (1.75)	-2.40 [-6.77; 1.97]	0.279
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	18.52 (10.62)	20.57 (12.59)		
Week 52 Mean (SD)	3.83 (5.38)	3.69 (5.85)		
Week 52 Adjusted Mean Change (SE)	-13.82 (0.78)	-14.38 (0.84)	0.55 [-1.72; 2.83]	0.630

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

26.4 TJC78 - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.320				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	18.61 (10.51)	20.13 (12.18)		
Week 52 Mean (SD)	3.81 (4.32)	5.23 (7.56)		
Week 52 Adjusted Mean Change (SE)	-14.43 (1.06)	-13.05 (1.09)	-1.38 [-4.39; 1.63]	0.366
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	16.39 (10.24)	17.87 (11.83)		
Week 52 Mean (SD)	3.08 (5.60)	2.44 (2.93)		
Week 52 Adjusted Mean Change (SE)	-13.85 (0.90)	-15.05 (1.06)	1.20 [-1.56; 3.96]	0.393

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

26.5 TJC78 - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.314				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	17.58 (11.26)	17.59 (13.11)		
Week 52 Mean (SD)	2.95 (3.87)	2.63 (3.55)		
Week 52 Adjusted Mean Change (SE)	-14.94 (0.87)	-14.52 (1.13)	-0.42 [-3.24; 2.40]	0.768
> Median, N	**26**	**33**		
N'	26	32		
Baseline Mean (SD)	16.96 (8.93)	20.30 (10.92)		
Week 52 Mean (SD)	4.08 (6.59)	4.50 (6.75)		
Week 52 Adjusted Mean Change (SE)	-12.86 (1.08)	-13.71 (1.01)	0.85 [-2.08; 3.77]	0.568

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

26.6 TJC78 - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.289				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	14.62 (8.11)	13.09 (6.67)		
Week 52 Mean (SD)	2.74 (4.21)	2.68 (3.96)		
Week 52 Adjusted Mean Change (SE)	-13.98 (0.97)	-14.57 (1.24)	0.59 [-2.45; 3.63]	0.702
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	20.22 (11.72)	22.30 (13.01)		
Week 52 Mean (SD)	4.03 (5.81)	4.46 (6.61)		
Week 52 Adjusted Mean Change (SE)	-14.29 (0.97)	-13.83 (0.98)	-0.46 [-3.14; 2.22]	0.735

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

26.7 TJC78 - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.160				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	19.17 (10.88)	19.56 (13.30)		
Week 52 Mean (SD)	4.78 (6.49)	2.55 (3.17)		
Week 52 Adjusted Mean Change (SE)	-12.93 (1.16)	-15.14 (1.29)	2.21 [-1.24; 5.66]	0.207
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	16.45 (9.99)	18.21 (11.64)		
Week 52 Mean (SD)	3.20 (3.97)	5.00 (8.56)		
Week 52 Adjusted Mean Change (SE)	-14.67 (1.36)	-12.86 (1.50)	-1.81 [-5.82; 2.20]	0.372

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

26.8 TJC78 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.564				
Non-carrier, N	**28**	**19**		
N'	28	19		
Baseline Mean (SD)	20.68 (12.53)	17.89 (8.48)		
Week 52 Mean (SD)	3.19 (4.13)	1.79 (2.01)		
Week 52 Adjusted Mean Change (SE)	-15.98 (1.18)	-15.56 (1.55)	-0.41 [-4.29; 3.47]	0.833
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	15.09 (6.01)	21.00 (14.31)		
Week 52 Mean (SD)	5.53 (7.13)	5.82 (8.43)		
Week 52 Adjusted Mean Change (SE)	-11.45 (1.38)	-13.49 (1.46)	2.04 [-2.00; 6.08]	0.318

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

26.9 TJC78 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.260				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	21.16 (12.46)	17.76 (10.75)		
Week 52 Mean (SD)	4.79 (5.15)	2.94 (3.38)		
Week 52 Adjusted Mean Change (SE)	-14.11 (1.53)	-13.93 (1.56)	-0.18 [-4.54; 4.17]	0.933
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	16.10 (8.83)	20.09 (14.04)		
Week 52 Mean (SD)	3.78 (5.94)	4.20 (7.81)		
Week 52 Adjusted Mean Change (SE)	-13.22 (1.25)	-14.19 (1.42)	0.98 [-2.79; 4.75]	0.608

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

26.10 TJC78 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.239				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	17.84 (10.30)	19.28 (13.78)		
Week 52 Mean (SD)	3.48 (5.01)	4.62 (7.03)		
Week 52 Adjusted Mean Change (SE)	-14.70 (1.27)	-13.32 (1.15)	-1.37 [-4.78; 2.03]	0.425
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	18.15 (10.87)	18.17 (8.56)		
Week 52 Mean (SD)	4.71 (6.10)	1.10 (1.45)		
Week 52 Adjusted Mean Change (SE)	-12.72 (1.24)	-16.22 (1.91)	3.50 [-1.03; 8.03]	0.128

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

26.11 TJC78 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.186				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	17.55 (10.10)	19.73 (12.34)		
Week 52 Mean (SD)	4.32 (6.30)	3.32 (4.38)		
Week 52 Adjusted Mean Change (SE)	-13.02 (0.96)	-13.94 (1.08)	0.91 [-1.97; 3.80]	0.531
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	19.17 (12.41)	12.44 (5.03)		
Week 52 Mean (SD)	3.58 (3.12)	1.78 (1.99)		
Week 52 Adjusted Mean Change (SE)	-14.30 (1.67)	-15.42 (1.94)	1.12 [-3.99; 6.23]	0.663

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

26.11 TJC78 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

26.12 TJC78 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.630				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	19.53 (11.13)	18.47 (11.65)		
Week 52 Mean (SD)	4.18 (5.61)	2.62 (4.00)		
Week 52 Adjusted Mean Change (SE)	-14.44 (1.07)	-14.82 (1.15)	0.38 [-2.75; 3.51]	0.808
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	14.08 (8.36)	20.70 (15.60)		
Week 52 Mean (SD)	4.42 (5.99)	6.30 (9.70)		
Week 52 Adjusted Mean Change (SE)	-10.90 (1.78)	-12.18 (2.00)	1.28 [-4.08; 6.64]	0.635

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

26.13 TJC78 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.919				
Non-carrier, N	**42**	**36**		
N'	42	36		
Baseline Mean (SD)	18.14 (10.87)	18.75 (12.08)		
Week 52 Mean (SD)	4.50 (6.04)	3.77 (6.54)		
Week 52 Adjusted Mean Change (SE)	-13.54 (1.00)	-14.31 (1.11)	0.77 [-2.20; 3.73]	0.609
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	17.33 (9.03)	25.20 (17.34)		
Week 52 Mean (SD)	2.44 (2.35)	5.33 (5.86)		
Week 52 Adjusted Mean Change (SE)	-15.71 (2.11)	-13.19 (3.11)	-2.52 [-10.01; 4.96]	0.504

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

26.14 TJC78 - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.668				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	21.64 (11.24)	17.00 (9.75)		
Week 52 Mean (SD)	3.40 (5.72)	2.63 (3.30)		
Week 52 Adjusted Mean Change (SE)	-15.36 (1.93)	-14.58 (1.46)	-0.79 [-5.62; 4.05]	0.747
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	17.00 (10.20)	20.95 (14.70)		
Week 52 Mean (SD)	4.30 (5.59)	4.45 (7.78)		
Week 52 Adjusted Mean Change (SE)	-13.20 (1.01)	-13.87 (1.36)	0.67 [-2.70; 4.04]	0.693

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

26.15 TJC78 - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC **(N=66)**	**ADA** **(N=62)**	**Mean Difference** **[95% CI]**	**p-value**
Interaction test: p=0.790				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	20.26 (12.31)	18.35 (10.97)		
Week 52 Mean (SD)	3.60 (4.48)	1.71 (1.83)		
Week 52 Adjusted Mean Change (SE)	-15.24 (1.10)	-15.00 (1.37)	-0.24 [-3.74; 3.26]	0.891
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	14.50 (5.39)	19.67 (14.21)		
Week 52 Mean (SD)	5.00 (7.16)	5.37 (8.06)		
Week 52 Adjusted Mean Change (SE)	-11.05 (1.42)	-13.38 (1.35)	2.33 [-1.60; 6.26]	0.242

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

26.16 TJC78 - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.290				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	21.16 (12.46)	17.90 (11.01)		
Week 52 Mean (SD)	4.79 (5.15)	3.07 (3.45)		
Week 52 Adjusted Mean Change (SE)	-14.07 (1.52)	-13.69 (1.59)	-0.39 [-4.77; 3.99]	0.861
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	16.13 (8.81)	19.88 (13.77)		
Week 52 Mean (SD)	3.64 (5.88)	4.05 (7.65)		
Week 52 Adjusted Mean Change (SE)	-13.20 (1.21)	-14.28 (1.38)	1.09 [-2.57; 4.74]	0.556

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

26.17 TJC78 - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.239				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	17.84 (10.30)	19.28 (13.78)		
Week 52 Mean (SD)	3.48 (5.01)	4.62 (7.03)		
Week 52 Adjusted Mean Change (SE)	-14.70 (1.27)	-13.32 (1.15)	-1.37 [-4.78; 2.03]	0.425
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	18.15 (10.87)	18.17 (8.56)		
Week 52 Mean (SD)	4.71 (6.10)	1.10 (1.45)		
Week 52 Adjusted Mean Change (SE)	-12.72 (1.24)	-16.22 (1.91)	3.50 [-1.03; 8.03]	0.128

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

26.18 TJC78 - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.771				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	17.64 (9.98)	19.31 (12.17)		
Week 52 Mean (SD)	4.29 (6.21)	3.30 (4.30)		
Week 52 Adjusted Mean Change (SE)	-12.83 (1.05)	-13.90 (1.15)	1.07 [-2.03; 4.18]	0.493
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	16.27 (7.67)	17.67 (14.38)		
Week 52 Mean (SD)	2.91 (2.17)	4.67 (10.32)		
Week 52 Adjusted Mean Change (SE)	-14.58 (1.94)	-13.13 (2.13)	-1.45 [-7.18; 4.28]	0.616

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

27.1 ACR Response ACR20 / ACR50 / ACR70 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
ACR20 Week 52, N' n (%)	62 52.33 (79.29)	46 48.61 (78.40)	1.08 [0.42; 2.76] 0.876	1.01 [0.83; 1.23] 0.906	0.009 [-0.144; 0.161] 0.909
ACR50 Week 52, N' n (%)	62 40.30 (61.06)	46 33.33 (53.76)	1.40 [0.64; 3.06] 0.397	1.14 [0.83; 1.56] 0.430	0.073 [-0.107; 0.253] 0.427
ACR70 Week 52, N' n (%)	62 23.31 (35.32)	46 18.70 (30.16)	1.28 [0.59; 2.78] 0.525	1.17 [0.70; 1.96] 0.545	0.052 [-0.115; 0.218] 0.544

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.
RR and RD calculated directly without adjustment.

All results are combined over MI:
n and % are averages of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

27.2 ACR Response ACR20 / ACR50 / ACR70 by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
ACR20 Week 52	p=0.450				
ACR50 Week 52	p=0.415				
ACR70 Week 52	p=0.379				
Male (N)	**42**	**33**			
ACR20 Week 52, N' n (%)	39 33.33 (79.36)	24 28.13 (85.24)	0.68 [0.16; 2.88] 0.600	0.93 [0.74; 1.17] 0.548	-0.059 [-0.248; 0.130] 0.542
ACR50 Week 52, N' n (%)	39 26.31 (62.64)	24 21.35 (64.70)	0.96 [0.33; 2.80] 0.940	0.97 [0.67; 1.39] 0.866	-0.021 [-0.251; 0.210] 0.862
ACR70 Week 52, N' n (%)	39 16.41 (39.07)	24 13.98 (42.36)	0.91 [0.34; 2.44] 0.850	0.92 [0.52; 1.63] 0.786	-0.033 [-0.265; 0.199] 0.781
Female (N)	**24**	**29**			
ACR20 Week 52, N' n (%)	23 19.00 (79.17)	22 20.48 (70.62)	1.47 [0.37; 5.77] 0.582	1.12 [0.80; 1.57] 0.495	0.085 [-0.159; 0.330] 0.494
ACR50 Week 52, N' n (%)	23 13.99 (58.29)	22 11.98 (41.31)	1.88 [0.55; 6.35] 0.312	1.42 [0.79; 2.53] 0.240	0.170 [-0.107; 0.447] 0.229
ACR70 Week 52, N' n (%)	23 6.90 (28.75)	22 4.72 (16.28)	1.97 [0.49; 7.97] 0.343	1.78 [0.60; 5.27] 0.296	0.125 [-0.106; 0.356] 0.290

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

27.3 ACR Response ACR20 / ACR50 / ACR70 by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
ACR20 Week 52	p=0.194				
ACR50 Week 52	p=0.151				
ACR70 Week 52	p=0.131				
PASDAS < 5.4 (N)	**16**	**13**			
ACR20 Week 52, N' n (%)	16 13.00 (81.25)	8 7.81 (60.08)	3.17 [0.48; 21.07] 0.232	1.36 [0.77; 2.40] 0.284	0.212 [-0.145; 0.569] 0.245
ACR50 Week 52, N' n (%)	16 11.00 (68.75)	8 4.87 (37.46)	4.55 [0.74; 27.79] 0.101	1.87 [0.78; 4.49] 0.163	0.313 [-0.060; 0.685] 0.100
ACR70 Week 52, N' n (%)	16 7.00 (43.75)	8 1.80 (13.85)	5.70 [0.63; 51.36] 0.120	3.41 [0.58; 20.06] 0.175	0.299 [-0.024; 0.622] 0.069
PASDAS ≥ 5.4 (N)	**50**	**49**			
ACR20 Week 52, N' n (%)	46 39.33 (78.66)	38 40.80 (83.27)	0.74 [0.24; 2.27] 0.602	0.95 [0.77; 1.16] 0.588	-0.046 [-0.211; 0.119] 0.584
ACR50 Week 52, N' n (%)	46 29.30 (58.60)	38 28.46 (58.08)	1.03 [0.42; 2.50] 0.947	1.01 [0.71; 1.44] 0.956	0.005 [-0.200; 0.210] 0.960
ACR70 Week 52, N' n (%)	46 16.31 (32.62)	38 16.90 (34.49)	0.92 [0.39; 2.19] 0.852	0.95 [0.54; 1.67] 0.849	-0.019 [-0.209; 0.171] 0.847

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

27.4 ACR Response ACR20 / ACR50 / ACR70 by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
ACR20 Week 52	p=0.780				
ACR50 Week 52	p=0.537				
ACR70 Week 52	p=0.054				
Moderate/Severe Psoriasis (Def D): No (N)	**28**	**32**			
ACR20 Week 52, N' n (%)	26 21.94 (78.36)	22 25.10 (78.44)	0.93 [0.23; 3.71] 0.921	1.00 [0.75; 1.33] 0.999	-0.001 [-0.225; 0.223] 0.994
ACR50 Week 52, N' n (%)	26 14.66 (52.36)	22 15.65 (48.91)	1.03 [0.33; 3.22] 0.953	1.07 [0.63; 1.82] 0.794	0.035 [-0.232; 0.301] 0.799
ACR70 Week 52, N' n (%)	26 4.13 (14.75)	22 8.76 (27.38)	0.41 [0.10; 1.65] 0.211	0.54 [0.18; 1.61] 0.268	-0.126 [-0.337; 0.084] 0.240
Moderate/Severe Psoriasis (Def D): Yes (N)	**38**	**30**			
ACR20 Week 52, N' n (%)	36 30.39 (79.97)	24 23.51 (78.37)	1.22 [0.34; 4.44] 0.763	1.02 [0.78; 1.33] 0.876	0.016 [-0.191; 0.223] 0.879
ACR50 Week 52, N' n (%)	36 25.64 (67.47)	24 17.68 (58.93)	1.70 [0.57; 5.07] 0.343	1.15 [0.78; 1.69] 0.492	0.085 [-0.155; 0.326] 0.487
ACR70 Week 52, N' n (%)	36 19.18 (50.47)	24 9.94 (33.13)	2.31 [0.81; 6.62] 0.118	1.53 [0.82; 2.85] 0.182	0.173 [-0.065; 0.412] 0.154

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

27.5 ACR Response ACR20 / ACR50 / ACR70 by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
ACR20 Week 52	p=0.533				
ACR50 Week 52	p=0.921				
ACR70 Week 52	p=0.492				
≤ Median (N)	**40**	**29**			
ACR20 Week 52, N' n (%)	38 31.88 (79.70)	19 24.71 (85.21)	0.71 [0.15; 3.32] 0.663	0.94 [0.74; 1.19] 0.595	-0.055 [-0.254; 0.144] 0.588
ACR50 Week 52, N' n (%)	38 24.30 (60.75)	19 15.85 (54.66)	1.46 [0.47; 4.50] 0.512	1.12 [0.71; 1.76] 0.638	0.061 [-0.195; 0.317] 0.641
ACR70 Week 52, N' n (%)	38 15.41 (38.53)	19 8.52 (29.38)	1.64 [0.55; 4.85] 0.375	1.32 [0.64; 2.70] 0.454	0.091 [-0.141; 0.324] 0.441
> Median (N)	**26**	**33**			
ACR20 Week 52, N' n (%)	24 20.45 (78.65)	27 23.90 (72.42)	1.34 [0.37; 4.87] 0.657	1.09 [0.80; 1.47] 0.595	0.062 [-0.167; 0.292] 0.595
ACR50 Week 52, N' n (%)	24 16.00 (61.54)	27 17.48 (52.97)	1.35 [0.44; 4.09] 0.600	1.16 [0.74; 1.83] 0.515	0.086 [-0.173; 0.344] 0.516
ACR70 Week 52, N' n (%)	24 7.90 (30.38)	27 10.18 (30.85)	0.93 [0.29; 2.98] 0.908	0.99 [0.45; 2.19] 0.975	-0.005 [-0.247; 0.238] 0.970

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

27.6 ACR Response ACR20 / ACR50 / ACR70 by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
ACR20 Week 52	p=0.609				
ACR50 Week 52	p=0.870				
ACR70 Week 52	p=0.903				
Enthesitis: No (N)	**34**	**22**			
ACR20 Week 52, N' n (%)	31 26.39 (77.62)	18 17.80 (80.91)	0.79 [0.18; 3.48] 0.751	0.96 [0.72; 1.29] 0.785	-0.033 [-0.264; 0.198] 0.780
ACR50 Week 52, N' n (%)	31 20.67 (60.79)	18 11.90 (54.09)	1.27 [0.38; 4.18] 0.698	1.13 [0.69; 1.84] 0.637	0.067 [-0.209; 0.343] 0.634
ACR70 Week 52, N' n (%)	31 12.13 (35.68)	18 6.88 (31.27)	1.19 [0.36; 3.95] 0.780	1.15 [0.52; 2.54] 0.738	0.044 [-0.216; 0.304] 0.740
Enthesitis: Yes (N)	**32**	**40**			
ACR20 Week 52, N' n (%)	31 25.94 (81.06)	28 30.81 (77.03)	1.30 [0.37; 4.57] 0.677	1.05 [0.82; 1.36] 0.690	0.040 [-0.160; 0.241] 0.693
ACR50 Week 52, N' n (%)	31 19.63 (61.34)	28 21.43 (53.58)	1.44 [0.51; 4.08] 0.488	1.15 [0.75; 1.74] 0.522	0.078 [-0.161; 0.316] 0.524
ACR70 Week 52, N' n (%)	31 11.18 (34.94)	28 11.82 (29.55)	1.31 [0.47; 3.69] 0.609	1.19 [0.59; 2.37] 0.631	0.054 [-0.169; 0.277] 0.635

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

27.7 ACR Response ACR20 / ACR50 / ACR70 by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
ACR20 Week 52	p=0.542				
ACR50 Week 52	p=0.199				
ACR70 Week 52	p=0.233				
Non-carrier (N)	**29**	**25**			
ACR20 Week 52, N' n (%)	27 23.45 (80.86)	19 20.84 (83.36)	0.85 [0.16; 4.39] 0.843	0.97 [0.74; 1.27] 0.827	-0.025 [-0.243; 0.193] 0.822
ACR50 Week 52, N' n (%)	27 17.00 (58.62)	19 16.59 (66.36)	0.66 [0.19; 2.34] 0.521	0.88 [0.58; 1.35] 0.572	-0.077 [-0.343; 0.188] 0.567
ACR70 Week 52, N' n (%)	27 7.90 (27.24)	19 9.26 (37.04)	0.60 [0.17; 2.08] 0.423	0.74 [0.33; 1.65] 0.457	-0.098 [-0.354; 0.158] 0.453
Carrier (N)	**22**	**19**			
ACR20 Week 52, N' n (%)	20 16.88 (76.73)	16 13.07 (68.79)	1.69 [0.36; 7.89] 0.502	1.12 [0.75; 1.67] 0.588	0.079 [-0.205; 0.364] 0.585
ACR50 Week 52, N' n (%)	20 12.30 (55.91)	16 7.20 (37.89)	2.31 [0.56; 9.63] 0.249	1.48 [0.71; 3.08] 0.292	0.180 [-0.138; 0.498] 0.267
ACR70 Week 52, N' n (%)	20 9.41 (42.77)	16 5.58 (29.37)	1.88 [0.47; 7.63] 0.375	1.46 [0.60; 3.53] 0.399	0.134 [-0.166; 0.434] 0.381

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

27.8 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
ACR20 Week 52	p=0.637				
ACR50 Week 52	p=0.670				
ACR70 Week 52	p=0.861				
Non-carrier (N)	**28**	**19**			
ACR20 Week 52, N' n (%)	27 23.94 (85.50)	13 14.95 (78.68)	1.89 [0.31; 11.49] 0.492	1.09 [0.80; 1.48] 0.591	0.068 [-0.178; 0.315] 0.588
ACR50 Week 52, N' n (%)	27 16.67 (59.54)	13 10.65 (56.05)	1.30 [0.34; 5.03] 0.700	1.06 [0.63; 1.81] 0.816	0.035 [-0.267; 0.336] 0.821
ACR70 Week 52, N' n (%)	27 10.23 (36.54)	13 7.66 (40.32)	0.91 [0.25; 3.33] 0.881	0.91 [0.42; 1.96] 0.811	-0.038 [-0.334; 0.258] 0.802
Carrier (N)	**22**	**19**			
ACR20 Week 52, N' n (%)	19 15.39 (69.95)	17 12.99 (68.37)	1.07 [0.24; 4.82] 0.926	1.02 [0.67; 1.58] 0.913	0.016 [-0.280; 0.312] 0.916
ACR50 Week 52, N' n (%)	19 11.63 (52.86)	17 10.46 (55.05)	0.86 [0.22; 3.35] 0.829	0.96 [0.54; 1.73] 0.893	-0.022 [-0.337; 0.293] 0.892
ACR70 Week 52, N' n (%)	19 6.08 (27.64)	17 6.10 (32.11)	0.76 [0.19; 3.12] 0.706	0.86 [0.33; 2.25] 0.757	-0.045 [-0.331; 0.242] 0.760

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

27.9 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
ACR20 Week 52	p=0.838				
ACR50 Week 52	p=0.416				
ACR70 Week 52	p=0.396				
Non-carrier (N)	**19**	**21**			
ACR20 Week 52, N' n (%)	19 14.00 (73.68)	15 14.71 (70.05)	1.25 [0.26; 6.05] 0.785	1.05 [0.70; 1.59] 0.801	0.036 [-0.258; 0.330] 0.808
ACR50 Week 52, N' n (%)	19 9.00 (47.37)	15 11.33 (53.95)	0.73 [0.18; 2.96] 0.657	0.88 [0.47; 1.67] 0.696	-0.066 [-0.386; 0.255] 0.687
ACR70 Week 52, N' n (%)	19 4.00 (21.05)	15 6.32 (30.10)	0.60 [0.13; 2.82] 0.517	0.70 [0.23; 2.14] 0.536	-0.090 [-0.366; 0.186] 0.521
Carrier (N)	**30**	**23**			
ACR20 Week 52, N' n (%)	27 24.39 (81.30)	20 19.20 (83.48)	0.99 [0.20; 4.85] 0.987	0.97 [0.75; 1.27] 0.845	-0.022 [-0.238; 0.194] 0.843
ACR50 Week 52, N' n (%)	27 18.67 (62.23)	20 12.46 (54.17)	1.58 [0.47; 5.34] 0.464	1.15 [0.71; 1.87] 0.573	0.081 [-0.196; 0.357] 0.568
ACR70 Week 52, N' n (%)	27 13.13 (43.77)	20 8.52 (37.04)	1.40 [0.43; 4.61] 0.577	1.18 [0.59; 2.36] 0.633	0.067 [-0.206; 0.340] 0.629

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

27.10 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
ACR20 Week 52	N.E.				
ACR50 Week 52	p=0.213				
ACR70 Week 52	p=0.263				
Non-carrier (N)	**25**	**32**			
ACR20 Week 52, N' n (%)	23 18.94 (75.76)	26 22.99 (71.84)	1.13 [0.30; 4.20] 0.860	1.06 [0.76; 1.46] 0.743	0.039 [-0.198; 0.276] 0.746
ACR50 Week 52, N' n (%)	23 16.62 (66.48)	26 15.82 (49.44)	1.89 [0.57; 6.33] 0.300	1.35 [0.84; 2.15] 0.211	0.170 [-0.092; 0.432] 0.202
ACR70 Week 52, N' n (%)	23 10.08 (40.32)	26 9.32 (29.13)	1.49 [0.45; 4.89] 0.513	1.39 [0.66; 2.93] 0.391	0.112 [-0.144; 0.368] 0.391
Carrier (N)	**26**	**12**			
ACR20 Week 52, N' n (%)	24 21.39 (82.27)	9 10.92 (91.00)	N.E.	0.91 [0.67; 1.22] 0.513	-0.087 [-0.341; 0.166] 0.500
ACR50 Week 52, N' n (%)	24 12.68 (48.77)	9 7.97 (66.42)	0.53 [0.11; 2.64] 0.441	0.74 [0.41; 1.33] 0.308	-0.176 [-0.521; 0.168] 0.315
ACR70 Week 52, N' n (%)	24 7.23 (27.81)	9 5.52 (46.00)	0.49 [0.11; 2.26] 0.361	0.61 [0.25; 1.49] 0.275	-0.182 [-0.522; 0.159] 0.295

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

27.11 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
ACR20 Week 52	p=0.482				
ACR50 Week 52	p=0.133				
ACR70 Week 52	p=0.382				
Non-carrier (N)	**38**	**33**			
ACR20 Week 52, N' n (%)	34 29.33 (77.18)	24 25.91 (78.52)	1.13 [0.30; 4.32] 0.853	0.98 [0.75; 1.29] 0.907	-0.013 [-0.223; 0.197] 0.901
ACR50 Week 52, N' n (%)	34 21.30 (56.05)	24 16.79 (50.88)	1.46 [0.50; 4.26] 0.492	1.10 [0.69; 1.75] 0.677	0.052 [-0.193; 0.296] 0.679
ACR70 Week 52, N' n (%)	34 11.31 (29.76)	24 9.84 (29.82)	1.09 [0.36; 3.26] 0.882	1.00 [0.47; 2.11] 1.000	-0.001 [-0.222; 0.221] 0.996
Carrier (N)	**12**	**9**			
ACR20 Week 52, N' n (%)	12 10.00 (83.33)	9 8.00 (88.89)	0.38 [0.03; 5.65] 0.483	0.94 [0.67; 1.32] 0.712	-0.056 [-0.350; 0.239] 0.711
ACR50 Week 52, N' n (%)	12 7.00 (58.33)	9 7.00 (77.78)	0.23 [0.03; 1.94] 0.178	0.75 [0.41; 1.36] 0.341	-0.194 [-0.584; 0.195] 0.328
ACR70 Week 52, N' n (%)	12 5.00 (41.67)	9 5.00 (55.56)	0.42 [0.06; 2.66] 0.353	0.75 [0.31; 1.82] 0.526	-0.139 [-0.567; 0.289] 0.525

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) ACR20, ACR50, ACR70, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

27.12 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
ACR20 Week 52	p=0.910				
ACR50 Week 52	p=0.863				
ACR70 Week 52	p=0.150				
Non-carrier (N)	**36**	**34**			
ACR20 Week 52, N' n (%)	33 28.88 (80.22)	25 25.91 (76.21)	1.12 [0.31; 4.06] 0.859	1.05 [0.81; 1.38] 0.702	0.040 [-0.168; 0.248] 0.705
ACR50 Week 52, N' n (%)	33 21.29 (59.14)	25 18.79 (55.26)	1.04 [0.36; 3.04] 0.944	1.07 [0.70; 1.65] 0.753	0.039 [-0.205; 0.282] 0.755
ACR70 Week 52, N' n (%)	33 11.31 (31.42)	25 12.84 (37.76)	0.66 [0.23; 1.95] 0.455	0.83 [0.43; 1.63] 0.592	-0.063 [-0.294; 0.167] 0.589
Carrier (N)	**13**	**10**			
ACR20 Week 52, N' n (%)	12 9.45 (72.69)	10 8.00 (80.00)	1.31 [0.13; 13.01] 0.818	0.91 [0.57; 1.45] 0.684	-0.073 [-0.427; 0.281] 0.686
ACR50 Week 52, N' n (%)	12 6.01 (46.23)	10 5.00 (50.00)	1.25 [0.20; 7.79] 0.809	0.92 [0.39; 2.17] 0.857	-0.038 [-0.450; 0.374] 0.858
ACR70 Week 52, N' n (%)	12 5.00 (38.46)	10 2.00 (20.00)	3.63 [0.48; 27.71] 0.214	1.92 [0.47; 7.94] 0.366	0.185 [-0.178; 0.547] 0.318

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) ACR70, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

27.13 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
ACR20 Week 52	p=0.522				
ACR50 Week 52	p=0.935				
ACR70 Week 52	p=0.836				
Non-carrier (N)	**42**	**36**			
ACR20 Week 52, N' n (%)	38 32.33 (76.98)	29 27.55 (76.53)	1.15 [0.34; 3.90] 0.822	1.01 [0.77; 1.31] 0.961	0.004 [-0.196; 0.205] 0.965
ACR50 Week 52, N' n (%)	38 25.30 (60.24)	29 19.96 (55.44)	1.35 [0.48; 3.81] 0.570	1.09 [0.73; 1.62] 0.682	0.048 [-0.181; 0.277] 0.682
ACR70 Week 52, N' n (%)	38 14.31 (34.07)	29 11.72 (32.56)	1.12 [0.40; 3.14] 0.826	1.05 [0.54; 2.02] 0.888	0.015 [-0.202; 0.232] 0.891
Carrier (N)	**9**	**5**			
ACR20 Week 52, N' n (%)	9 8.00 (88.89)	3 3.36 (67.20)	3.35 [0.16; 69.95] 0.435	1.34 [0.64; 2.79] 0.438	0.217 [-0.276; 0.710] 0.389
ACR50 Week 52, N' n (%)	9 4.00 (44.44)	3 1.83 (36.60)	1.20 [0.09; 16.67] 0.892	1.29 [0.25; 6.69] 0.758	0.078 [-0.498; 0.655] 0.790
ACR70 Week 52, N' n (%)	9 3.00 (33.33)	3 1.12 (22.40)	1.52 [0.11; 21.68] 0.757	1.53 [0.21; 11.04] 0.671	0.109 [-0.382; 0.601] 0.663

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

27.14 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
ACR20 Week 52	p=0.540				
ACR50 Week 52	p=0.782				
ACR70 Week 52	p=0.485				
Low score (N)	**11**	**22**			
ACR20 Week 52, N' n (%)	10 7.94 (72.18)	15 16.55 (75.23)	0.72 [0.11; 4.57] 0.727	0.96 [0.60; 1.53] 0.868	-0.030 [-0.368; 0.307] 0.860
ACR50 Week 52, N' n (%)	10 6.63 (60.27)	15 10.96 (49.82)	1.43 [0.27; 7.60] 0.672	1.21 [0.61; 2.41] 0.583	0.105 [-0.274; 0.483] 0.588
ACR70 Week 52, N' n (%)	10 2.18 (19.82)	15 6.72 (30.55)	0.52 [0.08; 3.41] 0.494	0.65 [0.16; 2.68] 0.547	-0.107 [-0.428; 0.213] 0.512
High score (N)	**40**	**22**			
ACR20 Week 52, N' n (%)	37 32.39 (80.98)	20 17.36 (78.91)	1.50 [0.35; 6.34] 0.582	1.03 [0.78; 1.35] 0.851	0.021 [-0.195; 0.236] 0.851
ACR50 Week 52, N' n (%)	37 22.67 (56.68)	20 12.83 (58.32)	1.08 [0.34; 3.42] 0.902	0.97 [0.61; 1.54] 0.906	-0.016 [-0.280; 0.248] 0.903
ACR70 Week 52, N' n (%)	37 15.13 (37.83)	20 8.12 (36.91)	1.14 [0.37; 3.51] 0.825	1.02 [0.52; 2.03] 0.944	0.009 [-0.245; 0.263] 0.944

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

27.15 ACR Response ACR20 / ACR50 / ACR70 by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
ACR20 Week 52	p=0.982				
ACR50 Week 52	p=0.957				
ACR70 Week 52	p=0.887				
Non-carrier (N)	**31**	**23**			
ACR20 Week 52, N' n (%)	30 24.94 (80.45)	16 18.92 (82.26)	1.10 [0.21; 5.83] 0.911	0.98 [0.74; 1.29] 0.882	-0.018 [-0.244; 0.207] 0.875
ACR50 Week 52, N' n (%)	30 17.67 (57.00)	16 13.33 (57.96)	1.12 [0.32; 3.92] 0.857	0.99 [0.61; 1.60] 0.952	-0.010 [-0.289; 0.270] 0.946
ACR70 Week 52, N' n (%)	30 11.23 (36.23)	16 8.74 (38.00)	1.03 [0.31; 3.50] 0.957	0.96 [0.46; 1.98] 0.905	-0.018 [-0.288; 0.253] 0.898
Carrier (N)	**20**	**21**			
ACR20 Week 52, N' n (%)	17 15.39 (76.95)	19 14.99 (71.38)	1.13 [0.24; 5.35] 0.879	1.08 [0.74; 1.58] 0.696	0.056 [-0.223; 0.335] 0.696
ACR50 Week 52, N' n (%)	17 11.63 (58.15)	19 10.46 (49.81)	1.18 [0.31; 4.52] 0.809	1.17 [0.65; 2.10] 0.604	0.083 [-0.230; 0.396] 0.601
ACR70 Week 52, N' n (%)	17 6.08 (30.40)	19 6.10 (29.05)	0.90 [0.22; 3.72] 0.888	1.04 [0.40; 2.74] 0.930	0.014 [-0.272; 0.299] 0.926

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

27.16 ACR Response ACR20 / ACR50 / ACR70 by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
ACR20 Week 52	p=0.756				
ACR50 Week 52	p=0.554				
ACR70 Week 52	p=0.706				
Non-carrier (N)	**19**	**20**			
ACR20 Week 52, N' n (%)	19 14.00 (73.68)	14 13.71 (68.55)	1.36 [0.28; 6.74] 0.703	1.08 [0.70; 1.65] 0.731	0.051 [-0.249; 0.352] 0.738
ACR50 Week 52, N' n (%)	19 9.00 (47.37)	14 10.33 (51.65)	0.83 [0.20; 3.43] 0.793	0.92 [0.48; 1.78] 0.806	-0.043 [-0.368; 0.283] 0.797
ACR70 Week 52, N' n (%)	19 4.00 (21.05)	14 5.32 (26.60)	0.74 [0.15; 3.64] 0.711	0.80 [0.25; 2.58] 0.706	-0.055 [-0.330; 0.219] 0.692
Carrier (N)	**32**	**24**			
ACR20 Week 52, N' n (%)	28 26.33 (82.28)	21 20.20 (84.17)	0.96 [0.20; 4.65] 0.955	0.98 [0.76; 1.26] 0.860	-0.019 [-0.226; 0.189] 0.859
ACR50 Week 52, N' n (%)	28 20.30 (63.44)	21 13.46 (56.08)	1.45 [0.44; 4.78] 0.543	1.13 [0.71; 1.79] 0.597	0.074 [-0.195; 0.343] 0.592
ACR70 Week 52, N' n (%)	28 13.31 (41.59)	21 9.52 (39.67)	1.08 [0.34; 3.42] 0.893	1.05 [0.54; 2.04] 0.887	0.019 [-0.248; 0.287] 0.888

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

27.17 ACR Response ACR20 / ACR50 / ACR70 by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
ACR20 Week 52	N.E.				
ACR50 Week 52	p=0.213				
ACR70 Week 52	p=0.263				
Non-carrier (N)	**25**	**32**			
ACR20 Week 52, N' n (%)	23 18.94 (75.76)	26 22.99 (71.84)	1.13 [0.30; 4.20] 0.860	1.06 [0.76; 1.46] 0.743	0.039 [-0.198; 0.276] 0.746
ACR50 Week 52, N' n (%)	23 16.62 (66.48)	26 15.82 (49.44)	1.89 [0.57; 6.33] 0.300	1.35 [0.84; 2.15] 0.211	0.170 [-0.092; 0.432] 0.202
ACR70 Week 52, N' n (%)	23 10.08 (40.32)	26 9.32 (29.13)	1.49 [0.45; 4.89] 0.513	1.39 [0.66; 2.93] 0.391	0.112 [-0.144; 0.368] 0.391
Carrier (N)	**26**	**12**			
ACR20 Week 52, N' n (%)	24 21.39 (82.27)	9 10.92 (91.00)	N.E.	0.91 [0.67; 1.22] 0.513	-0.087 [-0.341; 0.166] 0.500
ACR50 Week 52, N' n (%)	24 12.68 (48.77)	9 7.97 (66.42)	0.53 [0.11; 2.64] 0.441	0.74 [0.41; 1.33] 0.308	-0.176 [-0.521; 0.168] 0.315
ACR70 Week 52, N' n (%)	24 7.23 (27.81)	9 5.52 (46.00)	0.49 [0.11; 2.26] 0.361	0.61 [0.25; 1.49] 0.275	-0.182 [-0.522; 0.159] 0.295

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

27.18 ACR Response ACR20 / ACR50 / ACR70 by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
ACR20 Week 52	p=0.334				
ACR50 Week 52	p=0.081				
ACR70 Week 52	p=0.392				
Non-carrier (N)	**39**	**35**			
ACR20 Week 52, N' n (%)	35 30.33 (77.77)	26 25.91 (74.03)	1.54 [0.44; 5.42] 0.504	1.05 [0.79; 1.39] 0.725	0.037 [-0.173; 0.248] 0.727
ACR50 Week 52, N' n (%)	35 22.30 (57.18)	26 16.79 (47.97)	1.72 [0.60; 4.91] 0.311	1.19 [0.75; 1.90] 0.454	0.092 [-0.146; 0.331] 0.449
ACR70 Week 52, N' n (%)	35 12.31 (31.56)	26 9.84 (28.11)	1.28 [0.44; 3.78] 0.649	1.13 [0.54; 2.34] 0.752	0.034 [-0.181; 0.250] 0.754
Carrier (N)	**11**	**9**			
ACR20 Week 52, N' n (%)	11 9.00 (81.82)	9 8.00 (88.89)	0.35 [0.02; 5.19] 0.442	0.92 [0.64; 1.32] 0.653	-0.071 [-0.377; 0.236] 0.651
ACR50 Week 52, N' n (%)	11 6.00 (54.55)	9 7.00 (77.78)	0.20 [0.02; 1.73] 0.144	0.70 [0.37; 1.33] 0.279	-0.232 [-0.633; 0.168] 0.255
ACR70 Week 52, N' n (%)	11 5.00 (45.45)	9 5.00 (55.56)	0.50 [0.08; 3.28] 0.468	0.82 [0.34; 1.96] 0.652	-0.101 [-0.539; 0.337] 0.651

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) ACR20, ACR50, ACR70, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

28.0 DAPSA - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 4 Returns	64 (97.0)	58 (93.5)	122 (95.3)
Week 8 Returns	64 (97.0)	58 (93.5)	122 (95.3)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	63 (95.5)	53 (85.5)	116 (90.6)
Week 20 Returns	64 (97.0)	54 (87.1)	118 (92.2)
Week 24 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 28 Returns	60 (90.9)	47 (75.8)	107 (83.6)
Week 32 Returns	62 (93.9)	49 (79.0)	111 (86.7)
Week 36 Returns	60 (90.9)	49 (79.0)	109 (85.2)
Week 40 Returns	63 (95.5)	48 (77.4)	111 (86.7)
Week 44 Returns	62 (93.9)	47 (75.8)	109 (85.2)
Week 48 Returns	59 (89.4)	45 (72.6)	104 (81.3)
Week 52 Returns	62 (93.9)	46 (74.2)	108 (84.4)

28.1 DAPSA - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	61		
Baseline Mean (SD)	38.65 (14.93)	40.32 (16.52)		
Week 52 Mean (SD)	10.02 (9.57)	11.13 (10.50)		
Week 52 Adjusted Mean Change (SE)	-28.31 (1.24)	-27.27 (1.38)	-1.04 [-4.72; 2.63]	0.576

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

28.2 DAPSA - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.401				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	38.11 (14.90)	36.41 (13.09)		
Week 52 Mean (SD)	8.05 (5.83)	7.51 (7.17)		
Week 52 Adjusted Mean Change (SE)	-30.04 (1.50)	-30.22 (1.82)	0.18 [-4.47; 4.82]	0.940
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	39.61 (15.26)	44.77 (18.99)		
Week 52 Mean (SD)	13.35 (13.30)	15.09 (12.19)		
Week 52 Adjusted Mean Change (SE)	-25.28 (1.97)	-23.95 (1.96)	-1.33 [-6.80; 4.14]	0.631

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

28.3 DAPSA - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.846				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	28.14 (10.42)	27.51 (12.17)		
Week 52 Mean (SD)	6.42 (5.71)	10.75 (8.79)		
Week 52 Adjusted Mean Change (SE)	-30.18 (2.60)	-24.18 (3.26)	-6.00 [-14.01; 2.00]	0.140
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	42.01 (14.66)	43.72 (15.93)		
Week 52 Mean (SD)	11.27 (10.35)	11.21 (10.93)		
Week 52 Adjusted Mean Change (SE)	-27.67 (1.45)	-27.93 (1.56)	0.25 [-3.92; 4.43]	0.904

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

28.4 DAPSA - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.904				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	38.48 (14.38)	42.37 (17.99)		
Week 52 Mean (SD)	10.77 (6.51)	12.70 (13.37)		
Week 52 Adjusted Mean Change (SE)	-28.24 (1.96)	-27.08 (2.01)	-1.16 [-6.73; 4.42]	0.682
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	38.78 (15.52)	38.14 (14.80)		
Week 52 Mean (SD)	9.47 (11.34)	9.69 (6.93)		
Week 52 Adjusted Mean Change (SE)	-28.33 (1.66)	-27.42 (1.98)	-0.91 [-6.03; 4.21]	0.725

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

28.5 DAPSA - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.277				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	39.34 (16.87)	37.55 (18.40)		
Week 52 Mean (SD)	9.24 (7.02)	9.22 (7.18)		
Week 52 Adjusted Mean Change (SE)	-29.72 (1.59)	-28.18 (2.08)	-1.54 [-6.72; 3.64]	0.558
> Median, N	**26**	**33**		
N'	26	32		
Baseline Mean (SD)	37.59 (11.57)	42.76 (14.53)		
Week 52 Mean (SD)	11.25 (12.69)	12.48 (12.27)		
Week 52 Adjusted Mean Change (SE)	-26.16 (1.98)	-26.44 (1.87)	0.29 [-5.12; 5.69]	0.917

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

28.6 DAPSA - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.207				
Enthesitis: No, N	34	22		
N'	34	22		
Baseline Mean (SD)	33.85 (12.80)	31.40 (11.26)		
Week 52 Mean (SD)	8.22 (6.61)	8.84 (6.91)		
Week 52 Adjusted Mean Change (SE)	-28.79 (1.80)	-28.80 (2.32)	0.00 [-5.65; 5.66]	0.999
Enthesitis: Yes, N	32	40		
N'	32	39		
Baseline Mean (SD)	43.76 (15.53)	45.23 (17.01)		
Week 52 Mean (SD)	11.81 (11.66)	12.61 (12.16)		
Week 52 Adjusted Mean Change (SE)	-27.89 (1.81)	-26.32 (1.80)	-1.56 [-6.50; 3.38]	0.533

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

28.7 DAPSA - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.280				
Non-carrier, N	29	25		
N'	29	25		
Baseline Mean (SD)	40.63 (12.50)	40.43 (16.07)		
Week 52 Mean (SD)	12.37 (12.19)	8.95 (6.75)		
Week 52 Adjusted Mean Change (SE)	-26.31 (1.99)	-29.20 (2.24)	2.89 [-3.06; 8.84]	0.337
Carrier, N	22	19		
N'	22	19		
Baseline Mean (SD)	38.09 (17.27)	38.92 (17.73)		
Week 52 Mean (SD)	9.31 (7.56)	14.05 (14.51)		
Week 52 Adjusted Mean Change (SE)	-29.68 (2.32)	-24.72 (2.58)	-4.96 [-11.84; 1.93]	0.156

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

28.8 DAPSA - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.474				
Non-carrier, N	**28**	**19**		
N'	28	19		
Baseline Mean (SD)	42.77 (17.65)	40.16 (13.24)		
Week 52 Mean (SD)	10.09 (8.41)	9.19 (5.91)		
Week 52 Adjusted Mean Change (SE)	-30.73 (2.11)	-28.76 (2.81)	-1.98 [-8.96; 5.01]	0.575
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	36.14 (8.49)	41.89 (18.13)		
Week 52 Mean (SD)	12.89 (13.05)	14.15 (14.50)		
Week 52 Adjusted Mean Change (SE)	-25.19 (2.45)	-26.63 (2.60)	1.44 [-5.71; 8.58]	0.690

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

28.9 DAPSA - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.344				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	43.55 (14.89)	38.47 (14.82)		
Week 52 Mean (SD)	12.97 (8.97)	11.22 (7.40)		
Week 52 Adjusted Mean Change (SE)	-27.65 (2.56)	-26.07 (2.65)	-1.58 [-8.93; 5.77]	0.670
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	37.43 (14.09)	40.97 (18.36)		
Week 52 Mean (SD)	10.01 (11.52)	11.32 (13.45)		
Week 52 Adjusted Mean Change (SE)	-27.73 (2.08)	-28.27 (2.38)	0.54 [-5.76; 6.84]	0.865

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

28.10 DAPSA - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.083				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	38.39 (13.72)	38.63 (17.09)		
Week 52 Mean (SD)	9.64 (9.30)	13.59 (11.97)		
Week 52 Adjusted Mean Change (SE)	-29.51 (2.17)	-25.00 (1.97)	-4.50 [-10.31; 1.31]	0.127
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	40.64 (15.67)	42.85 (15.57)		
Week 52 Mean (SD)	12.44 (11.54)	4.59 (3.21)		
Week 52 Adjusted Mean Change (SE)	-26.03 (2.12)	-33.05 (3.34)	7.02 [-0.85; 14.89]	0.080

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

28.11 DAPSA - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.150				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	38.54 (14.05)	40.80 (16.18)		
Week 52 Mean (SD)	11.52 (11.42)	10.50 (7.45)		
Week 52 Adjusted Mean Change (SE)	-26.85 (1.66)	-27.09 (1.88)	0.24 [-4.75; 5.24]	0.923
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	41.85 (17.10)	30.81 (8.75)		
Week 52 Mean (SD)	10.17 (8.07)	7.26 (5.98)		
Week 52 Adjusted Mean Change (SE)	-28.00 (2.89)	-30.44 (3.35)	2.44 [-6.40; 11.28]	0.585

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

28.12 DAPSA - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.752				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	42.25 (15.20)	37.89 (14.42)		
Week 52 Mean (SD)	11.74 (11.45)	9.36 (7.26)		
Week 52 Adjusted Mean Change (SE)	-28.31 (1.84)	-28.30 (2.00)	-0.00 [-5.43; 5.42]	0.999
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	32.16 (11.53)	46.21 (22.30)		
Week 52 Mean (SD)	10.16 (8.22)	16.09 (17.05)		
Week 52 Adjusted Mean Change (SE)	-25.09 (3.08)	-23.70 (3.47)	-1.40 [-10.77; 7.98]	0.768

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

28.13 DAPSA - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.924				
Non-carrier, N	**42**	**36**		
N'	42	36		
Baseline Mean (SD)	39.34 (14.89)	39.53 (16.62)		
Week 52 Mean (SD)	11.53 (11.21)	11.18 (11.93)		
Week 52 Adjusted Mean Change (SE)	-27.39 (1.75)	-27.48 (1.96)	0.09 [-5.14; 5.33]	0.973
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	40.44 (14.22)	44.42 (20.23)		
Week 52 Mean (SD)	9.13 (6.72)	14.41 (8.07)		
Week 52 Adjusted Mean Change (SE)	-30.03 (3.71)	-22.48 (5.38)	-7.55 [-20.54; 5.43]	0.251

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

28.14 DAPSA - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.719				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	42.91 (13.05)	36.99 (12.56)		
Week 52 Mean (SD)	12.22 (10.94)	11.09 (6.91)		
Week 52 Adjusted Mean Change (SE)	-28.02 (3.36)	-26.42 (2.60)	-1.60 [-10.07; 6.86]	0.707
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	38.61 (15.07)	42.57 (19.79)		
Week 52 Mean (SD)	10.76 (10.49)	11.42 (13.64)		
Week 52 Adjusted Mean Change (SE)	-27.67 (1.75)	-27.88 (2.37)	0.21 [-5.66; 6.09]	0.942

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

28.15 DAPSA - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.676				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	42.17 (17.13)	39.71 (14.83)		
Week 52 Mean (SD)	10.59 (8.56)	8.49 (5.91)		
Week 52 Adjusted Mean Change (SE)	-29.69 (1.94)	-28.25 (2.44)	-1.44 [-7.65; 4.77]	0.647
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	35.45 (8.48)	39.85 (18.76)		
Week 52 Mean (SD)	11.92 (13.49)	13.63 (13.85)		
Week 52 Adjusted Mean Change (SE)	-24.53 (2.49)	-26.17 (2.38)	1.64 [-5.22; 8.51]	0.635

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

28.16 DAPSA - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.404				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	43.55 (14.89)	38.32 (15.19)		
Week 52 Mean (SD)	12.97 (8.97)	11.58 (7.54)		
Week 52 Adjusted Mean Change (SE)	-27.54 (2.54)	-25.46 (2.70)	-2.08 [-9.48; 5.32]	0.577
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	37.15 (14.19)	41.00 (17.96)		
Week 52 Mean (SD)	9.78 (11.37)	11.08 (13.16)		
Week 52 Adjusted Mean Change (SE)	-27.68 (2.01)	-28.42 (2.30)	0.73 [-5.37; 6.84]	0.812

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

28.17 DAPSA - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.083				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	38.39 (13.72)	38.63 (17.09)		
Week 52 Mean (SD)	9.64 (9.30)	13.59 (11.97)		
Week 52 Adjusted Mean Change (SE)	-29.51 (2.17)	-25.00 (1.97)	-4.50 [-10.31; 1.31]	0.127
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	40.64 (15.67)	42.85 (15.57)		
Week 52 Mean (SD)	12.44 (11.54)	4.59 (3.21)		
Week 52 Adjusted Mean Change (SE)	-26.03 (2.12)	-33.05 (3.34)	7.02 [-0.85; 14.89]	0.080

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

28.18 DAPSA - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.407				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	38.82 (13.97)	40.19 (16.10)		
Week 52 Mean (SD)	11.38 (11.28)	11.13 (7.50)		
Week 52 Adjusted Mean Change (SE)	-26.80 (1.78)	-26.67 (1.97)	-0.12 [-5.40; 5.15]	0.964
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	38.63 (13.58)	38.17 (19.49)		
Week 52 Mean (SD)	9.26 (7.79)	11.71 (18.69)		
Week 52 Adjusted Mean Change (SE)	-28.73 (3.28)	-26.85 (3.61)	-1.89 [-11.56; 7.79]	0.700

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

29.1 DAPSA Low Disease Activity / Remission (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
DAPSA Low Disease Activity Week 52, N' n (%)	62 50.04 (75.82)	46 40.73 (65.69)	1.69 [0.74; 3.84] 0.213	1.15 [0.91; 1.47] 0.237	0.101 [-0.064; 0.266] 0.229
DAPSA Remission Week 52, N' n (%)	62 18.75 (28.41)	46 16.25 (26.21)	1.13 [0.50; 2.57] 0.767	1.09 [0.60; 1.96] 0.783	0.022 [-0.138; 0.182] 0.787

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.
RR and RD calculated directly without adjustment.

All results are combined over MI:
n and % are averages of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

29.2 DAPSA Low Disease Activity / Remission by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DAPSA Low Disease Activity Week 52	p=0.432				
DAPSA Remission Week 52	p=0.195				
Male (N)	**42**	**33**			
DAPSA Low Disease Activity Week 52, N' n (%)	39 33.06 (78.71)	24 25.79 (78.15)	1.09 [0.31; 3.77] 0.894	1.01 [0.78; 1.31] 0.953	0.006 [-0.198; 0.209] 0.957
DAPSA Remission Week 52, N' n (%)	39 13.14 (31.29)	24 13.29 (40.27)	0.70 [0.25; 1.93] 0.486	0.78 [0.41; 1.47] 0.439	-0.090 [-0.317; 0.137] 0.438
Female (N)	**24**	**29**			
DAPSA Low Disease Activity Week 52, N' n (%)	23 16.98 (70.75)	22 14.94 (51.52)	2.18 [0.66; 7.28] 0.203	1.38 [0.87; 2.17] 0.170	0.192 [-0.073; 0.458] 0.156
DAPSA Remission Week 52, N' n (%)	23 5.61 (23.37)	22 2.96 (10.21)	2.59 [0.47; 14.12] 0.272	2.35 [0.56; 9.88] 0.243	0.132 [-0.080; 0.344] 0.223

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

29.3 DAPSA Low Disease Activity / Remission by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DAPSA Low Disease Activity Week 52	p=0.216				
DAPSA Remission Week 52	p=0.467				
PASDAS < 5.4 (N)	**16**	**13**			
DAPSA Low Disease Activity Week 52, N' n (%)	16 14.00 (87.50)	8 7.87 (60.54)	5.01 [0.71; 35.15] 0.105	1.45 [0.88; 2.40] 0.148	0.270 [-0.054; 0.593] 0.102
DAPSA Remission Week 52, N' n (%)	16 8.00 (50.00)	8 4.76 (36.62)	1.85 [0.34; 9.99] 0.477	1.39 [0.52; 3.71] 0.505	0.134 [-0.252; 0.520] 0.497
PASDAS ≥ 5.4 (N)	**50**	**49**			
DAPSA Low Disease Activity Week 52, N' n (%)	46 36.04 (72.08)	38 32.86 (67.06)	1.29 [0.51; 3.24] 0.587	1.08 [0.82; 1.42] 0.606	0.050 [-0.141; 0.241] 0.606
DAPSA Remission Week 52, N' n (%)	46 10.75 (21.50)	38 11.49 (23.45)	0.89 [0.34; 2.38] 0.822	0.92 [0.43; 1.95] 0.821	-0.019 [-0.188; 0.149] 0.821

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

29.4 DAPSA Low Disease Activity / Remission by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DAPSA Low Disease Activity Week 52	p=0.630				
DAPSA Remission Week 52	p=0.030				
Moderate/Severe Psoriasis (Def D): No (N)	**28**	**32**			
DAPSA Low Disease Activity Week 52, N' n (%)	26 21.59 (77.11)	22 19.69 (61.53)	2.07 [0.61; 6.96] 0.242	1.25 [0.87; 1.80] 0.220	0.156 [-0.087; 0.398] 0.208
DAPSA Remission Week 52, N' n (%)	26 3.72 (13.29)	22 9.46 (29.56)	0.32 [0.08; 1.39] 0.129	0.45 [0.14; 1.43] 0.175	-0.163 [-0.378; 0.053] 0.139
Moderate/Severe Psoriasis (Def D): Yes (N)	**38**	**30**			
DAPSA Low Disease Activity Week 52, N' n (%)	36 28.45 (74.87)	24 21.04 (70.13)	1.37 [0.43; 4.33] 0.593	1.07 [0.78; 1.46] 0.680	0.047 [-0.178; 0.273] 0.681
DAPSA Remission Week 52, N' n (%)	36 15.03 (39.55)	24 6.79 (22.63)	2.53 [0.82; 7.83] 0.107	1.76 [0.79; 3.89] 0.165	0.169 [-0.051; 0.389] 0.131

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

29.5 DAPSA Low Disease Activity / Remission by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DAPSA Low Disease Activity Week 52	p=0.588				
DAPSA Remission Week 52	p=0.648				
≤ Median (N)	**40**	**29**			
DAPSA Low Disease Activity Week 52, N' n (%)	38 30.04 (75.10)	19 20.64 (71.17)	1.31 [0.40; 4.31] 0.657	1.06 [0.77; 1.45] 0.734	0.039 [-0.190; 0.268] 0.737
DAPSA Remission Week 52, N' n (%)	38 12.14 (30.35)	19 7.54 (26.00)	1.34 [0.43; 4.18] 0.615	1.17 [0.52; 2.65] 0.698	0.044 [-0.179; 0.266] 0.701
> Median (N)	**26**	**33**			
DAPSA Low Disease Activity Week 52, N' n (%)	24 20.00 (76.92)	27 20.09 (60.88)	2.08 [0.64; 6.82] 0.225	1.26 [0.89; 1.81] 0.197	0.160 [-0.078; 0.399] 0.187
DAPSA Remission Week 52, N' n (%)	24 6.61 (25.42)	27 8.71 (26.39)	0.91 [0.26; 3.10] 0.875	0.96 [0.39; 2.38] 0.937	-0.010 [-0.242; 0.223] 0.935

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

29.6 DAPSA Low Disease Activity / Remission by Enthesitis at BL According to LEI (FAS)

| | Treatment Groups | | Comparison | | |
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DAPSA Low Disease Activity Week 52	p=0.929				
DAPSA Remission Week 52	p=0.518				
Enthesitis: No (N)	**34**	**22**			
DAPSA Low Disease Activity Week 52, N' n (%)	31 28.61 (84.15)	18 17.02 (77.36)	1.56 [0.36; 6.66] 0.550	1.09 [0.82; 1.44] 0.558	0.068 [-0.156; 0.291] 0.552
DAPSA Remission Week 52, N' n (%)	31 9.72 (28.59)	18 7.17 (32.59)	0.79 [0.23; 2.77] 0.717	0.88 [0.38; 2.06] 0.770	-0.040 [-0.301; 0.221] 0.763
Enthesitis: Yes (N)	**32**	**40**			
DAPSA Low Disease Activity Week 52, N' n (%)	31 21.43 (66.97)	28 23.71 (59.28)	1.44 [0.50; 4.08] 0.498	1.13 [0.78; 1.65] 0.519	0.077 [-0.157; 0.311] 0.520
DAPSA Remission Week 52, N' n (%)	31 9.03 (28.22)	28 9.08 (22.70)	1.38 [0.45; 4.18] 0.572	1.25 [0.55; 2.83] 0.595	0.055 [-0.152; 0.262] 0.601

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

29.7 DAPSA Low Disease Activity / Remission by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DAPSA Low Disease Activity Week 52	p=0.154				
DAPSA Remission Week 52	p=0.781				
Non-carrier (N)	**29**	**25**			
DAPSA Low Disease Activity Week 52, N' n (%)	27 20.00 (68.97)	19 18.71 (74.84)	0.74 [0.21; 2.66] 0.646	0.92 [0.65; 1.30] 0.644	-0.059 [-0.305; 0.188] 0.641
DAPSA Remission Week 52, N' n (%)	27 7.61 (26.24)	19 7.79 (31.16)	0.76 [0.21; 2.71] 0.674	0.84 [0.35; 2.02] 0.703	-0.049 [-0.298; 0.200] 0.699
Carrier (N)	**22**	**19**			
DAPSA Low Disease Activity Week 52, N' n (%)	20 17.04 (77.45)	16 10.43 (54.89)	3.06 [0.71; 13.24] 0.135	1.41 [0.86; 2.31] 0.168	0.226 [-0.072; 0.523] 0.138
DAPSA Remission Week 52, N' n (%)	20 5.14 (23.36)	16 4.37 (23.00)	1.01 [0.21; 4.77] 0.989	1.02 [0.32; 3.25] 0.972	0.004 [-0.264; 0.271] 0.979

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

29.8 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction test					
DAPSA Low Disease Activity Week 52	p=0.993				
DAPSA Remission Week 52	p=0.650				
Non-carrier (N)	**28**	**19**			
DAPSA Low Disease Activity Week 52, N' n (%)	27 21.61 (77.18)	13 13.35 (70.26)	1.54 [0.37; 6.47] 0.552	1.10 [0.76; 1.60] 0.618	0.069 [-0.200; 0.339] 0.615
DAPSA Remission Week 52, N' n (%)	27 8.11 (28.96)	13 5.79 (30.47)	1.01 [0.25; 4.05] 0.990	0.96 [0.38; 2.44] 0.927	-0.015 [-0.293; 0.262] 0.915
Carrier (N)	**22**	**19**			
DAPSA Low Disease Activity Week 52, N' n (%)	19 14.43 (65.59)	17 10.62 (55.89)	1.53 [0.40; 5.85] 0.533	1.17 [0.70; 1.97] 0.544	0.097 [-0.211; 0.404] 0.537
DAPSA Remission Week 52, N' n (%)	19 3.64 (16.55)	17 4.37 (23.00)	0.61 [0.11; 3.25] 0.560	0.72 [0.19; 2.68] 0.620	-0.065 [-0.320; 0.191] 0.620

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

29.9 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DAPSA Low Disease Activity Week 52	p=0.608				
DAPSA Remission Week 52	p=0.512				
Non-carrier (N)	**19**	**21**			
DAPSA Low Disease Activity Week 52, N' n (%)	19 11.00 (57.89)	15 12.06 (57.43)	1.04 [0.28; 3.90] 0.959	1.01 [0.58; 1.75] 0.971	0.005 [-0.310; 0.319] 0.977
DAPSA Remission Week 52, N' n (%)	19 2.00 (10.53)	15 4.30 (20.48)	0.44 [0.07; 2.96] 0.400	0.52 [0.11; 2.53] 0.416	-0.099 [-0.327; 0.128] 0.391
Carrier (N)	**30**	**23**			
DAPSA Low Disease Activity Week 52, N' n (%)	27 24.61 (82.03)	20 17.08 (74.26)	1.71 [0.43; 6.87] 0.448	1.10 [0.82; 1.49] 0.518	0.078 [-0.154; 0.310] 0.511
DAPSA Remission Week 52, N' n (%)	27 9.72 (32.40)	20 7.86 (34.17)	0.94 [0.28; 3.23] 0.925	0.95 [0.43; 2.10] 0.899	-0.018 [-0.281; 0.246] 0.895

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

29.10 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DAPSA Low Disease Activity Week 52	p=0.605				
DAPSA Remission Week 52	p=0.023				
Non-carrier (N)	**25**	**32**			
DAPSA Low Disease Activity Week 52, N' n (%)	23 18.41 (73.64)	26 18.88 (59.00)	1.88 [0.56; 6.30] 0.305	1.25 [0.85; 1.84] 0.259	0.146 [-0.104; 0.397] 0.253
DAPSA Remission Week 52, N' n (%)	23 9.64 (38.56)	26 6.87 (21.47)	2.13 [0.61; 7.42] 0.235	1.80 [0.76; 4.27] 0.179	0.171 [-0.073; 0.415] 0.170
Carrier (N)	**26**	**12**			
DAPSA Low Disease Activity Week 52, N' n (%)	24 18.63 (71.65)	9 10.26 (85.50)	0.46 [0.06; 3.65] 0.460	0.84 [0.59; 1.20] 0.340	-0.138 [-0.421; 0.144] 0.336
DAPSA Remission Week 52, N' n (%)	24 3.11 (11.96)	9 5.29 (44.08)	0.18 [0.03; 1.01] 0.052	0.27 [0.08; 0.95] 0.041	-0.321 [-0.638; -0.004] 0.047

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

29.11 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction test					
DAPSA Low Disease Activity Week 52	p=0.107				
DAPSA Remission Week 52	p=0.972				
Non-carrier (N)	**38**	**33**			
DAPSA Low Disease Activity Week 52, N' n (%)	34 28.04 (73.79)	24 21.14 (64.06)	1.80 [0.59; 5.50] 0.301	1.15 [0.82; 1.61] 0.406	0.097 [-0.128; 0.323] 0.398
DAPSA Remission Week 52, N' n (%)	34 8.75 (23.03)	24 9.16 (27.76)	0.83 [0.26; 2.63] 0.754	0.83 [0.36; 1.91] 0.664	-0.047 [-0.259; 0.164] 0.661
Carrier (N)	**12**	**9**			
DAPSA Low Disease Activity Week 52, N' n (%)	12 8.00 (66.67)	9 8.00 (88.89)	0.19 [0.02; 2.23] 0.187	0.75 [0.47; 1.19] 0.222	-0.222 [-0.559; 0.114] 0.196
DAPSA Remission Week 52, N' n (%)	12 4.00 (33.33)	9 3.00 (33.33)	0.80 [0.12; 5.41] 0.819	1.00 [0.29; 3.39] 1.000	0.000 [-0.407; 0.407] 1.000

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) DAPSA Low Disease Activity, DAPSA Remission, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

29.12 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DAPSA Low Disease Activity Week 52	p=0.282				
DAPSA Remission Week 52	p=0.235				
Non-carrier (N)	**36**	**34**			
DAPSA Low Disease Activity Week 52, N' n (%)	33 25.02 (69.50)	25 23.14 (68.06)	1.00 [0.34; 2.95] 0.995	1.02 [0.73; 1.42] 0.900	0.014 [-0.213; 0.242] 0.901
DAPSA Remission Week 52, N' n (%)	33 7.75 (21.53)	25 10.16 (29.88)	0.57 [0.18; 1.83] 0.344	0.72 [0.31; 1.67] 0.446	-0.084 [-0.296; 0.129] 0.440
Carrier (N)	**13**	**10**			
DAPSA Low Disease Activity Week 52, N' n (%)	12 10.02 (77.08)	10 6.00 (60.00)	3.45 [0.48; 24.64] 0.218	1.28 [0.71; 2.31] 0.403	0.171 [-0.210; 0.551] 0.379
DAPSA Remission Week 52, N' n (%)	12 4.00 (30.77)	10 2.00 (20.00)	2.38 [0.31; 18.46] 0.406	1.54 [0.35; 6.78] 0.569	0.108 [-0.245; 0.460] 0.550

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) DAPSA Remission, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

29.13 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DAPSA Low Disease Activity Week 52	p=0.393				
DAPSA Remission Week 52	N.E.				
Non-carrier (N)	**42**	**36**			
DAPSA Low Disease Activity Week 52, N' n (%)	38 30.04 (71.52)	29 24.00 (66.67)	1.34 [0.48; 3.79] 0.576	1.07 [0.79; 1.47] 0.657	0.049 [-0.165; 0.262] 0.656
DAPSA Remission Week 52, N' n (%)	38 9.75 (23.21)	29 11.87 (32.97)	0.62 [0.22; 1.78] 0.373	0.70 [0.34; 1.48] 0.354	-0.098 [-0.303; 0.108] 0.351
Carrier (N)	**9**	**5**			
DAPSA Low Disease Activity Week 52, N' n (%)	9 7.00 (77.78)	3 2.14 (42.80)	4.36 [0.36; 52.56] 0.247	1.85 [0.58; 5.88] 0.299	0.350 [-0.181; 0.881] 0.197
DAPSA Remission Week 52, N' n (%)	9 3.00 (33.33)	3 0.29 (5.80)	N.E.	3.21 [0.21; 48.21] 0.398	0.275 [-0.128; 0.679] 0.181

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

29.14 DAPSA Low Disease Activity / Remission by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DAPSA Low Disease Activity Week 52	p=0.816				
DAPSA Remission Week 52	p=0.989				
Low score (N)	**11**	**22**			
DAPSA Low Disease Activity Week 52, N' n (%)	10 7.43 (67.55)	15 14.00 (63.64)	1.14 [0.22; 5.99] 0.880	1.06 [0.61; 1.84] 0.834	0.039 [-0.323; 0.401] 0.832
DAPSA Remission Week 52, N' n (%)	10 2.03 (18.45)	15 4.87 (22.14)	0.77 [0.11; 5.23] 0.786	0.84 [0.19; 3.81] 0.822	-0.037 [-0.333; 0.259] 0.807
High score (N)	**40**	**22**			
DAPSA Low Disease Activity Week 52, N' n (%)	37 29.61 (74.03)	20 15.14 (68.82)	1.45 [0.43; 4.83] 0.546	1.08 [0.76; 1.52] 0.676	0.052 [-0.189; 0.293] 0.672
DAPSA Remission Week 52, N' n (%)	37 10.72 (26.80)	20 7.29 (33.14)	0.78 [0.24; 2.56] 0.681	0.81 [0.36; 1.80] 0.605	-0.063 [-0.308; 0.181] 0.612

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

29.15 DAPSA Low Disease Activity / Remission by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DAPSA Low Disease Activity Week 52	p=0.762				
DAPSA Remission Week 52	p=0.828				
Non-carrier (N)	**31**	**23**			
DAPSA Low Disease Activity Week 52, N' n (%)	30 22.61 (72.94)	16 16.52 (71.83)	1.18 [0.32; 4.38] 0.806	1.02 [0.72; 1.44] 0.927	0.011 [-0.241; 0.264] 0.931
DAPSA Remission Week 52, N' n (%)	30 9.11 (29.39)	16 7.79 (33.87)	0.89 [0.26; 3.13] 0.860	0.87 [0.38; 1.97] 0.740	-0.045 [-0.304; 0.215] 0.735
Carrier (N)	**20**	**21**			
DAPSA Low Disease Activity Week 52, N' n (%)	17 14.43 (72.15)	19 12.62 (60.10)	1.58 [0.40; 6.30] 0.514	1.20 [0.76; 1.90] 0.433	0.121 [-0.176; 0.417] 0.425
DAPSA Remission Week 52, N' n (%)	17 3.64 (18.20)	19 4.37 (20.81)	0.71 [0.13; 3.77] 0.686	0.87 [0.23; 3.26] 0.838	-0.026 [-0.279; 0.227] 0.840

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

29.16 DAPSA Low Disease Activity / Remission by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DAPSA Low Disease Activity Week 52	p=0.780				
DAPSA Remission Week 52	p=0.439				
Non-carrier (N)	**19**	**20**			
DAPSA Low Disease Activity Week 52, N' n (%)	19 11.00 (57.89)	14 11.06 (55.30)	1.14 [0.30; 4.35] 0.846	1.05 [0.59; 1.85] 0.868	0.026 [-0.294; 0.346] 0.874
DAPSA Remission Week 52, N' n (%)	19 2.00 (10.53)	14 4.30 (21.50)	0.42 [0.06; 2.83] 0.375	0.49 [0.10; 2.40] 0.382	-0.110 [-0.343; 0.124] 0.357
Carrier (N)	**32**	**24**			
DAPSA Low Disease Activity Week 52, N' n (%)	28 26.04 (81.38)	21 18.08 (75.33)	1.50 [0.38; 5.91] 0.563	1.08 [0.80; 1.45] 0.608	0.060 [-0.167; 0.288] 0.603
DAPSA Remission Week 52, N' n (%)	28 10.75 (33.59)	21 7.86 (32.75)	1.03 [0.31; 3.40] 0.968	1.03 [0.47; 2.24] 0.945	0.008 [-0.248; 0.265] 0.949

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

29.17 DAPSA Low Disease Activity / Remission by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DAPSA Low Disease Activity Week 52	p=0.605				
DAPSA Remission Week 52	p=0.023				
Non-carrier (N)	**25**	**32**			
DAPSA Low Disease Activity Week 52, N' n (%)	23 18.41 (73.64)	26 18.88 (59.00)	1.88 [0.56; 6.30] 0.305	1.25 [0.85; 1.84] 0.259	0.146 [-0.104; 0.397] 0.253
DAPSA Remission Week 52, N' n (%)	23 9.64 (38.56)	26 6.87 (21.47)	2.13 [0.61; 7.42] 0.235	1.80 [0.76; 4.27] 0.179	0.171 [-0.073; 0.415] 0.170
Carrier (N)	**26**	**12**			
DAPSA Low Disease Activity Week 52, N' n (%)	24 18.63 (71.65)	9 10.26 (85.50)	0.46 [0.06; 3.65] 0.460	0.84 [0.59; 1.20] 0.340	-0.138 [-0.421; 0.144] 0.336
DAPSA Remission Week 52, N' n (%)	24 3.11 (11.96)	9 5.29 (44.08)	0.18 [0.03; 1.01] 0.052	0.27 [0.08; 0.95] 0.041	-0.321 [-0.638; -0.004] 0.047

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

29.18 DAPSA Low Disease Activity / Remission by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DAPSA Low Disease Activity Week 52	p=0.124				
DAPSA Remission Week 52	p=0.942				
Non-carrier (N)	**39**	**35**			
DAPSA Low Disease Activity Week 52, N' n (%)	35 29.04 (74.46)	26 21.14 (60.40)	2.23 [0.74; 6.67] 0.152	1.23 [0.88; 1.73] 0.228	0.141 [-0.081; 0.362] 0.214
DAPSA Remission Week 52, N' n (%)	35 8.75 (22.44)	26 9.16 (26.17)	0.86 [0.28; 2.71] 0.801	0.86 [0.37; 1.99] 0.723	-0.037 [-0.241; 0.166] 0.719
Carrier (N)	**11**	**9**			
DAPSA Low Disease Activity Week 52, N' n (%)	11 8.00 (72.73)	9 8.00 (88.89)	0.25 [0.02; 3.14] 0.282	0.82 [0.53; 1.26] 0.360	-0.162 [-0.495; 0.172] 0.343
DAPSA Remission Week 52, N' n (%)	11 4.00 (36.36)	9 3.00 (33.33)	0.94 [0.13; 6.55] 0.949	1.09 [0.33; 3.66] 0.888	0.030 [-0.389; 0.449] 0.887

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) DAPSA Low Disease Activity, DAPSA Remission, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

30.0 DAS28 - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	65 (98.5)	61 (98.4)	126 (98.4)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 20 Returns	64 (97.0)	54 (87.1)	118 (92.2)
Week 24 Returns	64 (97.0)	55 (88.7)	119 (93.0)
Week 28 Returns	60 (90.9)	47 (75.8)	107 (83.6)
Week 32 Returns	62 (93.9)	49 (79.0)	111 (86.7)
Week 36 Returns	60 (90.9)	50 (80.6)	110 (85.9)
Week 40 Returns	63 (95.5)	48 (77.4)	111 (86.7)
Week 44 Returns	62 (93.9)	47 (75.8)	109 (85.2)
Week 48 Returns	60 (90.9)	46 (74.2)	106 (82.8)
Week 52 Returns	62 (93.9)	46 (74.2)	108 (84.4)

30.1 DAS28 - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N'	66	61		
Baseline Mean (SD)	4.73 (0.93)	4.70 (1.05)		
Week 52 Mean (SD)	2.47 (1.03)	2.59 (1.02)		
Week 52 Adjusted Mean Change (SE)	-2.22 (0.11)	-2.07 (0.13)	-0.16 [-0.49; 0.18]	0.358

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

30.2 DAS28 - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.086				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	4.65 (0.92)	4.50 (0.97)		
Week 52 Mean (SD)	2.22 (0.74)	2.04 (0.71)		
Week 52 Adjusted Mean Change (SE)	-2.43 (0.13)	-2.53 (0.16)	0.11 [-0.30; 0.51]	0.596
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	4.88 (0.96)	4.93 (1.10)		
Week 52 Mean (SD)	2.89 (1.32)	3.18 (0.98)		
Week 52 Adjusted Mean Change (SE)	-1.86 (0.17)	-1.55 (0.17)	-0.31 [-0.79; 0.16]	0.191

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

30.3 DAS28 - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.290				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	4.05 (0.52)	3.56 (1.10)		
Week 52 Mean (SD)	1.96 (0.68)	2.60 (1.07)		
Week 52 Adjusted Mean Change (SE)	-2.42 (0.23)	-1.52 (0.31)	-0.90 [-1.63; -0.18]	0.015
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	4.95 (0.93)	5.00 (0.80)		
Week 52 Mean (SD)	2.65 (1.08)	2.58 (1.02)		
Week 52 Adjusted Mean Change (SE)	-2.16 (0.13)	-2.20 (0.14)	0.04 [-0.33; 0.42]	0.832

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

30.4 DAS28 - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.776				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	4.58 (0.85)	4.72 (1.04)		
Week 52 Mean (SD)	2.55 (0.89)	2.80 (1.14)		
Week 52 Adjusted Mean Change (SE)	-2.11 (0.18)	-1.94 (0.18)	-0.16 [-0.67; 0.34]	0.522
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	4.85 (0.98)	4.67 (1.07)		
Week 52 Mean (SD)	2.41 (1.14)	2.39 (0.88)		
Week 52 Adjusted Mean Change (SE)	-2.30 (0.15)	-2.20 (0.18)	-0.10 [-0.57; 0.36]	0.659

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

30.5 DAS28 - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.166				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	4.73 (0.99)	4.38 (1.27)		
Week 52 Mean (SD)	2.40 (0.97)	2.41 (0.87)		
Week 52 Adjusted Mean Change (SE)	-2.31 (0.15)	-2.00 (0.19)	-0.30 [-0.78; 0.18]	0.214
> Median, N	**26**	**33**		
N'	26	32		
Baseline Mean (SD)	4.74 (0.85)	4.98 (0.70)		
Week 52 Mean (SD)	2.57 (1.14)	2.71 (1.11)		
Week 52 Adjusted Mean Change (SE)	-2.10 (0.18)	-2.11 (0.17)	0.01 [-0.49; 0.50]	0.975

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

30.6 DAS28 - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.659				
Enthesitis: No, N	**34**	**22**		
N'	34	22		
Baseline Mean (SD)	4.40 (0.85)	4.12 (1.08)		
Week 52 Mean (SD)	2.31 (0.90)	2.40 (0.90)		
Week 52 Adjusted Mean Change (SE)	-2.20 (0.16)	-2.10 (0.21)	-0.10 [-0.62; 0.42]	0.698
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	5.09 (0.89)	5.02 (0.89)		
Week 52 Mean (SD)	2.63 (1.15)	2.71 (1.09)		
Week 52 Adjusted Mean Change (SE)	-2.24 (0.17)	-2.04 (0.16)	-0.20 [-0.65; 0.26]	0.389

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

30.7 DAS28 - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.622				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	4.86 (0.90)	4.74 (0.81)		
Week 52 Mean (SD)	2.65 (1.20)	2.55 (0.86)		
Week 52 Adjusted Mean Change (SE)	-2.10 (0.18)	-2.20 (0.20)	0.10 [-0.43; 0.64]	0.699
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	4.71 (1.01)	4.47 (1.19)		
Week 52 Mean (SD)	2.59 (1.00)	2.68 (1.24)		
Week 52 Adjusted Mean Change (SE)	-2.09 (0.21)	-1.84 (0.23)	-0.25 [-0.86; 0.36]	0.418

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

30.8 DAS28 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.315				
Non-carrier, N	**28**	**19**		
N'	28	19		
Baseline Mean (SD)	4.90 (0.99)	4.75 (0.72)		
Week 52 Mean (SD)	2.51 (0.92)	2.45 (0.78)		
Week 52 Adjusted Mean Change (SE)	-2.33 (0.18)	-2.22 (0.25)	-0.11 [-0.72; 0.50]	0.724
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	4.69 (0.89)	4.66 (0.99)		
Week 52 Mean (SD)	2.85 (1.33)	2.81 (1.22)		
Week 52 Adjusted Mean Change (SE)	-1.81 (0.21)	-1.97 (0.23)	0.16 [-0.45; 0.77]	0.604

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

30.9 DAS28 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.092				
Non-carrier, N	**19**	**21**		
N'	19	21		
Baseline Mean (SD)	4.86 (1.13)	4.62 (1.05)		
Week 52 Mean (SD)	2.84 (1.01)	2.58 (0.92)		
Week 52 Adjusted Mean Change (SE)	-1.97 (0.22)	-2.04 (0.23)	0.07 [-0.57; 0.70]	0.830
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	4.75 (0.80)	4.63 (0.96)		
Week 52 Mean (SD)	2.52 (1.17)	2.64 (1.14)		
Week 52 Adjusted Mean Change (SE)	-2.14 (0.18)	-2.07 (0.21)	-0.07 [-0.61; 0.48]	0.808

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

30.9 DAS28 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

30.10 DAS28 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.117				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	4.62 (1.06)	4.60 (1.03)		
Week 52 Mean (SD)	2.36 (1.00)	2.82 (1.07)		
Week 52 Adjusted Mean Change (SE)	-2.29 (0.19)	-1.88 (0.17)	-0.41 [-0.92; 0.10]	0.113
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	4.96 (0.80)	4.69 (0.92)		
Week 52 Mean (SD)	2.87 (1.17)	2.01 (0.68)		
Week 52 Adjusted Mean Change (SE)	-1.91 (0.19)	-2.53 (0.29)	0.63 [-0.06; 1.31]	0.073

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

30.11 DAS28 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.591				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	4.72 (0.90)	4.63 (0.99)		
Week 52 Mean (SD)	2.64 (1.15)	2.57 (0.92)		
Week 52 Adjusted Mean Change (SE)	-2.05 (0.16)	-2.09 (0.18)	0.05 [-0.42; 0.52]	0.841
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	5.00 (1.10)	4.38 (0.89)		
Week 52 Mean (SD)	2.57 (1.09)	2.43 (0.96)		
Week 52 Adjusted Mean Change (SE)	-2.17 (0.28)	-2.11 (0.32)	-0.06 [-0.90; 0.78]	0.892

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

30.12 DAS28 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.670				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	4.95 (0.94)	4.52 (1.00)		
Week 52 Mean (SD)	2.66 (1.15)	2.41 (0.94)		
Week 52 Adjusted Mean Change (SE)	-2.16 (0.16)	-2.19 (0.18)	0.03 [-0.45; 0.51]	0.916
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	4.40 (0.59)	4.96 (0.92)		
Week 52 Mean (SD)	2.54 (1.10)	3.12 (1.14)		
Week 52 Adjusted Mean Change (SE)	-1.89 (0.27)	-1.62 (0.30)	-0.28 [-1.08; 0.53]	0.499

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

30.13 DAS28 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.851				
Non-carrier, N	42	36		
N'	42	36		
Baseline Mean (SD)	4.83 (0.89)	4.60 (0.97)		
Week 52 Mean (SD)	2.67 (1.16)	2.63 (1.06)		
Week 52 Adjusted Mean Change (SE)	-2.08 (0.15)	-2.02 (0.17)	-0.07 [-0.52; 0.38]	0.768
Carrier, N	9	5		
N'	9	5		
Baseline Mean (SD)	4.59 (1.20)	4.81 (1.21)		
Week 52 Mean (SD)	2.44 (0.89)	2.67 (1.06)		
Week 52 Adjusted Mean Change (SE)	-2.17 (0.32)	-2.18 (0.47)	0.00 [-1.12; 1.13]	0.995

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

30.14 DAS28 - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.824				
Low score, N	**11**	**22**		
N'	11	22		
Baseline Mean (SD)	4.94 (1.00)	4.52 (1.00)		
Week 52 Mean (SD)	2.64 (1.21)	2.51 (0.87)		
Week 52 Adjusted Mean Change (SE)	-2.14 (0.29)	-2.11 (0.23)	-0.03 [-0.77; 0.70]	0.926
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	4.75 (0.93)	4.73 (0.99)		
Week 52 Mean (SD)	2.62 (1.10)	2.69 (1.16)		
Week 52 Adjusted Mean Change (SE)	-2.08 (0.15)	-2.02 (0.21)	-0.06 [-0.57; 0.45]	0.818

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

30.15 DAS28 - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.409				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	4.89 (0.97)	4.72 (0.79)		
Week 52 Mean (SD)	2.56 (0.97)	2.42 (0.75)		
Week 52 Adjusted Mean Change (SE)	-2.26 (0.17)	-2.18 (0.21)	-0.08 [-0.62; 0.46]	0.771
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	4.64 (0.90)	4.52 (1.18)		
Week 52 Mean (SD)	2.72 (1.35)	2.78 (1.22)		
Week 52 Adjusted Mean Change (SE)	-1.83 (0.22)	-1.92 (0.21)	0.09 [-0.51; 0.69]	0.766

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

30.16 DAS28 - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.126				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	4.86 (1.13)	4.59 (1.07)		
Week 52 Mean (SD)	2.84 (1.01)	2.66 (0.91)		
Week 52 Adjusted Mean Change (SE)	-1.97 (0.22)	-1.94 (0.24)	-0.03 [-0.68; 0.61]	0.917
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	4.75 (0.83)	4.65 (0.95)		
Week 52 Mean (SD)	2.48 (1.17)	2.58 (1.14)		
Week 52 Adjusted Mean Change (SE)	-2.15 (0.17)	-2.14 (0.20)	-0.01 [-0.54; 0.52]	0.966

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

30.17 DAS28 - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.117				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	4.62 (1.06)	4.60 (1.03)		
Week 52 Mean (SD)	2.36 (1.00)	2.82 (1.07)		
Week 52 Adjusted Mean Change (SE)	-2.29 (0.19)	-1.88 (0.17)	-0.41 [-0.92; 0.10]	0.113
Carrier, N	**26**	**12**		
N'	26	12		
Baseline Mean (SD)	4.96 (0.80)	4.69 (0.92)		
Week 52 Mean (SD)	2.87 (1.17)	2.01 (0.68)		
Week 52 Adjusted Mean Change (SE)	-1.91 (0.19)	-2.53 (0.29)	0.63 [-0.06; 1.31]	0.073

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

30.18 DAS28 - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.368				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	4.73 (0.90)	4.62 (0.96)		
Week 52 Mean (SD)	2.64 (1.13)	2.62 (0.94)		
Week 52 Adjusted Mean Change (SE)	-2.03 (0.16)	-2.05 (0.17)	0.01 [-0.45; 0.48]	0.954
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	4.83 (0.98)	4.63 (1.15)		
Week 52 Mean (SD)	2.54 (1.14)	2.59 (1.34)		
Week 52 Adjusted Mean Change (SE)	-2.13 (0.29)	-2.05 (0.32)	-0.09 [-0.94; 0.77]	0.843

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

31.1 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
EULAR Low Disease Activity Week 52, N' n (%)	62 55.28 (83.76)	46 44.26 (71.39)	2.21 [0.88; 5.56] 0.091	1.17 [0.96; 1.43] 0.116	0.124 [-0.026; 0.274] 0.106
EULAR Remission Week 52, N' n (%)	62 38.72 (58.67)	46 33.24 (53.61)	1.25 [0.60; 2.60] 0.555	1.09 [0.80; 1.51] 0.578	0.051 [-0.127; 0.228] 0.577
EULAR Moderate-to-Good Response Week 52, N' n (%)	62 62.56 (94.79)	46 53.90 (86.94)	2.90 [0.67; 12.46] 0.153	1.09 [0.96; 1.23] 0.171	0.079 [-0.031; 0.188] 0.161

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.
RR and RD calculated directly without adjustment.

All results are combined over MI:
n and % are averages of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

31.2 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
EULAR Low Disease Activity Week 52	p=0.252				
EULAR Remission Week 52	p=0.380				
EULAR Moderate-to-Good Response Week 52	N.E.				
Male (N)	**42**	**33**			
EULAR Low Disease Activity Week 52, N' n (%)	39 36.28 (86.38)	24 28.81 (87.30)	1.00 [0.21; 4.80] 0.998	0.99 [0.82; 1.20] 0.918	-0.009 [-0.176; 0.157] 0.913
EULAR Remission Week 52, N' n (%)	39 28.75 (68.45)	24 24.66 (74.73)	0.76 [0.25; 2.31] 0.629	0.92 [0.68; 1.24] 0.568	-0.063 [-0.277; 0.151] 0.566
EULAR Moderate-to-Good Response Week 52, N' n (%)	39 41.56 (98.95)	24 31.10 (94.24)	N.E.	1.05 [0.94; 1.18] 0.397	0.047 [-0.060; 0.154] 0.387
Female (N)	**24**	**29**			
EULAR Low Disease Activity Week 52, N' n (%)	23 19.00 (79.17)	22 15.45 (53.28)	3.33 [0.89; 12.50] 0.074	1.49 [0.98; 2.26] 0.061	0.259 [0.008; 0.510] 0.043
EULAR Remission Week 52, N' n (%)	23 9.97 (41.54)	22 8.58 (29.59)	1.59 [0.47; 5.30] 0.454	1.41 [0.66; 3.02] 0.376	0.120 [-0.144; 0.383] 0.374
EULAR Moderate-to-Good Response Week 52, N' n (%)	23 21.00 (87.50)	22 22.80 (78.62)	1.78 [0.35; 8.95] 0.485	1.11 [0.86; 1.44] 0.408	0.089 [-0.119; 0.297] 0.403

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

31.3 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
EULAR Low Disease Activity Week 52	p=0.292				
EULAR Remission Week 52	p=0.500				
EULAR Moderate-to-Good Response Week 52	N.E.				
PASDAS < 5.4 (N)	**16**	**13**			
EULAR Low Disease Activity Week 52, N' n (%)	16 15.00 (93.75)	8 9.24 (71.08)	7.52 [0.60; 94.81] 0.119	1.32 [0.89; 1.95] 0.162	0.227 [-0.059; 0.513] 0.120
EULAR Remission Week 52, N' n (%)	16 12.00 (75.00)	8 7.86 (60.46)	2.05 [0.39; 10.92] 0.399	1.24 [0.72; 2.15] 0.433	0.145 [-0.205; 0.496] 0.416
EULAR Moderate-to-Good Response Week 52, N' n (%)	16 16.00 (100.00)	8 9.59 (73.77)	N.E.	1.36 [0.96; 1.92] 0.085	0.262 [0.009; 0.515] 0.042
PASDAS ≥ 5.4 (N)	**50**	**49**			
EULAR Low Disease Activity Week 52, N' n (%)	46 40.28 (80.56)	38 35.02 (71.47)	1.74 [0.63; 4.78] 0.282	1.13 [0.89; 1.43] 0.317	0.091 [-0.085; 0.266] 0.310
EULAR Remission Week 52, N' n (%)	46 26.72 (53.44)	38 25.38 (51.80)	1.08 [0.47; 2.48] 0.862	1.03 [0.70; 1.52] 0.873	0.016 [-0.188; 0.221] 0.875
EULAR Moderate-to-Good Response Week 52, N' n (%)	46 46.56 (93.12)	38 44.31 (90.43)	1.63 [0.29; 9.15] 0.577	1.03 [0.90; 1.18] 0.661	0.027 [-0.094; 0.147] 0.662

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

31.4 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
EULAR Low Disease Activity Week 52	p=0.572				
EULAR Remission Week 52	p=0.521				
EULAR Moderate-to-Good Response Week 52	p=0.656				
Moderate/Severe Psoriasis (Def D): No (N)	**28**	**32**			
EULAR Low Disease Activity Week 52, N' n (%)	26 23.81 (85.04)	22 21.32 (66.63)	2.89 [0.73; 11.51] 0.132	1.28 [0.94; 1.74] 0.121	0.184 [-0.038; 0.406] 0.104
EULAR Remission Week 52, N' n (%)	26 15.50 (55.36)	22 14.04 (43.88)	1.54 [0.52; 4.55] 0.439	1.26 [0.74; 2.17] 0.396	0.115 [-0.149; 0.379] 0.393
EULAR Moderate-to-Good Response Week 52, N' n (%)	26 27.00 (96.43)	22 27.52 (86.00)	4.40 [0.42; 46.47] 0.218	1.12 [0.94; 1.34] 0.199	0.104 [-0.049; 0.257] 0.182
Moderate/Severe Psoriasis (Def D): Yes (N)	**38**	**30**			
EULAR Low Disease Activity Week 52, N' n (%)	36 31.47 (82.82)	24 22.94 (76.47)	1.68 [0.47; 6.00] 0.421	1.08 [0.84; 1.40] 0.539	0.063 [-0.137; 0.264] 0.535
EULAR Remission Week 52, N' n (%)	36 23.22 (61.11)	24 19.20 (64.00)	0.94 [0.33; 2.64] 0.902	0.96 [0.65; 1.40] 0.815	-0.029 [-0.267; 0.209] 0.812
EULAR Moderate-to-Good Response Week 52, N' n (%)	36 35.56 (93.58)	24 26.38 (87.93)	2.24 [0.34; 14.63] 0.400	1.06 [0.90; 1.26] 0.472	0.056 [-0.095; 0.208] 0.465

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

31.5 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
EULAR Low Disease Activity Week 52	p=0.284				
EULAR Remission Week 52	p=0.772				
EULAR Moderate-to-Good Response Week 52	p=0.442				
≤ Median (N)	**40**	**29**			
EULAR Low Disease Activity Week 52, N' n (%)	38 32.23 (80.58)	19 22.43 (77.34)	1.36 [0.37; 4.94] 0.644	1.04 [0.80; 1.36] 0.758	0.032 [-0.174; 0.239] 0.759
EULAR Remission Week 52, N' n (%)	38 23.74 (59.35)	19 15.37 (53.00)	1.38 [0.50; 3.86] 0.536	1.12 [0.72; 1.75] 0.616	0.064 [-0.183; 0.310] 0.614
EULAR Moderate-to-Good Response Week 52, N' n (%)	38 38.97 (97.43)	19 25.78 (88.90)	5.40 [0.45; 65.03] 0.184	1.10 [0.94; 1.28] 0.252	0.085 [-0.055; 0.226] 0.234
> Median (N)	**26**	**33**			
EULAR Low Disease Activity Week 52, N' n (%)	24 23.05 (88.65)	27 21.83 (66.15)	3.96 [0.91; 17.25] 0.067	1.34 [1.00; 1.80] 0.050	0.225 [0.015; 0.435] 0.036
EULAR Remission Week 52, N' n (%)	24 14.98 (57.62)	27 17.87 (54.15)	1.11 [0.38; 3.25] 0.851	1.07 [0.67; 1.70] 0.791	0.035 [-0.227; 0.296] 0.795
EULAR Moderate-to-Good Response Week 52, N' n (%)	24 23.59 (90.73)	27 28.12 (85.21)	1.65 [0.28; 9.84] 0.585	1.06 [0.87; 1.30] 0.542	0.055 [-0.121; 0.231] 0.539

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

31.6 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
EULAR Low Disease Activity Week 52	p=0.610				
EULAR Remission Week 52	p=0.272				
EULAR Moderate-to-Good Response Week 52	p=0.362				
Enthesitis: No (N)	**34**	**22**			
EULAR Low Disease Activity Week 52, N' n (%)	31 29.86 (87.82)	18 18.56 (84.36)	1.37 [0.26; 7.33] 0.712	1.04 [0.83; 1.31] 0.730	0.035 [-0.161; 0.231] 0.729
EULAR Remission Week 52, N' n (%)	31 20.51 (60.32)	18 15.03 (68.32)	0.68 [0.20; 2.26] 0.526	0.88 [0.59; 1.33] 0.554	-0.080 [-0.344; 0.184] 0.553
EULAR Moderate-to-Good Response Week 52, N' n (%)	31 32.59 (95.85)	18 17.78 (80.82)	6.11 [0.64; 58.28] 0.116	1.19 [0.95; 1.48] 0.133	0.150 [-0.033; 0.334] 0.108
Enthesitis: Yes (N)	**32**	**40**			
EULAR Low Disease Activity Week 52, N' n (%)	31 25.42 (79.44)	28 25.70 (64.25)	2.33 [0.72; 7.54] 0.156	1.24 [0.91; 1.68] 0.173	0.152 [-0.061; 0.365] 0.163
EULAR Remission Week 52, N' n (%)	31 18.21 (56.91)	28 18.21 (45.53)	1.63 [0.61; 4.36] 0.333	1.25 [0.78; 2.01] 0.351	0.114 [-0.124; 0.352] 0.349
EULAR Moderate-to-Good Response Week 52, N' n (%)	31 29.97 (93.66)	28 36.12 (90.30)	1.56 [0.22; 11.14] 0.660	1.04 [0.89; 1.21] 0.635	0.034 [-0.106; 0.173] 0.636

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

31.7 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
EULAR Low Disease Activity Week 52	p=0.576				
EULAR Remission Week 52	p=0.851				
EULAR Moderate-to-Good Response Week 52	p=0.168				
Non-carrier (N)	**29**	**25**			
EULAR Low Disease Activity Week 52, N' n (%)	27 22.05 (76.03)	19 18.68 (74.72)	1.10 [0.29; 4.20] 0.892	1.02 [0.74; 1.40] 0.911	0.013 [-0.224; 0.250] 0.913
EULAR Remission Week 52, N' n (%)	27 14.98 (51.66)	19 13.98 (55.92)	0.84 [0.28; 2.55] 0.760	0.92 [0.56; 1.53] 0.761	-0.043 [-0.314; 0.229] 0.758
EULAR Moderate-to-Good Response Week 52, N' n (%)	27 26.59 (91.69)	19 23.57 (94.28)	0.70 [0.06; 8.80] 0.779	0.97 [0.83; 1.14] 0.735	-0.026 [-0.174; 0.123] 0.732
Carrier (N)	**22**	**19**			
EULAR Low Disease Activity Week 52, N' n (%)	20 18.23 (82.86)	16 13.84 (72.84)	2.02 [0.38; 10.71] 0.410	1.14 [0.80; 1.63] 0.476	0.100 [-0.169; 0.370] 0.466
EULAR Remission Week 52, N' n (%)	20 10.74 (48.82)	16 9.37 (49.32)	0.99 [0.27; 3.66] 0.990	0.99 [0.51; 1.92] 0.978	-0.005 [-0.327; 0.317] 0.976
EULAR Moderate-to-Good Response Week 52, N' n (%)	20 20.97 (95.32)	16 14.48 (76.21)	7.70 [0.71; 83.21] 0.093	1.25 [0.94; 1.66] 0.118	0.191 [-0.029; 0.411] 0.089

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

31.8 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
EULAR Low Disease Activity Week 52	p=0.781				
EULAR Remission Week 52	p=0.887				
EULAR Moderate-to-Good Response Week 52	p=0.785				
Non-carrier (N)	**28**	**19**			
EULAR Low Disease Activity Week 52, N' n (%)	27 23.81 (85.04)	13 16.21 (85.32)	1.02 [0.14; 7.48] 0.982	1.00 [0.76; 1.31] 0.989	-0.003 [-0.230; 0.224] 0.981
EULAR Remission Week 52, N' n (%)	27 14.53 (51.89)	13 10.46 (55.05)	0.91 [0.26; 3.16] 0.881	0.94 [0.53; 1.67] 0.845	-0.032 [-0.336; 0.273] 0.839
EULAR Moderate-to-Good Response Week 52, N' n (%)	27 27.00 (96.43)	13 17.21 (90.58)	2.90 [0.17; 49.40] 0.461	1.07 [0.88; 1.28] 0.503	0.058 [-0.109; 0.226] 0.493
Carrier (N)	**22**	**19**			
EULAR Low Disease Activity Week 52, N' n (%)	19 15.47 (70.32)	17 11.95 (62.89)	1.44 [0.36; 5.86] 0.607	1.12 [0.72; 1.75] 0.625	0.074 [-0.219; 0.368] 0.620
EULAR Remission Week 52, N' n (%)	19 10.19 (46.32)	17 9.82 (51.68)	0.80 [0.23; 2.83] 0.728	0.90 [0.47; 1.70] 0.736	-0.054 [-0.365; 0.258] 0.736
EULAR Moderate-to-Good Response Week 52, N' n (%)	19 19.56 (88.91)	17 15.85 (83.42)	1.80 [0.24; 13.38] 0.564	1.07 [0.82; 1.38] 0.632	0.055 [-0.167; 0.276] 0.627

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

31.9 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
EULAR Low Disease Activity Week 52	p=0.634				
EULAR Remission Week 52	p=0.126				
EULAR Moderate-to-Good Response Week 52	p=0.411				
Non-carrier (N)	**19**	**21**			
EULAR Low Disease Activity Week 52, N' n (%)	19 14.00 (73.68)	15 15.20 (72.38)	1.10 [0.23; 5.20] 0.904	1.02 [0.69; 1.52] 0.923	0.013 [-0.275; 0.301] 0.929
EULAR Remission Week 52, N' n (%)	19 6.00 (31.58)	15 11.35 (54.05)	0.39 [0.10; 1.49] 0.169	0.59 [0.27; 1.28] 0.182	-0.225 [-0.533; 0.083] 0.153
EULAR Moderate-to-Good Response Week 52, N' n (%)	19 18.00 (94.74)	15 17.07 (81.29)	4.83 [0.41; 57.43] 0.213	1.17 [0.91; 1.50] 0.230	0.135 [-0.075; 0.344] 0.207
Carrier (N)	**30**	**23**			
EULAR Low Disease Activity Week 52, N' n (%)	27 24.86 (82.87)	20 17.32 (75.30)	1.84 [0.44; 7.81] 0.406	1.10 [0.82; 1.48] 0.522	0.076 [-0.153; 0.304] 0.516
EULAR Remission Week 52, N' n (%)	27 18.51 (61.70)	20 12.00 (52.17)	1.53 [0.49; 4.74] 0.460	1.18 [0.72; 1.93] 0.502	0.095 [-0.177; 0.368] 0.493
EULAR Moderate-to-Good Response Week 52, N' n (%)	27 27.59 (91.97)	20 20.98 (91.22)	1.28 [0.16; 10.24] 0.815	1.01 [0.85; 1.19] 0.926	0.007 [-0.147; 0.162] 0.924

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

31.10 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
EULAR Low Disease Activity Week 52	N.E.				
EULAR Remission Week 52	p=0.038				
EULAR Moderate-to-Good Response Week 52	N.E.				
Non-carrier (N)	**25**	**32**			
EULAR Low Disease Activity Week 52, N' n (%)	23 20.42 (81.68)	26 21.67 (67.72)	2.12 [0.53; 8.47] 0.288	1.21 [0.88; 1.65] 0.241	0.140 [-0.090; 0.369] 0.232
EULAR Remission Week 52, N' n (%)	23 16.18 (64.72)	26 15.01 (46.91)	2.03 [0.67; 6.12] 0.211	1.38 [0.85; 2.23] 0.187	0.178 [-0.082; 0.438] 0.179
EULAR Moderate-to-Good Response Week 52, N' n (%)	23 23.97 (95.88)	26 26.50 (82.81)	4.89 [0.51; 46.54] 0.168	1.16 [0.96; 1.39] 0.120	0.131 [-0.027; 0.288] 0.104
Carrier (N)	**26**	**12**			
EULAR Low Disease Activity Week 52, N' n (%)	24 19.86 (76.38)	9 10.85 (90.42)	N.E.	0.85 [0.62; 1.16] 0.296	-0.140 [-0.398; 0.118] 0.287
EULAR Remission Week 52, N' n (%)	24 9.54 (36.69)	9 8.34 (69.50)	0.26 [0.05; 1.29] 0.100	0.53 [0.27; 1.03] 0.060	-0.328 [-0.669; 0.012] 0.059
EULAR Moderate-to-Good Response Week 52, N' n (%)	24 23.59 (90.73)	9 11.55 (96.25)	N.E.	0.94 [0.77; 1.15] 0.572	-0.055 [-0.239; 0.128] 0.555

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

31.11 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
EULAR Low Disease Activity Week 52	p=0.437				
EULAR Remission Week 52	p=0.208				
EULAR Moderate-to-Good Response Week 52	N.E.				
Non-carrier (N)	**38**	**33**			
EULAR Low Disease Activity Week 52, N' n (%)	34 30.28 (79.68)	24 24.52 (74.30)	1.66 [0.47; 5.85] 0.431	1.07 [0.82; 1.41] 0.613	0.054 [-0.154; 0.262] 0.612
EULAR Remission Week 52, N' n (%)	34 21.72 (57.16)	24 17.35 (52.58)	1.30 [0.48; 3.52] 0.611	1.09 [0.70; 1.70] 0.710	0.046 [-0.196; 0.287] 0.710
EULAR Moderate-to-Good Response Week 52, N' n (%)	34 34.56 (90.95)	24 29.05 (88.03)	1.55 [0.26; 9.12] 0.625	1.03 [0.87; 1.23] 0.714	0.029 [-0.127; 0.185] 0.714
Carrier (N)	**12**	**9**			
EULAR Low Disease Activity Week 52, N' n (%)	12 9.00 (75.00)	9 7.00 (77.78)	0.61 [0.07; 5.20] 0.651	0.96 [0.60; 1.56] 0.882	-0.028 [-0.394; 0.338] 0.882
EULAR Remission Week 52, N' n (%)	12 4.00 (33.33)	9 5.00 (55.56)	0.34 [0.05; 2.09] 0.244	0.60 [0.22; 1.62] 0.312	-0.222 [-0.642; 0.198] 0.300
EULAR Moderate-to-Good Response Week 52, N' n (%)	12 12.00 (100.00)	9 8.00 (88.89)	N.E.	1.13 [0.89; 1.42] 0.318	0.111 [-0.094; 0.316] 0.289

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) EULAR Low Disease Activity, EULAR Remission, EULAR Moderate-to-Good Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

31.12 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
EULAR Low Disease Activity Week 52	p=0.471				
EULAR Remission Week 52	p=0.217				
EULAR Moderate-to-Good Response Week 52	p=0.646				
Non-carrier (N)	**36**	**34**			
EULAR Low Disease Activity Week 52, N' n (%)	33 28.23 (78.42)	25 25.52 (75.06)	1.10 [0.32; 3.72] 0.882	1.05 [0.79; 1.38] 0.752	0.034 [-0.176; 0.243] 0.753
EULAR Remission Week 52, N' n (%)	33 18.71 (51.97)	25 20.35 (59.85)	0.68 [0.25; 1.86] 0.455	0.87 [0.56; 1.34] 0.525	-0.079 [-0.320; 0.162] 0.522
EULAR Moderate-to-Good Response Week 52, N' n (%)	33 33.97 (94.36)	25 30.05 (88.38)	2.02 [0.31; 13.20] 0.462	1.07 [0.91; 1.25] 0.412	0.060 [-0.081; 0.201] 0.405
Carrier (N)	**13**	**10**			
EULAR Low Disease Activity Week 52, N' n (%)	12 10.05 (77.31)	10 7.00 (70.00)	2.74 [0.32; 23.14] 0.356	1.10 [0.67; 1.83] 0.700	0.073 [-0.292; 0.438] 0.695
EULAR Remission Week 52, N' n (%)	12 6.01 (46.23)	10 3.00 (30.00)	2.51 [0.42; 15.06] 0.315	1.54 [0.51; 4.69] 0.447	0.162 [-0.231; 0.555] 0.418
EULAR Moderate-to-Good Response Week 52, N' n (%)	12 11.59 (89.15)	10 8.00 (80.00)	4.66 [0.22; 100.35] 0.326	1.11 [0.77; 1.62] 0.573	0.092 [-0.217; 0.400] 0.561

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale
with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters,
subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of
imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

31.13 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
EULAR Low Disease Activity Week 52	p=0.973				
EULAR Remission Week 52	p=0.598				
EULAR Moderate-to-Good Response Week 52	N.E.				
Non-carrier (N)	**42**	**36**			
EULAR Low Disease Activity Week 52, N' n (%)	38 33.28 (79.24)	29 27.16 (75.44)	1.39 [0.43; 4.56] 0.582	1.05 [0.81; 1.36] 0.704	0.038 [-0.158; 0.233] 0.704
EULAR Remission Week 52, N' n (%)	38 20.72 (49.33)	29 19.28 (53.56)	0.86 [0.34; 2.21] 0.761	0.92 [0.59; 1.44] 0.721	-0.042 [-0.272; 0.188] 0.719
EULAR Moderate-to-Good Response Week 52, N' n (%)	38 38.56 (91.81)	29 30.06 (83.50)	2.56 [0.52; 12.63] 0.249	1.10 [0.92; 1.32] 0.309	0.083 [-0.074; 0.240] 0.299
Carrier (N)	**9**	**5**			
EULAR Low Disease Activity Week 52, N' n (%)	9 7.00 (77.78)	3 3.36 (67.20)	1.47 [0.10; 21.70] 0.781	1.17 [0.54; 2.53] 0.692	0.106 [-0.416; 0.628] 0.691
EULAR Remission Week 52, N' n (%)	9 5.00 (55.56)	3 2.07 (41.40)	1.67 [0.17; 16.12] 0.656	1.35 [0.40; 4.58] 0.630	0.142 [-0.406; 0.689] 0.612
EULAR Moderate-to-Good Response Week 52, N' n (%)	9 9.00 (100.00)	3 4.99 (99.80)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

31.14 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction test					
EULAR Low Disease Activity Week 52	p=0.426				
EULAR Remission Week 52	p=0.618				
EULAR Moderate-to-Good Response Week 52	p=0.568				
Low score (N)	**11**	**22**			
EULAR Low Disease Activity Week 52, N' n (%)	10 8.42 (76.55)	15 17.16 (78.00)	0.82 [0.12; 5.79] 0.846	0.98 [0.64; 1.50] 0.930	-0.015 [-0.341; 0.312] 0.930
EULAR Remission Week 52, N' n (%)	10 5.21 (47.36)	15 12.28 (55.82)	0.68 [0.15; 3.18] 0.628	0.85 [0.40; 1.81] 0.671	-0.085 [-0.461; 0.291] 0.659
EULAR Moderate-to-Good Response Week 52, N' n (%)	10 9.97 (90.64)	15 19.06 (86.64)	1.33 [0.10; 16.92] 0.827	1.05 [0.80; 1.37] 0.738	0.040 [-0.197; 0.277] 0.741
High score (N)	**40**	**22**			
EULAR Low Disease Activity Week 52, N' n (%)	37 31.86 (79.65)	20 15.36 (69.82)	2.14 [0.59; 7.80] 0.250	1.14 [0.83; 1.58] 0.424	0.098 [-0.135; 0.332] 0.409
EULAR Remission Week 52, N' n (%)	37 20.51 (51.28)	20 11.07 (50.32)	1.10 [0.38; 3.19] 0.860	1.02 [0.61; 1.71] 0.944	0.010 [-0.253; 0.272] 0.943
EULAR Moderate-to-Good Response Week 52, N' n (%)	37 37.59 (93.98)	20 18.99 (86.32)	3.40 [0.46; 25.32] 0.232	1.09 [0.90; 1.31] 0.372	0.077 [-0.087; 0.240] 0.359

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

31.15 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
EULAR Low Disease Activity Week 52	p=0.447				
EULAR Remission Week 52	p=0.974				
EULAR Moderate-to-Good Response Week 52	p=0.661				
Non-carrier (N)	**31**	**23**			
EULAR Low Disease Activity Week 52, N' n (%)	30 24.81 (80.03)	16 19.57 (85.09)	0.80 [0.14; 4.47] 0.800	0.94 [0.72; 1.23] 0.659	-0.051 [-0.270; 0.169] 0.652
EULAR Remission Week 52, N' n (%)	30 15.53 (50.10)	16 12.53 (54.48)	0.89 [0.28; 2.80] 0.840	0.92 [0.54; 1.58] 0.764	-0.044 [-0.324; 0.237] 0.760
EULAR Moderate-to-Good Response Week 52, N' n (%)	30 30.00 (96.77)	16 21.20 (92.17)	3.48 [0.18; 68.32] 0.411	1.05 [0.90; 1.23] 0.533	0.046 [-0.097; 0.189] 0.527
Carrier (N)	**20**	**21**			
EULAR Low Disease Activity Week 52, N' n (%)	17 15.47 (77.35)	19 12.95 (61.67)	1.92 [0.45; 8.20] 0.380	1.25 [0.82; 1.91] 0.290	0.157 [-0.126; 0.439] 0.276
EULAR Remission Week 52, N' n (%)	17 10.19 (50.95)	19 10.82 (51.52)	0.91 [0.26; 3.22] 0.888	0.99 [0.54; 1.82] 0.970	-0.006 [-0.317; 0.305] 0.971
EULAR Moderate-to-Good Response Week 52, N' n (%)	17 17.56 (87.80)	19 16.85 (80.24)	1.59 [0.24; 10.30] 0.628	1.09 [0.83; 1.45] 0.528	0.076 [-0.156; 0.307] 0.522

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

31.16 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
EULAR Low Disease Activity Week 52	p=0.805				
EULAR Remission Week 52	p=0.192				
EULAR Moderate-to-Good Response Week 52	p=0.377				
Non-carrier (N)	**19**	**20**			
EULAR Low Disease Activity Week 52, N' n (%)	19 14.00 (73.68)	14 14.20 (71.00)	1.19 [0.25; 5.65] 0.823	1.04 [0.69; 1.57] 0.851	0.027 [-0.267; 0.321] 0.858
EULAR Remission Week 52, N' n (%)	19 6.00 (31.58)	14 10.35 (51.75)	0.43 [0.11; 1.68] 0.224	0.61 [0.27; 1.37] 0.231	-0.202 [-0.515; 0.111] 0.207
EULAR Moderate-to-Good Response Week 52, N' n (%)	19 18.00 (94.74)	14 16.07 (80.35)	5.19 [0.43; 62.32] 0.194	1.18 [0.91; 1.54] 0.217	0.144 [-0.072; 0.360] 0.192
Carrier (N)	**32**	**24**			
EULAR Low Disease Activity Week 52, N' n (%)	28 26.28 (82.13)	21 18.32 (76.33)	1.56 [0.38; 6.40] 0.540	1.08 [0.81; 1.43] 0.616	0.058 [-0.166; 0.282] 0.612
EULAR Remission Week 52, N' n (%)	28 19.72 (61.63)	21 13.00 (54.17)	1.38 [0.46; 4.16] 0.569	1.14 [0.71; 1.82] 0.590	0.075 [-0.192; 0.341] 0.583
EULAR Moderate-to-Good Response Week 52, N' n (%)	28 29.56 (92.38)	21 21.98 (91.58)	1.25 [0.16; 9.81] 0.833	1.01 [0.86; 1.18] 0.918	0.008 [-0.140; 0.156] 0.916

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

31.17 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
EULAR Low Disease Activity Week 52	N.E.				
EULAR Remission Week 52	p=0.038				
EULAR Moderate-to-Good Response Week 52	N.E.				
Non-carrier (N)	**25**	**32**			
EULAR Low Disease Activity Week 52, N' n (%)	23 20.42 (81.68)	26 21.67 (67.72)	2.12 [0.53; 8.47] 0.288	1.21 [0.88; 1.65] 0.241	0.140 [-0.090; 0.369] 0.232
EULAR Remission Week 52, N' n (%)	23 16.18 (64.72)	26 15.01 (46.91)	2.03 [0.67; 6.12] 0.211	1.38 [0.85; 2.23] 0.187	0.178 [-0.082; 0.438] 0.179
EULAR Moderate-to-Good Response Week 52, N' n (%)	23 23.97 (95.88)	26 26.50 (82.81)	4.89 [0.51; 46.54] 0.168	1.16 [0.96; 1.39] 0.120	0.131 [-0.027; 0.288] 0.104
Carrier (N)	**26**	**12**			
EULAR Low Disease Activity Week 52, N' n (%)	24 19.86 (76.38)	9 10.85 (90.42)	N.E.	0.85 [0.62; 1.16] 0.296	-0.140 [-0.398; 0.118] 0.287
EULAR Remission Week 52, N' n (%)	24 9.54 (36.69)	9 8.34 (69.50)	0.26 [0.05; 1.29] 0.100	0.53 [0.27; 1.03] 0.060	-0.328 [-0.669; 0.012] 0.059
EULAR Moderate-to-Good Response Week 52, N' n (%)	24 23.59 (90.73)	9 11.55 (96.25)	N.E.	0.94 [0.77; 1.15] 0.572	-0.055 [-0.239; 0.128] 0.555

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N': Number of patients with available response value					

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

31.18 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
EULAR Low Disease Activity Week 52	p=0.343				
EULAR Remission Week 52	p=0.283				
EULAR Moderate-to-Good Response Week 52	N.E.				
Non-carrier (N)	**39**	**35**			
EULAR Low Disease Activity Week 52, N' n (%)	35 31.28 (80.21)	26 25.52 (72.91)	1.85 [0.54; 6.31] 0.329	1.10 [0.84; 1.44] 0.487	0.073 [-0.131; 0.277] 0.483
EULAR Remission Week 52, N' n (%)	35 21.72 (55.69)	26 18.35 (52.43)	1.22 [0.46; 3.24] 0.686	1.06 [0.68; 1.65] 0.786	0.033 [-0.204; 0.269] 0.787
EULAR Moderate-to-Good Response Week 52, N' n (%)	35 35.56 (91.18)	26 30.05 (85.86)	1.99 [0.37; 10.71] 0.421	1.06 [0.89; 1.27] 0.511	0.053 [-0.104; 0.210] 0.507
Carrier (N)	**11**	**9**			
EULAR Low Disease Activity Week 52, N' n (%)	11 8.00 (72.73)	9 7.00 (77.78)	0.55 [0.06; 4.74] 0.583	0.94 [0.57; 1.55] 0.794	-0.051 [-0.429; 0.328] 0.794
EULAR Remission Week 52, N' n (%)	11 4.00 (36.36)	9 5.00 (55.56)	0.39 [0.06; 2.45] 0.314	0.65 [0.25; 1.74] 0.395	-0.192 [-0.623; 0.240] 0.383
EULAR Moderate-to-Good Response Week 52, N' n (%)	11 11.00 (100.00)	9 8.00 (88.89)	N.E.	1.13 [0.89; 1.42] 0.318	0.111 [-0.094; 0.316] 0.289

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) EULAR Low Disease Activity, EULAR Remission, EULAR Moderate-to-Good Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

32.0 mCPDAI - Return Rates (FAS)

	Treatment Groups		
	SEC **(N=66)**	**ADA** **(N=62)**	**Total** **(N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 4 Returns	66 (100.0)	58 (93.5)	124 (96.9)
Week 12 Returns	64 (97.0)	57 (91.9)	121 (94.5)
Week 16 Returns	63 (95.5)	53 (85.5)	116 (90.6)
Week 24 Returns	62 (93.9)	53 (85.5)	115 (89.8)
Week 32 Returns	61 (92.4)	49 (79.0)	110 (85.9)
Week 40 Returns	63 (95.5)	47 (75.8)	110 (85.9)
Week 52 Returns	62 (93.9)	46 (74.2)	108 (84.4)

32.1 mCPDAI - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N'	66	60		
Baseline Mean (SD)	9.15 (1.72)	8.89 (1.90)		
Week 52 Mean (SD)	4.77 (3.04)	5.22 (2.59)		
Week 52 Adjusted Mean Change (SE)	-4.29 (0.34)	-3.74 (0.37)	-0.55 [-1.54; 0.45]	0.280

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

32.2 mCPDAI - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.612				
Male, N	42	33		
N'	42	32		
Baseline Mean (SD)	9.12 (1.88)	8.45 (2.22)		
Week 52 Mean (SD)	4.23 (3.06)	4.17 (2.53)		
Week 52 Adjusted Mean Change (SE)	-4.74 (0.41)	-4.61 (0.50)	-0.13 [-1.41; 1.15]	0.840
Female, N	24	29		
N'	24	28		
Baseline Mean (SD)	9.21 (1.44)	9.38 (1.32)		
Week 52 Mean (SD)	5.70 (2.84)	6.36 (2.17)		
Week 52 Adjusted Mean Change (SE)	-3.50 (0.54)	-2.78 (0.53)	-0.71 [-2.21; 0.78]	0.347

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

32.3 mCPDAI - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.742				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	7.69 (2.12)	6.23 (1.83)		
Week 52 Mean (SD)	2.94 (2.82)	4.50 (3.02)		
Week 52 Adjusted Mean Change (SE)	-5.64 (0.71)	-4.00 (0.94)	-1.64 [-3.80; 0.52]	0.135
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	47		
Baseline Mean (SD)	9.62 (1.28)	9.59 (1.15)		
Week 52 Mean (SD)	5.41 (2.87)	5.37 (2.51)		
Week 52 Adjusted Mean Change (SE)	-3.82 (0.39)	-3.67 (0.42)	-0.16 [-1.27; 0.96]	0.780

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

32.4 mCPDAI - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.351				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	31		
Baseline Mean (SD)	8.75 (1.60)	8.47 (2.00)		
Week 52 Mean (SD)	5.46 (2.63)	5.00 (2.94)		
Week 52 Adjusted Mean Change (SE)	-3.53 (0.52)	-3.77 (0.53)	0.24 [-1.22; 1.69]	0.749
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	9.45 (1.77)	9.33 (1.71)		
Week 52 Mean (SD)	4.28 (3.25)	5.42 (2.26)		
Week 52 Adjusted Mean Change (SE)	-4.85 (0.44)	-3.74 (0.52)	-1.11 [-2.46; 0.24]	0.106

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

32.5 mCPDAI - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.198				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	9.48 (1.66)	8.55 (1.94)		
Week 52 Mean (SD)	4.58 (2.96)	5.00 (2.69)		
Week 52 Adjusted Mean Change (SE)	-4.64 (0.44)	-3.33 (0.57)	-1.31 [-2.74; 0.13]	0.074
> Median, N	**26**	**33**		
N'	26	31		
Baseline Mean (SD)	8.65 (1.72)	9.18 (1.84)		
Week 52 Mean (SD)	5.08 (3.20)	5.37 (2.56)		
Week 52 Adjusted Mean Change (SE)	-3.77 (0.55)	-4.00 (0.51)	0.24 [-1.25; 1.73]	0.754

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

32.6 mCPDAI - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.389				
Enthesitis: No, N	**34**	**22**		
N'	34	21		
Baseline Mean (SD)	8.53 (1.83)	8.50 (1.99)		
Week 52 Mean (SD)	4.16 (2.89)	5.11 (2.65)		
Week 52 Adjusted Mean Change (SE)	-4.63 (0.48)	-4.03 (0.61)	-0.60 [-2.13; 0.93]	0.440
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	9.81 (1.33)	9.10 (1.84)		
Week 52 Mean (SD)	5.39 (3.11)	5.29 (2.59)		
Week 52 Adjusted Mean Change (SE)	-3.94 (0.49)	-3.65 (0.47)	-0.29 [-1.63; 1.06]	0.673

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

32.7 mCPDAI - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.500				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	9.45 (1.12)	9.08 (1.96)		
Week 52 Mean (SD)	5.37 (3.05)	4.68 (2.73)		
Week 52 Adjusted Mean Change (SE)	-3.91 (0.52)	-4.74 (0.58)	0.83 [-0.72; 2.37]	0.290
Carrier, N	**22**	**19**		
N'	22	18		
Baseline Mean (SD)	8.91 (2.00)	8.68 (1.67)		
Week 52 Mean (SD)	4.75 (2.88)	5.44 (2.61)		
Week 52 Adjusted Mean Change (SE)	-4.09 (0.60)	-3.10 (0.67)	-0.99 [-2.77; 0.79]	0.271

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

32.8 mCPDAI - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.796				
Non-carrier, N	**28**	**19**		
N'	28	18		
Baseline Mean (SD)	9.46 (1.20)	9.00 (1.76)		
Week 52 Mean (SD)	5.00 (3.11)	5.15 (2.61)		
Week 52 Adjusted Mean Change (SE)	-4.27 (0.54)	-4.14 (0.73)	-0.13 [-1.93; 1.67]	0.886
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	8.91 (1.95)	9.00 (1.89)		
Week 52 Mean (SD)	5.32 (2.89)	5.12 (2.78)		
Week 52 Adjusted Mean Change (SE)	-3.65 (0.63)	-4.05 (0.67)	0.40 [-1.43; 2.22]	0.666

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

32.9 mCPDAI - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.449				
Non-carrier, N	**19**	**21**		
N'	19	20		
Baseline Mean (SD)	9.26 (1.56)	9.10 (1.84)		
Week 52 Mean (SD)	5.32 (3.09)	5.27 (2.71)		
Week 52 Adjusted Mean Change (SE)	-3.91 (0.64)	-3.66 (0.67)	-0.25 [-2.08; 1.59]	0.791
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	9.27 (1.53)	8.74 (1.84)		
Week 52 Mean (SD)	5.11 (2.87)	4.85 (2.68)		
Week 52 Adjusted Mean Change (SE)	-4.01 (0.52)	-4.30 (0.60)	0.29 [-1.29; 1.88]	0.713

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

32.10 mCPDAI - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.056				
Non-carrier, N	25	32		
N'	25	32		
Baseline Mean (SD)	9.48 (1.64)	9.03 (1.93)		
Week 52 Mean (SD)	5.00 (3.21)	5.62 (2.47)		
Week 52 Adjusted Mean Change (SE)	-4.25 (0.56)	-3.60 (0.51)	-0.65 [-2.14; 0.85]	0.392
Carrier, N	26	12		
N'	26	11		
Baseline Mean (SD)	8.96 (1.48)	8.58 (1.56)		
Week 52 Mean (SD)	5.21 (2.78)	3.33 (2.60)		
Week 52 Adjusted Mean Change (SE)	-3.74 (0.54)	-5.36 (0.87)	1.62 [-0.41; 3.64]	0.116

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

32.10 mCPDAI - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

32.11 mCPDAI - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.956				
Non-carrier, N	**38**	**33**		
N'	38	32		
Baseline Mean (SD)	9.16 (1.55)	8.97 (1.83)		
Week 52 Mean (SD)	5.47 (2.93)	5.17 (2.58)		
Week 52 Adjusted Mean Change (SE)	-3.58 (0.46)	-3.92 (0.52)	0.34 [-1.04; 1.72]	0.622
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	9.25 (1.66)	8.33 (1.87)		
Week 52 Mean (SD)	4.25 (3.08)	4.00 (2.69)		
Week 52 Adjusted Mean Change (SE)	-4.79 (0.80)	-4.71 (0.93)	-0.09 [-2.53; 2.35]	0.944

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

32.12 mCPDAI - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.508				
Non-carrier, N	**36**	**34**		
N'	36	33		
Baseline Mean (SD)	9.31 (1.37)	8.82 (1.99)		
Week 52 Mean (SD)	5.27 (3.05)	4.84 (2.61)		
Week 52 Adjusted Mean Change (SE)	-3.91 (0.46)	-4.17 (0.50)	0.25 [-1.11; 1.62]	0.710
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	8.85 (2.08)	9.20 (1.14)		
Week 52 Mean (SD)	5.00 (2.66)	5.50 (2.88)		
Week 52 Adjusted Mean Change (SE)	-3.77 (0.76)	-3.50 (0.86)	-0.27 [-2.56; 2.02]	0.816

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

32.13 mCPDAI - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.884				
Non-carrier, N	**42**	**36**		
N'	42	35		
Baseline Mean (SD)	9.12 (1.68)	8.97 (1.78)		
Week 52 Mean (SD)	5.00 (2.93)	5.07 (2.84)		
Week 52 Adjusted Mean Change (SE)	-4.05 (0.44)	-4.05 (0.50)	-0.01 [-1.33; 1.32]	0.994
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	9.67 (0.71)	8.40 (2.07)		
Week 52 Mean (SD)	5.56 (3.24)	5.00 (1.00)		
Week 52 Adjusted Mean Change (SE)	-3.75 (0.94)	-3.97 (1.42)	0.21 [-3.19; 3.62]	0.900

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

32.13 mCPDAI - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

32.14 mCPDAI - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.837				
Low score, N	**11**	**22**		
N'	11	21		
Baseline Mean (SD)	9.09 (1.64)	9.14 (2.03)		
Week 52 Mean (SD)	4.30 (3.43)	5.60 (2.59)		
Week 52 Adjusted Mean Change (SE)	-4.53 (0.85)	-3.64 (0.66)	-0.90 [-3.03; 1.24]	0.406
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	9.25 (1.56)	8.68 (1.62)		
Week 52 Mean (SD)	5.32 (2.84)	4.60 (2.70)		
Week 52 Adjusted Mean Change (SE)	-3.83 (0.44)	-4.27 (0.60)	0.44 [-1.06; 1.94]	0.560

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

32.15 mCPDAI - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.617				
Non-carrier, N	**31**	**23**		
N'	31	22		
Baseline Mean (SD)	9.45 (1.15)	8.91 (1.78)		
Week 52 Mean (SD)	5.13 (3.03)	5.00 (2.63)		
Week 52 Adjusted Mean Change (SE)	-4.15 (0.50)	-3.99 (0.64)	-0.16 [-1.77; 1.46]	0.845
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	8.85 (2.03)	8.90 (1.92)		
Week 52 Mean (SD)	5.06 (2.95)	5.05 (2.76)		
Week 52 Adjusted Mean Change (SE)	-3.75 (0.64)	-4.01 (0.62)	0.26 [-1.51; 2.03]	0.768

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

32.16 mCPDAI - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.388				
Non-carrier, N	**19**	**20**		
N'	19	19		
Baseline Mean (SD)	9.26 (1.56)	9.05 (1.88)		
Week 52 Mean (SD)	5.32 (3.09)	5.21 (2.81)		
Week 52 Adjusted Mean Change (SE)	-3.90 (0.64)	-3.64 (0.69)	-0.26 [-2.13; 1.61]	0.782
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	9.19 (1.60)	8.79 (1.82)		
Week 52 Mean (SD)	4.96 (2.92)	4.90 (2.62)		
Week 52 Adjusted Mean Change (SE)	-4.01 (0.51)	-4.27 (0.59)	0.25 [-1.29; 1.80]	0.745

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

32.17 mCPDAI - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.056				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	9.48 (1.64)	9.03 (1.93)		
Week 52 Mean (SD)	5.00 (3.21)	5.62 (2.47)		
Week 52 Adjusted Mean Change (SE)	-4.25 (0.56)	-3.60 (0.51)	-0.65 [-2.14; 0.85]	0.392
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	8.96 (1.48)	8.58 (1.56)		
Week 52 Mean (SD)	5.21 (2.78)	3.33 (2.60)		
Week 52 Adjusted Mean Change (SE)	-3.74 (0.54)	-5.36 (0.87)	1.62 [-0.41; 3.64]	0.116

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

32.18 mCPDAI - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC **(N=66)**	**ADA** **(N=62)**	**Mean Difference** **[95% CI]**	**p-value**
Interaction test: p=0.879				
Non-carrier, N	**39**	**35**		
N'	39	34		
Baseline Mean (SD)	9.21 (1.56)	9.00 (1.78)		
Week 52 Mean (SD)	5.40 (2.91)	5.35 (2.56)		
Week 52 Adjusted Mean Change (SE)	-3.70 (0.45)	-3.82 (0.50)	0.12 [-1.21; 1.45]	0.856
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	9.09 (1.64)	8.56 (2.07)		
Week 52 Mean (SD)	3.82 (2.82)	4.11 (2.89)		
Week 52 Adjusted Mean Change (SE)	-5.16 (0.82)	-4.72 (0.91)	-0.44 [-2.87; 2.00]	0.723

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

33.1 mCPDAI Low Disease Activity (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
mCPDAI Low Disease Activity Week 52, N' n (%)	62 20.58 (31.18)	46 14.07 (22.69)	1.57 [0.68; 3.63] 0.290	1.38 [0.75; 2.55] 0.305	0.085 [-0.074; 0.244] 0.295

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.
RR and RD calculated directly without adjustment.

All results are combined over MI:
n and % are averages of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

33.2 mCPDAI Low Disease Activity by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
mCPDAI Low Disease Activity Week 52	p=0.507				
Male (N)	**42**	**33**			
mCPDAI Low Disease Activity Week 52, N' n (%)	39 15.08 (35.90)	24 10.85 (32.88)	1.20 [0.43; 3.35] 0.727	1.10 [0.56; 2.13] 0.785	0.030 [-0.195; 0.256] 0.793
Female (N)	**24**	**29**			
mCPDAI Low Disease Activity Week 52, N' n (%)	23 5.50 (22.92)	22 3.22 (11.10)	2.31 [0.45; 11.90] 0.317	2.11 [0.53; 8.42] 0.289	0.118 [-0.095; 0.331] 0.277

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

33.3 mCPDAI Low Disease Activity by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction test					
mCPDAI Low Disease Activity Week 52	p=0.558				
PASDAS < 5.4 (N)	**16**	**13**			
mCPDAI Low Disease Activity Week 52, N' n (%)	16 10.00 (62.50)	8 5.61 (43.15)	2.32 [0.45; 11.87] 0.314	1.47 [0.66; 3.28] 0.351	0.193 [-0.187; 0.574] 0.319
PASDAS ≥ 5.4 (N)	**50**	**49**			
mCPDAI Low Disease Activity Week 52, N' n (%)	46 10.58 (21.16)	38 8.46 (17.27)	1.30 [0.45; 3.73] 0.628	1.23 [0.53; 2.88] 0.633	0.039 [-0.122; 0.200] 0.635

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

33.4 mCPDAI Low Disease Activity by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
mCPDAI Low Disease Activity Week 52	p=0.080				
Moderate/Severe Psoriasis (Def D): No (N)	**28**	**32**			
mCPDAI Low Disease Activity Week 52, N' n (%)	26 6.56 (23.43)	22 9.33 (29.16)	0.70 [0.20; 2.43] 0.573	0.81 [0.32; 2.00] 0.641	-0.057 [-0.291; 0.177] 0.632
Moderate/Severe Psoriasis (Def D): Yes (N)	**38**	**30**			
mCPDAI Low Disease Activity Week 52, N' n (%)	36 14.02 (36.89)	24 4.74 (15.80)	3.45 [0.97; 12.27] 0.056	2.36 [0.88; 6.35] 0.088	0.211 [0.004; 0.418] 0.046

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

33.5 mCPDAI Low Disease Activity by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
mCPDAI Low Disease Activity Week 52	p=0.873				
≤ Median (N)	**40**	**29**			
mCPDAI Low Disease Activity Week 52, N' n (%)	38 12.08 (30.20)	19 6.86 (23.66)	1.48 [0.47; 4.69] 0.502	1.29 [0.55; 3.00] 0.561	0.065 [-0.152; 0.283] 0.555
> Median (N)	**26**	**33**			
mCPDAI Low Disease Activity Week 52, N' n (%)	24 8.50 (32.69)	27 7.21 (21.85)	1.70 [0.49; 5.86] 0.400	1.51 [0.61; 3.73] 0.374	0.108 [-0.131; 0.347] 0.374

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

33.6 mCPDAI Low Disease Activity by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
mCPDAI Low Disease Activity Week 52	p=0.876				
Enthesitis: No (N)	**34**	**22**			
mCPDAI Low Disease Activity Week 52, N' n (%)	31 12.56 (36.94)	18 5.98 (27.18)	1.55 [0.44; 5.42] 0.492	1.37 [0.58; 3.26] 0.477	0.098 [-0.160; 0.356] 0.458
Enthesitis: Yes (N)	**32**	**40**			
mCPDAI Low Disease Activity Week 52, N' n (%)	31 8.02 (25.06)	28 8.09 (20.23)	1.35 [0.42; 4.36] 0.612	1.25 [0.51; 3.07] 0.628	0.048 [-0.153; 0.250] 0.638

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

33.7 mCPDAI Low Disease Activity by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
mCPDAI Low Disease Activity Week 52	p=0.647				
Non-carrier (N)	**29**	**25**			
mCPDAI Low Disease Activity Week 52, N' n (%)	27 7.50 (25.86)	19 7.39 (29.56)	0.83 [0.23; 3.01] 0.775	0.88 [0.35; 2.21] 0.787	-0.037 [-0.291; 0.217] 0.775
Carrier (N)	**22**	**19**			
mCPDAI Low Disease Activity Week 52, N' n (%)	20 6.08 (27.64)	16 4.33 (22.79)	1.31 [0.30; 5.72] 0.720	1.22 [0.41; 3.65] 0.724	0.048 [-0.223; 0.320] 0.726

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

33.8 mCPDAI Low Disease Activity by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
mCPDAI Low Disease Activity Week 52	p=0.883				
Non-carrier (N)	**28**	**19**			
mCPDAI Low Disease Activity Week 52, N' n (%)	27 8.06 (28.79)	13 5.13 (27.00)	1.19 [0.28; 5.11] 0.814	1.08 [0.39; 3.04] 0.877	0.018 [-0.261; 0.296] 0.900
Carrier (N)	**22**	**19**			
mCPDAI Low Disease Activity Week 52, N' n (%)	19 5.52 (25.09)	17 4.58 (24.11)	1.02 [0.22; 4.61] 0.983	1.04 [0.34; 3.20] 0.941	0.010 [-0.263; 0.282] 0.943

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

33.9 mCPDAI Low Disease Activity by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
mCPDAI Low Disease Activity Week 52	p=0.856				
Non-carrier (N)	**19**	**21**			
mCPDAI Low Disease Activity Week 52, N' n (%)	19 5.00 (26.32)	15 5.33 (25.38)	1.07 [0.24; 4.85] 0.929	1.05 [0.35; 3.16] 0.932	0.009 [-0.273; 0.292] 0.948
Carrier (N)	**30**	**23**			
mCPDAI Low Disease Activity Week 52, N' n (%)	27 7.56 (25.20)	20 6.39 (27.78)	0.89 [0.25; 3.24] 0.862	0.91 [0.36; 2.32] 0.840	-0.026 [-0.274; 0.222] 0.838

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

33.10 mCPDAI Low Disease Activity by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
mCPDAI Low Disease Activity Week 52	p=0.090				
Non-carrier (N)	**25**	**32**			
mCPDAI Low Disease Activity Week 52, N' n (%)	23 7.52 (30.08)	26 5.74 (17.94)	1.87 [0.50; 7.06] 0.355	1.69 [0.62; 4.65] 0.308	0.121 [-0.111; 0.354] 0.306
Carrier (N)	**26**	**12**			
mCPDAI Low Disease Activity Week 52, N' n (%)	24 6.06 (23.31)	9 5.98 (49.83)	0.32 [0.07; 1.51] 0.151	0.47 [0.19; 1.19] 0.111	-0.265 [-0.607; 0.076] 0.128

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

33.11 mCPDAI Low Disease Activity by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
mCPDAI Low Disease Activity Week 52	p=0.720				
Non-carrier (N)	**38**	**33**			
mCPDAI Low Disease Activity Week 52, N' n (%)	34 8.58 (22.58)	24 8.72 (26.42)	0.85 [0.27; 2.74] 0.791	0.86 [0.36; 2.05] 0.733	-0.038 [-0.251; 0.174] 0.723
Carrier (N)	**12**	**9**			
mCPDAI Low Disease Activity Week 52, N' n (%)	12 5.00 (41.67)	9 3.00 (33.33)	1.27 [0.20; 7.92] 0.796	1.25 [0.40; 3.91] 0.701	0.083 [-0.332; 0.499] 0.694

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) mCPDAI Low Disease Activity, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

33.12 mCPDAI Low Disease Activity by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
mCPDAI Low Disease Activity Week 52	p=0.865				
Non-carrier (N)	**36**	**34**			
mCPDAI Low Disease Activity Week 52, N' n (%)	33 9.58 (26.61)	25 8.72 (25.65)	1.00 [0.32; 3.16] 0.999	1.04 [0.45; 2.42] 0.920	0.010 [-0.208; 0.227] 0.931
Carrier (N)	**13**	**10**			
mCPDAI Low Disease Activity Week 52, N' n (%)	12 3.00 (23.08)	10 3.00 (30.00)	0.82 [0.12; 5.56] 0.843	0.77 [0.20; 3.03] 0.708	-0.069 [-0.434; 0.296] 0.710

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) mCPDAI Low Disease Activity, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

33.13 mCPDAI Low Disease Activity by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
mCPDAI Low Disease Activity Week 52	N.E.				
Non-carrier (N)	**42**	**36**			
mCPDAI Low Disease Activity Week 52, N' n (%)	38 11.58 (27.57)	29 10.15 (28.19)	1.00 [0.35; 2.84] 0.993	0.98 [0.46; 2.07] 0.960	-0.006 [-0.214; 0.202] 0.953
Carrier (N)	**9**	**5**			
mCPDAI Low Disease Activity Week 52, N' n (%)	9 2.00 (22.22)	3 0.57 (11.40)	N.E.	1.71 [0.12; 24.73] 0.694	0.108 [-0.322; 0.538] 0.622

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

33.14 mCPDAI Low Disease Activity by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
mCPDAI Low Disease Activity Week 52	p=0.401				
Low score (N)	**11**	**22**			
mCPDAI Low Disease Activity Week 52, N' n (%)	10 4.02 (36.55)	15 5.15 (23.41)	1.88 [0.35; 10.07] 0.462	1.59 [0.50; 5.07] 0.435	0.131 [-0.214; 0.477] 0.456
High score (N)	**40**	**22**			
mCPDAI Low Disease Activity Week 52, N' n (%)	37 9.56 (23.90)	20 6.57 (29.86)	0.77 [0.23; 2.61] 0.678	0.80 [0.34; 1.91] 0.618	-0.060 [-0.298; 0.179] 0.624

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

33.15 mCPDAI Low Disease Activity by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
mCPDAI Low Disease Activity Week 52	p=0.929				
Non-carrier (N)	**31**	**23**			
mCPDAI Low Disease Activity Week 52, N' n (%)	30 8.06 (26.00)	16 6.14 (26.70)	1.05 [0.28; 3.96] 0.946	0.99 [0.38; 2.58] 0.976	-0.007 [-0.258; 0.245] 0.957
Carrier (N)	**20**	**21**			
mCPDAI Low Disease Activity Week 52, N' n (%)	17 5.52 (27.60)	19 5.58 (26.57)	0.96 [0.23; 4.06] 0.953	1.04 [0.37; 2.94] 0.943	0.010 [-0.270; 0.290] 0.943

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

33.16 mCPDAI Low Disease Activity by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction test					
mCPDAI Low Disease Activity Week 52	p=0.997				
Non-carrier (N)	**19**	**20**			
mCPDAI Low Disease Activity Week 52, N' n (%)	19 5.00 (26.32)	14 5.33 (26.65)	1.01 [0.22; 4.61] 0.990	1.00 [0.33; 3.00] 0.999	-0.003 [-0.292; 0.285] 0.982
Carrier (N)	**32**	**24**			
mCPDAI Low Disease Activity Week 52, N' n (%)	28 8.58 (26.81)	21 6.39 (26.63)	1.01 [0.29; 3.52] 0.992	1.01 [0.41; 2.51] 0.985	0.002 [-0.240; 0.243] 0.988

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

33.17 mCPDAI Low Disease Activity by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
mCPDAI Low Disease Activity Week 52	p=0.090				
Non-carrier (N)	**25**	**32**			
mCPDAI Low Disease Activity Week 52, N' n (%)	23 7.52 (30.08)	26 5.74 (17.94)	1.87 [0.50; 7.06] 0.355	1.69 [0.62; 4.65] 0.308	0.121 [-0.111; 0.354] 0.306
Carrier (N)	**26**	**12**			
mCPDAI Low Disease Activity Week 52, N' n (%)	24 6.06 (23.31)	9 5.98 (49.83)	0.32 [0.07; 1.51] 0.151	0.47 [0.19; 1.19] 0.111	-0.265 [-0.607; 0.076] 0.128

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

33.18 mCPDAI Low Disease Activity by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
mCPDAI Low Disease Activity Week 52	p=0.645				
Non-carrier (N)	**39**	**35**			
mCPDAI Low Disease Activity Week 52, N' n (%)	35 8.58 (22.00)	26 8.72 (24.91)	0.89 [0.28; 2.84] 0.847	0.89 [0.37; 2.13] 0.790	-0.029 [-0.234; 0.176] 0.780
Carrier (N)	**11**	**9**			
mCPDAI Low Disease Activity Week 52, N' n (%)	11 5.00 (45.45)	9 3.00 (33.33)	1.49 [0.23; 9.56] 0.672	1.36 [0.44; 4.21] 0.590	0.121 [-0.305; 0.547] 0.577

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) mCPDAI Low Disease Activity, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

34.1 MDA Minimal Disease Activity / Very Low Disease Activity (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Minimal Disease Activity Week 52, N' n (%)	63 30.39 (46.05)	49 25.43 (41.02)	1.24 [0.60; 2.56] 0.558	1.12 [0.75; 1.69] 0.576	0.050 [-0.125; 0.226] 0.575
Very Low Disease Activity Week 52, N' n (%)	63 10.26 (15.55)	49 10.90 (17.58)	0.87 [0.33; 2.29] 0.779	0.89 [0.40; 1.97] 0.766	-0.020 [-0.153; 0.112] 0.763

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.
RR and RD calculated directly without adjustment.

All results are combined over MI:
n and % are averages of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

34.2 MDA Minimal Disease Activity / Very Low Disease Activity by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
Minimal Disease Activity Week 52	p=0.421				
Very Low Disease Activity Week 52	p=0.180				
Male (N)	**42**	**33**			
Minimal Disease Activity Week 52, N' n (%)	40 23.46 (55.86)	26 20.06 (60.79)	0.85 [0.32; 2.27] 0.740	0.92 [0.62; 1.37] 0.679	-0.049 [-0.281; 0.183] 0.677
Very Low Disease Activity Week 52, N' n (%)	40 7.04 (16.76)	26 9.51 (28.82)	0.51 [0.16; 1.62] 0.255	0.58 [0.24; 1.39] 0.225	-0.121 [-0.316; 0.074] 0.226
Female (N)	**24**	**29**			
Minimal Disease Activity Week 52, N' n (%)	23 6.93 (28.87)	23 5.37 (18.52)	1.68 [0.44; 6.49] 0.449	1.57 [0.56; 4.36] 0.388	0.104 [-0.131; 0.338] 0.387
Very Low Disease Activity Week 52, N' n (%)	23 3.22 (13.42)	23 1.39 (4.79)	3.00 [0.30; 30.25] 0.352	2.96 [0.35; 24.86] 0.319	0.086 [-0.078; 0.250] 0.303

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

34.3 MDA Minimal Disease Activity / Very Low Disease Activity by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
Minimal Disease Activity Week 52	p=0.211				
Very Low Disease Activity Week 52	p=0.539				
PASDAS < 5.4 (N)	**16**	**13**			
Minimal Disease Activity Week 52, N' n (%)	16 12.00 (75.00)	9 6.59 (50.69)	3.08 [0.58; 16.24] 0.185	1.49 [0.78; 2.85] 0.230	0.243 [-0.116; 0.603] 0.185
Very Low Disease Activity Week 52, N' n (%)	16 5.00 (31.25)	9 3.54 (27.23)	1.28 [0.23; 7.26] 0.777	1.16 [0.35; 3.87] 0.806	0.040 [-0.302; 0.383] 0.818
PASDAS ≥ 5.4 (N)	**50**	**49**			
Minimal Disease Activity Week 52, N' n (%)	47 18.39 (36.78)	40 18.84 (38.45)	0.93 [0.40; 2.17] 0.874	0.96 [0.57; 1.61] 0.869	-0.017 [-0.212; 0.179] 0.867
Very Low Disease Activity Week 52, N' n (%)	47 5.26 (10.52)	40 7.36 (15.02)	0.66 [0.19; 2.27] 0.510	0.70 [0.24; 2.05] 0.514	-0.045 [-0.179; 0.089] 0.511

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

34.4 MDA Minimal Disease Activity / Very Low Disease Activity by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
Minimal Disease Activity Week 52	p=0.318				
Very Low Disease Activity Week 52	p=0.097				
Moderate/Severe Psoriasis (Def D): No (N)	**28**	**32**			
Minimal Disease Activity Week 52, N' n (%)	26 9.28 (33.14)	23 12.09 (37.78)	0.78 [0.26; 2.37] 0.658	0.88 [0.43; 1.79] 0.720	-0.046 [-0.296; 0.203] 0.715
Very Low Disease Activity Week 52, N' n (%)	26 3.25 (11.61)	23 7.70 (24.06)	0.36 [0.08; 1.63] 0.185	0.48 [0.14; 1.66] 0.247	-0.125 [-0.322; 0.072] 0.215
Moderate/Severe Psoriasis (Def D): Yes (N)	**38**	**30**			
Minimal Disease Activity Week 52, N' n (%)	37 21.11 (55.55)	26 13.34 (44.47)	1.67 [0.62; 4.49] 0.313	1.25 [0.76; 2.06] 0.381	0.111 [-0.131; 0.353] 0.369
Very Low Disease Activity Week 52, N' n (%)	37 7.01 (18.45)	26 3.20 (10.67)	2.19 [0.50; 9.60] 0.299	1.74 [0.49; 6.14] 0.388	0.078 [-0.090; 0.246] 0.363

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

34.5 MDA Minimal Disease Activity / Very Low Disease Activity by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction test					
Minimal Disease Activity Week 52	p=0.780				
Very Low Disease Activity Week 52	p=0.783				
≤ Median (N)	**40**	**29**			
Minimal Disease Activity Week 52, N' n (%)	38 18.46 (46.15)	21 12.99 (44.79)	1.11 [0.41; 2.99] 0.841	1.03 [0.60; 1.76] 0.911	0.014 [-0.230; 0.257] 0.913
Very Low Disease Activity Week 52, N' n (%)	38 6.04 (15.10)	21 5.83 (20.10)	0.76 [0.20; 2.85] 0.687	0.76 [0.26; 2.20] 0.608	-0.050 [-0.240; 0.140] 0.606
> Median (N)	**26**	**33**			
Minimal Disease Activity Week 52, N' n (%)	25 11.93 (45.88)	28 12.44 (37.70)	1.36 [0.46; 4.01] 0.572	1.22 [0.65; 2.27] 0.532	0.082 [-0.177; 0.340] 0.535
Very Low Disease Activity Week 52, N' n (%)	25 4.22 (16.23)	28 5.07 (15.36)	1.00 [0.24; 4.29] 0.995	1.05 [0.31; 3.53] 0.933	0.009 [-0.183; 0.200] 0.929

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

34.6 MDA Minimal Disease Activity / Very Low Disease Activity by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
Minimal Disease Activity Week 52	p=0.694				
Very Low Disease Activity Week 52	p=0.902				
Enthesitis: No (N)	**34**	**22**			
Minimal Disease Activity Week 52, N' n (%)	32 19.28 (56.71)	19 10.99 (49.95)	1.29 [0.42; 3.98] 0.657	1.14 [0.67; 1.93] 0.635	0.068 [-0.207; 0.343] 0.630
Very Low Disease Activity Week 52, N' n (%)	32 6.25 (18.38)	19 4.40 (20.00)	0.85 [0.20; 3.58] 0.829	0.92 [0.30; 2.87] 0.890	-0.016 [-0.234; 0.202] 0.884
Enthesitis: Yes (N)	**32**	**40**			
Minimal Disease Activity Week 52, N' n (%)	31 11.11 (34.72)	30 14.44 (36.10)	0.95 [0.35; 2.60] 0.926	0.96 [0.51; 1.83] 0.909	-0.014 [-0.241; 0.213] 0.905
Very Low Disease Activity Week 52, N' n (%)	31 4.01 (12.53)	30 6.50 (16.25)	0.75 [0.19; 2.99] 0.688	0.77 [0.24; 2.50] 0.669	-0.037 [-0.202; 0.128] 0.658

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

34.7 MDA Minimal Disease Activity / Very Low Disease Activity by HLA-DQA1*05 (FAS)

| | Treatment Groups | | Comparison | | |
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
Minimal Disease Activity Week 52	p=0.953				
Very Low Disease Activity Week 52	p=0.929				
Non-carrier (N)	**29**	**25**			
Minimal Disease Activity Week 52, N' n (%)	28 11.93 (41.14)	22 10.90 (43.60)	0.90 [0.29; 2.75] 0.851	0.94 [0.50; 1.78] 0.859	-0.025 [-0.292; 0.243] 0.857
Very Low Disease Activity Week 52, N' n (%)	28 4.22 (14.55)	22 6.45 (25.80)	0.46 [0.11; 1.99] 0.300	0.56 [0.18; 1.77] 0.325	-0.112 [-0.334; 0.109] 0.320
Carrier (N)	**22**	**19**			
Minimal Disease Activity Week 52, N' n (%)	20 9.46 (43.00)	16 8.47 (44.58)	0.95 [0.26; 3.48] 0.934	0.97 [0.47; 1.98] 0.923	-0.016 [-0.330; 0.298] 0.921
Very Low Disease Activity Week 52, N' n (%)	20 2.04 (9.27)	16 3.01 (15.84)	0.52 [0.07; 3.61] 0.505	0.58 [0.11; 3.13] 0.530	-0.066 [-0.271; 0.139] 0.530

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

34.8 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
Minimal Disease Activity Week 52	p=0.983				
Non-carrier (N)	**28**	**19**			
Minimal Disease Activity Week 52, N' n (%)	27 11.35 (40.54)	14 8.25 (43.42)	0.93 [0.27; 3.23] 0.913	0.94 [0.46; 1.89] 0.852	-0.029 [-0.324; 0.266] 0.848
Carrier (N)	**22**	**19**			
Minimal Disease Activity Week 52, N' n (%)	20 9.04 (41.09)	18 8.12 (42.74)	0.91 [0.25; 3.31] 0.892	0.96 [0.46; 2.00] 0.916	-0.016 [-0.324; 0.291] 0.916

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

34.9 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
Minimal Disease Activity Week 52	p=0.620				
Very Low Disease Activity Week 52	p=0.429				
Non-carrier (N)	**19**	**21**			
Minimal Disease Activity Week 52, N' n (%)	19 7.00 (36.84)	16 9.49 (45.19)	0.70 [0.19; 2.65] 0.602	0.82 [0.38; 1.76] 0.607	-0.083 [-0.394; 0.227] 0.598
Very Low Disease Activity Week 52, N' n (%)	19 2.00 (10.53)	16 2.31 (11.00)	0.98 [0.12; 8.09] 0.982	0.97 [0.15; 6.15] 0.978	-0.005 [-0.202; 0.192] 0.962
Carrier (N)	**30**	**23**			
Minimal Disease Activity Week 52, N' n (%)	28 13.28 (44.27)	22 9.88 (42.96)	1.09 [0.35; 3.37] 0.878	1.03 [0.55; 1.93] 0.926	0.013 [-0.259; 0.285] 0.925
Very Low Disease Activity Week 52, N' n (%)	28 4.25 (14.17)	22 7.15 (31.09)	0.35 [0.08; 1.45] 0.148	0.45 [0.15; 1.36] 0.158	-0.169 [-0.400; 0.061] 0.150

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

34.10 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
Minimal Disease Activity Week 52	p=0.352				
Non-carrier (N)	**25**	**32**			
Minimal Disease Activity Week 52, N' n (%)	23 12.04 (48.16)	28 13.02 (40.69)	1.27 [0.43; 3.80] 0.666	1.18 [0.65; 2.14] 0.577	0.075 [-0.188; 0.338] 0.578
Carrier (N)	**26**	**12**			
Minimal Disease Activity Week 52, N' n (%)	25 9.35 (35.96)	10 6.35 (52.92)	0.54 [0.13; 2.29] 0.400	0.68 [0.32; 1.46] 0.322	-0.170 [-0.516; 0.177] 0.338

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

34.11 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
Minimal Disease Activity Week 52	p=0.833				
Non-carrier (N)	**38**	**33**			
Minimal Disease Activity Week 52, N' n (%)	35 14.39 (37.87)	27 14.37 (43.55)	0.84 [0.31; 2.25] 0.727	0.87 [0.49; 1.55] 0.635	-0.057 [-0.291; 0.177] 0.634
Carrier (N)	**12**	**9**			
Minimal Disease Activity Week 52, N' n (%)	12 6.00 (50.00)	9 5.00 (55.56)	0.67 [0.11; 3.99] 0.663	0.90 [0.40; 2.03] 0.800	-0.056 [-0.486; 0.375] 0.800

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) Minimal Disease Activity, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

34.12 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
Minimal Disease Activity Week 52	p=0.880				
Very Low Disease Activity Week 52	p=0.941				
Non-carrier (N)	**36**	**34**			
Minimal Disease Activity Week 52, N' n (%)	33 16.39 (45.53)	28 15.37 (45.21)	0.95 [0.35; 2.54] 0.914	1.01 [0.60; 1.71] 0.978	0.003 [-0.235; 0.241] 0.979
Very Low Disease Activity Week 52, N' n (%)	33 4.26 (11.83)	28 7.46 (21.94)	0.41 [0.10; 1.66] 0.212	0.54 [0.17; 1.66] 0.282	-0.101 [-0.281; 0.079] 0.270
Carrier (N)	**13**	**10**			
Minimal Disease Activity Week 52, N' n (%)	13 4.00 (30.77)	10 4.00 (40.00)	0.81 [0.14; 4.81] 0.816	0.77 [0.25; 2.34] 0.644	-0.092 [-0.486; 0.302] 0.646
Very Low Disease Activity Week 52, N' n (%)	13 1.00 (7.69)	10 2.00 (20.00)	0.37 [0.03; 5.18] 0.460	0.38 [0.04; 3.67] 0.406	-0.123 [-0.410; 0.164] 0.401

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) Minimal Disease Activity, Very Low Disease Activity, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

34.13 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
Minimal Disease Activity Week 52	p=0.655				
Very Low Disease Activity Week 52	N.E.				
Non-carrier (N)	**42**	**36**			
Minimal Disease Activity Week 52, N' n (%)	39 18.39 (43.79)	30 16.37 (45.47)	0.97 [0.38; 2.47] 0.943	0.96 [0.58; 1.60] 0.885	-0.017 [-0.242; 0.209] 0.884
Very Low Disease Activity Week 52, N' n (%)	39 4.26 (10.14)	30 8.46 (23.50)	0.36 [0.10; 1.37] 0.135	0.43 [0.14; 1.30] 0.136	-0.134 [-0.304; 0.037] 0.125
Carrier (N)	**9**	**5**			
Minimal Disease Activity Week 52, N' n (%)	9 3.00 (33.33)	5 1.00 (20.00)	1.82 [0.13; 24.53] 0.653	1.67 [0.23; 12.09] 0.613	0.133 [-0.333; 0.600] 0.575
Very Low Disease Activity Week 52, N' n (%)	9 2.00 (22.22)	5 0.00 (0.00)	N.E.	3.00 [0.17; 52.53] 0.452	0.222 [-0.049; 0.494] 0.109

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) Minimal Disease Activity, Very Low Disease Activity, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

34.14 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
Minimal Disease Activity Week 52	p=0.444				
Very Low Disease Activity Week 52	p=0.535				
Low score (N)	**11**	**22**			
Minimal Disease Activity Week 52, N' n (%)	10 6.11 (55.55)	16 9.37 (42.59)	1.64 [0.35; 7.55] 0.528	1.31 [0.62; 2.74] 0.480	0.130 [-0.239; 0.498] 0.490
Very Low Disease Activity Week 52, N' n (%)	10 1.01 (9.18)	16 2.46 (11.18)	0.80 [0.06; 10.21] 0.866	0.84 [0.09; 8.12] 0.881	-0.020 [-0.242; 0.202] 0.860
High score (N)	**40**	**22**			
Minimal Disease Activity Week 52, N' n (%)	38 15.28 (38.20)	22 10.00 (45.45)	0.79 [0.27; 2.32] 0.663	0.84 [0.46; 1.54] 0.574	-0.073 [-0.331; 0.186] 0.582
Very Low Disease Activity Week 52, N' n (%)	38 5.25 (13.13)	22 7.00 (31.82)	0.32 [0.09; 1.23] 0.097	0.41 [0.15; 1.14] 0.087	-0.187 [-0.409; 0.035] 0.099

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

34.15 MDA Minimal Disease Activity / Very Low Disease Activity by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
Minimal Disease Activity Week 52	p=0.917				
Non-carrier (N)	**31**	**23**			
Minimal Disease Activity Week 52, N' n (%)	30 12.35 (39.84)	18 10.25 (44.57)	0.89 [0.28; 2.79] 0.838	0.89 [0.47; 1.70] 0.735	-0.047 [-0.319; 0.225] 0.734
Carrier (N)	**20**	**21**			
Minimal Disease Activity Week 52, N' n (%)	18 9.04 (45.20)	20 9.12 (43.43)	0.97 [0.27; 3.48] 0.966	1.04 [0.52; 2.09] 0.912	0.018 [-0.291; 0.327] 0.910

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

34.16 MDA Minimal Disease Activity / Very Low Disease Activity by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
Minimal Disease Activity Week 52	p=0.496				
Very Low Disease Activity Week 52	p=0.423				
Non-carrier (N)	**19**	**20**			
Minimal Disease Activity Week 52, N' n (%)	19 7.00 (36.84)	15 9.49 (47.45)	0.64 [0.17; 2.47] 0.521	0.78 [0.36; 1.67] 0.519	-0.106 [-0.421; 0.209] 0.509
Very Low Disease Activity Week 52, N' n (%)	19 2.00 (10.53)	15 2.31 (11.55)	0.94 [0.11; 7.82] 0.954	0.93 [0.15; 5.85] 0.937	-0.010 [-0.212; 0.191] 0.921
Carrier (N)	**32**	**24**			
Minimal Disease Activity Week 52, N' n (%)	29 14.39 (44.97)	23 9.88 (41.17)	1.18 [0.39; 3.54] 0.770	1.09 [0.59; 2.03] 0.781	0.038 [-0.227; 0.303] 0.778
Very Low Disease Activity Week 52, N' n (%)	29 4.26 (13.31)	23 7.15 (29.79)	0.33 [0.08; 1.37] 0.127	0.44 [0.15; 1.34] 0.151	-0.165 [-0.386; 0.057] 0.145

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

34.17 MDA Minimal Disease Activity / Very Low Disease Activity by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
Minimal Disease Activity Week 52	p=0.352				
Non-carrier (N)	**25**	**32**			
Minimal Disease Activity Week 52, N' n (%)	23 12.04 (48.16)	28 13.02 (40.69)	1.27 [0.43; 3.80] 0.666	1.18 [0.65; 2.14] 0.577	0.075 [-0.188; 0.338] 0.578
Carrier (N)	**26**	**12**			
Minimal Disease Activity Week 52, N' n (%)	25 9.35 (35.96)	10 6.35 (52.92)	0.54 [0.13; 2.29] 0.400	0.68 [0.32; 1.46] 0.322	-0.170 [-0.516; 0.177] 0.338

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

34.18 MDA Minimal Disease Activity / Very Low Disease Activity by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
Minimal Disease Activity Week 52	p=0.850				
Non-carrier (N)	**39**	**35**			
Minimal Disease Activity Week 52, N' n (%)	36 15.39 (39.46)	29 14.37 (41.06)	0.99 [0.38; 2.62] 0.989	0.96 [0.54; 1.70] 0.892	-0.016 [-0.244; 0.213] 0.891
Carrier (N)	**11**	**9**			
Minimal Disease Activity Week 52, N' n (%)	11 6.00 (54.55)	9 5.00 (55.56)	0.81 [0.13; 5.02] 0.824	0.98 [0.44; 2.17] 0.964	-0.010 [-0.448; 0.428] 0.964

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) Minimal Disease Activity, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

35.0 PASDAS - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 4 Returns	64 (97.0)	56 (90.3)	120 (93.8)
Week 12 Returns	64 (97.0)	58 (93.5)	122 (95.3)
Week 16 Returns	62 (93.9)	51 (82.3)	113 (88.3)
Week 24 Returns	63 (95.5)	53 (85.5)	116 (90.6)
Week 32 Returns	60 (90.9)	48 (77.4)	108 (84.4)
Week 40 Returns	63 (95.5)	46 (74.2)	109 (85.2)
Week 52 Returns	62 (93.9)	46 (74.2)	108 (84.4)

35.1 PASDAS - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N'	66	60		
Baseline Mean (SD)	6.08 (0.91)	6.15 (0.93)		
Week 52 Mean (SD)	3.03 (1.34)	3.04 (1.21)		
Week 52 Adjusted Mean Change (SE)	-3.03 (0.16)	-2.88 (0.18)	-0.15 [-0.63; 0.32]	0.525

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

35.2 PASDAS - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC **(N=66)**	**ADA** **(N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.097				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	5.96 (0.90)	5.97 (0.91)		
Week 52 Mean (SD)	2.79 (1.15)	2.59 (1.11)		
Week 52 Adjusted Mean Change (SE)	-3.25 (0.19)	-3.35 (0.23)	0.09 [-0.51; 0.69]	0.765
Female, N	**24**	**29**		
N'	24	28		
Baseline Mean (SD)	6.29 (0.92)	6.35 (0.92)		
Week 52 Mean (SD)	3.46 (1.54)	3.53 (1.15)		
Week 52 Adjusted Mean Change (SE)	-2.65 (0.25)	-2.33 (0.25)	-0.32 [-1.02; 0.38]	0.363

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

35.3 PASDAS - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC **(N=66)**	**ADA** **(N=62)**	**Mean Difference** **[95% CI]**	**p-value**
Interaction test: p=0.826				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	4.93 (0.36)	4.82 (0.58)		
Week 52 Mean (SD)	2.39 (1.10)	3.05 (1.38)		
Week 52 Adjusted Mean Change (SE)	-3.65 (0.39)	-2.83 (0.47)	-0.82 [-1.84; 0.20]	0.115
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	47		
Baseline Mean (SD)	6.45 (0.71)	6.50 (0.64)		
Week 52 Mean (SD)	3.26 (1.34)	3.04 (1.20)		
Week 52 Adjusted Mean Change (SE)	-2.84 (0.19)	-2.87 (0.21)	0.03 [-0.50; 0.57]	0.909

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

35.4 PASDAS - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.966				
Moderate/Severe Psoriasis (Def D): No, N	28	32		
N'	28	31		
Baseline Mean (SD)	5.86 (0.84)	6.07 (0.99)		
Week 52 Mean (SD)	3.29 (1.09)	3.06 (1.38)		
Week 52 Adjusted Mean Change (SE)	-2.81 (0.25)	-2.79 (0.25)	-0.01 [-0.72; 0.69]	0.972
Moderate/Severe Psoriasis (Def D): Yes, N	38	30		
N'	38	29		
Baseline Mean (SD)	6.25 (0.94)	6.23 (0.87)		
Week 52 Mean (SD)	2.85 (1.48)	3.02 (1.07)		
Week 52 Adjusted Mean Change (SE)	-3.20 (0.21)	-2.99 (0.25)	-0.21 [-0.86; 0.44]	0.528

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

35.5 PASDAS - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.549				
≤ Median, N	40	29		
N'	40	29		
Baseline Mean (SD)	6.19 (1.03)	5.94 (1.08)		
Week 52 Mean (SD)	2.87 (1.25)	2.83 (1.00)		
Week 52 Adjusted Mean Change (SE)	-3.24 (0.21)	-2.89 (0.27)	-0.34 [-1.02; 0.33]	0.318
> Median, N	26	33		
N'	26	31		
Baseline Mean (SD)	5.92 (0.70)	6.33 (0.75)		
Week 52 Mean (SD)	3.29 (1.46)	3.18 (1.34)		
Week 52 Adjusted Mean Change (SE)	-2.72 (0.26)	-2.86 (0.24)	0.14 [-0.57; 0.85]	0.695

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

35.6 PASDAS - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		**Comparison**	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.573				
Enthesitis: No, N	**34**	**22**		
N'	34	21		
Baseline Mean (SD)	5.66 (0.73)	5.72 (0.98)		
Week 52 Mean (SD)	2.82 (1.23)	2.89 (1.14)		
Week 52 Adjusted Mean Change (SE)	-3.19 (0.24)	-3.06 (0.30)	-0.13 [-0.86; 0.61]	0.731
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	6.54 (0.88)	6.38 (0.83)		
Week 52 Mean (SD)	3.25 (1.42)	3.14 (1.27)		
Week 52 Adjusted Mean Change (SE)	-2.88 (0.24)	-2.78 (0.23)	-0.10 [-0.74; 0.55]	0.768

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

35.6 PASDAS - Change from Baseline by Enthesitis at BL According to LEI (FAS)

35.7 PASDAS - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.581				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	6.16 (0.69)	6.18 (0.93)		
Week 52 Mean (SD)	3.21 (1.54)	2.76 (1.21)		
Week 52 Adjusted Mean Change (SE)	-2.86 (0.25)	-3.26 (0.29)	0.40 [-0.36; 1.17]	0.294
Carrier, N	**22**	**19**		
N'	22	18		
Baseline Mean (SD)	6.04 (1.06)	5.95 (0.88)		
Week 52 Mean (SD)	3.00 (1.26)	3.30 (1.36)		
Week 52 Adjusted Mean Change (SE)	-3.05 (0.29)	-2.50 (0.33)	-0.54 [-1.42; 0.33]	0.221

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

35.8 PASDAS - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.125				
Non-carrier, N	**28**	**19**		
N'	28	18		
Baseline Mean (SD)	6.06 (0.84)	6.06 (0.71)		
Week 52 Mean (SD)	2.96 (1.40)	2.86 (0.90)		
Week 52 Adjusted Mean Change (SE)	-3.16 (0.27)	-2.86 (0.36)	-0.30 [-1.19; 0.58]	0.499
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	6.18 (0.91)	6.17 (0.87)		
Week 52 Mean (SD)	3.41 (1.46)	3.22 (1.55)		
Week 52 Adjusted Mean Change (SE)	-2.63 (0.30)	-2.96 (0.33)	0.33 [-0.56; 1.22]	0.462

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

35.9 PASDAS - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.240				
Non-carrier, N	**19**	**21**		
N'	19	20		
Baseline Mean (SD)	6.16 (1.02)	6.05 (0.85)		
Week 52 Mean (SD)	3.44 (1.36)	2.88 (1.22)		
Week 52 Adjusted Mean Change (SE)	-2.70 (0.31)	-2.74 (0.33)	0.04 [-0.87; 0.95]	0.931
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	6.09 (0.71)	6.10 (0.96)		
Week 52 Mean (SD)	2.95 (1.45)	3.10 (1.36)		
Week 52 Adjusted Mean Change (SE)	-3.08 (0.26)	-3.07 (0.29)	-0.02 [-0.79; 0.76]	0.968

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

35.10 PASDAS - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.229				
Non-carrier, N	25	32		
N'	25	32		
Baseline Mean (SD)	6.15 (0.94)	5.99 (0.92)		
Week 52 Mean (SD)	2.85 (1.61)	3.24 (1.33)		
Week 52 Adjusted Mean Change (SE)	-3.21 (0.27)	-2.79 (0.25)	-0.42 [-1.16; 0.32]	0.260
Carrier, N	26	12		
N'	26	11		
Baseline Mean (SD)	6.07 (0.79)	6.32 (0.84)		
Week 52 Mean (SD)	3.38 (1.19)	2.34 (0.93)		
Week 52 Adjusted Mean Change (SE)	-2.67 (0.27)	-3.28 (0.42)	0.61 [-0.39; 1.61]	0.228

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

35.11 PASDAS - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.710				
Non-carrier, N	**38**	**33**		
N'	38	32		
Baseline Mean (SD)	6.17 (0.77)	6.09 (0.95)		
Week 52 Mean (SD)	3.20 (1.42)	2.95 (1.12)		
Week 52 Adjusted Mean Change (SE)	-2.89 (0.22)	-2.89 (0.25)	0.01 [-0.66; 0.68]	0.982
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	5.93 (1.14)	5.91 (0.79)		
Week 52 Mean (SD)	2.96 (1.51)	2.70 (1.26)		
Week 52 Adjusted Mean Change (SE)	-2.97 (0.39)	-3.32 (0.45)	0.35 [-0.82; 1.53]	0.550

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

35.12 PASDAS - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.835				
Non-carrier, N	**36**	**34**		
N'	36	33		
Baseline Mean (SD)	6.23 (0.83)	6.03 (0.98)		
Week 52 Mean (SD)	3.22 (1.49)	2.88 (1.18)		
Week 52 Adjusted Mean Change (SE)	-2.91 (0.23)	-2.98 (0.25)	0.08 [-0.59; 0.75]	0.818
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	5.63 (0.74)	6.25 (0.60)		
Week 52 Mean (SD)	3.02 (1.21)	3.34 (1.56)		
Week 52 Adjusted Mean Change (SE)	-2.75 (0.38)	-2.69 (0.43)	-0.07 [-1.22; 1.09]	0.910

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

35.13 PASDAS - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.814				
Non-carrier, N	42	36		
N'	42	35		
Baseline Mean (SD)	6.03 (0.84)	6.06 (0.87)		
Week 52 Mean (SD)	3.19 (1.41)	3.01 (1.37)		
Week 52 Adjusted Mean Change (SE)	-2.85 (0.22)	-2.86 (0.24)	0.01 [-0.64; 0.66]	0.966
Carrier, N	9	5		
N'	9	5		
Baseline Mean (SD)	6.49 (0.87)	6.07 (1.36)		
Week 52 Mean (SD)	2.84 (1.50)	3.25 (0.66)		
Week 52 Adjusted Mean Change (SE)	-3.30 (0.46)	-3.09 (0.68)	-0.21 [-1.85; 1.43]	0.796

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

35.14 PASDAS - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.856				
Low score, N	**11**	**22**		
N'	11	21		
Baseline Mean (SD)	6.13 (0.76)	5.99 (0.87)		
Week 52 Mean (SD)	3.18 (1.61)	3.04 (1.04)		
Week 52 Adjusted Mean Change (SE)	-2.83 (0.42)	-2.67 (0.33)	-0.16 [-1.22; 0.90]	0.764
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	6.10 (0.89)	6.17 (0.94)		
Week 52 Mean (SD)	3.11 (1.39)	2.98 (1.48)		
Week 52 Adjusted Mean Change (SE)	-2.97 (0.22)	-3.12 (0.30)	0.16 [-0.58; 0.89]	0.670

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

35.15 PASDAS - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.202				
Non-carrier, N	**31**	**23**		
N'	31	22		
Baseline Mean (SD)	6.07 (0.90)	6.06 (0.85)		
Week 52 Mean (SD)	3.04 (1.41)	2.77 (0.99)		
Week 52 Adjusted Mean Change (SE)	-3.09 (0.24)	-2.96 (0.31)	-0.13 [-0.92; 0.65]	0.738
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	6.18 (0.80)	6.10 (0.98)		
Week 52 Mean (SD)	3.26 (1.47)	3.21 (1.50)		
Week 52 Adjusted Mean Change (SE)	-2.71 (0.31)	-2.92 (0.30)	0.21 [-0.65; 1.08]	0.622

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

35.16 PASDAS - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.248				
Non-carrier, N	**19**	**20**		
N'	19	19		
Baseline Mean (SD)	6.16 (1.02)	6.04 (0.87)		
Week 52 Mean (SD)	3.44 (1.36)	2.90 (1.27)		
Week 52 Adjusted Mean Change (SE)	-2.70 (0.32)	-2.67 (0.34)	-0.03 [-0.95; 0.89]	0.950
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	6.08 (0.76)	6.11 (0.94)		
Week 52 Mean (SD)	2.91 (1.44)	3.08 (1.33)		
Week 52 Adjusted Mean Change (SE)	-3.08 (0.25)	-3.09 (0.29)	0.01 [-0.75; 0.77]	0.976

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

35.17 PASDAS - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.229				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	6.15 (0.94)	5.99 (0.92)		
Week 52 Mean (SD)	2.85 (1.61)	3.24 (1.33)		
Week 52 Adjusted Mean Change (SE)	-3.21 (0.27)	-2.79 (0.25)	-0.42 [-1.16; 0.32]	0.260
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	6.07 (0.79)	6.32 (0.84)		
Week 52 Mean (SD)	3.38 (1.19)	2.34 (0.93)		
Week 52 Adjusted Mean Change (SE)	-2.67 (0.27)	-3.28 (0.42)	0.61 [-0.39; 1.61]	0.228

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

35.18 PASDAS - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.768				
Non-carrier, N	**39**	**35**		
N'	39	34		
Baseline Mean (SD)	6.16 (0.76)	6.09 (0.93)		
Week 52 Mean (SD)	3.18 (1.41)	3.05 (1.15)		
Week 52 Adjusted Mean Change (SE)	-2.91 (0.22)	-2.84 (0.25)	-0.07 [-0.73; 0.60]	0.842
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	5.82 (1.12)	6.02 (0.86)		
Week 52 Mean (SD)	2.83 (1.50)	2.90 (1.72)		
Week 52 Adjusted Mean Change (SE)	-3.08 (0.42)	-3.15 (0.45)	0.07 [-1.16; 1.29]	0.914

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

36.1 PASDAS Good Response / Moderate-to-Good Response (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASDAS Good Response Week 52, N' n (%)	62 33.00 (50.00)	46 31.79 (51.27)	0.96 [0.46; 1.98] 0.907	0.98 [0.68; 1.39] 0.894	-0.013 [-0.193; 0.167] 0.890
PASDAS Moderate-to-Good Response Week 52, N' n (%)	62 60.41 (91.53)	46 54.65 (88.15)	1.57 [0.43; 5.75] 0.495	1.04 [0.92; 1.18] 0.556	0.034 [-0.079; 0.146] 0.556

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.
RR and RD calculated directly without adjustment.

All results are combined over MI:
n and % are averages of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

36.2 PASDAS Good Response / Moderate-to-Good Response by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASDAS Good Response Week 52	p=0.613				
PASDAS Moderate-to-Good Response Week 52	p=0.834				
Male (N)	**42**	**33**			
PASDAS Good Response Week 52, N' n (%)	39 25.01 (59.55)	24 22.77 (69.00)	0.68 [0.23; 1.95] 0.470	0.86 [0.60; 1.24] 0.426	-0.095 [-0.325; 0.136] 0.422
PASDAS Moderate-to-Good Response Week 52, N' n (%)	39 39.41 (93.83)	24 31.10 (94.24)	1.09 [0.11; 10.75] 0.942	1.00 [0.88; 1.13] 0.946	-0.004 [-0.120; 0.112] 0.945
Female (N)	**24**	**29**			
PASDAS Good Response Week 52, N' n (%)	23 7.99 (33.29)	22 9.02 (31.10)	1.03 [0.31; 3.45] 0.965	1.07 [0.48; 2.40] 0.861	0.022 [-0.237; 0.280] 0.868
PASDAS Moderate-to-Good Response Week 52, N' n (%)	23 21.00 (87.50)	22 23.55 (81.21)	1.48 [0.27; 8.06] 0.652	1.08 [0.84; 1.38] 0.552	0.063 [-0.145; 0.271] 0.552

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

36.3 PASDAS Good Response / Moderate-to-Good Response by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASDAS Good Response Week 52	p=0.260				
PASDAS Moderate-to-Good Response Week 52	p=0.087				
PASDAS < 5.4 (N)	**16**	**13**			
PASDAS Good Response Week 52, N' n (%)	16 11.00 (68.75)	8 6.73 (51.77)	2.13 [0.42; 10.77] 0.360	1.34 [0.69; 2.61] 0.394	0.170 [-0.201; 0.541] 0.370
PASDAS Moderate-to-Good Response Week 52, N' n (%)	16 15.00 (93.75)	8 8.64 (66.46)	10.20 [0.75; 138.34] 0.081	1.42 [0.91; 2.20] 0.123	0.273 [-0.029; 0.574] 0.076
PASDAS ≥ 5.4 (N)	**50**	**49**			
PASDAS Good Response Week 52, N' n (%)	46 22.00 (44.00)	38 25.06 (51.14)	0.75 [0.33; 1.71] 0.496	0.86 [0.56; 1.32] 0.494	-0.071 [-0.274; 0.132] 0.490
PASDAS Moderate-to-Good Response Week 52, N' n (%)	46 45.41 (90.82)	38 46.01 (93.90)	0.63 [0.10; 4.07] 0.624	0.97 [0.85; 1.10] 0.603	-0.031 [-0.145; 0.084] 0.598

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

36.4 PASDAS Good Response / Moderate-to-Good Response by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASDAS Good Response Week 52	p=0.930				
PASDAS Moderate-to-Good Response Week 52	p=0.578				
Moderate/Severe Psoriasis (Def D): No (N)	**28**	**32**			
PASDAS Good Response Week 52, N' n (%)	26 11.76 (42.00)	22 14.17 (44.28)	0.88 [0.30; 2.59] 0.810	0.95 [0.52; 1.75] 0.872	-0.023 [-0.285; 0.240] 0.865
PASDAS Moderate-to-Good Response Week 52, N' n (%)	26 24.99 (89.25)	22 26.19 (81.84)	1.85 [0.35; 9.63] 0.467	1.09 [0.87; 1.37] 0.444	0.074 [-0.114; 0.262] 0.441
Moderate/Severe Psoriasis (Def D): Yes (N)	**38**	**30**			
PASDAS Good Response Week 52, N' n (%)	36 21.24 (55.89)	24 17.62 (58.73)	0.94 [0.34; 2.61] 0.900	0.95 [0.62; 1.47] 0.827	-0.028 [-0.276; 0.219] 0.822
PASDAS Moderate-to-Good Response Week 52, N' n (%)	36 35.42 (93.21)	24 28.46 (94.87)	0.81 [0.07; 8.96] 0.860	0.98 [0.86; 1.12] 0.795	-0.017 [-0.140; 0.107] 0.792

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

36.5 PASDAS Good Response / Moderate-to-Good Response by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASDAS Good Response Week 52	p=0.854				
PASDAS Moderate-to-Good Response Week 52	p=0.463				
≤ Median (N)	**40**	**29**			
PASDAS Good Response Week 52, N' n (%)	38 20.00 (50.00)	19 15.69 (54.10)	0.89 [0.32; 2.47] 0.816	0.93 [0.57; 1.50] 0.755	-0.041 [-0.292; 0.210] 0.749
PASDAS Moderate-to-Good Response Week 52, N' n (%)	38 37.96 (94.90)	19 26.16 (90.21)	2.55 [0.29; 22.16] 0.396	1.05 [0.90; 1.23] 0.519	0.047 [-0.094; 0.188] 0.515
> Median (N)	**26**	**33**			
PASDAS Good Response Week 52, N' n (%)	24 13.00 (50.00)	27 16.10 (48.79)	1.02 [0.35; 2.96] 0.974	1.03 [0.60; 1.76] 0.923	0.012 [-0.252; 0.276] 0.928
PASDAS Moderate-to-Good Response Week 52, N' n (%)	24 22.45 (86.35)	27 28.49 (86.33)	0.92 [0.17; 4.87] 0.918	1.00 [0.80; 1.25] 0.996	0.000 [-0.189; 0.189] 0.999

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

36.6 PASDAS Good Response / Moderate-to-Good Response by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASDAS Good Response Week 52	p=0.841				
PASDAS Moderate-to-Good Response Week 52	p=0.516				
Enthesitis: No (N)	**34**	**22**			
PASDAS Good Response Week 52, N' n (%)	31 17.77 (52.26)	18 11.30 (51.36)	1.02 [0.33; 3.15] 0.977	1.02 [0.59; 1.75] 0.944	0.009 [-0.269; 0.287] 0.949
PASDAS Moderate-to-Good Response Week 52, N' n (%)	31 30.44 (89.53)	18 19.82 (90.09)	0.92 [0.11; 7.56] 0.941	0.99 [0.82; 1.21] 0.955	-0.006 [-0.182; 0.171] 0.950
Enthesitis: Yes (N)	**32**	**40**			
PASDAS Good Response Week 52, N' n (%)	31 15.23 (47.59)	28 20.49 (51.23)	0.87 [0.33; 2.32] 0.783	0.93 [0.57; 1.52] 0.774	-0.036 [-0.278; 0.205] 0.768
PASDAS Moderate-to-Good Response Week 52, N' n (%)	31 29.97 (93.66)	28 34.83 (87.08)	2.32 [0.37; 14.41] 0.365	1.08 [0.92; 1.26] 0.369	0.066 [-0.076; 0.208] 0.365

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

36.7 PASDAS Good Response / Moderate-to-Good Response by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASDAS Good Response Week 52	p=0.294				
PASDAS Moderate-to-Good Response Week 52	N.E.				
Non-carrier (N)	**29**	**25**			
PASDAS Good Response Week 52, N' n (%)	27 13.00 (44.83)	19 15.85 (63.40)	0.45 [0.14; 1.47] 0.186	0.71 [0.42; 1.19] 0.193	-0.186 [-0.459; 0.087] 0.183
PASDAS Moderate-to-Good Response Week 52, N' n (%)	27 24.45 (84.31)	19 24.09 (96.36)	N.E.	0.88 [0.72; 1.06] 0.166	-0.120 [-0.285; 0.044] 0.151
Carrier (N)	**22**	**19**			
PASDAS Good Response Week 52, N' n (%)	20 11.00 (50.00)	16 8.91 (46.89)	1.16 [0.31; 4.27] 0.828	1.07 [0.55; 2.07] 0.846	0.031 [-0.287; 0.349] 0.848
PASDAS Moderate-to-Good Response Week 52, N' n (%)	20 20.96 (95.27)	16 15.25 (80.26)	6.69 [0.50; 89.83] 0.151	1.19 [0.92; 1.54] 0.192	0.150 [-0.062; 0.362] 0.165

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

36.8 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASDAS Good Response Week 52	p=0.485				
PASDAS Moderate-to-Good Response Week 52	N.E.				
Non-carrier (N)	**28**	**19**			
PASDAS Good Response Week 52, N' n (%)	27 13.77 (49.18)	13 10.11 (53.21)	0.89 [0.25; 3.21] 0.860	0.93 [0.51; 1.70] 0.809	-0.040 [-0.349; 0.269] 0.798
PASDAS Moderate-to-Good Response Week 52, N' n (%)	27 25.99 (92.82)	13 17.45 (91.84)	N.E.	1.01 [0.83; 1.24] 0.907	0.010 [-0.175; 0.194] 0.917
Carrier (N)	**22**	**19**			
PASDAS Good Response Week 52, N' n (%)	19 9.23 (41.95)	17 11.38 (59.89)	0.46 [0.12; 1.72] 0.249	0.70 [0.37; 1.31] 0.268	-0.179 [-0.489; 0.130] 0.256
PASDAS Moderate-to-Good Response Week 52, N' n (%)	19 18.42 (83.73)	17 15.89 (83.63)	1.16 [0.16; 8.22] 0.885	1.00 [0.76; 1.32] 0.995	0.001 [-0.233; 0.235] 0.994

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

36.9 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASDAS Good Response Week 52	p=0.478				
PASDAS Moderate-to-Good Response Week 52	N.E.				
Non-carrier (N)	**19**	**21**			
PASDAS Good Response Week 52, N' n (%)	19 7.00 (36.84)	15 11.64 (55.43)	0.45 [0.12; 1.78] 0.258	0.67 [0.32; 1.38] 0.273	-0.186 [-0.503; 0.131] 0.251
PASDAS Moderate-to-Good Response Week 52, N' n (%)	19 16.00 (84.21)	15 19.36 (92.19)	N.E.	0.91 [0.71; 1.18] 0.492	-0.080 [-0.300; 0.141] 0.478
Carrier (N)	**30**	**23**			
PASDAS Good Response Week 52, N' n (%)	27 15.77 (52.57)	20 13.12 (57.04)	0.86 [0.28; 2.70] 0.802	0.92 [0.56; 1.52] 0.752	-0.045 [-0.320; 0.231] 0.750
PASDAS Moderate-to-Good Response Week 52, N' n (%)	27 27.44 (91.47)	20 19.98 (86.87)	2.10 [0.28; 15.49] 0.467	1.05 [0.86; 1.28] 0.609	0.046 [-0.128; 0.220] 0.605

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

36.10 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASDAS Good Response Week 52	p=0.270				
PASDAS Moderate-to-Good Response Week 52	N.E.				
Non-carrier (N)	**25**	**32**			
PASDAS Good Response Week 52, N' n (%)	23 14.22 (56.88)	26 17.15 (53.59)	1.07 [0.35; 3.29] 0.904	1.06 [0.65; 1.73] 0.807	0.033 [-0.236; 0.302] 0.811
PASDAS Moderate-to-Good Response Week 52, N' n (%)	23 21.97 (87.88)	26 28.27 (88.34)	0.94 [0.15; 5.88] 0.946	0.99 [0.82; 1.21] 0.960	-0.005 [-0.178; 0.169] 0.958
Carrier (N)	**26**	**12**			
PASDAS Good Response Week 52, N' n (%)	24 9.78 (37.62)	9 7.61 (63.42)	0.37 [0.08; 1.70] 0.200	0.59 [0.30; 1.18] 0.137	-0.258 [-0.605; 0.089] 0.145
PASDAS Moderate-to-Good Response Week 52, N' n (%)	24 23.44 (90.15)	9 11.07 (92.25)	N.E.	0.98 [0.76; 1.27] 0.874	-0.021 [-0.249; 0.207] 0.857

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

36.11 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASDAS Good Response Week 52	p=0.660				
PASDAS Moderate-to-Good Response Week 52	N.E.				
Non-carrier (N)	**38**	**33**			
PASDAS Good Response Week 52, N' n (%)	34 17.00 (44.74)	24 18.76 (56.85)	0.65 [0.24; 1.79] 0.405	0.79 [0.49; 1.28] 0.336	-0.121 [-0.365; 0.123] 0.330
PASDAS Moderate-to-Good Response Week 52, N' n (%)	34 33.41 (87.92)	24 29.34 (88.91)	1.32 [0.21; 8.48] 0.770	0.99 [0.82; 1.19] 0.909	-0.010 [-0.171; 0.151] 0.904
Carrier (N)	**12**	**9**			
PASDAS Good Response Week 52, N' n (%)	12 6.00 (50.00)	9 6.00 (66.67)	0.40 [0.06; 2.56] 0.337	0.75 [0.36; 1.56] 0.440	-0.167 [-0.585; 0.252] 0.435
PASDAS Moderate-to-Good Response Week 52, N' n (%)	12 11.00 (91.67)	9 9.00 (100.00)	N.E.	0.92 [0.77; 1.09] 0.317	-0.083 [-0.240; 0.073] 0.296

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) PASDAS Good Response, PASDAS Moderate-to-Good Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

36.12 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs8007401 (FAS)

| | Treatment Groups | | Comparison | | |
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASDAS Good Response Week 52	p=0.870				
PASDAS Moderate-to-Good Response Week 52	p=0.922				
Non-carrier (N)	**36**	**34**			
PASDAS Good Response Week 52, N' n (%)	33 17.99 (49.97)	25 19.76 (58.12)	0.66 [0.24; 1.84] 0.426	0.86 [0.55; 1.36] 0.519	-0.081 [-0.326; 0.163] 0.513
PASDAS Moderate-to-Good Response Week 52, N' n (%)	33 32.96 (91.56)	25 30.34 (89.24)	1.11 [0.18; 6.99] 0.909	1.03 [0.87; 1.21] 0.758	0.023 [-0.126; 0.173] 0.761
Carrier (N)	**13**	**10**			
PASDAS Good Response Week 52, N' n (%)	12 5.01 (38.54)	10 5.00 (50.00)	0.78 [0.14; 4.41] 0.779	0.77 [0.31; 1.94] 0.581	-0.115 [-0.522; 0.293] 0.582
PASDAS Moderate-to-Good Response Week 52, N' n (%)	12 10.45 (80.38)	10 9.00 (90.00)	1.33 [0.06; 28.87] 0.855	0.89 [0.63; 1.27] 0.526	-0.096 [-0.390; 0.198] 0.522

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

36.13 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASDAS Good Response Week 52	p=0.609				
PASDAS Moderate-to-Good Response Week 52	N.E.				
Non-carrier (N)	**42**	**36**			
PASDAS Good Response Week 52, N' n (%)	38 20.00 (47.62)	29 19.55 (54.31)	0.79 [0.30; 2.04] 0.619	0.88 [0.56; 1.38] 0.573	-0.067 [-0.297; 0.164] 0.570
PASDAS Moderate-to-Good Response Week 52, N' n (%)	38 36.41 (86.69)	29 32.35 (89.86)	0.87 [0.16; 4.82] 0.869	0.97 [0.81; 1.15] 0.689	-0.032 [-0.185; 0.122] 0.685
Carrier (N)	**9**	**5**			
PASDAS Good Response Week 52, N' n (%)	9 4.00 (44.44)	3 3.21 (64.20)	0.39 [0.03; 4.83] 0.463	0.70 [0.25; 2.00] 0.507	-0.198 [-0.759; 0.364] 0.491
PASDAS Moderate-to-Good Response Week 52, N' n (%)	9 9.00 (100.00)	3 3.99 (79.80)	N.E.	1.25 [0.80; 1.96] 0.320	0.202 [-0.152; 0.556] 0.263

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

36.14 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASDAS Good Response Week 52	p=0.824				
PASDAS Moderate-to-Good Response Week 52	N.E.				
Low score (N)	**11**	**22**			
PASDAS Good Response Week 52, N' n (%)	10 5.23 (47.55)	15 11.55 (52.50)	0.77 [0.16; 3.68] 0.747	0.91 [0.42; 1.97] 0.804	-0.050 [-0.428; 0.329] 0.798
PASDAS Moderate-to-Good Response Week 52, N' n (%)	10 8.97 (81.55)	15 20.35 (92.50)	N.E.	0.88 [0.64; 1.22] 0.447	-0.110 [-0.379; 0.160] 0.425
High score (N)	**40**	**22**			
PASDAS Good Response Week 52, N' n (%)	37 18.77 (46.93)	20 13.21 (60.05)	0.62 [0.21; 1.87] 0.399	0.78 [0.48; 1.27] 0.318	-0.131 [-0.392; 0.130] 0.325
PASDAS Moderate-to-Good Response Week 52, N' n (%)	37 36.44 (91.10)	20 18.99 (86.32)	3.00 [0.40; 22.65] 0.287	1.06 [0.87; 1.28] 0.589	0.048 [-0.123; 0.219] 0.583

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

36.15 PASDAS Good Response / Moderate-to-Good Response by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASDAS Good Response Week 52	p=0.598				
PASDAS Moderate-to-Good Response Week 52	N.E.				
Non-carrier (N)	**31**	**23**			
PASDAS Good Response Week 52, N' n (%)	30 14.77 (47.65)	16 12.38 (53.83)	0.84 [0.26; 2.76] 0.779	0.89 [0.51; 1.55] 0.677	-0.062 [-0.346; 0.223] 0.670
PASDAS Moderate-to-Good Response Week 52, N' n (%)	30 27.99 (90.29)	16 21.45 (93.26)	N.E.	0.97 [0.81; 1.16] 0.738	-0.030 [-0.197; 0.138] 0.728
Carrier (N)	**20**	**21**			
PASDAS Good Response Week 52, N' n (%)	17 9.23 (46.15)	19 12.38 (58.95)	0.53 [0.14; 1.92] 0.332	0.78 [0.43; 1.44] 0.429	-0.128 [-0.438; 0.182] 0.419
PASDAS Moderate-to-Good Response Week 52, N' n (%)	17 17.42 (87.10)	19 17.89 (85.19)	0.99 [0.14; 7.12] 0.990	1.02 [0.79; 1.32] 0.867	0.019 [-0.200; 0.238] 0.864

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

36.16 PASDAS Good Response / Moderate-to-Good Response by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction test					
PASDAS Good Response Week 52	p=0.615				
PASDAS Moderate-to-Good Response Week 52	N.E.				
Non-carrier (N)	**19**	**20**			
PASDAS Good Response Week 52, N' n (%)	19 7.00 (36.84)	14 10.64 (53.20)	0.51 [0.13; 2.01] 0.333	0.70 [0.33; 1.46] 0.338	-0.164 [-0.486; 0.159] 0.320
PASDAS Moderate-to-Good Response Week 52, N' n (%)	19 16.00 (84.21)	14 18.36 (91.80)	N.E.	0.92 [0.71; 1.19] 0.523	-0.076 [-0.301; 0.150] 0.509
Carrier (N)	**32**	**24**			
PASDAS Good Response Week 52, N' n (%)	28 17.00 (53.13)	21 14.12 (58.83)	0.80 [0.26; 2.44] 0.691	0.90 [0.56; 1.46] 0.678	-0.057 [-0.326; 0.212] 0.677
PASDAS Moderate-to-Good Response Week 52, N' n (%)	28 29.41 (91.91)	21 20.98 (87.42)	2.02 [0.28; 14.59] 0.486	1.05 [0.87; 1.27] 0.602	0.045 [-0.122; 0.212] 0.598

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

36.17 PASDAS Good Response / Moderate-to-Good Response by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASDAS Good Response Week 52	p=0.270				
PASDAS Moderate-to-Good Response Week 52	N.E.				
Non-carrier (N)	**25**	**32**			
PASDAS Good Response Week 52, N' n (%)	23 14.22 (56.88)	26 17.15 (53.59)	1.07 [0.35; 3.29] 0.904	1.06 [0.65; 1.73] 0.807	0.033 [-0.236; 0.302] 0.811
PASDAS Moderate-to-Good Response Week 52, N' n (%)	23 21.97 (87.88)	26 28.27 (88.34)	0.94 [0.15; 5.88] 0.946	0.99 [0.82; 1.21] 0.960	-0.005 [-0.178; 0.169] 0.958
Carrier (N)	**26**	**12**			
PASDAS Good Response Week 52, N' n (%)	24 9.78 (37.62)	9 7.61 (63.42)	0.37 [0.08; 1.70] 0.200	0.59 [0.30; 1.18] 0.137	-0.258 [-0.605; 0.089] 0.145
PASDAS Moderate-to-Good Response Week 52, N' n (%)	24 23.44 (90.15)	9 11.07 (92.25)	N.E.	0.98 [0.76; 1.27] 0.874	-0.021 [-0.249; 0.207] 0.857

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

36.18 PASDAS Good Response / Moderate-to-Good Response by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PASDAS Good Response Week 52	p=0.659				
PASDAS Moderate-to-Good Response Week 52	p=0.734				
Non-carrier (N)	**39**	**35**			
PASDAS Good Response Week 52, N' n (%)	35 18.00 (46.15)	26 18.76 (53.60)	0.79 [0.29; 2.11] 0.634	0.86 [0.53; 1.39] 0.546	-0.074 [-0.313; 0.164] 0.541
PASDAS Moderate-to-Good Response Week 52, N' n (%)	35 34.41 (88.23)	26 31.34 (89.54)	1.27 [0.20; 7.99] 0.801	0.99 [0.83; 1.17] 0.872	-0.013 [-0.168; 0.142] 0.868
Carrier (N)	**11**	**9**			
PASDAS Good Response Week 52, N' n (%)	11 6.00 (54.55)	9 6.00 (66.67)	0.49 [0.07; 3.21] 0.454	0.82 [0.40; 1.66] 0.580	-0.121 [-0.547; 0.305] 0.577
PASDAS Moderate-to-Good Response Week 52, N' n (%)	11 10.00 (90.91)	9 8.00 (88.89)	0.67 [0.03; 14.87] 0.799	1.02 [0.76; 1.38] 0.882	0.020 [-0.246; 0.287] 0.882

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) PASDAS Good Response, PASDAS Moderate-to-Good Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

37.1 PsARC Response (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PsARC Response Week 52, N' n (%)	62 61.81 (93.65)	46 56.04 (90.39)	1.84 [0.41; 8.15] 0.422	1.04 [0.93; 1.16] 0.528	0.033 [-0.069; 0.134] 0.527

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.
RR and RD calculated directly without adjustment.

All results are combined over MI:
n and % are averages of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

37.2 PsARC Response by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PsARC Response Week 52	p=0.419				
Male (N)	**42**	**33**			
PsARC Response Week 52, N' n (%)	39 40.81 (97.17)	24 30.91 (93.67)	4.00 [0.20; 81.65] 0.368	1.04 [0.92; 1.17] 0.534	0.035 [-0.074; 0.144] 0.530
Female (N)	**24**	**29**			
PsARC Response Week 52, N' n (%)	23 21.00 (87.50)	22 25.13 (86.66)	0.92 [0.15; 5.84] 0.934	1.01 [0.81; 1.26] 0.927	0.008 [-0.180; 0.197] 0.930

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

37.3 PsARC Response by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PsARC Response Week 52	N.E.				
PASDAS < 5.4 (N)	**16**	**13**			
PsARC Response Week 52, N' n (%)	16 16.00 (100.00)	8 11.02 (84.77)	N.E.	1.18 [0.91; 1.54] 0.215	0.152 [-0.067; 0.372] 0.173
PASDAS ≥ 5.4 (N)	**50**	**49**			
PsARC Response Week 52, N' n (%)	46 45.81 (91.62)	38 45.02 (91.88)	1.16 [0.22; 6.26] 0.859	1.00 [0.88; 1.13] 0.967	-0.003 [-0.117; 0.112] 0.965

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

37.4 PsARC Response by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PsARC Response Week 52	p=0.421				
Moderate/Severe Psoriasis (Def D): No (N)	28	32			
PsARC Response Week 52, N' n (%)	26 27.00 (96.43)	22 28.40 (88.75)	4.43 [0.31; 63.56] 0.273	1.09 [0.93; 1.28] 0.305	0.077 [-0.066; 0.220] 0.293
Moderate/Severe Psoriasis (Def D): Yes (N)	38	30			
PsARC Response Week 52, N' n (%)	36 34.81 (91.61)	24 27.64 (92.13)	1.16 [0.16; 8.14] 0.883	0.99 [0.86; 1.16] 0.942	-0.005 [-0.143; 0.133] 0.940

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

37.5 PsARC Response by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PsARC Response Week 52	N.E.				
≤ Median (N)	**40**	**29**			
PsARC Response Week 52, N' n (%)	38 38.99 (97.48)	19 28.19 (97.21)	N.E.	1.00 [0.91; 1.11] 0.950	0.003 [-0.091; 0.096] 0.955
> Median (N)	**26**	**33**			
PsARC Response Week 52, N' n (%)	24 22.82 (87.77)	27 27.85 (84.39)	1.26 [0.22; 7.37] 0.798	1.04 [0.84; 1.29] 0.720	0.034 [-0.151; 0.219] 0.721

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

37.6 PsARC Response by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PsARC Response Week 52	N.E.				
Enthesitis: No (N)	**34**	**22**			
PsARC Response Week 52, N' n (%)	31 31.82 (93.59)	18 21.65 (98.41)	N.E.	0.95 [0.85; 1.07] 0.408	-0.048 [-0.160; 0.063] 0.396
Enthesitis: Yes (N)	**32**	**40**			
PsARC Response Week 52, N' n (%)	31 29.99 (93.72)	28 34.39 (85.98)	2.90 [0.43; 19.59] 0.274	1.09 [0.92; 1.29] 0.303	0.077 [-0.068; 0.223] 0.296

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

37.7 PsARC Response by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PsARC Response Week 52	p=0.200				
Non-carrier (N)	**29**	**25**			
PsARC Response Week 52, N' n (%)	27 25.82 (89.03)	19 23.13 (92.52)	0.68 [0.07; 6.74] 0.743	0.96 [0.80; 1.15] 0.681	-0.035 [-0.199; 0.129] 0.677
Carrier (N)	**22**	**19**			
PsARC Response Week 52, N' n (%)	20 20.99 (95.41)	16 15.69 (82.58)	6.21 [0.50; 76.98] 0.155	1.16 [0.91; 1.46] 0.227	0.128 [-0.070; 0.326] 0.205

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

37.8 PsARC Response by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction test					
PsARC Response Week 52	p=0.837				
Non-carrier (N)	**28**	**19**			
PsARC Response Week 52, N' n (%)	27 26.00 (92.86)	13 17.03 (89.63)	1.70 [0.15; 19.18] 0.668	1.04 [0.85; 1.27] 0.726	0.032 [-0.149; 0.214] 0.728
Carrier (N)	**22**	**19**			
PsARC Response Week 52, N' n (%)	19 19.81 (90.05)	17 15.80 (83.16)	2.38 [0.28; 19.85] 0.424	1.08 [0.84; 1.40] 0.540	0.069 [-0.148; 0.286] 0.533

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

37.9 PsARC Response by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PsARC Response Week 52	p=0.989				
Non-carrier (N)	**19**	**21**			
PsARC Response Week 52, N' n (%)	19 17.00 (89.47)	15 17.93 (85.38)	1.73 [0.19; 15.41] 0.622	1.05 [0.82; 1.35] 0.708	0.041 [-0.174; 0.256] 0.709
Carrier (N)	**30**	**23**			
PsARC Response Week 52, N' n (%)	27 27.82 (92.73)	20 20.89 (90.83)	1.70 [0.20; 14.65] 0.631	1.02 [0.86; 1.21] 0.810	0.019 [-0.136; 0.174] 0.809

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

37.10 PsARC Response by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PsARC Response Week 52	N.E.				
Non-carrier (N)	**25**	**32**			
PsARC Response Week 52, N' n (%)	23 23.99 (95.96)	26 27.12 (84.75)	4.72 [0.44; 50.86] 0.201	1.13 [0.95; 1.35] 0.162	0.112 [-0.040; 0.264] 0.148
Carrier (N)	**26**	**12**			
PsARC Response Week 52, N' n (%)	24 22.82 (87.77)	9 11.70 (97.50)	N.E.	0.90 [0.74; 1.10] 0.302	-0.097 [-0.274; 0.080] 0.281

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

37.11 PsARC Response by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PsARC Response Week 52	N.E.				
Non-carrier (N)	**38**	**33**			
PsARC Response Week 52, N' n (%)	34 33.81 (88.97)	24 28.82 (87.33)	1.59 [0.29; 8.61] 0.592	1.02 [0.85; 1.22] 0.838	0.016 [-0.143; 0.176] 0.840
Carrier (N)	**12**	**9**			
PsARC Response Week 52, N' n (%)	12 12.00 (100.00)	9 9.00 (100.00)	N.E.	N.E.	N.E.

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

37.12 PsARC Response by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PsARC Response Week 52	p=0.193				
Non-carrier (N)	**36**	**34**			
PsARC Response Week 52, N' n (%)	33 32.99 (91.64)	25 30.82 (90.65)	0.94 [0.15; 6.12] 0.952	1.01 [0.87; 1.18] 0.887	0.010 [-0.131; 0.151] 0.890
Carrier (N)	**13**	**10**			
PsARC Response Week 52, N' n (%)	12 11.82 (90.92)	10 8.00 (80.00)	14.92 [0.38; 581.52] 0.148	1.14 [0.79; 1.63] 0.489	0.109 [-0.189; 0.408] 0.473

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

37.13 PsARC Response by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PsARC Response Week 52	N.E.				
Non-carrier (N)	**42**	**36**			
PsARC Response Week 52, N' n (%)	38 37.81 (90.02)	29 31.91 (88.64)	1.47 [0.28; 7.76] 0.653	1.02 [0.86; 1.20] 0.850	0.014 [-0.131; 0.158] 0.851
Carrier (N)	**9**	**5**			
PsARC Response Week 52, N' n (%)	9 9.00 (100.00)	3 3.91 (78.20)	N.E.	1.28 [0.77; 2.14] 0.339	0.218 [-0.161; 0.597] 0.260

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

37.14 PsARC Response by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PsARC Response Week 52	p=0.281				
Low score (N)	**11**	**22**			
PsARC Response Week 52, N' n (%)	10 8.99 (81.73)	15 18.91 (85.95)	0.57 [0.07; 5.03] 0.616	0.95 [0.68; 1.33] 0.772	-0.042 [-0.321; 0.237] 0.766
High score (N)	**40**	**22**			
PsARC Response Week 52, N' n (%)	37 37.82 (94.55)	20 19.91 (90.50)	3.41 [0.33; 35.34] 0.304	1.04 [0.89; 1.23] 0.590	0.040 [-0.105; 0.186] 0.585

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

37.15 PsARC Response by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PsARC Response Week 52	p=0.729				
Non-carrier (N)	**31**	**23**			
PsARC Response Week 52, N' n (%)	30 29.00 (93.55)	16 21.02 (91.39)	2.21 [0.17; 28.55] 0.542	1.02 [0.86; 1.21] 0.783	0.022 [-0.133; 0.177] 0.785
Carrier (N)	**20**	**21**			
PsARC Response Week 52, N' n (%)	17 17.81 (89.05)	19 17.80 (84.76)	1.24 [0.17; 9.24] 0.833	1.05 [0.82; 1.34] 0.695	0.043 [-0.170; 0.256] 0.693

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

37.16 PsARC Response by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PsARC Response Week 52	p=0.935				
Non-carrier (N)	**19**	**20**			
PsARC Response Week 52, N' n (%)	19 17.00 (89.47)	14 16.93 (84.65)	1.86 [0.21; 16.68] 0.581	1.06 [0.82; 1.37] 0.668	0.048 [-0.173; 0.269] 0.669
Carrier (N)	**32**	**24**			
PsARC Response Week 52, N' n (%)	28 29.81 (93.16)	21 21.89 (91.21)	1.64 [0.19; 13.93] 0.652	1.02 [0.87; 1.20] 0.797	0.019 [-0.128; 0.167] 0.796

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

37.17 PsARC Response by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction test					
PsARC Response Week 52	N.E.				
Non-carrier (N)	**25**	**32**			
PsARC Response Week 52, N' n (%)	23 23.99 (95.96)	26 27.12 (84.75)	4.72 [0.44; 50.86] 0.201	1.13 [0.95; 1.35] 0.162	0.112 [-0.040; 0.264] 0.148
Carrier (N)	**26**	**12**			
PsARC Response Week 52, N' n (%)	24 22.82 (87.77)	9 11.70 (97.50)	N.E.	0.90 [0.74; 1.10] 0.302	-0.097 [-0.274; 0.080] 0.281

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

37.18 PsARC Response by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
PsARC Response Week 52	N.E.				
Non-carrier (N)	**39**	**35**			
PsARC Response Week 52, N' n (%)	35 34.81 (89.26)	26 30.82 (88.06)	1.51 [0.28; 8.07] 0.632	1.01 [0.85; 1.21] 0.876	0.012 [-0.141; 0.165] 0.878
Carrier (N)	**11**	**9**			
PsARC Response Week 52, N' n (%)	11 11.00 (100.00)	9 8.00 (88.89)	N.E.	1.13 [0.89; 1.42] 0.318	0.111 [-0.094; 0.316] 0.289

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) PsARC Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

38.0 DLQI - Return Rates (FAS)

	Treatment Groups		
	SEC **(N=66)**	**ADA** **(N=62)**	**Total** **(N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	57 (91.9)	122 (95.3)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	48 (77.4)	111 (86.7)

38.1 DLQI - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N'	66	60		
Baseline Mean (SD)	12.68 (8.44)	13.31 (7.33)		
Week 52 Mean (SD)	2.92 (4.30)	4.94 (6.74)		
Week 4 Adjusted Mean Change (SE)	-7.14 (0.62)	-5.32 (0.65)		
Week 12 Adjusted Mean Change (SE)	-9.07 (0.66)	-6.86 (0.69)		
Week 16 Adjusted Mean Change (SE)	-8.77 (0.60)	-6.60 (0.63)		
Week 24 Adjusted Mean Change (SE)	-8.97 (0.65)	-7.45 (0.70)		
Week 32 Adjusted Mean Change (SE)	-9.45 (0.61)	-8.05 (0.66)		
Week 40 Adjusted Mean Change (SE)	-9.14 (0.58)	-8.24 (0.65)		
Week 52 Adjusted Mean Change (SE)	-9.92 (0.63)	-7.65 (0.71)	-2.27 [-4.16; -0.39]	0.018

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

38.2 DLQI - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.355				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	13.69 (8.41)	12.42 (6.81)		
Week 52 Mean (SD)	3.23 (4.99)	4.88 (6.07)		
Week 4 Adjusted Mean Change (SE)	-8.02 (0.78)	-4.91 (0.89)		
Week 12 Adjusted Mean Change (SE)	-9.98 (0.82)	-6.91 (0.93)		
Week 16 Adjusted Mean Change (SE)	-8.98 (0.76)	-6.74 (0.86)		
Week 24 Adjusted Mean Change (SE)	-9.73 (0.81)	-7.78 (0.96)		
Week 32 Adjusted Mean Change (SE)	-9.51 (0.78)	-7.67 (0.91)		
Week 40 Adjusted Mean Change (SE)	-9.73 (0.74)	-8.02 (0.88)		
Week 52 Adjusted Mean Change (SE)	-9.83 (0.81)	-7.97 (0.98)	-1.86 [-4.38; 0.65]	0.145
Female, N	**24**	**29**		
N'	24	28		
Baseline Mean (SD)	10.92 (8.38)	14.31 (7.87)		
Week 52 Mean (SD)	2.39 (2.74)	5.00 (7.60)		
Week 4 Adjusted Mean Change (SE)	-5.57 (1.04)	-5.79 (0.95)		
Week 12 Adjusted Mean Change (SE)	-7.43 (1.09)	-6.80 (1.00)		
Week 16 Adjusted Mean Change (SE)	-8.38 (1.00)	-6.43 (0.94)		
Week 24 Adjusted Mean Change (SE)	-7.59 (1.09)	-7.01 (1.04)		
Week 32 Adjusted Mean Change (SE)	-9.38 (1.03)	-8.47 (0.97)		
Week 40 Adjusted Mean Change (SE)	-8.11 (0.97)	-8.48 (0.96)		
Week 52 Adjusted Mean Change (SE)	-10.08 (1.07)	-7.25 (1.06)	-2.83 [-5.82; 0.16]	0.063

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

38.3 DLQI - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.271				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	9.44 (6.58)	6.77 (3.59)		
Week 52 Mean (SD)	1.13 (1.71)	4.22 (5.72)		
Week 4 Adjusted Mean Change (SE)	-8.73 (1.28)	-5.74 (1.45)		
Week 12 Adjusted Mean Change (SE)	-10.42 (1.35)	-8.02 (1.52)		
Week 16 Adjusted Mean Change (SE)	-10.26 (1.22)	-7.83 (1.38)		
Week 24 Adjusted Mean Change (SE)	-10.28 (1.35)	-6.56 (1.59)		
Week 32 Adjusted Mean Change (SE)	-9.98 (1.27)	-7.33 (1.54)		
Week 40 Adjusted Mean Change (SE)	-10.88 (1.20)	-6.77 (1.50)		
Week 52 Adjusted Mean Change (SE)	-10.84 (1.30)	-6.63 (1.66)	-4.21 [-8.30; -0.12]	0.044
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	47		
Baseline Mean (SD)	13.72 (8.76)	15.04 (7.09)		
Week 52 Mean (SD)	3.53 (4.74)	5.10 (7.01)		
Week 4 Adjusted Mean Change (SE)	-6.63 (0.72)	-5.19 (0.75)		
Week 12 Adjusted Mean Change (SE)	-8.64 (0.75)	-6.53 (0.78)		
Week 16 Adjusted Mean Change (SE)	-8.29 (0.68)	-6.24 (0.72)		
Week 24 Adjusted Mean Change (SE)	-8.55 (0.74)	-7.66 (0.80)		
Week 32 Adjusted Mean Change (SE)	-9.29 (0.71)	-8.21 (0.75)		
Week 40 Adjusted Mean Change (SE)	-8.60 (0.66)	-8.58 (0.72)		
Week 52 Adjusted Mean Change (SE)	-9.63 (0.74)	-7.87 (0.80)	-1.76 [-3.90; 0.38]	0.107

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

38.4 DLQI - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.204				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	31		
Baseline Mean (SD)	9.29 (6.44)	11.69 (7.07)		
Week 52 Mean (SD)	2.62 (4.83)	3.61 (6.09)		
Week 4 Adjusted Mean Change (SE)	-7.38 (0.98)	-6.20 (0.92)		
Week 12 Adjusted Mean Change (SE)	-8.36 (1.02)	-7.62 (0.96)		
Week 16 Adjusted Mean Change (SE)	-7.95 (0.93)	-7.32 (0.88)		
Week 24 Adjusted Mean Change (SE)	-9.12 (1.03)	-7.28 (0.99)		
Week 32 Adjusted Mean Change (SE)	-9.36 (0.97)	-8.83 (0.93)		
Week 40 Adjusted Mean Change (SE)	-9.12 (0.92)	-9.01 (0.92)		
Week 52 Adjusted Mean Change (SE)	-9.39 (1.01)	-8.69 (1.01)	-0.70 [-3.49; 2.10]	0.622
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	15.18 (8.93)	15.03 (7.31)		
Week 52 Mean (SD)	3.14 (3.94)	6.16 (7.19)		
Week 4 Adjusted Mean Change (SE)	-6.96 (0.83)	-4.37 (0.95)		
Week 12 Adjusted Mean Change (SE)	-9.60 (0.88)	-6.04 (1.00)		
Week 16 Adjusted Mean Change (SE)	-9.38 (0.79)	-5.84 (0.91)		
Week 24 Adjusted Mean Change (SE)	-8.88 (0.87)	-7.67 (1.04)		
Week 32 Adjusted Mean Change (SE)	-9.52 (0.82)	-7.23 (0.96)		
Week 40 Adjusted Mean Change (SE)	-9.15 (0.78)	-7.50 (0.92)		
Week 52 Adjusted Mean Change (SE)	-10.29 (0.84)	-6.65 (1.00)	-3.64 [-6.21; -1.07]	0.006

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

38.5 DLQI - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.779				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	13.83 (7.89)	11.28 (6.42)		
Week 52 Mean (SD)	2.82 (3.78)	3.48 (4.77)		
Week 4 Adjusted Mean Change (SE)	-7.56 (0.80)	-6.07 (0.95)		
Week 12 Adjusted Mean Change (SE)	-9.00 (0.85)	-7.14 (1.00)		
Week 16 Adjusted Mean Change (SE)	-8.95 (0.77)	-7.03 (0.92)		
Week 24 Adjusted Mean Change (SE)	-9.10 (0.83)	-8.63 (1.03)		
Week 32 Adjusted Mean Change (SE)	-9.67 (0.79)	-8.97 (0.97)		
Week 40 Adjusted Mean Change (SE)	-9.92 (0.75)	-8.07 (0.96)		
Week 52 Adjusted Mean Change (SE)	-10.27 (0.82)	-8.36 (1.07)	-1.91 [-4.59; 0.77]	0.160
> Median, N	**26**	**33**		
N'	26	31		
Baseline Mean (SD)	10.92 (9.09)	15.09 (7.69)		
Week 52 Mean (SD)	3.08 (5.07)	6.07 (7.84)		
Week 4 Adjusted Mean Change (SE)	-6.47 (1.00)	-4.61 (0.92)		
Week 12 Adjusted Mean Change (SE)	-9.15 (1.05)	-6.60 (0.97)		
Week 16 Adjusted Mean Change (SE)	-8.50 (0.96)	-6.20 (0.88)		
Week 24 Adjusted Mean Change (SE)	-8.80 (1.04)	-6.38 (0.98)		
Week 32 Adjusted Mean Change (SE)	-9.09 (0.97)	-7.23 (0.92)		
Week 40 Adjusted Mean Change (SE)	-7.98 (0.93)	-8.31 (0.89)		
Week 52 Adjusted Mean Change (SE)	-9.40 (1.02)	-7.01 (0.97)	-2.38 [-5.20; 0.43]	0.096

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

38.6 DLQI - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.329				
Enthesitis: No, N	**34**	**22**		
N'	34	21		
Baseline Mean (SD)	12.03 (7.87)	12.36 (8.39)		
Week 52 Mean (SD)	2.66 (4.74)	2.39 (3.53)		
Week 4 Adjusted Mean Change (SE)	-7.88 (0.86)	-6.87 (1.10)		
Week 12 Adjusted Mean Change (SE)	-9.31 (0.91)	-8.67 (1.16)		
Week 16 Adjusted Mean Change (SE)	-8.80 (0.81)	-8.75 (1.05)		
Week 24 Adjusted Mean Change (SE)	-9.95 (0.90)	-8.86 (1.15)		
Week 32 Adjusted Mean Change (SE)	-9.89 (0.86)	-9.39 (1.08)		
Week 40 Adjusted Mean Change (SE)	-10.07 (0.82)	-9.06 (1.05)		
Week 52 Adjusted Mean Change (SE)	-10.08 (0.88)	-9.45 (1.15)	-0.63 [-3.49; 2.23]	0.662
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	13.38 (9.08)	13.83 (6.72)		
Week 52 Mean (SD)	3.19 (3.86)	6.47 (7.73)		
Week 4 Adjusted Mean Change (SE)	-6.36 (0.89)	-4.48 (0.81)		
Week 12 Adjusted Mean Change (SE)	-8.82 (0.93)	-5.87 (0.84)		
Week 16 Adjusted Mean Change (SE)	-8.75 (0.84)	-5.43 (0.77)		
Week 24 Adjusted Mean Change (SE)	-7.96 (0.92)	-6.66 (0.88)		
Week 32 Adjusted Mean Change (SE)	-9.00 (0.87)	-7.31 (0.84)		
Week 40 Adjusted Mean Change (SE)	-8.19 (0.83)	-7.79 (0.82)		
Week 52 Adjusted Mean Change (SE)	-9.74 (0.90)	-6.61 (0.89)	-3.13 [-5.62; -0.63]	0.015

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

38.7 DLQI - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.410				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	12.83 (9.12)	13.00 (6.90)		
Week 52 Mean (SD)	3.00 (4.84)	2.10 (3.46)		
Week 4 Adjusted Mean Change (SE)	-7.53 (0.96)	-5.82 (1.03)		
Week 12 Adjusted Mean Change (SE)	-9.64 (0.98)	-7.74 (1.06)		
Week 16 Adjusted Mean Change (SE)	-9.19 (0.87)	-7.46 (0.95)		
Week 24 Adjusted Mean Change (SE)	-9.95 (0.98)	-8.43 (1.10)		
Week 32 Adjusted Mean Change (SE)	-9.95 (0.90)	-8.44 (1.00)		
Week 40 Adjusted Mean Change (SE)	-9.43 (0.82)	-9.59 (0.92)		
Week 52 Adjusted Mean Change (SE)	-9.97 (0.88)	-10.42 (0.99)	0.46 [-2.18; 3.10]	0.731
Carrier, N	**22**	**19**		
N'	22	18		
Baseline Mean (SD)	11.91 (7.18)	14.63 (8.36)		
Week 52 Mean (SD)	2.10 (3.28)	7.00 (8.61)		
Week 4 Adjusted Mean Change (SE)	-7.19 (1.10)	-5.18 (1.22)		
Week 12 Adjusted Mean Change (SE)	-9.12 (1.13)	-6.41 (1.24)		
Week 16 Adjusted Mean Change (SE)	-9.06 (1.01)	-7.25 (1.10)		
Week 24 Adjusted Mean Change (SE)	-8.51 (1.14)	-6.97 (1.27)		
Week 32 Adjusted Mean Change (SE)	-10.13 (1.07)	-8.07 (1.16)		
Week 40 Adjusted Mean Change (SE)	-10.06 (0.96)	-7.73 (1.10)		
Week 52 Adjusted Mean Change (SE)	-10.41 (1.03)	-6.04 (1.15)	-4.37 [-7.45; -1.29]	0.006

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

38.8 DLQI - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.697				
Non-carrier, N	**28**	**19**		
N'	28	18		
Baseline Mean (SD)	13.32 (8.03)	13.63 (6.92)		
Week 52 Mean (SD)	2.89 (4.97)	3.00 (6.76)		
Week 4 Adjusted Mean Change (SE)	-7.44 (0.98)	-6.07 (1.22)		
Week 12 Adjusted Mean Change (SE)	-10.30 (0.96)	-9.45 (1.20)		
Week 16 Adjusted Mean Change (SE)	-10.58 (0.87)	-8.49 (1.09)		
Week 24 Adjusted Mean Change (SE)	-10.17 (1.02)	-7.87 (1.33)		
Week 32 Adjusted Mean Change (SE)	-10.25 (0.91)	-10.36 (1.18)		
Week 40 Adjusted Mean Change (SE)	-10.66 (0.87)	-9.76 (1.15)		
Week 52 Adjusted Mean Change (SE)	-10.19 (0.98)	-8.81 (1.34)	-1.38 [-4.68; 1.93]	0.410
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	11.55 (8.77)	14.00 (8.55)		
Week 52 Mean (SD)	2.35 (3.22)	4.89 (7.09)		
Week 4 Adjusted Mean Change (SE)	-7.38 (1.11)	-5.23 (1.19)		
Week 12 Adjusted Mean Change (SE)	-8.44 (1.10)	-5.37 (1.18)		
Week 16 Adjusted Mean Change (SE)	-7.34 (0.99)	-6.13 (1.07)		
Week 24 Adjusted Mean Change (SE)	-8.41 (1.17)	-7.41 (1.28)		
Week 32 Adjusted Mean Change (SE)	-9.85 (1.04)	-6.42 (1.12)		
Week 40 Adjusted Mean Change (SE)	-8.61 (0.97)	-8.20 (1.08)		
Week 52 Adjusted Mean Change (SE)	-10.27 (1.12)	-8.24 (1.21)	-2.04 [-5.33; 1.26]	0.222

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

38.9 DLQI - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.150				
Non-carrier, N	**19**	**21**		
N'	19	20		
Baseline Mean (SD)	12.00 (9.26)	15.81 (7.14)		
Week 52 Mean (SD)	2.68 (5.43)	3.40 (6.84)		
Week 4 Adjusted Mean Change (SE)	-7.96 (1.16)	-7.49 (1.14)		
Week 12 Adjusted Mean Change (SE)	-10.56 (1.18)	-9.11 (1.18)		
Week 16 Adjusted Mean Change (SE)	-10.05 (1.06)	-8.68 (1.05)		
Week 24 Adjusted Mean Change (SE)	-9.95 (1.23)	-9.13 (1.27)		
Week 32 Adjusted Mean Change (SE)	-10.06 (1.07)	-10.49 (1.10)		
Week 40 Adjusted Mean Change (SE)	-9.29 (1.03)	-10.03 (1.07)		
Week 52 Adjusted Mean Change (SE)	-10.05 (1.15)	-9.31 (1.23)	-0.74 [-4.11; 2.62]	0.662
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	12.83 (7.93)	11.78 (7.49)		
Week 52 Mean (SD)	2.64 (3.40)	4.77 (6.54)		
Week 4 Adjusted Mean Change (SE)	-7.07 (0.92)	-3.95 (1.06)		
Week 12 Adjusted Mean Change (SE)	-8.92 (0.94)	-5.65 (1.08)		
Week 16 Adjusted Mean Change (SE)	-8.71 (0.84)	-6.33 (0.97)		
Week 24 Adjusted Mean Change (SE)	-9.25 (0.97)	-6.78 (1.13)		
Week 32 Adjusted Mean Change (SE)	-10.27 (0.87)	-6.53 (0.99)		
Week 40 Adjusted Mean Change (SE)	-10.10 (0.83)	-7.87 (0.96)		
Week 52 Adjusted Mean Change (SE)	-10.36 (0.93)	-7.83 (1.07)	-2.53 [-5.35; 0.28]	0.077

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

38.10 DLQI - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.620				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	14.24 (7.90)	14.28 (7.45)		
Week 52 Mean (SD)	3.26 (5.16)	4.79 (7.06)		
Week 4 Adjusted Mean Change (SE)	-8.10 (1.03)	-5.50 (0.91)		
Week 12 Adjusted Mean Change (SE)	-9.93 (1.07)	-6.85 (0.94)		
Week 16 Adjusted Mean Change (SE)	-9.55 (0.94)	-6.98 (0.83)		
Week 24 Adjusted Mean Change (SE)	-10.05 (1.06)	-7.53 (0.99)		
Week 32 Adjusted Mean Change (SE)	-9.57 (0.99)	-8.42 (0.89)		
Week 40 Adjusted Mean Change (SE)	-10.08 (0.89)	-9.33 (0.83)		
Week 52 Adjusted Mean Change (SE)	-9.96 (1.02)	-8.56 (0.93)	-1.40 [-4.13; 1.34]	0.313
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	10.69 (8.40)	12.17 (7.83)		
Week 52 Mean (SD)	2.04 (3.17)	2.44 (4.82)		
Week 4 Adjusted Mean Change (SE)	-6.68 (1.02)	-5.73 (1.55)		
Week 12 Adjusted Mean Change (SE)	-8.94 (1.05)	-8.14 (1.59)		
Week 16 Adjusted Mean Change (SE)	-8.72 (0.92)	-8.58 (1.43)		
Week 24 Adjusted Mean Change (SE)	-8.65 (1.06)	-8.57 (1.60)		
Week 32 Adjusted Mean Change (SE)	-10.39 (0.97)	-7.93 (1.46)		
Week 40 Adjusted Mean Change (SE)	-9.29 (0.89)	-7.40 (1.37)		
Week 52 Adjusted Mean Change (SE)	-10.30 (1.00)	-8.42 (1.59)	-1.87 [-5.58; 1.83]	0.317

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

38.11 DLQI - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.996				
Non-carrier, N	**38**	**33**		
N'	38	32		
Baseline Mean (SD)	12.45 (7.91)	13.73 (6.79)		
Week 52 Mean (SD)	2.69 (3.22)	4.35 (6.19)		
Week 4 Adjusted Mean Change (SE)	-6.80 (0.82)	-5.10 (0.90)		
Week 12 Adjusted Mean Change (SE)	-8.68 (0.82)	-6.77 (0.89)		
Week 16 Adjusted Mean Change (SE)	-8.41 (0.73)	-7.25 (0.79)		
Week 24 Adjusted Mean Change (SE)	-8.70 (0.82)	-7.51 (0.93)		
Week 32 Adjusted Mean Change (SE)	-9.99 (0.75)	-8.39 (0.83)		
Week 40 Adjusted Mean Change (SE)	-9.60 (0.69)	-8.40 (0.79)		
Week 52 Adjusted Mean Change (SE)	-9.91 (0.76)	-8.01 (0.87)	-1.90 [-4.19; 0.39]	0.102
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	12.50 (10.03)	10.00 (6.12)		
Week 52 Mean (SD)	2.67 (6.64)	1.67 (1.73)		
Week 4 Adjusted Mean Change (SE)	-8.36 (1.47)	-6.09 (1.70)		
Week 12 Adjusted Mean Change (SE)	-10.78 (1.46)	-7.73 (1.71)		
Week 16 Adjusted Mean Change (SE)	-10.36 (1.30)	-7.86 (1.53)		
Week 24 Adjusted Mean Change (SE)	-10.47 (1.50)	-8.05 (1.74)		
Week 32 Adjusted Mean Change (SE)	-9.12 (1.32)	-7.38 (1.51)		
Week 40 Adjusted Mean Change (SE)	-8.78 (1.23)	-9.53 (1.41)		
Week 52 Adjusted Mean Change (SE)	-9.70 (1.32)	-10.21 (1.52)	0.51 [-3.49; 4.52]	0.800

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

38.11 DLQI - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

38.12 DLQI - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.805				
Non-carrier, N	**36**	**34**		
N'	36	33		
Baseline Mean (SD)	13.00 (8.33)	13.68 (7.61)		
Week 52 Mean (SD)	3.03 (4.68)	2.93 (4.04)		
Week 4 Adjusted Mean Change (SE)	-7.78 (0.83)	-6.00 (0.87)		
Week 12 Adjusted Mean Change (SE)	-10.16 (0.86)	-7.27 (0.91)		
Week 16 Adjusted Mean Change (SE)	-9.76 (0.77)	-7.43 (0.81)		
Week 24 Adjusted Mean Change (SE)	-9.54 (0.89)	-8.57 (0.96)		
Week 32 Adjusted Mean Change (SE)	-10.18 (0.82)	-8.34 (0.88)		
Week 40 Adjusted Mean Change (SE)	-9.78 (0.76)	-9.21 (0.82)		
Week 52 Adjusted Mean Change (SE)	-9.86 (0.82)	-9.68 (0.89)	-0.18 [-2.59; 2.24]	0.885
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	10.69 (8.81)	13.80 (7.61)		
Week 52 Mean (SD)	2.00 (3.16)	7.70 (10.44)		
Week 4 Adjusted Mean Change (SE)	-6.46 (1.40)	-4.07 (1.60)		
Week 12 Adjusted Mean Change (SE)	-6.92 (1.45)	-6.91 (1.65)		
Week 16 Adjusted Mean Change (SE)	-6.90 (1.29)	-7.25 (1.47)		
Week 24 Adjusted Mean Change (SE)	-8.86 (1.47)	-5.50 (1.68)		
Week 32 Adjusted Mean Change (SE)	-9.56 (1.36)	-8.07 (1.55)		
Week 40 Adjusted Mean Change (SE)	-9.44 (1.26)	-7.68 (1.46)		
Week 52 Adjusted Mean Change (SE)	-10.33 (1.34)	-5.23 (1.53)	-5.10 [-9.18; -1.02]	0.015

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

38.13 DLQI - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.194				
Non-carrier, N	**42**	**36**		
N'	42	35		
Baseline Mean (SD)	11.52 (8.30)	14.06 (7.71)		
Week 52 Mean (SD)	2.59 (4.35)	4.41 (7.31)		
Week 4 Adjusted Mean Change (SE)	-7.50 (0.78)	-6.13 (0.85)		
Week 12 Adjusted Mean Change (SE)	-9.14 (0.80)	-7.75 (0.88)		
Week 16 Adjusted Mean Change (SE)	-8.82 (0.73)	-7.50 (0.80)		
Week 24 Adjusted Mean Change (SE)	-8.97 (0.82)	-8.02 (0.92)		
Week 32 Adjusted Mean Change (SE)	-9.56 (0.75)	-8.49 (0.84)		
Week 40 Adjusted Mean Change (SE)	-9.43 (0.70)	-8.99 (0.80)		
Week 52 Adjusted Mean Change (SE)	-9.95 (0.80)	-8.33 (0.91)	-1.61 [-4.04; 0.81]	0.188
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	16.67 (7.07)	12.00 (8.31)		
Week 52 Mean (SD)	2.78 (3.99)	4.20 (3.49)		
Week 4 Adjusted Mean Change (SE)	-6.94 (1.70)	-4.10 (2.26)		
Week 12 Adjusted Mean Change (SE)	-10.73 (1.74)	-5.75 (2.30)		
Week 16 Adjusted Mean Change (SE)	-10.58 (1.58)	-5.91 (2.10)		
Week 24 Adjusted Mean Change (SE)	-11.14 (1.76)	-4.33 (2.33)		
Week 32 Adjusted Mean Change (SE)	-12.08 (1.61)	-7.97 (2.13)		
Week 40 Adjusted Mean Change (SE)	-10.93 (1.51)	-7.98 (2.00)		
Week 52 Adjusted Mean Change (SE)	-11.14 (1.71)	-8.41 (2.26)	-2.72 [-8.37; 2.93]	0.340

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

38.14 DLQI - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.184				
Low score, N	**11**	**22**		
N'	11	21		
Baseline Mean (SD)	10.82 (7.32)	15.41 (6.98)		
Week 52 Mean (SD)	4.00 (7.15)	3.73 (6.79)		
Week 4 Adjusted Mean Change (SE)	-7.38 (1.56)	-5.85 (1.14)		
Week 12 Adjusted Mean Change (SE)	-9.80 (1.59)	-7.98 (1.16)		
Week 16 Adjusted Mean Change (SE)	-9.59 (1.43)	-8.14 (1.04)		
Week 24 Adjusted Mean Change (SE)	-9.13 (1.60)	-8.74 (1.24)		
Week 32 Adjusted Mean Change (SE)	-8.38 (1.41)	-9.93 (1.10)		
Week 40 Adjusted Mean Change (SE)	-8.87 (1.35)	-9.81 (1.07)		
Week 52 Adjusted Mean Change (SE)	-8.01 (1.52)	-9.05 (1.21)	1.04 [-2.85; 4.93]	0.596
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	12.88 (8.55)	12.00 (7.81)		
Week 52 Mean (SD)	2.26 (3.13)	4.55 (6.62)		
Week 4 Adjusted Mean Change (SE)	-7.38 (0.81)	-5.27 (1.10)		
Week 12 Adjusted Mean Change (SE)	-9.31 (0.83)	-6.41 (1.13)		
Week 16 Adjusted Mean Change (SE)	-9.01 (0.73)	-6.68 (1.00)		
Week 24 Adjusted Mean Change (SE)	-9.40 (0.84)	-7.02 (1.14)		
Week 32 Adjusted Mean Change (SE)	-10.48 (0.75)	-6.94 (1.00)		
Week 40 Adjusted Mean Change (SE)	-9.91 (0.71)	-7.99 (0.96)		
Week 52 Adjusted Mean Change (SE)	-10.70 (0.79)	-7.97 (1.05)	-2.73 [-5.35; -0.11]	0.041

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

38.15 DLQI - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.782				
Non-carrier, N	**31**	**23**		
N'	31	22		
Baseline Mean (SD)	12.32 (8.28)	13.70 (6.83)		
Week 52 Mean (SD)	2.70 (4.75)	3.59 (6.60)		
Week 4 Adjusted Mean Change (SE)	-7.52 (0.92)	-6.18 (1.10)		
Week 12 Adjusted Mean Change (SE)	-10.15 (0.91)	-9.06 (1.08)		
Week 16 Adjusted Mean Change (SE)	-10.34 (0.81)	-8.38 (0.96)		
Week 24 Adjusted Mean Change (SE)	-9.98 (0.95)	-7.79 (1.17)		
Week 32 Adjusted Mean Change (SE)	-10.19 (0.84)	-10.05 (1.03)		
Week 40 Adjusted Mean Change (SE)	-10.46 (0.80)	-9.36 (0.99)		
Week 52 Adjusted Mean Change (SE)	-10.09 (0.91)	-8.56 (1.15)	-1.54 [-4.46; 1.39]	0.299
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	12.60 (8.48)	13.71 (8.38)		
Week 52 Mean (SD)	2.50 (3.35)	4.75 (6.73)		
Week 4 Adjusted Mean Change (SE)	-7.17 (1.15)	-4.89 (1.12)		
Week 12 Adjusted Mean Change (SE)	-8.32 (1.14)	-5.16 (1.12)		
Week 16 Adjusted Mean Change (SE)	-7.17 (1.01)	-6.35 (0.99)		
Week 24 Adjusted Mean Change (SE)	-8.38 (1.20)	-7.83 (1.19)		
Week 32 Adjusted Mean Change (SE)	-9.79 (1.06)	-6.49 (1.03)		
Week 40 Adjusted Mean Change (SE)	-8.51 (0.99)	-8.28 (0.99)		
Week 52 Adjusted Mean Change (SE)	-10.30 (1.15)	-8.27 (1.12)	-2.03 [-5.21; 1.16]	0.209

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

38.16 DLQI - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.141				
Non-carrier, N	**19**	**20**		
N'	19	19		
Baseline Mean (SD)	12.00 (9.26)	15.55 (7.22)		
Week 52 Mean (SD)	2.68 (5.43)	3.64 (7.03)		
Week 4 Adjusted Mean Change (SE)	-7.93 (1.14)	-7.84 (1.15)		
Week 12 Adjusted Mean Change (SE)	-10.53 (1.16)	-9.52 (1.18)		
Week 16 Adjusted Mean Change (SE)	-10.02 (1.04)	-9.08 (1.06)		
Week 24 Adjusted Mean Change (SE)	-9.91 (1.20)	-9.99 (1.27)		
Week 32 Adjusted Mean Change (SE)	-10.03 (1.08)	-10.07 (1.14)		
Week 40 Adjusted Mean Change (SE)	-9.26 (1.03)	-9.65 (1.10)		
Week 52 Adjusted Mean Change (SE)	-10.01 (1.15)	-8.77 (1.27)	-1.25 [-4.65; 2.16]	0.468
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	12.69 (7.77)	12.17 (7.56)		
Week 52 Mean (SD)	2.59 (3.35)	4.57 (6.47)		
Week 4 Adjusted Mean Change (SE)	-7.04 (0.88)	-3.76 (1.01)		
Week 12 Adjusted Mean Change (SE)	-8.75 (0.90)	-5.40 (1.03)		
Week 16 Adjusted Mean Change (SE)	-8.59 (0.81)	-6.06 (0.93)		
Week 24 Adjusted Mean Change (SE)	-9.02 (0.91)	-6.25 (1.07)		
Week 32 Adjusted Mean Change (SE)	-10.01 (0.85)	-6.93 (0.98)		
Week 40 Adjusted Mean Change (SE)	-9.96 (0.80)	-8.15 (0.94)		
Week 52 Adjusted Mean Change (SE)	-10.23 (0.91)	-8.14 (1.04)	-2.09 [-4.83; 0.65]	0.133

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

38.17 DLQI - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.620				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	14.24 (7.90)	14.28 (7.45)		
Week 52 Mean (SD)	3.26 (5.16)	4.79 (7.06)		
Week 4 Adjusted Mean Change (SE)	-8.10 (1.03)	-5.50 (0.91)		
Week 12 Adjusted Mean Change (SE)	-9.93 (1.07)	-6.85 (0.94)		
Week 16 Adjusted Mean Change (SE)	-9.55 (0.94)	-6.98 (0.83)		
Week 24 Adjusted Mean Change (SE)	-10.05 (1.06)	-7.53 (0.99)		
Week 32 Adjusted Mean Change (SE)	-9.57 (0.99)	-8.42 (0.89)		
Week 40 Adjusted Mean Change (SE)	-10.08 (0.89)	-9.33 (0.83)		
Week 52 Adjusted Mean Change (SE)	-9.96 (1.02)	-8.56 (0.93)	-1.40 [-4.13; 1.34]	0.313
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	10.69 (8.40)	12.17 (7.83)		
Week 52 Mean (SD)	2.04 (3.17)	2.44 (4.82)		
Week 4 Adjusted Mean Change (SE)	-6.68 (1.02)	-5.73 (1.55)		
Week 12 Adjusted Mean Change (SE)	-8.94 (1.05)	-8.14 (1.59)		
Week 16 Adjusted Mean Change (SE)	-8.72 (0.92)	-8.58 (1.43)		
Week 24 Adjusted Mean Change (SE)	-8.65 (1.06)	-8.57 (1.60)		
Week 32 Adjusted Mean Change (SE)	-10.39 (0.97)	-7.93 (1.46)		
Week 40 Adjusted Mean Change (SE)	-9.29 (0.89)	-7.40 (1.37)		
Week 52 Adjusted Mean Change (SE)	-10.30 (1.00)	-8.42 (1.59)	-1.87 [-5.58; 1.83]	0.317

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

38.18 DLQI - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.512				
Non-carrier, N	**39**	**35**		
N'	39	34		
Baseline Mean (SD)	12.41 (7.81)	13.97 (7.27)		
Week 52 Mean (SD)	2.61 (3.21)	4.18 (5.99)		
Week 4 Adjusted Mean Change (SE)	-6.93 (0.83)	-5.55 (0.89)		
Week 12 Adjusted Mean Change (SE)	-8.83 (0.85)	-7.23 (0.91)		
Week 16 Adjusted Mean Change (SE)	-8.58 (0.74)	-7.41 (0.79)		
Week 24 Adjusted Mean Change (SE)	-8.88 (0.85)	-7.93 (0.95)		
Week 32 Adjusted Mean Change (SE)	-10.16 (0.78)	-8.54 (0.85)		
Week 40 Adjusted Mean Change (SE)	-9.80 (0.73)	-8.80 (0.81)		
Week 52 Adjusted Mean Change (SE)	-10.09 (0.82)	-8.40 (0.91)	-1.69 [-4.13; 0.75]	0.172
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	11.18 (9.37)	12.67 (8.80)		
Week 52 Mean (SD)	2.73 (6.96)	4.33 (8.66)		
Week 4 Adjusted Mean Change (SE)	-8.43 (1.57)	-5.11 (1.72)		
Week 12 Adjusted Mean Change (SE)	-10.34 (1.60)	-6.56 (1.75)		
Week 16 Adjusted Mean Change (SE)	-9.71 (1.40)	-6.97 (1.56)		
Week 24 Adjusted Mean Change (SE)	-10.87 (1.65)	-6.89 (1.77)		
Week 32 Adjusted Mean Change (SE)	-9.62 (1.46)	-6.78 (1.60)		
Week 40 Adjusted Mean Change (SE)	-8.98 (1.37)	-8.38 (1.53)		
Week 52 Adjusted Mean Change (SE)	-9.35 (1.52)	-8.34 (1.66)	-1.01 [-5.49; 3.46]	0.654

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

39.1 DLQI 0/1 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
DLQI 0/1 Week 52, N' n (%)	63 35.33 (53.53)	48 23.12 (37.29)	1.99 [0.94; 4.21] 0.070	1.44 [0.95; 2.17] 0.085	0.162 [-0.014; 0.339] 0.072

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.
RR and RD calculated directly without adjustment.

All results are combined over MI:
n and % are averages of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

39.2 DLQI 0/1 by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DLQI 0/1 Week 52	p=0.633				
Male (N)	**42**	**33**			
DLQI 0/1 Week 52, N' n (%)	40 23.44 (55.81)	26 12.27 (37.18)	2.28 [0.83; 6.27] 0.110	1.51 [0.86; 2.64] 0.151	0.186 [-0.050; 0.422] 0.122
Female (N)	**24**	**29**			
DLQI 0/1 Week 52, N' n (%)	23 11.89 (49.54)	22 10.85 (37.41)	1.56 [0.49; 4.97] 0.449	1.33 [0.70; 2.53] 0.389	0.121 [-0.153; 0.396] 0.387

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

39.3 DLQI 0/1 by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DLQI 0/1 Week 52	p=0.129				
PASDAS < 5.4 (N)	**16**	**13**			
DLQI 0/1 Week 52, N' n (%)	16 12.00 (75.00)	9 4.38 (33.69)	6.70 [1.10; 40.59] 0.039	2.28 [0.89; 5.81] 0.086	0.413 [0.054; 0.772] 0.024
PASDAS ≥ 5.4 (N)	**50**	**49**			
DLQI 0/1 Week 52, N' n (%)	47 23.33 (46.66)	39 18.74 (38.24)	1.43 [0.62; 3.32] 0.401	1.22 [0.76; 1.98] 0.415	0.084 [-0.116; 0.285] 0.410

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

39.4 DLQI 0/1 by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DLQI 0/1 Week 52	p=0.500				
Moderate/Severe Psoriasis (Def D): No (N)	**28**	**32**			
DLQI 0/1 Week 52, N' n (%)	26 16.25 (58.04)	23 14.44 (45.13)	1.62 [0.54; 4.91] 0.392	1.29 [0.76; 2.19] 0.347	0.129 [-0.136; 0.394] 0.340
Moderate/Severe Psoriasis (Def D): Yes (N)	**38**	**30**			
DLQI 0/1 Week 52, N' n (%)	37 19.08 (50.21)	25 8.68 (28.93)	2.75 [0.95; 7.97] 0.062	1.74 [0.89; 3.40] 0.103	0.213 [-0.020; 0.445] 0.073

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

39.5 DLQI 0/1 by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DLQI 0/1 Week 52	p=0.924				
≤ Median (N)	**40**	**29**			
DLQI 0/1 Week 52, N' n (%)	38 21.44 (53.60)	21 11.48 (39.59)	1.91 [0.68; 5.38] 0.221	1.36 [0.77; 2.39] 0.287	0.140 [-0.106; 0.386] 0.264
> Median (N)	**26**	**33**			
DLQI 0/1 Week 52, N' n (%)	25 13.89 (53.42)	27 11.64 (35.27)	2.05 [0.69; 6.13] 0.197	1.52 [0.83; 2.79] 0.178	0.182 [-0.077; 0.440] 0.168

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

39.6 DLQI 0/1 by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DLQI 0/1 Week 52	p=0.607				
Enthesitis: No (N)	**34**	**22**			
DLQI 0/1 Week 52, N' n (%)	32 20.25 (59.56)	18 11.05 (50.23)	1.43 [0.45; 4.57] 0.542	1.19 [0.70; 2.01] 0.520	0.093 [-0.185; 0.372] 0.511
Enthesitis: Yes (N)	**32**	**40**			
DLQI 0/1 Week 52, N' n (%)	31 15.08 (47.13)	30 12.07 (30.18)	2.16 [0.77; 6.03] 0.143	1.57 [0.84; 2.94] 0.160	0.169 [-0.061; 0.400] 0.150

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

39.7 DLQI 0/1 by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DLQI 0/1 Week 52	p=0.015				
Non-carrier (N)	**29**	**25**			
DLQI 0/1 Week 52, N' n (%)	28 14.89 (51.34)	21 14.90 (59.60)	0.70 [0.22; 2.21] 0.543	0.86 [0.53; 1.41] 0.555	-0.083 [-0.354; 0.189] 0.551
Carrier (N)	**22**	**19**			
DLQI 0/1 Week 52, N' n (%)	20 14.44 (65.64)	16 4.36 (22.95)	7.08 [1.64; 30.58] 0.009	2.88 [1.16; 7.16] 0.023	0.427 [0.145; 0.709] 0.003

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

39.8 DLQI 0/1 by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DLQI 0/1 Week 52	p=0.984				
Non-carrier (N)	**28**	**19**			
DLQI 0/1 Week 52, N' n (%)	27 16.36 (58.43)	13 9.22 (48.53)	1.61 [0.45; 5.75] 0.466	1.21 [0.67; 2.19] 0.533	0.099 [-0.206; 0.404] 0.525
Carrier (N)	**22**	**19**			
DLQI 0/1 Week 52, N' n (%)	20 11.97 (54.41)	18 8.04 (42.32)	1.64 [0.46; 5.84] 0.448	1.29 [0.67; 2.47] 0.451	0.121 [-0.185; 0.427] 0.439

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

39.9 DLQI 0/1 by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DLQI 0/1 Week 52	p=0.760				
Non-carrier (N)	**19**	**21**			
DLQI 0/1 Week 52, N' n (%)	19 11.00 (57.89)	15 9.89 (47.10)	1.61 [0.43; 6.09] 0.484	1.23 [0.67; 2.28] 0.505	0.108 [-0.208; 0.424] 0.503
Carrier (N)	**30**	**23**			
DLQI 0/1 Week 52, N' n (%)	28 17.25 (57.50)	22 9.37 (40.74)	2.12 [0.67; 6.71] 0.203	1.41 [0.78; 2.56] 0.255	0.168 [-0.105; 0.441] 0.229

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

39.10 DLQI 0/1 by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DLQI 0/1 Week 52	p=0.577				
Non-carrier (N)	**25**	**32**			
DLQI 0/1 Week 52, N' n (%)	23 11.97 (47.88)	28 12.94 (40.44)	1.25 [0.41; 3.80] 0.700	1.19 [0.65; 2.16] 0.578	0.074 [-0.190; 0.339] 0.581
Carrier (N)	**26**	**12**			
DLQI 0/1 Week 52, N' n (%)	25 17.36 (66.77)	9 6.32 (52.67)	2.12 [0.48; 9.46] 0.323	1.27 [0.68; 2.37] 0.452	0.141 [-0.205; 0.487] 0.425

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

39.11 DLQI 0/1 by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DLQI 0/1 Week 52	p=0.846				
Non-carrier (N)	**38**	**33**			
DLQI 0/1 Week 52, N' n (%)	35 19.33 (50.87)	26 13.26 (40.18)	1.68 [0.62; 4.55] 0.310	1.27 [0.74; 2.18] 0.390	0.107 [-0.132; 0.345] 0.380
Carrier (N)	**12**	**9**			
DLQI 0/1 Week 52, N' n (%)	12 9.00 (75.00)	9 5.00 (55.56)	2.08 [0.31; 13.72] 0.449	1.35 [0.69; 2.64] 0.380	0.194 [-0.212; 0.601] 0.349

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) DLQI 0/1, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

39.12 DLQI 0/1 by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DLQI 0/1 Week 52	p=0.381				
Non-carrier (N)	**36**	**34**			
DLQI 0/1 Week 52, N' n (%)	33 19.33 (53.69)	27 15.26 (44.88)	1.35 [0.50; 3.65] 0.555	1.20 [0.73; 1.97] 0.478	0.088 [-0.153; 0.329] 0.473
Carrier (N)	**13**	**10**			
DLQI 0/1 Week 52, N' n (%)	13 8.00 (61.54)	10 4.00 (40.00)	3.39 [0.56; 20.33] 0.182	1.54 [0.64; 3.68] 0.333	0.215 [-0.187; 0.618] 0.294

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) DLQI 0/1, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

39.13 DLQI 0/1 by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DLQI 0/1 Week 52	p=0.452				
Non-carrier (N)	**42**	**36**			
DLQI 0/1 Week 52, N' n (%)	39 24.33 (57.93)	29 17.26 (47.94)	1.60 [0.62; 4.16] 0.335	1.21 [0.78; 1.88] 0.399	0.100 [-0.128; 0.328] 0.391
Carrier (N)	**9**	**5**			
DLQI 0/1 Week 52, N' n (%)	9 5.00 (55.56)	5 1.00 (20.00)	4.58 [0.35; 59.59] 0.245	2.78 [0.44; 17.63] 0.279	0.356 [-0.122; 0.833] 0.145

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) DLQI 0/1, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

39.14 DLQI 0/1 by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DLQI 0/1 Week 52	p=0.905				
Low score (N)	**11**	**22**			
DLQI 0/1 Week 52, N' n (%)	10 6.08 (55.27)	15 9.26 (42.09)	1.65 [0.36; 7.62] 0.520	1.32 [0.62; 2.79] 0.471	0.132 [-0.236; 0.499] 0.482
High score (N)	**40**	**22**			
DLQI 0/1 Week 52, N' n (%)	38 23.25 (58.13)	22 10.00 (45.45)	1.85 [0.63; 5.47] 0.265	1.28 [0.75; 2.17] 0.364	0.127 [-0.133; 0.387] 0.339

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

39.15 DLQI 0/1 by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DLQI 0/1 Week 52	p=0.963				
Non-carrier (N)	**31**	**23**			
DLQI 0/1 Week 52, N' n (%)	30 18.36 (59.23)	17 11.22 (48.78)	1.72 [0.53; 5.60] 0.366	1.22 [0.71; 2.08] 0.474	0.104 [-0.175; 0.384] 0.464
Carrier (N)	**20**	**21**			
DLQI 0/1 Week 52, N' n (%)	18 10.97 (54.85)	20 8.04 (38.29)	1.79 [0.50; 6.43] 0.369	1.43 [0.73; 2.82] 0.299	0.166 [-0.138; 0.469] 0.285

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

39.16 DLQI 0/1 by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DLQI 0/1 Week 52	p=0.997				
Non-carrier (N)	**19**	**20**			
DLQI 0/1 Week 52, N' n (%)	19 11.00 (57.89)	14 8.89 (44.45)	1.81 [0.47; 6.98] 0.387	1.31 [0.68; 2.50] 0.417	0.134 [-0.185; 0.454] 0.410
Carrier (N)	**32**	**24**			
DLQI 0/1 Week 52, N' n (%)	29 18.33 (57.28)	23 10.37 (43.21)	1.82 [0.60; 5.53] 0.292	1.33 [0.76; 2.32] 0.322	0.141 [-0.126; 0.408] 0.302

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

39.17 DLQI 0/1 by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DLQI 0/1 Week 52	p=0.577				
Non-carrier (N)	**25**	**32**			
DLQI 0/1 Week 52, N' n (%)	23 11.97 (47.88)	28 12.94 (40.44)	1.25 [0.41; 3.80] 0.700	1.19 [0.65; 2.16] 0.578	0.074 [-0.190; 0.339] 0.581
Carrier (N)	**26**	**12**			
DLQI 0/1 Week 52, N' n (%)	25 17.36 (66.77)	9 6.32 (52.67)	2.12 [0.48; 9.46] 0.323	1.27 [0.68; 2.37] 0.452	0.141 [-0.205; 0.487] 0.425

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

39.18 DLQI 0/1 by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
DLQI 0/1 Week 52	p=0.606				
Non-carrier (N)	**39**	**35**			
DLQI 0/1 Week 52, N' n (%)	36 20.33 (52.13)	28 14.26 (40.74)	1.73 [0.65; 4.59] 0.273	1.28 [0.76; 2.15] 0.349	0.114 [-0.119; 0.347] 0.339
Carrier (N)	**11**	**9**			
DLQI 0/1 Week 52, N' n (%)	11 9.00 (81.82)	9 5.00 (55.56)	3.15 [0.40; 24.60] 0.274	1.47 [0.77; 2.81] 0.241	0.263 [-0.134; 0.659] 0.194

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) DLQI 0/1, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

40.0 EQ-5D VAS Score - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	57 (91.9)	122 (95.3)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	48 (77.4)	111 (86.7)

40.1 EQ-5D VAS Score - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	60		
Baseline Mean (SD)	49.27 (22.72)	47.60 (22.80)		
Week 52 Mean (SD)	66.71 (22.78)	70.33 (19.11)		
Week 4 Adjusted Mean Change (SE)	11.98 (2.07)	13.23 (2.17)		
Week 12 Adjusted Mean Change (SE)	12.82 (2.36)	12.57 (2.47)		
Week 16 Adjusted Mean Change (SE)	17.09 (2.30)	12.73 (2.43)		
Week 24 Adjusted Mean Change (SE)	17.03 (2.49)	15.35 (2.69)		
Week 32 Adjusted Mean Change (SE)	16.36 (2.53)	15.68 (2.71)		
Week 40 Adjusted Mean Change (SE)	15.87 (2.58)	17.45 (2.83)		
Week 52 Adjusted Mean Change (SE)	18.27 (2.50)	21.24 (2.82)	-2.97 [-10.43; 4.50]	0.433

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

40.2 EQ-5D VAS Score - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.068				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	52.17 (23.47)	51.21 (23.84)		
Week 52 Mean (SD)	68.63 (21.05)	74.85 (19.80)		
Week 4 Adjusted Mean Change (SE)	13.04 (2.59)	17.51 (2.95)		
Week 12 Adjusted Mean Change (SE)	14.41 (2.98)	15.68 (3.38)		
Week 16 Adjusted Mean Change (SE)	18.43 (2.85)	18.64 (3.24)		
Week 24 Adjusted Mean Change (SE)	18.35 (3.01)	23.91 (3.53)		
Week 32 Adjusted Mean Change (SE)	18.19 (3.03)	25.45 (3.54)		
Week 40 Adjusted Mean Change (SE)	15.70 (3.20)	24.43 (3.79)		
Week 52 Adjusted Mean Change (SE)	19.63 (3.14)	25.24 (3.82)	-5.61 [-15.38; 4.15]	0.257
Female, N	**24**	**29**		
N'	24	28		
Baseline Mean (SD)	44.21 (20.85)	43.48 (21.22)		
Week 52 Mean (SD)	63.39 (25.66)	65.00 (17.19)		
Week 4 Adjusted Mean Change (SE)	10.18 (3.43)	8.34 (3.16)		
Week 12 Adjusted Mean Change (SE)	10.14 (3.96)	9.10 (3.65)		
Week 16 Adjusted Mean Change (SE)	14.81 (3.76)	5.72 (3.56)		
Week 24 Adjusted Mean Change (SE)	14.69 (4.02)	5.37 (3.83)		
Week 32 Adjusted Mean Change (SE)	12.99 (4.02)	4.53 (3.77)		
Week 40 Adjusted Mean Change (SE)	16.10 (4.20)	9.48 (4.12)		
Week 52 Adjusted Mean Change (SE)	15.94 (4.15)	16.61 (4.15)	-0.66 [-12.23; 10.90]	0.910

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

40.3 EQ-5D VAS Score - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.795				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	69.81 (16.75)	65.31 (25.02)		
Week 52 Mean (SD)	80.75 (12.37)	72.67 (23.73)		
Week 4 Adjusted Mean Change (SE)	17.43 (4.37)	24.31 (4.70)		
Week 12 Adjusted Mean Change (SE)	19.23 (5.16)	16.91 (5.46)		
Week 16 Adjusted Mean Change (SE)	23.38 (4.85)	26.31 (5.21)		
Week 24 Adjusted Mean Change (SE)	24.86 (5.34)	26.19 (5.93)		
Week 32 Adjusted Mean Change (SE)	19.27 (5.45)	24.54 (6.29)		
Week 40 Adjusted Mean Change (SE)	24.14 (5.57)	24.87 (6.47)		
Week 52 Adjusted Mean Change (SE)	27.18 (5.31)	20.89 (6.50)	6.29 [-9.68; 22.26]	0.437
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	47		
Baseline Mean (SD)	42.70 (20.42)	42.90 (19.92)		
Week 52 Mean (SD)	61.94 (23.61)	69.79 (18.20)		
Week 4 Adjusted Mean Change (SE)	10.29 (2.36)	10.12 (2.42)		
Week 12 Adjusted Mean Change (SE)	10.84 (2.75)	11.37 (2.82)		
Week 16 Adjusted Mean Change (SE)	15.12 (2.63)	8.72 (2.72)		
Week 24 Adjusted Mean Change (SE)	14.60 (2.85)	12.34 (3.01)		
Week 32 Adjusted Mean Change (SE)	15.50 (2.95)	13.28 (3.05)		
Week 40 Adjusted Mean Change (SE)	13.28 (2.98)	15.27 (3.17)		
Week 52 Adjusted Mean Change (SE)	15.40 (2.92)	20.90 (3.12)	-5.50 [-13.85; 2.86]	0.195

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

40.4 EQ-5D VAS Score - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.941				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	31		
Baseline Mean (SD)	51.61 (22.68)	48.63 (22.08)		
Week 52 Mean (SD)	67.08 (19.01)	72.52 (16.13)		
Week 4 Adjusted Mean Change (SE)	12.66 (3.20)	14.65 (3.04)		
Week 12 Adjusted Mean Change (SE)	11.40 (3.64)	12.73 (3.46)		
Week 16 Adjusted Mean Change (SE)	15.26 (3.54)	13.44 (3.42)		
Week 24 Adjusted Mean Change (SE)	17.77 (3.87)	15.88 (3.77)		
Week 32 Adjusted Mean Change (SE)	16.64 (3.92)	14.77 (3.82)		
Week 40 Adjusted Mean Change (SE)	17.50 (3.99)	14.80 (4.04)		
Week 52 Adjusted Mean Change (SE)	18.11 (3.92)	22.99 (4.07)	-4.89 [-16.07; 6.30]	0.389
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	47.55 (22.90)	46.50 (23.88)		
Week 52 Mean (SD)	66.46 (25.34)	68.32 (21.63)		
Week 4 Adjusted Mean Change (SE)	11.49 (2.74)	11.71 (3.14)		
Week 12 Adjusted Mean Change (SE)	13.93 (3.16)	12.43 (3.60)		
Week 16 Adjusted Mean Change (SE)	18.48 (3.06)	12.01 (3.51)		
Week 24 Adjusted Mean Change (SE)	16.49 (3.30)	14.67 (3.93)		
Week 32 Adjusted Mean Change (SE)	16.16 (3.36)	16.60 (3.92)		
Week 40 Adjusted Mean Change (SE)	14.68 (3.41)	19.71 (4.03)		
Week 52 Adjusted Mean Change (SE)	18.41 (3.30)	19.55 (3.96)	-1.14 [-11.35; 9.08]	0.826

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

40.5 EQ-5D VAS Score - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.950				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	50.40 (22.75)	52.31 (22.72)		
Week 52 Mean (SD)	68.66 (22.09)	73.95 (18.27)		
Week 4 Adjusted Mean Change (SE)	14.39 (2.64)	15.76 (3.11)		
Week 12 Adjusted Mean Change (SE)	15.47 (3.05)	12.31 (3.56)		
Week 16 Adjusted Mean Change (SE)	18.27 (2.93)	18.43 (3.49)		
Week 24 Adjusted Mean Change (SE)	18.24 (3.16)	20.44 (3.90)		
Week 32 Adjusted Mean Change (SE)	14.66 (3.28)	16.67 (3.96)		
Week 40 Adjusted Mean Change (SE)	18.70 (3.35)	17.53 (4.21)		
Week 52 Adjusted Mean Change (SE)	19.76 (3.26)	21.36 (4.28)	-1.59 [-12.23; 9.05]	0.767
> Median, N	**26**	**33**		
N'	26	31		
Baseline Mean (SD)	47.54 (23.01)	43.45 (22.40)		
Week 52 Mean (SD)	63.76 (23.93)	67.52 (19.60)		
Week 4 Adjusted Mean Change (SE)	8.28 (3.27)	10.84 (3.02)		
Week 12 Adjusted Mean Change (SE)	8.87 (3.74)	12.91 (3.47)		
Week 16 Adjusted Mean Change (SE)	15.26 (3.61)	7.50 (3.35)		
Week 24 Adjusted Mean Change (SE)	15.21 (3.95)	10.80 (3.71)		
Week 32 Adjusted Mean Change (SE)	18.74 (3.98)	14.82 (3.76)		
Week 40 Adjusted Mean Change (SE)	11.65 (4.11)	16.96 (3.92)		
Week 52 Adjusted Mean Change (SE)	16.02 (4.02)	20.78 (3.85)	-4.76 [-15.77; 6.25]	0.393

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

40.6 EQ-5D VAS Score - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.697				
Enthesitis: No, N	**34**	**22**		
N'	34	21		
Baseline Mean (SD)	53.47 (22.82)	47.32 (22.33)		
Week 52 Mean (SD)	68.41 (22.82)	72.72 (21.69)		
Week 4 Adjusted Mean Change (SE)	14.71 (2.88)	17.64 (3.65)		
Week 12 Adjusted Mean Change (SE)	14.99 (3.33)	14.67 (4.24)		
Week 16 Adjusted Mean Change (SE)	16.37 (3.16)	20.47 (4.04)		
Week 24 Adjusted Mean Change (SE)	18.74 (3.51)	17.21 (4.47)		
Week 32 Adjusted Mean Change (SE)	19.39 (3.56)	18.15 (4.46)		
Week 40 Adjusted Mean Change (SE)	18.48 (3.64)	20.59 (4.65)		
Week 52 Adjusted Mean Change (SE)	18.92 (3.55)	25.38 (4.65)	-6.46 [-18.04; 5.12]	0.271
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	44.81 (22.10)	47.75 (23.34)		
Week 52 Mean (SD)	64.97 (22.97)	68.90 (17.61)		
Week 4 Adjusted Mean Change (SE)	9.11 (2.96)	10.85 (2.67)		
Week 12 Adjusted Mean Change (SE)	10.51 (3.42)	11.33 (3.07)		
Week 16 Adjusted Mean Change (SE)	17.97 (3.27)	8.56 (2.97)		
Week 24 Adjusted Mean Change (SE)	15.23 (3.60)	14.41 (3.41)		
Week 32 Adjusted Mean Change (SE)	13.20 (3.62)	14.36 (3.42)		
Week 40 Adjusted Mean Change (SE)	13.17 (3.70)	15.76 (3.60)		
Week 52 Adjusted Mean Change (SE)	17.63 (3.61)	18.92 (3.57)	-1.29 [-11.33; 8.76]	0.800

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

40.6 EQ-5D VAS Score - Change from Baseline by Enthesitis at BL According to LEI (FAS)

40.7 EQ-5D VAS Score - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.862				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	43.79 (22.35)	48.04 (24.06)		
Week 52 Mean (SD)	62.43 (24.33)	71.90 (17.91)		
Week 4 Adjusted Mean Change (SE)	9.24 (3.26)	16.87 (3.48)		
Week 12 Adjusted Mean Change (SE)	14.30 (3.49)	10.26 (3.78)		
Week 16 Adjusted Mean Change (SE)	17.35 (3.47)	13.46 (3.79)		
Week 24 Adjusted Mean Change (SE)	19.38 (3.86)	16.09 (4.28)		
Week 32 Adjusted Mean Change (SE)	22.01 (3.87)	17.74 (4.29)		
Week 40 Adjusted Mean Change (SE)	17.31 (4.07)	20.09 (4.49)		
Week 52 Adjusted Mean Change (SE)	16.39 (3.95)	25.28 (4.46)	-8.88 [-20.69; 2.92]	0.138
Carrier, N	**22**	**19**		
N'	22	18		
Baseline Mean (SD)	51.50 (20.54)	51.32 (23.68)		
Week 52 Mean (SD)	68.15 (24.07)	70.19 (21.25)		
Week 4 Adjusted Mean Change (SE)	14.10 (3.72)	12.13 (4.12)		
Week 12 Adjusted Mean Change (SE)	12.29 (4.04)	18.18 (4.43)		
Week 16 Adjusted Mean Change (SE)	17.49 (4.01)	15.29 (4.40)		
Week 24 Adjusted Mean Change (SE)	14.65 (4.45)	13.22 (4.98)		
Week 32 Adjusted Mean Change (SE)	12.20 (4.64)	12.43 (5.02)		
Week 40 Adjusted Mean Change (SE)	17.56 (4.70)	13.55 (5.41)		
Week 52 Adjusted Mean Change (SE)	19.34 (4.61)	18.73 (5.21)	0.62 [-13.16; 14.40]	0.929

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

40.8 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.154				
Non-carrier, N	**28**	**19**		
N'	28	18		
Baseline Mean (SD)	44.71 (22.44)	48.58 (22.10)		
Week 52 Mean (SD)	62.63 (26.55)	67.38 (18.69)		
Week 4 Adjusted Mean Change (SE)	15.26 (3.25)	8.63 (4.05)		
Week 12 Adjusted Mean Change (SE)	14.95 (3.54)	13.50 (4.41)		
Week 16 Adjusted Mean Change (SE)	19.95 (3.52)	11.95 (4.45)		
Week 24 Adjusted Mean Change (SE)	19.19 (3.69)	9.78 (4.75)		
Week 32 Adjusted Mean Change (SE)	19.80 (3.82)	13.94 (4.91)		
Week 40 Adjusted Mean Change (SE)	21.37 (3.89)	10.30 (5.06)		
Week 52 Adjusted Mean Change (SE)	16.38 (4.02)	19.28 (5.55)	-2.90 [-16.55; 10.74]	0.673
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	50.09 (21.41)	47.21 (23.95)		
Week 52 Mean (SD)	66.25 (20.47)	73.06 (18.52)		
Week 4 Adjusted Mean Change (SE)	6.54 (3.66)	19.77 (3.94)		
Week 12 Adjusted Mean Change (SE)	13.09 (4.03)	16.76 (4.33)		
Week 16 Adjusted Mean Change (SE)	14.75 (4.01)	15.81 (4.32)		
Week 24 Adjusted Mean Change (SE)	18.78 (4.20)	20.78 (4.59)		
Week 32 Adjusted Mean Change (SE)	20.31 (4.38)	15.19 (4.66)		
Week 40 Adjusted Mean Change (SE)	16.28 (4.35)	23.89 (4.80)		
Week 52 Adjusted Mean Change (SE)	19.61 (4.60)	25.50 (4.91)	-5.89 [-19.29; 7.51]	0.384

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

40.9 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.533				
Non-carrier, N	**19**	**21**		
N'	19	20		
Baseline Mean (SD)	43.42 (22.51)	50.24 (27.54)		
Week 52 Mean (SD)	62.84 (22.80)	72.27 (23.83)		
Week 4 Adjusted Mean Change (SE)	9.18 (3.96)	15.31 (3.86)		
Week 12 Adjusted Mean Change (SE)	13.45 (4.25)	19.76 (4.20)		
Week 16 Adjusted Mean Change (SE)	15.12 (4.26)	16.52 (4.21)		
Week 24 Adjusted Mean Change (SE)	17.36 (4.90)	15.51 (4.92)		
Week 32 Adjusted Mean Change (SE)	18.88 (4.92)	15.43 (4.99)		
Week 40 Adjusted Mean Change (SE)	18.39 (5.08)	18.71 (5.20)		
Week 52 Adjusted Mean Change (SE)	16.97 (4.86)	22.45 (5.29)	-5.48 [-19.83; 8.87]	0.450
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	46.60 (19.04)	48.74 (20.13)		
Week 52 Mean (SD)	65.39 (25.45)	70.41 (15.79)		
Week 4 Adjusted Mean Change (SE)	14.36 (3.13)	15.35 (3.59)		
Week 12 Adjusted Mean Change (SE)	15.21 (3.39)	9.44 (3.85)		
Week 16 Adjusted Mean Change (SE)	20.45 (3.37)	13.26 (3.90)		
Week 24 Adjusted Mean Change (SE)	18.16 (3.83)	14.85 (4.44)		
Week 32 Adjusted Mean Change (SE)	18.70 (4.03)	16.27 (4.53)		
Week 40 Adjusted Mean Change (SE)	17.83 (4.05)	17.06 (4.71)		
Week 52 Adjusted Mean Change (SE)	19.10 (3.95)	23.10 (4.48)	-4.00 [-15.87; 7.87]	0.504

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

40.10 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.316				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	47.28 (22.96)	52.38 (23.88)		
Week 52 Mean (SD)	69.61 (25.01)	70.29 (20.05)		
Week 4 Adjusted Mean Change (SE)	11.46 (3.53)	14.96 (3.13)		
Week 12 Adjusted Mean Change (SE)	14.37 (3.80)	11.76 (3.37)		
Week 16 Adjusted Mean Change (SE)	18.01 (3.65)	10.88 (3.23)		
Week 24 Adjusted Mean Change (SE)	20.53 (4.11)	12.76 (3.78)		
Week 32 Adjusted Mean Change (SE)	20.56 (4.30)	17.32 (3.85)		
Week 40 Adjusted Mean Change (SE)	20.05 (4.35)	18.76 (4.01)		
Week 52 Adjusted Mean Change (SE)	22.21 (4.27)	21.74 (3.85)	0.47 [-10.98; 11.92]	0.935
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	46.96 (20.91)	41.67 (22.22)		
Week 52 Mean (SD)	60.40 (22.91)	73.89 (16.88)		
Week 4 Adjusted Mean Change (SE)	11.22 (3.46)	14.65 (5.32)		
Week 12 Adjusted Mean Change (SE)	12.58 (3.69)	18.91 (5.67)		
Week 16 Adjusted Mean Change (SE)	16.85 (3.54)	24.47 (5.58)		
Week 24 Adjusted Mean Change (SE)	14.28 (4.07)	20.51 (6.20)		
Week 32 Adjusted Mean Change (SE)	15.59 (4.17)	11.03 (6.32)		
Week 40 Adjusted Mean Change (SE)	14.80 (4.30)	14.01 (6.68)		
Week 52 Adjusted Mean Change (SE)	13.32 (4.13)	24.69 (6.72)	-11.38 [-27.05; 4.29]	0.153

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

40.11 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.220				
Non-carrier, N	**38**	**33**		
N'	38	32		
Baseline Mean (SD)	49.87 (20.58)	53.09 (23.22)		
Week 52 Mean (SD)	63.43 (23.69)	70.81 (19.06)		
Week 4 Adjusted Mean Change (SE)	11.81 (2.79)	13.25 (3.06)		
Week 12 Adjusted Mean Change (SE)	13.50 (3.13)	13.42 (3.41)		
Week 16 Adjusted Mean Change (SE)	17.83 (3.01)	14.01 (3.30)		
Week 24 Adjusted Mean Change (SE)	18.97 (3.24)	12.08 (3.66)		
Week 32 Adjusted Mean Change (SE)	18.55 (3.53)	17.58 (3.92)		
Week 40 Adjusted Mean Change (SE)	16.98 (3.52)	14.86 (4.00)		
Week 52 Adjusted Mean Change (SE)	15.66 (3.42)	20.31 (3.95)	-4.64 [-15.01; 5.73]	0.376
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	37.92 (24.43)	40.56 (24.20)		
Week 52 Mean (SD)	66.75 (26.19)	76.67 (13.58)		
Week 4 Adjusted Mean Change (SE)	6.90 (5.07)	22.32 (5.74)		
Week 12 Adjusted Mean Change (SE)	11.16 (5.65)	11.04 (6.59)		
Week 16 Adjusted Mean Change (SE)	14.30 (5.43)	20.31 (6.33)		
Week 24 Adjusted Mean Change (SE)	10.60 (6.03)	28.71 (6.84)		
Week 32 Adjusted Mean Change (SE)	14.39 (6.26)	11.47 (7.11)		
Week 40 Adjusted Mean Change (SE)	16.40 (6.35)	28.58 (7.21)		
Week 52 Adjusted Mean Change (SE)	20.48 (6.03)	30.46 (6.84)	-9.98 [-27.91; 7.94]	0.271

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

40.12 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.792				
Non-carrier, N	**36**	**34**		
N'	36	33		
Baseline Mean (SD)	47.36 (23.10)	48.94 (26.22)		
Week 52 Mean (SD)	62.97 (25.80)	70.33 (20.41)		
Week 4 Adjusted Mean Change (SE)	10.80 (2.87)	16.50 (3.00)		
Week 12 Adjusted Mean Change (SE)	14.92 (3.11)	11.92 (3.28)		
Week 16 Adjusted Mean Change (SE)	18.46 (3.11)	15.33 (3.29)		
Week 24 Adjusted Mean Change (SE)	17.96 (3.44)	14.72 (3.71)		
Week 32 Adjusted Mean Change (SE)	20.37 (3.46)	17.85 (3.69)		
Week 40 Adjusted Mean Change (SE)	17.37 (3.61)	18.78 (3.91)		
Week 52 Adjusted Mean Change (SE)	15.60 (3.58)	21.55 (3.92)	-5.95 [-16.52; 4.61]	0.266
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	48.92 (18.65)	51.20 (12.41)		
Week 52 Mean (SD)	66.77 (20.26)	73.40 (16.05)		
Week 4 Adjusted Mean Change (SE)	8.92 (4.77)	8.41 (5.49)		
Week 12 Adjusted Mean Change (SE)	6.24 (5.17)	17.80 (5.94)		
Week 16 Adjusted Mean Change (SE)	12.09 (5.14)	9.84 (5.91)		
Week 24 Adjusted Mean Change (SE)	11.13 (5.70)	13.83 (6.53)		
Week 32 Adjusted Mean Change (SE)	8.07 (5.65)	7.34 (6.48)		
Week 40 Adjusted Mean Change (SE)	12.60 (5.98)	12.01 (6.99)		
Week 52 Adjusted Mean Change (SE)	18.40 (5.78)	23.15 (6.63)	-4.75 [-22.30; 12.80]	0.592

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

40.13 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.252				
Non-carrier, N	**42**	**36**		
N'	42	35		
Baseline Mean (SD)	48.79 (22.21)	47.56 (24.39)		
Week 52 Mean (SD)	64.21 (24.93)	71.69 (20.47)		
Week 4 Adjusted Mean Change (SE)	11.91 (2.74)	15.72 (3.00)		
Week 12 Adjusted Mean Change (SE)	12.99 (2.94)	13.46 (3.22)		
Week 16 Adjusted Mean Change (SE)	16.59 (2.84)	14.76 (3.14)		
Week 24 Adjusted Mean Change (SE)	15.50 (3.16)	14.68 (3.57)		
Week 32 Adjusted Mean Change (SE)	17.22 (3.28)	14.58 (3.65)		
Week 40 Adjusted Mean Change (SE)	16.12 (3.40)	16.51 (3.87)		
Week 52 Adjusted Mean Change (SE)	16.65 (3.32)	23.52 (3.80)	-6.86 [-16.91; 3.18]	0.178
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	39.33 (18.37)	67.00 (5.61)		
Week 52 Mean (SD)	67.44 (21.45)	69.80 (11.30)		
Week 4 Adjusted Mean Change (SE)	8.21 (5.98)	6.86 (8.10)		
Week 12 Adjusted Mean Change (SE)	15.06 (6.36)	6.39 (8.62)		
Week 16 Adjusted Mean Change (SE)	21.06 (6.15)	0.36 (8.34)		
Week 24 Adjusted Mean Change (SE)	25.25 (6.87)	10.49 (9.32)		
Week 32 Adjusted Mean Change (SE)	21.90 (7.00)	10.29 (9.49)		
Week 40 Adjusted Mean Change (SE)	22.76 (7.38)	16.00 (10.01)		
Week 52 Adjusted Mean Change (SE)	21.55 (7.06)	15.13 (9.58)	6.41 [-17.60; 30.42]	0.596

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

40.14 EQ-5D VAS Score - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.569				
Low score, N	**11**	**22**		
N'	11	21		
Baseline Mean (SD)	52.00 (28.94)	50.77 (27.64)		
Week 52 Mean (SD)	58.00 (28.67)	67.80 (23.53)		
Week 4 Adjusted Mean Change (SE)	8.03 (5.28)	12.56 (3.84)		
Week 12 Adjusted Mean Change (SE)	9.00 (5.67)	15.77 (4.13)		
Week 16 Adjusted Mean Change (SE)	10.74 (5.71)	14.43 (4.11)		
Week 24 Adjusted Mean Change (SE)	14.00 (6.14)	8.70 (4.67)		
Week 32 Adjusted Mean Change (SE)	16.48 (6.32)	19.79 (4.87)		
Week 40 Adjusted Mean Change (SE)	10.55 (6.50)	13.61 (5.04)		
Week 52 Adjusted Mean Change (SE)	9.25 (6.45)	18.86 (5.16)	-9.62 [-26.02; 6.79]	0.247
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	45.78 (19.53)	48.14 (19.51)		
Week 52 Mean (SD)	66.61 (22.89)	73.45 (15.71)		
Week 4 Adjusted Mean Change (SE)	12.26 (2.77)	17.06 (3.74)		
Week 12 Adjusted Mean Change (SE)	14.69 (2.99)	11.50 (4.06)		
Week 16 Adjusted Mean Change (SE)	19.14 (2.92)	14.17 (3.99)		
Week 24 Adjusted Mean Change (SE)	18.28 (3.24)	19.72 (4.38)		
Week 32 Adjusted Mean Change (SE)	18.56 (3.39)	11.92 (4.47)		
Week 40 Adjusted Mean Change (SE)	19.28 (3.43)	20.31 (4.64)		
Week 52 Adjusted Mean Change (SE)	19.87 (3.34)	24.92 (4.42)	-5.04 [-16.06; 5.97]	0.365

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

40.15 EQ-5D VAS Score - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.278				
Non-carrier, N	31	23		
N'	31	22		
Baseline Mean (SD)	45.58 (21.88)	50.65 (21.15)		
Week 52 Mean (SD)	63.20 (26.22)	68.71 (19.73)		
Week 4 Adjusted Mean Change (SE)	14.66 (3.07)	10.25 (3.64)		
Week 12 Adjusted Mean Change (SE)	14.09 (3.38)	10.29 (4.01)		
Week 16 Adjusted Mean Change (SE)	17.88 (3.34)	11.66 (4.01)		
Week 24 Adjusted Mean Change (SE)	16.10 (3.69)	10.70 (4.50)		
Week 32 Adjusted Mean Change (SE)	16.09 (3.82)	13.60 (4.65)		
Week 40 Adjusted Mean Change (SE)	17.90 (3.90)	12.11 (4.80)		
Week 52 Adjusted Mean Change (SE)	16.42 (3.81)	20.32 (4.92)	-3.89 [-16.30; 8.51]	0.534
Carrier, N	20	21		
N'	20	21		
Baseline Mean (SD)	49.50 (21.81)	48.14 (26.64)		
Week 52 Mean (SD)	67.50 (20.63)	73.25 (18.92)		
Week 4 Adjusted Mean Change (SE)	6.26 (3.82)	19.65 (3.72)		
Week 12 Adjusted Mean Change (SE)	12.51 (4.26)	17.14 (4.15)		
Week 16 Adjusted Mean Change (SE)	16.62 (4.20)	16.96 (4.09)		
Week 24 Adjusted Mean Change (SE)	19.48 (4.63)	19.11 (4.58)		
Week 32 Adjusted Mean Change (SE)	21.58 (4.85)	17.48 (4.67)		
Week 40 Adjusted Mean Change (SE)	16.59 (4.81)	22.72 (4.81)		
Week 52 Adjusted Mean Change (SE)	19.73 (4.85)	24.87 (4.64)	-5.14 [-18.50; 8.22]	0.446

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

40.16 EQ-5D VAS Score - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.431				
Non-carrier, N	**19**	**20**		
N'	19	19		
Baseline Mean (SD)	43.42 (22.51)	49.25 (27.87)		
Week 52 Mean (SD)	62.84 (22.80)	71.93 (24.69)		
Week 4 Adjusted Mean Change (SE)	8.54 (4.04)	16.51 (4.02)		
Week 12 Adjusted Mean Change (SE)	12.80 (4.25)	20.60 (4.29)		
Week 16 Adjusted Mean Change (SE)	14.46 (4.23)	18.23 (4.28)		
Week 24 Adjusted Mean Change (SE)	16.89 (4.85)	16.10 (5.00)		
Week 32 Adjusted Mean Change (SE)	18.31 (4.87)	14.76 (5.07)		
Week 40 Adjusted Mean Change (SE)	17.86 (5.04)	18.50 (5.28)		
Week 52 Adjusted Mean Change (SE)	16.38 (4.85)	21.45 (5.42)	-5.07 [-19.56; 9.43]	0.489
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	49.31 (21.29)	49.63 (20.16)		
Week 52 Mean (SD)	66.10 (25.28)	70.70 (15.49)		
Week 4 Adjusted Mean Change (SE)	12.99 (3.09)	13.61 (3.58)		
Week 12 Adjusted Mean Change (SE)	13.80 (3.28)	8.41 (3.76)		
Week 16 Adjusted Mean Change (SE)	19.18 (3.27)	11.20 (3.79)		
Week 24 Adjusted Mean Change (SE)	17.64 (3.67)	13.61 (4.30)		
Week 32 Adjusted Mean Change (SE)	17.85 (3.85)	15.84 (4.38)		
Week 40 Adjusted Mean Change (SE)	17.06 (3.89)	16.37 (4.56)		
Week 52 Adjusted Mean Change (SE)	18.37 (3.85)	22.66 (4.36)	-4.29 [-15.84; 7.27]	0.463

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

40.17 EQ-5D VAS Score - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.316				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	47.28 (22.96)	52.38 (23.88)		
Week 52 Mean (SD)	69.61 (25.01)	70.29 (20.05)		
Week 4 Adjusted Mean Change (SE)	11.46 (3.53)	14.96 (3.13)		
Week 12 Adjusted Mean Change (SE)	14.37 (3.80)	11.76 (3.37)		
Week 16 Adjusted Mean Change (SE)	18.01 (3.65)	10.88 (3.23)		
Week 24 Adjusted Mean Change (SE)	20.53 (4.11)	12.76 (3.78)		
Week 32 Adjusted Mean Change (SE)	20.56 (4.30)	17.32 (3.85)		
Week 40 Adjusted Mean Change (SE)	20.05 (4.35)	18.76 (4.01)		
Week 52 Adjusted Mean Change (SE)	22.21 (4.27)	21.74 (3.85)	0.47 [-10.98; 11.92]	0.935
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	46.96 (20.91)	41.67 (22.22)		
Week 52 Mean (SD)	60.40 (22.91)	73.89 (16.88)		
Week 4 Adjusted Mean Change (SE)	11.22 (3.46)	14.65 (5.32)		
Week 12 Adjusted Mean Change (SE)	12.58 (3.69)	18.91 (5.67)		
Week 16 Adjusted Mean Change (SE)	16.85 (3.54)	24.47 (5.58)		
Week 24 Adjusted Mean Change (SE)	14.28 (4.07)	20.51 (6.20)		
Week 32 Adjusted Mean Change (SE)	15.59 (4.17)	11.03 (6.32)		
Week 40 Adjusted Mean Change (SE)	14.80 (4.30)	14.01 (6.68)		
Week 52 Adjusted Mean Change (SE)	13.32 (4.13)	24.69 (6.72)	-11.38 [-27.05; 4.29]	0.153

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

40.18 EQ-5D VAS Score - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.086				
Non-carrier, N	**39**	**35**		
N'	39	34		
Baseline Mean (SD)	49.95 (20.32)	51.74 (23.34)		
Week 52 Mean (SD)	64.17 (23.76)	68.71 (20.52)		
Week 4 Adjusted Mean Change (SE)	12.30 (2.82)	13.16 (3.02)		
Week 12 Adjusted Mean Change (SE)	13.74 (3.07)	12.78 (3.30)		
Week 16 Adjusted Mean Change (SE)	17.85 (2.97)	12.06 (3.19)		
Week 24 Adjusted Mean Change (SE)	18.89 (3.22)	10.27 (3.57)		
Week 32 Adjusted Mean Change (SE)	18.84 (3.49)	15.36 (3.79)		
Week 40 Adjusted Mean Change (SE)	17.22 (3.41)	13.18 (3.79)		
Week 52 Adjusted Mean Change (SE)	16.19 (3.38)	18.73 (3.80)	-2.55 [-12.65; 7.55]	0.617
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	40.45 (23.91)	40.56 (24.20)		
Week 52 Mean (SD)	65.36 (27.00)	78.78 (12.06)		
Week 4 Adjusted Mean Change (SE)	7.34 (5.38)	19.92 (5.88)		
Week 12 Adjusted Mean Change (SE)	10.57 (5.82)	15.58 (6.37)		
Week 16 Adjusted Mean Change (SE)	13.14 (5.63)	21.09 (6.35)		
Week 24 Adjusted Mean Change (SE)	10.48 (6.27)	28.95 (6.71)		
Week 32 Adjusted Mean Change (SE)	14.97 (6.50)	14.79 (7.12)		
Week 40 Adjusted Mean Change (SE)	14.28 (6.47)	30.89 (7.24)		
Week 52 Adjusted Mean Change (SE)	18.73 (6.27)	32.92 (6.86)	-14.19 [-32.50; 4.12]	0.127

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

41.0 FACIT Fatigue - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	57 (91.9)	122 (95.3)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	48 (77.4)	111 (86.7)

41.1 FACIT Fatigue - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	60		
Baseline Mean (SD)	29.26 (11.71)	30.11 (11.48)		
Week 52 Mean (SD)	37.02 (10.71)	36.94 (11.91)		
Week 4 Adjusted Mean Change (SE)	5.27 (0.92)	4.83 (0.96)		
Week 12 Adjusted Mean Change (SE)	5.27 (1.02)	4.34 (1.07)		
Week 16 Adjusted Mean Change (SE)	7.21 (1.09)	4.67 (1.16)		
Week 24 Adjusted Mean Change (SE)	6.50 (1.07)	5.29 (1.16)		
Week 32 Adjusted Mean Change (SE)	7.37 (1.19)	6.45 (1.27)		
Week 40 Adjusted Mean Change (SE)	7.13 (1.09)	6.30 (1.19)		
Week 52 Adjusted Mean Change (SE)	7.70 (1.18)	6.43 (1.31)	1.27 [-2.23; 4.77]	0.473

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

41.2 FACIT Fatigue - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.838				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	31.40 (11.75)	33.24 (10.39)		
Week 52 Mean (SD)	38.98 (10.86)	38.35 (11.39)		
Week 4 Adjusted Mean Change (SE)	5.59 (1.17)	5.17 (1.35)		
Week 12 Adjusted Mean Change (SE)	6.62 (1.28)	4.86 (1.47)		
Week 16 Adjusted Mean Change (SE)	7.61 (1.39)	5.66 (1.60)		
Week 24 Adjusted Mean Change (SE)	6.47 (1.36)	7.27 (1.59)		
Week 32 Adjusted Mean Change (SE)	7.53 (1.51)	7.58 (1.77)		
Week 40 Adjusted Mean Change (SE)	7.46 (1.39)	6.78 (1.65)		
Week 52 Adjusted Mean Change (SE)	8.29 (1.50)	6.91 (1.82)	1.38 [-3.25; 6.02]	0.555
Female, N	**24**	**29**		
N'	24	28		
Baseline Mean (SD)	25.50 (10.88)	26.55 (11.79)		
Week 52 Mean (SD)	33.61 (9.76)	35.27 (12.55)		
Week 4 Adjusted Mean Change (SE)	4.72 (1.57)	4.46 (1.43)		
Week 12 Adjusted Mean Change (SE)	2.84 (1.73)	3.80 (1.57)		
Week 16 Adjusted Mean Change (SE)	6.48 (1.85)	3.56 (1.74)		
Week 24 Adjusted Mean Change (SE)	6.56 (1.83)	2.96 (1.71)		
Week 32 Adjusted Mean Change (SE)	7.07 (2.02)	5.17 (1.87)		
Week 40 Adjusted Mean Change (SE)	6.55 (1.85)	5.81 (1.77)		
Week 52 Adjusted Mean Change (SE)	6.67 (2.00)	5.91 (1.95)	0.76 [-4.72; 6.23]	0.785

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

41.3 FACIT Fatigue - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.283				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	38.56 (8.59)	39.46 (7.90)		
Week 52 Mean (SD)	43.50 (7.07)	36.22 (13.66)		
Week 4 Adjusted Mean Change (SE)	5.23 (1.96)	3.60 (2.18)		
Week 12 Adjusted Mean Change (SE)	6.54 (2.20)	4.84 (2.40)		
Week 16 Adjusted Mean Change (SE)	9.07 (2.33)	4.42 (2.58)		
Week 24 Adjusted Mean Change (SE)	8.04 (2.31)	4.30 (2.61)		
Week 32 Adjusted Mean Change (SE)	8.31 (2.53)	4.89 (2.92)		
Week 40 Adjusted Mean Change (SE)	8.74 (2.33)	3.83 (2.74)		
Week 52 Adjusted Mean Change (SE)	9.10 (2.48)	2.68 (3.03)	6.43 [-1.07; 13.93]	0.092
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	47		
Baseline Mean (SD)	26.28 (11.05)	27.63 (11.04)		
Week 52 Mean (SD)	34.81 (10.90)	37.10 (11.66)		
Week 4 Adjusted Mean Change (SE)	5.30 (1.08)	5.16 (1.10)		
Week 12 Adjusted Mean Change (SE)	4.86 (1.20)	4.22 (1.22)		
Week 16 Adjusted Mean Change (SE)	6.59 (1.29)	4.77 (1.32)		
Week 24 Adjusted Mean Change (SE)	6.00 (1.26)	5.57 (1.31)		
Week 32 Adjusted Mean Change (SE)	7.07 (1.40)	6.84 (1.43)		
Week 40 Adjusted Mean Change (SE)	6.61 (1.28)	6.90 (1.33)		
Week 52 Adjusted Mean Change (SE)	7.25 (1.39)	7.34 (1.46)	-0.09 [-4.05; 3.87]	0.964

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

41.4 FACIT Fatigue - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.096				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	31		
Baseline Mean (SD)	30.07 (12.18)	28.50 (10.97)		
Week 52 Mean (SD)	35.85 (10.12)	37.87 (10.31)		
Week 4 Adjusted Mean Change (SE)	5.23 (1.42)	5.77 (1.35)		
Week 12 Adjusted Mean Change (SE)	3.49 (1.52)	6.58 (1.45)		
Week 16 Adjusted Mean Change (SE)	4.48 (1.65)	5.59 (1.60)		
Week 24 Adjusted Mean Change (SE)	5.56 (1.66)	5.91 (1.61)		
Week 32 Adjusted Mean Change (SE)	6.08 (1.83)	7.19 (1.78)		
Week 40 Adjusted Mean Change (SE)	5.41 (1.69)	6.48 (1.69)		
Week 52 Adjusted Mean Change (SE)	6.49 (1.83)	7.43 (1.87)	-0.95 [-6.14; 4.25]	0.719
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	28.66 (11.48)	31.83 (11.95)		
Week 52 Mean (SD)	37.84 (11.17)	36.08 (13.37)		
Week 4 Adjusted Mean Change (SE)	5.31 (1.22)	3.82 (1.40)		
Week 12 Adjusted Mean Change (SE)	6.60 (1.33)	1.88 (1.52)		
Week 16 Adjusted Mean Change (SE)	9.26 (1.43)	3.65 (1.64)		
Week 24 Adjusted Mean Change (SE)	7.22 (1.42)	4.59 (1.68)		
Week 32 Adjusted Mean Change (SE)	8.32 (1.57)	5.63 (1.83)		
Week 40 Adjusted Mean Change (SE)	8.37 (1.45)	5.94 (1.70)		
Week 52 Adjusted Mean Change (SE)	8.58 (1.56)	5.39 (1.86)	3.18 [-1.63; 8.00]	0.193

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

41.5 FACIT Fatigue - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.186				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	30.05 (9.42)	32.72 (12.15)		
Week 52 Mean (SD)	38.68 (9.36)	39.86 (9.90)		
Week 4 Adjusted Mean Change (SE)	5.62 (1.19)	4.32 (1.41)		
Week 12 Adjusted Mean Change (SE)	6.57 (1.32)	3.85 (1.54)		
Week 16 Adjusted Mean Change (SE)	7.78 (1.41)	4.86 (1.70)		
Week 24 Adjusted Mean Change (SE)	7.77 (1.37)	4.37 (1.69)		
Week 32 Adjusted Mean Change (SE)	8.21 (1.53)	5.51 (1.86)		
Week 40 Adjusted Mean Change (SE)	8.44 (1.40)	4.74 (1.75)		
Week 52 Adjusted Mean Change (SE)	8.62 (1.53)	6.47 (1.97)	2.15 [-2.79; 7.08]	0.391
> Median, N	**26**	**33**		
N'	26	31		
Baseline Mean (SD)	28.04 (14.68)	27.82 (10.51)		
Week 52 Mean (SD)	34.48 (12.27)	34.67 (12.99)		
Week 4 Adjusted Mean Change (SE)	4.76 (1.47)	5.31 (1.35)		
Week 12 Adjusted Mean Change (SE)	3.31 (1.61)	4.81 (1.49)		
Week 16 Adjusted Mean Change (SE)	6.29 (1.75)	4.52 (1.61)		
Week 24 Adjusted Mean Change (SE)	4.51 (1.72)	6.11 (1.60)		
Week 32 Adjusted Mean Change (SE)	6.06 (1.89)	7.29 (1.76)		
Week 40 Adjusted Mean Change (SE)	5.14 (1.73)	7.65 (1.63)		
Week 52 Adjusted Mean Change (SE)	6.28 (1.89)	6.50 (1.79)	-0.22 [-5.37; 4.93]	0.933

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

41.6 FACIT Fatigue - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.161				
Enthesitis: No, N	**34**	**22**		
N'	34	21		
Baseline Mean (SD)	30.59 (11.35)	31.77 (12.89)		
Week 52 Mean (SD)	37.22 (10.64)	41.44 (10.00)		
Week 4 Adjusted Mean Change (SE)	5.68 (1.28)	6.78 (1.64)		
Week 12 Adjusted Mean Change (SE)	6.13 (1.40)	7.84 (1.80)		
Week 16 Adjusted Mean Change (SE)	7.69 (1.49)	8.90 (1.93)		
Week 24 Adjusted Mean Change (SE)	6.78 (1.50)	7.69 (1.92)		
Week 32 Adjusted Mean Change (SE)	7.94 (1.66)	9.12 (2.11)		
Week 40 Adjusted Mean Change (SE)	8.07 (1.52)	8.85 (1.96)		
Week 52 Adjusted Mean Change (SE)	7.45 (1.63)	10.60 (2.13)	-3.15 [-8.44; 2.14]	0.241
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	27.84 (12.10)	29.20 (10.69)		
Week 52 Mean (SD)	36.81 (10.96)	34.23 (12.29)		
Week 4 Adjusted Mean Change (SE)	4.84 (1.32)	3.80 (1.20)		
Week 12 Adjusted Mean Change (SE)	4.34 (1.45)	2.51 (1.30)		
Week 16 Adjusted Mean Change (SE)	6.68 (1.55)	2.42 (1.41)		
Week 24 Adjusted Mean Change (SE)	6.18 (1.54)	4.05 (1.45)		
Week 32 Adjusted Mean Change (SE)	6.77 (1.70)	5.07 (1.59)		
Week 40 Adjusted Mean Change (SE)	6.15 (1.56)	5.00 (1.49)		
Week 52 Adjusted Mean Change (SE)	7.94 (1.67)	4.10 (1.63)	3.84 [-0.76; 8.45]	0.101

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

41.7 FACIT Fatigue - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.081				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	26.34 (11.77)	31.76 (11.77)		
Week 52 Mean (SD)	34.82 (11.78)	42.05 (9.09)		
Week 4 Adjusted Mean Change (SE)	5.43 (1.31)	7.57 (1.40)		
Week 12 Adjusted Mean Change (SE)	6.16 (1.48)	6.63 (1.60)		
Week 16 Adjusted Mean Change (SE)	6.93 (1.59)	7.18 (1.73)		
Week 24 Adjusted Mean Change (SE)	6.97 (1.51)	8.11 (1.65)		
Week 32 Adjusted Mean Change (SE)	7.70 (1.67)	9.60 (1.83)		
Week 40 Adjusted Mean Change (SE)	8.21 (1.61)	9.46 (1.76)		
Week 52 Adjusted Mean Change (SE)	7.52 (1.60)	11.85 (1.78)	-4.33 [-9.11; 0.45]	0.075
Carrier, N	**22**	**19**		
N'	22	18		
Baseline Mean (SD)	31.00 (8.42)	30.00 (11.56)		
Week 52 Mean (SD)	38.65 (7.56)	33.50 (12.77)		
Week 4 Adjusted Mean Change (SE)	6.30 (1.49)	3.83 (1.64)		
Week 12 Adjusted Mean Change (SE)	4.77 (1.71)	3.34 (1.86)		
Week 16 Adjusted Mean Change (SE)	7.16 (1.82)	4.22 (1.99)		
Week 24 Adjusted Mean Change (SE)	7.40 (1.72)	3.49 (1.92)		
Week 32 Adjusted Mean Change (SE)	8.54 (1.95)	3.78 (2.13)		
Week 40 Adjusted Mean Change (SE)	6.98 (1.84)	4.27 (2.09)		
Week 52 Adjusted Mean Change (SE)	8.02 (1.85)	3.25 (2.07)	4.78 [-0.73; 10.28]	0.088

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

41.8 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.263				
Non-carrier, N	**28**	**19**		
N'	28	18		
Baseline Mean (SD)	26.57 (10.47)	31.42 (11.47)		
Week 52 Mean (SD)	35.70 (11.01)	38.00 (11.64)		
Week 4 Adjusted Mean Change (SE)	6.78 (1.37)	5.79 (1.71)		
Week 12 Adjusted Mean Change (SE)	7.08 (1.53)	5.46 (1.91)		
Week 16 Adjusted Mean Change (SE)	8.87 (1.60)	3.81 (2.03)		
Week 24 Adjusted Mean Change (SE)	7.74 (1.57)	3.72 (2.01)		
Week 32 Adjusted Mean Change (SE)	9.00 (1.78)	6.90 (2.27)		
Week 40 Adjusted Mean Change (SE)	8.32 (1.70)	5.43 (2.19)		
Week 52 Adjusted Mean Change (SE)	7.97 (1.78)	8.01 (2.38)	-0.04 [-5.98; 5.90]	0.988
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	30.05 (10.61)	30.47 (12.50)		
Week 52 Mean (SD)	37.05 (9.69)	38.56 (12.51)		
Week 4 Adjusted Mean Change (SE)	4.80 (1.54)	5.81 (1.65)		
Week 12 Adjusted Mean Change (SE)	4.00 (1.74)	5.73 (1.88)		
Week 16 Adjusted Mean Change (SE)	4.83 (1.81)	6.95 (1.96)		
Week 24 Adjusted Mean Change (SE)	6.74 (1.77)	7.88 (1.93)		
Week 32 Adjusted Mean Change (SE)	7.36 (2.00)	6.50 (2.16)		
Week 40 Adjusted Mean Change (SE)	7.42 (1.88)	8.58 (2.08)		
Week 52 Adjusted Mean Change (SE)	7.76 (2.00)	8.89 (2.16)	-1.13 [-6.98; 4.72]	0.702

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

41.9 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.757				
Non-carrier, N	**19**	**21**		
N'	19	20		
Baseline Mean (SD)	26.37 (12.16)	30.05 (13.62)		
Week 52 Mean (SD)	36.11 (11.35)	39.73 (14.24)		
Week 4 Adjusted Mean Change (SE)	5.44 (1.60)	8.22 (1.55)		
Week 12 Adjusted Mean Change (SE)	7.82 (1.84)	6.17 (1.81)		
Week 16 Adjusted Mean Change (SE)	7.40 (1.98)	5.92 (1.94)		
Week 24 Adjusted Mean Change (SE)	7.60 (1.92)	5.66 (1.91)		
Week 32 Adjusted Mean Change (SE)	8.91 (2.11)	9.19 (2.10)		
Week 40 Adjusted Mean Change (SE)	8.46 (2.01)	7.84 (2.03)		
Week 52 Adjusted Mean Change (SE)	8.59 (2.06)	9.83 (2.16)	-1.24 [-7.19; 4.71]	0.679
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	29.00 (9.64)	31.87 (9.56)		
Week 52 Mean (SD)	36.32 (9.83)	37.41 (9.45)		
Week 4 Adjusted Mean Change (SE)	6.53 (1.26)	4.11 (1.45)		
Week 12 Adjusted Mean Change (SE)	4.36 (1.47)	4.55 (1.67)		
Week 16 Adjusted Mean Change (SE)	7.06 (1.56)	6.07 (1.82)		
Week 24 Adjusted Mean Change (SE)	7.06 (1.50)	6.56 (1.75)		
Week 32 Adjusted Mean Change (SE)	7.66 (1.69)	5.46 (1.94)		
Week 40 Adjusted Mean Change (SE)	7.98 (1.60)	6.76 (1.86)		
Week 52 Adjusted Mean Change (SE)	7.53 (1.65)	6.98 (1.90)	0.55 [-4.47; 5.57]	0.828

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

41.10 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.315				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	27.44 (11.53)	30.88 (11.81)		
Week 52 Mean (SD)	36.70 (11.64)	37.18 (12.61)		
Week 4 Adjusted Mean Change (SE)	6.38 (1.42)	5.58 (1.25)		
Week 12 Adjusted Mean Change (SE)	4.47 (1.61)	4.51 (1.41)		
Week 16 Adjusted Mean Change (SE)	6.51 (1.69)	4.47 (1.48)		
Week 24 Adjusted Mean Change (SE)	7.02 (1.59)	4.45 (1.44)		
Week 32 Adjusted Mean Change (SE)	7.83 (1.86)	7.05 (1.66)		
Week 40 Adjusted Mean Change (SE)	7.82 (1.75)	6.55 (1.59)		
Week 52 Adjusted Mean Change (SE)	8.56 (1.82)	7.73 (1.65)	0.83 [-4.06; 5.73]	0.736
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	29.23 (9.82)	31.33 (11.41)		
Week 52 Mean (SD)	36.16 (9.18)	42.00 (6.20)		
Week 4 Adjusted Mean Change (SE)	5.27 (1.39)	7.19 (2.14)		
Week 12 Adjusted Mean Change (SE)	6.56 (1.55)	7.51 (2.39)		
Week 16 Adjusted Mean Change (SE)	7.50 (1.63)	10.33 (2.59)		
Week 24 Adjusted Mean Change (SE)	7.27 (1.57)	10.89 (2.40)		
Week 32 Adjusted Mean Change (SE)	8.20 (1.81)	7.60 (2.77)		
Week 40 Adjusted Mean Change (SE)	7.55 (1.72)	9.40 (2.68)		
Week 52 Adjusted Mean Change (SE)	6.95 (1.77)	9.57 (2.83)	-2.61 [-9.26; 4.03]	0.437

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

41.11 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.742				
Non-carrier, N	**38**	**33**		
N'	38	32		
Baseline Mean (SD)	29.00 (10.45)	31.33 (10.91)		
Week 52 Mean (SD)	36.46 (9.72)	38.69 (10.91)		
Week 4 Adjusted Mean Change (SE)	5.59 (1.12)	6.44 (1.22)		
Week 12 Adjusted Mean Change (SE)	4.13 (1.25)	5.73 (1.35)		
Week 16 Adjusted Mean Change (SE)	6.69 (1.36)	6.08 (1.49)		
Week 24 Adjusted Mean Change (SE)	7.39 (1.28)	6.63 (1.42)		
Week 32 Adjusted Mean Change (SE)	7.86 (1.48)	8.34 (1.63)		
Week 40 Adjusted Mean Change (SE)	7.35 (1.38)	7.69 (1.54)		
Week 52 Adjusted Mean Change (SE)	7.29 (1.45)	8.16 (1.65)	-0.86 [-5.24; 3.52]	0.697
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	26.25 (11.79)	34.11 (11.58)		
Week 52 Mean (SD)	35.50 (12.38)	43.00 (6.10)		
Week 4 Adjusted Mean Change (SE)	5.36 (2.02)	7.41 (2.30)		
Week 12 Adjusted Mean Change (SE)	8.32 (2.24)	5.75 (2.65)		
Week 16 Adjusted Mean Change (SE)	6.13 (2.43)	8.16 (2.88)		
Week 24 Adjusted Mean Change (SE)	4.57 (2.34)	8.21 (2.68)		
Week 32 Adjusted Mean Change (SE)	6.85 (2.62)	5.75 (3.00)		
Week 40 Adjusted Mean Change (SE)	7.31 (2.46)	9.67 (2.82)		
Week 52 Adjusted Mean Change (SE)	7.08 (2.56)	11.05 (2.93)	-3.97 [-11.76; 3.82]	0.314

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

41.12 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.554				
Non-carrier, N	**36**	**34**		
N'	36	33		
Baseline Mean (SD)	27.81 (10.80)	32.09 (11.82)		
Week 52 Mean (SD)	35.67 (10.03)	39.52 (11.23)		
Week 4 Adjusted Mean Change (SE)	5.34 (1.15)	7.27 (1.21)		
Week 12 Adjusted Mean Change (SE)	5.84 (1.34)	5.22 (1.42)		
Week 16 Adjusted Mean Change (SE)	6.96 (1.45)	5.84 (1.54)		
Week 24 Adjusted Mean Change (SE)	6.32 (1.35)	6.07 (1.45)		
Week 32 Adjusted Mean Change (SE)	7.70 (1.54)	7.68 (1.64)		
Week 40 Adjusted Mean Change (SE)	6.93 (1.47)	7.60 (1.59)		
Week 52 Adjusted Mean Change (SE)	7.24 (1.54)	8.64 (1.67)	-1.39 [-5.95; 3.16]	0.545
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	31.31 (9.38)	27.30 (10.38)		
Week 52 Mean (SD)	38.31 (11.32)	35.20 (12.25)		
Week 4 Adjusted Mean Change (SE)	5.75 (1.90)	1.60 (2.19)		
Week 12 Adjusted Mean Change (SE)	3.70 (2.22)	4.87 (2.55)		
Week 16 Adjusted Mean Change (SE)	6.64 (2.38)	5.61 (2.74)		
Week 24 Adjusted Mean Change (SE)	7.35 (2.23)	5.83 (2.56)		
Week 32 Adjusted Mean Change (SE)	7.47 (2.52)	4.96 (2.89)		
Week 40 Adjusted Mean Change (SE)	8.23 (2.43)	5.74 (2.82)		
Week 52 Adjusted Mean Change (SE)	7.91 (2.50)	6.37 (2.86)	1.55 [-6.05; 9.14]	0.686

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

41.13 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.454				
Non-carrier, N	**42**	**36**		
N'	42	35		
Baseline Mean (SD)	28.98 (10.95)	30.53 (12.13)		
Week 52 Mean (SD)	36.13 (10.47)	39.21 (11.85)		
Week 4 Adjusted Mean Change (SE)	5.83 (1.11)	5.84 (1.22)		
Week 12 Adjusted Mean Change (SE)	5.67 (1.24)	5.19 (1.36)		
Week 16 Adjusted Mean Change (SE)	7.27 (1.29)	6.06 (1.43)		
Week 24 Adjusted Mean Change (SE)	7.15 (1.27)	6.57 (1.43)		
Week 32 Adjusted Mean Change (SE)	7.94 (1.42)	6.49 (1.58)		
Week 40 Adjusted Mean Change (SE)	7.48 (1.36)	6.88 (1.54)		
Week 52 Adjusted Mean Change (SE)	7.30 (1.37)	9.60 (1.55)	-2.30 [-6.42; 1.82]	0.270
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	25.44 (8.88)	31.00 (8.09)		
Week 52 Mean (SD)	37.67 (10.15)	33.60 (9.79)		
Week 4 Adjusted Mean Change (SE)	6.28 (2.41)	5.96 (3.21)		
Week 12 Adjusted Mean Change (SE)	5.70 (2.67)	2.68 (3.55)		
Week 16 Adjusted Mean Change (SE)	6.70 (2.78)	1.04 (3.70)		
Week 24 Adjusted Mean Change (SE)	7.86 (2.76)	3.00 (3.67)		
Week 32 Adjusted Mean Change (SE)	9.14 (3.05)	8.63 (4.07)		
Week 40 Adjusted Mean Change (SE)	9.25 (2.95)	7.03 (3.92)		
Week 52 Adjusted Mean Change (SE)	10.37 (2.93)	3.33 (3.91)	7.03 [-2.71; 16.77]	0.155

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

41.14 FACIT Fatigue - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.627				
Low score, N	11	22		
N'	11	21		
Baseline Mean (SD)	27.91 (13.87)	31.59 (13.23)		
Week 52 Mean (SD)	34.80 (13.07)	37.27 (13.97)		
Week 4 Adjusted Mean Change (SE)	5.42 (2.13)	7.07 (1.56)		
Week 12 Adjusted Mean Change (SE)	6.98 (2.40)	5.13 (1.76)		
Week 16 Adjusted Mean Change (SE)	8.82 (2.59)	4.07 (1.87)		
Week 24 Adjusted Mean Change (SE)	7.67 (2.38)	2.95 (1.80)		
Week 32 Adjusted Mean Change (SE)	7.46 (2.75)	7.32 (2.09)		
Week 40 Adjusted Mean Change (SE)	5.28 (2.59)	5.41 (1.99)		
Week 52 Adjusted Mean Change (SE)	6.01 (2.74)	7.31 (2.15)	-1.30 [-8.23; 5.64]	0.711
High score, N	40	22		
N'	40	22		
Baseline Mean (SD)	28.48 (9.75)	30.41 (9.92)		
Week 52 Mean (SD)	36.84 (9.63)	39.09 (9.76)		
Week 4 Adjusted Mean Change (SE)	5.92 (1.12)	4.98 (1.51)		
Week 12 Adjusted Mean Change (SE)	5.17 (1.27)	5.37 (1.73)		
Week 16 Adjusted Mean Change (SE)	6.58 (1.33)	7.69 (1.81)		
Week 24 Adjusted Mean Change (SE)	7.04 (1.25)	8.96 (1.70)		
Week 32 Adjusted Mean Change (SE)	8.17 (1.46)	6.97 (1.95)		
Week 40 Adjusted Mean Change (SE)	8.37 (1.37)	8.77 (1.85)		
Week 52 Adjusted Mean Change (SE)	8.21 (1.43)	8.95 (1.90)	-0.74 [-5.48; 4.00]	0.756

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

41.15 FACIT Fatigue - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.276				
Non-carrier, N	**31**	**23**		
N'	31	22		
Baseline Mean (SD)	27.74 (10.59)	30.78 (10.58)		
Week 52 Mean (SD)	36.33 (10.61)	38.12 (10.83)		
Week 4 Adjusted Mean Change (SE)	6.19 (1.28)	5.85 (1.52)		
Week 12 Adjusted Mean Change (SE)	6.85 (1.42)	4.78 (1.69)		
Week 16 Adjusted Mean Change (SE)	8.36 (1.50)	4.25 (1.80)		
Week 24 Adjusted Mean Change (SE)	7.53 (1.45)	4.36 (1.76)		
Week 32 Adjusted Mean Change (SE)	8.40 (1.66)	7.34 (2.00)		
Week 40 Adjusted Mean Change (SE)	7.94 (1.57)	5.74 (1.92)		
Week 52 Adjusted Mean Change (SE)	7.94 (1.63)	8.24 (2.05)	-0.30 [-5.52; 4.92]	0.910
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	29.30 (10.86)	31.24 (12.84)		
Week 52 Mean (SD)	36.56 (10.12)	38.55 (12.32)		
Week 4 Adjusted Mean Change (SE)	5.24 (1.59)	6.14 (1.55)		
Week 12 Adjusted Mean Change (SE)	3.54 (1.80)	5.74 (1.75)		
Week 16 Adjusted Mean Change (SE)	4.95 (1.89)	7.67 (1.85)		
Week 24 Adjusted Mean Change (SE)	6.62 (1.82)	8.05 (1.79)		
Week 32 Adjusted Mean Change (SE)	7.42 (2.07)	6.96 (2.02)		
Week 40 Adjusted Mean Change (SE)	7.28 (1.94)	8.84 (1.93)		
Week 52 Adjusted Mean Change (SE)	7.38 (2.04)	8.32 (1.99)	-0.94 [-6.62; 4.74]	0.742

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

41.16 FACIT Fatigue - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.790				
Non-carrier, N	**19**	**20**		
N'	19	19		
Baseline Mean (SD)	26.37 (12.16)	30.45 (13.85)		
Week 52 Mean (SD)	36.11 (11.35)	39.50 (14.74)		
Week 4 Adjusted Mean Change (SE)	5.35 (1.61)	8.19 (1.60)		
Week 12 Adjusted Mean Change (SE)	7.75 (1.82)	6.57 (1.83)		
Week 16 Adjusted Mean Change (SE)	7.31 (1.96)	6.97 (1.97)		
Week 24 Adjusted Mean Change (SE)	7.54 (1.91)	6.33 (1.95)		
Week 32 Adjusted Mean Change (SE)	8.83 (2.10)	8.37 (2.15)		
Week 40 Adjusted Mean Change (SE)	8.35 (2.02)	7.29 (2.09)		
Week 52 Adjusted Mean Change (SE)	8.50 (2.07)	9.25 (2.23)	-0.76 [-6.81; 5.30]	0.804
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	29.53 (9.60)	31.46 (9.57)		
Week 52 Mean (SD)	36.62 (9.78)	37.65 (9.31)		
Week 4 Adjusted Mean Change (SE)	6.09 (1.23)	4.26 (1.43)		
Week 12 Adjusted Mean Change (SE)	4.26 (1.40)	4.22 (1.61)		
Week 16 Adjusted Mean Change (SE)	6.89 (1.51)	5.11 (1.76)		
Week 24 Adjusted Mean Change (SE)	6.94 (1.44)	5.93 (1.69)		
Week 32 Adjusted Mean Change (SE)	7.56 (1.63)	6.14 (1.88)		
Week 40 Adjusted Mean Change (SE)	7.30 (1.55)	7.15 (1.82)		
Week 52 Adjusted Mean Change (SE)	7.25 (1.61)	7.43 (1.85)	-0.18 [-5.06; 4.70]	0.941

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

41.16 FACIT Fatigue - Change from Baseline by Linkage Variant rs12065362 (FAS)

41.17 FACIT Fatigue - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.315				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	27.44 (11.53)	30.88 (11.81)		
Week 52 Mean (SD)	36.70 (11.64)	37.18 (12.61)		
Week 4 Adjusted Mean Change (SE)	6.38 (1.42)	5.58 (1.25)		
Week 12 Adjusted Mean Change (SE)	4.47 (1.61)	4.51 (1.41)		
Week 16 Adjusted Mean Change (SE)	6.51 (1.69)	4.47 (1.48)		
Week 24 Adjusted Mean Change (SE)	7.02 (1.59)	4.45 (1.44)		
Week 32 Adjusted Mean Change (SE)	7.83 (1.86)	7.05 (1.66)		
Week 40 Adjusted Mean Change (SE)	7.82 (1.75)	6.55 (1.59)		
Week 52 Adjusted Mean Change (SE)	8.56 (1.82)	7.73 (1.65)	0.83 [-4.06; 5.73]	0.736
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	29.23 (9.82)	31.33 (11.41)		
Week 52 Mean (SD)	36.16 (9.18)	42.00 (6.20)		
Week 4 Adjusted Mean Change (SE)	5.27 (1.39)	7.19 (2.14)		
Week 12 Adjusted Mean Change (SE)	6.56 (1.55)	7.51 (2.39)		
Week 16 Adjusted Mean Change (SE)	7.50 (1.63)	10.33 (2.59)		
Week 24 Adjusted Mean Change (SE)	7.27 (1.57)	10.89 (2.40)		
Week 32 Adjusted Mean Change (SE)	8.20 (1.81)	7.60 (2.77)		
Week 40 Adjusted Mean Change (SE)	7.55 (1.72)	9.40 (2.68)		
Week 52 Adjusted Mean Change (SE)	6.95 (1.77)	9.57 (2.83)	-2.61 [-9.26; 4.03]	0.437

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

41.18 FACIT Fatigue - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.905				
Non-carrier, N	**39**	**35**		
N'	39	34		
Baseline Mean (SD)	29.00 (10.31)	30.97 (11.46)		
Week 52 Mean (SD)	36.72 (9.71)	37.89 (11.79)		
Week 4 Adjusted Mean Change (SE)	5.78 (1.14)	6.11 (1.22)		
Week 12 Adjusted Mean Change (SE)	4.55 (1.28)	5.56 (1.37)		
Week 16 Adjusted Mean Change (SE)	7.10 (1.37)	5.47 (1.46)		
Week 24 Adjusted Mean Change (SE)	7.71 (1.31)	5.97 (1.44)		
Week 32 Adjusted Mean Change (SE)	8.25 (1.48)	7.97 (1.60)		
Week 40 Adjusted Mean Change (SE)	7.58 (1.41)	7.12 (1.55)		
Week 52 Adjusted Mean Change (SE)	7.68 (1.47)	7.68 (1.63)	0.01 [-4.35; 4.36]	0.998
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	28.00 (10.61)	31.11 (12.72)		
Week 52 Mean (SD)	37.18 (11.46)	39.78 (11.11)		
Week 4 Adjusted Mean Change (SE)	5.93 (2.17)	5.19 (2.37)		
Week 12 Adjusted Mean Change (SE)	8.32 (2.41)	3.58 (2.64)		
Week 16 Adjusted Mean Change (SE)	5.45 (2.57)	7.04 (2.90)		
Week 24 Adjusted Mean Change (SE)	5.15 (2.52)	6.35 (2.72)		
Week 32 Adjusted Mean Change (SE)	7.23 (2.76)	3.80 (3.02)		
Week 40 Adjusted Mean Change (SE)	8.13 (2.66)	7.32 (2.96)		
Week 52 Adjusted Mean Change (SE)	8.00 (2.72)	9.25 (2.99)	-1.25 [-9.29; 6.78]	0.757

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

42.1 FACIT 4-Point Response (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
FACIT 4-Point Response Week 52, N' n (%)	63 44.74 (67.79)	48 35.11 (56.63)	1.63 [0.76; 3.50] 0.207	1.20 [0.90; 1.60] 0.223	0.112 [-0.064; 0.287] 0.213

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.
RR and RD calculated directly without adjustment.

All results are combined over MI:
n and % are averages of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

42.2 FACIT 4-Point Response by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
FACIT 4-Point Response Week 52	p=0.864				
Male (N)	**42**	**33**			
FACIT 4-Point Response Week 52, N' n (%)	40 28.74 (68.43)	26 18.72 (56.73)	1.71 [0.62; 4.72] 0.304	1.21 [0.82; 1.79] 0.342	0.117 [-0.117; 0.351] 0.328
Female (N)	**24**	**29**			
FACIT 4-Point Response Week 52, N' n (%)	23 16.00 (66.67)	22 16.39 (56.52)	1.49 [0.46; 4.79] 0.505	1.18 [0.76; 1.85] 0.463	0.101 [-0.169; 0.372] 0.462

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

42.3 FACIT 4-Point Response by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
FACIT 4-Point Response Week 52	p=0.427				
PASDAS < 5.4 (N)	**16**	**13**			
FACIT 4-Point Response Week 52, N' n (%)	16 9.00 (56.25)	9 3.93 (30.23)	3.11 [0.59; 16.50] 0.182	1.90 [0.68; 5.29] 0.222	0.260 [-0.105; 0.626] 0.163
PASDAS ≥ 5.4 (N)	**50**	**49**			
FACIT 4-Point Response Week 52, N' n (%)	47 35.74 (71.48)	39 31.18 (63.63)	1.44 [0.59; 3.55] 0.424	1.12 [0.84; 1.51] 0.434	0.078 [-0.116; 0.273] 0.430

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

42.4 FACIT 4-Point Response by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
FACIT 4-Point Response Week 52	p=0.150				
Moderate/Severe Psoriasis (Def D): No (N)	**28**	**32**			
FACIT 4-Point Response Week 52, N' n (%)	26 16.38 (58.50)	23 19.28 (60.25)	0.90 [0.30; 2.70] 0.849	0.97 [0.62; 1.51] 0.901	-0.017 [-0.280; 0.245] 0.896
Moderate/Severe Psoriasis (Def D): Yes (N)	**38**	**30**			
FACIT 4-Point Response Week 52, N' n (%)	37 28.36 (74.63)	25 15.83 (52.77)	2.79 [0.95; 8.23] 0.062	1.42 [0.94; 2.14] 0.096	0.219 [-0.018; 0.456] 0.071

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

42.5 FACIT 4-Point Response by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
FACIT 4-Point Response Week 52	p=0.102				
≤ Median (N)	**40**	**29**			
FACIT 4-Point Response Week 52, N' n (%)	38 29.74 (74.35)	21 14.72 (50.76)	2.99 [0.99; 9.09] 0.053	1.47 [0.94; 2.29] 0.089	0.236 [-0.009; 0.481] 0.059
> Median (N)	**26**	**33**			
FACIT 4-Point Response Week 52, N' n (%)	25 15.00 (57.69)	27 20.39 (61.79)	0.82 [0.28; 2.41] 0.714	0.93 [0.60; 1.44] 0.761	-0.041 [-0.299; 0.217] 0.756

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

42.6 FACIT 4-Point Response by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
FACIT 4-Point Response Week 52	p=0.978				
Enthesitis: No (N)	**34**	**22**			
FACIT 4-Point Response Week 52, N' n (%)	32 22.38 (65.82)	18 11.82 (53.73)	1.65 [0.53; 5.11] 0.387	1.23 [0.77; 1.96] 0.395	0.121 [-0.148; 0.389] 0.377
Enthesitis: Yes (N)	**32**	**40**			
FACIT 4-Point Response Week 52, N' n (%)	31 22.36 (69.88)	30 23.29 (58.23)	1.68 [0.59; 4.80] 0.330	1.20 [0.83; 1.75] 0.335	0.117 [-0.118; 0.351] 0.330

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

42.7 FACIT 4-Point Response by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
FACIT 4-Point Response Week 52	p=0.337				
Non-carrier (N)	**29**	**25**			
FACIT 4-Point Response Week 52, N' n (%)	28 19.00 (65.52)	21 16.48 (65.92)	0.99 [0.30; 3.24] 0.981	1.00 [0.67; 1.49] 0.982	-0.004 [-0.267; 0.259] 0.976
Carrier (N)	**22**	**19**			
FACIT 4-Point Response Week 52, N' n (%)	20 15.74 (71.55)	16 9.93 (52.26)	2.40 [0.60; 9.51] 0.214	1.37 [0.80; 2.34] 0.245	0.193 [-0.114; 0.500] 0.218

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

42.8 FACIT 4-Point Response by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
FACIT 4-Point Response Week 52	p=0.469				
Non-carrier (N)	**28**	**19**			
FACIT 4-Point Response Week 52, N' n (%)	27 22.38 (79.93)	13 12.77 (67.21)	2.06 [0.47; 9.01] 0.335	1.19 [0.80; 1.78] 0.391	0.127 [-0.153; 0.407] 0.373
Carrier (N)	**22**	**19**			
FACIT 4-Point Response Week 52, N' n (%)	20 12.36 (56.18)	18 10.64 (56.00)	1.00 [0.28; 3.63] 0.996	1.00 [0.58; 1.75] 0.990	0.002 [-0.309; 0.313] 0.991

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

42.9 FACIT 4-Point Response by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
FACIT 4-Point Response Week 52	p=0.874				
Non-carrier (N)	**19**	**21**			
FACIT 4-Point Response Week 52, N' n (%)	19 14.00 (73.68)	15 14.05 (66.90)	1.42 [0.33; 6.24] 0.639	1.10 [0.72; 1.70] 0.653	0.068 [-0.231; 0.367] 0.657
Carrier (N)	**30**	**23**			
FACIT 4-Point Response Week 52, N' n (%)	28 19.38 (64.60)	22 12.36 (53.74)	1.66 [0.53; 5.23] 0.388	1.20 [0.75; 1.93] 0.443	0.109 [-0.162; 0.379] 0.432

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

42.10 FACIT 4-Point Response by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
FACIT 4-Point Response Week 52	p=0.226				
Non-carrier (N)	**25**	**32**			
FACIT 4-Point Response Week 52, N' n (%)	23 19.36 (77.44)	28 18.29 (57.16)	2.53 [0.73; 8.73] 0.142	1.36 [0.92; 2.00] 0.123	0.203 [-0.045; 0.451] 0.109
Carrier (N)	**26**	**12**			
FACIT 4-Point Response Week 52, N' n (%)	25 15.38 (59.15)	9 8.12 (67.67)	0.73 [0.15; 3.50] 0.698	0.88 [0.51; 1.50] 0.631	-0.085 [-0.429; 0.259] 0.627

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

42.11 FACIT 4-Point Response by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
FACIT 4-Point Response Week 52	p=0.943				
Non-carrier (N)	**38**	**33**			
FACIT 4-Point Response Week 52, N' n (%)	35 24.74 (65.11)	26 20.41 (61.85)	1.23 [0.43; 3.49] 0.704	1.05 [0.72; 1.54] 0.785	0.033 [-0.205; 0.270] 0.788
Carrier (N)	**12**	**9**			
FACIT 4-Point Response Week 52, N' n (%)	12 9.00 (75.00)	9 6.00 (66.67)	1.33 [0.19; 9.16] 0.774	1.13 [0.64; 1.98] 0.683	0.083 [-0.310; 0.477] 0.678

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) FACIT 4-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

42.12 FACIT 4-Point Response by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
FACIT 4-Point Response Week 52	p=0.602				
Non-carrier (N)	**36**	**34**			
FACIT 4-Point Response Week 52, N' n (%)	33 25.74 (71.50)	27 20.41 (60.03)	1.61 [0.56; 4.67] 0.380	1.19 [0.83; 1.72] 0.345	0.115 [-0.119; 0.348] 0.336
Carrier (N)	**13**	**10**			
FACIT 4-Point Response Week 52, N' n (%)	13 7.00 (53.85)	10 6.00 (60.00)	0.94 [0.17; 5.24] 0.943	0.90 [0.44; 1.83] 0.766	-0.062 [-0.469; 0.345] 0.767

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) FACIT 4-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

42.13 FACIT 4-Point Response by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
FACIT 4-Point Response Week 52	N.E.				
Non-carrier (N)	**42**	**36**			
FACIT 4-Point Response Week 52, N' n (%)	39 25.74 (61.29)	29 23.41 (65.03)	0.88 [0.32; 2.36] 0.793	0.94 [0.66; 1.35] 0.749	-0.037 [-0.263; 0.188] 0.745
Carrier (N)	**9**	**5**			
FACIT 4-Point Response Week 52, N' n (%)	9 9.00 (100.00)	5 2.00 (40.00)	N.E.	2.50 [0.85; 7.31] 0.094	0.600 [0.171; 1.029] 0.006

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) FACIT 4-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

42.14 FACIT 4-Point Response by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
FACIT 4-Point Response Week 52	p=0.793				
Low score (N)	**11**	**22**			
FACIT 4-Point Response Week 52, N' n (%)	10 7.36 (66.91)	15 13.41 (60.95)	1.25 [0.24; 6.56] 0.790	1.10 [0.62; 1.96] 0.748	0.060 [-0.309; 0.428] 0.751
High score (N)	**40**	**22**			
FACIT 4-Point Response Week 52, N' n (%)	38 27.38 (68.45)	22 13.00 (59.09)	1.64 [0.54; 4.95] 0.384	1.16 [0.77; 1.74] 0.480	0.094 [-0.158; 0.346] 0.467

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

42.15 FACIT 4-Point Response by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
FACIT 4-Point Response Week 52	p=0.467				
Non-carrier (N)	**31**	**23**			
FACIT 4-Point Response Week 52, N' n (%)	30 24.38 (78.65)	17 15.77 (68.57)	1.91 [0.49; 7.45] 0.353	1.15 [0.80; 1.65] 0.449	0.101 [-0.154; 0.356] 0.439
Carrier (N)	**20**	**21**			
FACIT 4-Point Response Week 52, N' n (%)	18 10.36 (51.80)	20 10.64 (50.67)	0.95 [0.27; 3.40] 0.939	1.02 [0.55; 1.88] 0.944	0.011 [-0.301; 0.324] 0.943

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

42.16 FACIT 4-Point Response by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
FACIT 4-Point Response Week 52	p=0.978				
Non-carrier (N)	**19**	**20**			
FACIT 4-Point Response Week 52, N' n (%)	19 14.00 (73.68)	14 13.05 (65.25)	1.54 [0.35; 6.83] 0.567	1.13 [0.72; 1.78] 0.588	0.084 [-0.221; 0.390] 0.588
Carrier (N)	**32**	**24**			
FACIT 4-Point Response Week 52, N' n (%)	29 20.74 (64.81)	23 13.36 (55.67)	1.50 [0.49; 4.64] 0.477	1.16 [0.74; 1.82] 0.506	0.091 [-0.173; 0.356] 0.498

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

42.17 FACIT 4-Point Response by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
FACIT 4-Point Response Week 52	p=0.226				
Non-carrier (N)	**25**	**32**			
FACIT 4-Point Response Week 52, N' n (%)	23 19.36 (77.44)	28 18.29 (57.16)	2.53 [0.73; 8.73] 0.142	1.36 [0.92; 2.00] 0.123	0.203 [-0.045; 0.451] 0.109
Carrier (N)	**26**	**12**			
FACIT 4-Point Response Week 52, N' n (%)	25 15.38 (59.15)	9 8.12 (67.67)	0.73 [0.15; 3.50] 0.698	0.88 [0.51; 1.50] 0.631	-0.085 [-0.429; 0.259] 0.627

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

42.18 FACIT 4-Point Response by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
FACIT 4-Point Response Week 52	p=0.844				
Non-carrier (N)	**39**	**35**			
FACIT 4-Point Response Week 52, N' n (%)	36 25.74 (66.00)	28 20.41 (58.31)	1.48 [0.54; 4.08] 0.450	1.13 [0.77; 1.66] 0.520	0.077 [-0.156; 0.309] 0.517
Carrier (N)	**11**	**9**			
FACIT 4-Point Response Week 52, N' n (%)	11 8.00 (72.73)	9 6.00 (66.67)	1.19 [0.17; 8.30] 0.864	1.09 [0.61; 1.96] 0.771	0.061 [-0.345; 0.466] 0.769

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) FACIT 4-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

43.0 SF-36 Bodily Pain - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	57 (91.9)	122 (95.3)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	48 (77.4)	111 (86.7)

43.1 SF-36 Bodily Pain - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N'	66	60		
Baseline Mean (SD)	33.82 (20.51)	36.15 (21.39)		
Week 52 Mean (SD)	62.22 (24.84)	60.06 (23.93)		
Week 4 Adjusted Mean Change (SE)	17.26 (2.17)	16.17 (2.28)		
Week 12 Adjusted Mean Change (SE)	22.78 (2.49)	19.04 (2.60)		
Week 16 Adjusted Mean Change (SE)	25.12 (2.53)	20.89 (2.68)		
Week 24 Adjusted Mean Change (SE)	23.78 (2.59)	21.75 (2.80)		
Week 32 Adjusted Mean Change (SE)	27.36 (2.97)	25.77 (3.18)		
Week 40 Adjusted Mean Change (SE)	28.52 (2.75)	23.19 (3.03)		
Week 52 Adjusted Mean Change (SE)	27.77 (2.79)	23.11 (3.13)	4.66 [-3.64; 12.97]	0.268

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

43.2 SF-36 Bodily Pain - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.655				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	34.10 (21.26)	42.12 (21.41)		
Week 52 Mean (SD)	65.50 (25.49)	66.42 (25.40)		
Week 4 Adjusted Mean Change (SE)	21.86 (2.66)	20.25 (3.09)		
Week 12 Adjusted Mean Change (SE)	27.70 (3.00)	24.05 (3.46)		
Week 16 Adjusted Mean Change (SE)	29.42 (3.09)	27.11 (3.57)		
Week 24 Adjusted Mean Change (SE)	26.69 (3.06)	31.96 (3.65)		
Week 32 Adjusted Mean Change (SE)	30.17 (3.66)	33.56 (4.34)		
Week 40 Adjusted Mean Change (SE)	31.87 (3.42)	28.18 (4.11)		
Week 52 Adjusted Mean Change (SE)	31.08 (3.44)	28.01 (4.24)	3.07 [-7.76; 13.89]	0.576
Female, N	**24**	**29**		
N'	24	28		
Baseline Mean (SD)	33.33 (19.56)	29.34 (19.57)		
Week 52 Mean (SD)	56.52 (23.09)	52.55 (20.10)		
Week 4 Adjusted Mean Change (SE)	9.14 (3.53)	11.65 (3.27)		
Week 12 Adjusted Mean Change (SE)	13.96 (4.00)	13.48 (3.70)		
Week 16 Adjusted Mean Change (SE)	17.47 (4.07)	13.93 (3.88)		
Week 24 Adjusted Mean Change (SE)	18.42 (4.10)	10.03 (3.93)		
Week 32 Adjusted Mean Change (SE)	22.46 (4.85)	17.08 (4.59)		
Week 40 Adjusted Mean Change (SE)	22.56 (4.48)	17.68 (4.43)		
Week 52 Adjusted Mean Change (SE)	21.81 (4.54)	17.49 (4.55)	4.32 [-8.36; 17.00]	0.501

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

43.3 SF-36 Bodily Pain - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.668				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	51.38 (23.78)	60.00 (20.46)		
Week 52 Mean (SD)	77.94 (17.36)	57.33 (31.40)		
Week 4 Adjusted Mean Change (SE)	21.52 (4.62)	23.26 (5.35)		
Week 12 Adjusted Mean Change (SE)	25.25 (5.32)	31.80 (6.02)		
Week 16 Adjusted Mean Change (SE)	29.30 (5.42)	24.67 (6.27)		
Week 24 Adjusted Mean Change (SE)	24.80 (5.59)	18.68 (6.69)		
Week 32 Adjusted Mean Change (SE)	35.46 (6.36)	30.72 (7.74)		
Week 40 Adjusted Mean Change (SE)	33.44 (5.96)	26.15 (7.42)		
Week 52 Adjusted Mean Change (SE)	35.27 (5.76)	11.55 (7.49)	23.72 [6.12; 41.32]	0.009
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	47		
Baseline Mean (SD)	28.20 (15.87)	29.82 (16.79)		
Week 52 Mean (SD)	56.87 (24.86)	60.69 (22.33)		
Week 4 Adjusted Mean Change (SE)	15.76 (2.56)	14.36 (2.60)		
Week 12 Adjusted Mean Change (SE)	21.76 (2.89)	15.66 (2.94)		
Week 16 Adjusted Mean Change (SE)	23.67 (3.01)	19.99 (3.09)		
Week 24 Adjusted Mean Change (SE)	23.46 (3.07)	22.49 (3.21)		
Week 32 Adjusted Mean Change (SE)	24.60 (3.52)	24.51 (3.61)		
Week 40 Adjusted Mean Change (SE)	26.82 (3.27)	22.42 (3.43)		
Week 52 Adjusted Mean Change (SE)	25.35 (3.24)	25.81 (3.43)	-0.47 [-9.64; 8.71]	0.920

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

43.4 SF-36 Bodily Pain - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.118				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	31		
Baseline Mean (SD)	36.68 (19.94)	35.81 (21.57)		
Week 52 Mean (SD)	60.54 (24.36)	60.13 (22.46)		
Week 4 Adjusted Mean Change (SE)	13.78 (3.33)	17.16 (3.17)		
Week 12 Adjusted Mean Change (SE)	18.70 (3.77)	21.68 (3.59)		
Week 16 Adjusted Mean Change (SE)	18.38 (3.83)	20.21 (3.70)		
Week 24 Adjusted Mean Change (SE)	20.10 (4.00)	21.30 (3.89)		
Week 32 Adjusted Mean Change (SE)	21.99 (4.54)	28.69 (4.42)		
Week 40 Adjusted Mean Change (SE)	21.99 (4.21)	22.78 (4.28)		
Week 52 Adjusted Mean Change (SE)	25.47 (4.36)	23.29 (4.49)	2.18 [-10.22; 14.59]	0.728
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	31.71 (20.93)	36.50 (21.56)		
Week 52 Mean (SD)	63.41 (25.43)	60.00 (25.67)		
Week 4 Adjusted Mean Change (SE)	19.84 (2.87)	15.09 (3.28)		
Week 12 Adjusted Mean Change (SE)	25.78 (3.29)	16.12 (3.74)		
Week 16 Adjusted Mean Change (SE)	30.19 (3.32)	21.47 (3.80)		
Week 24 Adjusted Mean Change (SE)	26.56 (3.42)	22.18 (4.06)		
Week 32 Adjusted Mean Change (SE)	31.32 (3.91)	22.64 (4.54)		
Week 40 Adjusted Mean Change (SE)	33.33 (3.61)	23.28 (4.24)		
Week 52 Adjusted Mean Change (SE)	29.49 (3.70)	22.72 (4.44)	6.77 [-4.72; 18.26]	0.246

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

43.5 SF-36 Bodily Pain - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.353				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	32.28 (18.27)	40.00 (23.49)		
Week 52 Mean (SD)	64.47 (24.12)	61.43 (23.38)		
Week 4 Adjusted Mean Change (SE)	18.25 (2.81)	16.63 (3.32)		
Week 12 Adjusted Mean Change (SE)	24.29 (3.23)	19.92 (3.77)		
Week 16 Adjusted Mean Change (SE)	26.78 (3.28)	23.60 (3.92)		
Week 24 Adjusted Mean Change (SE)	28.44 (3.26)	25.25 (4.03)		
Week 32 Adjusted Mean Change (SE)	30.72 (3.85)	26.04 (4.66)		
Week 40 Adjusted Mean Change (SE)	32.36 (3.56)	21.99 (4.49)		
Week 52 Adjusted Mean Change (SE)	30.33 (3.62)	19.36 (4.73)	10.97 [-0.90; 22.84]	0.070
> Median, N	**26**	**33**		
N'	26	31		
Baseline Mean (SD)	36.19 (23.73)	32.76 (19.09)		
Week 52 Mean (SD)	58.80 (26.00)	59.00 (24.73)		
Week 4 Adjusted Mean Change (SE)	15.74 (3.48)	15.75 (3.20)		
Week 12 Adjusted Mean Change (SE)	20.45 (3.95)	18.24 (3.65)		
Week 16 Adjusted Mean Change (SE)	22.49 (4.03)	18.45 (3.72)		
Week 24 Adjusted Mean Change (SE)	16.42 (4.06)	18.65 (3.80)		
Week 32 Adjusted Mean Change (SE)	22.22 (4.70)	25.52 (4.41)		
Week 40 Adjusted Mean Change (SE)	22.73 (4.36)	23.99 (4.15)		
Week 52 Adjusted Mean Change (SE)	23.96 (4.46)	25.93 (4.26)	-1.97 [-14.21; 10.27]	0.751

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

43.6 SF-36 Bodily Pain - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.382				
Enthesitis: No, N	34	22		
N'	34	21		
Baseline Mean (SD)	37.53 (22.86)	40.00 (24.30)		
Week 52 Mean (SD)	65.88 (24.22)	65.56 (24.56)		
Week 4 Adjusted Mean Change (SE)	20.36 (2.96)	24.36 (3.79)		
Week 12 Adjusted Mean Change (SE)	26.40 (3.39)	27.18 (4.36)		
Week 16 Adjusted Mean Change (SE)	25.55 (3.44)	31.01 (4.46)		
Week 24 Adjusted Mean Change (SE)	24.80 (3.60)	28.46 (4.64)		
Week 32 Adjusted Mean Change (SE)	31.55 (4.13)	32.15 (5.25)		
Week 40 Adjusted Mean Change (SE)	32.58 (3.84)	28.61 (4.95)		
Week 52 Adjusted Mean Change (SE)	30.34 (3.90)	28.74 (5.12)	1.60 [-11.08; 14.28]	0.803
Enthesitis: Yes, N	32	40		
N'	32	39		
Baseline Mean (SD)	29.88 (17.16)	34.03 (19.62)		
Week 52 Mean (SD)	58.45 (25.29)	56.77 (23.33)		
Week 4 Adjusted Mean Change (SE)	13.89 (3.07)	11.86 (2.76)		
Week 12 Adjusted Mean Change (SE)	18.76 (3.51)	14.78 (3.13)		
Week 16 Adjusted Mean Change (SE)	24.68 (3.60)	15.48 (3.25)		
Week 24 Adjusted Mean Change (SE)	22.64 (3.72)	18.25 (3.51)		
Week 32 Adjusted Mean Change (SE)	22.87 (4.25)	22.55 (3.97)		
Week 40 Adjusted Mean Change (SE)	24.25 (3.93)	20.55 (3.80)		
Week 52 Adjusted Mean Change (SE)	25.00 (4.00)	20.05 (3.95)	4.95 [-6.15; 16.05]	0.379

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

43.7 SF-36 Bodily Pain - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.764				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	29.24 (16.49)	36.96 (19.75)		
Week 52 Mean (SD)	59.21 (26.48)	65.62 (20.38)		
Week 4 Adjusted Mean Change (SE)	17.97 (3.25)	16.66 (3.46)		
Week 12 Adjusted Mean Change (SE)	23.18 (3.76)	21.70 (4.05)		
Week 16 Adjusted Mean Change (SE)	26.26 (3.51)	20.99 (3.82)		
Week 24 Adjusted Mean Change (SE)	25.17 (3.90)	22.33 (4.29)		
Week 32 Adjusted Mean Change (SE)	27.18 (4.27)	27.14 (4.65)		
Week 40 Adjusted Mean Change (SE)	29.77 (4.01)	25.00 (4.40)		
Week 52 Adjusted Mean Change (SE)	27.95 (3.98)	29.73 (4.47)	-1.78 [-13.70; 10.15]	0.768
Carrier, N	**22**	**19**		
N'	22	18		
Baseline Mean (SD)	38.32 (21.11)	37.89 (26.19)		
Week 52 Mean (SD)	63.35 (20.84)	57.38 (25.94)		
Week 4 Adjusted Mean Change (SE)	14.98 (3.69)	14.97 (4.08)		
Week 12 Adjusted Mean Change (SE)	19.98 (4.34)	17.47 (4.73)		
Week 16 Adjusted Mean Change (SE)	18.98 (4.04)	26.82 (4.42)		
Week 24 Adjusted Mean Change (SE)	20.85 (4.47)	22.78 (4.98)		
Week 32 Adjusted Mean Change (SE)	26.80 (4.99)	25.60 (5.45)		
Week 40 Adjusted Mean Change (SE)	23.60 (4.63)	24.73 (5.33)		
Week 52 Adjusted Mean Change (SE)	25.81 (4.63)	18.82 (5.19)	6.99 [-6.77; 20.76]	0.315

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

43.7 SF-36 Bodily Pain - Change from Baseline by HLA-DQA1*05 (FAS)

43.8 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.188				
Non-carrier, N	**28**	**19**		
N'	28	18		
Baseline Mean (SD)	31.57 (18.01)	32.47 (19.25)		
Week 52 Mean (SD)	59.70 (25.08)	60.46 (21.09)		
Week 4 Adjusted Mean Change (SE)	18.83 (3.27)	10.39 (4.07)		
Week 12 Adjusted Mean Change (SE)	26.22 (3.75)	19.73 (4.67)		
Week 16 Adjusted Mean Change (SE)	27.01 (3.63)	20.31 (4.57)		
Week 24 Adjusted Mean Change (SE)	25.87 (3.94)	21.60 (5.08)		
Week 32 Adjusted Mean Change (SE)	31.57 (4.33)	23.86 (5.56)		
Week 40 Adjusted Mean Change (SE)	29.59 (4.14)	19.70 (5.43)		
Week 52 Adjusted Mean Change (SE)	27.24 (4.22)	26.66 (5.82)	0.58 [-13.72; 14.89]	0.935
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	33.32 (18.90)	38.47 (23.46)		
Week 52 Mean (SD)	61.95 (23.84)	62.44 (26.18)		
Week 4 Adjusted Mean Change (SE)	15.28 (3.68)	19.60 (3.99)		
Week 12 Adjusted Mean Change (SE)	17.74 (4.28)	20.79 (4.64)		
Week 16 Adjusted Mean Change (SE)	19.90 (4.13)	24.14 (4.48)		
Week 24 Adjusted Mean Change (SE)	20.39 (4.48)	24.29 (4.92)		
Week 32 Adjusted Mean Change (SE)	21.29 (4.93)	28.73 (5.33)		
Week 40 Adjusted Mean Change (SE)	26.01 (4.62)	27.65 (5.18)		
Week 52 Adjusted Mean Change (SE)	29.48 (4.83)	26.77 (5.21)	2.71 [-11.44; 16.85]	0.704

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

43.9 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.260				
Non-carrier, N	**19**	**21**		
N'	19	20		
Baseline Mean (SD)	32.16 (22.13)	36.43 (26.68)		
Week 52 Mean (SD)	56.21 (23.66)	64.13 (24.58)		
Week 4 Adjusted Mean Change (SE)	14.41 (3.97)	18.60 (3.87)		
Week 12 Adjusted Mean Change (SE)	22.31 (4.64)	22.99 (4.59)		
Week 16 Adjusted Mean Change (SE)	22.20 (4.39)	24.11 (4.33)		
Week 24 Adjusted Mean Change (SE)	17.81 (4.79)	25.38 (4.80)		
Week 32 Adjusted Mean Change (SE)	25.93 (5.16)	27.20 (5.19)		
Week 40 Adjusted Mean Change (SE)	25.51 (4.90)	25.72 (5.04)		
Week 52 Adjusted Mean Change (SE)	23.27 (4.87)	26.78 (5.26)	-3.52 [-17.79; 10.76]	0.626
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	32.13 (15.02)	38.22 (18.40)		
Week 52 Mean (SD)	63.32 (24.49)	60.64 (22.30)		
Week 4 Adjusted Mean Change (SE)	19.20 (3.16)	13.90 (3.62)		
Week 12 Adjusted Mean Change (SE)	22.46 (3.73)	17.57 (4.23)		
Week 16 Adjusted Mean Change (SE)	24.51 (3.49)	23.48 (4.04)		
Week 24 Adjusted Mean Change (SE)	27.74 (3.76)	20.48 (4.36)		
Week 32 Adjusted Mean Change (SE)	29.49 (4.19)	26.03 (4.76)		
Week 40 Adjusted Mean Change (SE)	30.20 (3.94)	24.47 (4.60)		
Week 52 Adjusted Mean Change (SE)	30.50 (3.96)	24.11 (4.53)	6.39 [-5.62; 18.40]	0.293

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

43.10 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.166				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	31.84 (16.91)	39.41 (22.67)		
Week 52 Mean (SD)	64.30 (28.15)	58.57 (23.15)		
Week 4 Adjusted Mean Change (SE)	19.03 (3.46)	16.42 (3.06)		
Week 12 Adjusted Mean Change (SE)	20.08 (4.06)	17.94 (3.59)		
Week 16 Adjusted Mean Change (SE)	22.61 (3.77)	20.52 (3.34)		
Week 24 Adjusted Mean Change (SE)	26.25 (4.10)	19.37 (3.76)		
Week 32 Adjusted Mean Change (SE)	29.45 (4.58)	25.03 (4.11)		
Week 40 Adjusted Mean Change (SE)	29.21 (4.30)	24.64 (3.98)		
Week 52 Adjusted Mean Change (SE)	30.48 (4.28)	22.23 (3.90)	8.25 [-3.29; 19.79]	0.159
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	34.42 (21.03)	31.92 (21.94)		
Week 52 Mean (SD)	57.84 (19.84)	72.89 (19.82)		
Week 4 Adjusted Mean Change (SE)	14.38 (3.38)	14.68 (5.19)		
Week 12 Adjusted Mean Change (SE)	23.37 (3.92)	25.49 (6.02)		
Week 16 Adjusted Mean Change (SE)	23.62 (3.65)	32.88 (5.74)		
Week 24 Adjusted Mean Change (SE)	20.47 (4.05)	31.14 (6.15)		
Week 32 Adjusted Mean Change (SE)	24.36 (4.45)	30.59 (6.78)		
Week 40 Adjusted Mean Change (SE)	25.10 (4.26)	25.64 (6.61)		
Week 52 Adjusted Mean Change (SE)	23.78 (4.15)	33.33 (6.68)	-9.56 [-25.18; 6.07]	0.227

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

43.11 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

| | Treatment Groups | | Comparison | |
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.228				
Non-carrier, N	**38**	**33**		
N'	38	32		
Baseline Mean (SD)	33.47 (17.74)	40.03 (22.67)		
Week 52 Mean (SD)	60.26 (22.73)	64.38 (21.95)		
Week 4 Adjusted Mean Change (SE)	17.69 (2.76)	16.59 (3.01)		
Week 12 Adjusted Mean Change (SE)	22.01 (3.22)	18.84 (3.49)		
Week 16 Adjusted Mean Change (SE)	23.59 (3.09)	22.60 (3.37)		
Week 24 Adjusted Mean Change (SE)	25.29 (3.31)	21.12 (3.71)		
Week 32 Adjusted Mean Change (SE)	28.07 (3.69)	29.17 (4.09)		
Week 40 Adjusted Mean Change (SE)	27.59 (3.48)	24.00 (3.95)		
Week 52 Adjusted Mean Change (SE)	26.35 (3.56)	25.03 (4.09)	1.31 [-9.52; 12.15]	0.810
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	32.25 (24.00)	34.78 (18.83)		
Week 52 Mean (SD)	61.83 (29.58)	64.33 (20.89)		
Week 4 Adjusted Mean Change (SE)	10.22 (4.94)	14.28 (5.62)		
Week 12 Adjusted Mean Change (SE)	17.04 (5.71)	28.54 (6.73)		
Week 16 Adjusted Mean Change (SE)	19.06 (5.48)	26.11 (6.43)		
Week 24 Adjusted Mean Change (SE)	14.87 (6.04)	31.62 (6.92)		
Week 32 Adjusted Mean Change (SE)	19.76 (6.50)	22.65 (7.43)		
Week 40 Adjusted Mean Change (SE)	21.74 (6.17)	30.33 (7.05)		
Week 52 Adjusted Mean Change (SE)	25.78 (6.19)	28.67 (7.07)	-2.89 [-21.57; 15.79]	0.759

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

43.12 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.980				
Non-carrier, N	**36**	**34**		
N'	36	33		
Baseline Mean (SD)	32.67 (19.57)	37.97 (24.36)		
Week 52 Mean (SD)	59.64 (23.85)	63.04 (23.72)		
Week 4 Adjusted Mean Change (SE)	17.75 (2.81)	18.04 (2.95)		
Week 12 Adjusted Mean Change (SE)	24.48 (3.31)	20.13 (3.50)		
Week 16 Adjusted Mean Change (SE)	24.58 (3.21)	24.15 (3.39)		
Week 24 Adjusted Mean Change (SE)	21.83 (3.53)	22.57 (3.79)		
Week 32 Adjusted Mean Change (SE)	26.59 (3.76)	27.59 (4.00)		
Week 40 Adjusted Mean Change (SE)	27.24 (3.52)	26.18 (3.82)		
Week 52 Adjusted Mean Change (SE)	25.78 (3.58)	25.66 (3.93)	0.13 [-10.47; 10.73]	0.981
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	36.23 (18.75)	35.30 (15.20)		
Week 52 Mean (SD)	62.77 (24.43)	59.40 (21.84)		
Week 4 Adjusted Mean Change (SE)	11.21 (4.67)	8.60 (5.36)		
Week 12 Adjusted Mean Change (SE)	12.21 (5.50)	18.40 (6.31)		
Week 16 Adjusted Mean Change (SE)	19.30 (5.30)	21.40 (6.07)		
Week 24 Adjusted Mean Change (SE)	25.73 (5.82)	21.70 (6.67)		
Week 32 Adjusted Mean Change (SE)	22.78 (6.18)	22.40 (7.07)		
Week 40 Adjusted Mean Change (SE)	21.51 (5.80)	19.91 (6.82)		
Week 52 Adjusted Mean Change (SE)	27.58 (5.79)	22.60 (6.63)	4.98 [-12.59; 22.55]	0.574

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

43.13 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.665				
Non-carrier, N	**42**	**36**		
N'	42	35		
Baseline Mean (SD)	35.40 (19.47)	35.36 (22.75)		
Week 52 Mean (SD)	61.59 (24.80)	62.03 (23.33)		
Week 4 Adjusted Mean Change (SE)	17.35 (2.70)	15.02 (2.96)		
Week 12 Adjusted Mean Change (SE)	22.11 (3.07)	20.69 (3.37)		
Week 16 Adjusted Mean Change (SE)	23.40 (2.86)	22.50 (3.16)		
Week 24 Adjusted Mean Change (SE)	22.53 (3.08)	23.23 (3.46)		
Week 32 Adjusted Mean Change (SE)	26.61 (3.55)	26.59 (3.94)		
Week 40 Adjusted Mean Change (SE)	27.37 (3.33)	23.02 (3.81)		
Week 52 Adjusted Mean Change (SE)	27.02 (3.33)	26.00 (3.82)	1.02 [-9.06; 11.10]	0.841
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	22.67 (12.56)	47.60 (25.13)		
Week 52 Mean (SD)	58.11 (22.13)	56.40 (19.92)		
Week 4 Adjusted Mean Change (SE)	14.10 (5.94)	22.57 (7.91)		
Week 12 Adjusted Mean Change (SE)	21.25 (6.71)	8.87 (8.93)		
Week 16 Adjusted Mean Change (SE)	22.64 (6.26)	15.78 (8.33)		
Week 24 Adjusted Mean Change (SE)	27.65 (6.74)	15.18 (8.97)		
Week 32 Adjusted Mean Change (SE)	28.61 (7.71)	24.36 (10.26)		
Week 40 Adjusted Mean Change (SE)	26.99 (7.29)	28.30 (9.70)		
Week 52 Adjusted Mean Change (SE)	28.06 (7.15)	15.47 (9.52)	12.59 [-11.44; 36.62]	0.300

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

43.14 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.715				
Low score, N	**11**	**22**		
N'	11	21		
Baseline Mean (SD)	36.55 (23.67)	36.73 (25.61)		
Week 52 Mean (SD)	58.20 (31.02)	60.40 (24.39)		
Week 4 Adjusted Mean Change (SE)	18.45 (5.20)	15.35 (3.79)		
Week 12 Adjusted Mean Change (SE)	27.32 (6.04)	21.05 (4.39)		
Week 16 Adjusted Mean Change (SE)	26.50 (5.84)	22.99 (4.20)		
Week 24 Adjusted Mean Change (SE)	20.50 (6.21)	18.95 (4.72)		
Week 32 Adjusted Mean Change (SE)	26.25 (6.82)	25.36 (5.18)		
Week 40 Adjusted Mean Change (SE)	28.26 (6.46)	22.65 (5.03)		
Week 52 Adjusted Mean Change (SE)	21.11 (6.59)	23.88 (5.26)	-2.77 [-19.51; 13.98]	0.743
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	32.23 (17.71)	38.00 (19.43)		
Week 52 Mean (SD)	61.66 (22.44)	63.18 (22.48)		
Week 4 Adjusted Mean Change (SE)	16.15 (2.74)	16.59 (3.70)		
Week 12 Adjusted Mean Change (SE)	20.21 (3.20)	18.74 (4.35)		
Week 16 Adjusted Mean Change (SE)	22.21 (3.00)	24.28 (4.10)		
Week 24 Adjusted Mean Change (SE)	24.09 (3.29)	25.66 (4.45)		
Week 32 Adjusted Mean Change (SE)	27.01 (3.64)	27.50 (4.84)		
Week 40 Adjusted Mean Change (SE)	26.76 (3.42)	26.85 (4.64)		
Week 52 Adjusted Mean Change (SE)	28.61 (3.43)	26.12 (4.55)	2.49 [-8.88; 13.86]	0.664

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

43.14 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Allele Score (FAS)

43.15 SF-36 Bodily Pain - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.492				
Non-carrier, N	**31**	**23**		
N'	31	22		
Baseline Mean (SD)	33.90 (19.06)	34.00 (18.54)		
Week 52 Mean (SD)	59.63 (24.15)	61.59 (20.05)		
Week 4 Adjusted Mean Change (SE)	17.60 (3.09)	13.28 (3.66)		
Week 12 Adjusted Mean Change (SE)	23.70 (3.61)	19.83 (4.28)		
Week 16 Adjusted Mean Change (SE)	24.94 (3.40)	22.58 (4.07)		
Week 24 Adjusted Mean Change (SE)	24.49 (3.74)	23.66 (4.57)		
Week 32 Adjusted Mean Change (SE)	30.01 (4.06)	26.09 (4.92)		
Week 40 Adjusted Mean Change (SE)	27.82 (3.88)	22.34 (4.78)		
Week 52 Adjusted Mean Change (SE)	25.58 (3.87)	25.48 (4.97)	0.10 [-12.42; 12.63]	0.987
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	32.00 (19.28)	41.05 (26.09)		
Week 52 Mean (SD)	63.11 (24.66)	62.45 (25.72)		
Week 4 Adjusted Mean Change (SE)	15.15 (3.86)	18.86 (3.78)		
Week 12 Adjusted Mean Change (SE)	18.72 (4.57)	19.93 (4.48)		
Week 16 Adjusted Mean Change (SE)	20.16 (4.29)	24.79 (4.21)		
Week 24 Adjusted Mean Change (SE)	21.51 (4.73)	21.35 (4.69)		
Week 32 Adjusted Mean Change (SE)	21.56 (5.12)	27.09 (5.00)		
Week 40 Adjusted Mean Change (SE)	25.91 (4.80)	27.65 (4.86)		
Week 52 Adjusted Mean Change (SE)	29.72 (4.91)	24.84 (4.78)	4.88 [-8.81; 18.58]	0.480

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

43.15 SF-36 Bodily Pain - Change from Baseline by Linkage Variant rs10891185 (FAS)

43.16 SF-36 Bodily Pain - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.296				
Non-carrier, N	**19**	**20**		
N'	19	19		
Baseline Mean (SD)	32.16 (22.13)	37.65 (26.76)		
Week 52 Mean (SD)	56.21 (23.66)	63.43 (25.35)		
Week 4 Adjusted Mean Change (SE)	14.17 (3.94)	19.29 (3.94)		
Week 12 Adjusted Mean Change (SE)	22.02 (4.59)	24.00 (4.66)		
Week 16 Adjusted Mean Change (SE)	21.99 (4.35)	26.25 (4.41)		
Week 24 Adjusted Mean Change (SE)	17.59 (4.74)	27.17 (4.89)		
Week 32 Adjusted Mean Change (SE)	25.61 (5.20)	25.93 (5.37)		
Week 40 Adjusted Mean Change (SE)	25.14 (4.93)	24.37 (5.21)		
Week 52 Adjusted Mean Change (SE)	22.98 (4.87)	24.84 (5.43)	-1.86 [-16.39; 12.67]	0.800
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	33.75 (17.18)	37.13 (18.78)		
Week 52 Mean (SD)	64.03 (24.35)	61.22 (21.97)		
Week 4 Adjusted Mean Change (SE)	18.12 (3.03)	13.38 (3.50)		
Week 12 Adjusted Mean Change (SE)	21.59 (3.56)	16.77 (4.08)		
Week 16 Adjusted Mean Change (SE)	23.74 (3.37)	21.56 (3.90)		
Week 24 Adjusted Mean Change (SE)	26.49 (3.60)	19.18 (4.21)		
Week 32 Adjusted Mean Change (SE)	27.37 (4.07)	26.82 (4.68)		
Week 40 Adjusted Mean Change (SE)	28.24 (3.83)	25.17 (4.50)		
Week 52 Adjusted Mean Change (SE)	29.53 (3.86)	25.11 (4.41)	4.42 [-7.25; 16.08]	0.454

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

43.16 SF-36 Bodily Pain - Change from Baseline by Linkage Variant rs12065362 (FAS)

43.17 SF-36 Bodily Pain - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.166				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	31.84 (16.91)	39.41 (22.67)		
Week 52 Mean (SD)	64.30 (28.15)	58.57 (23.15)		
Week 4 Adjusted Mean Change (SE)	19.03 (3.46)	16.42 (3.06)		
Week 12 Adjusted Mean Change (SE)	20.08 (4.06)	17.94 (3.59)		
Week 16 Adjusted Mean Change (SE)	22.61 (3.77)	20.52 (3.34)		
Week 24 Adjusted Mean Change (SE)	26.25 (4.10)	19.37 (3.76)		
Week 32 Adjusted Mean Change (SE)	29.45 (4.58)	25.03 (4.11)		
Week 40 Adjusted Mean Change (SE)	29.21 (4.30)	24.64 (3.98)		
Week 52 Adjusted Mean Change (SE)	30.48 (4.28)	22.23 (3.90)	8.25 [-3.29; 19.79]	0.159
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	34.42 (21.03)	31.92 (21.94)		
Week 52 Mean (SD)	57.84 (19.84)	72.89 (19.82)		
Week 4 Adjusted Mean Change (SE)	14.38 (3.38)	14.68 (5.19)		
Week 12 Adjusted Mean Change (SE)	23.37 (3.92)	25.49 (6.02)		
Week 16 Adjusted Mean Change (SE)	23.62 (3.65)	32.88 (5.74)		
Week 24 Adjusted Mean Change (SE)	20.47 (4.05)	31.14 (6.15)		
Week 32 Adjusted Mean Change (SE)	24.36 (4.45)	30.59 (6.78)		
Week 40 Adjusted Mean Change (SE)	25.10 (4.26)	25.64 (6.61)		
Week 52 Adjusted Mean Change (SE)	23.78 (4.15)	33.33 (6.68)	-9.56 [-25.18; 6.07]	0.227

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

43.18 SF-36 Bodily Pain - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.087				
Non-carrier, N	**39**	**35**		
N'	39	34		
Baseline Mean (SD)	33.44 (17.51)	38.91 (23.01)		
Week 52 Mean (SD)	60.64 (22.52)	62.04 (22.96)		
Week 4 Adjusted Mean Change (SE)	18.44 (2.78)	15.64 (2.98)		
Week 12 Adjusted Mean Change (SE)	23.00 (3.23)	17.33 (3.46)		
Week 16 Adjusted Mean Change (SE)	24.18 (3.04)	21.05 (3.26)		
Week 24 Adjusted Mean Change (SE)	25.56 (3.26)	19.59 (3.61)		
Week 32 Adjusted Mean Change (SE)	28.68 (3.69)	26.31 (4.00)		
Week 40 Adjusted Mean Change (SE)	28.45 (3.43)	22.19 (3.80)		
Week 52 Adjusted Mean Change (SE)	27.03 (3.51)	23.93 (3.95)	3.11 [-7.42; 13.64]	0.559
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	34.27 (24.08)	31.33 (20.33)		
Week 52 Mean (SD)	63.73 (30.25)	62.11 (24.44)		
Week 4 Adjusted Mean Change (SE)	9.65 (5.26)	16.46 (5.77)		
Week 12 Adjusted Mean Change (SE)	16.39 (6.05)	28.39 (6.65)		
Week 16 Adjusted Mean Change (SE)	19.28 (5.71)	32.56 (6.45)		
Week 24 Adjusted Mean Change (SE)	16.52 (6.29)	32.33 (6.76)		
Week 32 Adjusted Mean Change (SE)	19.41 (6.85)	26.93 (7.54)		
Week 40 Adjusted Mean Change (SE)	22.73 (6.42)	34.36 (7.26)		
Week 52 Adjusted Mean Change (SE)	27.11 (6.46)	28.26 (7.11)	-1.15 [-20.23; 17.93]	0.905

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

44.0 SF-36 General Health - Return Rates (FAS)

	Treatment Groups		
	SEC **(N=66)**	**ADA** **(N=62)**	**Total** **(N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	57 (91.9)	122 (95.3)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	48 (77.4)	111 (86.7)

44.0 SF-36 General Health - Return Rates (FAS)

44.1 SF-36 General Health - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	60		
Baseline Mean (SD)	41.05 (19.00)	42.02 (19.81)		
Week 52 Mean (SD)	52.59 (23.06)	52.38 (19.59)		
Week 4 Adjusted Mean Change (SE)	9.33 (1.68)	8.00 (1.76)		
Week 12 Adjusted Mean Change (SE)	9.48 (1.94)	12.14 (2.03)		
Week 16 Adjusted Mean Change (SE)	12.15 (2.05)	9.53 (2.17)		
Week 24 Adjusted Mean Change (SE)	11.88 (1.96)	10.14 (2.10)		
Week 32 Adjusted Mean Change (SE)	12.82 (2.01)	8.31 (2.14)		
Week 40 Adjusted Mean Change (SE)	11.37 (2.10)	9.37 (2.28)		
Week 52 Adjusted Mean Change (SE)	11.82 (2.23)	10.21 (2.45)	1.62 [-4.94; 8.18]	0.627

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

44.2 SF-36 General Health - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.840				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	45.57 (19.38)	47.85 (20.73)		
Week 52 Mean (SD)	57.58 (23.80)	54.42 (18.86)		
Week 4 Adjusted Mean Change (SE)	10.98 (2.14)	8.19 (2.47)		
Week 12 Adjusted Mean Change (SE)	10.29 (2.47)	12.60 (2.83)		
Week 16 Adjusted Mean Change (SE)	14.33 (2.59)	10.68 (2.98)		
Week 24 Adjusted Mean Change (SE)	12.05 (2.49)	12.50 (2.92)		
Week 32 Adjusted Mean Change (SE)	13.74 (2.55)	10.94 (3.00)		
Week 40 Adjusted Mean Change (SE)	12.28 (2.69)	11.31 (3.18)		
Week 52 Adjusted Mean Change (SE)	13.75 (2.83)	9.19 (3.40)	4.56 [-4.08; 13.20]	0.298
Female, N	**24**	**29**		
N'	24	28		
Baseline Mean (SD)	33.13 (15.73)	35.38 (16.68)		
Week 52 Mean (SD)	43.91 (19.26)	49.95 (20.59)		
Week 4 Adjusted Mean Change (SE)	6.44 (2.87)	7.82 (2.62)		
Week 12 Adjusted Mean Change (SE)	8.10 (3.33)	11.71 (3.03)		
Week 16 Adjusted Mean Change (SE)	8.34 (3.46)	8.22 (3.25)		
Week 24 Adjusted Mean Change (SE)	11.67 (3.35)	7.41 (3.13)		
Week 32 Adjusted Mean Change (SE)	11.14 (3.44)	5.36 (3.17)		
Week 40 Adjusted Mean Change (SE)	9.77 (3.58)	7.10 (3.42)		
Week 52 Adjusted Mean Change (SE)	8.52 (3.79)	11.42 (3.64)	-2.90 [-13.12; 7.32]	0.575

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

44.2 SF-36 General Health - Change from Baseline by Gender (FAS)

44.3 SF-36 General Health - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.860				
PASDAS < 5.4, N	16	13		
N'	16	13		
Baseline Mean (SD)	57.00 (18.65)	60.08 (21.62)		
Week 52 Mean (SD)	67.25 (17.17)	59.33 (18.89)		
Week 4 Adjusted Mean Change (SE)	14.91 (3.55)	11.50 (3.97)		
Week 12 Adjusted Mean Change (SE)	14.83 (4.14)	18.25 (4.56)		
Week 16 Adjusted Mean Change (SE)	16.51 (4.34)	15.97 (4.86)		
Week 24 Adjusted Mean Change (SE)	13.59 (4.23)	14.68 (4.81)		
Week 32 Adjusted Mean Change (SE)	14.20 (4.30)	11.08 (5.03)		
Week 40 Adjusted Mean Change (SE)	14.94 (4.50)	8.94 (5.31)		
Week 52 Adjusted Mean Change (SE)	16.73 (4.73)	9.37 (5.75)	7.36 [-6.69; 21.40]	0.302
PASDAS ≥ 5.4, N	50	49		
N'	50	47		
Baseline Mean (SD)	35.94 (16.20)	37.22 (16.44)		
Week 52 Mean (SD)	47.60 (22.81)	50.77 (19.63)		
Week 4 Adjusted Mean Change (SE)	7.51 (1.95)	7.10 (1.99)		
Week 12 Adjusted Mean Change (SE)	7.73 (2.25)	10.53 (2.29)		
Week 16 Adjusted Mean Change (SE)	10.68 (2.40)	7.80 (2.47)		
Week 24 Adjusted Mean Change (SE)	11.27 (2.30)	8.92 (2.39)		
Week 32 Adjusted Mean Change (SE)	12.39 (2.38)	7.50 (2.43)		
Week 40 Adjusted Mean Change (SE)	10.21 (2.47)	9.23 (2.58)		
Week 52 Adjusted Mean Change (SE)	10.18 (2.63)	10.17 (2.76)	0.01 [-7.44; 7.45]	0.999

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

44.4 SF-36 General Health - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.051				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	31		
Baseline Mean (SD)	39.68 (20.11)	44.25 (18.63)		
Week 52 Mean (SD)	49.38 (22.11)	58.43 (18.76)		
Week 4 Adjusted Mean Change (SE)	7.66 (2.56)	10.86 (2.45)		
Week 12 Adjusted Mean Change (SE)	10.85 (2.95)	14.25 (2.81)		
Week 16 Adjusted Mean Change (SE)	7.06 (3.08)	10.76 (2.99)		
Week 24 Adjusted Mean Change (SE)	8.96 (2.99)	13.11 (2.90)		
Week 32 Adjusted Mean Change (SE)	12.86 (3.04)	12.98 (2.95)		
Week 40 Adjusted Mean Change (SE)	8.71 (3.22)	12.81 (3.21)		
Week 52 Adjusted Mean Change (SE)	9.72 (3.41)	14.83 (3.45)	-5.11 [-14.74; 4.52]	0.295
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	42.05 (18.34)	39.63 (21.06)		
Week 52 Mean (SD)	54.84 (23.74)	46.80 (19.01)		
Week 4 Adjusted Mean Change (SE)	10.56 (2.20)	4.96 (2.52)		
Week 12 Adjusted Mean Change (SE)	8.32 (2.56)	9.94 (2.92)		
Week 16 Adjusted Mean Change (SE)	15.98 (2.66)	8.18 (3.06)		
Week 24 Adjusted Mean Change (SE)	14.03 (2.55)	6.95 (3.01)		
Week 32 Adjusted Mean Change (SE)	12.72 (2.61)	3.33 (3.03)		
Week 40 Adjusted Mean Change (SE)	13.34 (2.75)	5.67 (3.23)		
Week 52 Adjusted Mean Change (SE)	13.40 (2.90)	5.45 (3.43)	7.94 [-0.95; 16.84]	0.080

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

44.5 SF-36 General Health - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.830				
≤ Median, N	40	29		
N'	40	29		
Baseline Mean (SD)	42.55 (17.29)	47.41 (20.52)		
Week 52 Mean (SD)	56.39 (20.07)	60.48 (17.73)		
Week 4 Adjusted Mean Change (SE)	10.97 (2.15)	9.70 (2.56)		
Week 12 Adjusted Mean Change (SE)	11.06 (2.51)	12.25 (2.95)		
Week 16 Adjusted Mean Change (SE)	14.26 (2.61)	12.82 (3.15)		
Week 24 Adjusted Mean Change (SE)	12.99 (2.52)	12.38 (3.10)		
Week 32 Adjusted Mean Change (SE)	14.29 (2.60)	10.34 (3.16)		
Week 40 Adjusted Mean Change (SE)	12.38 (2.73)	10.16 (3.42)		
Week 52 Adjusted Mean Change (SE)	14.56 (2.87)	11.59 (3.68)	2.98 [-6.24; 12.19]	0.524
> Median, N	26	33		
N'	26	31		
Baseline Mean (SD)	38.73 (21.52)	37.27 (18.17)		
Week 52 Mean (SD)	46.80 (26.37)	46.07 (18.91)		
Week 4 Adjusted Mean Change (SE)	6.79 (2.67)	6.43 (2.46)		
Week 12 Adjusted Mean Change (SE)	7.09 (3.09)	12.11 (2.86)		
Week 16 Adjusted Mean Change (SE)	8.89 (3.23)	6.60 (2.99)		
Week 24 Adjusted Mean Change (SE)	10.18 (3.14)	8.11 (2.93)		
Week 32 Adjusted Mean Change (SE)	10.53 (3.19)	6.51 (2.99)		
Week 40 Adjusted Mean Change (SE)	9.78 (3.38)	8.52 (3.19)		
Week 52 Adjusted Mean Change (SE)	7.60 (3.55)	8.81 (3.36)	-1.21 [-10.84; 8.43]	0.804

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

44.6 SF-36 General Health - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.356				
Enthesitis: No, N	**34**	**22**		
N'	34	21		
Baseline Mean (SD)	42.18 (19.51)	42.86 (22.49)		
Week 52 Mean (SD)	53.47 (24.92)	58.00 (19.56)		
Week 4 Adjusted Mean Change (SE)	10.67 (2.32)	12.54 (2.97)		
Week 12 Adjusted Mean Change (SE)	12.19 (2.68)	14.61 (3.43)		
Week 16 Adjusted Mean Change (SE)	10.06 (2.78)	16.25 (3.59)		
Week 24 Adjusted Mean Change (SE)	11.29 (2.75)	11.97 (3.52)		
Week 32 Adjusted Mean Change (SE)	13.49 (2.83)	10.14 (3.58)		
Week 40 Adjusted Mean Change (SE)	12.33 (2.95)	12.10 (3.79)		
Week 52 Adjusted Mean Change (SE)	11.77 (3.11)	15.31 (4.05)	-3.54 [-13.64; 6.56]	0.489
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	39.84 (18.67)	41.55 (18.47)		
Week 52 Mean (SD)	51.68 (21.34)	49.00 (19.14)		
Week 4 Adjusted Mean Change (SE)	7.92 (2.39)	5.56 (2.17)		
Week 12 Adjusted Mean Change (SE)	6.57 (2.77)	10.81 (2.49)		
Week 16 Adjusted Mean Change (SE)	14.48 (2.89)	5.89 (2.63)		
Week 24 Adjusted Mean Change (SE)	12.51 (2.82)	9.39 (2.65)		
Week 32 Adjusted Mean Change (SE)	12.10 (2.90)	7.49 (2.71)		
Week 40 Adjusted Mean Change (SE)	10.39 (3.02)	8.04 (2.88)		
Week 52 Adjusted Mean Change (SE)	11.91 (3.19)	7.43 (3.08)	4.48 [-4.30; 13.26]	0.314

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

44.7 SF-36 General Health - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.599				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	35.45 (17.71)	41.84 (20.71)		
Week 52 Mean (SD)	49.96 (25.20)	56.19 (20.71)		
Week 4 Adjusted Mean Change (SE)	11.74 (2.43)	10.40 (2.58)		
Week 12 Adjusted Mean Change (SE)	12.13 (3.07)	14.18 (3.29)		
Week 16 Adjusted Mean Change (SE)	14.68 (3.12)	13.75 (3.37)		
Week 24 Adjusted Mean Change (SE)	13.46 (3.09)	14.32 (3.35)		
Week 32 Adjusted Mean Change (SE)	15.73 (3.23)	12.11 (3.50)		
Week 40 Adjusted Mean Change (SE)	14.68 (3.34)	15.15 (3.61)		
Week 52 Adjusted Mean Change (SE)	13.29 (3.39)	16.84 (3.70)	-3.54 [-13.51; 6.43]	0.482
Carrier, N	**22**	**19**		
N'	22	18		
Baseline Mean (SD)	44.23 (18.87)	45.79 (20.90)		
Week 52 Mean (SD)	50.95 (21.99)	48.63 (20.73)		
Week 4 Adjusted Mean Change (SE)	7.08 (2.76)	3.78 (3.07)		
Week 12 Adjusted Mean Change (SE)	4.77 (3.52)	10.43 (3.87)		
Week 16 Adjusted Mean Change (SE)	7.18 (3.57)	7.23 (3.93)		
Week 24 Adjusted Mean Change (SE)	10.61 (3.53)	5.01 (3.94)		
Week 32 Adjusted Mean Change (SE)	10.12 (3.78)	4.31 (4.14)		
Week 40 Adjusted Mean Change (SE)	7.88 (3.82)	2.80 (4.33)		
Week 52 Adjusted Mean Change (SE)	8.78 (3.90)	1.90 (4.38)	6.88 [-4.71; 18.47]	0.241

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

44.8 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.927				
Non-carrier, N	**28**	**19**		
N'	28	18		
Baseline Mean (SD)	37.86 (17.32)	42.63 (16.45)		
Week 52 Mean (SD)	52.52 (23.21)	55.77 (20.38)		
Week 4 Adjusted Mean Change (SE)	11.63 (2.46)	9.10 (3.07)		
Week 12 Adjusted Mean Change (SE)	11.38 (3.16)	15.20 (3.94)		
Week 16 Adjusted Mean Change (SE)	14.37 (3.15)	12.95 (3.96)		
Week 24 Adjusted Mean Change (SE)	14.52 (3.20)	10.04 (4.07)		
Week 32 Adjusted Mean Change (SE)	16.35 (3.30)	13.48 (4.19)		
Week 40 Adjusted Mean Change (SE)	13.13 (3.47)	11.86 (4.44)		
Week 52 Adjusted Mean Change (SE)	13.86 (3.53)	16.73 (4.62)	-2.87 [-14.44; 8.69]	0.623
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	40.50 (20.61)	43.42 (23.22)		
Week 52 Mean (SD)	47.40 (25.16)	50.39 (21.94)		
Week 4 Adjusted Mean Change (SE)	7.58 (2.77)	6.11 (2.99)		
Week 12 Adjusted Mean Change (SE)	6.14 (3.59)	9.33 (3.88)		
Week 16 Adjusted Mean Change (SE)	7.98 (3.57)	7.47 (3.86)		
Week 24 Adjusted Mean Change (SE)	9.30 (3.62)	9.46 (3.95)		
Week 32 Adjusted Mean Change (SE)	9.71 (3.75)	3.59 (4.03)		
Week 40 Adjusted Mean Change (SE)	10.90 (3.89)	7.86 (4.26)		
Week 52 Adjusted Mean Change (SE)	8.63 (3.99)	6.50 (4.31)	2.13 [-9.55; 13.81]	0.718

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

44.9 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.945				
Non-carrier, N	**19**	**21**		
N'	19	20		
Baseline Mean (SD)	36.89 (20.70)	42.52 (23.26)		
Week 52 Mean (SD)	50.63 (20.93)	53.13 (22.43)		
Week 4 Adjusted Mean Change (SE)	9.97 (3.08)	9.51 (2.99)		
Week 12 Adjusted Mean Change (SE)	14.25 (3.68)	13.47 (3.62)		
Week 16 Adjusted Mean Change (SE)	12.01 (3.81)	14.65 (3.74)		
Week 24 Adjusted Mean Change (SE)	13.31 (3.88)	10.47 (3.84)		
Week 32 Adjusted Mean Change (SE)	16.24 (4.04)	9.56 (4.02)		
Week 40 Adjusted Mean Change (SE)	14.60 (4.22)	9.44 (4.22)		
Week 52 Adjusted Mean Change (SE)	12.63 (4.32)	11.30 (4.42)	1.33 [-10.97; 13.63]	0.830
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	37.77 (13.65)	44.48 (18.43)		
Week 52 Mean (SD)	48.89 (25.13)	52.77 (20.12)		
Week 4 Adjusted Mean Change (SE)	10.48 (2.44)	6.38 (2.81)		
Week 12 Adjusted Mean Change (SE)	7.88 (2.94)	12.14 (3.36)		
Week 16 Adjusted Mean Change (SE)	13.05 (3.02)	8.28 (3.50)		
Week 24 Adjusted Mean Change (SE)	12.93 (3.06)	10.38 (3.54)		
Week 32 Adjusted Mean Change (SE)	12.58 (3.27)	8.67 (3.72)		
Week 40 Adjusted Mean Change (SE)	11.08 (3.37)	10.98 (3.90)		
Week 52 Adjusted Mean Change (SE)	10.89 (3.47)	10.44 (3.98)	0.45 [-10.08; 10.98]	0.933

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

44.10 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.023				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	42.72 (20.70)	44.53 (20.17)		
Week 52 Mean (SD)	54.30 (28.23)	49.61 (20.49)		
Week 4 Adjusted Mean Change (SE)	12.67 (2.60)	6.46 (2.30)		
Week 12 Adjusted Mean Change (SE)	12.07 (3.29)	10.50 (2.91)		
Week 16 Adjusted Mean Change (SE)	16.09 (3.34)	9.66 (2.95)		
Week 24 Adjusted Mean Change (SE)	16.05 (3.26)	7.83 (2.95)		
Week 32 Adjusted Mean Change (SE)	15.55 (3.51)	6.74 (3.13)		
Week 40 Adjusted Mean Change (SE)	14.73 (3.57)	7.06 (3.24)		
Week 52 Adjusted Mean Change (SE)	13.31 (3.71)	8.03 (3.34)	5.28 [-4.62; 15.17]	0.292
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	35.88 (15.94)	40.92 (22.58)		
Week 52 Mean (SD)	46.76 (18.39)	63.22 (19.17)		
Week 4 Adjusted Mean Change (SE)	6.77 (2.57)	11.38 (3.90)		
Week 12 Adjusted Mean Change (SE)	5.79 (3.22)	19.24 (4.89)		
Week 16 Adjusted Mean Change (SE)	6.93 (3.28)	15.46 (5.07)		
Week 24 Adjusted Mean Change (SE)	8.31 (3.24)	17.84 (4.90)		
Week 32 Adjusted Mean Change (SE)	11.06 (3.45)	15.16 (5.19)		
Week 40 Adjusted Mean Change (SE)	8.76 (3.56)	18.96 (5.44)		
Week 52 Adjusted Mean Change (SE)	9.26 (3.67)	18.25 (5.70)	-8.99 [-22.47; 4.49]	0.189

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

44.11 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.277				
Non-carrier, N	**38**	**33**		
N'	38	32		
Baseline Mean (SD)	40.82 (19.54)	43.73 (20.22)		
Week 52 Mean (SD)	52.89 (24.07)	52.38 (20.05)		
Week 4 Adjusted Mean Change (SE)	10.59 (2.12)	6.25 (2.30)		
Week 12 Adjusted Mean Change (SE)	7.61 (2.65)	14.33 (2.86)		
Week 16 Adjusted Mean Change (SE)	11.87 (2.79)	11.75 (3.03)		
Week 24 Adjusted Mean Change (SE)	14.67 (2.61)	9.77 (2.88)		
Week 32 Adjusted Mean Change (SE)	14.94 (2.86)	10.24 (3.13)		
Week 40 Adjusted Mean Change (SE)	12.28 (2.93)	10.25 (3.25)		
Week 52 Adjusted Mean Change (SE)	12.53 (3.03)	10.12 (3.38)	2.41 [-6.62; 11.43]	0.598
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	33.75 (15.39)	47.00 (23.05)		
Week 52 Mean (SD)	42.92 (22.87)	61.78 (17.90)		
Week 4 Adjusted Mean Change (SE)	6.36 (3.84)	15.53 (4.34)		
Week 12 Adjusted Mean Change (SE)	11.94 (4.76)	11.59 (5.54)		
Week 16 Adjusted Mean Change (SE)	9.53 (5.00)	12.19 (5.82)		
Week 24 Adjusted Mean Change (SE)	3.08 (4.76)	18.33 (5.44)		
Week 32 Adjusted Mean Change (SE)	8.11 (5.08)	8.16 (5.78)		
Week 40 Adjusted Mean Change (SE)	9.09 (5.26)	15.80 (5.99)		
Week 52 Adjusted Mean Change (SE)	6.73 (5.39)	16.94 (6.14)	-10.21 [-26.55; 6.13]	0.218

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

44.12 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.632				
Non-carrier, N	**36**	**34**		
N'	36	33		
Baseline Mean (SD)	38.33 (20.22)	44.62 (22.70)		
Week 52 Mean (SD)	47.42 (24.09)	51.63 (19.52)		
Week 4 Adjusted Mean Change (SE)	8.39 (2.20)	8.11 (2.31)		
Week 12 Adjusted Mean Change (SE)	9.25 (2.75)	11.88 (2.91)		
Week 16 Adjusted Mean Change (SE)	10.37 (2.86)	10.36 (3.02)		
Week 24 Adjusted Mean Change (SE)	10.58 (2.78)	9.29 (2.97)		
Week 32 Adjusted Mean Change (SE)	12.04 (2.91)	7.20 (3.08)		
Week 40 Adjusted Mean Change (SE)	10.55 (3.00)	8.20 (3.21)		
Week 52 Adjusted Mean Change (SE)	9.42 (3.08)	8.61 (3.31)	0.80 [-8.24; 9.84]	0.860
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	41.62 (14.03)	39.90 (11.32)		
Week 52 Mean (SD)	53.77 (20.63)	56.40 (24.65)		
Week 4 Adjusted Mean Change (SE)	11.26 (3.65)	6.39 (4.20)		
Week 12 Adjusted Mean Change (SE)	5.31 (4.56)	15.39 (5.24)		
Week 16 Adjusted Mean Change (SE)	12.62 (4.72)	13.69 (5.41)		
Week 24 Adjusted Mean Change (SE)	13.34 (4.60)	13.98 (5.28)		
Week 32 Adjusted Mean Change (SE)	13.47 (4.77)	14.07 (5.47)		
Week 40 Adjusted Mean Change (SE)	10.87 (4.96)	15.96 (5.73)		
Week 52 Adjusted Mean Change (SE)	12.22 (5.04)	16.42 (5.78)	-4.20 [-19.49; 11.08]	0.586

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

44.13 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.070				
Non-carrier, N	**42**	**36**		
N'	42	35		
Baseline Mean (SD)	40.57 (18.58)	41.00 (20.60)		
Week 52 Mean (SD)	50.00 (24.12)	54.24 (22.26)		
Week 4 Adjusted Mean Change (SE)	10.62 (2.01)	9.24 (2.19)		
Week 12 Adjusted Mean Change (SE)	8.40 (2.57)	13.22 (2.81)		
Week 16 Adjusted Mean Change (SE)	10.46 (2.53)	11.41 (2.78)		
Week 24 Adjusted Mean Change (SE)	11.00 (2.60)	10.71 (2.89)		
Week 32 Adjusted Mean Change (SE)	12.78 (2.71)	10.59 (2.99)		
Week 40 Adjusted Mean Change (SE)	11.40 (2.81)	12.04 (3.15)		
Week 52 Adjusted Mean Change (SE)	10.20 (2.81)	14.05 (3.15)	-3.85 [-12.23; 4.53]	0.364
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	33.00 (18.19)	57.60 (12.52)		
Week 52 Mean (SD)	52.00 (22.91)	46.60 (7.80)		
Week 4 Adjusted Mean Change (SE)	5.93 (4.37)	-2.94 (5.93)		
Week 12 Adjusted Mean Change (SE)	12.07 (5.57)	3.47 (7.57)		
Week 16 Adjusted Mean Change (SE)	17.03 (5.48)	-0.95 (7.45)		
Week 24 Adjusted Mean Change (SE)	18.01 (5.64)	4.51 (7.67)		
Week 32 Adjusted Mean Change (SE)	16.74 (5.83)	-0.15 (7.92)		
Week 40 Adjusted Mean Change (SE)	14.22 (6.11)	-3.97 (8.30)		
Week 52 Adjusted Mean Change (SE)	17.11 (6.06)	-6.45 (8.24)	23.55 [2.96; 44.14]	0.025

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

44.14 SF-36 General Health - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.769				
Low score, N	**11**	**22**		
N'	11	21		
Baseline Mean (SD)	46.45 (28.16)	44.09 (22.86)		
Week 52 Mean (SD)	54.70 (26.97)	50.53 (22.65)		
Week 4 Adjusted Mean Change (SE)	9.43 (4.01)	7.22 (2.91)		
Week 12 Adjusted Mean Change (SE)	7.95 (5.02)	13.32 (3.64)		
Week 16 Adjusted Mean Change (SE)	9.71 (5.19)	12.54 (3.73)		
Week 24 Adjusted Mean Change (SE)	12.72 (5.01)	6.40 (3.72)		
Week 32 Adjusted Mean Change (SE)	14.91 (5.28)	8.33 (3.96)		
Week 40 Adjusted Mean Change (SE)	10.61 (5.50)	6.66 (4.13)		
Week 52 Adjusted Mean Change (SE)	11.76 (5.68)	8.37 (4.34)	3.39 [-10.76; 17.54]	0.635
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	37.25 (14.82)	43.00 (18.70)		
Week 52 Mean (SD)	49.24 (22.99)	54.55 (19.78)		
Week 4 Adjusted Mean Change (SE)	9.76 (2.11)	8.13 (2.84)		
Week 12 Adjusted Mean Change (SE)	9.18 (2.66)	12.06 (3.59)		
Week 16 Adjusted Mean Change (SE)	11.88 (2.69)	9.77 (3.64)		
Week 24 Adjusted Mean Change (SE)	11.97 (2.64)	13.85 (3.56)		
Week 32 Adjusted Mean Change (SE)	12.80 (2.82)	9.33 (3.73)		
Week 40 Adjusted Mean Change (SE)	12.00 (2.90)	12.83 (3.90)		
Week 52 Adjusted Mean Change (SE)	11.14 (2.98)	12.36 (3.97)	-1.22 [-11.13; 8.69]	0.807

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

44.15 SF-36 General Health - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.723				
Non-carrier, N	**31**	**23**		
N'	31	22		
Baseline Mean (SD)	39.26 (17.01)	42.65 (16.37)		
Week 52 Mean (SD)	51.90 (22.62)	55.53 (19.39)		
Week 4 Adjusted Mean Change (SE)	10.47 (2.38)	8.89 (2.81)		
Week 12 Adjusted Mean Change (SE)	10.44 (2.96)	14.58 (3.51)		
Week 16 Adjusted Mean Change (SE)	12.99 (3.03)	12.52 (3.62)		
Week 24 Adjusted Mean Change (SE)	12.64 (3.01)	10.63 (3.62)		
Week 32 Adjusted Mean Change (SE)	14.65 (3.11)	13.43 (3.74)		
Week 40 Adjusted Mean Change (SE)	11.53 (3.30)	11.89 (3.99)		
Week 52 Adjusted Mean Change (SE)	11.99 (3.34)	15.52 (4.10)	-3.53 [-14.05; 6.98]	0.506
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	39.20 (21.21)	44.52 (24.90)		
Week 52 Mean (SD)	47.83 (25.80)	50.70 (22.13)		
Week 4 Adjusted Mean Change (SE)	8.48 (2.96)	6.43 (2.89)		
Week 12 Adjusted Mean Change (SE)	6.43 (3.73)	10.73 (3.64)		
Week 16 Adjusted Mean Change (SE)	8.95 (3.82)	9.68 (3.72)		
Week 24 Adjusted Mean Change (SE)	11.39 (3.77)	10.31 (3.71)		
Week 32 Adjusted Mean Change (SE)	11.11 (3.92)	4.27 (3.80)		
Week 40 Adjusted Mean Change (SE)	11.89 (4.08)	8.35 (4.05)		
Week 52 Adjusted Mean Change (SE)	10.03 (4.18)	6.06 (4.08)	3.96 [-7.68; 15.61]	0.500

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

44.16 SF-36 General Health - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.972				
Non-carrier, N	**19**	**20**		
N'	19	19		
Baseline Mean (SD)	36.89 (20.70)	41.90 (23.68)		
Week 52 Mean (SD)	50.63 (20.93)	53.21 (23.27)		
Week 4 Adjusted Mean Change (SE)	9.61 (3.04)	10.10 (3.03)		
Week 12 Adjusted Mean Change (SE)	13.67 (3.75)	14.30 (3.77)		
Week 16 Adjusted Mean Change (SE)	11.48 (3.84)	15.44 (3.86)		
Week 24 Adjusted Mean Change (SE)	12.88 (3.89)	11.18 (3.95)		
Week 32 Adjusted Mean Change (SE)	15.77 (4.02)	8.41 (4.10)		
Week 40 Adjusted Mean Change (SE)	14.12 (4.21)	9.70 (4.32)		
Week 52 Adjusted Mean Change (SE)	12.29 (4.29)	11.31 (4.51)	0.98 [-11.39; 13.35]	0.875
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	40.63 (17.36)	44.92 (18.15)		
Week 52 Mean (SD)	50.21 (25.67)	52.74 (19.65)		
Week 4 Adjusted Mean Change (SE)	9.75 (2.33)	5.76 (2.70)		
Week 12 Adjusted Mean Change (SE)	6.02 (2.89)	11.44 (3.34)		
Week 16 Adjusted Mean Change (SE)	11.50 (2.96)	7.71 (3.45)		
Week 24 Adjusted Mean Change (SE)	11.71 (2.96)	9.67 (3.46)		
Week 32 Adjusted Mean Change (SE)	11.77 (3.14)	9.11 (3.61)		
Week 40 Adjusted Mean Change (SE)	10.25 (3.24)	10.22 (3.79)		
Week 52 Adjusted Mean Change (SE)	10.66 (3.34)	9.84 (3.85)	0.82 [-9.32; 10.95]	0.873

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

44.17 SF-36 General Health - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.023				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	42.72 (20.70)	44.53 (20.17)		
Week 52 Mean (SD)	54.30 (28.23)	49.61 (20.49)		
Week 4 Adjusted Mean Change (SE)	12.67 (2.60)	6.46 (2.30)		
Week 12 Adjusted Mean Change (SE)	12.07 (3.29)	10.50 (2.91)		
Week 16 Adjusted Mean Change (SE)	16.09 (3.34)	9.66 (2.95)		
Week 24 Adjusted Mean Change (SE)	16.05 (3.26)	7.83 (2.95)		
Week 32 Adjusted Mean Change (SE)	15.55 (3.51)	6.74 (3.13)		
Week 40 Adjusted Mean Change (SE)	14.73 (3.57)	7.06 (3.24)		
Week 52 Adjusted Mean Change (SE)	13.31 (3.71)	8.03 (3.34)	5.28 [-4.62; 15.17]	0.292
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	35.88 (15.94)	40.92 (22.58)		
Week 52 Mean (SD)	46.76 (18.39)	63.22 (19.17)		
Week 4 Adjusted Mean Change (SE)	6.77 (2.57)	11.38 (3.90)		
Week 12 Adjusted Mean Change (SE)	5.79 (3.22)	19.24 (4.89)		
Week 16 Adjusted Mean Change (SE)	6.93 (3.28)	15.46 (5.07)		
Week 24 Adjusted Mean Change (SE)	8.31 (3.24)	17.84 (4.90)		
Week 32 Adjusted Mean Change (SE)	11.06 (3.45)	15.16 (5.19)		
Week 40 Adjusted Mean Change (SE)	8.76 (3.56)	18.96 (5.44)		
Week 52 Adjusted Mean Change (SE)	9.26 (3.67)	18.25 (5.70)	-8.99 [-22.47; 4.49]	0.189

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

44.18 SF-36 General Health - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.402				
Non-carrier, N	**39**	**35**		
N'	39	34		
Baseline Mean (SD)	40.92 (19.30)	42.51 (20.32)		
Week 52 Mean (SD)	52.86 (23.72)	51.04 (20.05)		
Week 4 Adjusted Mean Change (SE)	10.57 (2.11)	6.78 (2.25)		
Week 12 Adjusted Mean Change (SE)	7.82 (2.66)	13.91 (2.85)		
Week 16 Adjusted Mean Change (SE)	11.87 (2.69)	11.27 (2.88)		
Week 24 Adjusted Mean Change (SE)	14.56 (2.61)	8.97 (2.84)		
Week 32 Adjusted Mean Change (SE)	14.80 (2.84)	9.26 (3.05)		
Week 40 Adjusted Mean Change (SE)	12.25 (2.94)	9.06 (3.20)		
Week 52 Adjusted Mean Change (SE)	12.47 (3.02)	9.80 (3.30)	2.67 [-6.23; 11.57]	0.553
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	35.00 (15.49)	47.56 (22.64)		
Week 52 Mean (SD)	43.18 (23.97)	58.78 (23.13)		
Week 4 Adjusted Mean Change (SE)	5.31 (4.03)	10.92 (4.39)		
Week 12 Adjusted Mean Change (SE)	12.45 (5.04)	8.10 (5.53)		
Week 16 Adjusted Mean Change (SE)	7.02 (5.10)	9.94 (5.70)		
Week 24 Adjusted Mean Change (SE)	1.89 (5.03)	15.23 (5.45)		
Week 32 Adjusted Mean Change (SE)	7.85 (5.32)	7.22 (5.84)		
Week 40 Adjusted Mean Change (SE)	9.09 (5.58)	13.55 (6.18)		
Week 52 Adjusted Mean Change (SE)	6.32 (5.68)	13.49 (6.23)	-7.18 [-24.02; 9.66]	0.399

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.0 SF-36 Mental Health - Return Rates (FAS)

	Treatment Groups		
	SEC **(N=66)**	**ADA** **(N=62)**	**Total** **(N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	57 (91.9)	122 (95.3)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	48 (77.4)	111 (86.7)

45.0 SF-36 Mental Health - Return Rates (FAS)

45.1 SF-36 Mental Health - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N'	66	60		
Baseline Mean (SD)	53.64 (22.47)	54.68 (24.14)		
Week 52 Mean (SD)	67.38 (21.53)	65.00 (23.81)		
Week 4 Adjusted Mean Change (SE)	10.42 (1.96)	8.22 (2.06)		
Week 12 Adjusted Mean Change (SE)	11.94 (1.83)	9.26 (1.91)		
Week 16 Adjusted Mean Change (SE)	12.74 (1.85)	8.24 (1.96)		
Week 24 Adjusted Mean Change (SE)	14.21 (2.17)	9.30 (2.36)		
Week 32 Adjusted Mean Change (SE)	15.94 (2.27)	9.14 (2.44)		
Week 40 Adjusted Mean Change (SE)	13.12 (2.09)	9.04 (2.34)		
Week 52 Adjusted Mean Change (SE)	13.95 (2.36)	10.03 (2.65)	3.93 [-3.11; 10.96]	0.272

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

45.2 SF-36 Mental Health - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.814				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	56.79 (23.53)	59.39 (24.10)		
Week 52 Mean (SD)	68.00 (23.06)	66.35 (21.89)		
Week 4 Adjusted Mean Change (SE)	14.03 (2.43)	10.74 (2.80)		
Week 12 Adjusted Mean Change (SE)	13.35 (2.32)	9.05 (2.64)		
Week 16 Adjusted Mean Change (SE)	13.48 (2.35)	8.12 (2.68)		
Week 24 Adjusted Mean Change (SE)	14.10 (2.74)	12.17 (3.24)		
Week 32 Adjusted Mean Change (SE)	17.17 (2.88)	9.13 (3.40)		
Week 40 Adjusted Mean Change (SE)	12.89 (2.66)	8.30 (3.22)		
Week 52 Adjusted Mean Change (SE)	12.77 (3.00)	9.38 (3.66)	3.38 [-5.96; 12.73]	0.475
Female, N	**24**	**29**		
N'	24	28		
Baseline Mean (SD)	48.13 (19.77)	49.31 (23.44)		
Week 52 Mean (SD)	66.30 (19.02)	63.41 (26.34)		
Week 4 Adjusted Mean Change (SE)	4.09 (3.24)	5.44 (2.97)		
Week 12 Adjusted Mean Change (SE)	9.47 (3.11)	9.55 (2.84)		
Week 16 Adjusted Mean Change (SE)	11.48 (3.11)	8.62 (2.95)		
Week 24 Adjusted Mean Change (SE)	14.48 (3.68)	5.84 (3.51)		
Week 32 Adjusted Mean Change (SE)	13.79 (3.85)	9.15 (3.59)		
Week 40 Adjusted Mean Change (SE)	13.58 (3.51)	10.08 (3.49)		
Week 52 Adjusted Mean Change (SE)	15.99 (3.98)	10.94 (3.96)	5.05 [-5.98; 16.08]	0.366

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.2 SF-36 Mental Health - Change from Baseline by Gender (FAS)

45.3 SF-36 Mental Health - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.251				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	63.44 (19.12)	62.69 (24.63)		
Week 52 Mean (SD)	75.94 (15.94)	63.33 (24.37)		
Week 4 Adjusted Mean Change (SE)	18.26 (3.98)	6.89 (4.39)		
Week 12 Adjusted Mean Change (SE)	12.83 (3.84)	8.97 (4.14)		
Week 16 Adjusted Mean Change (SE)	16.68 (3.78)	6.78 (4.18)		
Week 24 Adjusted Mean Change (SE)	17.00 (4.54)	8.34 (5.19)		
Week 32 Adjusted Mean Change (SE)	23.40 (4.58)	6.50 (5.48)		
Week 40 Adjusted Mean Change (SE)	15.64 (4.35)	10.74 (5.40)		
Week 52 Adjusted Mean Change (SE)	17.23 (4.83)	10.96 (6.13)	6.27 [-9.16; 21.69]	0.423
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	47		
Baseline Mean (SD)	50.50 (22.73)	52.55 (23.81)		
Week 52 Mean (SD)	64.47 (22.54)	65.38 (23.99)		
Week 4 Adjusted Mean Change (SE)	7.90 (2.24)	8.63 (2.29)		
Week 12 Adjusted Mean Change (SE)	11.58 (2.12)	9.33 (2.18)		
Week 16 Adjusted Mean Change (SE)	11.47 (2.14)	8.68 (2.23)		
Week 24 Adjusted Mean Change (SE)	13.25 (2.52)	9.60 (2.67)		
Week 32 Adjusted Mean Change (SE)	13.48 (2.60)	9.80 (2.69)		
Week 40 Adjusted Mean Change (SE)	12.32 (2.44)	8.71 (2.63)		
Week 52 Adjusted Mean Change (SE)	12.90 (2.76)	9.89 (2.97)	3.01 [-5.03; 11.06]	0.459

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.4 SF-36 Mental Health - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.157				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	31		
Baseline Mean (SD)	55.36 (23.41)	54.53 (24.04)		
Week 52 Mean (SD)	65.58 (22.73)	66.30 (24.60)		
Week 4 Adjusted Mean Change (SE)	8.55 (3.03)	7.15 (2.89)		
Week 12 Adjusted Mean Change (SE)	10.57 (2.80)	9.44 (2.66)		
Week 16 Adjusted Mean Change (SE)	7.71 (2.78)	8.34 (2.70)		
Week 24 Adjusted Mean Change (SE)	11.24 (3.36)	10.56 (3.28)		
Week 32 Adjusted Mean Change (SE)	14.58 (3.49)	10.81 (3.42)		
Week 40 Adjusted Mean Change (SE)	10.47 (3.20)	12.59 (3.32)		
Week 52 Adjusted Mean Change (SE)	11.52 (3.68)	11.51 (3.81)	0.01 [-10.48; 10.50]	0.999
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	52.37 (21.99)	54.83 (24.65)		
Week 52 Mean (SD)	68.65 (20.87)	63.80 (23.51)		
Week 4 Adjusted Mean Change (SE)	11.81 (2.60)	9.36 (2.98)		
Week 12 Adjusted Mean Change (SE)	12.90 (2.45)	9.07 (2.79)		
Week 16 Adjusted Mean Change (SE)	16.55 (2.40)	8.15 (2.76)		
Week 24 Adjusted Mean Change (SE)	16.41 (2.86)	7.96 (3.42)		
Week 32 Adjusted Mean Change (SE)	16.95 (3.01)	7.40 (3.51)		
Week 40 Adjusted Mean Change (SE)	15.08 (2.73)	5.75 (3.26)		
Week 52 Adjusted Mean Change (SE)	15.74 (3.11)	8.49 (3.75)	7.25 [-2.41; 16.91]	0.140

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.5 SF-36 Mental Health - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.941				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	54.75 (19.84)	61.21 (21.03)		
Week 52 Mean (SD)	69.47 (21.01)	73.57 (21.40)		
Week 4 Adjusted Mean Change (SE)	10.94 (2.53)	9.87 (3.01)		
Week 12 Adjusted Mean Change (SE)	12.81 (2.39)	8.77 (2.78)		
Week 16 Adjusted Mean Change (SE)	13.24 (2.38)	10.53 (2.88)		
Week 24 Adjusted Mean Change (SE)	16.95 (2.76)	11.73 (3.45)		
Week 32 Adjusted Mean Change (SE)	16.45 (2.95)	10.80 (3.61)		
Week 40 Adjusted Mean Change (SE)	15.41 (2.69)	10.81 (3.50)		
Week 52 Adjusted Mean Change (SE)	15.17 (3.03)	13.97 (3.99)	1.21 [-8.73; 11.14]	0.811
> Median, N	**26**	**33**		
N'	26	31		
Baseline Mean (SD)	51.92 (26.35)	48.94 (25.52)		
Week 52 Mean (SD)	64.20 (22.35)	58.33 (23.82)		
Week 4 Adjusted Mean Change (SE)	9.61 (3.15)	6.70 (2.89)		
Week 12 Adjusted Mean Change (SE)	10.61 (2.91)	9.77 (2.71)		
Week 16 Adjusted Mean Change (SE)	11.91 (2.94)	6.18 (2.73)		
Week 24 Adjusted Mean Change (SE)	9.87 (3.46)	7.17 (3.25)		
Week 32 Adjusted Mean Change (SE)	15.02 (3.58)	7.71 (3.39)		
Week 40 Adjusted Mean Change (SE)	9.64 (3.31)	7.55 (3.18)		
Week 52 Adjusted Mean Change (SE)	12.06 (3.74)	6.80 (3.59)	5.26 [-5.00; 15.51]	0.312

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.5 SF-36 Mental Health - Change from Baseline by Lymphocyte Count at BL (FAS)

45.6 SF-36 Mental Health - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.516				
Enthesitis: No, N	**34**	**22**		
N'	34	21		
Baseline Mean (SD)	55.74 (22.02)	57.73 (25.58)		
Week 52 Mean (SD)	68.44 (21.23)	73.89 (23.98)		
Week 4 Adjusted Mean Change (SE)	15.25 (2.68)	11.81 (3.43)		
Week 12 Adjusted Mean Change (SE)	14.40 (2.51)	14.62 (3.23)		
Week 16 Adjusted Mean Change (SE)	12.73 (2.57)	11.06 (3.33)		
Week 24 Adjusted Mean Change (SE)	15.37 (3.06)	11.18 (3.92)		
Week 32 Adjusted Mean Change (SE)	17.86 (3.15)	14.90 (3.99)		
Week 40 Adjusted Mean Change (SE)	15.09 (2.93)	12.17 (3.81)		
Week 52 Adjusted Mean Change (SE)	13.97 (3.27)	17.32 (4.30)	-3.35 [-14.02; 7.33]	0.536
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	51.41 (23.08)	53.00 (23.47)		
Week 52 Mean (SD)	66.29 (22.13)	59.67 (22.44)		
Week 4 Adjusted Mean Change (SE)	5.29 (2.77)	6.33 (2.50)		
Week 12 Adjusted Mean Change (SE)	9.32 (2.59)	6.51 (2.32)		
Week 16 Adjusted Mean Change (SE)	12.80 (2.68)	6.70 (2.44)		
Week 24 Adjusted Mean Change (SE)	12.97 (3.14)	8.33 (2.99)		
Week 32 Adjusted Mean Change (SE)	13.87 (3.22)	5.92 (3.07)		
Week 40 Adjusted Mean Change (SE)	11.14 (2.99)	7.35 (2.98)		
Week 52 Adjusted Mean Change (SE)	13.89 (3.34)	5.82 (3.33)	8.07 [-1.26; 17.40]	0.089

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.7 SF-36 Mental Health - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.143				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	49.14 (21.47)	59.20 (21.20)		
Week 52 Mean (SD)	65.18 (22.79)	75.24 (19.01)		
Week 4 Adjusted Mean Change (SE)	15.27 (3.01)	12.96 (3.27)		
Week 12 Adjusted Mean Change (SE)	13.20 (2.80)	10.63 (3.08)		
Week 16 Adjusted Mean Change (SE)	12.10 (2.83)	11.11 (3.15)		
Week 24 Adjusted Mean Change (SE)	15.90 (3.18)	15.74 (3.57)		
Week 32 Adjusted Mean Change (SE)	16.37 (3.31)	15.03 (3.70)		
Week 40 Adjusted Mean Change (SE)	13.01 (3.30)	15.46 (3.69)		
Week 52 Adjusted Mean Change (SE)	15.19 (3.33)	19.60 (3.74)	-4.41 [-14.42; 5.59]	0.383
Carrier, N	**22**	**19**		
N'	22	18		
Baseline Mean (SD)	56.14 (22.52)	47.63 (24.52)		
Week 52 Mean (SD)	70.75 (19.42)	53.13 (24.21)		
Week 4 Adjusted Mean Change (SE)	5.76 (3.45)	5.45 (3.82)		
Week 12 Adjusted Mean Change (SE)	11.82 (3.27)	8.49 (3.55)		
Week 16 Adjusted Mean Change (SE)	13.08 (3.29)	7.87 (3.59)		
Week 24 Adjusted Mean Change (SE)	13.95 (3.69)	4.91 (4.12)		
Week 32 Adjusted Mean Change (SE)	16.76 (3.97)	1.42 (4.30)		
Week 40 Adjusted Mean Change (SE)	15.44 (3.83)	5.82 (4.38)		
Week 52 Adjusted Mean Change (SE)	16.29 (3.87)	3.63 (4.36)	12.66 [1.04; 24.28]	0.033

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.8 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.794				
Non-carrier, N	**28**	**19**		
N'	28	18		
Baseline Mean (SD)	48.57 (20.94)	56.05 (22.08)		
Week 52 Mean (SD)	66.67 (24.30)	63.46 (20.95)		
Week 4 Adjusted Mean Change (SE)	14.48 (3.18)	9.71 (3.98)		
Week 12 Adjusted Mean Change (SE)	13.76 (2.86)	12.85 (3.58)		
Week 16 Adjusted Mean Change (SE)	13.79 (2.91)	8.57 (3.70)		
Week 24 Adjusted Mean Change (SE)	13.37 (3.25)	10.51 (4.21)		
Week 32 Adjusted Mean Change (SE)	17.94 (3.51)	11.54 (4.53)		
Week 40 Adjusted Mean Change (SE)	13.63 (3.47)	9.22 (4.56)		
Week 52 Adjusted Mean Change (SE)	16.24 (3.67)	10.99 (4.90)	5.26 [-6.95; 17.46]	0.394
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	56.36 (23.41)	52.37 (26.63)		
Week 52 Mean (SD)	68.00 (17.80)	66.39 (28.43)		
Week 4 Adjusted Mean Change (SE)	7.55 (3.59)	7.11 (3.85)		
Week 12 Adjusted Mean Change (SE)	11.12 (3.29)	6.50 (3.53)		
Week 16 Adjusted Mean Change (SE)	10.68 (3.33)	8.86 (3.58)		
Week 24 Adjusted Mean Change (SE)	17.52 (3.70)	13.18 (4.04)		
Week 32 Adjusted Mean Change (SE)	13.98 (4.02)	7.50 (4.28)		
Week 40 Adjusted Mean Change (SE)	14.38 (3.88)	13.60 (4.28)		
Week 52 Adjusted Mean Change (SE)	14.83 (4.14)	13.89 (4.47)	0.94 [-11.20; 13.07]	0.878

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.9 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.280				
Non-carrier, N	**19**	**21**		
N'	19	20		
Baseline Mean (SD)	48.42 (23.16)	54.76 (20.89)		
Week 52 Mean (SD)	64.47 (20.61)	69.67 (27.22)		
Week 4 Adjusted Mean Change (SE)	10.44 (3.64)	14.08 (3.56)		
Week 12 Adjusted Mean Change (SE)	15.63 (3.25)	15.82 (3.23)		
Week 16 Adjusted Mean Change (SE)	11.87 (3.52)	11.60 (3.49)		
Week 24 Adjusted Mean Change (SE)	13.36 (4.07)	11.55 (4.12)		
Week 32 Adjusted Mean Change (SE)	18.22 (4.17)	14.34 (4.25)		
Week 40 Adjusted Mean Change (SE)	13.24 (4.10)	10.88 (4.22)		
Week 52 Adjusted Mean Change (SE)	14.71 (4.28)	15.43 (4.48)	-0.73 [-13.07; 11.61]	0.907
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	52.50 (20.16)	53.70 (25.50)		
Week 52 Mean (SD)	69.11 (22.36)	62.95 (21.47)		
Week 4 Adjusted Mean Change (SE)	12.79 (2.89)	6.37 (3.31)		
Week 12 Adjusted Mean Change (SE)	12.03 (2.61)	4.87 (2.95)		
Week 16 Adjusted Mean Change (SE)	13.24 (2.79)	8.52 (3.24)		
Week 24 Adjusted Mean Change (SE)	16.76 (3.20)	11.05 (3.71)		
Week 32 Adjusted Mean Change (SE)	15.65 (3.41)	5.17 (3.85)		
Week 40 Adjusted Mean Change (SE)	16.14 (3.27)	11.81 (3.80)		
Week 52 Adjusted Mean Change (SE)	17.07 (3.44)	10.84 (3.95)	6.23 [-4.18; 16.64]	0.237

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.10 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.301				
Non-carrier, N	25	32		
N'	25	32		
Baseline Mean (SD)	49.20 (22.94)	53.59 (21.90)		
Week 52 Mean (SD)	63.26 (23.29)	63.57 (25.53)		
Week 4 Adjusted Mean Change (SE)	15.04 (3.31)	9.68 (2.91)		
Week 12 Adjusted Mean Change (SE)	14.30 (3.05)	8.48 (2.67)		
Week 16 Adjusted Mean Change (SE)	13.35 (3.00)	6.48 (2.62)		
Week 24 Adjusted Mean Change (SE)	15.31 (3.46)	8.75 (3.18)		
Week 32 Adjusted Mean Change (SE)	16.03 (3.78)	9.57 (3.38)		
Week 40 Adjusted Mean Change (SE)	14.23 (3.62)	10.73 (3.33)		
Week 52 Adjusted Mean Change (SE)	13.53 (3.77)	12.02 (3.42)	1.52 [-8.60; 11.63]	0.766
Carrier, N	26	12		
N'	26	11		
Baseline Mean (SD)	55.00 (21.07)	55.83 (27.21)		
Week 52 Mean (SD)	71.40 (19.18)	72.22 (17.16)		
Week 4 Adjusted Mean Change (SE)	7.46 (3.25)	10.11 (4.99)		
Week 12 Adjusted Mean Change (SE)	10.97 (2.94)	13.36 (4.52)		
Week 16 Adjusted Mean Change (SE)	11.60 (2.89)	19.82 (4.58)		
Week 24 Adjusted Mean Change (SE)	14.95 (3.41)	17.83 (5.21)		
Week 32 Adjusted Mean Change (SE)	16.94 (3.65)	8.83 (5.55)		
Week 40 Adjusted Mean Change (SE)	13.80 (3.57)	13.17 (5.56)		
Week 52 Adjusted Mean Change (SE)	17.36 (3.69)	15.44 (5.84)	1.92 [-11.77; 15.61]	0.781

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.11 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.292				
Non-carrier, N	**38**	**33**		
N'	38	32		
Baseline Mean (SD)	53.68 (20.56)	53.33 (21.24)		
Week 52 Mean (SD)	68.29 (19.92)	65.38 (21.81)		
Week 4 Adjusted Mean Change (SE)	12.38 (2.74)	9.85 (2.97)		
Week 12 Adjusted Mean Change (SE)	10.46 (2.39)	8.76 (2.57)		
Week 16 Adjusted Mean Change (SE)	13.98 (2.42)	9.47 (2.63)		
Week 24 Adjusted Mean Change (SE)	16.83 (2.77)	11.22 (3.12)		
Week 32 Adjusted Mean Change (SE)	17.34 (3.03)	11.10 (3.35)		
Week 40 Adjusted Mean Change (SE)	13.81 (2.85)	10.11 (3.23)		
Week 52 Adjusted Mean Change (SE)	15.53 (3.06)	13.01 (3.47)	2.53 [-6.67; 11.73]	0.586
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	46.25 (26.72)	67.22 (19.22)		
Week 52 Mean (SD)	64.17 (26.53)	76.67 (20.16)		
Week 4 Adjusted Mean Change (SE)	5.25 (4.93)	10.94 (5.72)		
Week 12 Adjusted Mean Change (SE)	18.20 (4.27)	12.39 (5.12)		
Week 16 Adjusted Mean Change (SE)	6.00 (4.33)	16.50 (5.20)		
Week 24 Adjusted Mean Change (SE)	8.43 (5.07)	15.13 (5.92)		
Week 32 Adjusted Mean Change (SE)	12.26 (5.33)	6.63 (6.20)		
Week 40 Adjusted Mean Change (SE)	12.51 (5.10)	20.04 (5.93)		
Week 52 Adjusted Mean Change (SE)	13.72 (5.43)	16.23 (6.31)	-2.51 [-19.28; 14.26]	0.766

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.12 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.483				
Non-carrier, N	**36**	**34**		
N'	36	33		
Baseline Mean (SD)	51.39 (24.04)	56.03 (22.86)		
Week 52 Mean (SD)	65.30 (22.57)	67.78 (24.97)		
Week 4 Adjusted Mean Change (SE)	11.88 (2.74)	11.56 (2.89)		
Week 12 Adjusted Mean Change (SE)	13.74 (2.50)	9.35 (2.66)		
Week 16 Adjusted Mean Change (SE)	11.45 (2.57)	8.94 (2.73)		
Week 24 Adjusted Mean Change (SE)	12.92 (2.91)	11.65 (3.16)		
Week 32 Adjusted Mean Change (SE)	14.07 (3.09)	10.97 (3.30)		
Week 40 Adjusted Mean Change (SE)	11.92 (3.03)	11.59 (3.30)		
Week 52 Adjusted Mean Change (SE)	14.23 (3.16)	13.95 (3.44)	0.28 [-9.03; 9.59]	0.953
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	53.85 (17.93)	48.00 (24.29)		
Week 52 Mean (SD)	70.38 (18.98)	60.00 (20.55)		
Week 4 Adjusted Mean Change (SE)	6.60 (4.57)	4.25 (5.25)		
Week 12 Adjusted Mean Change (SE)	8.31 (4.16)	11.00 (4.79)		
Week 16 Adjusted Mean Change (SE)	14.48 (4.24)	12.43 (4.88)		
Week 24 Adjusted Mean Change (SE)	19.16 (4.81)	9.71 (5.53)		
Week 32 Adjusted Mean Change (SE)	20.84 (5.04)	4.20 (5.79)		
Week 40 Adjusted Mean Change (SE)	18.43 (5.01)	10.77 (5.82)		
Week 52 Adjusted Mean Change (SE)	17.32 (5.17)	9.42 (5.93)	7.90 [-7.80; 23.60]	0.320

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.13 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.845				
Non-carrier, N	**42**	**36**		
N'	42	35		
Baseline Mean (SD)	54.88 (22.46)	53.89 (24.61)		
Week 52 Mean (SD)	68.85 (20.21)	65.34 (23.64)		
Week 4 Adjusted Mean Change (SE)	11.69 (2.55)	11.12 (2.79)		
Week 12 Adjusted Mean Change (SE)	12.02 (2.26)	11.09 (2.47)		
Week 16 Adjusted Mean Change (SE)	13.50 (2.32)	9.50 (2.57)		
Week 24 Adjusted Mean Change (SE)	15.95 (2.71)	11.56 (3.06)		
Week 32 Adjusted Mean Change (SE)	16.83 (2.83)	8.32 (3.14)		
Week 40 Adjusted Mean Change (SE)	13.44 (2.81)	10.23 (3.20)		
Week 52 Adjusted Mean Change (SE)	15.78 (2.86)	13.11 (3.26)	2.68 [-5.94; 11.29]	0.538
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	39.44 (14.67)	49.00 (14.32)		
Week 52 Mean (SD)	61.67 (26.58)	65.00 (27.16)		
Week 4 Adjusted Mean Change (SE)	10.17 (5.59)	0.43 (7.37)		
Week 12 Adjusted Mean Change (SE)	16.18 (4.90)	2.95 (6.46)		
Week 16 Adjusted Mean Change (SE)	8.92 (5.05)	3.80 (6.65)		
Week 24 Adjusted Mean Change (SE)	12.36 (5.92)	6.69 (7.80)		
Week 32 Adjusted Mean Change (SE)	16.36 (6.08)	18.45 (8.01)		
Week 40 Adjusted Mean Change (SE)	17.86 (6.12)	16.68 (8.07)		
Week 52 Adjusted Mean Change (SE)	16.41 (6.20)	14.60 (8.17)	1.82 [-18.55; 22.18]	0.860

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.14 SF-36 Mental Health - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.928				
Low score, N	**11**	**22**		
N'	11	21		
Baseline Mean (SD)	55.91 (29.22)	55.68 (21.45)		
Week 52 Mean (SD)	64.00 (27.16)	64.00 (26.94)		
Week 4 Adjusted Mean Change (SE)	13.95 (4.98)	13.93 (3.63)		
Week 12 Adjusted Mean Change (SE)	15.27 (4.50)	12.29 (3.28)		
Week 16 Adjusted Mean Change (SE)	16.15 (4.70)	7.88 (3.37)		
Week 24 Adjusted Mean Change (SE)	11.75 (5.16)	6.77 (3.95)		
Week 32 Adjusted Mean Change (SE)	18.50 (5.53)	10.38 (4.28)		
Week 40 Adjusted Mean Change (SE)	8.21 (5.30)	6.53 (4.14)		
Week 52 Adjusted Mean Change (SE)	10.75 (5.65)	11.55 (4.43)	-0.80 [-15.05; 13.44]	0.911
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	51.13 (19.89)	52.73 (25.15)		
Week 52 Mean (SD)	68.42 (19.97)	66.82 (22.07)		
Week 4 Adjusted Mean Change (SE)	10.40 (2.61)	5.94 (3.53)		
Week 12 Adjusted Mean Change (SE)	11.86 (2.38)	7.22 (3.25)		
Week 16 Adjusted Mean Change (SE)	11.63 (2.39)	11.66 (3.28)		
Week 24 Adjusted Mean Change (SE)	16.05 (2.72)	14.79 (3.69)		
Week 32 Adjusted Mean Change (SE)	15.78 (2.97)	8.22 (3.92)		
Week 40 Adjusted Mean Change (SE)	15.69 (2.79)	15.13 (3.77)		
Week 52 Adjusted Mean Change (SE)	17.00 (2.95)	13.89 (3.94)	3.11 [-6.69; 12.90]	0.530

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.15 SF-36 Mental Health - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.819				
Non-carrier, N	**31**	**23**		
N'	31	22		
Baseline Mean (SD)	49.68 (20.81)	54.57 (20.50)		
Week 52 Mean (SD)	67.00 (23.14)	63.82 (20.04)		
Week 4 Adjusted Mean Change (SE)	13.14 (3.00)	10.81 (3.56)		
Week 12 Adjusted Mean Change (SE)	13.24 (2.69)	12.39 (3.19)		
Week 16 Adjusted Mean Change (SE)	13.38 (2.74)	9.67 (3.30)		
Week 24 Adjusted Mean Change (SE)	13.54 (3.12)	9.55 (3.81)		
Week 32 Adjusted Mean Change (SE)	18.72 (3.31)	10.85 (4.03)		
Week 40 Adjusted Mean Change (SE)	13.64 (3.26)	9.59 (4.02)		
Week 52 Adjusted Mean Change (SE)	16.04 (3.38)	11.68 (4.23)	4.36 [-6.42; 15.14]	0.424
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	56.00 (23.71)	53.81 (26.26)		
Week 52 Mean (SD)	68.33 (18.79)	67.25 (27.07)		
Week 4 Adjusted Mean Change (SE)	8.13 (3.74)	8.74 (3.63)		
Week 12 Adjusted Mean Change (SE)	11.67 (3.42)	6.84 (3.32)		
Week 16 Adjusted Mean Change (SE)	11.12 (3.47)	9.98 (3.37)		
Week 24 Adjusted Mean Change (SE)	17.72 (3.92)	12.75 (3.87)		
Week 32 Adjusted Mean Change (SE)	12.74 (4.20)	7.58 (4.05)		
Week 40 Adjusted Mean Change (SE)	14.69 (4.02)	12.99 (4.01)		
Week 52 Adjusted Mean Change (SE)	15.08 (4.23)	13.82 (4.13)	1.26 [-10.49; 13.01]	0.831

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.16 SF-36 Mental Health - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.378				
Non-carrier, N	**19**	**20**		
N'	19	19		
Baseline Mean (SD)	48.42 (23.16)	55.50 (21.14)		
Week 52 Mean (SD)	64.47 (20.61)	68.21 (27.64)		
Week 4 Adjusted Mean Change (SE)	10.00 (3.77)	15.82 (3.77)		
Week 12 Adjusted Mean Change (SE)	15.42 (3.30)	16.62 (3.36)		
Week 16 Adjusted Mean Change (SE)	11.66 (3.47)	13.04 (3.54)		
Week 24 Adjusted Mean Change (SE)	13.18 (4.04)	11.74 (4.20)		
Week 32 Adjusted Mean Change (SE)	17.92 (4.21)	11.85 (4.40)		
Week 40 Adjusted Mean Change (SE)	12.96 (4.13)	8.27 (4.36)		
Week 52 Adjusted Mean Change (SE)	14.39 (4.28)	13.36 (4.61)	1.03 [-11.50; 13.56]	0.871
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	54.38 (21.32)	53.13 (25.10)		
Week 52 Mean (SD)	69.48 (22.05)	64.13 (21.72)		
Week 4 Adjusted Mean Change (SE)	11.87 (2.90)	5.12 (3.34)		
Week 12 Adjusted Mean Change (SE)	10.84 (2.56)	4.62 (2.92)		
Week 16 Adjusted Mean Change (SE)	13.03 (2.69)	7.26 (3.12)		
Week 24 Adjusted Mean Change (SE)	16.21 (3.07)	10.52 (3.60)		
Week 32 Adjusted Mean Change (SE)	15.51 (3.33)	7.17 (3.80)		
Week 40 Adjusted Mean Change (SE)	14.69 (3.19)	13.21 (3.74)		
Week 52 Adjusted Mean Change (SE)	16.37 (3.34)	12.22 (3.85)	4.15 [-5.99; 14.29]	0.418

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.17 SF-36 Mental Health - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.301				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	49.20 (22.94)	53.59 (21.90)		
Week 52 Mean (SD)	63.26 (23.29)	63.57 (25.53)		
Week 4 Adjusted Mean Change (SE)	15.04 (3.31)	9.68 (2.91)		
Week 12 Adjusted Mean Change (SE)	14.30 (3.05)	8.48 (2.67)		
Week 16 Adjusted Mean Change (SE)	13.35 (3.00)	6.48 (2.62)		
Week 24 Adjusted Mean Change (SE)	15.31 (3.46)	8.75 (3.18)		
Week 32 Adjusted Mean Change (SE)	16.03 (3.78)	9.57 (3.38)		
Week 40 Adjusted Mean Change (SE)	14.23 (3.62)	10.73 (3.33)		
Week 52 Adjusted Mean Change (SE)	13.53 (3.77)	12.02 (3.42)	1.52 [-8.60; 11.63]	0.766
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	55.00 (21.07)	55.83 (27.21)		
Week 52 Mean (SD)	71.40 (19.18)	72.22 (17.16)		
Week 4 Adjusted Mean Change (SE)	7.46 (3.25)	10.11 (4.99)		
Week 12 Adjusted Mean Change (SE)	10.97 (2.94)	13.36 (4.52)		
Week 16 Adjusted Mean Change (SE)	11.60 (2.89)	19.82 (4.58)		
Week 24 Adjusted Mean Change (SE)	14.95 (3.41)	17.83 (5.21)		
Week 32 Adjusted Mean Change (SE)	16.94 (3.65)	8.83 (5.55)		
Week 40 Adjusted Mean Change (SE)	13.80 (3.57)	13.17 (5.56)		
Week 52 Adjusted Mean Change (SE)	17.36 (3.69)	15.44 (5.84)	1.92 [-11.77; 15.61]	0.781

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.18 SF-36 Mental Health - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.426				
Non-carrier, N	**39**	**35**		
N'	39	34		
Baseline Mean (SD)	53.97 (20.36)	53.14 (21.86)		
Week 52 Mean (SD)	68.61 (19.73)	64.11 (23.26)		
Week 4 Adjusted Mean Change (SE)	12.62 (2.69)	9.31 (2.87)		
Week 12 Adjusted Mean Change (SE)	10.65 (2.41)	9.34 (2.57)		
Week 16 Adjusted Mean Change (SE)	14.25 (2.43)	8.57 (2.59)		
Week 24 Adjusted Mean Change (SE)	16.77 (2.77)	10.12 (3.08)		
Week 32 Adjusted Mean Change (SE)	17.46 (2.92)	10.39 (3.17)		
Week 40 Adjusted Mean Change (SE)	14.09 (2.86)	9.17 (3.18)		
Week 52 Adjusted Mean Change (SE)	15.78 (3.04)	12.22 (3.38)	3.56 [-5.48; 12.60]	0.436
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	49.09 (26.06)	58.33 (28.72)		
Week 52 Mean (SD)	65.91 (27.09)	70.56 (26.39)		
Week 4 Adjusted Mean Change (SE)	4.66 (5.09)	10.74 (5.59)		
Week 12 Adjusted Mean Change (SE)	19.37 (4.52)	10.47 (4.96)		
Week 16 Adjusted Mean Change (SE)	5.67 (4.56)	14.16 (5.19)		
Week 24 Adjusted Mean Change (SE)	9.23 (5.34)	14.19 (5.77)		
Week 32 Adjusted Mean Change (SE)	15.91 (5.41)	4.79 (5.95)		
Week 40 Adjusted Mean Change (SE)	14.36 (5.39)	18.74 (6.03)		
Week 52 Adjusted Mean Change (SE)	14.34 (5.68)	14.45 (6.25)	-0.10 [-16.93; 16.72]	0.990

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

45.18 SF-36 Mental Health - Change from Baseline by Linkage Variant rs7787032 (FAS)

46.0 SF-36 Physical Functioning - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	**ADA (N=62)**	**Total (N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	57 (91.9)	122 (95.3)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	48 (77.4)	111 (86.7)

46.0 SF-36 Physical Functioning - Return Rates (FAS)

46.1 SF-36 Physical Functioning - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N'	66	60		
Baseline Mean (SD)	41.67 (26.32)	43.07 (27.50)		
Week 52 Mean (SD)	64.76 (29.59)	64.58 (29.19)		
Week 4 Adjusted Mean Change (SE)	11.16 (1.94)	11.06 (2.03)		
Week 12 Adjusted Mean Change (SE)	17.27 (2.54)	16.43 (2.66)		
Week 16 Adjusted Mean Change (SE)	19.17 (2.53)	15.84 (2.68)		
Week 24 Adjusted Mean Change (SE)	20.07 (2.70)	18.05 (2.89)		
Week 32 Adjusted Mean Change (SE)	21.38 (2.82)	21.17 (3.01)		
Week 40 Adjusted Mean Change (SE)	23.53 (2.75)	19.27 (3.00)		
Week 52 Adjusted Mean Change (SE)	22.98 (2.96)	21.26 (3.25)	1.72 [-6.98; 10.42]	0.696

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

46.2 SF-36 Physical Functioning - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.409				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	45.00 (28.20)	52.42 (27.30)		
Week 52 Mean (SD)	67.50 (29.83)	73.46 (27.96)		
Week 4 Adjusted Mean Change (SE)	13.69 (2.44)	13.34 (2.83)		
Week 12 Adjusted Mean Change (SE)	18.84 (3.18)	20.60 (3.67)		
Week 16 Adjusted Mean Change (SE)	21.44 (3.17)	20.03 (3.66)		
Week 24 Adjusted Mean Change (SE)	21.38 (3.37)	23.07 (3.98)		
Week 32 Adjusted Mean Change (SE)	22.82 (3.51)	27.21 (4.14)		
Week 40 Adjusted Mean Change (SE)	23.22 (3.46)	23.83 (4.14)		
Week 52 Adjusted Mean Change (SE)	22.79 (3.75)	24.11 (4.53)	-1.32 [-12.87; 10.23]	0.821
Female, N	**24**	**29**		
N'	24	28		
Baseline Mean (SD)	35.83 (22.00)	32.41 (23.97)		
Week 52 Mean (SD)	60.00 (29.19)	54.09 (27.63)		
Week 4 Adjusted Mean Change (SE)	6.73 (3.25)	8.53 (3.00)		
Week 12 Adjusted Mean Change (SE)	14.49 (4.25)	11.74 (3.94)		
Week 16 Adjusted Mean Change (SE)	15.20 (4.20)	11.13 (3.99)		
Week 24 Adjusted Mean Change (SE)	17.78 (4.51)	12.37 (4.29)		
Week 32 Adjusted Mean Change (SE)	18.75 (4.67)	14.36 (4.41)		
Week 40 Adjusted Mean Change (SE)	23.94 (4.57)	14.06 (4.46)		
Week 52 Adjusted Mean Change (SE)	23.24 (4.98)	18.13 (4.86)	5.12 [-8.51; 18.74]	0.459

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

46.3 SF-36 Physical Functioning - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.973				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	66.88 (23.37)	72.69 (26.19)		
Week 52 Mean (SD)	81.56 (21.11)	76.11 (27.70)		
Week 4 Adjusted Mean Change (SE)	12.14 (4.28)	8.67 (4.81)		
Week 12 Adjusted Mean Change (SE)	14.51 (5.65)	17.86 (6.27)		
Week 16 Adjusted Mean Change (SE)	18.52 (5.58)	18.08 (6.28)		
Week 24 Adjusted Mean Change (SE)	14.33 (5.94)	13.05 (6.80)		
Week 32 Adjusted Mean Change (SE)	17.41 (6.18)	17.49 (7.21)		
Week 40 Adjusted Mean Change (SE)	23.90 (6.07)	16.88 (7.27)		
Week 52 Adjusted Mean Change (SE)	22.33 (6.47)	16.24 (7.86)	6.09 [-12.67; 24.85]	0.521
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	47		
Baseline Mean (SD)	33.60 (21.85)	35.20 (22.10)		
Week 52 Mean (SD)	59.04 (30.05)	61.92 (29.21)		
Week 4 Adjusted Mean Change (SE)	10.86 (2.31)	11.71 (2.36)		
Week 12 Adjusted Mean Change (SE)	18.11 (3.02)	16.01 (3.09)		
Week 16 Adjusted Mean Change (SE)	19.35 (3.02)	15.15 (3.12)		
Week 24 Adjusted Mean Change (SE)	21.90 (3.19)	19.29 (3.32)		
Week 32 Adjusted Mean Change (SE)	22.68 (3.35)	22.03 (3.45)		
Week 40 Adjusted Mean Change (SE)	23.43 (3.27)	19.83 (3.42)		
Week 52 Adjusted Mean Change (SE)	23.18 (3.53)	22.44 (3.71)	0.74 [-9.19; 10.68]	0.883

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

46.4 SF-36 Physical Functioning - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.170				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	31		
Baseline Mean (SD)	42.68 (24.48)	39.53 (27.51)		
Week 52 Mean (SD)	60.58 (28.65)	66.30 (28.97)		
Week 4 Adjusted Mean Change (SE)	10.02 (2.98)	13.22 (2.84)		
Week 12 Adjusted Mean Change (SE)	15.77 (3.89)	18.59 (3.70)		
Week 16 Adjusted Mean Change (SE)	13.80 (3.83)	18.15 (3.70)		
Week 24 Adjusted Mean Change (SE)	17.78 (4.17)	18.81 (4.05)		
Week 32 Adjusted Mean Change (SE)	18.38 (4.34)	22.88 (4.22)		
Week 40 Adjusted Mean Change (SE)	18.59 (4.22)	19.39 (4.26)		
Week 52 Adjusted Mean Change (SE)	19.40 (4.57)	23.99 (4.61)	-4.58 [-17.43; 8.27]	0.481
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	40.92 (27.90)	46.83 (27.43)		
Week 52 Mean (SD)	67.70 (30.27)	63.00 (29.89)		
Week 4 Adjusted Mean Change (SE)	12.02 (2.56)	8.74 (2.94)		
Week 12 Adjusted Mean Change (SE)	18.26 (3.37)	14.09 (3.86)		
Week 16 Adjusted Mean Change (SE)	23.21 (3.30)	13.40 (3.80)		
Week 24 Adjusted Mean Change (SE)	21.81 (3.57)	17.24 (4.20)		
Week 32 Adjusted Mean Change (SE)	23.57 (3.73)	19.36 (4.34)		
Week 40 Adjusted Mean Change (SE)	27.13 (3.61)	18.93 (4.25)		
Week 52 Adjusted Mean Change (SE)	25.55 (3.88)	18.54 (4.60)	7.02 [-4.92; 18.96]	0.247

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

46.5 SF-36 Physical Functioning - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.302				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	41.63 (24.35)	45.86 (28.91)		
Week 52 Mean (SD)	67.24 (29.36)	68.57 (29.07)		
Week 4 Adjusted Mean Change (SE)	12.63 (2.50)	11.51 (2.95)		
Week 12 Adjusted Mean Change (SE)	19.86 (3.28)	14.83 (3.82)		
Week 16 Adjusted Mean Change (SE)	21.46 (3.26)	17.62 (3.89)		
Week 24 Adjusted Mean Change (SE)	23.47 (3.45)	19.09 (4.21)		
Week 32 Adjusted Mean Change (SE)	21.37 (3.65)	18.81 (4.39)		
Week 40 Adjusted Mean Change (SE)	27.80 (3.51)	18.38 (4.38)		
Week 52 Adjusted Mean Change (SE)	24.42 (3.85)	18.61 (4.86)	5.80 [-6.48; 18.08]	0.352
> Median, N	**26**	**33**		
N'	26	31		
Baseline Mean (SD)	41.73 (29.60)	40.61 (26.39)		
Week 52 Mean (SD)	61.00 (30.14)	61.48 (29.44)		
Week 4 Adjusted Mean Change (SE)	8.91 (3.10)	10.63 (2.85)		
Week 12 Adjusted Mean Change (SE)	13.31 (4.02)	17.97 (3.72)		
Week 16 Adjusted Mean Change (SE)	15.62 (4.03)	14.27 (3.72)		
Week 24 Adjusted Mean Change (SE)	14.68 (4.30)	17.07 (4.00)		
Week 32 Adjusted Mean Change (SE)	21.16 (4.48)	23.25 (4.18)		
Week 40 Adjusted Mean Change (SE)	17.09 (4.32)	20.17 (4.08)		
Week 52 Adjusted Mean Change (SE)	20.79 (4.75)	23.51 (4.48)	-2.73 [-15.67; 10.22]	0.677

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

46.6 SF-36 Physical Functioning - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.095				
Enthesitis: No, N	**34**	**22**		
N'	34	21		
Baseline Mean (SD)	46.47 (28.35)	44.77 (26.79)		
Week 52 Mean (SD)	68.44 (30.12)	70.56 (29.15)		
Week 4 Adjusted Mean Change (SE)	11.84 (2.69)	16.96 (3.43)		
Week 12 Adjusted Mean Change (SE)	20.25 (3.51)	22.84 (4.48)		
Week 16 Adjusted Mean Change (SE)	18.29 (3.44)	25.89 (4.41)		
Week 24 Adjusted Mean Change (SE)	16.96 (3.74)	23.87 (4.77)		
Week 32 Adjusted Mean Change (SE)	19.58 (3.94)	26.33 (4.99)		
Week 40 Adjusted Mean Change (SE)	24.16 (3.84)	27.01 (4.93)		
Week 52 Adjusted Mean Change (SE)	24.47 (4.12)	30.00 (5.33)	-5.53 [-18.83; 7.78]	0.412
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	36.56 (23.33)	42.13 (28.17)		
Week 52 Mean (SD)	60.97 (29.02)	61.00 (29.11)		
Week 4 Adjusted Mean Change (SE)	10.45 (2.78)	7.91 (2.50)		
Week 12 Adjusted Mean Change (SE)	14.12 (3.62)	12.99 (3.24)		
Week 16 Adjusted Mean Change (SE)	20.12 (3.57)	10.43 (3.23)		
Week 24 Adjusted Mean Change (SE)	23.35 (3.85)	15.12 (3.59)		
Week 32 Adjusted Mean Change (SE)	23.29 (4.05)	18.61 (3.77)		
Week 40 Adjusted Mean Change (SE)	22.88 (3.92)	15.06 (3.76)		
Week 52 Adjusted Mean Change (SE)	21.43 (4.22)	16.50 (4.05)	4.93 [-6.64; 16.50]	0.400

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

46.7 SF-36 Physical Functioning - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.653				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	36.21 (26.58)	46.60 (24.91)		
Week 52 Mean (SD)	60.00 (30.12)	70.48 (29.32)		
Week 4 Adjusted Mean Change (SE)	12.66 (2.99)	15.81 (3.22)		
Week 12 Adjusted Mean Change (SE)	19.11 (3.97)	18.68 (4.30)		
Week 16 Adjusted Mean Change (SE)	20.55 (3.83)	19.17 (4.18)		
Week 24 Adjusted Mean Change (SE)	23.70 (4.10)	22.77 (4.48)		
Week 32 Adjusted Mean Change (SE)	25.75 (4.15)	26.87 (4.54)		
Week 40 Adjusted Mean Change (SE)	23.43 (4.13)	25.65 (4.53)		
Week 52 Adjusted Mean Change (SE)	23.64 (4.49)	29.69 (4.97)	-6.06 [-19.41; 7.30]	0.370
Carrier, N	**22**	**19**		
N'	22	18		
Baseline Mean (SD)	42.96 (24.48)	43.16 (33.67)		
Week 52 Mean (SD)	67.75 (30.71)	64.06 (31.95)		
Week 4 Adjusted Mean Change (SE)	11.32 (3.41)	11.04 (3.78)		
Week 12 Adjusted Mean Change (SE)	19.07 (4.57)	16.19 (5.01)		
Week 16 Adjusted Mean Change (SE)	19.57 (4.41)	17.55 (4.84)		
Week 24 Adjusted Mean Change (SE)	16.32 (4.69)	16.58 (5.23)		
Week 32 Adjusted Mean Change (SE)	16.15 (4.81)	19.60 (5.31)		
Week 40 Adjusted Mean Change (SE)	22.67 (4.76)	17.44 (5.43)		
Week 52 Adjusted Mean Change (SE)	23.32 (5.19)	15.93 (5.80)	7.39 [-8.08; 22.86]	0.345

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

46.8 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.546				
Non-carrier, N	**28**	**19**		
N'	28	18		
Baseline Mean (SD)	41.97 (26.68)	41.84 (25.12)		
Week 52 Mean (SD)	64.07 (30.32)	65.38 (28.90)		
Week 4 Adjusted Mean Change (SE)	16.00 (3.01)	14.01 (3.75)		
Week 12 Adjusted Mean Change (SE)	22.52 (4.11)	18.90 (5.12)		
Week 16 Adjusted Mean Change (SE)	23.00 (3.99)	17.76 (5.02)		
Week 24 Adjusted Mean Change (SE)	23.35 (4.31)	19.96 (5.50)		
Week 32 Adjusted Mean Change (SE)	23.25 (4.38)	26.88 (5.60)		
Week 40 Adjusted Mean Change (SE)	23.07 (4.34)	22.26 (5.62)		
Week 52 Adjusted Mean Change (SE)	22.30 (4.75)	26.59 (6.30)	-4.29 [-19.99; 11.40]	0.588
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	34.09 (23.89)	45.79 (30.33)		
Week 52 Mean (SD)	60.25 (30.50)	70.55 (30.38)		
Week 4 Adjusted Mean Change (SE)	6.73 (3.42)	16.42 (3.67)		
Week 12 Adjusted Mean Change (SE)	15.05 (4.71)	17.53 (5.06)		
Week 16 Adjusted Mean Change (SE)	16.79 (4.56)	20.50 (4.90)		
Week 24 Adjusted Mean Change (SE)	16.53 (4.93)	23.46 (5.33)		
Week 32 Adjusted Mean Change (SE)	19.61 (5.00)	23.90 (5.39)		
Week 40 Adjusted Mean Change (SE)	23.73 (4.89)	23.68 (5.37)		
Week 52 Adjusted Mean Change (SE)	25.09 (5.43)	25.51 (5.82)	-0.42 [-16.38; 15.54]	0.958

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

46.9 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.501				
Non-carrier, N	**19**	**21**		
N'	19	20		
Baseline Mean (SD)	36.05 (28.99)	45.95 (29.69)		
Week 52 Mean (SD)	60.00 (29.15)	71.33 (32.54)		
Week 4 Adjusted Mean Change (SE)	8.73 (3.68)	15.69 (3.60)		
Week 12 Adjusted Mean Change (SE)	19.37 (4.82)	19.50 (4.76)		
Week 16 Adjusted Mean Change (SE)	19.39 (4.73)	20.17 (4.66)		
Week 24 Adjusted Mean Change (SE)	18.92 (5.15)	21.67 (5.12)		
Week 32 Adjusted Mean Change (SE)	24.47 (5.18)	22.74 (5.19)		
Week 40 Adjusted Mean Change (SE)	20.80 (5.09)	24.44 (5.18)		
Week 52 Adjusted Mean Change (SE)	22.72 (5.55)	25.78 (5.79)	-3.06 [-19.08; 12.95]	0.704
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	39.33 (22.35)	44.35 (28.42)		
Week 52 Mean (SD)	64.29 (31.38)	65.23 (29.05)		
Week 4 Adjusted Mean Change (SE)	14.94 (2.91)	12.36 (3.34)		
Week 12 Adjusted Mean Change (SE)	20.99 (3.85)	16.16 (4.37)		
Week 16 Adjusted Mean Change (SE)	21.72 (3.75)	17.25 (4.32)		
Week 24 Adjusted Mean Change (SE)	22.61 (4.06)	18.99 (4.68)		
Week 32 Adjusted Mean Change (SE)	21.47 (4.15)	24.79 (4.75)		
Week 40 Adjusted Mean Change (SE)	26.12 (4.07)	20.62 (4.71)		
Week 52 Adjusted Mean Change (SE)	25.41 (4.47)	22.64 (5.10)	2.77 [-10.73; 16.26]	0.684

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

46.10 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.030				
Non-carrier, N	25	32		
N'	25	32		
Baseline Mean (SD)	35.60 (25.38)	47.50 (29.38)		
Week 52 Mean (SD)	63.04 (33.94)	63.39 (31.83)		
Week 4 Adjusted Mean Change (SE)	16.65 (3.16)	12.08 (2.78)		
Week 12 Adjusted Mean Change (SE)	20.85 (4.30)	15.94 (3.79)		
Week 16 Adjusted Mean Change (SE)	23.21 (4.05)	14.66 (3.57)		
Week 24 Adjusted Mean Change (SE)	23.62 (4.32)	15.08 (3.89)		
Week 32 Adjusted Mean Change (SE)	22.88 (4.52)	19.83 (4.04)		
Week 40 Adjusted Mean Change (SE)	24.13 (4.44)	19.37 (4.04)		
Week 52 Adjusted Mean Change (SE)	25.74 (4.83)	19.38 (4.34)	6.35 [-6.64; 19.34]	0.334
Carrier, N	26	12		
N'	26	11		
Baseline Mean (SD)	42.50 (25.97)	38.75 (26.98)		
Week 52 Mean (SD)	63.40 (27.22)	81.11 (20.58)		
Week 4 Adjusted Mean Change (SE)	7.77 (3.08)	18.58 (4.71)		
Week 12 Adjusted Mean Change (SE)	17.43 (4.16)	22.63 (6.38)		
Week 16 Adjusted Mean Change (SE)	17.22 (3.92)	29.59 (6.12)		
Week 24 Adjusted Mean Change (SE)	17.59 (4.22)	34.03 (6.45)		
Week 32 Adjusted Mean Change (SE)	20.61 (4.38)	34.88 (6.70)		
Week 40 Adjusted Mean Change (SE)	22.12 (4.36)	30.20 (6.77)		
Week 52 Adjusted Mean Change (SE)	21.35 (4.69)	36.75 (7.41)	-15.40 [-32.83; 2.03]	0.083

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

46.11 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.667				
Non-carrier, N	**38**	**33**		
N'	38	32		
Baseline Mean (SD)	37.63 (25.80)	46.67 (28.88)		
Week 52 Mean (SD)	61.00 (29.67)	70.96 (26.57)		
Week 4 Adjusted Mean Change (SE)	13.09 (2.66)	14.26 (2.88)		
Week 12 Adjusted Mean Change (SE)	17.58 (3.50)	17.61 (3.78)		
Week 16 Adjusted Mean Change (SE)	19.78 (3.40)	18.62 (3.70)		
Week 24 Adjusted Mean Change (SE)	21.88 (3.62)	20.51 (4.00)		
Week 32 Adjusted Mean Change (SE)	21.37 (3.74)	24.96 (4.11)		
Week 40 Adjusted Mean Change (SE)	23.31 (3.63)	22.21 (4.05)		
Week 52 Adjusted Mean Change (SE)	22.35 (3.96)	25.92 (4.45)	-3.57 [-15.48; 8.34]	0.553
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	41.67 (26.05)	48.89 (24.72)		
Week 52 Mean (SD)	67.50 (33.13)	72.78 (27.85)		
Week 4 Adjusted Mean Change (SE)	9.11 (4.76)	14.80 (5.42)		
Week 12 Adjusted Mean Change (SE)	21.98 (6.20)	22.27 (7.29)		
Week 16 Adjusted Mean Change (SE)	19.49 (6.03)	21.93 (7.05)		
Week 24 Adjusted Mean Change (SE)	14.62 (6.49)	24.78 (7.47)		
Week 32 Adjusted Mean Change (SE)	20.71 (6.58)	26.06 (7.56)		
Week 40 Adjusted Mean Change (SE)	21.91 (6.42)	28.37 (7.37)		
Week 52 Adjusted Mean Change (SE)	24.41 (6.94)	26.15 (7.97)	-1.74 [-22.77; 19.30]	0.870

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

46.12 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.997				
Non-carrier, N	**36**	**34**		
N'	36	33		
Baseline Mean (SD)	39.03 (28.46)	47.65 (30.23)		
Week 52 Mean (SD)	61.67 (29.57)	69.63 (31.35)		
Week 4 Adjusted Mean Change (SE)	10.53 (2.65)	14.05 (2.81)		
Week 12 Adjusted Mean Change (SE)	18.63 (3.55)	16.57 (3.77)		
Week 16 Adjusted Mean Change (SE)	20.06 (3.46)	17.66 (3.68)		
Week 24 Adjusted Mean Change (SE)	18.19 (3.67)	18.49 (3.93)		
Week 32 Adjusted Mean Change (SE)	20.84 (3.77)	22.68 (4.03)		
Week 40 Adjusted Mean Change (SE)	20.94 (3.72)	23.12 (4.02)		
Week 52 Adjusted Mean Change (SE)	21.88 (4.09)	24.01 (4.44)	-2.13 [-14.21; 9.94]	0.726
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	40.77 (18.13)	36.50 (21.86)		
Week 52 Mean (SD)	64.61 (33.75)	62.50 (27.81)		
Week 4 Adjusted Mean Change (SE)	14.84 (4.41)	12.97 (5.09)		
Week 12 Adjusted Mean Change (SE)	17.88 (5.90)	20.81 (6.78)		
Week 16 Adjusted Mean Change (SE)	19.81 (5.73)	21.33 (6.59)		
Week 24 Adjusted Mean Change (SE)	22.55 (6.08)	25.05 (6.98)		
Week 32 Adjusted Mean Change (SE)	20.16 (6.22)	27.16 (7.14)		
Week 40 Adjusted Mean Change (SE)	25.03 (6.14)	19.01 (7.16)		
Week 52 Adjusted Mean Change (SE)	23.90 (6.69)	23.18 (7.68)	0.72 [-19.59; 21.04]	0.944

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

46.13 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.083				
Non-carrier, N	**42**	**36**		
N'	42	35		
Baseline Mean (SD)	42.74 (24.12)	42.50 (28.07)		
Week 52 Mean (SD)	64.49 (29.49)	67.58 (30.46)		
Week 4 Adjusted Mean Change (SE)	11.07 (2.47)	15.69 (2.70)		
Week 12 Adjusted Mean Change (SE)	18.26 (3.24)	18.85 (3.55)		
Week 16 Adjusted Mean Change (SE)	18.69 (3.13)	19.05 (3.45)		
Week 24 Adjusted Mean Change (SE)	19.31 (3.39)	21.48 (3.77)		
Week 32 Adjusted Mean Change (SE)	21.54 (3.48)	25.50 (3.86)		
Week 40 Adjusted Mean Change (SE)	22.97 (3.38)	24.34 (3.82)		
Week 52 Adjusted Mean Change (SE)	22.29 (3.73)	25.70 (4.21)	-3.42 [-14.60; 7.77]	0.545
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	22.22 (27.28)	62.00 (34.02)		
Week 52 Mean (SD)	57.78 (34.92)	67.00 (24.13)		
Week 4 Adjusted Mean Change (SE)	17.41 (5.49)	3.64 (7.26)		
Week 12 Adjusted Mean Change (SE)	23.51 (7.16)	4.84 (9.49)		
Week 16 Adjusted Mean Change (SE)	27.38 (6.92)	5.27 (9.17)		
Week 24 Adjusted Mean Change (SE)	26.59 (7.51)	7.92 (9.95)		
Week 32 Adjusted Mean Change (SE)	23.25 (7.66)	12.71 (10.15)		
Week 40 Adjusted Mean Change (SE)	24.25 (7.48)	7.62 (9.90)		
Week 52 Adjusted Mean Change (SE)	29.24 (8.17)	11.03 (10.83)	18.21 [-9.37; 45.80]	0.192

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

46.14 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.753				
Low score, N	11	22		
N'	11	21		
Baseline Mean (SD)	50.91 (33.00)	47.05 (30.89)		
Week 52 Mean (SD)	61.50 (34.32)	64.33 (35.75)		
Week 4 Adjusted Mean Change (SE)	6.88 (4.84)	12.17 (3.53)		
Week 12 Adjusted Mean Change (SE)	10.43 (6.37)	15.53 (4.63)		
Week 16 Adjusted Mean Change (SE)	13.77 (6.25)	14.11 (4.50)		
Week 24 Adjusted Mean Change (SE)	16.03 (6.63)	13.99 (4.94)		
Week 32 Adjusted Mean Change (SE)	16.68 (6.80)	19.19 (5.11)		
Week 40 Adjusted Mean Change (SE)	14.34 (6.65)	18.96 (5.09)		
Week 52 Adjusted Mean Change (SE)	10.07 (7.30)	20.30 (5.63)	-10.23 [-28.45; 8.00]	0.268
High score, N	40	22		
N'	40	22		
Baseline Mean (SD)	35.88 (22.70)	43.18 (26.93)		
Week 52 Mean (SD)	63.68 (29.63)	70.00 (26.46)		
Week 4 Adjusted Mean Change (SE)	13.56 (2.54)	15.26 (3.41)		
Week 12 Adjusted Mean Change (SE)	21.56 (3.37)	19.44 (4.53)		
Week 16 Adjusted Mean Change (SE)	21.88 (3.23)	22.60 (4.36)		
Week 24 Adjusted Mean Change (SE)	21.78 (3.50)	25.62 (4.68)		
Week 32 Adjusted Mean Change (SE)	23.14 (3.61)	27.87 (4.78)		
Week 40 Adjusted Mean Change (SE)	25.57 (3.52)	25.02 (4.71)		
Week 52 Adjusted Mean Change (SE)	27.17 (3.82)	26.82 (5.06)	0.35 [-12.29; 12.99]	0.956

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

46.15 SF-36 Physical Functioning - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.729				
Non-carrier, N	**31**	**23**		
N'	31	22		
Baseline Mean (SD)	41.45 (26.46)	43.26 (26.22)		
Week 52 Mean (SD)	63.33 (30.55)	65.88 (28.68)		
Week 4 Adjusted Mean Change (SE)	15.45 (2.84)	12.65 (3.37)		
Week 12 Adjusted Mean Change (SE)	21.57 (3.79)	19.14 (4.50)		
Week 16 Adjusted Mean Change (SE)	22.38 (3.67)	17.10 (4.38)		
Week 24 Adjusted Mean Change (SE)	21.90 (3.98)	19.20 (4.80)		
Week 32 Adjusted Mean Change (SE)	22.38 (4.07)	26.20 (4.92)		
Week 40 Adjusted Mean Change (SE)	22.88 (4.02)	22.80 (4.91)		
Week 52 Adjusted Mean Change (SE)	21.88 (4.39)	24.80 (5.45)	-2.92 [-16.84; 11.00]	0.678
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	35.50 (24.60)	47.14 (31.72)		
Week 52 Mean (SD)	63.06 (30.73)	69.25 (32.13)		
Week 4 Adjusted Mean Change (SE)	6.80 (3.56)	15.13 (3.46)		
Week 12 Adjusted Mean Change (SE)	15.13 (4.80)	16.08 (4.67)		
Week 16 Adjusted Mean Change (SE)	16.49 (4.63)	20.14 (4.51)		
Week 24 Adjusted Mean Change (SE)	18.34 (5.01)	21.34 (4.92)		
Week 32 Adjusted Mean Change (SE)	20.58 (5.13)	21.52 (5.00)		
Week 40 Adjusted Mean Change (SE)	23.28 (5.00)	21.65 (4.98)		
Week 52 Adjusted Mean Change (SE)	26.17 (5.54)	22.98 (5.38)	3.19 [-12.27; 18.64]	0.682

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

46.16 SF-36 Physical Functioning - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.404				
Non-carrier, N	**19**	**20**		
N'	19	19		
Baseline Mean (SD)	36.05 (28.99)	47.00 (30.06)		
Week 52 Mean (SD)	60.00 (29.15)	72.86 (33.21)		
Week 4 Adjusted Mean Change (SE)	8.61 (3.66)	17.03 (3.67)		
Week 12 Adjusted Mean Change (SE)	19.15 (4.87)	21.71 (4.94)		
Week 16 Adjusted Mean Change (SE)	19.20 (4.71)	22.33 (4.76)		
Week 24 Adjusted Mean Change (SE)	18.72 (5.12)	24.00 (5.23)		
Week 32 Adjusted Mean Change (SE)	24.30 (5.22)	23.27 (5.37)		
Week 40 Adjusted Mean Change (SE)	20.52 (5.09)	25.54 (5.32)		
Week 52 Adjusted Mean Change (SE)	22.50 (5.58)	25.49 (5.98)	-2.98 [-19.32; 13.35]	0.717
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	40.94 (23.78)	43.54 (28.07)		
Week 52 Mean (SD)	65.34 (31.34)	64.56 (28.56)		
Week 4 Adjusted Mean Change (SE)	14.10 (2.81)	11.34 (3.24)		
Week 12 Adjusted Mean Change (SE)	19.00 (3.76)	14.55 (4.31)		
Week 16 Adjusted Mean Change (SE)	20.59 (3.63)	15.60 (4.20)		
Week 24 Adjusted Mean Change (SE)	21.44 (3.90)	17.28 (4.54)		
Week 32 Adjusted Mean Change (SE)	19.93 (4.04)	24.06 (4.67)		
Week 40 Adjusted Mean Change (SE)	24.58 (3.93)	19.73 (4.59)		
Week 52 Adjusted Mean Change (SE)	23.98 (4.36)	22.54 (5.00)	1.44 [-11.75; 14.64]	0.828

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

46.17 SF-36 Physical Functioning - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.030				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	35.60 (25.38)	47.50 (29.38)		
Week 52 Mean (SD)	63.04 (33.94)	63.39 (31.83)		
Week 4 Adjusted Mean Change (SE)	16.65 (3.16)	12.08 (2.78)		
Week 12 Adjusted Mean Change (SE)	20.85 (4.30)	15.94 (3.79)		
Week 16 Adjusted Mean Change (SE)	23.21 (4.05)	14.66 (3.57)		
Week 24 Adjusted Mean Change (SE)	23.62 (4.32)	15.08 (3.89)		
Week 32 Adjusted Mean Change (SE)	22.88 (4.52)	19.83 (4.04)		
Week 40 Adjusted Mean Change (SE)	24.13 (4.44)	19.37 (4.04)		
Week 52 Adjusted Mean Change (SE)	25.74 (4.83)	19.38 (4.34)	6.35 [-6.64; 19.34]	0.334
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	42.50 (25.97)	38.75 (26.98)		
Week 52 Mean (SD)	63.40 (27.22)	81.11 (20.58)		
Week 4 Adjusted Mean Change (SE)	7.77 (3.08)	18.58 (4.71)		
Week 12 Adjusted Mean Change (SE)	17.43 (4.16)	22.63 (6.38)		
Week 16 Adjusted Mean Change (SE)	17.22 (3.92)	29.59 (6.12)		
Week 24 Adjusted Mean Change (SE)	17.59 (4.22)	34.03 (6.45)		
Week 32 Adjusted Mean Change (SE)	20.61 (4.38)	34.88 (6.70)		
Week 40 Adjusted Mean Change (SE)	22.12 (4.36)	30.20 (6.77)		
Week 52 Adjusted Mean Change (SE)	21.35 (4.69)	36.75 (7.41)	-15.40 [-32.83; 2.03]	0.083

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

46.18 SF-36 Physical Functioning - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.726				
Non-carrier, N	**39**	**35**		
N'	39	34		
Baseline Mean (SD)	38.33 (25.84)	45.43 (29.11)		
Week 52 Mean (SD)	61.81 (29.64)	68.39 (28.87)		
Week 4 Adjusted Mean Change (SE)	12.92 (2.59)	13.86 (2.76)		
Week 12 Adjusted Mean Change (SE)	18.16 (3.43)	16.62 (3.68)		
Week 16 Adjusted Mean Change (SE)	20.23 (3.31)	17.69 (3.55)		
Week 24 Adjusted Mean Change (SE)	22.12 (3.56)	19.11 (3.88)		
Week 32 Adjusted Mean Change (SE)	21.87 (3.69)	23.18 (3.99)		
Week 40 Adjusted Mean Change (SE)	23.28 (3.58)	21.04 (3.92)		
Week 52 Adjusted Mean Change (SE)	22.97 (3.96)	24.44 (4.36)	-1.47 [-13.22; 10.28]	0.804
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	42.73 (27.05)	43.89 (28.70)		
Week 52 Mean (SD)	69.55 (33.95)	65.55 (35.92)		
Week 4 Adjusted Mean Change (SE)	10.81 (4.90)	13.43 (5.34)		
Week 12 Adjusted Mean Change (SE)	20.40 (6.44)	21.30 (7.07)		
Week 16 Adjusted Mean Change (SE)	17.66 (6.23)	21.48 (6.96)		
Week 24 Adjusted Mean Change (SE)	16.03 (6.77)	23.44 (7.37)		
Week 32 Adjusted Mean Change (SE)	21.80 (6.90)	25.81 (7.58)		
Week 40 Adjusted Mean Change (SE)	24.17 (6.71)	26.44 (7.50)		
Week 52 Adjusted Mean Change (SE)	25.96 (7.36)	22.09 (8.09)	3.87 [-17.87; 25.62]	0.724

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

47.0 SF-36 Role Emotional - Return Rates (FAS)

	Treatment Groups		
	SEC **(N=66)**	**ADA** **(N=62)**	**Total** **(N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	57 (91.9)	122 (95.3)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	48 (77.4)	111 (86.7)

47.1 SF-36 Role Emotional - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	60		
Baseline Mean (SD)	61.24 (29.69)	60.89 (26.98)		
Week 52 Mean (SD)	79.50 (24.49)	75.17 (28.94)		
Week 4 Adjusted Mean Change (SE)	10.84 (2.44)	12.64 (2.55)		
Week 12 Adjusted Mean Change (SE)	13.63 (2.32)	11.94 (2.42)		
Week 16 Adjusted Mean Change (SE)	15.44 (2.34)	10.82 (2.49)		
Week 24 Adjusted Mean Change (SE)	15.21 (2.65)	12.44 (2.88)		
Week 32 Adjusted Mean Change (SE)	17.34 (2.64)	12.17 (2.83)		
Week 40 Adjusted Mean Change (SE)	16.53 (2.72)	11.70 (3.04)		
Week 52 Adjusted Mean Change (SE)	18.76 (2.80)	15.73 (3.15)	3.03 [-5.31; 11.37]	0.473

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

47.2 SF-36 Role Emotional - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.681				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	64.88 (29.82)	67.93 (23.95)		
Week 52 Mean (SD)	83.75 (24.09)	75.64 (29.99)		
Week 4 Adjusted Mean Change (SE)	12.36 (3.10)	13.11 (3.56)		
Week 12 Adjusted Mean Change (SE)	14.39 (2.94)	12.45 (3.35)		
Week 16 Adjusted Mean Change (SE)	15.89 (2.98)	12.24 (3.40)		
Week 24 Adjusted Mean Change (SE)	15.74 (3.35)	10.83 (3.97)		
Week 32 Adjusted Mean Change (SE)	16.90 (3.36)	11.78 (3.94)		
Week 40 Adjusted Mean Change (SE)	15.59 (3.49)	11.48 (4.18)		
Week 52 Adjusted Mean Change (SE)	20.67 (3.53)	12.78 (4.30)	7.90 [-3.07; 18.87]	0.157
Female, N	**24**	**29**		
N'	24	28		
Baseline Mean (SD)	54.86 (28.96)	52.87 (28.37)		
Week 52 Mean (SD)	72.10 (23.92)	74.62 (28.34)		
Week 4 Adjusted Mean Change (SE)	8.20 (4.11)	12.13 (3.79)		
Week 12 Adjusted Mean Change (SE)	12.33 (3.94)	11.35 (3.62)		
Week 16 Adjusted Mean Change (SE)	14.66 (3.93)	9.02 (3.77)		
Week 24 Adjusted Mean Change (SE)	14.30 (4.50)	14.37 (4.31)		
Week 32 Adjusted Mean Change (SE)	18.11 (4.48)	12.65 (4.19)		
Week 40 Adjusted Mean Change (SE)	18.06 (4.56)	11.88 (4.56)		
Week 52 Adjusted Mean Change (SE)	15.45 (4.68)	19.23 (4.69)	-3.78 [-16.76; 9.21]	0.566

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

47.3 SF-36 Role Emotional - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.314				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	79.69 (20.85)	75.64 (25.11)		
Week 52 Mean (SD)	90.10 (16.45)	79.63 (22.86)		
Week 4 Adjusted Mean Change (SE)	16.55 (5.11)	12.49 (5.58)		
Week 12 Adjusted Mean Change (SE)	12.55 (4.95)	14.26 (5.28)		
Week 16 Adjusted Mean Change (SE)	13.71 (4.92)	8.46 (5.37)		
Week 24 Adjusted Mean Change (SE)	20.10 (5.59)	5.05 (6.32)		
Week 32 Adjusted Mean Change (SE)	17.46 (5.52)	5.43 (6.44)		
Week 40 Adjusted Mean Change (SE)	22.62 (5.72)	2.99 (6.89)		
Week 52 Adjusted Mean Change (SE)	19.84 (5.84)	16.77 (7.25)	3.07 [-15.18; 21.32]	0.740
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	47		
Baseline Mean (SD)	55.33 (29.82)	56.97 (26.32)		
Week 52 Mean (SD)	75.89 (25.85)	74.15 (30.34)		
Week 4 Adjusted Mean Change (SE)	9.03 (2.83)	12.71 (2.90)		
Week 12 Adjusted Mean Change (SE)	13.98 (2.70)	11.28 (2.76)		
Week 16 Adjusted Mean Change (SE)	16.02 (2.74)	11.47 (2.85)		
Week 24 Adjusted Mean Change (SE)	13.71 (3.04)	14.35 (3.23)		
Week 32 Adjusted Mean Change (SE)	17.35 (3.07)	13.81 (3.16)		
Week 40 Adjusted Mean Change (SE)	14.65 (3.13)	13.86 (3.36)		
Week 52 Adjusted Mean Change (SE)	18.46 (3.30)	15.56 (3.54)	2.89 [-6.63; 12.42]	0.549

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

47.4 SF-36 Role Emotional - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.385				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	31		
Baseline Mean (SD)	65.18 (28.51)	58.85 (28.55)		
Week 52 Mean (SD)	77.89 (25.49)	76.81 (25.99)		
Week 4 Adjusted Mean Change (SE)	7.92 (3.75)	10.79 (3.57)		
Week 12 Adjusted Mean Change (SE)	10.22 (3.53)	12.89 (3.35)		
Week 16 Adjusted Mean Change (SE)	10.97 (3.55)	8.24 (3.45)		
Week 24 Adjusted Mean Change (SE)	12.62 (4.10)	14.39 (4.00)		
Week 32 Adjusted Mean Change (SE)	14.17 (4.07)	10.45 (3.97)		
Week 40 Adjusted Mean Change (SE)	14.09 (4.23)	8.67 (4.37)		
Week 52 Adjusted Mean Change (SE)	14.99 (4.35)	19.10 (4.51)	-4.12 [-16.55; 8.32]	0.513
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	58.33 (30.57)	63.06 (25.49)		
Week 52 Mean (SD)	80.63 (24.06)	73.67 (31.89)		
Week 4 Adjusted Mean Change (SE)	12.99 (3.22)	14.62 (3.69)		
Week 12 Adjusted Mean Change (SE)	16.18 (3.09)	10.83 (3.51)		
Week 16 Adjusted Mean Change (SE)	18.80 (3.08)	13.46 (3.53)		
Week 24 Adjusted Mean Change (SE)	17.14 (3.49)	10.14 (4.18)		
Week 32 Adjusted Mean Change (SE)	19.68 (3.50)	13.90 (4.07)		
Week 40 Adjusted Mean Change (SE)	18.31 (3.61)	14.28 (4.28)		
Week 52 Adjusted Mean Change (SE)	21.47 (3.67)	12.70 (4.41)	8.77 [-2.61; 20.15]	0.130

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

47.5 SF-36 Role Emotional - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.681				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	58.13 (25.98)	68.97 (26.53)		
Week 52 Mean (SD)	82.02 (21.00)	83.33 (22.20)		
Week 4 Adjusted Mean Change (SE)	13.85 (3.12)	14.75 (3.70)		
Week 12 Adjusted Mean Change (SE)	14.70 (3.02)	14.09 (3.51)		
Week 16 Adjusted Mean Change (SE)	16.49 (3.03)	13.78 (3.65)		
Week 24 Adjusted Mean Change (SE)	18.59 (3.36)	16.46 (4.21)		
Week 32 Adjusted Mean Change (SE)	19.76 (3.43)	11.82 (4.18)		
Week 40 Adjusted Mean Change (SE)	21.15 (3.48)	14.96 (4.48)		
Week 52 Adjusted Mean Change (SE)	22.47 (3.59)	18.61 (4.73)	3.86 [-7.96; 15.68]	0.519
> Median, N	**26**	**33**		
N'	26	31		
Baseline Mean (SD)	66.03 (34.63)	53.79 (25.69)		
Week 52 Mean (SD)	75.67 (29.06)	68.83 (32.24)		
Week 4 Adjusted Mean Change (SE)	6.21 (3.88)	10.66 (3.56)		
Week 12 Adjusted Mean Change (SE)	11.96 (3.68)	9.91 (3.42)		
Week 16 Adjusted Mean Change (SE)	13.75 (3.73)	8.11 (3.47)		
Week 24 Adjusted Mean Change (SE)	9.99 (4.22)	8.76 (3.97)		
Week 32 Adjusted Mean Change (SE)	13.60 (4.17)	12.45 (3.95)		
Week 40 Adjusted Mean Change (SE)	9.62 (4.26)	8.95 (4.11)		
Week 52 Adjusted Mean Change (SE)	13.14 (4.43)	13.28 (4.28)	-0.14 [-12.43; 12.15]	0.982

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

47.6 SF-36 Role Emotional - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.309				
Enthesitis: No, N	**34**	**22**		
N'	34	21		
Baseline Mean (SD)	67.40 (29.04)	66.67 (27.70)		
Week 52 Mean (SD)	83.85 (23.47)	85.19 (23.84)		
Week 4 Adjusted Mean Change (SE)	12.71 (3.39)	20.21 (4.32)		
Week 12 Adjusted Mean Change (SE)	14.79 (3.24)	17.70 (4.15)		
Week 16 Adjusted Mean Change (SE)	16.97 (3.27)	15.29 (4.24)		
Week 24 Adjusted Mean Change (SE)	17.31 (3.74)	16.56 (4.78)		
Week 32 Adjusted Mean Change (SE)	19.16 (3.69)	19.17 (4.64)		
Week 40 Adjusted Mean Change (SE)	17.68 (3.86)	16.65 (4.96)		
Week 52 Adjusted Mean Change (SE)	19.63 (3.95)	21.62 (5.17)	-1.99 [-14.81; 10.83]	0.759
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	54.69 (29.40)	57.71 (26.38)		
Week 52 Mean (SD)	75.00 (25.09)	69.17 (30.41)		
Week 4 Adjusted Mean Change (SE)	8.89 (3.49)	8.61 (3.15)		
Week 12 Adjusted Mean Change (SE)	12.43 (3.34)	8.90 (2.97)		
Week 16 Adjusted Mean Change (SE)	13.82 (3.41)	8.44 (3.09)		
Week 24 Adjusted Mean Change (SE)	13.03 (3.82)	10.26 (3.65)		
Week 32 Adjusted Mean Change (SE)	15.43 (3.76)	8.24 (3.56)		
Week 40 Adjusted Mean Change (SE)	15.32 (3.91)	8.91 (3.88)		
Week 52 Adjusted Mean Change (SE)	17.87 (4.03)	12.42 (4.00)	5.45 [-5.72; 16.61]	0.336

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

47.7 SF-36 Role Emotional - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.346				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	56.03 (31.09)	64.33 (27.17)		
Week 52 Mean (SD)	73.81 (26.81)	85.71 (26.50)		
Week 4 Adjusted Mean Change (SE)	14.81 (3.60)	15.57 (3.86)		
Week 12 Adjusted Mean Change (SE)	14.16 (3.50)	17.21 (3.82)		
Week 16 Adjusted Mean Change (SE)	14.76 (3.50)	7.20 (3.86)		
Week 24 Adjusted Mean Change (SE)	16.44 (3.97)	18.23 (4.43)		
Week 32 Adjusted Mean Change (SE)	16.25 (3.98)	16.89 (4.40)		
Week 40 Adjusted Mean Change (SE)	15.86 (4.33)	15.36 (4.79)		
Week 52 Adjusted Mean Change (SE)	16.34 (4.04)	26.68 (4.57)	-10.34 [-22.44; 1.76]	0.093
Carrier, N	**22**	**19**		
N'	22	18		
Baseline Mean (SD)	68.56 (24.25)	57.89 (25.53)		
Week 52 Mean (SD)	86.67 (19.38)	65.10 (30.31)		
Week 4 Adjusted Mean Change (SE)	5.48 (4.15)	10.18 (4.54)		
Week 12 Adjusted Mean Change (SE)	10.41 (4.10)	8.69 (4.42)		
Week 16 Adjusted Mean Change (SE)	12.42 (4.08)	13.40 (4.42)		
Week 24 Adjusted Mean Change (SE)	13.76 (4.63)	6.38 (5.12)		
Week 32 Adjusted Mean Change (SE)	19.20 (4.77)	6.31 (5.14)		
Week 40 Adjusted Mean Change (SE)	14.38 (5.06)	10.98 (5.76)		
Week 52 Adjusted Mean Change (SE)	21.32 (4.74)	6.30 (5.27)	15.02 [0.91; 29.13]	0.037

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

47.8 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.965				
Non-carrier, N	28	19		
N'	28	18		
Baseline Mean (SD)	57.74 (24.84)	65.79 (29.38)		
Week 52 Mean (SD)	79.01 (25.57)	80.77 (21.35)		
Week 4 Adjusted Mean Change (SE)	15.57 (3.74)	15.78 (4.70)		
Week 12 Adjusted Mean Change (SE)	13.87 (3.71)	16.35 (4.65)		
Week 16 Adjusted Mean Change (SE)	15.21 (3.65)	11.51 (4.65)		
Week 24 Adjusted Mean Change (SE)	14.26 (3.87)	14.41 (5.01)		
Week 32 Adjusted Mean Change (SE)	18.93 (4.16)	13.78 (5.37)		
Week 40 Adjusted Mean Change (SE)	15.41 (4.53)	14.21 (5.95)		
Week 52 Adjusted Mean Change (SE)	19.29 (4.41)	22.25 (6.08)	-2.96 [-17.91; 12.00]	0.695
Carrier, N	22	19		
N'	22	19		
Baseline Mean (SD)	65.53 (33.66)	56.58 (24.78)		
Week 52 Mean (SD)	79.58 (24.55)	71.76 (36.95)		
Week 4 Adjusted Mean Change (SE)	5.25 (4.23)	11.63 (4.55)		
Week 12 Adjusted Mean Change (SE)	11.54 (4.26)	13.05 (4.60)		
Week 16 Adjusted Mean Change (SE)	12.48 (4.18)	9.93 (4.51)		
Week 24 Adjusted Mean Change (SE)	17.53 (4.42)	13.34 (4.83)		
Week 32 Adjusted Mean Change (SE)	14.84 (4.76)	11.30 (5.09)		
Week 40 Adjusted Mean Change (SE)	15.75 (5.07)	16.22 (5.63)		
Week 52 Adjusted Mean Change (SE)	18.03 (5.06)	13.51 (5.43)	4.52 [-10.27; 19.31]	0.545

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

47.9 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.508				
Non-carrier, N	19	21		
N'	19	20		
Baseline Mean (SD)	54.39 (29.18)	65.48 (29.14)		
Week 52 Mean (SD)	77.19 (27.19)	84.44 (26.14)		
Week 4 Adjusted Mean Change (SE)	14.49 (4.33)	20.28 (4.23)		
Week 12 Adjusted Mean Change (SE)	18.19 (4.22)	16.22 (4.21)		
Week 16 Adjusted Mean Change (SE)	14.88 (4.25)	16.62 (4.22)		
Week 24 Adjusted Mean Change (SE)	18.72 (5.03)	9.84 (5.09)		
Week 32 Adjusted Mean Change (SE)	19.90 (4.96)	19.82 (5.04)		
Week 40 Adjusted Mean Change (SE)	17.27 (5.29)	18.59 (5.46)		
Week 52 Adjusted Mean Change (SE)	20.19 (5.21)	24.13 (5.62)	-3.93 [-19.20; 11.34]	0.610
Carrier, N	30	23		
N'	30	23		
Baseline Mean (SD)	63.33 (27.56)	57.97 (23.63)		
Week 52 Mean (SD)	79.76 (23.29)	71.59 (31.36)		
Week 4 Adjusted Mean Change (SE)	10.33 (3.43)	7.81 (3.92)		
Week 12 Adjusted Mean Change (SE)	10.89 (3.39)	11.70 (3.82)		
Week 16 Adjusted Mean Change (SE)	14.52 (3.37)	4.90 (3.91)		
Week 24 Adjusted Mean Change (SE)	14.28 (3.94)	15.70 (4.57)		
Week 32 Adjusted Mean Change (SE)	15.96 (4.05)	6.83 (4.58)		
Week 40 Adjusted Mean Change (SE)	15.69 (4.24)	9.76 (4.93)		
Week 52 Adjusted Mean Change (SE)	17.90 (4.22)	13.85 (4.82)	4.05 [-8.71; 16.81]	0.530

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

47.10 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.317				
Non-carrier, N	25	32		
N'	25	32		
Baseline Mean (SD)	63.00 (29.86)	59.90 (27.23)		
Week 52 Mean (SD)	77.54 (26.28)	74.70 (31.30)		
Week 4 Adjusted Mean Change (SE)	13.81 (3.92)	12.59 (3.45)		
Week 12 Adjusted Mean Change (SE)	11.05 (3.84)	11.67 (3.37)		
Week 16 Adjusted Mean Change (SE)	11.65 (3.73)	6.11 (3.28)		
Week 24 Adjusted Mean Change (SE)	14.42 (4.12)	7.25 (3.80)		
Week 32 Adjusted Mean Change (SE)	16.04 (4.45)	12.86 (4.00)		
Week 40 Adjusted Mean Change (SE)	15.39 (4.64)	11.52 (4.29)		
Week 52 Adjusted Mean Change (SE)	17.19 (4.65)	17.30 (4.24)	-0.12 [-12.62; 12.39]	0.985
Carrier, N	26	12		
N'	26	11		
Baseline Mean (SD)	59.94 (28.19)	65.97 (24.48)		
Week 52 Mean (SD)	80.67 (23.41)	83.33 (24.30)		
Week 4 Adjusted Mean Change (SE)	7.90 (3.84)	15.57 (5.92)		
Week 12 Adjusted Mean Change (SE)	13.92 (3.71)	19.13 (5.72)		
Week 16 Adjusted Mean Change (SE)	15.58 (3.61)	21.91 (5.76)		
Week 24 Adjusted Mean Change (SE)	16.18 (4.07)	28.96 (6.23)		
Week 32 Adjusted Mean Change (SE)	18.40 (4.32)	11.75 (6.59)		
Week 40 Adjusted Mean Change (SE)	14.96 (4.60)	18.90 (7.18)		
Week 52 Adjusted Mean Change (SE)	19.46 (4.51)	19.13 (7.29)	0.33 [-16.71; 17.38]	0.969

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

47.11 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.219				
Non-carrier, N	**38**	**33**		
N'	38	32		
Baseline Mean (SD)	61.84 (28.38)	63.64 (24.90)		
Week 52 Mean (SD)	79.76 (22.80)	81.09 (20.76)		
Week 4 Adjusted Mean Change (SE)	10.99 (2.98)	10.95 (3.24)		
Week 12 Adjusted Mean Change (SE)	9.44 (3.01)	13.02 (3.23)		
Week 16 Adjusted Mean Change (SE)	15.57 (3.01)	9.21 (3.27)		
Week 24 Adjusted Mean Change (SE)	16.03 (3.42)	12.70 (3.85)		
Week 32 Adjusted Mean Change (SE)	18.71 (3.55)	12.33 (3.91)		
Week 40 Adjusted Mean Change (SE)	14.57 (3.65)	12.77 (4.12)		
Week 52 Adjusted Mean Change (SE)	18.07 (3.66)	21.54 (4.19)	-3.47 [-14.52; 7.58]	0.534
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	61.11 (32.24)	64.81 (24.22)		
Week 52 Mean (SD)	75.69 (30.46)	78.70 (38.44)		
Week 4 Adjusted Mean Change (SE)	5.38 (5.34)	18.68 (6.09)		
Week 12 Adjusted Mean Change (SE)	17.09 (5.33)	18.16 (6.36)		
Week 16 Adjusted Mean Change (SE)	3.97 (5.33)	13.23 (6.34)		
Week 24 Adjusted Mean Change (SE)	8.49 (6.26)	20.91 (7.23)		
Week 32 Adjusted Mean Change (SE)	8.72 (6.20)	15.31 (7.10)		
Week 40 Adjusted Mean Change (SE)	12.14 (6.47)	22.87 (7.42)		
Week 52 Adjusted Mean Change (SE)	14.28 (6.37)	15.29 (7.30)	-1.01 [-20.27; 18.26]	0.918

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

47.12 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.219				
Non-carrier, N	**36**	**34**		
N'	36	33		
Baseline Mean (SD)	60.42 (29.30)	62.50 (26.45)		
Week 52 Mean (SD)	76.26 (25.78)	78.40 (30.16)		
Week 4 Adjusted Mean Change (SE)	12.00 (3.26)	16.40 (3.42)		
Week 12 Adjusted Mean Change (SE)	15.69 (3.07)	15.81 (3.26)		
Week 16 Adjusted Mean Change (SE)	12.64 (3.19)	11.86 (3.38)		
Week 24 Adjusted Mean Change (SE)	13.53 (3.64)	13.98 (3.95)		
Week 32 Adjusted Mean Change (SE)	17.04 (3.67)	15.14 (3.92)		
Week 40 Adjusted Mean Change (SE)	13.80 (3.89)	16.71 (4.23)		
Week 52 Adjusted Mean Change (SE)	16.60 (3.90)	19.71 (4.27)	-3.11 [-14.60; 8.37]	0.591
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	60.26 (28.29)	58.33 (27.22)		
Week 52 Mean (SD)	83.33 (22.05)	72.50 (29.41)		
Week 4 Adjusted Mean Change (SE)	8.24 (5.42)	4.11 (6.22)		
Week 12 Adjusted Mean Change (SE)	3.09 (5.11)	7.31 (5.87)		
Week 16 Adjusted Mean Change (SE)	15.93 (5.26)	4.94 (6.04)		
Week 24 Adjusted Mean Change (SE)	19.79 (6.02)	10.89 (6.90)		
Week 32 Adjusted Mean Change (SE)	17.83 (6.01)	4.74 (6.89)		
Week 40 Adjusted Mean Change (SE)	19.11 (6.43)	3.84 (7.55)		
Week 52 Adjusted Mean Change (SE)	22.97 (6.31)	13.15 (7.22)	9.82 [-9.30; 28.93]	0.310

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

47.13 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.532				
Non-carrier, N	**42**	**36**		
N'	42	35		
Baseline Mean (SD)	64.29 (30.20)	62.73 (27.20)		
Week 52 Mean (SD)	79.27 (25.06)	77.87 (31.20)		
Week 4 Adjusted Mean Change (SE)	9.18 (3.03)	14.17 (3.31)		
Week 12 Adjusted Mean Change (SE)	12.29 (2.96)	14.32 (3.24)		
Week 16 Adjusted Mean Change (SE)	12.79 (2.91)	9.39 (3.22)		
Week 24 Adjusted Mean Change (SE)	15.28 (3.33)	11.15 (3.76)		
Week 32 Adjusted Mean Change (SE)	15.74 (3.32)	12.90 (3.68)		
Week 40 Adjusted Mean Change (SE)	15.07 (3.64)	10.65 (4.15)		
Week 52 Adjusted Mean Change (SE)	16.75 (3.46)	18.95 (3.96)	-2.20 [-12.66; 8.26]	0.676
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	48.15 (16.02)	53.33 (29.23)		
Week 52 Mean (SD)	78.70 (23.98)	76.67 (17.08)		
Week 4 Adjusted Mean Change (SE)	18.31 (6.60)	3.75 (8.75)		
Week 12 Adjusted Mean Change (SE)	13.74 (6.39)	11.57 (8.48)		
Week 16 Adjusted Mean Change (SE)	18.26 (6.30)	2.06 (8.35)		
Week 24 Adjusted Mean Change (SE)	15.16 (7.23)	10.75 (9.60)		
Week 32 Adjusted Mean Change (SE)	24.69 (7.11)	14.81 (9.43)		
Week 40 Adjusted Mean Change (SE)	15.84 (7.89)	21.16 (10.47)		
Week 52 Adjusted Mean Change (SE)	25.14 (7.41)	20.08 (9.84)	5.06 [-19.32; 29.44]	0.681

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

47.14 SF-36 Role Emotional - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.827				
Low score, N	**11**	**22**		
N'	11	21		
Baseline Mean (SD)	65.15 (33.30)	65.91 (29.76)		
Week 52 Mean (SD)	79.17 (29.98)	80.00 (26.13)		
Week 4 Adjusted Mean Change (SE)	17.61 (5.82)	17.87 (4.25)		
Week 12 Adjusted Mean Change (SE)	17.80 (5.71)	14.63 (4.17)		
Week 16 Adjusted Mean Change (SE)	18.01 (5.82)	13.41 (4.18)		
Week 24 Adjusted Mean Change (SE)	16.53 (6.46)	7.75 (4.95)		
Week 32 Adjusted Mean Change (SE)	20.97 (6.54)	12.84 (5.05)		
Week 40 Adjusted Mean Change (SE)	13.48 (7.01)	12.66 (5.48)		
Week 52 Adjusted Mean Change (SE)	17.57 (7.02)	21.14 (5.60)	-3.57 [-21.39; 14.25]	0.692
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	60.42 (27.78)	57.20 (22.32)		
Week 52 Mean (SD)	79.17 (23.47)	74.62 (32.27)		
Week 4 Adjusted Mean Change (SE)	8.93 (3.05)	9.07 (4.13)		
Week 12 Adjusted Mean Change (SE)	11.09 (3.02)	12.68 (4.13)		
Week 16 Adjusted Mean Change (SE)	12.69 (2.95)	6.85 (4.07)		
Week 24 Adjusted Mean Change (SE)	14.95 (3.40)	17.59 (4.63)		
Week 32 Adjusted Mean Change (SE)	16.26 (3.51)	11.79 (4.64)		
Week 40 Adjusted Mean Change (SE)	15.72 (3.70)	13.83 (5.02)		
Week 52 Adjusted Mean Change (SE)	18.60 (3.64)	15.74 (4.85)	2.86 [-9.18; 14.90]	0.638

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

47.15 SF-36 Role Emotional - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.882				
Non-carrier, N	**31**	**23**		
N'	31	22		
Baseline Mean (SD)	58.87 (24.24)	64.49 (27.43)		
Week 52 Mean (SD)	79.17 (24.64)	80.88 (21.20)		
Week 4 Adjusted Mean Change (SE)	14.75 (3.47)	14.91 (4.13)		
Week 12 Adjusted Mean Change (SE)	12.99 (3.43)	14.51 (4.07)		
Week 16 Adjusted Mean Change (SE)	13.39 (3.41)	9.85 (4.11)		
Week 24 Adjusted Mean Change (SE)	14.30 (3.89)	11.36 (4.77)		
Week 32 Adjusted Mean Change (SE)	18.63 (3.95)	13.19 (4.80)		
Week 40 Adjusted Mean Change (SE)	15.82 (4.20)	10.97 (5.19)		
Week 52 Adjusted Mean Change (SE)	18.77 (4.09)	22.75 (5.26)	-3.98 [-17.23; 9.28]	0.553
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	65.42 (34.97)	58.33 (25.41)		
Week 52 Mean (SD)	79.17 (25.28)	73.33 (35.52)		
Week 4 Adjusted Mean Change (SE)	4.65 (4.33)	11.67 (4.21)		
Week 12 Adjusted Mean Change (SE)	11.90 (4.35)	12.63 (4.23)		
Week 16 Adjusted Mean Change (SE)	14.33 (4.32)	10.22 (4.20)		
Week 24 Adjusted Mean Change (SE)	16.98 (4.91)	15.17 (4.86)		
Week 32 Adjusted Mean Change (SE)	15.28 (5.00)	11.60 (4.83)		
Week 40 Adjusted Mean Change (SE)	14.38 (5.19)	15.93 (5.20)		
Week 52 Adjusted Mean Change (SE)	17.87 (5.20)	13.96 (5.02)	3.91 [-10.48; 18.30]	0.590

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

47.16 SF-36 Role Emotional - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.683				
Non-carrier, N	**19**	**20**		
N'	19	19		
Baseline Mean (SD)	54.39 (29.18)	68.33 (26.71)		
Week 52 Mean (SD)	77.19 (27.19)	83.93 (27.05)		
Week 4 Adjusted Mean Change (SE)	13.93 (4.38)	21.51 (4.41)		
Week 12 Adjusted Mean Change (SE)	17.64 (4.31)	17.32 (4.43)		
Week 16 Adjusted Mean Change (SE)	14.37 (4.23)	17.66 (4.33)		
Week 24 Adjusted Mean Change (SE)	18.47 (4.99)	8.44 (5.21)		
Week 32 Adjusted Mean Change (SE)	19.51 (4.95)	18.03 (5.19)		
Week 40 Adjusted Mean Change (SE)	16.78 (5.36)	15.29 (5.70)		
Week 52 Adjusted Mean Change (SE)	19.83 (5.22)	21.34 (5.82)	-1.51 [-17.12; 14.09]	0.848
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	65.63 (28.14)	55.90 (25.24)		
Week 52 Mean (SD)	80.46 (23.18)	72.46 (30.92)		
Week 4 Adjusted Mean Change (SE)	8.95 (3.37)	6.93 (3.89)		
Week 12 Adjusted Mean Change (SE)	9.47 (3.35)	10.56 (3.82)		
Week 16 Adjusted Mean Change (SE)	13.47 (3.28)	4.09 (3.81)		
Week 24 Adjusted Mean Change (SE)	13.42 (3.79)	16.01 (4.45)		
Week 32 Adjusted Mean Change (SE)	16.03 (3.90)	8.04 (4.48)		
Week 40 Adjusted Mean Change (SE)	14.31 (4.16)	11.87 (4.89)		
Week 52 Adjusted Mean Change (SE)	17.59 (4.13)	15.61 (4.74)	1.98 [-10.57; 14.53]	0.754

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

47.17 SF-36 Role Emotional - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.317				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	63.00 (29.86)	59.90 (27.23)		
Week 52 Mean (SD)	77.54 (26.28)	74.70 (31.30)		
Week 4 Adjusted Mean Change (SE)	13.81 (3.92)	12.59 (3.45)		
Week 12 Adjusted Mean Change (SE)	11.05 (3.84)	11.67 (3.37)		
Week 16 Adjusted Mean Change (SE)	11.65 (3.73)	6.11 (3.28)		
Week 24 Adjusted Mean Change (SE)	14.42 (4.12)	7.25 (3.80)		
Week 32 Adjusted Mean Change (SE)	16.04 (4.45)	12.86 (4.00)		
Week 40 Adjusted Mean Change (SE)	15.39 (4.64)	11.52 (4.29)		
Week 52 Adjusted Mean Change (SE)	17.19 (4.65)	17.30 (4.24)	-0.12 [-12.62; 12.39]	0.985
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	59.94 (28.19)	65.97 (24.48)		
Week 52 Mean (SD)	80.67 (23.41)	83.33 (24.30)		
Week 4 Adjusted Mean Change (SE)	7.90 (3.84)	15.57 (5.92)		
Week 12 Adjusted Mean Change (SE)	13.92 (3.71)	19.13 (5.72)		
Week 16 Adjusted Mean Change (SE)	15.58 (3.61)	21.91 (5.76)		
Week 24 Adjusted Mean Change (SE)	16.18 (4.07)	28.96 (6.23)		
Week 32 Adjusted Mean Change (SE)	18.40 (4.32)	11.75 (6.59)		
Week 40 Adjusted Mean Change (SE)	14.96 (4.60)	18.90 (7.18)		
Week 52 Adjusted Mean Change (SE)	19.46 (4.51)	19.13 (7.29)	0.33 [-16.71; 17.38]	0.969

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

47.18 SF-36 Role Emotional - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.698				
Non-carrier, N	**39**	**35**		
N'	39	34		
Baseline Mean (SD)	61.54 (28.07)	62.38 (25.03)		
Week 52 Mean (SD)	80.32 (22.73)	79.76 (22.95)		
Week 4 Adjusted Mean Change (SE)	12.22 (3.16)	13.04 (3.38)		
Week 12 Adjusted Mean Change (SE)	10.78 (3.08)	13.61 (3.30)		
Week 16 Adjusted Mean Change (SE)	16.63 (3.01)	9.71 (3.22)		
Week 24 Adjusted Mean Change (SE)	17.14 (3.45)	12.49 (3.84)		
Week 32 Adjusted Mean Change (SE)	19.78 (3.51)	13.19 (3.79)		
Week 40 Adjusted Mean Change (SE)	15.79 (3.71)	12.16 (4.12)		
Week 52 Adjusted Mean Change (SE)	19.31 (3.66)	20.90 (4.10)	-1.59 [-12.52; 9.33]	0.773
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	65.15 (30.46)	58.33 (32.54)		
Week 52 Mean (SD)	80.30 (27.20)	67.59 (45.35)		
Week 4 Adjusted Mean Change (SE)	5.91 (5.99)	13.55 (6.57)		
Week 12 Adjusted Mean Change (SE)	16.71 (5.79)	12.46 (6.34)		
Week 16 Adjusted Mean Change (SE)	4.39 (5.66)	9.94 (6.46)		
Week 24 Adjusted Mean Change (SE)	9.88 (6.69)	14.61 (7.17)		
Week 32 Adjusted Mean Change (SE)	10.84 (6.49)	8.59 (7.11)		
Week 40 Adjusted Mean Change (SE)	14.77 (6.97)	17.38 (7.87)		
Week 52 Adjusted Mean Change (SE)	16.78 (6.76)	7.77 (7.42)	9.02 [-10.94; 28.98]	0.371

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

48.0 SF-36 Role Physical - Return Rates (FAS)

	Treatment Groups		
	SEC **(N=66)**	**ADA** **(N=62)**	**Total** **(N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	57 (91.9)	122 (95.3)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	48 (77.4)	111 (86.7)

48.1 SF-36 Role Physical - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	60		
Baseline Mean (SD)	42.42 (27.51)	47.38 (26.51)		
Week 52 Mean (SD)	66.27 (25.16)	65.89 (27.95)		
Week 4 Adjusted Mean Change (SE)	12.65 (2.17)	8.90 (2.28)		
Week 12 Adjusted Mean Change (SE)	16.38 (2.49)	14.09 (2.60)		
Week 16 Adjusted Mean Change (SE)	17.93 (2.28)	13.10 (2.42)		
Week 24 Adjusted Mean Change (SE)	19.52 (2.78)	20.22 (3.00)		
Week 32 Adjusted Mean Change (SE)	21.90 (2.58)	16.22 (2.77)		
Week 40 Adjusted Mean Change (SE)	19.38 (2.68)	15.88 (2.96)		
Week 52 Adjusted Mean Change (SE)	22.54 (2.85)	19.37 (3.18)	3.17 [-5.29; 11.64]	0.459
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, treatment x visit, baseline value x visit Covariance structure: unstructured (un)				

48.2 SF-36 Role Physical - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.523				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	45.98 (28.01)	54.73 (26.79)		
Week 52 Mean (SD)	70.63 (26.41)	73.08 (26.44)		
Week 4 Adjusted Mean Change (SE)	14.37 (2.75)	8.82 (3.20)		
Week 12 Adjusted Mean Change (SE)	17.76 (3.10)	17.98 (3.59)		
Week 16 Adjusted Mean Change (SE)	19.86 (2.88)	14.41 (3.34)		
Week 24 Adjusted Mean Change (SE)	19.61 (3.47)	24.00 (4.14)		
Week 32 Adjusted Mean Change (SE)	22.71 (3.20)	22.02 (3.80)		
Week 40 Adjusted Mean Change (SE)	18.27 (3.38)	19.31 (4.07)		
Week 52 Adjusted Mean Change (SE)	24.33 (3.56)	23.00 (4.37)	1.32 [-9.78; 12.43]	0.814
Female, N	**24**	**29**		
N'	24	28		
Baseline Mean (SD)	36.20 (26.00)	39.01 (23.95)		
Week 52 Mean (SD)	58.70 (21.30)	57.39 (27.86)		
Week 4 Adjusted Mean Change (SE)	9.60 (3.69)	9.06 (3.37)		
Week 12 Adjusted Mean Change (SE)	13.71 (4.18)	9.77 (3.81)		
Week 16 Adjusted Mean Change (SE)	14.55 (3.84)	11.87 (3.62)		
Week 24 Adjusted Mean Change (SE)	19.46 (4.69)	16.02 (4.43)		
Week 32 Adjusted Mean Change (SE)	20.17 (4.30)	9.80 (4.01)		
Week 40 Adjusted Mean Change (SE)	21.12 (4.48)	12.02 (4.37)		
Week 52 Adjusted Mean Change (SE)	19.23 (4.75)	15.24 (4.68)	3.99 [-9.09; 17.07]	0.547

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

48.3 SF-36 Role Physical - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.878				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	71.88 (18.68)	74.52 (22.60)		
Week 52 Mean (SD)	82.03 (12.47)	72.22 (31.58)		
Week 4 Adjusted Mean Change (SE)	17.13 (4.83)	11.86 (5.34)		
Week 12 Adjusted Mean Change (SE)	18.44 (5.61)	17.95 (6.10)		
Week 16 Adjusted Mean Change (SE)	18.18 (5.07)	16.53 (5.61)		
Week 24 Adjusted Mean Change (SE)	19.85 (6.23)	21.12 (7.11)		
Week 32 Adjusted Mean Change (SE)	16.72 (5.74)	16.17 (6.67)		
Week 40 Adjusted Mean Change (SE)	17.65 (6.05)	16.39 (7.15)		
Week 52 Adjusted Mean Change (SE)	22.72 (6.32)	14.11 (7.68)	8.61 [-9.69; 26.90]	0.353
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	47		
Baseline Mean (SD)	33.00 (22.87)	40.18 (22.64)		
Week 52 Mean (SD)	60.90 (26.21)	64.42 (27.29)		
Week 4 Adjusted Mean Change (SE)	11.07 (2.64)	8.26 (2.60)		
Week 12 Adjusted Mean Change (SE)	15.63 (3.04)	13.14 (2.97)		
Week 16 Adjusted Mean Change (SE)	17.80 (2.77)	12.21 (2.77)		
Week 24 Adjusted Mean Change (SE)	19.42 (3.38)	19.95 (3.42)		
Week 32 Adjusted Mean Change (SE)	23.69 (3.14)	16.10 (3.12)		
Week 40 Adjusted Mean Change (SE)	19.92 (3.26)	15.67 (3.33)		
Week 52 Adjusted Mean Change (SE)	22.51 (3.47)	20.52 (3.58)	1.99 [-7.73; 11.71]	0.686

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

48.4 SF-36 Role Physical - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.299				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	31		
Baseline Mean (SD)	44.87 (25.52)	45.90 (26.78)		
Week 52 Mean (SD)	62.98 (23.91)	64.95 (26.63)		
Week 4 Adjusted Mean Change (SE)	11.63 (3.33)	12.12 (3.17)		
Week 12 Adjusted Mean Change (SE)	13.20 (3.79)	14.47 (3.61)		
Week 16 Adjusted Mean Change (SE)	12.53 (3.45)	12.25 (3.35)		
Week 24 Adjusted Mean Change (SE)	16.15 (4.28)	21.50 (4.17)		
Week 32 Adjusted Mean Change (SE)	18.01 (3.95)	15.46 (3.87)		
Week 40 Adjusted Mean Change (SE)	16.36 (4.14)	14.11 (4.22)		
Week 52 Adjusted Mean Change (SE)	18.70 (4.41)	18.26 (4.53)	0.44 [-12.09; 12.96]	0.945
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	40.63 (29.09)	48.96 (26.57)		
Week 52 Mean (SD)	68.58 (26.08)	66.75 (29.63)		
Week 4 Adjusted Mean Change (SE)	13.42 (2.87)	5.43 (3.28)		
Week 12 Adjusted Mean Change (SE)	18.73 (3.31)	13.67 (3.77)		
Week 16 Adjusted Mean Change (SE)	22.01 (2.99)	13.92 (3.44)		
Week 24 Adjusted Mean Change (SE)	22.07 (3.66)	18.67 (4.35)		
Week 32 Adjusted Mean Change (SE)	24.78 (3.41)	16.96 (3.99)		
Week 40 Adjusted Mean Change (SE)	21.61 (3.55)	17.37 (4.20)		
Week 52 Adjusted Mean Change (SE)	25.28 (3.75)	20.21 (4.50)	5.07 [-6.59; 16.72]	0.391

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

48.5 SF-36 Role Physical - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.454				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	41.56 (22.93)	51.51 (27.68)		
Week 52 Mean (SD)	71.55 (22.17)	74.11 (24.87)		
Week 4 Adjusted Mean Change (SE)	15.23 (2.77)	11.72 (3.28)		
Week 12 Adjusted Mean Change (SE)	19.07 (3.19)	17.81 (3.72)		
Week 16 Adjusted Mean Change (SE)	19.88 (2.94)	16.00 (3.52)		
Week 24 Adjusted Mean Change (SE)	25.14 (3.50)	20.79 (4.31)		
Week 32 Adjusted Mean Change (SE)	23.24 (3.34)	17.56 (4.08)		
Week 40 Adjusted Mean Change (SE)	22.58 (3.46)	15.47 (4.40)		
Week 52 Adjusted Mean Change (SE)	27.30 (3.62)	21.40 (4.73)	5.90 [-5.94; 17.74]	0.325
> Median, N	**26**	**33**		
N'	26	31		
Baseline Mean (SD)	43.75 (33.82)	43.75 (25.29)		
Week 52 Mean (SD)	58.25 (27.70)	59.49 (28.97)		
Week 4 Adjusted Mean Change (SE)	8.64 (3.43)	6.29 (3.15)		
Week 12 Adjusted Mean Change (SE)	12.17 (3.89)	10.58 (3.60)		
Week 16 Adjusted Mean Change (SE)	14.87 (3.61)	10.43 (3.34)		
Week 24 Adjusted Mean Change (SE)	10.79 (4.36)	19.52 (4.06)		
Week 32 Adjusted Mean Change (SE)	19.61 (4.08)	14.90 (3.83)		
Week 40 Adjusted Mean Change (SE)	14.49 (4.23)	15.88 (4.04)		
Week 52 Adjusted Mean Change (SE)	15.22 (4.46)	17.54 (4.25)	-2.33 [-14.54; 9.89]	0.707

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

48.6 SF-36 Role Physical - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.483				
Enthesitis: No, N	**34**	**22**		
N'	34	21		
Baseline Mean (SD)	45.96 (27.69)	50.28 (28.57)		
Week 52 Mean (SD)	69.73 (26.52)	73.96 (28.54)		
Week 4 Adjusted Mean Change (SE)	16.19 (2.88)	19.56 (3.69)		
Week 12 Adjusted Mean Change (SE)	20.14 (3.38)	21.70 (4.35)		
Week 16 Adjusted Mean Change (SE)	20.81 (3.05)	22.28 (3.97)		
Week 24 Adjusted Mean Change (SE)	22.95 (3.85)	24.27 (4.95)		
Week 32 Adjusted Mean Change (SE)	24.36 (3.60)	18.89 (4.57)		
Week 40 Adjusted Mean Change (SE)	22.77 (3.72)	21.60 (4.80)		
Week 52 Adjusted Mean Change (SE)	24.56 (3.93)	28.00 (5.14)	-3.44 [-16.23; 9.35]	0.595
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	38.67 (27.24)	45.78 (25.53)		
Week 52 Mean (SD)	62.70 (23.58)	61.04 (26.90)		
Week 4 Adjusted Mean Change (SE)	8.79 (2.98)	3.29 (2.69)		
Week 12 Adjusted Mean Change (SE)	12.27 (3.51)	10.09 (3.13)		
Week 16 Adjusted Mean Change (SE)	14.81 (3.19)	8.25 (2.89)		
Week 24 Adjusted Mean Change (SE)	15.84 (3.98)	18.53 (3.75)		
Week 32 Adjusted Mean Change (SE)	19.29 (3.71)	15.10 (3.50)		
Week 40 Adjusted Mean Change (SE)	15.79 (3.81)	13.03 (3.72)		
Week 52 Adjusted Mean Change (SE)	20.38 (4.03)	14.67 (3.98)	5.71 [-5.52; 16.93]	0.316

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

48.7 SF-36 Role Physical - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.678				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	32.33 (22.54)	49.00 (24.18)		
Week 52 Mean (SD)	58.93 (27.08)	73.51 (26.88)		
Week 4 Adjusted Mean Change (SE)	15.35 (3.38)	14.34 (3.57)		
Week 12 Adjusted Mean Change (SE)	19.25 (3.97)	17.53 (4.24)		
Week 16 Adjusted Mean Change (SE)	19.82 (3.56)	14.89 (3.84)		
Week 24 Adjusted Mean Change (SE)	23.71 (4.26)	26.75 (4.62)		
Week 32 Adjusted Mean Change (SE)	25.31 (3.94)	22.75 (4.26)		
Week 40 Adjusted Mean Change (SE)	20.02 (4.04)	23.98 (4.37)		
Week 52 Adjusted Mean Change (SE)	23.01 (4.43)	28.96 (4.88)	-5.94 [-19.17; 7.28]	0.374
Carrier, N	**22**	**19**		
N'	22	18		
Baseline Mean (SD)	48.01 (26.12)	46.05 (31.13)		
Week 52 Mean (SD)	70.31 (22.66)	61.33 (31.14)		
Week 4 Adjusted Mean Change (SE)	9.85 (3.80)	6.68 (4.19)		
Week 12 Adjusted Mean Change (SE)	15.54 (4.51)	13.02 (4.92)		
Week 16 Adjusted Mean Change (SE)	13.70 (4.06)	15.04 (4.41)		
Week 24 Adjusted Mean Change (SE)	17.63 (4.81)	19.95 (5.35)		
Week 32 Adjusted Mean Change (SE)	21.22 (4.56)	18.14 (4.97)		
Week 40 Adjusted Mean Change (SE)	19.68 (4.59)	15.01 (5.25)		
Week 52 Adjusted Mean Change (SE)	22.64 (5.09)	14.91 (5.67)	7.73 [-7.32; 22.78]	0.310

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

48.8 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.507				
Non-carrier, N	**28**	**19**		
N'	28	18		
Baseline Mean (SD)	39.96 (23.96)	43.75 (23.48)		
Week 52 Mean (SD)	61.57 (26.67)	63.94 (27.62)		
Week 4 Adjusted Mean Change (SE)	16.57 (3.42)	14.54 (4.27)		
Week 12 Adjusted Mean Change (SE)	22.67 (4.01)	19.44 (5.00)		
Week 16 Adjusted Mean Change (SE)	20.58 (3.64)	17.36 (4.61)		
Week 24 Adjusted Mean Change (SE)	22.94 (4.32)	22.27 (5.56)		
Week 32 Adjusted Mean Change (SE)	24.34 (4.05)	15.10 (5.20)		
Week 40 Adjusted Mean Change (SE)	18.42 (4.10)	13.30 (5.31)		
Week 52 Adjusted Mean Change (SE)	20.48 (4.60)	22.91 (6.27)	-2.43 [-17.89; 13.04]	0.756
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	36.08 (25.94)	48.36 (30.18)		
Week 52 Mean (SD)	65.63 (25.20)	68.75 (31.58)		
Week 4 Adjusted Mean Change (SE)	9.02 (3.87)	9.89 (4.18)		
Week 12 Adjusted Mean Change (SE)	11.93 (4.61)	12.61 (4.97)		
Week 16 Adjusted Mean Change (SE)	14.38 (4.17)	14.71 (4.51)		
Week 24 Adjusted Mean Change (SE)	19.71 (4.94)	29.63 (5.40)		
Week 32 Adjusted Mean Change (SE)	23.33 (4.66)	25.34 (4.99)		
Week 40 Adjusted Mean Change (SE)	23.24 (4.61)	26.32 (5.11)		
Week 52 Adjusted Mean Change (SE)	27.67 (5.28)	24.62 (5.68)	3.05 [-12.48; 18.57]	0.697

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

48.9 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.524				
Non-carrier, N	**19**	**21**		
N'	19	20		
Baseline Mean (SD)	32.24 (26.04)	47.62 (29.74)		
Week 52 Mean (SD)	58.22 (24.83)	73.33 (35.63)		
Week 4 Adjusted Mean Change (SE)	16.56 (4.07)	18.86 (3.92)		
Week 12 Adjusted Mean Change (SE)	23.19 (4.81)	19.67 (4.69)		
Week 16 Adjusted Mean Change (SE)	17.84 (4.30)	22.46 (4.20)		
Week 24 Adjusted Mean Change (SE)	22.72 (5.38)	24.32 (5.29)		
Week 32 Adjusted Mean Change (SE)	25.79 (4.79)	20.65 (4.76)		
Week 40 Adjusted Mean Change (SE)	22.40 (4.90)	23.42 (4.93)		
Week 52 Adjusted Mean Change (SE)	21.28 (5.51)	27.36 (5.76)	-6.07 [-22.02; 9.87]	0.451
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	43.13 (22.10)	47.83 (25.11)		
Week 52 Mean (SD)	66.74 (26.41)	64.77 (23.82)		
Week 4 Adjusted Mean Change (SE)	10.30 (3.17)	4.62 (3.65)		
Week 12 Adjusted Mean Change (SE)	15.12 (3.79)	11.98 (4.31)		
Week 16 Adjusted Mean Change (SE)	17.18 (3.35)	8.75 (3.90)		
Week 24 Adjusted Mean Change (SE)	20.53 (4.14)	23.18 (4.81)		
Week 32 Adjusted Mean Change (SE)	23.23 (3.82)	20.65 (4.36)		
Week 40 Adjusted Mean Change (SE)	20.18 (3.86)	17.52 (4.51)		
Week 52 Adjusted Mean Change (SE)	24.40 (4.38)	19.92 (5.02)	4.49 [-8.75; 17.72]	0.502

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

48.10 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.427				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	38.50 (24.12)	47.66 (26.22)		
Week 52 Mean (SD)	63.86 (27.76)	65.63 (30.92)		
Week 4 Adjusted Mean Change (SE)	16.34 (3.58)	10.68 (3.17)		
Week 12 Adjusted Mean Change (SE)	23.13 (4.19)	14.85 (3.68)		
Week 16 Adjusted Mean Change (SE)	20.01 (3.77)	13.55 (3.33)		
Week 24 Adjusted Mean Change (SE)	21.78 (4.51)	21.84 (4.11)		
Week 32 Adjusted Mean Change (SE)	23.76 (4.26)	20.45 (3.80)		
Week 40 Adjusted Mean Change (SE)	19.20 (4.28)	22.47 (3.92)		
Week 52 Adjusted Mean Change (SE)	23.66 (4.82)	22.14 (4.37)	1.52 [-11.45; 14.49]	0.816
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	39.66 (26.57)	47.92 (30.54)		
Week 52 Mean (SD)	63.50 (24.25)	76.39 (21.60)		
Week 4 Adjusted Mean Change (SE)	9.63 (3.51)	12.74 (5.40)		
Week 12 Adjusted Mean Change (SE)	12.45 (4.05)	17.94 (6.23)		
Week 16 Adjusted Mean Change (SE)	14.40 (3.66)	19.97 (5.76)		
Week 24 Adjusted Mean Change (SE)	20.35 (4.45)	29.72 (6.79)		
Week 32 Adjusted Mean Change (SE)	23.40 (4.12)	22.23 (6.29)		
Week 40 Adjusted Mean Change (SE)	20.56 (4.23)	14.03 (6.59)		
Week 52 Adjusted Mean Change (SE)	21.91 (4.68)	25.44 (7.53)	-3.54 [-21.22; 14.15]	0.692

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

48.11 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.422				
Non-carrier, N	**38**	**33**		
N'	38	32		
Baseline Mean (SD)	38.98 (23.98)	48.67 (25.81)		
Week 52 Mean (SD)	63.57 (24.93)	68.99 (26.01)		
Week 4 Adjusted Mean Change (SE)	12.50 (2.94)	9.52 (3.19)		
Week 12 Adjusted Mean Change (SE)	14.40 (3.34)	15.65 (3.59)		
Week 16 Adjusted Mean Change (SE)	18.34 (3.11)	14.46 (3.38)		
Week 24 Adjusted Mean Change (SE)	19.69 (3.58)	23.92 (3.98)		
Week 32 Adjusted Mean Change (SE)	23.93 (3.37)	21.62 (3.69)		
Week 40 Adjusted Mean Change (SE)	18.52 (3.44)	21.31 (3.86)		
Week 52 Adjusted Mean Change (SE)	21.99 (3.81)	23.10 (4.34)	-1.11 [-12.65; 10.44]	0.849
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	40.10 (30.56)	54.86 (25.54)		
Week 52 Mean (SD)	63.02 (29.85)	80.56 (21.07)		
Week 4 Adjusted Mean Change (SE)	10.25 (5.24)	16.17 (6.02)		
Week 12 Adjusted Mean Change (SE)	22.66 (5.89)	23.59 (6.98)		
Week 16 Adjusted Mean Change (SE)	10.70 (5.50)	17.50 (6.52)		
Week 24 Adjusted Mean Change (SE)	19.66 (6.46)	29.45 (7.49)		
Week 32 Adjusted Mean Change (SE)	18.86 (5.87)	25.97 (6.77)		
Week 40 Adjusted Mean Change (SE)	19.33 (6.07)	24.04 (7.01)		
Week 52 Adjusted Mean Change (SE)	20.77 (6.64)	31.34 (7.68)	-10.57 [-30.83; 9.70]	0.302

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

48.12 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.743				
Non-carrier, N	**36**	**34**		
N'	36	33		
Baseline Mean (SD)	34.55 (23.36)	50.00 (28.04)		
Week 52 Mean (SD)	62.12 (25.86)	71.53 (29.74)		
Week 4 Adjusted Mean Change (SE)	14.12 (3.09)	11.19 (3.23)		
Week 12 Adjusted Mean Change (SE)	21.95 (3.45)	16.83 (3.63)		
Week 16 Adjusted Mean Change (SE)	19.02 (3.20)	16.18 (3.38)		
Week 24 Adjusted Mean Change (SE)	22.59 (3.89)	23.93 (4.13)		
Week 32 Adjusted Mean Change (SE)	25.54 (3.54)	23.14 (3.74)		
Week 40 Adjusted Mean Change (SE)	22.33 (3.58)	23.52 (3.84)		
Week 52 Adjusted Mean Change (SE)	23.68 (4.08)	24.77 (4.43)	-1.09 [-13.24; 11.05]	0.858
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	50.00 (25.90)	40.00 (23.24)		
Week 52 Mean (SD)	66.83 (24.92)	59.38 (26.39)		
Week 4 Adjusted Mean Change (SE)	9.11 (5.08)	11.07 (5.80)		
Week 12 Adjusted Mean Change (SE)	5.37 (5.67)	11.46 (6.46)		
Week 16 Adjusted Mean Change (SE)	10.66 (5.22)	11.65 (5.96)		
Week 24 Adjusted Mean Change (SE)	15.89 (6.32)	23.36 (7.20)		
Week 32 Adjusted Mean Change (SE)	17.37 (5.73)	13.77 (6.53)		
Week 40 Adjusted Mean Change (SE)	11.73 (5.84)	10.12 (6.79)		
Week 52 Adjusted Mean Change (SE)	20.12 (6.57)	18.01 (7.48)	2.11 [-17.79; 22.01]	0.833

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

48.13 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.362				
Non-carrier, N	42	36		
N'	42	35		
Baseline Mean (SD)	40.77 (26.63)	45.31 (27.73)		
Week 52 Mean (SD)	63.78 (25.01)	69.18 (30.80)		
Week 4 Adjusted Mean Change (SE)	13.89 (2.72)	13.65 (2.99)		
Week 12 Adjusted Mean Change (SE)	16.91 (3.21)	16.61 (3.52)		
Week 16 Adjusted Mean Change (SE)	15.94 (2.86)	14.81 (3.17)		
Week 24 Adjusted Mean Change (SE)	21.13 (3.45)	25.34 (3.88)		
Week 32 Adjusted Mean Change (SE)	23.25 (3.25)	19.63 (3.62)		
Week 40 Adjusted Mean Change (SE)	20.19 (3.30)	18.09 (3.75)		
Week 52 Adjusted Mean Change (SE)	21.90 (3.61)	25.52 (4.13)	-3.62 [-14.55; 7.31]	0.512
Carrier, N	9	5		
N'	9	5		
Baseline Mean (SD)	31.25 (15.31)	57.50 (20.92)		
Week 52 Mean (SD)	63.19 (30.21)	61.25 (21.83)		
Week 4 Adjusted Mean Change (SE)	9.46 (5.94)	-0.89 (7.96)		
Week 12 Adjusted Mean Change (SE)	22.52 (6.95)	6.51 (9.31)		
Week 16 Adjusted Mean Change (SE)	24.00 (6.21)	7.92 (8.31)		
Week 24 Adjusted Mean Change (SE)	21.90 (7.49)	18.90 (10.04)		
Week 32 Adjusted Mean Change (SE)	25.90 (6.98)	21.34 (9.35)		
Week 40 Adjusted Mean Change (SE)	19.44 (7.15)	24.12 (9.59)		
Week 52 Adjusted Mean Change (SE)	27.51 (7.74)	9.78 (10.38)	17.73 [-8.30; 43.76]	0.179

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

48.14 SF-36 Role Physical - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.494				
Low score, N	**11**	**22**		
N'	11	21		
Baseline Mean (SD)	32.95 (27.26)	48.01 (28.89)		
Week 52 Mean (SD)	58.75 (30.36)	66.67 (34.69)		
Week 4 Adjusted Mean Change (SE)	23.53 (5.32)	13.23 (3.86)		
Week 12 Adjusted Mean Change (SE)	24.79 (6.26)	19.22 (4.53)		
Week 16 Adjusted Mean Change (SE)	25.40 (5.75)	18.18 (4.12)		
Week 24 Adjusted Mean Change (SE)	26.11 (6.71)	17.36 (5.03)		
Week 32 Adjusted Mean Change (SE)	27.74 (6.26)	18.34 (4.75)		
Week 40 Adjusted Mean Change (SE)	17.80 (6.47)	21.31 (4.96)		
Week 52 Adjusted Mean Change (SE)	19.17 (7.29)	22.28 (5.71)	-3.11 [-21.57; 15.35]	0.738
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	40.78 (24.64)	47.44 (25.85)		
Week 52 Mean (SD)	64.97 (24.64)	69.32 (25.29)		
Week 4 Adjusted Mean Change (SE)	10.07 (2.77)	9.14 (3.76)		
Week 12 Adjusted Mean Change (SE)	15.65 (3.28)	12.11 (4.46)		
Week 16 Adjusted Mean Change (SE)	15.03 (2.92)	12.13 (4.01)		
Week 24 Adjusted Mean Change (SE)	19.62 (3.51)	29.32 (4.76)		
Week 32 Adjusted Mean Change (SE)	22.37 (3.32)	22.60 (4.42)		
Week 40 Adjusted Mean Change (SE)	20.38 (3.39)	19.28 (4.61)		
Week 52 Adjusted Mean Change (SE)	23.72 (3.76)	23.92 (5.03)	-0.21 [-12.72; 12.31]	0.974

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

48.15 SF-36 Role Physical - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.646				
Non-carrier, N	**31**	**23**		
N'	31	22		
Baseline Mean (SD)	41.33 (24.56)	45.38 (23.55)		
Week 52 Mean (SD)	62.29 (25.56)	67.28 (27.11)		
Week 4 Adjusted Mean Change (SE)	15.49 (3.20)	14.02 (3.80)		
Week 12 Adjusted Mean Change (SE)	21.18 (3.69)	18.62 (4.38)		
Week 16 Adjusted Mean Change (SE)	18.70 (3.38)	15.44 (4.06)		
Week 24 Adjusted Mean Change (SE)	22.02 (4.04)	21.56 (4.92)		
Week 32 Adjusted Mean Change (SE)	23.27 (3.72)	17.10 (4.52)		
Week 40 Adjusted Mean Change (SE)	18.58 (3.78)	14.51 (4.63)		
Week 52 Adjusted Mean Change (SE)	19.79 (4.25)	23.62 (5.39)	-3.83 [-17.49; 9.82]	0.578
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	35.63 (26.29)	50.30 (30.90)		
Week 52 Mean (SD)	65.97 (26.54)	69.06 (31.25)		
Week 4 Adjusted Mean Change (SE)	8.91 (4.02)	8.31 (3.91)		
Week 12 Adjusted Mean Change (SE)	11.77 (4.70)	12.37 (4.57)		
Week 16 Adjusted Mean Change (SE)	14.74 (4.29)	14.86 (4.19)		
Week 24 Adjusted Mean Change (SE)	19.26 (5.13)	26.58 (5.05)		
Week 32 Adjusted Mean Change (SE)	23.81 (4.76)	24.74 (4.59)		
Week 40 Adjusted Mean Change (SE)	21.47 (4.71)	26.32 (4.72)		
Week 52 Adjusted Mean Change (SE)	27.77 (5.41)	22.92 (5.25)	4.85 [-10.25; 19.95]	0.525

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

48.16 SF-36 Role Physical - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.436				
Non-carrier, N	**19**	**20**		
N'	19	19		
Baseline Mean (SD)	32.24 (26.04)	48.75 (30.05)		
Week 52 Mean (SD)	58.22 (24.83)	75.00 (36.36)		
Week 4 Adjusted Mean Change (SE)	16.54 (4.00)	20.04 (3.95)		
Week 12 Adjusted Mean Change (SE)	22.84 (4.77)	21.13 (4.78)		
Week 16 Adjusted Mean Change (SE)	17.62 (4.24)	23.64 (4.25)		
Week 24 Adjusted Mean Change (SE)	22.46 (5.33)	25.69 (5.40)		
Week 32 Adjusted Mean Change (SE)	25.27 (4.84)	20.79 (4.95)		
Week 40 Adjusted Mean Change (SE)	22.10 (4.95)	23.59 (5.14)		
Week 52 Adjusted Mean Change (SE)	21.09 (5.46)	27.80 (5.90)	-6.71 [-22.80; 9.38]	0.410
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	43.16 (24.09)	46.88 (25.00)		
Week 52 Mean (SD)	67.24 (26.07)	64.13 (23.48)		
Week 4 Adjusted Mean Change (SE)	10.80 (3.02)	4.19 (3.50)		
Week 12 Adjusted Mean Change (SE)	14.51 (3.64)	11.31 (4.18)		
Week 16 Adjusted Mean Change (SE)	16.91 (3.23)	8.48 (3.75)		
Week 24 Adjusted Mean Change (SE)	20.20 (3.97)	22.26 (4.65)		
Week 32 Adjusted Mean Change (SE)	22.52 (3.74)	20.70 (4.30)		
Week 40 Adjusted Mean Change (SE)	18.46 (3.78)	17.56 (4.44)		
Week 52 Adjusted Mean Change (SE)	23.99 (4.24)	19.79 (4.86)	4.19 [-8.60; 16.99]	0.516

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

48.17 SF-36 Role Physical - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.427				
Non-carrier, N	25	32		
N'	25	32		
Baseline Mean (SD)	38.50 (24.12)	47.66 (26.22)		
Week 52 Mean (SD)	63.86 (27.76)	65.63 (30.92)		
Week 4 Adjusted Mean Change (SE)	16.34 (3.58)	10.68 (3.17)		
Week 12 Adjusted Mean Change (SE)	23.13 (4.19)	14.85 (3.68)		
Week 16 Adjusted Mean Change (SE)	20.01 (3.77)	13.55 (3.33)		
Week 24 Adjusted Mean Change (SE)	21.78 (4.51)	21.84 (4.11)		
Week 32 Adjusted Mean Change (SE)	23.76 (4.26)	20.45 (3.80)		
Week 40 Adjusted Mean Change (SE)	19.20 (4.28)	22.47 (3.92)		
Week 52 Adjusted Mean Change (SE)	23.66 (4.82)	22.14 (4.37)	1.52 [-11.45; 14.49]	0.816
Carrier, N	26	12		
N'	26	11		
Baseline Mean (SD)	39.66 (26.57)	47.92 (30.54)		
Week 52 Mean (SD)	63.50 (24.25)	76.39 (21.60)		
Week 4 Adjusted Mean Change (SE)	9.63 (3.51)	12.74 (5.40)		
Week 12 Adjusted Mean Change (SE)	12.45 (4.05)	17.94 (6.23)		
Week 16 Adjusted Mean Change (SE)	14.40 (3.66)	19.97 (5.76)		
Week 24 Adjusted Mean Change (SE)	20.35 (4.45)	29.72 (6.79)		
Week 32 Adjusted Mean Change (SE)	23.40 (4.12)	22.23 (6.29)		
Week 40 Adjusted Mean Change (SE)	20.56 (4.23)	14.03 (6.59)		
Week 52 Adjusted Mean Change (SE)	21.91 (4.68)	25.44 (7.53)	-3.54 [-21.22; 14.15]	0.692

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

48.18 SF-36 Role Physical - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.540				
Non-carrier, N	**39**	**35**		
N'	39	34		
Baseline Mean (SD)	38.78 (23.70)	47.32 (26.36)		
Week 52 Mean (SD)	63.89 (24.65)	67.19 (28.50)		
Week 4 Adjusted Mean Change (SE)	13.57 (2.93)	10.25 (3.12)		
Week 12 Adjusted Mean Change (SE)	15.70 (3.37)	14.58 (3.59)		
Week 16 Adjusted Mean Change (SE)	18.98 (3.04)	14.93 (3.25)		
Week 24 Adjusted Mean Change (SE)	21.23 (3.64)	22.72 (4.00)		
Week 32 Adjusted Mean Change (SE)	24.72 (3.40)	19.55 (3.66)		
Week 40 Adjusted Mean Change (SE)	19.51 (3.47)	19.42 (3.81)		
Week 52 Adjusted Mean Change (SE)	22.95 (3.88)	22.33 (4.31)	0.62 [-10.94; 12.18]	0.915
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	43.75 (29.18)	49.31 (31.47)		
Week 52 Mean (SD)	65.91 (29.50)	71.53 (32.19)		
Week 4 Adjusted Mean Change (SE)	9.58 (5.51)	14.05 (6.05)		
Week 12 Adjusted Mean Change (SE)	20.98 (6.28)	18.74 (6.90)		
Week 16 Adjusted Mean Change (SE)	10.72 (5.69)	15.04 (6.43)		
Week 24 Adjusted Mean Change (SE)	20.28 (6.95)	27.70 (7.53)		
Week 32 Adjusted Mean Change (SE)	19.86 (6.27)	24.65 (6.90)		
Week 40 Adjusted Mean Change (SE)	21.01 (6.48)	22.76 (7.32)		
Week 52 Adjusted Mean Change (SE)	22.15 (7.14)	24.86 (7.87)	-2.71 [-23.83; 18.41]	0.799

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

49.0 SF-36 Social Functioning - Return Rates (FAS)

	Treatment Groups		
	SEC **(N=66)**	**ADA** **(N=62)**	**Total** **(N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	57 (91.9)	122 (95.3)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	48 (77.4)	111 (86.7)

49.0 SF-36 Social Functioning - Return Rates (FAS)

49.1 SF-36 Social Functioning - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
N'	66	60		
Baseline Mean (SD)	60.04 (29.84)	56.25 (26.66)		
Week 52 Mean (SD)	79.37 (25.12)	75.00 (28.01)		
Week 4 Adjusted Mean Change (SE)	12.03 (2.65)	13.51 (2.78)		
Week 12 Adjusted Mean Change (SE)	15.34 (2.66)	14.78 (2.78)		
Week 16 Adjusted Mean Change (SE)	16.23 (2.82)	12.68 (2.99)		
Week 24 Adjusted Mean Change (SE)	17.14 (2.69)	14.63 (2.92)		
Week 32 Adjusted Mean Change (SE)	21.22 (2.60)	18.15 (2.80)		
Week 40 Adjusted Mean Change (SE)	18.68 (2.74)	11.15 (3.02)		
Week 52 Adjusted Mean Change (SE)	20.38 (3.02)	16.91 (3.37)	3.47 [-5.49; 12.43]	0.444
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, treatment x visit, baseline value x visit Covariance structure: unstructured (un)				

49.2 SF-36 Social Functioning - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.173				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	66.07 (30.90)	57.95 (26.67)		
Week 52 Mean (SD)	80.00 (26.67)	76.92 (30.14)		
Week 4 Adjusted Mean Change (SE)	13.75 (3.41)	15.00 (3.83)		
Week 12 Adjusted Mean Change (SE)	16.14 (3.41)	16.13 (3.81)		
Week 16 Adjusted Mean Change (SE)	15.11 (3.60)	16.94 (4.02)		
Week 24 Adjusted Mean Change (SE)	13.17 (3.40)	15.95 (3.94)		
Week 32 Adjusted Mean Change (SE)	19.21 (3.33)	20.28 (3.84)		
Week 40 Adjusted Mean Change (SE)	16.53 (3.50)	15.10 (4.10)		
Week 52 Adjusted Mean Change (SE)	17.77 (3.86)	18.97 (4.61)	-1.19 [-13.11; 10.72]	0.843
Female, N	**24**	**29**		
N'	24	28		
Baseline Mean (SD)	49.48 (25.13)	54.31 (26.99)		
Week 52 Mean (SD)	78.26 (22.68)	72.73 (25.77)		
Week 4 Adjusted Mean Change (SE)	9.09 (4.50)	11.78 (4.10)		
Week 12 Adjusted Mean Change (SE)	13.86 (4.53)	13.25 (4.12)		
Week 16 Adjusted Mean Change (SE)	18.17 (4.72)	7.43 (4.47)		
Week 24 Adjusted Mean Change (SE)	24.21 (4.54)	13.41 (4.29)		
Week 32 Adjusted Mean Change (SE)	24.65 (4.39)	15.79 (4.10)		
Week 40 Adjusted Mean Change (SE)	22.37 (4.58)	6.57 (4.46)		
Week 52 Adjusted Mean Change (SE)	24.87 (5.09)	14.71 (4.97)	10.16 [-3.85; 24.17]	0.154

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

49.3 SF-36 Social Functioning - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.504				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	78.91 (22.23)	77.88 (25.08)		
Week 52 Mean (SD)	90.63 (16.77)	72.22 (34.67)		
Week 4 Adjusted Mean Change (SE)	19.67 (5.60)	14.94 (6.14)		
Week 12 Adjusted Mean Change (SE)	17.61 (5.70)	14.44 (6.15)		
Week 16 Adjusted Mean Change (SE)	21.32 (5.92)	20.79 (6.50)		
Week 24 Adjusted Mean Change (SE)	18.98 (5.77)	18.39 (6.54)		
Week 32 Adjusted Mean Change (SE)	26.98 (5.50)	18.66 (6.41)		
Week 40 Adjusted Mean Change (SE)	28.01 (5.82)	12.65 (6.91)		
Week 52 Adjusted Mean Change (SE)	23.99 (6.29)	10.33 (7.77)	13.66 [-5.66; 32.98]	0.164
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	47		
Baseline Mean (SD)	54.00 (29.61)	50.51 (24.20)		
Week 52 Mean (SD)	75.53 (26.45)	75.64 (26.74)		
Week 4 Adjusted Mean Change (SE)	9.68 (3.06)	13.07 (3.18)		
Week 12 Adjusted Mean Change (SE)	14.64 (3.08)	14.88 (3.21)		
Week 16 Adjusted Mean Change (SE)	14.70 (3.26)	10.21 (3.44)		
Week 24 Adjusted Mean Change (SE)	16.53 (3.11)	13.58 (3.35)		
Week 32 Adjusted Mean Change (SE)	19.48 (3.01)	17.83 (3.17)		
Week 40 Adjusted Mean Change (SE)	15.88 (3.14)	10.56 (3.39)		
Week 52 Adjusted Mean Change (SE)	19.31 (3.50)	18.34 (3.78)	0.97 [-9.15; 11.09]	0.850

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

49.4 SF-36 Social Functioning - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.240				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	31		
Baseline Mean (SD)	63.39 (26.77)	56.25 (24.80)		
Week 52 Mean (SD)	81.25 (24.56)	77.17 (24.03)		
Week 4 Adjusted Mean Change (SE)	10.13 (4.12)	13.91 (3.91)		
Week 12 Adjusted Mean Change (SE)	11.41 (4.03)	18.04 (3.83)		
Week 16 Adjusted Mean Change (SE)	10.93 (4.31)	12.10 (4.18)		
Week 24 Adjusted Mean Change (SE)	13.13 (4.14)	17.29 (4.03)		
Week 32 Adjusted Mean Change (SE)	16.66 (4.00)	20.24 (3.90)		
Week 40 Adjusted Mean Change (SE)	17.40 (4.27)	10.00 (4.34)		
Week 52 Adjusted Mean Change (SE)	21.50 (4.74)	17.87 (4.84)	3.63 [-9.81; 17.07]	0.593
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	57.57 (32.04)	56.25 (28.95)		
Week 52 Mean (SD)	78.04 (25.75)	73.00 (31.60)		
Week 4 Adjusted Mean Change (SE)	13.43 (3.52)	13.09 (4.04)		
Week 12 Adjusted Mean Change (SE)	18.25 (3.51)	11.19 (4.00)		
Week 16 Adjusted Mean Change (SE)	20.17 (3.72)	13.29 (4.27)		
Week 24 Adjusted Mean Change (SE)	20.05 (3.52)	11.64 (4.22)		
Week 32 Adjusted Mean Change (SE)	24.59 (3.41)	15.93 (4.00)		
Week 40 Adjusted Mean Change (SE)	19.65 (3.64)	11.69 (4.32)		
Week 52 Adjusted Mean Change (SE)	19.68 (4.00)	15.65 (4.80)	4.03 [-8.34; 16.41]	0.520

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

49.5 SF-36 Social Functioning - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.953				
≤ Median, N	40	29		
N'	40	29		
Baseline Mean (SD)	59.06 (25.94)	63.36 (27.13)		
Week 52 Mean (SD)	79.61 (23.33)	79.17 (28.32)		
Week 4 Adjusted Mean Change (SE)	12.96 (3.43)	13.83 (4.05)		
Week 12 Adjusted Mean Change (SE)	15.51 (3.46)	12.43 (4.02)		
Week 16 Adjusted Mean Change (SE)	16.12 (3.63)	17.33 (4.34)		
Week 24 Adjusted Mean Change (SE)	17.90 (3.47)	15.64 (4.29)		
Week 32 Adjusted Mean Change (SE)	21.42 (3.38)	17.28 (4.11)		
Week 40 Adjusted Mean Change (SE)	21.89 (3.49)	15.35 (4.40)		
Week 52 Adjusted Mean Change (SE)	20.46 (3.92)	15.74 (5.07)	4.71 [-7.99; 17.42]	0.464
> Median, N	26	33		
N'	26	31		
Baseline Mean (SD)	61.54 (35.52)	50.00 (25.00)		
Week 52 Mean (SD)	79.00 (28.12)	71.76 (27.86)		
Week 4 Adjusted Mean Change (SE)	10.61 (4.26)	13.21 (3.93)		
Week 12 Adjusted Mean Change (SE)	15.07 (4.23)	17.11 (3.94)		
Week 16 Adjusted Mean Change (SE)	16.40 (4.47)	8.47 (4.17)		
Week 24 Adjusted Mean Change (SE)	16.03 (4.34)	13.78 (4.10)		
Week 32 Adjusted Mean Change (SE)	20.77 (4.14)	18.94 (3.92)		
Week 40 Adjusted Mean Change (SE)	14.00 (4.28)	7.74 (4.11)		
Week 52 Adjusted Mean Change (SE)	20.29 (4.84)	17.89 (4.66)	2.40 [-10.97; 15.78]	0.723

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

49.6 SF-36 Social Functioning - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.008				
Enthesitis: No, N	**34**	**22**		
N'	34	21		
Baseline Mean (SD)	65.07 (30.43)	54.55 (27.70)		
Week 52 Mean (SD)	80.08 (26.91)	83.33 (23.48)		
Week 4 Adjusted Mean Change (SE)	14.69 (3.66)	23.10 (4.63)		
Week 12 Adjusted Mean Change (SE)	14.18 (3.72)	20.48 (4.74)		
Week 16 Adjusted Mean Change (SE)	14.84 (3.70)	28.89 (4.75)		
Week 24 Adjusted Mean Change (SE)	15.03 (3.74)	22.37 (4.75)		
Week 32 Adjusted Mean Change (SE)	21.06 (3.61)	27.71 (4.54)		
Week 40 Adjusted Mean Change (SE)	19.14 (3.80)	22.16 (4.85)		
Week 52 Adjusted Mean Change (SE)	19.21 (4.20)	26.99 (5.46)	-7.78 [-21.44; 5.87]	0.261
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	54.69 (28.71)	57.19 (26.39)		
Week 52 Mean (SD)	78.63 (23.54)	70.00 (29.65)		
Week 4 Adjusted Mean Change (SE)	9.26 (3.75)	8.34 (3.39)		
Week 12 Adjusted Mean Change (SE)	16.61 (3.81)	11.60 (3.41)		
Week 16 Adjusted Mean Change (SE)	17.80 (3.83)	4.00 (3.48)		
Week 24 Adjusted Mean Change (SE)	19.33 (3.80)	10.40 (3.65)		
Week 32 Adjusted Mean Change (SE)	21.46 (3.66)	12.86 (3.48)		
Week 40 Adjusted Mean Change (SE)	18.29 (3.83)	4.96 (3.77)		
Week 52 Adjusted Mean Change (SE)	21.60 (4.25)	11.28 (4.20)	10.31 [-1.51; 22.13]	0.087

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

49.7 SF-36 Social Functioning - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.483				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	53.45 (30.96)	60.50 (24.39)		
Week 52 Mean (SD)	75.89 (27.62)	86.90 (23.21)		
Week 4 Adjusted Mean Change (SE)	14.98 (4.01)	19.58 (4.30)		
Week 12 Adjusted Mean Change (SE)	15.95 (3.70)	19.13 (4.02)		
Week 16 Adjusted Mean Change (SE)	16.11 (4.11)	14.80 (4.55)		
Week 24 Adjusted Mean Change (SE)	19.73 (3.92)	17.21 (4.41)		
Week 32 Adjusted Mean Change (SE)	21.04 (3.62)	25.93 (4.01)		
Week 40 Adjusted Mean Change (SE)	19.53 (3.98)	16.24 (4.41)		
Week 52 Adjusted Mean Change (SE)	20.47 (3.99)	28.62 (4.51)	-8.14 [-20.11; 3.82]	0.180
Carrier, N	**22**	**19**		
N'	22	18		
Baseline Mean (SD)	67.61 (23.99)	55.92 (31.83)		
Week 52 Mean (SD)	84.38 (22.17)	66.41 (28.03)		
Week 4 Adjusted Mean Change (SE)	8.73 (4.63)	6.27 (5.06)		
Week 12 Adjusted Mean Change (SE)	9.59 (4.34)	12.73 (4.66)		
Week 16 Adjusted Mean Change (SE)	11.27 (4.82)	16.05 (5.19)		
Week 24 Adjusted Mean Change (SE)	11.51 (4.59)	12.73 (5.07)		
Week 32 Adjusted Mean Change (SE)	18.82 (4.34)	12.71 (4.67)		
Week 40 Adjusted Mean Change (SE)	17.08 (4.66)	10.53 (5.30)		
Week 52 Adjusted Mean Change (SE)	20.55 (4.70)	8.11 (5.21)	12.44 [-1.51; 26.39]	0.080

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

49.8 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.149				
Non-carrier, N	**28**	**19**		
N'	28	18		
Baseline Mean (SD)	55.36 (28.95)	59.21 (24.95)		
Week 52 Mean (SD)	78.24 (26.54)	79.81 (24.23)		
Week 4 Adjusted Mean Change (SE)	18.30 (4.07)	9.18 (5.08)		
Week 12 Adjusted Mean Change (SE)	17.48 (3.87)	17.06 (4.83)		
Week 16 Adjusted Mean Change (SE)	18.00 (4.24)	11.93 (5.40)		
Week 24 Adjusted Mean Change (SE)	14.29 (4.08)	13.69 (5.32)		
Week 32 Adjusted Mean Change (SE)	22.74 (3.79)	18.22 (4.88)		
Week 40 Adjusted Mean Change (SE)	19.07 (4.08)	7.16 (5.35)		
Week 52 Adjusted Mean Change (SE)	21.01 (4.43)	23.11 (6.03)	-2.09 [-17.00; 12.81]	0.780
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	64.20 (28.94)	57.24 (31.54)		
Week 52 Mean (SD)	80.00 (25.13)	77.78 (31.08)		
Week 4 Adjusted Mean Change (SE)	4.02 (4.61)	16.42 (4.94)		
Week 12 Adjusted Mean Change (SE)	7.78 (4.45)	18.46 (4.78)		
Week 16 Adjusted Mean Change (SE)	8.43 (4.88)	16.31 (5.25)		
Week 24 Adjusted Mean Change (SE)	18.59 (4.69)	17.02 (5.15)		
Week 32 Adjusted Mean Change (SE)	16.23 (4.32)	24.36 (4.63)		
Week 40 Adjusted Mean Change (SE)	17.96 (4.55)	20.08 (5.05)		
Week 52 Adjusted Mean Change (SE)	19.56 (5.06)	20.56 (5.41)	-1.00 [-15.77; 13.77]	0.893

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

49.9 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.496				
Non-carrier, N	**19**	**21**		
N'	19	20		
Baseline Mean (SD)	59.87 (31.34)	57.14 (26.98)		
Week 52 Mean (SD)	84.21 (24.59)	82.50 (29.05)		
Week 4 Adjusted Mean Change (SE)	11.35 (4.95)	20.84 (4.83)		
Week 12 Adjusted Mean Change (SE)	18.92 (4.48)	19.91 (4.44)		
Week 16 Adjusted Mean Change (SE)	15.20 (5.02)	19.83 (4.99)		
Week 24 Adjusted Mean Change (SE)	16.69 (4.96)	14.14 (5.05)		
Week 32 Adjusted Mean Change (SE)	23.84 (4.49)	25.81 (4.56)		
Week 40 Adjusted Mean Change (SE)	17.82 (4.93)	16.13 (5.08)		
Week 52 Adjusted Mean Change (SE)	25.68 (5.06)	24.67 (5.43)	1.02 [-13.71; 15.75]	0.891
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	57.08 (27.01)	59.78 (28.69)		
Week 52 Mean (SD)	75.45 (26.24)	75.00 (25.88)		
Week 4 Adjusted Mean Change (SE)	14.28 (3.94)	8.74 (4.50)		
Week 12 Adjusted Mean Change (SE)	11.18 (3.60)	13.87 (4.07)		
Week 16 Adjusted Mean Change (SE)	15.17 (3.99)	12.37 (4.64)		
Week 24 Adjusted Mean Change (SE)	17.35 (3.87)	16.41 (4.51)		
Week 32 Adjusted Mean Change (SE)	18.91 (3.66)	16.39 (4.15)		
Week 40 Adjusted Mean Change (SE)	20.75 (3.96)	12.08 (4.61)		
Week 52 Adjusted Mean Change (SE)	18.14 (4.11)	16.38 (4.68)	1.76 [-10.63; 14.15]	0.778

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

49.10 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.930				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	54.50 (29.51)	58.20 (25.72)		
Week 52 Mean (SD)	76.63 (27.77)	76.34 (28.94)		
Week 4 Adjusted Mean Change (SE)	14.57 (4.42)	15.69 (3.88)		
Week 12 Adjusted Mean Change (SE)	15.12 (4.07)	15.24 (3.57)		
Week 16 Adjusted Mean Change (SE)	12.31 (4.48)	13.36 (3.92)		
Week 24 Adjusted Mean Change (SE)	14.63 (4.23)	12.68 (3.92)		
Week 32 Adjusted Mean Change (SE)	18.01 (4.05)	22.07 (3.64)		
Week 40 Adjusted Mean Change (SE)	17.25 (4.31)	14.18 (3.99)		
Week 52 Adjusted Mean Change (SE)	20.17 (4.62)	19.89 (4.18)	0.28 [-12.06; 12.62]	0.964
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	64.42 (27.77)	59.38 (33.34)		
Week 52 Mean (SD)	82.00 (23.68)	83.33 (20.73)		
Week 4 Adjusted Mean Change (SE)	10.08 (4.34)	9.13 (6.63)		
Week 12 Adjusted Mean Change (SE)	11.50 (3.95)	19.84 (6.03)		
Week 16 Adjusted Mean Change (SE)	15.67 (4.33)	22.19 (6.86)		
Week 24 Adjusted Mean Change (SE)	17.85 (4.20)	22.27 (6.34)		
Week 32 Adjusted Mean Change (SE)	21.96 (3.96)	15.95 (5.98)		
Week 40 Adjusted Mean Change (SE)	19.61 (4.29)	12.39 (6.63)		
Week 52 Adjusted Mean Change (SE)	20.64 (4.50)	20.95 (7.18)	-0.32 [-17.10; 16.46]	0.970

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

49.11 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.230				
Non-carrier, N	**38**	**33**		
N'	38	32		
Baseline Mean (SD)	58.88 (26.14)	59.47 (26.52)		
Week 52 Mean (SD)	79.29 (23.47)	78.37 (23.86)		
Week 4 Adjusted Mean Change (SE)	12.64 (3.64)	13.27 (3.95)		
Week 12 Adjusted Mean Change (SE)	10.86 (3.22)	15.03 (3.46)		
Week 16 Adjusted Mean Change (SE)	14.44 (3.58)	15.59 (3.89)		
Week 24 Adjusted Mean Change (SE)	17.99 (3.39)	14.36 (3.83)		
Week 32 Adjusted Mean Change (SE)	21.10 (3.27)	22.00 (3.62)		
Week 40 Adjusted Mean Change (SE)	20.00 (3.34)	12.09 (3.77)		
Week 52 Adjusted Mean Change (SE)	20.49 (3.65)	19.49 (4.14)	0.99 [-9.99; 11.97]	0.858
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	59.38 (37.36)	65.28 (26.35)		
Week 52 Mean (SD)	78.13 (32.48)	90.28 (21.45)		
Week 4 Adjusted Mean Change (SE)	8.07 (6.51)	15.95 (7.47)		
Week 12 Adjusted Mean Change (SE)	18.49 (5.72)	23.43 (6.81)		
Week 16 Adjusted Mean Change (SE)	10.15 (6.34)	20.51 (7.59)		
Week 24 Adjusted Mean Change (SE)	11.78 (6.26)	21.24 (7.25)		
Week 32 Adjusted Mean Change (SE)	15.36 (5.75)	20.19 (6.58)		
Week 40 Adjusted Mean Change (SE)	13.28 (5.93)	25.59 (6.79)		
Week 52 Adjusted Mean Change (SE)	17.44 (6.36)	28.25 (7.29)	-10.81 [-30.05; 8.44]	0.267

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

49.12 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.522				
Non-carrier, N	**36**	**34**		
N'	36	33		
Baseline Mean (SD)	58.33 (30.76)	58.82 (29.28)		
Week 52 Mean (SD)	77.65 (26.29)	81.02 (26.94)		
Week 4 Adjusted Mean Change (SE)	13.76 (3.54)	18.30 (3.71)		
Week 12 Adjusted Mean Change (SE)	14.92 (3.26)	15.29 (3.44)		
Week 16 Adjusted Mean Change (SE)	13.99 (3.66)	18.53 (3.89)		
Week 24 Adjusted Mean Change (SE)	14.74 (3.53)	12.74 (3.85)		
Week 32 Adjusted Mean Change (SE)	20.17 (3.30)	23.34 (3.53)		
Week 40 Adjusted Mean Change (SE)	16.61 (3.58)	15.51 (3.89)		
Week 52 Adjusted Mean Change (SE)	18.96 (3.82)	22.82 (4.16)	-3.85 [-15.09; 7.38]	0.497
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	64.42 (24.92)	57.50 (22.20)		
Week 52 Mean (SD)	81.73 (25.83)	70.00 (27.13)		
Week 4 Adjusted Mean Change (SE)	6.66 (5.91)	-0.72 (6.76)		
Week 12 Adjusted Mean Change (SE)	4.60 (5.44)	19.58 (6.23)		
Week 16 Adjusted Mean Change (SE)	11.12 (6.05)	5.62 (6.92)		
Week 24 Adjusted Mean Change (SE)	16.35 (5.85)	22.02 (6.69)		
Week 32 Adjusted Mean Change (SE)	16.14 (5.43)	10.57 (6.21)		
Week 40 Adjusted Mean Change (SE)	20.74 (5.93)	7.36 (6.95)		
Week 52 Adjusted Mean Change (SE)	20.60 (6.20)	10.66 (7.09)	9.93 [-8.88; 28.74]	0.296

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

49.13 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.669				
Non-carrier, N	42	36		
N'	42	35		
Baseline Mean (SD)	61.90 (29.60)	56.25 (28.58)		
Week 52 Mean (SD)	79.81 (25.43)	80.60 (27.67)		
Week 4 Adjusted Mean Change (SE)	13.69 (3.39)	15.38 (3.70)		
Week 12 Adjusted Mean Change (SE)	14.31 (3.03)	19.10 (3.31)		
Week 16 Adjusted Mean Change (SE)	15.14 (3.40)	16.60 (3.78)		
Week 24 Adjusted Mean Change (SE)	16.98 (3.33)	14.89 (3.80)		
Week 32 Adjusted Mean Change (SE)	20.38 (3.06)	20.64 (3.41)		
Week 40 Adjusted Mean Change (SE)	19.64 (3.36)	13.42 (3.84)		
Week 52 Adjusted Mean Change (SE)	19.94 (3.32)	23.99 (3.79)	-4.05 [-14.10; 6.00]	0.425
Carrier, N	9	5		
N'	9	5		
Baseline Mean (SD)	48.61 (22.92)	67.50 (20.92)		
Week 52 Mean (SD)	77.78 (27.80)	72.50 (20.54)		
Week 4 Adjusted Mean Change (SE)	7.30 (7.34)	2.84 (9.80)		
Week 12 Adjusted Mean Change (SE)	9.12 (6.51)	3.63 (8.69)		
Week 16 Adjusted Mean Change (SE)	10.45 (7.32)	-0.01 (9.77)		
Week 24 Adjusted Mean Change (SE)	14.18 (7.18)	16.59 (9.58)		
Week 32 Adjusted Mean Change (SE)	19.94 (6.54)	27.71 (8.72)		
Week 40 Adjusted Mean Change (SE)	14.51 (7.24)	15.09 (9.66)		
Week 52 Adjusted Mean Change (SE)	23.80 (7.05)	9.19 (9.41)	14.61 [-8.91; 38.12]	0.220

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

49.14 SF-36 Social Functioning - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.617				
Low score, N	**11**	**22**		
N'	11	21		
Baseline Mean (SD)	63.64 (33.75)	59.09 (27.87)		
Week 52 Mean (SD)	80.00 (31.29)	75.83 (30.05)		
Week 4 Adjusted Mean Change (SE)	17.92 (6.62)	16.60 (4.80)		
Week 12 Adjusted Mean Change (SE)	20.44 (5.99)	15.64 (4.35)		
Week 16 Adjusted Mean Change (SE)	17.26 (6.88)	16.80 (4.91)		
Week 24 Adjusted Mean Change (SE)	11.43 (6.27)	8.34 (4.82)		
Week 32 Adjusted Mean Change (SE)	20.11 (6.03)	19.92 (4.64)		
Week 40 Adjusted Mean Change (SE)	14.21 (6.36)	8.04 (4.97)		
Week 52 Adjusted Mean Change (SE)	17.92 (6.95)	18.96 (5.50)	-1.04 [-18.65; 16.57]	0.907
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	58.44 (27.65)	57.95 (27.96)		
Week 52 Mean (SD)	79.28 (24.36)	79.55 (25.46)		
Week 4 Adjusted Mean Change (SE)	10.75 (3.46)	11.56 (4.68)		
Week 12 Adjusted Mean Change (SE)	11.22 (3.16)	17.32 (4.32)		
Week 16 Adjusted Mean Change (SE)	13.27 (3.47)	14.23 (4.79)		
Week 24 Adjusted Mean Change (SE)	17.61 (3.31)	21.25 (4.51)		
Week 32 Adjusted Mean Change (SE)	19.99 (3.21)	20.66 (4.27)		
Week 40 Adjusted Mean Change (SE)	19.66 (3.36)	18.22 (4.55)		
Week 52 Adjusted Mean Change (SE)	21.03 (3.61)	20.72 (4.80)	0.30 [-11.64; 12.25]	0.960

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

49.15 SF-36 Social Functioning - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.231				
Non-carrier, N	**31**	**23**		
N'	31	22		
Baseline Mean (SD)	58.06 (28.97)	58.15 (24.31)		
Week 52 Mean (SD)	79.58 (25.74)	78.68 (23.29)		
Week 4 Adjusted Mean Change (SE)	16.02 (3.90)	10.67 (4.62)		
Week 12 Adjusted Mean Change (SE)	16.15 (3.56)	15.05 (4.22)		
Week 16 Adjusted Mean Change (SE)	16.46 (3.94)	13.65 (4.76)		
Week 24 Adjusted Mean Change (SE)	13.30 (3.79)	13.99 (4.67)		
Week 32 Adjusted Mean Change (SE)	22.79 (3.57)	17.36 (4.35)		
Week 40 Adjusted Mean Change (SE)	19.02 (3.84)	8.63 (4.75)		
Week 52 Adjusted Mean Change (SE)	21.22 (4.10)	21.68 (5.21)	-0.46 [-13.64; 12.72]	0.945
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	61.88 (29.10)	58.93 (31.41)		
Week 52 Mean (SD)	79.17 (26.08)	77.50 (30.51)		
Week 4 Adjusted Mean Change (SE)	6.49 (4.86)	17.52 (4.73)		
Week 12 Adjusted Mean Change (SE)	8.56 (4.52)	17.90 (4.40)		
Week 16 Adjusted Mean Change (SE)	10.29 (5.01)	17.44 (4.88)		
Week 24 Adjusted Mean Change (SE)	21.21 (4.80)	16.64 (4.76)		
Week 32 Adjusted Mean Change (SE)	15.51 (4.50)	23.43 (4.37)		
Week 40 Adjusted Mean Change (SE)	17.60 (4.74)	18.85 (4.77)		
Week 52 Adjusted Mean Change (SE)	19.38 (5.18)	19.30 (5.01)	0.08 [-14.26; 14.42]	0.991

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

49.16 SF-36 Social Functioning - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.438				
Non-carrier, N	**19**	**20**		
N'	19	19		
Baseline Mean (SD)	59.87 (31.34)	57.50 (27.63)		
Week 52 Mean (SD)	84.21 (24.59)	82.14 (30.11)		
Week 4 Adjusted Mean Change (SE)	10.97 (4.93)	23.04 (4.93)		
Week 12 Adjusted Mean Change (SE)	18.66 (4.46)	22.18 (4.54)		
Week 16 Adjusted Mean Change (SE)	14.86 (4.95)	22.77 (5.06)		
Week 24 Adjusted Mean Change (SE)	16.43 (4.95)	14.64 (5.19)		
Week 32 Adjusted Mean Change (SE)	23.46 (4.55)	24.05 (4.74)		
Week 40 Adjusted Mean Change (SE)	17.49 (4.92)	15.98 (5.22)		
Week 52 Adjusted Mean Change (SE)	25.35 (5.08)	23.56 (5.61)	1.79 [-13.25; 16.83]	0.814
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	59.38 (27.68)	59.38 (28.13)		
Week 52 Mean (SD)	76.29 (26.17)	75.54 (25.42)		
Week 4 Adjusted Mean Change (SE)	13.08 (3.79)	6.88 (4.38)		
Week 12 Adjusted Mean Change (SE)	9.89 (3.47)	11.97 (3.96)		
Week 16 Adjusted Mean Change (SE)	13.68 (3.86)	9.78 (4.48)		
Week 24 Adjusted Mean Change (SE)	16.11 (3.75)	15.42 (4.40)		
Week 32 Adjusted Mean Change (SE)	17.89 (3.58)	17.41 (4.11)		
Week 40 Adjusted Mean Change (SE)	19.04 (3.83)	11.70 (4.50)		
Week 52 Adjusted Mean Change (SE)	17.18 (4.03)	16.93 (4.60)	0.24 [-11.91; 12.39]	0.968

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

49.17 SF-36 Social Functioning - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.930				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	54.50 (29.51)	58.20 (25.72)		
Week 52 Mean (SD)	76.63 (27.77)	76.34 (28.94)		
Week 4 Adjusted Mean Change (SE)	14.57 (4.42)	15.69 (3.88)		
Week 12 Adjusted Mean Change (SE)	15.12 (4.07)	15.24 (3.57)		
Week 16 Adjusted Mean Change (SE)	12.31 (4.48)	13.36 (3.92)		
Week 24 Adjusted Mean Change (SE)	14.63 (4.23)	12.68 (3.92)		
Week 32 Adjusted Mean Change (SE)	18.01 (4.05)	22.07 (3.64)		
Week 40 Adjusted Mean Change (SE)	17.25 (4.31)	14.18 (3.99)		
Week 52 Adjusted Mean Change (SE)	20.17 (4.62)	19.89 (4.18)	0.28 [-12.06; 12.62]	0.964
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	64.42 (27.77)	59.38 (33.34)		
Week 52 Mean (SD)	82.00 (23.68)	83.33 (20.73)		
Week 4 Adjusted Mean Change (SE)	10.08 (4.34)	9.13 (6.63)		
Week 12 Adjusted Mean Change (SE)	11.50 (3.95)	19.84 (6.03)		
Week 16 Adjusted Mean Change (SE)	15.67 (4.33)	22.19 (6.86)		
Week 24 Adjusted Mean Change (SE)	17.85 (4.20)	22.27 (6.34)		
Week 32 Adjusted Mean Change (SE)	21.96 (3.96)	15.95 (5.98)		
Week 40 Adjusted Mean Change (SE)	19.61 (4.29)	12.39 (6.63)		
Week 52 Adjusted Mean Change (SE)	20.64 (4.50)	20.95 (7.18)	-0.32 [-17.10; 16.46]	0.970

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

49.18 SF-36 Social Functioning - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.312				
Non-carrier, N	**39**	**35**		
N'	39	34		
Baseline Mean (SD)	59.62 (26.20)	58.21 (26.94)		
Week 52 Mean (SD)	79.86 (23.39)	77.23 (25.47)		
Week 4 Adjusted Mean Change (SE)	13.03 (3.55)	13.88 (3.79)		
Week 12 Adjusted Mean Change (SE)	11.14 (3.17)	14.14 (3.38)		
Week 16 Adjusted Mean Change (SE)	14.84 (3.50)	14.64 (3.74)		
Week 24 Adjusted Mean Change (SE)	17.16 (3.40)	13.31 (3.82)		
Week 32 Adjusted Mean Change (SE)	20.94 (3.27)	20.88 (3.55)		
Week 40 Adjusted Mean Change (SE)	19.53 (3.42)	10.82 (3.79)		
Week 52 Adjusted Mean Change (SE)	20.76 (3.71)	19.11 (4.13)	1.65 [-9.38; 12.68]	0.767
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	64.77 (33.92)	59.72 (31.73)		
Week 52 Mean (SD)	80.68 (32.77)	80.56 (33.14)		
Week 4 Adjusted Mean Change (SE)	6.58 (6.73)	12.44 (7.37)		
Week 12 Adjusted Mean Change (SE)	15.78 (5.96)	23.49 (6.51)		
Week 16 Adjusted Mean Change (SE)	6.15 (6.57)	16.97 (7.54)		
Week 24 Adjusted Mean Change (SE)	10.87 (6.65)	20.72 (7.06)		
Week 32 Adjusted Mean Change (SE)	15.71 (6.09)	16.60 (6.66)		
Week 40 Adjusted Mean Change (SE)	14.45 (6.43)	22.57 (7.23)		
Week 52 Adjusted Mean Change (SE)	17.58 (6.86)	20.75 (7.51)	-3.17 [-23.37; 17.03]	0.756

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.0 SF-36 Vitality - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	57 (91.9)	122 (95.3)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	48 (77.4)	111 (86.7)

50.1 SF-36 Vitality - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	60		
Baseline Mean (SD)	37.78 (21.10)	41.43 (21.36)		
Week 52 Mean (SD)	53.67 (22.30)	52.47 (22.43)		
Week 4 Adjusted Mean Change (SE)	9.60 (2.00)	10.21 (2.10)		
Week 12 Adjusted Mean Change (SE)	12.08 (2.33)	9.44 (2.43)		
Week 16 Adjusted Mean Change (SE)	15.93 (2.19)	10.06 (2.33)		
Week 24 Adjusted Mean Change (SE)	14.09 (2.48)	13.70 (2.67)		
Week 32 Adjusted Mean Change (SE)	15.89 (2.40)	13.95 (2.58)		
Week 40 Adjusted Mean Change (SE)	13.75 (2.36)	11.58 (2.61)		
Week 52 Adjusted Mean Change (SE)	14.92 (2.48)	10.23 (2.77)	4.70 [-2.69; 12.08]	0.210

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

50.2 SF-36 Vitality - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.336				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	41.82 (22.95)	45.83 (20.71)		
Week 52 Mean (SD)	55.31 (23.15)	54.09 (21.72)		
Week 4 Adjusted Mean Change (SE)	10.03 (2.55)	11.55 (2.94)		
Week 12 Adjusted Mean Change (SE)	12.86 (2.94)	11.18 (3.37)		
Week 16 Adjusted Mean Change (SE)	15.22 (2.78)	12.14 (3.20)		
Week 24 Adjusted Mean Change (SE)	13.52 (3.11)	18.12 (3.68)		
Week 32 Adjusted Mean Change (SE)	14.50 (3.04)	16.27 (3.58)		
Week 40 Adjusted Mean Change (SE)	12.51 (3.00)	12.27 (3.60)		
Week 52 Adjusted Mean Change (SE)	13.94 (3.14)	10.42 (3.84)	3.52 [-6.24; 13.27]	0.476
Female, N	**24**	**29**		
N'	24	28		
Baseline Mean (SD)	30.73 (15.41)	36.42 (21.33)		
Week 52 Mean (SD)	50.82 (20.93)	50.57 (23.62)		
Week 4 Adjusted Mean Change (SE)	8.79 (3.44)	8.73 (3.10)		
Week 12 Adjusted Mean Change (SE)	10.58 (3.98)	7.50 (3.60)		
Week 16 Adjusted Mean Change (SE)	17.12 (3.73)	7.70 (3.48)		
Week 24 Adjusted Mean Change (SE)	14.95 (4.22)	8.54 (3.94)		
Week 32 Adjusted Mean Change (SE)	18.34 (4.10)	11.27 (3.78)		
Week 40 Adjusted Mean Change (SE)	15.88 (4.00)	10.84 (3.87)		
Week 52 Adjusted Mean Change (SE)	16.65 (4.22)	10.03 (4.11)	6.62 [-4.94; 18.18]	0.259

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.3 SF-36 Vitality - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.711				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	50.78 (24.25)	48.08 (22.15)		
Week 52 Mean (SD)	59.38 (18.40)	45.83 (25.96)		
Week 4 Adjusted Mean Change (SE)	12.97 (4.16)	9.09 (4.57)		
Week 12 Adjusted Mean Change (SE)	19.05 (4.76)	18.77 (5.12)		
Week 16 Adjusted Mean Change (SE)	18.95 (4.54)	12.06 (4.99)		
Week 24 Adjusted Mean Change (SE)	15.06 (5.21)	13.72 (5.86)		
Week 32 Adjusted Mean Change (SE)	17.38 (4.98)	12.54 (5.80)		
Week 40 Adjusted Mean Change (SE)	15.40 (4.92)	10.52 (5.94)		
Week 52 Adjusted Mean Change (SE)	14.13 (5.08)	6.48 (6.33)	7.64 [-8.34; 23.63]	0.346
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	47		
Baseline Mean (SD)	33.63 (18.38)	39.67 (21.02)		
Week 52 Mean (SD)	51.73 (23.34)	54.01 (21.63)		
Week 4 Adjusted Mean Change (SE)	8.49 (2.35)	10.56 (2.38)		
Week 12 Adjusted Mean Change (SE)	9.77 (2.65)	6.93 (2.69)		
Week 16 Adjusted Mean Change (SE)	14.91 (2.58)	9.55 (2.65)		
Week 24 Adjusted Mean Change (SE)	13.73 (2.91)	13.65 (3.02)		
Week 32 Adjusted Mean Change (SE)	15.40 (2.82)	14.24 (2.89)		
Week 40 Adjusted Mean Change (SE)	13.21 (2.76)	11.74 (2.92)		
Week 52 Adjusted Mean Change (SE)	15.21 (2.91)	11.04 (3.09)	4.17 [-4.29; 12.62]	0.331

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.4 SF-36 Vitality - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.306				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	31		
Baseline Mean (SD)	35.71 (22.43)	38.09 (21.44)		
Week 52 Mean (SD)	52.40 (23.26)	54.89 (22.05)		
Week 4 Adjusted Mean Change (SE)	12.58 (3.09)	10.02 (2.93)		
Week 12 Adjusted Mean Change (SE)	12.03 (3.56)	11.54 (3.37)		
Week 16 Adjusted Mean Change (SE)	13.00 (3.34)	12.74 (3.23)		
Week 24 Adjusted Mean Change (SE)	12.96 (3.81)	17.69 (3.69)		
Week 32 Adjusted Mean Change (SE)	15.80 (3.69)	17.57 (3.59)		
Week 40 Adjusted Mean Change (SE)	11.70 (3.66)	12.73 (3.73)		
Week 52 Adjusted Mean Change (SE)	15.65 (3.86)	13.17 (3.97)	2.48 [-8.47; 13.43]	0.654
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	39.31 (20.23)	45.00 (21.04)		
Week 52 Mean (SD)	54.56 (21.88)	50.25 (23.00)		
Week 4 Adjusted Mean Change (SE)	7.42 (2.64)	10.39 (3.05)		
Week 12 Adjusted Mean Change (SE)	12.10 (3.10)	7.14 (3.55)		
Week 16 Adjusted Mean Change (SE)	18.15 (2.88)	7.28 (3.33)		
Week 24 Adjusted Mean Change (SE)	14.96 (3.24)	9.37 (3.86)		
Week 32 Adjusted Mean Change (SE)	16.00 (3.16)	10.09 (3.71)		
Week 40 Adjusted Mean Change (SE)	15.26 (3.11)	10.08 (3.71)		
Week 52 Adjusted Mean Change (SE)	14.49 (3.25)	7.00 (3.94)	7.49 [-2.64; 17.63]	0.146

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.5 SF-36 Vitality - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.677				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	37.97 (17.64)	46.12 (22.12)		
Week 52 Mean (SD)	56.91 (22.03)	58.04 (22.81)		
Week 4 Adjusted Mean Change (SE)	9.02 (2.59)	11.57 (3.07)		
Week 12 Adjusted Mean Change (SE)	14.45 (3.01)	8.17 (3.51)		
Week 16 Adjusted Mean Change (SE)	16.47 (2.84)	11.99 (3.41)		
Week 24 Adjusted Mean Change (SE)	15.88 (3.18)	15.81 (3.92)		
Week 32 Adjusted Mean Change (SE)	16.04 (3.11)	16.01 (3.80)		
Week 40 Adjusted Mean Change (SE)	16.15 (3.04)	8.60 (3.89)		
Week 52 Adjusted Mean Change (SE)	17.44 (3.19)	10.71 (4.18)	6.73 [-3.74; 17.19]	0.205
> Median, N	**26**	**33**		
N'	26	31		
Baseline Mean (SD)	37.50 (25.92)	37.31 (20.10)		
Week 52 Mean (SD)	48.75 (22.24)	48.15 (21.57)		
Week 4 Adjusted Mean Change (SE)	10.47 (3.21)	8.96 (2.94)		
Week 12 Adjusted Mean Change (SE)	8.63 (3.67)	10.65 (3.41)		
Week 16 Adjusted Mean Change (SE)	15.02 (3.50)	8.35 (3.23)		
Week 24 Adjusted Mean Change (SE)	11.23 (3.97)	11.85 (3.69)		
Week 32 Adjusted Mean Change (SE)	15.45 (3.81)	12.17 (3.57)		
Week 40 Adjusted Mean Change (SE)	10.17 (3.73)	13.75 (3.55)		
Week 52 Adjusted Mean Change (SE)	11.08 (3.93)	9.69 (3.75)	1.39 [-9.36; 12.15]	0.798

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.6 SF-36 Vitality - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.437				
Enthesitis: No, N	**34**	**22**		
N'	34	21		
Baseline Mean (SD)	37.32 (22.06)	45.74 (24.43)		
Week 52 Mean (SD)	52.93 (21.42)	59.72 (21.99)		
Week 4 Adjusted Mean Change (SE)	13.63 (2.71)	17.20 (3.49)		
Week 12 Adjusted Mean Change (SE)	14.60 (3.19)	16.68 (4.12)		
Week 16 Adjusted Mean Change (SE)	16.36 (2.99)	17.87 (3.90)		
Week 24 Adjusted Mean Change (SE)	15.85 (3.48)	16.49 (4.48)		
Week 32 Adjusted Mean Change (SE)	18.31 (3.35)	18.67 (4.27)		
Week 40 Adjusted Mean Change (SE)	17.44 (3.27)	15.91 (4.25)		
Week 52 Adjusted Mean Change (SE)	14.94 (3.45)	16.30 (4.54)	-1.36 [-12.67; 9.95]	0.812
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	38.28 (20.38)	39.06 (19.39)		
Week 52 Mean (SD)	54.44 (23.51)	48.13 (21.91)		
Week 4 Adjusted Mean Change (SE)	5.27 (2.79)	6.52 (2.52)		
Week 12 Adjusted Mean Change (SE)	9.27 (3.28)	5.69 (2.94)		
Week 16 Adjusted Mean Change (SE)	15.48 (3.10)	5.97 (2.83)		
Week 24 Adjusted Mean Change (SE)	12.18 (3.57)	12.59 (3.36)		
Week 32 Adjusted Mean Change (SE)	13.31 (3.42)	11.66 (3.23)		
Week 40 Adjusted Mean Change (SE)	9.94 (3.32)	9.45 (3.26)		
Week 52 Adjusted Mean Change (SE)	14.86 (3.51)	6.98 (3.48)	7.88 [-1.91; 17.67]	0.114

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.6 SF-36 Vitality - Change from Baseline by Enthesitis at BL According to LEI (FAS)

50.7 SF-36 Vitality - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.454				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	30.17 (21.33)	45.25 (18.69)		
Week 52 Mean (SD)	49.11 (24.10)	60.12 (18.90)		
Week 4 Adjusted Mean Change (SE)	13.63 (3.16)	16.78 (3.42)		
Week 12 Adjusted Mean Change (SE)	13.83 (3.67)	11.13 (4.01)		
Week 16 Adjusted Mean Change (SE)	16.46 (3.10)	13.86 (3.43)		
Week 24 Adjusted Mean Change (SE)	17.21 (3.74)	20.03 (4.16)		
Week 32 Adjusted Mean Change (SE)	18.40 (3.64)	18.20 (4.04)		
Week 40 Adjusted Mean Change (SE)	19.16 (3.64)	17.90 (4.02)		
Week 52 Adjusted Mean Change (SE)	16.62 (3.71)	17.83 (4.18)	-1.20 [-12.54; 10.13]	0.833
Carrier, N	**22**	**19**		
N'	22	18		
Baseline Mean (SD)	39.49 (13.42)	34.21 (22.76)		
Week 52 Mean (SD)	57.50 (20.03)	42.58 (25.13)		
Week 4 Adjusted Mean Change (SE)	6.56 (3.57)	6.76 (3.94)		
Week 12 Adjusted Mean Change (SE)	10.35 (4.21)	9.93 (4.57)		
Week 16 Adjusted Mean Change (SE)	14.72 (3.55)	11.70 (3.87)		
Week 24 Adjusted Mean Change (SE)	14.91 (4.26)	12.82 (4.74)		
Week 32 Adjusted Mean Change (SE)	16.77 (4.25)	9.33 (4.63)		
Week 40 Adjusted Mean Change (SE)	14.23 (4.15)	7.08 (4.73)		
Week 52 Adjusted Mean Change (SE)	17.91 (4.26)	5.09 (4.78)	12.82 [0.08; 25.57]	0.049

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.7 SF-36 Vitality - Change from Baseline by HLA-DQA1*05 (FAS)

50.8 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.561				
Non-carrier, N	**28**	**19**		
N'	28	18		
Baseline Mean (SD)	32.37 (16.93)	40.13 (21.98)		
Week 52 Mean (SD)	51.16 (23.77)	52.40 (19.52)		
Week 4 Adjusted Mean Change (SE)	11.63 (3.33)	13.39 (4.14)		
Week 12 Adjusted Mean Change (SE)	15.05 (3.68)	9.83 (4.58)		
Week 16 Adjusted Mean Change (SE)	15.97 (3.19)	11.21 (4.04)		
Week 24 Adjusted Mean Change (SE)	14.45 (3.83)	15.35 (4.91)		
Week 32 Adjusted Mean Change (SE)	17.85 (3.77)	15.28 (4.83)		
Week 40 Adjusted Mean Change (SE)	16.81 (3.73)	8.60 (4.87)		
Week 52 Adjusted Mean Change (SE)	17.14 (3.91)	12.16 (5.28)	4.98 [-8.17; 18.12]	0.454
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	35.80 (21.23)	40.46 (23.14)		
Week 52 Mean (SD)	53.44 (21.60)	53.13 (28.22)		
Week 4 Adjusted Mean Change (SE)	9.65 (3.73)	12.27 (4.03)		
Week 12 Adjusted Mean Change (SE)	9.09 (4.19)	13.66 (4.54)		
Week 16 Adjusted Mean Change (SE)	15.32 (3.63)	13.90 (3.93)		
Week 24 Adjusted Mean Change (SE)	18.37 (4.33)	20.98 (4.75)		
Week 32 Adjusted Mean Change (SE)	17.19 (4.27)	14.42 (4.61)		
Week 40 Adjusted Mean Change (SE)	17.79 (4.14)	19.23 (4.60)		
Week 52 Adjusted Mean Change (SE)	17.19 (4.40)	13.71 (4.77)	3.48 [-9.45; 16.42]	0.593

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.9 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.816				
Non-carrier, N	**19**	**21**		
N'	19	20		
Baseline Mean (SD)	32.24 (21.68)	39.29 (22.37)		
Week 52 Mean (SD)	50.33 (22.68)	54.17 (25.19)		
Week 4 Adjusted Mean Change (SE)	11.38 (3.89)	17.62 (3.79)		
Week 12 Adjusted Mean Change (SE)	19.09 (4.38)	12.93 (4.33)		
Week 16 Adjusted Mean Change (SE)	14.85 (3.76)	13.27 (3.72)		
Week 24 Adjusted Mean Change (SE)	13.66 (4.61)	14.28 (4.61)		
Week 32 Adjusted Mean Change (SE)	18.74 (4.48)	17.37 (4.51)		
Week 40 Adjusted Mean Change (SE)	19.57 (4.43)	11.98 (4.53)		
Week 52 Adjusted Mean Change (SE)	16.51 (4.56)	12.21 (4.83)	4.30 [-8.96; 17.56]	0.521
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	34.17 (16.47)	41.58 (20.17)		
Week 52 Mean (SD)	54.24 (23.33)	51.42 (22.32)		
Week 4 Adjusted Mean Change (SE)	11.10 (3.09)	8.37 (3.55)		
Week 12 Adjusted Mean Change (SE)	9.65 (3.51)	8.92 (3.99)		
Week 16 Adjusted Mean Change (SE)	17.46 (2.98)	12.94 (3.47)		
Week 24 Adjusted Mean Change (SE)	19.23 (3.62)	19.09 (4.20)		
Week 32 Adjusted Mean Change (SE)	18.01 (3.63)	11.98 (4.14)		
Week 40 Adjusted Mean Change (SE)	17.63 (3.55)	14.74 (4.13)		
Week 52 Adjusted Mean Change (SE)	19.70 (3.68)	12.47 (4.22)	7.23 [-3.95; 18.41]	0.202

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.10 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.175				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	32.25 (20.55)	41.60 (18.89)		
Week 52 Mean (SD)	51.63 (23.48)	50.67 (23.90)		
Week 4 Adjusted Mean Change (SE)	16.46 (3.36)	11.12 (2.97)		
Week 12 Adjusted Mean Change (SE)	11.63 (3.94)	8.80 (3.46)		
Week 16 Adjusted Mean Change (SE)	15.73 (3.27)	9.91 (2.87)		
Week 24 Adjusted Mean Change (SE)	18.39 (3.91)	13.09 (3.57)		
Week 32 Adjusted Mean Change (SE)	17.35 (3.99)	14.52 (3.57)		
Week 40 Adjusted Mean Change (SE)	18.41 (3.93)	12.69 (3.60)		
Week 52 Adjusted Mean Change (SE)	17.34 (4.09)	11.43 (3.71)	5.91 [-5.14; 16.96]	0.290
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	36.06 (17.08)	37.50 (26.65)		
Week 52 Mean (SD)	53.50 (22.32)	58.33 (21.19)		
Week 4 Adjusted Mean Change (SE)	5.07 (3.27)	16.46 (5.01)		
Week 12 Adjusted Mean Change (SE)	12.84 (3.78)	16.13 (5.80)		
Week 16 Adjusted Mean Change (SE)	15.67 (3.14)	22.33 (4.96)		
Week 24 Adjusted Mean Change (SE)	14.16 (3.83)	27.27 (5.84)		
Week 32 Adjusted Mean Change (SE)	18.05 (3.85)	14.75 (5.86)		
Week 40 Adjusted Mean Change (SE)	15.87 (3.86)	15.77 (6.02)		
Week 52 Adjusted Mean Change (SE)	17.17 (3.97)	15.31 (6.34)	1.86 [-13.01; 16.73]	0.804

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.11 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.374				
Non-carrier, N	**38**	**33**		
N'	38	32		
Baseline Mean (SD)	33.39 (17.81)	39.58 (19.31)		
Week 52 Mean (SD)	52.68 (21.13)	54.57 (20.66)		
Week 4 Adjusted Mean Change (SE)	12.78 (2.78)	13.38 (3.00)		
Week 12 Adjusted Mean Change (SE)	9.41 (3.16)	11.21 (3.38)		
Week 16 Adjusted Mean Change (SE)	17.49 (2.56)	13.91 (2.75)		
Week 24 Adjusted Mean Change (SE)	18.02 (3.10)	17.86 (3.45)		
Week 32 Adjusted Mean Change (SE)	19.20 (3.19)	16.84 (3.49)		
Week 40 Adjusted Mean Change (SE)	16.13 (3.11)	13.58 (3.47)		
Week 52 Adjusted Mean Change (SE)	17.72 (3.30)	14.36 (3.73)	3.36 [-6.59; 13.32]	0.503
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	34.90 (22.05)	50.69 (22.85)		
Week 52 Mean (SD)	50.52 (27.63)	56.94 (22.63)		
Week 4 Adjusted Mean Change (SE)	2.83 (4.95)	14.94 (5.77)		
Week 12 Adjusted Mean Change (SE)	18.60 (5.56)	11.90 (6.74)		
Week 16 Adjusted Mean Change (SE)	8.04 (4.51)	18.16 (5.43)		
Week 24 Adjusted Mean Change (SE)	7.74 (5.61)	23.23 (6.59)		
Week 32 Adjusted Mean Change (SE)	11.20 (5.56)	12.66 (6.51)		
Week 40 Adjusted Mean Change (SE)	17.54 (5.48)	21.81 (6.41)		
Week 52 Adjusted Mean Change (SE)	13.60 (5.73)	12.31 (6.72)	1.29 [-16.36; 18.94]	0.885

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.12 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.513				
Non-carrier, N	**36**	**34**		
N'	36	33		
Baseline Mean (SD)	33.68 (19.84)	41.73 (21.58)		
Week 52 Mean (SD)	49.43 (23.04)	53.47 (23.41)		
Week 4 Adjusted Mean Change (SE)	9.51 (2.84)	14.62 (2.98)		
Week 12 Adjusted Mean Change (SE)	13.41 (3.22)	11.31 (3.41)		
Week 16 Adjusted Mean Change (SE)	14.54 (2.77)	13.26 (2.94)		
Week 24 Adjusted Mean Change (SE)	14.61 (3.35)	17.44 (3.61)		
Week 32 Adjusted Mean Change (SE)	15.44 (3.26)	14.63 (3.49)		
Week 40 Adjusted Mean Change (SE)	15.48 (3.30)	14.03 (3.57)		
Week 52 Adjusted Mean Change (SE)	14.34 (3.39)	11.84 (3.71)	2.50 [-7.60; 12.59]	0.624
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	37.50 (16.34)	36.25 (19.50)		
Week 52 Mean (SD)	58.65 (22.03)	50.00 (23.75)		
Week 4 Adjusted Mean Change (SE)	10.30 (4.70)	5.33 (5.39)		
Week 12 Adjusted Mean Change (SE)	5.99 (5.33)	7.69 (6.10)		
Week 16 Adjusted Mean Change (SE)	16.07 (4.54)	11.63 (5.21)		
Week 24 Adjusted Mean Change (SE)	17.52 (5.50)	14.71 (6.31)		
Week 32 Adjusted Mean Change (SE)	19.92 (5.33)	12.87 (6.11)		
Week 40 Adjusted Mean Change (SE)	18.00 (5.41)	10.84 (6.30)		
Week 52 Adjusted Mean Change (SE)	21.37 (5.48)	12.79 (6.28)	8.58 [-8.06; 25.22]	0.308

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.13 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.965				
Non-carrier, N	**42**	**36**		
N'	42	35		
Baseline Mean (SD)	35.12 (19.86)	39.76 (21.03)		
Week 52 Mean (SD)	52.72 (21.97)	53.02 (23.06)		
Week 4 Adjusted Mean Change (SE)	11.43 (2.65)	14.48 (2.92)		
Week 12 Adjusted Mean Change (SE)	12.44 (2.99)	10.51 (3.29)		
Week 16 Adjusted Mean Change (SE)	16.86 (2.48)	12.64 (2.75)		
Week 24 Adjusted Mean Change (SE)	16.00 (3.06)	15.30 (3.45)		
Week 32 Adjusted Mean Change (SE)	18.94 (3.02)	13.64 (3.36)		
Week 40 Adjusted Mean Change (SE)	17.02 (3.00)	12.98 (3.44)		
Week 52 Adjusted Mean Change (SE)	17.32 (3.01)	13.39 (3.46)	3.93 [-5.22; 13.08]	0.396
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	29.86 (12.41)	33.75 (20.06)		
Week 52 Mean (SD)	52.08 (26.88)	46.25 (19.57)		
Week 4 Adjusted Mean Change (SE)	8.37 (5.76)	1.50 (7.67)		
Week 12 Adjusted Mean Change (SE)	13.69 (6.44)	12.38 (8.58)		
Week 16 Adjusted Mean Change (SE)	11.86 (5.34)	7.75 (7.11)		
Week 24 Adjusted Mean Change (SE)	18.59 (6.61)	21.42 (8.81)		
Week 32 Adjusted Mean Change (SE)	14.04 (6.45)	20.29 (8.59)		
Week 40 Adjusted Mean Change (SE)	19.54 (6.48)	16.24 (8.63)		
Week 52 Adjusted Mean Change (SE)	19.33 (6.44)	11.43 (8.58)	7.89 [-13.42; 29.20]	0.463

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.14 SF-36 Vitality - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.759				
Low score, N	**11**	**22**		
N'	11	21		
Baseline Mean (SD)	34.66 (27.86)	41.19 (21.10)		
Week 52 Mean (SD)	46.88 (26.88)	50.83 (24.53)		
Week 4 Adjusted Mean Change (SE)	14.49 (5.15)	15.69 (3.76)		
Week 12 Adjusted Mean Change (SE)	15.30 (5.84)	10.10 (4.27)		
Week 16 Adjusted Mean Change (SE)	17.27 (5.05)	10.87 (3.64)		
Week 24 Adjusted Mean Change (SE)	11.10 (5.80)	10.33 (4.40)		
Week 32 Adjusted Mean Change (SE)	16.82 (5.85)	13.75 (4.49)		
Week 40 Adjusted Mean Change (SE)	11.42 (5.68)	7.75 (4.42)		
Week 52 Adjusted Mean Change (SE)	9.64 (6.03)	9.74 (4.79)	-0.10 [-15.44; 15.23]	0.989
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	34.06 (15.88)	39.77 (21.44)		
Week 52 Mean (SD)	54.11 (21.57)	53.69 (22.79)		
Week 4 Adjusted Mean Change (SE)	9.51 (2.71)	9.60 (3.66)		
Week 12 Adjusted Mean Change (SE)	11.41 (3.10)	11.20 (4.21)		
Week 16 Adjusted Mean Change (SE)	15.41 (2.58)	15.01 (3.53)		
Week 24 Adjusted Mean Change (SE)	17.75 (3.07)	22.70 (4.15)		
Week 32 Adjusted Mean Change (SE)	17.87 (3.13)	14.94 (4.15)		
Week 40 Adjusted Mean Change (SE)	18.71 (3.01)	18.38 (4.07)		
Week 52 Adjusted Mean Change (SE)	19.33 (3.16)	14.84 (4.20)	4.49 [-5.99; 14.97]	0.397

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.15 SF-36 Vitality - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.763				
Non-carrier, N	**31**	**23**		
N'	31	22		
Baseline Mean (SD)	33.06 (17.32)	39.40 (20.07)		
Week 52 Mean (SD)	51.46 (23.02)	53.31 (18.63)		
Week 4 Adjusted Mean Change (SE)	10.56 (3.13)	12.96 (3.69)		
Week 12 Adjusted Mean Change (SE)	14.84 (3.47)	8.82 (4.09)		
Week 16 Adjusted Mean Change (SE)	14.90 (2.96)	11.56 (3.54)		
Week 24 Adjusted Mean Change (SE)	14.12 (3.56)	14.15 (4.31)		
Week 32 Adjusted Mean Change (SE)	17.20 (3.55)	15.43 (4.28)		
Week 40 Adjusted Mean Change (SE)	16.84 (3.47)	9.09 (4.25)		
Week 52 Adjusted Mean Change (SE)	16.88 (3.64)	13.72 (4.58)	3.16 [-8.53; 14.85]	0.592
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	35.94 (21.16)	41.67 (22.48)		
Week 52 Mean (SD)	54.51 (22.57)	51.88 (26.99)		
Week 4 Adjusted Mean Change (SE)	10.67 (3.87)	12.13 (3.79)		
Week 12 Adjusted Mean Change (SE)	8.11 (4.37)	12.58 (4.27)		
Week 16 Adjusted Mean Change (SE)	16.99 (3.72)	14.55 (3.64)		
Week 24 Adjusted Mean Change (SE)	19.65 (4.44)	19.99 (4.41)		
Week 32 Adjusted Mean Change (SE)	18.38 (4.45)	13.40 (4.34)		
Week 40 Adjusted Mean Change (SE)	17.41 (4.26)	18.24 (4.28)		
Week 52 Adjusted Mean Change (SE)	17.75 (4.54)	11.62 (4.45)	6.12 [-6.55; 18.80]	0.339

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.15 SF-36 Vitality - Change from Baseline by Linkage Variant rs10891185 (FAS)

50.16 SF-36 Vitality - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.996				
Non-carrier, N	**19**	**20**		
N'	19	19		
Baseline Mean (SD)	32.24 (21.68)	39.69 (22.88)		
Week 52 Mean (SD)	50.33 (22.68)	53.57 (26.03)		
Week 4 Adjusted Mean Change (SE)	11.23 (3.90)	18.45 (3.89)		
Week 12 Adjusted Mean Change (SE)	18.82 (4.36)	13.96 (4.43)		
Week 16 Adjusted Mean Change (SE)	14.65 (3.77)	14.30 (3.82)		
Week 24 Adjusted Mean Change (SE)	13.41 (4.62)	13.88 (4.75)		
Week 32 Adjusted Mean Change (SE)	18.54 (4.48)	14.95 (4.63)		
Week 40 Adjusted Mean Change (SE)	19.28 (4.49)	11.11 (4.70)		
Week 52 Adjusted Mean Change (SE)	16.21 (4.60)	11.00 (5.02)	5.21 [-8.39; 18.80]	0.449
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	35.35 (17.07)	41.15 (19.84)		
Week 52 Mean (SD)	54.09 (22.92)	51.90 (21.93)		
Week 4 Adjusted Mean Change (SE)	10.24 (2.99)	7.87 (3.46)		
Week 12 Adjusted Mean Change (SE)	8.33 (3.38)	8.13 (3.87)		
Week 16 Adjusted Mean Change (SE)	16.38 (2.92)	12.02 (3.39)		
Week 24 Adjusted Mean Change (SE)	17.83 (3.51)	19.06 (4.11)		
Week 32 Adjusted Mean Change (SE)	17.13 (3.51)	13.86 (4.04)		
Week 40 Adjusted Mean Change (SE)	15.77 (3.47)	15.14 (4.07)		
Week 52 Adjusted Mean Change (SE)	17.93 (3.61)	13.28 (4.15)	4.65 [-6.32; 15.62]	0.401

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.17 SF-36 Vitality - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.175				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	32.25 (20.55)	41.60 (18.89)		
Week 52 Mean (SD)	51.63 (23.48)	50.67 (23.90)		
Week 4 Adjusted Mean Change (SE)	16.46 (3.36)	11.12 (2.97)		
Week 12 Adjusted Mean Change (SE)	11.63 (3.94)	8.80 (3.46)		
Week 16 Adjusted Mean Change (SE)	15.73 (3.27)	9.91 (2.87)		
Week 24 Adjusted Mean Change (SE)	18.39 (3.91)	13.09 (3.57)		
Week 32 Adjusted Mean Change (SE)	17.35 (3.99)	14.52 (3.57)		
Week 40 Adjusted Mean Change (SE)	18.41 (3.93)	12.69 (3.60)		
Week 52 Adjusted Mean Change (SE)	17.34 (4.09)	11.43 (3.71)	5.91 [-5.14; 16.96]	0.290
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	36.06 (17.08)	37.50 (26.65)		
Week 52 Mean (SD)	53.50 (22.32)	58.33 (21.19)		
Week 4 Adjusted Mean Change (SE)	5.07 (3.27)	16.46 (5.01)		
Week 12 Adjusted Mean Change (SE)	12.84 (3.78)	16.13 (5.80)		
Week 16 Adjusted Mean Change (SE)	15.67 (3.14)	22.33 (4.96)		
Week 24 Adjusted Mean Change (SE)	14.16 (3.83)	27.27 (5.84)		
Week 32 Adjusted Mean Change (SE)	18.05 (3.85)	14.75 (5.86)		
Week 40 Adjusted Mean Change (SE)	15.87 (3.86)	15.77 (6.02)		
Week 52 Adjusted Mean Change (SE)	17.17 (3.97)	15.31 (6.34)	1.86 [-13.01; 16.73]	0.804

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.18 SF-36 Vitality - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.692				
Non-carrier, N	**39**	**35**		
N'	39	34		
Baseline Mean (SD)	33.97 (17.95)	39.29 (19.97)		
Week 52 Mean (SD)	53.30 (21.15)	52.90 (21.41)		
Week 4 Adjusted Mean Change (SE)	12.97 (2.77)	12.58 (2.95)		
Week 12 Adjusted Mean Change (SE)	10.29 (3.14)	11.39 (3.35)		
Week 16 Adjusted Mean Change (SE)	18.10 (2.60)	12.61 (2.77)		
Week 24 Adjusted Mean Change (SE)	18.72 (3.15)	16.39 (3.47)		
Week 32 Adjusted Mean Change (SE)	19.74 (3.13)	15.16 (3.37)		
Week 40 Adjusted Mean Change (SE)	16.81 (3.12)	12.73 (3.43)		
Week 52 Adjusted Mean Change (SE)	18.36 (3.25)	13.27 (3.61)	5.09 [-4.61; 14.79]	0.300
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	34.09 (22.94)	45.14 (25.54)		
Week 52 Mean (SD)	51.70 (28.65)	51.39 (29.61)		
Week 4 Adjusted Mean Change (SE)	3.80 (5.22)	12.47 (5.76)		
Week 12 Adjusted Mean Change (SE)	19.86 (5.87)	8.06 (6.49)		
Week 16 Adjusted Mean Change (SE)	9.57 (4.87)	14.64 (5.55)		
Week 24 Adjusted Mean Change (SE)	9.19 (6.05)	18.78 (6.56)		
Week 32 Adjusted Mean Change (SE)	14.10 (5.79)	11.55 (6.39)		
Week 40 Adjusted Mean Change (SE)	19.94 (5.85)	17.01 (6.60)		
Week 52 Adjusted Mean Change (SE)	15.59 (6.01)	9.39 (6.64)	6.20 [-11.66; 24.06]	0.492

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

50.18 SF-36 Vitality - Change from Baseline by Linkage Variant rs7787032 (FAS)

51.0 SF-36 MCS - Return Rates (FAS)

	Treatment Groups		
	SEC **(N=66)**	**ADA** **(N=62)**	**Total** **(N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	57 (91.9)	122 (95.3)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	48 (77.4)	111 (86.7)

51.1 SF-36 MCS - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	60		
Baseline Mean (SD)	42.13 (12.11)	41.85 (11.41)		
Week 52 Mean (SD)	48.50 (10.86)	46.60 (12.24)		
Week 4 Adjusted Mean Change (SE)	4.66 (1.00)	4.91 (1.05)		
Week 12 Adjusted Mean Change (SE)	5.26 (0.96)	4.21 (1.00)		
Week 16 Adjusted Mean Change (SE)	5.95 (0.97)	3.67 (1.03)		
Week 24 Adjusted Mean Change (SE)	6.08 (1.15)	4.21 (1.25)		
Week 32 Adjusted Mean Change (SE)	7.16 (1.17)	4.33 (1.26)		
Week 40 Adjusted Mean Change (SE)	5.71 (1.08)	3.48 (1.21)		
Week 52 Adjusted Mean Change (SE)	6.58 (1.21)	4.74 (1.35)	1.84 [-1.75; 5.43]	0.312

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

51.2 SF-36 MCS - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.961				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	44.18 (12.20)	43.60 (11.01)		
Week 52 Mean (SD)	49.14 (11.02)	46.02 (11.42)		
Week 4 Adjusted Mean Change (SE)	5.34 (1.27)	5.26 (1.45)		
Week 12 Adjusted Mean Change (SE)	5.29 (1.22)	3.67 (1.38)		
Week 16 Adjusted Mean Change (SE)	5.28 (1.24)	3.67 (1.41)		
Week 24 Adjusted Mean Change (SE)	5.17 (1.45)	3.84 (1.71)		
Week 32 Adjusted Mean Change (SE)	6.52 (1.48)	3.41 (1.74)		
Week 40 Adjusted Mean Change (SE)	4.82 (1.38)	2.82 (1.65)		
Week 52 Adjusted Mean Change (SE)	5.97 (1.53)	3.46 (1.85)	2.51 [-2.23; 7.25]	0.296
Female, N	**24**	**29**		
N'	24	28		
Baseline Mean (SD)	38.56 (11.31)	39.86 (11.73)		
Week 52 Mean (SD)	47.39 (10.72)	47.27 (13.38)		
Week 4 Adjusted Mean Change (SE)	3.45 (1.69)	4.52 (1.55)		
Week 12 Adjusted Mean Change (SE)	5.22 (1.64)	4.84 (1.49)		
Week 16 Adjusted Mean Change (SE)	7.10 (1.64)	3.63 (1.56)		
Week 24 Adjusted Mean Change (SE)	7.69 (1.95)	4.64 (1.85)		
Week 32 Adjusted Mean Change (SE)	8.27 (1.98)	5.38 (1.85)		
Week 40 Adjusted Mean Change (SE)	7.24 (1.82)	4.24 (1.80)		
Week 52 Adjusted Mean Change (SE)	7.65 (2.03)	6.26 (2.00)	1.39 [-4.21; 7.00]	0.623

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

51.3 SF-36 MCS - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.223				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	47.20 (9.61)	44.84 (11.44)		
Week 52 Mean (SD)	51.57 (8.34)	44.86 (11.03)		
Week 4 Adjusted Mean Change (SE)	7.20 (2.05)	3.08 (2.25)		
Week 12 Adjusted Mean Change (SE)	5.32 (2.02)	3.95 (2.17)		
Week 16 Adjusted Mean Change (SE)	6.15 (2.01)	2.30 (2.20)		
Week 24 Adjusted Mean Change (SE)	7.23 (2.40)	2.21 (2.74)		
Week 32 Adjusted Mean Change (SE)	9.03 (2.40)	1.28 (2.84)		
Week 40 Adjusted Mean Change (SE)	7.65 (2.25)	1.56 (2.76)		
Week 52 Adjusted Mean Change (SE)	6.92 (2.48)	4.27 (3.11)	2.65 [-5.23; 10.53]	0.507
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	47		
Baseline Mean (SD)	40.51 (12.45)	41.06 (11.39)		
Week 52 Mean (SD)	47.45 (11.48)	47.00 (12.60)		
Week 4 Adjusted Mean Change (SE)	3.84 (1.15)	5.42 (1.18)		
Week 12 Adjusted Mean Change (SE)	5.24 (1.11)	4.27 (1.15)		
Week 16 Adjusted Mean Change (SE)	5.89 (1.13)	4.06 (1.18)		
Week 24 Adjusted Mean Change (SE)	5.70 (1.32)	4.75 (1.41)		
Week 32 Adjusted Mean Change (SE)	6.57 (1.35)	5.08 (1.41)		
Week 40 Adjusted Mean Change (SE)	5.11 (1.25)	3.98 (1.35)		
Week 52 Adjusted Mean Change (SE)	6.50 (1.41)	4.91 (1.52)	1.59 [-2.51; 5.69]	0.444

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

51.4 SF-36 MCS - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.285				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	31		
Baseline Mean (SD)	43.18 (12.75)	41.44 (11.39)		
Week 52 Mean (SD)	48.42 (11.80)	47.56 (12.09)		
Week 4 Adjusted Mean Change (SE)	3.94 (1.54)	3.94 (1.47)		
Week 12 Adjusted Mean Change (SE)	4.22 (1.47)	4.77 (1.40)		
Week 16 Adjusted Mean Change (SE)	3.87 (1.48)	3.25 (1.43)		
Week 24 Adjusted Mean Change (SE)	4.73 (1.77)	5.49 (1.73)		
Week 32 Adjusted Mean Change (SE)	6.15 (1.81)	4.69 (1.77)		
Week 40 Adjusted Mean Change (SE)	5.04 (1.68)	3.81 (1.74)		
Week 52 Adjusted Mean Change (SE)	5.92 (1.88)	5.89 (1.94)	0.03 [-5.32; 5.37]	0.993
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	41.36 (11.72)	42.29 (11.61)		
Week 52 Mean (SD)	48.56 (10.30)	45.71 (12.55)		
Week 4 Adjusted Mean Change (SE)	5.18 (1.32)	5.95 (1.52)		
Week 12 Adjusted Mean Change (SE)	6.03 (1.28)	3.58 (1.46)		
Week 16 Adjusted Mean Change (SE)	7.53 (1.28)	4.10 (1.47)		
Week 24 Adjusted Mean Change (SE)	7.06 (1.51)	2.78 (1.80)		
Week 32 Adjusted Mean Change (SE)	7.92 (1.55)	3.92 (1.82)		
Week 40 Adjusted Mean Change (SE)	6.21 (1.44)	3.04 (1.72)		
Week 52 Adjusted Mean Change (SE)	7.08 (1.59)	3.63 (1.91)	3.45 [-1.48; 8.37]	0.168

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

51.5 SF-36 MCS - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.998				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	41.79 (10.54)	45.65 (10.64)		
Week 52 Mean (SD)	49.30 (10.04)	50.48 (11.39)		
Week 4 Adjusted Mean Change (SE)	5.12 (1.29)	5.61 (1.54)		
Week 12 Adjusted Mean Change (SE)	5.59 (1.25)	4.02 (1.47)		
Week 16 Adjusted Mean Change (SE)	6.03 (1.26)	4.88 (1.52)		
Week 24 Adjusted Mean Change (SE)	6.96 (1.47)	5.37 (1.84)		
Week 32 Adjusted Mean Change (SE)	7.65 (1.52)	4.78 (1.87)		
Week 40 Adjusted Mean Change (SE)	7.12 (1.39)	4.58 (1.80)		
Week 52 Adjusted Mean Change (SE)	7.44 (1.55)	6.39 (2.04)	1.05 [-4.04; 6.13]	0.684
> Median, N	**26**	**33**		
N'	26	31		
Baseline Mean (SD)	42.67 (14.40)	38.51 (11.16)		
Week 52 Mean (SD)	47.28 (12.10)	43.58 (12.22)		
Week 4 Adjusted Mean Change (SE)	3.94 (1.60)	4.26 (1.48)		
Week 12 Adjusted Mean Change (SE)	4.79 (1.53)	4.42 (1.43)		
Week 16 Adjusted Mean Change (SE)	5.81 (1.55)	2.57 (1.44)		
Week 24 Adjusted Mean Change (SE)	4.73 (1.84)	3.18 (1.74)		
Week 32 Adjusted Mean Change (SE)	6.38 (1.86)	3.93 (1.76)		
Week 40 Adjusted Mean Change (SE)	3.60 (1.70)	2.55 (1.65)		
Week 52 Adjusted Mean Change (SE)	5.28 (1.91)	3.39 (1.85)	1.88 [-3.40; 7.16]	0.481

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

51.6 SF-36 MCS - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.224				
Enthesitis: No, N	**34**	**22**		
N'	34	21		
Baseline Mean (SD)	43.62 (11.00)	43.56 (11.58)		
Week 52 Mean (SD)	49.00 (10.54)	51.22 (11.31)		
Week 4 Adjusted Mean Change (SE)	6.32 (1.38)	7.59 (1.76)		
Week 12 Adjusted Mean Change (SE)	5.41 (1.34)	6.51 (1.72)		
Week 16 Adjusted Mean Change (SE)	5.83 (1.35)	5.87 (1.75)		
Week 24 Adjusted Mean Change (SE)	6.59 (1.62)	5.49 (2.07)		
Week 32 Adjusted Mean Change (SE)	7.81 (1.63)	7.69 (2.06)		
Week 40 Adjusted Mean Change (SE)	6.29 (1.52)	5.59 (1.97)		
Week 52 Adjusted Mean Change (SE)	6.14 (1.68)	7.91 (2.21)	-1.77 [-7.25; 3.71]	0.523
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	40.55 (13.17)	40.91 (11.36)		
Week 52 Mean (SD)	47.99 (11.33)	43.82 (12.10)		
Week 4 Adjusted Mean Change (SE)	2.90 (1.42)	3.48 (1.29)		
Week 12 Adjusted Mean Change (SE)	5.12 (1.38)	2.99 (1.24)		
Week 16 Adjusted Mean Change (SE)	6.11 (1.41)	2.49 (1.28)		
Week 24 Adjusted Mean Change (SE)	5.54 (1.65)	3.56 (1.59)		
Week 32 Adjusted Mean Change (SE)	6.50 (1.66)	2.42 (1.59)		
Week 40 Adjusted Mean Change (SE)	5.13 (1.55)	2.30 (1.54)		
Week 52 Adjusted Mean Change (SE)	7.05 (1.72)	2.95 (1.71)	4.10 [-0.68; 8.88]	0.092

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

51.7 SF-36 MCS - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.238				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	39.67 (12.82)	44.05 (10.38)		
Week 52 Mean (SD)	46.88 (11.65)	52.11 (10.05)		
Week 4 Adjusted Mean Change (SE)	7.24 (1.49)	7.18 (1.61)		
Week 12 Adjusted Mean Change (SE)	5.81 (1.45)	5.56 (1.58)		
Week 16 Adjusted Mean Change (SE)	5.67 (1.49)	3.69 (1.65)		
Week 24 Adjusted Mean Change (SE)	7.02 (1.69)	6.97 (1.89)		
Week 32 Adjusted Mean Change (SE)	6.95 (1.78)	7.02 (1.98)		
Week 40 Adjusted Mean Change (SE)	6.29 (1.74)	5.84 (1.94)		
Week 52 Adjusted Mean Change (SE)	6.63 (1.66)	9.87 (1.86)	-3.24 [-8.22; 1.73]	0.199
Carrier, N	**22**	**19**		
N'	22	18		
Baseline Mean (SD)	44.62 (10.30)	38.74 (11.26)		
Week 52 Mean (SD)	51.19 (8.99)	40.18 (12.44)		
Week 4 Adjusted Mean Change (SE)	1.96 (1.71)	2.65 (1.89)		
Week 12 Adjusted Mean Change (SE)	3.73 (1.70)	3.38 (1.83)		
Week 16 Adjusted Mean Change (SE)	4.95 (1.74)	4.13 (1.89)		
Week 24 Adjusted Mean Change (SE)	5.50 (1.97)	1.85 (2.18)		
Week 32 Adjusted Mean Change (SE)	7.79 (2.12)	0.28 (2.30)		
Week 40 Adjusted Mean Change (SE)	5.78 (2.03)	2.10 (2.31)		
Week 52 Adjusted Mean Change (SE)	7.97 (1.94)	0.65 (2.17)	7.32 [1.51; 13.13]	0.014

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

51.8 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.791				
Non-carrier, N	**28**	**19**		
N'	28	18		
Baseline Mean (SD)	39.36 (10.39)	43.74 (11.36)		
Week 52 Mean (SD)	48.22 (11.89)	47.82 (9.17)		
Week 4 Adjusted Mean Change (SE)	6.71 (1.58)	5.50 (1.97)		
Week 12 Adjusted Mean Change (SE)	5.44 (1.53)	5.62 (1.91)		
Week 16 Adjusted Mean Change (SE)	5.86 (1.56)	3.43 (1.98)		
Week 24 Adjusted Mean Change (SE)	4.97 (1.61)	4.60 (2.10)		
Week 32 Adjusted Mean Change (SE)	7.82 (1.85)	4.90 (2.39)		
Week 40 Adjusted Mean Change (SE)	5.99 (1.81)	3.05 (2.37)		
Week 52 Adjusted Mean Change (SE)	7.72 (1.86)	6.33 (2.50)	1.39 [-4.83; 7.61]	0.658
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	44.85 (13.54)	40.06 (11.76)		
Week 52 Mean (SD)	49.18 (9.54)	45.88 (15.90)		
Week 4 Adjusted Mean Change (SE)	2.83 (1.79)	4.12 (1.91)		
Week 12 Adjusted Mean Change (SE)	4.26 (1.76)	4.44 (1.89)		
Week 16 Adjusted Mean Change (SE)	4.55 (1.78)	3.72 (1.92)		
Week 24 Adjusted Mean Change (SE)	8.29 (1.85)	5.37 (2.01)		
Week 32 Adjusted Mean Change (SE)	6.04 (2.12)	3.73 (2.26)		
Week 40 Adjusted Mean Change (SE)	6.08 (2.02)	6.24 (2.23)		
Week 52 Adjusted Mean Change (SE)	6.32 (2.11)	5.21 (2.27)	1.10 [-5.10; 7.30]	0.724

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

51.9 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.537				
Non-carrier, N	**19**	**21**		
N'	19	20		
Baseline Mean (SD)	39.96 (13.36)	42.38 (10.45)		
Week 52 Mean (SD)	48.53 (11.54)	49.45 (11.97)		
Week 4 Adjusted Mean Change (SE)	5.69 (1.80)	8.29 (1.75)		
Week 12 Adjusted Mean Change (SE)	7.78 (1.71)	6.54 (1.70)		
Week 16 Adjusted Mean Change (SE)	5.57 (1.82)	5.61 (1.81)		
Week 24 Adjusted Mean Change (SE)	6.70 (2.13)	3.46 (2.16)		
Week 32 Adjusted Mean Change (SE)	8.50 (2.22)	7.63 (2.26)		
Week 40 Adjusted Mean Change (SE)	6.68 (2.14)	4.73 (2.21)		
Week 52 Adjusted Mean Change (SE)	8.06 (2.17)	7.81 (2.30)	0.26 [-6.04; 6.55]	0.935
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	41.86 (10.41)	41.20 (11.63)		
Week 52 Mean (SD)	48.62 (10.55)	45.25 (12.86)		
Week 4 Adjusted Mean Change (SE)	5.30 (1.43)	2.89 (1.63)		
Week 12 Adjusted Mean Change (SE)	3.90 (1.38)	3.15 (1.56)		
Week 16 Adjusted Mean Change (SE)	5.79 (1.45)	2.69 (1.68)		
Week 24 Adjusted Mean Change (SE)	6.68 (1.68)	5.86 (1.95)		
Week 32 Adjusted Mean Change (SE)	6.51 (1.80)	1.44 (2.05)		
Week 40 Adjusted Mean Change (SE)	6.53 (1.72)	3.96 (2.00)		
Week 52 Adjusted Mean Change (SE)	7.02 (1.75)	4.56 (2.01)	2.46 [-2.85; 7.76]	0.359

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

51.10 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.545				
Non-carrier, N	25	32		
N'	25	32		
Baseline Mean (SD)	41.03 (12.97)	41.07 (10.83)		
Week 52 Mean (SD)	46.78 (11.41)	46.31 (13.06)		
Week 4 Adjusted Mean Change (SE)	6.89 (1.65)	5.25 (1.46)		
Week 12 Adjusted Mean Change (SE)	4.92 (1.58)	3.90 (1.39)		
Week 16 Adjusted Mean Change (SE)	4.71 (1.59)	2.41 (1.40)		
Week 24 Adjusted Mean Change (SE)	6.08 (1.80)	3.12 (1.66)		
Week 32 Adjusted Mean Change (SE)	6.59 (2.00)	5.00 (1.80)		
Week 40 Adjusted Mean Change (SE)	6.11 (1.89)	3.92 (1.75)		
Week 52 Adjusted Mean Change (SE)	6.17 (1.92)	6.07 (1.75)	0.11 [-5.05; 5.27]	0.967
Carrier, N	26	12		
N'	26	11		
Baseline Mean (SD)	42.55 (11.08)	43.60 (11.62)		
Week 52 Mean (SD)	50.41 (10.00)	48.95 (11.07)		
Week 4 Adjusted Mean Change (SE)	3.11 (1.62)	5.41 (2.50)		
Week 12 Adjusted Mean Change (SE)	4.89 (1.53)	6.79 (2.36)		
Week 16 Adjusted Mean Change (SE)	5.91 (1.53)	8.64 (2.44)		
Week 24 Adjusted Mean Change (SE)	6.68 (1.78)	9.40 (2.72)		
Week 32 Adjusted Mean Change (SE)	7.79 (1.94)	2.16 (2.97)		
Week 40 Adjusted Mean Change (SE)	5.99 (1.87)	5.13 (2.91)		
Week 52 Adjusted Mean Change (SE)	8.00 (1.87)	5.79 (2.99)	2.21 [-4.80; 9.22]	0.532

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

51.11 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.261				
Non-carrier, N	**38**	**33**		
N'	38	32		
Baseline Mean (SD)	42.22 (10.90)	41.69 (9.84)		
Week 52 Mean (SD)	49.18 (10.06)	47.57 (9.83)		
Week 4 Adjusted Mean Change (SE)	5.44 (1.34)	4.79 (1.46)		
Week 12 Adjusted Mean Change (SE)	3.51 (1.25)	4.24 (1.34)		
Week 16 Adjusted Mean Change (SE)	6.29 (1.26)	3.79 (1.37)		
Week 24 Adjusted Mean Change (SE)	7.15 (1.48)	4.70 (1.67)		
Week 32 Adjusted Mean Change (SE)	7.84 (1.62)	4.74 (1.80)		
Week 40 Adjusted Mean Change (SE)	5.97 (1.47)	3.53 (1.67)		
Week 52 Adjusted Mean Change (SE)	7.27 (1.55)	6.80 (1.77)	0.48 [-4.20; 5.15]	0.839
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	40.17 (15.62)	46.74 (10.61)		
Week 52 Mean (SD)	46.50 (12.96)	50.59 (15.31)		
Week 4 Adjusted Mean Change (SE)	2.04 (2.41)	6.71 (2.77)		
Week 12 Adjusted Mean Change (SE)	8.13 (2.22)	5.87 (2.65)		
Week 16 Adjusted Mean Change (SE)	1.36 (2.24)	6.53 (2.68)		
Week 24 Adjusted Mean Change (SE)	3.37 (2.69)	7.23 (3.13)		
Week 32 Adjusted Mean Change (SE)	4.25 (2.85)	3.52 (3.29)		
Week 40 Adjusted Mean Change (SE)	5.12 (2.62)	9.39 (3.03)		
Week 52 Adjusted Mean Change (SE)	5.52 (2.73)	6.14 (3.15)	-0.63 [-8.95; 7.70]	0.881

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

51.11 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

51.12 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.287				
Non-carrier, N	**36**	**34**		
N'	36	33		
Baseline Mean (SD)	41.47 (12.88)	42.19 (10.79)		
Week 52 Mean (SD)	47.33 (11.12)	47.85 (12.99)		
Week 4 Adjusted Mean Change (SE)	5.55 (1.36)	6.78 (1.42)		
Week 12 Adjusted Mean Change (SE)	5.87 (1.28)	4.87 (1.35)		
Week 16 Adjusted Mean Change (SE)	4.70 (1.35)	4.40 (1.43)		
Week 24 Adjusted Mean Change (SE)	5.43 (1.54)	4.90 (1.67)		
Week 32 Adjusted Mean Change (SE)	6.39 (1.65)	5.33 (1.77)		
Week 40 Adjusted Mean Change (SE)	5.02 (1.57)	4.86 (1.71)		
Week 52 Adjusted Mean Change (SE)	6.18 (1.60)	6.72 (1.75)	-0.54 [-5.26; 4.18]	0.820
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	42.08 (10.33)	40.29 (12.03)		
Week 52 Mean (SD)	50.71 (9.82)	44.54 (11.37)		
Week 4 Adjusted Mean Change (SE)	2.60 (2.26)	0.59 (2.60)		
Week 12 Adjusted Mean Change (SE)	1.35 (2.13)	4.03 (2.44)		
Week 16 Adjusted Mean Change (SE)	6.27 (2.22)	2.68 (2.55)		
Week 24 Adjusted Mean Change (SE)	8.18 (2.55)	4.51 (2.93)		
Week 32 Adjusted Mean Change (SE)	8.68 (2.71)	0.74 (3.10)		
Week 40 Adjusted Mean Change (SE)	8.56 (2.60)	2.38 (3.04)		
Week 52 Adjusted Mean Change (SE)	8.89 (2.61)	3.74 (3.00)	5.15 [-2.78; 13.09]	0.200

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

51.13 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.866				
Non-carrier, N	**42**	**36**		
N'	42	35		
Baseline Mean (SD)	42.88 (12.76)	42.03 (11.60)		
Week 52 Mean (SD)	48.93 (10.72)	47.37 (12.08)		
Week 4 Adjusted Mean Change (SE)	4.89 (1.26)	6.01 (1.37)		
Week 12 Adjusted Mean Change (SE)	4.86 (1.18)	5.20 (1.30)		
Week 16 Adjusted Mean Change (SE)	5.70 (1.23)	3.89 (1.36)		
Week 24 Adjusted Mean Change (SE)	6.61 (1.43)	4.10 (1.61)		
Week 32 Adjusted Mean Change (SE)	6.99 (1.48)	3.96 (1.65)		
Week 40 Adjusted Mean Change (SE)	5.86 (1.47)	3.31 (1.68)		
Week 52 Adjusted Mean Change (SE)	6.89 (1.39)	6.40 (1.59)	0.49 [-3.70; 4.69]	0.817
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	36.78 (4.79)	36.72 (7.18)		
Week 52 Mean (SD)	47.55 (11.41)	46.16 (12.84)		
Week 4 Adjusted Mean Change (SE)	5.80 (2.73)	-0.96 (3.64)		
Week 12 Adjusted Mean Change (SE)	5.59 (2.55)	3.40 (3.40)		
Week 16 Adjusted Mean Change (SE)	4.30 (2.66)	0.08 (3.55)		
Week 24 Adjusted Mean Change (SE)	5.75 (3.09)	5.26 (4.12)		
Week 32 Adjusted Mean Change (SE)	8.82 (3.17)	9.02 (4.23)		
Week 40 Adjusted Mean Change (SE)	7.36 (3.18)	8.57 (4.25)		
Week 52 Adjusted Mean Change (SE)	8.98 (2.99)	7.63 (3.99)	1.35 [-8.50; 11.20]	0.786

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

51.14 SF-36 MCS - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.769				
Low score, N	**11**	**22**		
N'	11	21		
Baseline Mean (SD)	42.97 (16.59)	42.95 (10.88)		
Week 52 Mean (SD)	47.75 (14.90)	47.22 (11.81)		
Week 4 Adjusted Mean Change (SE)	7.60 (2.46)	7.77 (1.79)		
Week 12 Adjusted Mean Change (SE)	7.65 (2.34)	5.13 (1.70)		
Week 16 Adjusted Mean Change (SE)	7.49 (2.47)	4.22 (1.77)		
Week 24 Adjusted Mean Change (SE)	4.73 (2.71)	2.00 (2.08)		
Week 32 Adjusted Mean Change (SE)	8.34 (2.97)	4.80 (2.29)		
Week 40 Adjusted Mean Change (SE)	3.92 (2.78)	1.84 (2.18)		
Week 52 Adjusted Mean Change (SE)	6.13 (2.91)	6.22 (2.29)	-0.09 [-7.43; 7.26]	0.982
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	41.49 (10.58)	40.57 (11.19)		
Week 52 Mean (SD)	48.92 (9.60)	46.77 (13.24)		
Week 4 Adjusted Mean Change (SE)	4.24 (1.29)	2.94 (1.74)		
Week 12 Adjusted Mean Change (SE)	4.15 (1.24)	4.22 (1.69)		
Week 16 Adjusted Mean Change (SE)	4.87 (1.25)	3.67 (1.72)		
Week 24 Adjusted Mean Change (SE)	6.82 (1.43)	7.15 (1.94)		
Week 32 Adjusted Mean Change (SE)	6.83 (1.58)	3.56 (2.10)		
Week 40 Adjusted Mean Change (SE)	6.66 (1.47)	6.13 (1.99)		
Week 52 Adjusted Mean Change (SE)	7.42 (1.51)	5.78 (2.02)	1.64 [-3.38; 6.66]	0.517

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

51.15 SF-36 MCS - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.766				
Non-carrier, N	**31**	**23**		
N'	31	22		
Baseline Mean (SD)	40.09 (10.65)	42.68 (10.59)		
Week 52 Mean (SD)	48.54 (11.36)	47.67 (8.94)		
Week 4 Adjusted Mean Change (SE)	6.01 (1.50)	5.74 (1.78)		
Week 12 Adjusted Mean Change (SE)	5.21 (1.41)	4.88 (1.67)		
Week 16 Adjusted Mean Change (SE)	5.29 (1.44)	3.71 (1.74)		
Week 24 Adjusted Mean Change (SE)	5.08 (1.63)	3.76 (2.00)		
Week 32 Adjusted Mean Change (SE)	8.06 (1.78)	4.48 (2.17)		
Week 40 Adjusted Mean Change (SE)	6.16 (1.69)	2.52 (2.08)		
Week 52 Adjusted Mean Change (SE)	7.68 (1.72)	6.86 (2.16)	0.82 [-4.67; 6.31]	0.767
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	44.46 (13.59)	40.75 (11.54)		
Week 52 Mean (SD)	48.89 (9.92)	46.34 (15.11)		
Week 4 Adjusted Mean Change (SE)	3.33 (1.88)	4.81 (1.82)		
Week 12 Adjusted Mean Change (SE)	4.47 (1.80)	4.40 (1.74)		
Week 16 Adjusted Mean Change (SE)	5.47 (1.83)	4.23 (1.78)		
Week 24 Adjusted Mean Change (SE)	8.53 (2.07)	5.90 (2.03)		
Week 32 Adjusted Mean Change (SE)	5.82 (2.25)	3.85 (2.18)		
Week 40 Adjusted Mean Change (SE)	5.98 (2.09)	5.95 (2.09)		
Week 52 Adjusted Mean Change (SE)	6.37 (2.16)	5.26 (2.10)	1.11 [-4.90; 7.11]	0.715

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

51.16 SF-36 MCS - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.763				
Non-carrier, N	**19**	**20**		
N'	19	19		
Baseline Mean (SD)	39.96 (13.36)	43.02 (10.29)		
Week 52 Mean (SD)	48.53 (11.54)	48.72 (12.06)		
Week 4 Adjusted Mean Change (SE)	5.44 (1.85)	9.09 (1.86)		
Week 12 Adjusted Mean Change (SE)	7.63 (1.73)	6.95 (1.77)		
Week 16 Adjusted Mean Change (SE)	5.41 (1.81)	6.21 (1.84)		
Week 24 Adjusted Mean Change (SE)	6.60 (2.12)	2.92 (2.21)		
Week 32 Adjusted Mean Change (SE)	8.33 (2.24)	6.22 (2.35)		
Week 40 Adjusted Mean Change (SE)	6.51 (2.16)	3.30 (2.29)		
Week 52 Adjusted Mean Change (SE)	7.90 (2.17)	6.61 (2.37)	1.29 [-5.11; 7.69]	0.690
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	42.90 (11.11)	40.71 (11.62)		
Week 52 Mean (SD)	48.77 (10.39)	45.88 (12.92)		
Week 4 Adjusted Mean Change (SE)	4.68 (1.43)	2.30 (1.64)		
Week 12 Adjusted Mean Change (SE)	3.26 (1.35)	2.85 (1.54)		
Week 16 Adjusted Mean Change (SE)	5.39 (1.40)	2.17 (1.63)		
Week 24 Adjusted Mean Change (SE)	6.22 (1.62)	5.99 (1.89)		
Week 32 Adjusted Mean Change (SE)	6.53 (1.76)	2.56 (2.03)		
Week 40 Adjusted Mean Change (SE)	5.80 (1.68)	4.83 (1.97)		
Week 52 Adjusted Mean Change (SE)	6.70 (1.71)	5.38 (1.96)	1.33 [-3.85; 6.51]	0.612

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

51.17 SF-36 MCS - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.545				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	41.03 (12.97)	41.07 (10.83)		
Week 52 Mean (SD)	46.78 (11.41)	46.31 (13.06)		
Week 4 Adjusted Mean Change (SE)	6.89 (1.65)	5.25 (1.46)		
Week 12 Adjusted Mean Change (SE)	4.92 (1.58)	3.90 (1.39)		
Week 16 Adjusted Mean Change (SE)	4.71 (1.59)	2.41 (1.40)		
Week 24 Adjusted Mean Change (SE)	6.08 (1.80)	3.12 (1.66)		
Week 32 Adjusted Mean Change (SE)	6.59 (2.00)	5.00 (1.80)		
Week 40 Adjusted Mean Change (SE)	6.11 (1.89)	3.92 (1.75)		
Week 52 Adjusted Mean Change (SE)	6.17 (1.92)	6.07 (1.75)	0.11 [-5.05; 5.27]	0.967
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	42.55 (11.08)	43.60 (11.62)		
Week 52 Mean (SD)	50.41 (10.00)	48.95 (11.07)		
Week 4 Adjusted Mean Change (SE)	3.11 (1.62)	5.41 (2.50)		
Week 12 Adjusted Mean Change (SE)	4.89 (1.53)	6.79 (2.36)		
Week 16 Adjusted Mean Change (SE)	5.91 (1.53)	8.64 (2.44)		
Week 24 Adjusted Mean Change (SE)	6.68 (1.78)	9.40 (2.72)		
Week 32 Adjusted Mean Change (SE)	7.79 (1.94)	2.16 (2.97)		
Week 40 Adjusted Mean Change (SE)	5.99 (1.87)	5.13 (2.91)		
Week 52 Adjusted Mean Change (SE)	8.00 (1.87)	5.79 (2.99)	2.21 [-4.80; 9.22]	0.532

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

51.18 SF-36 MCS - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.575				
Non-carrier, N	**39**	**35**		
N'	39	34		
Baseline Mean (SD)	42.31 (10.78)	41.45 (10.02)		
Week 52 Mean (SD)	49.40 (9.99)	47.11 (10.52)		
Week 4 Adjusted Mean Change (SE)	5.71 (1.34)	5.15 (1.43)		
Week 12 Adjusted Mean Change (SE)	3.80 (1.25)	4.58 (1.34)		
Week 16 Adjusted Mean Change (SE)	6.55 (1.27)	3.63 (1.36)		
Week 24 Adjusted Mean Change (SE)	7.19 (1.47)	4.47 (1.64)		
Week 32 Adjusted Mean Change (SE)	8.02 (1.57)	4.83 (1.71)		
Week 40 Adjusted Mean Change (SE)	6.18 (1.50)	3.27 (1.67)		
Week 52 Adjusted Mean Change (SE)	7.51 (1.55)	6.51 (1.72)	1.00 [-3.60; 5.61]	0.666
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	41.81 (15.26)	42.96 (14.76)		
Week 52 Mean (SD)	47.84 (12.68)	46.45 (18.16)		
Week 4 Adjusted Mean Change (SE)	1.74 (2.54)	5.34 (2.78)		
Week 12 Adjusted Mean Change (SE)	8.36 (2.35)	4.46 (2.58)		
Week 16 Adjusted Mean Change (SE)	1.09 (2.38)	4.76 (2.72)		
Week 24 Adjusted Mean Change (SE)	3.48 (2.83)	5.71 (3.05)		
Week 32 Adjusted Mean Change (SE)	5.58 (2.92)	1.44 (3.21)		
Week 40 Adjusted Mean Change (SE)	6.02 (2.82)	7.47 (3.17)		
Week 52 Adjusted Mean Change (SE)	6.01 (2.87)	3.99 (3.15)	2.03 [-6.45; 10.50]	0.636

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

52.1 SF-36 MCS 2.5-Point Response / 5-Point Response (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	63 44.98 (68.15)	48 36.83 (59.40)	1.46 [0.68; 3.12] 0.329	1.15 [0.87; 1.51] 0.326	0.087 [-0.085; 0.260] 0.320
SF-36 MCS 5-Point Response Week 52, N' n (%)	63 38.95 (59.02)	48 27.43 (44.24)	1.81 [0.87; 3.78] 0.112	1.34 [0.93; 1.92] 0.118	0.148 [-0.031; 0.326] 0.105

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.
RR and RD calculated directly without adjustment.

All results are combined over MI:
n and % are averages of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

52.2 SF-36 MCS 2.5-Point Response / 5-Point Response by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 MCS 2.5-Point Response Week 52	p=0.954				
SF-36 MCS 5-Point Response Week 52	p=0.615				
Male (N)	**42**	**33**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	40 27.00 (64.29)	26 17.55 (53.18)	1.54 [0.58; 4.15] 0.388	1.21 [0.80; 1.83] 0.364	0.111 [-0.123; 0.345] 0.351
SF-36 MCS 5-Point Response Week 52, N' n (%)	40 22.00 (52.38)	26 12.87 (39.00)	1.69 [0.63; 4.52] 0.295	1.35 [0.78; 2.34] 0.286	0.134 [-0.102; 0.369] 0.265
Female (N)	**24**	**29**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	23 17.98 (74.92)	22 19.28 (66.48)	1.62 [0.45; 5.79] 0.457	1.13 [0.78; 1.63] 0.519	0.084 [-0.172; 0.340] 0.518
SF-36 MCS 5-Point Response Week 52, N' n (%)	23 16.95 (70.62)	22 14.56 (50.21)	2.53 [0.76; 8.43] 0.131	1.41 [0.87; 2.28] 0.158	0.204 [-0.067; 0.475] 0.140

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

52.3 SF-36 MCS 2.5-Point Response / 5-Point Response by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 MCS 2.5-Point Response Week 52	p=0.501				
SF-36 MCS 5-Point Response Week 52	p=0.533				
PASDAS < 5.4 (N)	**16**	**13**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	16 10.00 (62.50)	9 5.33 (41.00)	2.44 [0.48; 12.32] 0.281	1.54 [0.68; 3.51] 0.302	0.215 [-0.161; 0.591] 0.263
SF-36 MCS 5-Point Response Week 52, N' n (%)	16 9.00 (56.25)	9 3.99 (30.69)	2.95 [0.56; 15.50] 0.201	1.87 [0.67; 5.18] 0.230	0.256 [-0.111; 0.622] 0.172
PASDAS ≥ 5.4 (N)	**50**	**49**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	47 34.98 (69.96)	39 31.50 (64.29)	1.29 [0.54; 3.12] 0.568	1.09 [0.82; 1.45] 0.562	0.057 [-0.135; 0.249] 0.562
SF-36 MCS 5-Point Response Week 52, N' n (%)	47 29.95 (59.90)	39 23.44 (47.84)	1.63 [0.71; 3.76] 0.252	1.25 [0.85; 1.86] 0.256	0.121 [-0.083; 0.324] 0.246

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

52.4 SF-36 MCS 2.5-Point Response / 5-Point Response by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 MCS 2.5-Point Response Week 52	p=0.361				
SF-36 MCS 5-Point Response Week 52	p=0.477				
Moderate/Severe Psoriasis (Def D): No (N)	**28**	**32**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	26 16.98 (60.64)	23 19.80 (61.88)	0.99 [0.33; 2.98] 0.986	0.98 [0.64; 1.50] 0.932	-0.012 [-0.270; 0.245] 0.925
SF-36 MCS 5-Point Response Week 52, N' n (%)	26 14.95 (53.39)	23 14.88 (46.50)	1.35 [0.47; 3.93] 0.577	1.15 [0.68; 1.96] 0.604	0.069 [-0.194; 0.332] 0.608
Moderate/Severe Psoriasis (Def D): Yes (N)	**38**	**30**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	37 28.00 (73.68)	25 17.03 (56.77)	2.03 [0.70; 5.89] 0.194	1.30 [0.89; 1.91] 0.181	0.169 [-0.066; 0.404] 0.158
SF-36 MCS 5-Point Response Week 52, N' n (%)	37 24.00 (63.16)	25 12.55 (41.83)	2.32 [0.83; 6.49] 0.110	1.52 [0.90; 2.55] 0.117	0.213 [-0.031; 0.457] 0.087

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

52.5 SF-36 MCS 2.5-Point Response / 5-Point Response by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 MCS 2.5-Point Response Week 52	p=0.152				
SF-36 MCS 5-Point Response Week 52	p=0.312				
≤ Median (N)	**40**	**29**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	38 31.00 (77.50)	21 16.80 (57.93)	2.41 [0.80; 7.32] 0.120	1.34 [0.92; 1.96] 0.129	0.196 [-0.039; 0.430] 0.102
SF-36 MCS 5-Point Response Week 52, N' n (%)	38 27.00 (67.50)	21 13.12 (45.24)	2.46 [0.86; 7.01] 0.092	1.50 [0.92; 2.45] 0.107	0.223 [-0.023; 0.468] 0.075
> Median (N)	**26**	**33**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	25 13.98 (53.77)	27 20.03 (60.70)	0.78 [0.26; 2.29] 0.646	0.89 [0.56; 1.41] 0.610	-0.069 [-0.330; 0.192] 0.603
SF-36 MCS 5-Point Response Week 52, N' n (%)	25 11.95 (45.96)	27 14.31 (43.36)	1.14 [0.39; 3.31] 0.815	1.06 [0.59; 1.92] 0.840	0.026 [-0.237; 0.289] 0.847

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

52.6 SF-36 MCS 2.5-Point Response / 5-Point Response by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 MCS 2.5-Point Response Week 52	p=0.975				
SF-36 MCS 5-Point Response Week 52	p=0.965				
Enthesitis: No (N)	**34**	**22**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	32 22.98 (67.59)	18 12.94 (58.82)	1.51 [0.47; 4.84] 0.488	1.15 [0.74; 1.78] 0.528	0.088 [-0.180; 0.355] 0.520
SF-36 MCS 5-Point Response Week 52, N' n (%)	32 19.95 (58.68)	18 9.59 (43.59)	1.87 [0.60; 5.81] 0.276	1.35 [0.76; 2.41] 0.309	0.151 [-0.123; 0.425] 0.281
Enthesitis: Yes (N)	**32**	**40**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	31 22.00 (68.75)	30 23.89 (59.73)	1.47 [0.53; 4.12] 0.460	1.15 [0.80; 1.66] 0.443	0.090 [-0.140; 0.321] 0.443
SF-36 MCS 5-Point Response Week 52, N' n (%)	31 19.00 (59.38)	30 17.84 (44.60)	1.81 [0.67; 4.89] 0.240	1.34 [0.83; 2.16] 0.237	0.148 [-0.093; 0.388] 0.229

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

52.7 SF-36 MCS 2.5-Point Response / 5-Point Response by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 MCS 2.5-Point Response Week 52	p=0.630				
SF-36 MCS 5-Point Response Week 52	p=0.173				
Non-carrier (N)	**29**	**25**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	28 20.98 (72.34)	21 16.37 (65.48)	1.37 [0.41; 4.59] 0.605	1.11 [0.76; 1.62] 0.601	0.069 [-0.188; 0.325] 0.600
SF-36 MCS 5-Point Response Week 52, N' n (%)	28 17.95 (61.90)	21 14.00 (56.00)	1.27 [0.41; 3.92] 0.672	1.11 [0.70; 1.76] 0.668	0.059 [-0.212; 0.330] 0.669
Carrier (N)	**22**	**19**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	20 16.00 (72.73)	16 10.54 (55.47)	2.14 [0.56; 8.08] 0.264	1.31 [0.80; 2.15] 0.278	0.173 [-0.124; 0.469] 0.255
SF-36 MCS 5-Point Response Week 52, N' n (%)	20 15.00 (68.18)	16 6.31 (33.21)	4.33 [1.12; 16.72] 0.034	2.06 [0.99; 4.31] 0.053	0.350 [0.054; 0.645] 0.020

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

52.8 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 MCS 2.5-Point Response Week 52	p=0.400				
SF-36 MCS 5-Point Response Week 52	p=0.205				
Non-carrier (N)	**28**	**19**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	27 23.00 (82.14)	13 12.16 (64.00)	2.52 [0.60; 10.60] 0.206	1.29 [0.85; 1.95] 0.232	0.181 [-0.096; 0.459] 0.199
SF-36 MCS 5-Point Response Week 52, N' n (%)	27 20.00 (71.43)	13 7.64 (40.21)	3.70 [1.01; 13.60] 0.049	1.79 [0.94; 3.42] 0.078	0.312 [0.020; 0.604] 0.036
Carrier (N)	**22**	**19**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	20 12.98 (59.00)	18 10.75 (56.58)	1.11 [0.31; 3.93] 0.872	1.04 [0.61; 1.78] 0.875	0.024 [-0.283; 0.331] 0.877
SF-36 MCS 5-Point Response Week 52, N' n (%)	20 11.95 (54.32)	18 9.67 (50.89)	1.15 [0.33; 4.01] 0.828	1.07 [0.59; 1.94] 0.827	0.034 [-0.276; 0.345] 0.829

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

52.9 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 MCS 2.5-Point Response Week 52	p=0.820				
SF-36 MCS 5-Point Response Week 52	p=0.633				
Non-carrier (N)	**19**	**21**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	19 15.00 (78.95)	15 14.62 (69.62)	1.62 [0.35; 7.37] 0.535	1.14 [0.77; 1.68] 0.522	0.093 [-0.191; 0.377] 0.519
SF-36 MCS 5-Point Response Week 52, N' n (%)	19 13.00 (68.42)	15 11.09 (52.81)	1.94 [0.50; 7.46] 0.335	1.30 [0.76; 2.23] 0.339	0.156 [-0.155; 0.468] 0.326
Carrier (N)	**30**	**23**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	28 20.98 (69.93)	22 12.29 (53.43)	2.02 [0.64; 6.33] 0.230	1.31 [0.83; 2.06] 0.244	0.165 [-0.100; 0.429] 0.221
SF-36 MCS 5-Point Response Week 52, N' n (%)	28 19.95 (66.50)	22 9.22 (40.09)	2.98 [0.95; 9.32] 0.060	1.66 [0.94; 2.93] 0.080	0.264 [-0.001; 0.529] 0.050

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

52.9 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs111937633 (FAS)

52.10 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 MCS 2.5-Point Response Week 52	p=0.988				
SF-36 MCS 5-Point Response Week 52	p=0.741				
Non-carrier (N)	**25**	**32**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	23 17.98 (71.92)	28 19.61 (61.28)	1.66 [0.52; 5.28] 0.390	1.17 [0.80; 1.72] 0.406	0.106 [-0.144; 0.356] 0.404
SF-36 MCS 5-Point Response Week 52, N' n (%)	23 15.95 (63.80)	28 15.31 (47.84)	1.93 [0.65; 5.77] 0.239	1.34 [0.83; 2.16] 0.238	0.160 [-0.102; 0.421] 0.231
Carrier (N)	**26**	**12**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	25 19.00 (73.08)	9 7.30 (60.83)	1.68 [0.36; 7.86] 0.507	1.21 [0.70; 2.09] 0.503	0.122 [-0.220; 0.465] 0.483
SF-36 MCS 5-Point Response Week 52, N' n (%)	25 17.00 (65.38)	9 5.00 (41.67)	2.64 [0.59; 11.82] 0.203	1.59 [0.72; 3.49] 0.253	0.237 [-0.114; 0.588] 0.185

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

52.11 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 MCS 2.5-Point Response Week 52	p=0.574				
SF-36 MCS 5-Point Response Week 52	p=0.706				
Non-carrier (N)	**38**	**33**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	35 26.98 (71.00)	26 20.91 (63.36)	1.38 [0.48; 3.92] 0.547	1.12 [0.79; 1.59] 0.514	0.076 [-0.151; 0.304] 0.511
SF-36 MCS 5-Point Response Week 52, N' n (%)	35 23.95 (63.03)	26 16.31 (49.42)	1.73 [0.64; 4.64] 0.279	1.28 [0.82; 1.99] 0.277	0.136 [-0.101; 0.373] 0.261
Carrier (N)	**12**	**9**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	12 9.00 (75.00)	9 5.00 (55.56)	2.55 [0.39; 16.60] 0.326	1.35 [0.69; 2.64] 0.380	0.194 [-0.212; 0.601] 0.349
SF-36 MCS 5-Point Response Week 52, N' n (%)	12 8.00 (66.67)	9 4.00 (44.44)	2.57 [0.43; 15.41] 0.303	1.50 [0.65; 3.45] 0.340	0.222 [-0.198; 0.642] 0.300

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) SF-36 MCS 2.5-Point Response, SF-36 MCS 5-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

52.12 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 MCS 2.5-Point Response Week 52	p=0.833				
SF-36 MCS 5-Point Response Week 52	p=0.233				
Non-carrier (N)	**36**	**34**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	33 24.98 (69.39)	27 19.91 (58.56)	1.65 [0.59; 4.58] 0.339	1.19 [0.82; 1.72] 0.369	0.108 [-0.124; 0.341] 0.361
SF-36 MCS 5-Point Response Week 52, N' n (%)	33 21.95 (60.97)	27 17.31 (50.91)	1.50 [0.56; 4.01] 0.415	1.20 [0.77; 1.86] 0.416	0.101 [-0.138; 0.340] 0.409
Carrier (N)	**13**	**10**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	13 10.00 (76.92)	10 7.00 (70.00)	1.31 [0.20; 8.64] 0.782	1.10 [0.66; 1.82] 0.713	0.069 [-0.296; 0.434] 0.710
SF-36 MCS 5-Point Response Week 52, N' n (%)	13 9.00 (69.23)	10 3.00 (30.00)	5.30 [0.86; 32.61] 0.072	2.31 [0.84; 6.36] 0.106	0.392 [0.013; 0.771] 0.042

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) SF-36 MCS 2.5-Point Response, SF-36 MCS 5-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

52.13 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 MCS 2.5-Point Response Week 52	p=0.361				
SF-36 MCS 5-Point Response Week 52	p=0.633				
Non-carrier (N)	**42**	**36**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	39 28.98 (69.00)	29 21.91 (60.86)	1.41 [0.53; 3.74] 0.486	1.14 [0.80; 1.60] 0.473	0.081 [-0.139; 0.301] 0.468
SF-36 MCS 5-Point Response Week 52, N' n (%)	39 26.95 (64.17)	29 15.31 (42.53)	2.43 [0.94; 6.25] 0.067	1.51 [0.95; 2.40] 0.080	0.216 [-0.008; 0.441] 0.058
Carrier (N)	**9**	**5**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	9 8.00 (88.89)	5 3.00 (60.00)	5.50 [0.35; 85.71] 0.224	1.48 [0.70; 3.14] 0.306	0.289 [-0.187; 0.765] 0.234
SF-36 MCS 5-Point Response Week 52, N' n (%)	9 6.00 (66.67)	5 3.00 (60.00)	1.33 [0.14; 12.84] 0.804	1.11 [0.47; 2.60] 0.808	0.067 [-0.462; 0.595] 0.805

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) SF-36 MCS 2.5-Point Response, SF-36 MCS 5-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

52.14 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 MCS 2.5-Point Response Week 52	p=0.488				
SF-36 MCS 5-Point Response Week 52	p=0.531				
Low score (N)	**11**	**22**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	10 7.00 (63.64)	15 13.91 (63.23)	1.03 [0.21; 4.91] 0.974	1.01 [0.57; 1.79] 0.974	0.004 [-0.357; 0.365] 0.982
SF-36 MCS 5-Point Response Week 52, N' n (%)	10 6.00 (54.55)	15 10.31 (46.86)	1.37 [0.30; 6.14] 0.683	1.17 [0.56; 2.43] 0.674	0.077 [-0.295; 0.449] 0.685
High score (N)	**40**	**22**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	38 29.98 (74.95)	22 13.00 (59.09)	2.03 [0.66; 6.19] 0.214	1.27 [0.86; 1.88] 0.234	0.159 [-0.087; 0.404] 0.206
SF-36 MCS 5-Point Response Week 52, N' n (%)	38 26.95 (67.38)	22 10.00 (45.45)	2.47 [0.84; 7.21] 0.099	1.48 [0.89; 2.46] 0.128	0.219 [-0.035; 0.473] 0.091

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

52.15 SF-36 MCS 2.5-Point Response / 5-Point Response by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 MCS 2.5-Point Response Week 52	p=0.558				
SF-36 MCS 5-Point Response Week 52	p=0.228				
Non-carrier (N)	**31**	**23**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	30 25.00 (80.65)	17 15.16 (65.91)	2.09 [0.56; 7.77] 0.269	1.23 [0.85; 1.77] 0.275	0.147 [-0.105; 0.400] 0.253
SF-36 MCS 5-Point Response Week 52, N' n (%)	30 22.00 (70.97)	17 9.64 (41.91)	3.40 [1.03; 11.22] 0.044	1.70 [0.96; 3.00] 0.066	0.291 [0.022; 0.559] 0.034
Carrier (N)	**20**	**21**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	18 11.98 (59.90)	20 11.75 (55.95)	1.21 [0.34; 4.28] 0.766	1.07 [0.63; 1.82] 0.799	0.039 [-0.266; 0.345] 0.800
SF-36 MCS 5-Point Response Week 52, N' n (%)	18 10.95 (54.75)	20 10.67 (50.81)	1.17 [0.34; 4.08] 0.805	1.08 [0.60; 1.94] 0.801	0.039 [-0.270; 0.349] 0.803

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

52.16 SF-36 MCS 2.5-Point Response / 5-Point Response by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 MCS 2.5-Point Response Week 52	p=0.983				
SF-36 MCS 5-Point Response Week 52	p=0.957				
Non-carrier (N)	**19**	**20**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	19 15.00 (78.95)	14 13.62 (68.10)	1.73 [0.38; 7.98] 0.481	1.16 [0.77; 1.75] 0.470	0.108 [-0.182; 0.399] 0.464
SF-36 MCS 5-Point Response Week 52, N' n (%)	19 13.00 (68.42)	14 10.09 (50.45)	2.13 [0.54; 8.33] 0.279	1.36 [0.77; 2.40] 0.286	0.180 [-0.137; 0.496] 0.266
Carrier (N)	**32**	**24**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	29 21.98 (68.69)	23 13.29 (55.38)	1.77 [0.58; 5.37] 0.316	1.24 [0.80; 1.92] 0.330	0.133 [-0.125; 0.391] 0.312
SF-36 MCS 5-Point Response Week 52, N' n (%)	29 19.95 (62.34)	23 10.22 (42.58)	2.23 [0.75; 6.65] 0.149	1.47 [0.85; 2.52] 0.168	0.198 [-0.064; 0.460] 0.139

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

52.17 SF-36 MCS 2.5-Point Response / 5-Point Response by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 MCS 2.5-Point Response Week 52	p=0.988				
SF-36 MCS 5-Point Response Week 52	p=0.741				
Non-carrier (N)	**25**	**32**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	23 17.98 (71.92)	28 19.61 (61.28)	1.66 [0.52; 5.28] 0.390	1.17 [0.80; 1.72] 0.406	0.106 [-0.144; 0.356] 0.404
SF-36 MCS 5-Point Response Week 52, N' n (%)	23 15.95 (63.80)	28 15.31 (47.84)	1.93 [0.65; 5.77] 0.239	1.34 [0.83; 2.16] 0.238	0.160 [-0.102; 0.421] 0.231
Carrier (N)	**26**	**12**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	25 19.00 (73.08)	9 7.30 (60.83)	1.68 [0.36; 7.86] 0.507	1.21 [0.70; 2.09] 0.503	0.122 [-0.220; 0.465] 0.483
SF-36 MCS 5-Point Response Week 52, N' n (%)	25 17.00 (65.38)	9 5.00 (41.67)	2.64 [0.59; 11.82] 0.203	1.59 [0.72; 3.49] 0.253	0.237 [-0.114; 0.588] 0.185

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

52.18 SF-36 MCS 2.5-Point Response / 5-Point Response by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 MCS 2.5-Point Response Week 52	p=0.693				
SF-36 MCS 5-Point Response Week 52	p=0.525				
Non-carrier (N)	**39**	**35**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	36 27.98 (71.74)	28 21.91 (62.60)	1.48 [0.53; 4.10] 0.453	1.15 [0.82; 1.61] 0.426	0.091 [-0.131; 0.313] 0.419
SF-36 MCS 5-Point Response Week 52, N' n (%)	36 24.95 (63.97)	28 17.31 (49.46)	1.80 [0.69; 4.74] 0.232	1.30 [0.85; 1.99] 0.234	0.145 [-0.086; 0.376] 0.218
Carrier (N)	**11**	**9**			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	11 8.00 (72.73)	9 5.00 (55.56)	2.28 [0.35; 15.01] 0.392	1.31 [0.66; 2.60] 0.442	0.172 [-0.246; 0.590] 0.421
SF-36 MCS 5-Point Response Week 52, N' n (%)	11 7.00 (63.64)	9 3.00 (33.33)	3.57 [0.55; 22.97] 0.181	1.91 [0.68; 5.33] 0.217	0.303 [-0.116; 0.722] 0.156

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) SF-36 MCS 2.5-Point Response, SF-36 MCS 5-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

53.0 SF-36 PCS - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	**ADA (N=62)**	**Total (N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	57 (91.9)	122 (95.3)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	48 (77.4)	111 (86.7)

53.1 SF-36 PCS - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	60		
Baseline Mean (SD)	36.01 (8.22)	37.22 (9.10)		
Week 52 Mean (SD)	44.60 (9.92)	44.86 (8.96)		
Week 4 Adjusted Mean Change (SE)	4.62 (0.70)	3.89 (0.74)		
Week 12 Adjusted Mean Change (SE)	6.51 (0.91)	6.11 (0.95)		
Week 16 Adjusted Mean Change (SE)	7.32 (0.89)	6.06 (0.94)		
Week 24 Adjusted Mean Change (SE)	7.32 (0.98)	7.23 (1.05)		
Week 32 Adjusted Mean Change (SE)	7.96 (1.00)	7.68 (1.06)		
Week 40 Adjusted Mean Change (SE)	8.34 (0.94)	7.17 (1.03)		
Week 52 Adjusted Mean Change (SE)	8.36 (1.00)	7.51 (1.10)	0.85 [-2.09; 3.80]	0.567

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

53.2 SF-36 PCS - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.444				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	36.89 (8.32)	39.97 (9.42)		
Week 52 Mean (SD)	46.12 (9.65)	48.06 (8.74)		
Week 4 Adjusted Mean Change (SE)	5.59 (0.88)	4.57 (1.03)		
Week 12 Adjusted Mean Change (SE)	7.41 (1.12)	7.82 (1.30)		
Week 16 Adjusted Mean Change (SE)	8.58 (1.10)	7.58 (1.28)		
Week 24 Adjusted Mean Change (SE)	7.90 (1.19)	9.90 (1.42)		
Week 32 Adjusted Mean Change (SE)	8.73 (1.21)	10.77 (1.43)		
Week 40 Adjusted Mean Change (SE)	8.81 (1.18)	9.25 (1.41)		
Week 52 Adjusted Mean Change (SE)	9.19 (1.24)	9.26 (1.51)	-0.08 [-3.93; 3.78]	0.969
Female, N	**24**	**29**		
N'	24	28		
Baseline Mean (SD)	34.46 (7.97)	34.10 (7.75)		
Week 52 Mean (SD)	41.95 (10.02)	41.09 (7.83)		
Week 4 Adjusted Mean Change (SE)	2.90 (1.18)	3.15 (1.09)		
Week 12 Adjusted Mean Change (SE)	4.87 (1.50)	4.23 (1.39)		
Week 16 Adjusted Mean Change (SE)	5.08 (1.46)	4.41 (1.38)		
Week 24 Adjusted Mean Change (SE)	6.26 (1.60)	4.21 (1.52)		
Week 32 Adjusted Mean Change (SE)	6.50 (1.62)	4.22 (1.52)		
Week 40 Adjusted Mean Change (SE)	7.44 (1.56)	4.82 (1.51)		
Week 52 Adjusted Mean Change (SE)	6.84 (1.65)	5.54 (1.61)	1.30 [-3.23; 5.83]	0.571

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

53.3 SF-36 PCS - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.811				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	45.14 (7.12)	48.25 (7.89)		
Week 52 Mean (SD)	51.05 (7.29)	47.67 (9.77)		
Week 4 Adjusted Mean Change (SE)	5.18 (1.58)	5.09 (1.82)		
Week 12 Adjusted Mean Change (SE)	6.78 (2.05)	8.20 (2.34)		
Week 16 Adjusted Mean Change (SE)	7.35 (1.99)	7.49 (2.30)		
Week 24 Adjusted Mean Change (SE)	5.14 (2.18)	6.22 (2.59)		
Week 32 Adjusted Mean Change (SE)	6.84 (2.24)	8.62 (2.68)		
Week 40 Adjusted Mean Change (SE)	8.03 (2.14)	7.33 (2.62)		
Week 52 Adjusted Mean Change (SE)	8.95 (2.21)	3.87 (2.77)	5.09 [-1.21; 11.38]	0.112
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	47		
Baseline Mean (SD)	33.08 (6.17)	34.30 (6.93)		
Week 52 Mean (SD)	42.40 (9.79)	44.22 (8.77)		
Week 4 Adjusted Mean Change (SE)	4.41 (0.86)	3.58 (0.86)		
Week 12 Adjusted Mean Change (SE)	6.39 (1.10)	5.56 (1.10)		
Week 16 Adjusted Mean Change (SE)	7.29 (1.08)	5.68 (1.10)		
Week 24 Adjusted Mean Change (SE)	8.07 (1.18)	7.44 (1.21)		
Week 32 Adjusted Mean Change (SE)	8.32 (1.21)	7.42 (1.23)		
Week 40 Adjusted Mean Change (SE)	8.43 (1.15)	7.07 (1.18)		
Week 52 Adjusted Mean Change (SE)	8.16 (1.20)	8.27 (1.24)	-0.11 [-3.43; 3.21]	0.949

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

53.4 SF-36 PCS - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.146				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	31		
Baseline Mean (SD)	36.11 (8.44)	36.82 (9.22)		
Week 52 Mean (SD)	43.26 (9.53)	45.44 (8.56)		
Week 4 Adjusted Mean Change (SE)	4.26 (1.07)	5.31 (1.02)		
Week 12 Adjusted Mean Change (SE)	5.91 (1.39)	6.96 (1.32)		
Week 16 Adjusted Mean Change (SE)	5.32 (1.35)	6.60 (1.30)		
Week 24 Adjusted Mean Change (SE)	6.34 (1.51)	7.58 (1.46)		
Week 32 Adjusted Mean Change (SE)	6.77 (1.53)	8.73 (1.48)		
Week 40 Adjusted Mean Change (SE)	6.56 (1.45)	7.25 (1.46)		
Week 52 Adjusted Mean Change (SE)	7.44 (1.55)	7.90 (1.57)	-0.46 [-4.84; 3.92]	0.837
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	35.93 (8.16)	37.65 (9.11)		
Week 52 Mean (SD)	45.54 (10.20)	44.33 (9.46)		
Week 4 Adjusted Mean Change (SE)	4.89 (0.92)	2.36 (1.05)		
Week 12 Adjusted Mean Change (SE)	6.93 (1.20)	5.21 (1.37)		
Week 16 Adjusted Mean Change (SE)	8.83 (1.16)	5.47 (1.34)		
Week 24 Adjusted Mean Change (SE)	8.07 (1.29)	6.87 (1.52)		
Week 32 Adjusted Mean Change (SE)	8.83 (1.31)	6.58 (1.53)		
Week 40 Adjusted Mean Change (SE)	9.65 (1.24)	6.98 (1.46)		
Week 52 Adjusted Mean Change (SE)	9.03 (1.32)	7.02 (1.57)	2.01 [-2.06; 6.07]	0.330

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

53.5 SF-36 PCS - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.325				
≤ Median, N	40	29		
N'	40	29		
Baseline Mean (SD)	36.02 (7.46)	37.88 (9.93)		
Week 52 Mean (SD)	45.95 (9.48)	46.00 (9.17)		
Week 4 Adjusted Mean Change (SE)	5.15 (0.91)	4.32 (1.07)		
Week 12 Adjusted Mean Change (SE)	7.51 (1.17)	6.26 (1.37)		
Week 16 Adjusted Mean Change (SE)	8.22 (1.14)	6.89 (1.36)		
Week 24 Adjusted Mean Change (SE)	8.70 (1.24)	7.61 (1.52)		
Week 32 Adjusted Mean Change (SE)	8.45 (1.29)	7.62 (1.55)		
Week 40 Adjusted Mean Change (SE)	9.39 (1.22)	6.51 (1.52)		
Week 52 Adjusted Mean Change (SE)	9.40 (1.29)	6.42 (1.64)	2.99 [-1.16; 7.13]	0.156
> Median, N	26	33		
N'	26	31		
Baseline Mean (SD)	35.98 (9.41)	36.64 (8.42)		
Week 52 Mean (SD)	42.55 (10.40)	43.98 (8.87)		
Week 4 Adjusted Mean Change (SE)	3.80 (1.12)	3.48 (1.03)		
Week 12 Adjusted Mean Change (SE)	4.98 (1.44)	5.97 (1.33)		
Week 16 Adjusted Mean Change (SE)	5.93 (1.41)	5.31 (1.30)		
Week 24 Adjusted Mean Change (SE)	5.16 (1.55)	6.87 (1.44)		
Week 32 Adjusted Mean Change (SE)	7.15 (1.59)	7.73 (1.47)		
Week 40 Adjusted Mean Change (SE)	6.73 (1.50)	7.65 (1.42)		
Week 52 Adjusted Mean Change (SE)	6.78 (1.59)	8.32 (1.50)	-1.54 [-5.89; 2.80]	0.482

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

53.6 SF-36 PCS - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.258				
Enthesitis: No, N	**34**	**22**		
N'	34	21		
Baseline Mean (SD)	37.03 (9.09)	37.65 (9.01)		
Week 52 Mean (SD)	45.67 (10.21)	46.36 (8.88)		
Week 4 Adjusted Mean Change (SE)	5.18 (0.95)	6.84 (1.22)		
Week 12 Adjusted Mean Change (SE)	7.89 (1.24)	8.43 (1.59)		
Week 16 Adjusted Mean Change (SE)	7.25 (1.19)	10.23 (1.53)		
Week 24 Adjusted Mean Change (SE)	7.07 (1.36)	9.15 (1.74)		
Week 32 Adjusted Mean Change (SE)	8.29 (1.40)	8.65 (1.78)		
Week 40 Adjusted Mean Change (SE)	9.23 (1.32)	9.26 (1.69)		
Week 52 Adjusted Mean Change (SE)	9.17 (1.39)	10.03 (1.81)	-0.86 [-5.36; 3.65]	0.707
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	34.92 (7.16)	36.98 (9.26)		
Week 52 Mean (SD)	43.49 (9.65)	43.97 (9.04)		
Week 4 Adjusted Mean Change (SE)	4.02 (0.99)	2.31 (0.89)		
Week 12 Adjusted Mean Change (SE)	5.02 (1.29)	4.87 (1.15)		
Week 16 Adjusted Mean Change (SE)	7.41 (1.23)	3.81 (1.12)		
Week 24 Adjusted Mean Change (SE)	7.59 (1.40)	6.31 (1.31)		
Week 32 Adjusted Mean Change (SE)	7.63 (1.44)	7.29 (1.34)		
Week 40 Adjusted Mean Change (SE)	7.43 (1.35)	6.07 (1.29)		
Week 52 Adjusted Mean Change (SE)	7.49 (1.42)	6.14 (1.38)	1.36 [-2.57; 5.28]	0.495

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

53.7 SF-36 PCS - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.976				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	33.55 (7.18)	37.32 (7.89)		
Week 52 Mean (SD)	42.94 (9.86)	45.90 (9.43)		
Week 4 Adjusted Mean Change (SE)	4.61 (1.05)	5.16 (1.11)		
Week 12 Adjusted Mean Change (SE)	7.47 (1.43)	6.85 (1.53)		
Week 16 Adjusted Mean Change (SE)	8.46 (1.32)	7.41 (1.43)		
Week 24 Adjusted Mean Change (SE)	8.63 (1.53)	8.38 (1.66)		
Week 32 Adjusted Mean Change (SE)	9.49 (1.52)	9.22 (1.64)		
Week 40 Adjusted Mean Change (SE)	9.11 (1.42)	9.26 (1.54)		
Week 52 Adjusted Mean Change (SE)	8.85 (1.52)	9.84 (1.67)	-0.98 [-5.50; 3.53]	0.665
Carrier, N	**22**	**19**		
N'	22	18		
Baseline Mean (SD)	36.90 (9.09)	38.65 (11.55)		
Week 52 Mean (SD)	44.58 (9.98)	45.55 (9.63)		
Week 4 Adjusted Mean Change (SE)	4.80 (1.18)	3.32 (1.32)		
Week 12 Adjusted Mean Change (SE)	6.08 (1.63)	5.69 (1.80)		
Week 16 Adjusted Mean Change (SE)	5.69 (1.51)	6.63 (1.66)		
Week 24 Adjusted Mean Change (SE)	6.09 (1.74)	7.23 (1.95)		
Week 32 Adjusted Mean Change (SE)	6.35 (1.75)	8.25 (1.94)		
Week 40 Adjusted Mean Change (SE)	7.13 (1.62)	6.49 (1.87)		
Week 52 Adjusted Mean Change (SE)	7.37 (1.75)	5.97 (1.97)	1.40 [-3.81; 6.62]	0.594

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

53.8 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.522				
Non-carrier, N	**28**	**19**		
N'	28	18		
Baseline Mean (SD)	35.92 (7.86)	35.57 (7.56)		
Week 52 Mean (SD)	43.67 (10.05)	44.84 (8.38)		
Week 4 Adjusted Mean Change (SE)	5.40 (1.06)	4.32 (1.32)		
Week 12 Adjusted Mean Change (SE)	8.49 (1.45)	6.98 (1.81)		
Week 16 Adjusted Mean Change (SE)	8.58 (1.37)	7.34 (1.72)		
Week 24 Adjusted Mean Change (SE)	8.93 (1.54)	7.73 (1.96)		
Week 32 Adjusted Mean Change (SE)	9.06 (1.58)	8.67 (2.02)		
Week 40 Adjusted Mean Change (SE)	8.54 (1.47)	7.23 (1.91)		
Week 52 Adjusted Mean Change (SE)	7.80 (1.58)	9.63 (2.09)	-1.83 [-7.05; 3.40]	0.489
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	33.15 (7.98)	38.85 (10.33)		
Week 52 Mean (SD)	43.10 (9.82)	46.42 (9.73)		
Week 4 Adjusted Mean Change (SE)	3.85 (1.21)	5.25 (1.31)		
Week 12 Adjusted Mean Change (SE)	5.04 (1.68)	5.98 (1.81)		
Week 16 Adjusted Mean Change (SE)	6.03 (1.57)	6.93 (1.70)		
Week 24 Adjusted Mean Change (SE)	5.44 (1.77)	9.01 (1.93)		
Week 32 Adjusted Mean Change (SE)	7.14 (1.82)	9.23 (1.96)		
Week 40 Adjusted Mean Change (SE)	8.44 (1.67)	8.49 (1.84)		
Week 52 Adjusted Mean Change (SE)	9.20 (1.81)	8.49 (1.96)	0.71 [-4.68; 6.10]	0.794

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

53.9 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.576				
Non-carrier, N	**19**	**21**		
N'	19	20		
Baseline Mean (SD)	34.27 (9.26)	37.37 (10.64)		
Week 52 Mean (SD)	42.32 (9.91)	46.16 (10.00)		
Week 4 Adjusted Mean Change (SE)	3.98 (1.29)	5.23 (1.25)		
Week 12 Adjusted Mean Change (SE)	7.33 (1.76)	6.91 (1.72)		
Week 16 Adjusted Mean Change (SE)	7.06 (1.63)	8.07 (1.60)		
Week 24 Adjusted Mean Change (SE)	6.74 (1.91)	8.84 (1.89)		
Week 32 Adjusted Mean Change (SE)	8.57 (1.87)	7.68 (1.86)		
Week 40 Adjusted Mean Change (SE)	8.13 (1.75)	8.65 (1.77)		
Week 52 Adjusted Mean Change (SE)	7.38 (1.88)	8.56 (1.95)	-1.18 [-6.59; 4.23]	0.666
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	35.04 (6.35)	38.37 (8.64)		
Week 52 Mean (SD)	44.12 (9.86)	45.47 (9.17)		
Week 4 Adjusted Mean Change (SE)	5.17 (1.02)	3.66 (1.17)		
Week 12 Adjusted Mean Change (SE)	7.04 (1.40)	5.98 (1.60)		
Week 16 Adjusted Mean Change (SE)	7.80 (1.29)	6.28 (1.50)		
Week 24 Adjusted Mean Change (SE)	8.35 (1.50)	7.17 (1.74)		
Week 32 Adjusted Mean Change (SE)	8.50 (1.50)	9.74 (1.72)		
Week 40 Adjusted Mean Change (SE)	8.85 (1.40)	7.86 (1.63)		
Week 52 Adjusted Mean Change (SE)	9.07 (1.51)	8.11 (1.74)	0.96 [-3.64; 5.56]	0.679

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

53.10 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.053				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	34.74 (7.19)	38.87 (9.41)		
Week 52 Mean (SD)	45.07 (11.31)	44.32 (9.53)		
Week 4 Adjusted Mean Change (SE)	5.77 (1.11)	3.93 (0.99)		
Week 12 Adjusted Mean Change (SE)	7.92 (1.53)	5.67 (1.36)		
Week 16 Adjusted Mean Change (SE)	8.59 (1.41)	6.31 (1.25)		
Week 24 Adjusted Mean Change (SE)	8.93 (1.61)	6.77 (1.47)		
Week 32 Adjusted Mean Change (SE)	8.97 (1.63)	7.57 (1.46)		
Week 40 Adjusted Mean Change (SE)	8.92 (1.52)	7.73 (1.40)		
Week 52 Adjusted Mean Change (SE)	9.66 (1.60)	6.78 (1.45)	2.88 [-1.44; 7.19]	0.189
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	35.24 (9.10)	35.30 (9.82)		
Week 52 Mean (SD)	42.29 (8.28)	50.21 (7.76)		
Week 4 Adjusted Mean Change (SE)	3.67 (1.08)	5.69 (1.66)		
Week 12 Adjusted Mean Change (SE)	5.84 (1.48)	8.41 (2.27)		
Week 16 Adjusted Mean Change (SE)	6.02 (1.37)	9.43 (2.14)		
Week 24 Adjusted Mean Change (SE)	6.19 (1.59)	11.06 (2.42)		
Week 32 Adjusted Mean Change (SE)	7.36 (1.59)	12.28 (2.42)		
Week 40 Adjusted Mean Change (SE)	7.61 (1.50)	9.30 (2.32)		
Week 52 Adjusted Mean Change (SE)	6.81 (1.56)	12.34 (2.46)	-5.53 [-11.32; 0.26]	0.061

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

53.11 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.517				
Non-carrier, N	**38**	**33**		
N'	38	32		
Baseline Mean (SD)	34.74 (7.86)	38.52 (9.63)		
Week 52 Mean (SD)	43.30 (9.93)	46.29 (8.28)		
Week 4 Adjusted Mean Change (SE)	4.85 (0.91)	4.37 (0.98)		
Week 12 Adjusted Mean Change (SE)	6.55 (1.24)	6.55 (1.34)		
Week 16 Adjusted Mean Change (SE)	7.14 (1.18)	7.03 (1.29)		
Week 24 Adjusted Mean Change (SE)	7.85 (1.34)	7.74 (1.48)		
Week 32 Adjusted Mean Change (SE)	8.23 (1.34)	9.41 (1.47)		
Week 40 Adjusted Mean Change (SE)	8.30 (1.25)	8.35 (1.40)		
Week 52 Adjusted Mean Change (SE)	8.03 (1.33)	8.13 (1.50)	-0.10 [-4.13; 3.93]	0.962
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	35.50 (9.61)	37.85 (9.30)		
Week 52 Mean (SD)	44.18 (10.33)	48.01 (10.07)		
Week 4 Adjusted Mean Change (SE)	3.69 (1.61)	5.70 (1.83)		
Week 12 Adjusted Mean Change (SE)	6.83 (2.19)	8.31 (2.55)		
Week 16 Adjusted Mean Change (SE)	7.21 (2.09)	7.70 (2.45)		
Week 24 Adjusted Mean Change (SE)	5.72 (2.40)	10.45 (2.76)		
Week 32 Adjusted Mean Change (SE)	7.19 (2.35)	9.45 (2.70)		
Week 40 Adjusted Mean Change (SE)	7.61 (2.21)	9.25 (2.53)		
Week 52 Adjusted Mean Change (SE)	8.01 (2.33)	10.66 (2.67)	-2.65 [-9.71; 4.41]	0.456

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

53.12 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.493				
Non-carrier, N	**36**	**34**		
N'	36	33		
Baseline Mean (SD)	34.43 (8.57)	38.52 (10.42)		
Week 52 Mean (SD)	43.15 (9.41)	46.09 (9.86)		
Week 4 Adjusted Mean Change (SE)	4.37 (0.94)	4.38 (0.98)		
Week 12 Adjusted Mean Change (SE)	7.33 (1.27)	6.13 (1.33)		
Week 16 Adjusted Mean Change (SE)	7.82 (1.20)	6.98 (1.27)		
Week 24 Adjusted Mean Change (SE)	7.47 (1.39)	7.40 (1.47)		
Week 32 Adjusted Mean Change (SE)	8.40 (1.37)	8.50 (1.45)		
Week 40 Adjusted Mean Change (SE)	8.47 (1.25)	8.38 (1.34)		
Week 52 Adjusted Mean Change (SE)	8.00 (1.36)	8.07 (1.48)	-0.07 [-4.10; 3.97]	0.974
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	37.21 (6.73)	35.78 (5.56)		
Week 52 Mean (SD)	44.23 (10.41)	44.85 (8.38)		
Week 4 Adjusted Mean Change (SE)	4.83 (1.54)	4.36 (1.78)		
Week 12 Adjusted Mean Change (SE)	4.43 (2.09)	7.01 (2.40)		
Week 16 Adjusted Mean Change (SE)	5.44 (1.97)	7.45 (2.26)		
Week 24 Adjusted Mean Change (SE)	6.52 (2.27)	9.31 (2.60)		
Week 32 Adjusted Mean Change (SE)	6.02 (2.24)	9.66 (2.57)		
Week 40 Adjusted Mean Change (SE)	5.82 (2.05)	7.20 (2.39)		
Week 52 Adjusted Mean Change (SE)	7.39 (2.21)	8.56 (2.54)	-1.17 [-7.89; 5.56]	0.731

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

53.13 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.105				
Non-carrier, N	**42**	**36**		
N'	42	35		
Baseline Mean (SD)	35.68 (8.23)	36.57 (9.18)		
Week 52 Mean (SD)	43.73 (9.81)	45.93 (9.31)		
Week 4 Adjusted Mean Change (SE)	5.03 (0.85)	4.92 (0.93)		
Week 12 Adjusted Mean Change (SE)	6.67 (1.16)	6.76 (1.27)		
Week 16 Adjusted Mean Change (SE)	6.82 (1.07)	7.24 (1.17)		
Week 24 Adjusted Mean Change (SE)	7.03 (1.23)	8.66 (1.37)		
Week 32 Adjusted Mean Change (SE)	8.18 (1.26)	9.27 (1.39)		
Week 40 Adjusted Mean Change (SE)	8.35 (1.17)	8.59 (1.32)		
Week 52 Adjusted Mean Change (SE)	7.90 (1.21)	9.27 (1.36)	-1.37 [-4.99; 2.25]	0.454
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	31.80 (7.35)	45.88 (9.45)		
Week 52 Mean (SD)	43.18 (10.57)	43.39 (5.88)		
Week 4 Adjusted Mean Change (SE)	3.30 (1.86)	2.41 (2.55)		
Week 12 Adjusted Mean Change (SE)	8.01 (2.52)	0.90 (3.45)		
Week 16 Adjusted Mean Change (SE)	9.82 (2.32)	2.14 (3.18)		
Week 24 Adjusted Mean Change (SE)	10.02 (2.68)	3.72 (3.67)		
Week 32 Adjusted Mean Change (SE)	8.34 (2.73)	4.20 (3.74)		
Week 40 Adjusted Mean Change (SE)	8.29 (2.55)	3.31 (3.50)		
Week 52 Adjusted Mean Change (SE)	9.72 (2.60)	0.77 (3.57)	8.95 [-0.04; 17.94]	0.051

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

53.14 SF-36 PCS - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.859				
Low score, N	**11**	**22**		
N'	11	21		
Baseline Mean (SD)	36.64 (10.78)	37.69 (10.37)		
Week 52 Mean (SD)	43.17 (12.32)	44.42 (10.81)		
Week 4 Adjusted Mean Change (SE)	4.73 (1.68)	3.62 (1.22)		
Week 12 Adjusted Mean Change (SE)	6.21 (2.30)	6.45 (1.67)		
Week 16 Adjusted Mean Change (SE)	6.72 (2.18)	6.85 (1.57)		
Week 24 Adjusted Mean Change (SE)	7.48 (2.45)	6.25 (1.84)		
Week 32 Adjusted Mean Change (SE)	7.70 (2.45)	7.57 (1.84)		
Week 40 Adjusted Mean Change (SE)	7.46 (2.29)	7.82 (1.75)		
Week 52 Adjusted Mean Change (SE)	5.55 (2.47)	7.06 (1.91)	-1.51 [-7.70; 4.68]	0.630
High score, N	**40**	**22**		
N'	40	22		
Baseline Mean (SD)	34.54 (7.37)	38.10 (8.88)		
Week 52 Mean (SD)	43.74 (9.27)	46.66 (8.43)		
Week 4 Adjusted Mean Change (SE)	4.68 (0.89)	5.14 (1.20)		
Week 12 Adjusted Mean Change (SE)	7.03 (1.22)	6.28 (1.65)		
Week 16 Adjusted Mean Change (SE)	7.40 (1.13)	7.37 (1.54)		
Week 24 Adjusted Mean Change (SE)	7.50 (1.30)	9.39 (1.75)		
Week 32 Adjusted Mean Change (SE)	8.25 (1.31)	9.89 (1.75)		
Week 40 Adjusted Mean Change (SE)	8.44 (1.22)	8.45 (1.64)		
Week 52 Adjusted Mean Change (SE)	8.89 (1.30)	9.12 (1.73)	-0.23 [-4.56; 4.09]	0.915

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

53.15 SF-36 PCS - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.947				
Non-carrier, N	**31**	**23**		
N'	31	22		
Baseline Mean (SD)	36.24 (8.02)	36.47 (7.99)		
Week 52 Mean (SD)	43.51 (9.90)	45.41 (8.44)		
Week 4 Adjusted Mean Change (SE)	5.07 (1.00)	4.25 (1.19)		
Week 12 Adjusted Mean Change (SE)	7.83 (1.35)	7.03 (1.60)		
Week 16 Adjusted Mean Change (SE)	8.01 (1.27)	7.17 (1.51)		
Week 24 Adjusted Mean Change (SE)	8.14 (1.47)	8.20 (1.77)		
Week 32 Adjusted Mean Change (SE)	8.30 (1.47)	9.17 (1.77)		
Week 40 Adjusted Mean Change (SE)	8.06 (1.37)	8.02 (1.67)		
Week 52 Adjusted Mean Change (SE)	7.30 (1.46)	9.06 (1.82)	-1.76 [-6.40; 2.89]	0.455
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	33.07 (8.17)	39.45 (10.99)		
Week 52 Mean (SD)	43.81 (10.03)	46.04 (10.33)		
Week 4 Adjusted Mean Change (SE)	4.07 (1.27)	4.56 (1.23)		
Week 12 Adjusted Mean Change (SE)	5.24 (1.73)	5.72 (1.68)		
Week 16 Adjusted Mean Change (SE)	6.05 (1.61)	7.10 (1.57)		
Week 24 Adjusted Mean Change (SE)	6.48 (1.88)	7.68 (1.84)		
Week 32 Adjusted Mean Change (SE)	7.85 (1.88)	8.50 (1.82)		
Week 40 Adjusted Mean Change (SE)	8.47 (1.72)	8.30 (1.71)		
Week 52 Adjusted Mean Change (SE)	9.73 (1.87)	7.50 (1.81)	2.23 [-3.02; 7.48]	0.400

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

53.16 SF-36 PCS - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.434				
Non-carrier, N	19	20		
N'	19	19		
Baseline Mean (SD)	34.27 (9.26)	37.44 (10.91)		
Week 52 Mean (SD)	42.32 (9.91)	46.73 (10.12)		
Week 4 Adjusted Mean Change (SE)	3.92 (1.28)	5.57 (1.27)		
Week 12 Adjusted Mean Change (SE)	7.29 (1.75)	7.52 (1.75)		
Week 16 Adjusted Mean Change (SE)	7.02 (1.62)	8.75 (1.63)		
Week 24 Adjusted Mean Change (SE)	6.73 (1.88)	9.77 (1.91)		
Week 32 Adjusted Mean Change (SE)	8.47 (1.89)	7.96 (1.92)		
Week 40 Adjusted Mean Change (SE)	8.08 (1.74)	9.28 (1.81)		
Week 52 Adjusted Mean Change (SE)	7.33 (1.87)	8.75 (1.99)	-1.42 [-6.87; 4.02]	0.605
Carrier, N	32	24		
N'	32	24		
Baseline Mean (SD)	35.43 (7.53)	38.27 (8.46)		
Week 52 Mean (SD)	44.48 (9.88)	45.15 (9.09)		
Week 4 Adjusted Mean Change (SE)	5.14 (0.98)	3.47 (1.13)		
Week 12 Adjusted Mean Change (SE)	6.57 (1.35)	5.51 (1.55)		
Week 16 Adjusted Mean Change (SE)	7.41 (1.25)	5.82 (1.45)		
Week 24 Adjusted Mean Change (SE)	7.96 (1.43)	6.54 (1.67)		
Week 32 Adjusted Mean Change (SE)	7.88 (1.46)	9.42 (1.69)		
Week 40 Adjusted Mean Change (SE)	8.32 (1.34)	7.33 (1.58)		
Week 52 Adjusted Mean Change (SE)	8.72 (1.46)	7.82 (1.68)	0.91 [-3.53; 5.34]	0.685

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

53.17 SF-36 PCS - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.053				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	34.74 (7.19)	38.87 (9.41)		
Week 52 Mean (SD)	45.07 (11.31)	44.32 (9.53)		
Week 4 Adjusted Mean Change (SE)	5.77 (1.11)	3.93 (0.99)		
Week 12 Adjusted Mean Change (SE)	7.92 (1.53)	5.67 (1.36)		
Week 16 Adjusted Mean Change (SE)	8.59 (1.41)	6.31 (1.25)		
Week 24 Adjusted Mean Change (SE)	8.93 (1.61)	6.77 (1.47)		
Week 32 Adjusted Mean Change (SE)	8.97 (1.63)	7.57 (1.46)		
Week 40 Adjusted Mean Change (SE)	8.92 (1.52)	7.73 (1.40)		
Week 52 Adjusted Mean Change (SE)	9.66 (1.60)	6.78 (1.45)	2.88 [-1.44; 7.19]	0.189
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	35.24 (9.10)	35.30 (9.82)		
Week 52 Mean (SD)	42.29 (8.28)	50.21 (7.76)		
Week 4 Adjusted Mean Change (SE)	3.67 (1.08)	5.69 (1.66)		
Week 12 Adjusted Mean Change (SE)	5.84 (1.48)	8.41 (2.27)		
Week 16 Adjusted Mean Change (SE)	6.02 (1.37)	9.43 (2.14)		
Week 24 Adjusted Mean Change (SE)	6.19 (1.59)	11.06 (2.42)		
Week 32 Adjusted Mean Change (SE)	7.36 (1.59)	12.28 (2.42)		
Week 40 Adjusted Mean Change (SE)	7.61 (1.50)	9.30 (2.32)		
Week 52 Adjusted Mean Change (SE)	6.81 (1.56)	12.34 (2.46)	-5.53 [-11.32; 0.26]	0.061

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

53.18 SF-36 PCS - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.403				
Non-carrier, N	**39**	**35**		
N'	39	34		
Baseline Mean (SD)	34.84 (7.77)	38.01 (9.70)		
Week 52 Mean (SD)	43.44 (9.82)	45.44 (8.74)		
Week 4 Adjusted Mean Change (SE)	4.97 (0.91)	4.19 (0.97)		
Week 12 Adjusted Mean Change (SE)	6.83 (1.23)	5.94 (1.32)		
Week 16 Adjusted Mean Change (SE)	7.26 (1.15)	6.79 (1.23)		
Week 24 Adjusted Mean Change (SE)	8.02 (1.32)	7.24 (1.44)		
Week 32 Adjusted Mean Change (SE)	8.40 (1.33)	8.42 (1.43)		
Week 40 Adjusted Mean Change (SE)	8.38 (1.23)	7.78 (1.35)		
Week 52 Adjusted Mean Change (SE)	8.18 (1.33)	7.83 (1.47)	0.35 [-3.61; 4.31]	0.861
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	35.83 (10.01)	37.46 (9.47)		
Week 52 Mean (SD)	44.55 (10.75)	46.71 (11.72)		
Week 4 Adjusted Mean Change (SE)	3.82 (1.71)	5.08 (1.87)		
Week 12 Adjusted Mean Change (SE)	6.18 (2.30)	7.96 (2.53)		
Week 16 Adjusted Mean Change (SE)	6.70 (2.15)	8.23 (2.42)		
Week 24 Adjusted Mean Change (SE)	5.86 (2.51)	10.29 (2.72)		
Week 32 Adjusted Mean Change (SE)	6.88 (2.48)	10.27 (2.72)		
Week 40 Adjusted Mean Change (SE)	7.87 (2.31)	9.50 (2.58)		
Week 52 Adjusted Mean Change (SE)	8.25 (2.46)	9.60 (2.70)	-1.35 [-8.63; 5.92]	0.712

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

54.1 SF-36 PCS 2.5-Point Response / 5-Point Response (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	63 48.89 (74.08)	48 43.94 (70.87)	1.21 [0.53; 2.76] 0.658	1.05 [0.84; 1.31] 0.694	0.032 [-0.128; 0.193] 0.696
SF-36 PCS 5-Point Response Week 52, N' n (%)	63 41.69 (63.17)	48 35.11 (56.63)	1.34 [0.63; 2.83] 0.447	1.12 [0.83; 1.51] 0.470	0.065 [-0.111; 0.242] 0.468

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.
RR and RD calculated directly without adjustment.

All results are combined over MI:
n and % are averages of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

54.2 SF-36 PCS 2.5-Point Response / 5-Point Response by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 PCS 2.5-Point Response Week 52	p=0.572				
SF-36 PCS 5-Point Response Week 52	p=0.671				
Male (N)	**42**	**33**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	40 30.89 (73.55)	26 22.10 (66.97)	1.47 [0.50; 4.31] 0.480	1.10 [0.80; 1.51] 0.556	0.066 [-0.152; 0.283] 0.553
SF-36 PCS 5-Point Response Week 52, N' n (%)	40 27.69 (65.93)	26 19.07 (57.79)	1.49 [0.54; 4.05] 0.440	1.14 [0.78; 1.68] 0.496	0.081 [-0.150; 0.313] 0.491
Female (N)	**24**	**29**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	23 18.00 (75.00)	22 21.84 (75.31)	0.89 [0.23; 3.42] 0.871	1.00 [0.72; 1.38] 0.985	-0.003 [-0.246; 0.239] 0.980
SF-36 PCS 5-Point Response Week 52, N' n (%)	23 14.00 (58.33)	22 16.04 (55.31)	1.06 [0.33; 3.38] 0.916	1.06 [0.65; 1.73] 0.824	0.030 [-0.247; 0.308] 0.831

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

54.3 SF-36 PCS 2.5-Point Response / 5-Point Response by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 PCS 2.5-Point Response Week 52	p=0.197				
SF-36 PCS 5-Point Response Week 52	p=0.506				
PASDAS < 5.4 (N)	**16**	**13**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	16 11.00 (68.75)	9 5.64 (43.38)	3.23 [0.60; 17.42] 0.172	1.60 [0.75; 3.41] 0.225	0.254 [-0.115; 0.622] 0.177
SF-36 PCS 5-Point Response Week 52, N' n (%)	16 8.00 (50.00)	9 4.11 (31.62)	2.31 [0.43; 12.41] 0.328	1.61 [0.57; 4.57] 0.368	0.184 [-0.187; 0.554] 0.331
PASDAS ≥ 5.4 (N)	**50**	**49**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	47 37.89 (75.78)	39 38.30 (78.16)	0.88 [0.32; 2.42] 0.808	0.97 [0.77; 1.22] 0.791	-0.024 [-0.197; 0.149] 0.787
SF-36 PCS 5-Point Response Week 52, N' n (%)	47 33.69 (67.38)	39 31.00 (63.27)	1.21 [0.50; 2.92] 0.666	1.07 [0.79; 1.44] 0.679	0.041 [-0.155; 0.237] 0.680

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

54.4 SF-36 PCS 2.5-Point Response / 5-Point Response by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 PCS 2.5-Point Response Week 52	p=0.314				
SF-36 PCS 5-Point Response Week 52	p=0.760				
Moderate/Severe Psoriasis (Def D): No (N)	**28**	**32**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	26 19.00 (67.86)	23 22.97 (71.78)	0.76 [0.23; 2.52] 0.656	0.95 [0.67; 1.34] 0.756	-0.039 [-0.281; 0.202] 0.750
SF-36 PCS 5-Point Response Week 52, N' n (%)	26 17.00 (60.71)	23 17.88 (55.88)	1.17 [0.39; 3.49] 0.778	1.09 [0.69; 1.71] 0.710	0.048 [-0.212; 0.309] 0.716
Moderate/Severe Psoriasis (Def D): Yes (N)	**38**	**30**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	37 29.89 (78.66)	25 20.97 (69.90)	1.80 [0.56; 5.79] 0.323	1.13 [0.83; 1.52] 0.437	0.088 [-0.129; 0.304] 0.429
SF-36 PCS 5-Point Response Week 52, N' n (%)	37 24.69 (64.97)	25 17.23 (57.43)	1.48 [0.52; 4.18] 0.458	1.13 [0.76; 1.70] 0.545	0.075 [-0.167; 0.317] 0.541

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

54.5 SF-36 PCS 2.5-Point Response / 5-Point Response by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 PCS 2.5-Point Response Week 52	p=0.745				
SF-36 PCS 5-Point Response Week 52	p=0.502				
≤ Median (N)	**40**	**29**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	38 29.89 (74.73)	21 20.44 (70.48)	1.37 [0.42; 4.42] 0.600	1.06 [0.77; 1.45] 0.710	0.042 [-0.183; 0.268] 0.712
SF-36 PCS 5-Point Response Week 52, N' n (%)	38 25.69 (64.23)	21 15.33 (52.86)	1.73 [0.60; 4.94] 0.309	1.22 [0.78; 1.90] 0.382	0.114 [-0.134; 0.361] 0.368
> Median (N)	**26**	**33**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	25 19.00 (73.08)	27 23.50 (71.21)	1.03 [0.31; 3.45] 0.956	1.03 [0.74; 1.43] 0.874	0.019 [-0.217; 0.255] 0.877
SF-36 PCS 5-Point Response Week 52, N' n (%)	25 16.00 (61.54)	27 19.78 (59.94)	1.03 [0.34; 3.07] 0.963	1.03 [0.67; 1.57] 0.899	0.016 [-0.241; 0.273] 0.903

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

54.6 SF-36 PCS 2.5-Point Response / 5-Point Response by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 PCS 2.5-Point Response Week 52	p=0.128				
SF-36 PCS 5-Point Response Week 52	p=0.744				
Enthesitis: No (N)	**34**	**22**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	32 25.00 (73.53)	18 18.94 (86.09)	0.41 [0.09; 1.99] 0.269	0.85 [0.65; 1.12] 0.255	-0.126 [-0.340; 0.088] 0.250
SF-36 PCS 5-Point Response Week 52, N' n (%)	32 23.00 (67.65)	18 14.55 (66.14)	1.05 [0.32; 3.46] 0.942	1.02 [0.69; 1.52] 0.905	0.015 [-0.245; 0.275] 0.909
Enthesitis: Yes (N)	**32**	**40**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	31 23.89 (74.66)	30 25.00 (62.50)	1.87 [0.62; 5.66] 0.267	1.20 [0.86; 1.66] 0.289	0.122 [-0.101; 0.344] 0.283
SF-36 PCS 5-Point Response Week 52, N' n (%)	31 18.69 (58.41)	30 20.56 (51.40)	1.36 [0.50; 3.71] 0.550	1.14 [0.73; 1.78] 0.568	0.070 [-0.172; 0.312] 0.570

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

54.7 SF-36 PCS 2.5-Point Response / 5-Point Response by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 PCS 2.5-Point Response Week 52	p=0.733				
SF-36 PCS 5-Point Response Week 52	p=0.727				
Non-carrier (N)	**29**	**25**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	28 22.00 (75.86)	21 19.44 (77.76)	0.90 [0.23; 3.58] 0.886	0.98 [0.72; 1.32] 0.873	-0.019 [-0.248; 0.211] 0.871
SF-36 PCS 5-Point Response Week 52, N' n (%)	28 20.00 (68.97)	21 17.14 (68.56)	1.03 [0.30; 3.49] 0.964	1.01 [0.70; 1.46] 0.972	0.004 [-0.249; 0.258] 0.975
Carrier (N)	**22**	**19**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	20 14.89 (67.68)	16 12.08 (63.58)	1.28 [0.31; 5.22] 0.734	1.07 [0.67; 1.70] 0.787	0.041 [-0.261; 0.343] 0.790
SF-36 PCS 5-Point Response Week 52, N' n (%)	20 11.69 (53.14)	16 8.60 (45.26)	1.42 [0.38; 5.32] 0.604	1.18 [0.61; 2.29] 0.629	0.079 [-0.240; 0.397] 0.628

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

54.8 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 PCS 2.5-Point Response Week 52	p=0.461				
SF-36 PCS 5-Point Response Week 52	p=0.877				
Non-carrier (N)	**28**	**19**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	27 20.00 (71.43)	13 16.02 (84.32)	0.46 [0.09; 2.49] 0.369	0.85 [0.62; 1.16] 0.309	-0.129 [-0.374; 0.116] 0.302
SF-36 PCS 5-Point Response Week 52, N' n (%)	27 18.00 (64.29)	13 12.51 (65.84)	0.98 [0.26; 3.76] 0.981	0.98 [0.62; 1.54] 0.927	-0.016 [-0.308; 0.277] 0.917
Carrier (N)	**22**	**19**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	20 15.89 (72.23)	18 13.50 (71.05)	1.07 [0.25; 4.64] 0.923	1.02 [0.68; 1.51] 0.933	0.012 [-0.271; 0.295] 0.935
SF-36 PCS 5-Point Response Week 52, N' n (%)	20 13.69 (62.23)	18 11.23 (59.11)	1.14 [0.31; 4.27] 0.844	1.05 [0.63; 1.75] 0.842	0.031 [-0.275; 0.337] 0.841

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

54.9 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 PCS 2.5-Point Response Week 52	p=0.723				
SF-36 PCS 5-Point Response Week 52	p=0.442				
Non-carrier (N)	**19**	**21**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	19 14.00 (73.68)	15 15.64 (74.48)	0.97 [0.20; 4.77] 0.975	0.99 [0.67; 1.46] 0.963	-0.008 [-0.291; 0.275] 0.956
SF-36 PCS 5-Point Response Week 52, N' n (%)	19 11.00 (57.89)	15 12.96 (61.71)	0.85 [0.22; 3.38] 0.822	0.94 [0.55; 1.60] 0.823	-0.038 [-0.355; 0.279] 0.813
Carrier (N)	**30**	**23**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	28 22.00 (73.33)	22 15.88 (69.04)	1.41 [0.39; 5.04] 0.596	1.06 [0.75; 1.51] 0.736	0.043 [-0.205; 0.291] 0.735
SF-36 PCS 5-Point Response Week 52, N' n (%)	28 20.00 (66.67)	22 12.78 (55.57)	1.73 [0.54; 5.52] 0.354	1.20 [0.77; 1.88] 0.426	0.111 [-0.155; 0.377] 0.414

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

54.10 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 PCS 2.5-Point Response Week 52	N.E.				
SF-36 PCS 5-Point Response Week 52	p=0.373				
Non-carrier (N)	**25**	**32**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	23 18.89 (75.56)	28 19.95 (62.34)	1.78 [0.50; 6.30] 0.369	1.21 [0.85; 1.74] 0.292	0.132 [-0.111; 0.375] 0.286
SF-36 PCS 5-Point Response Week 52, N' n (%)	23 16.69 (66.76)	28 17.42 (54.44)	1.60 [0.51; 5.03] 0.421	1.23 [0.80; 1.89] 0.354	0.123 [-0.136; 0.382] 0.351
Carrier (N)	**26**	**12**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	25 18.00 (69.23)	9 11.57 (96.42)	N.E.	0.72 [0.53; 0.97] 0.031	-0.272 [-0.499; -0.044] 0.019
SF-36 PCS 5-Point Response Week 52, N' n (%)	25 15.00 (57.69)	9 8.32 (69.33)	0.66 [0.13; 3.21] 0.604	0.83 [0.49; 1.42] 0.503	-0.116 [-0.456; 0.223] 0.501

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

54.11 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 PCS 2.5-Point Response Week 52	N.E.				
SF-36 PCS 5-Point Response Week 52	p=0.384				
Non-carrier (N)	**38**	**33**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	35 25.89 (68.13)	26 21.52 (65.21)	1.33 [0.45; 3.91] 0.604	1.05 [0.74; 1.47] 0.798	0.029 [-0.196; 0.255] 0.800
SF-36 PCS 5-Point Response Week 52, N' n (%)	35 22.69 (59.71)	26 18.74 (56.79)	1.24 [0.45; 3.43] 0.673	1.05 [0.70; 1.59] 0.807	0.029 [-0.209; 0.267] 0.810
Carrier (N)	**12**	**9**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	12 10.00 (83.33)	9 9.00 (100.00)	N.E.	0.83 [0.65; 1.07] 0.158	-0.167 [-0.378; 0.044] 0.121
SF-36 PCS 5-Point Response Week 52, N' n (%)	12 8.00 (66.67)	9 7.00 (77.78)	0.45 [0.06; 3.45] 0.441	0.86 [0.50; 1.46] 0.569	-0.111 [-0.492; 0.270] 0.567

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) SF-36 PCS 2.5-Point Response, SF-36 PCS 5-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

54.12 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 PCS 2.5-Point Response Week 52	p=0.558				
SF-36 PCS 5-Point Response Week 52	p=0.261				
Non-carrier (N)	**36**	**34**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	33 26.89 (74.69)	27 23.52 (69.18)	1.20 [0.39; 3.67] 0.746	1.08 [0.80; 1.46] 0.617	0.055 [-0.161; 0.271] 0.617
SF-36 PCS 5-Point Response Week 52, N' n (%)	33 23.69 (65.81)	27 18.74 (55.12)	1.49 [0.54; 4.13] 0.442	1.20 [0.80; 1.79] 0.383	0.107 [-0.129; 0.343] 0.375
Carrier (N)	**13**	**10**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	13 8.00 (61.54)	10 8.00 (80.00)	0.60 [0.08; 4.61] 0.623	0.77 [0.45; 1.31] 0.332	-0.185 [-0.547; 0.178] 0.318
SF-36 PCS 5-Point Response Week 52, N' n (%)	13 6.00 (46.15)	10 7.00 (70.00)	0.46 [0.08; 2.74] 0.391	0.66 [0.32; 1.35] 0.253	-0.238 [-0.631; 0.154] 0.234

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) SF-36 PCS 2.5-Point Response, SF-36 PCS 5-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

54.13 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 PCS 2.5-Point Response Week 52	N.E.				
SF-36 PCS 5-Point Response Week 52	N.E.				
Non-carrier (N)	**42**	**36**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	39 29.89 (71.17)	29 29.52 (82.00)	0.55 [0.17; 1.84] 0.334	0.87 [0.67; 1.12] 0.273	-0.108 [-0.300; 0.083] 0.267
SF-36 PCS 5-Point Response Week 52, N' n (%)	39 24.69 (58.79)	29 23.74 (65.94)	0.76 [0.28; 2.04] 0.585	0.89 [0.62; 1.28] 0.531	-0.072 [-0.294; 0.151] 0.528
Carrier (N)	**9**	**5**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	9 7.00 (77.78)	5 0.00 (0.00)	N.E.	9.00 [0.62; 130.99] 0.108	0.778 [0.506; 1.049] <.001
SF-36 PCS 5-Point Response Week 52, N' n (%)	9 7.00 (77.78)	5 0.00 (0.00)	N.E.	9.00 [0.62; 130.99] 0.108	0.778 [0.506; 1.049] <.001

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) SF-36 PCS 2.5-Point Response, SF-36 PCS 5-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

54.14 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 PCS 2.5-Point Response Week 52	p=0.759				
SF-36 PCS 5-Point Response Week 52	p=0.422				
Low score (N)	**11**	**22**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	10 6.89 (62.64)	15 14.52 (66.00)	0.77 [0.15; 3.90] 0.747	0.95 [0.54; 1.67] 0.858	-0.034 [-0.391; 0.324] 0.854
SF-36 PCS 5-Point Response Week 52, N' n (%)	10 4.69 (42.64)	15 11.74 (53.36)	0.60 [0.13; 2.90] 0.528	0.80 [0.35; 1.84] 0.597	-0.107 [-0.483; 0.269] 0.576
High score (N)	**40**	**22**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	38 30.00 (75.00)	22 17.00 (77.27)	1.06 [0.29; 3.85] 0.928	0.97 [0.73; 1.30] 0.839	-0.023 [-0.243; 0.198] 0.840
SF-36 PCS 5-Point Response Week 52, N' n (%)	38 27.00 (67.50)	22 14.00 (63.64)	1.33 [0.43; 4.10] 0.617	1.06 [0.72; 1.55] 0.762	0.039 [-0.209; 0.287] 0.760

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) SF-36 PCS 2.5-Point Response, SF-36 PCS 5-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

54.15 SF-36 PCS 2.5-Point Response / 5-Point Response by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 PCS 2.5-Point Response Week 52	p=0.550				
SF-36 PCS 5-Point Response Week 52	p=0.465				
Non-carrier (N)	**31**	**23**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	30 22.00 (70.97)	17 18.02 (78.35)	0.77 [0.19; 3.10] 0.712	0.91 [0.66; 1.25] 0.550	-0.074 [-0.313; 0.166] 0.546
SF-36 PCS 5-Point Response Week 52, N' n (%)	30 18.00 (58.06)	17 14.51 (63.09)	0.89 [0.27; 2.94] 0.842	0.92 [0.59; 1.45] 0.726	-0.050 [-0.324; 0.224] 0.719
Carrier (N)	**20**	**21**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	18 14.89 (74.45)	20 13.50 (64.29)	1.42 [0.34; 5.87] 0.632	1.16 [0.76; 1.76] 0.491	0.102 [-0.184; 0.387] 0.486
SF-36 PCS 5-Point Response Week 52, N' n (%)	18 13.69 (68.45)	20 11.23 (53.48)	1.73 [0.46; 6.53] 0.418	1.28 [0.77; 2.13] 0.341	0.150 [-0.151; 0.451] 0.330

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

54.16 SF-36 PCS 2.5-Point Response / 5-Point Response by Linkage Variant rs12065362 (FAS)

| | Treatment Groups | | Comparison | | |
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 PCS 2.5-Point Response Week 52	p=0.585				
SF-36 PCS 5-Point Response Week 52	p=0.382				
Non-carrier (N)	**19**	**20**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	19 14.00 (73.68)	14 15.64 (78.20)	0.78 [0.15; 4.14] 0.769	0.94 [0.65; 1.37] 0.760	-0.045 [-0.326; 0.236] 0.752
SF-36 PCS 5-Point Response Week 52, N' n (%)	19 11.00 (57.89)	14 12.96 (64.80)	0.75 [0.18; 3.07] 0.686	0.90 [0.53; 1.51] 0.682	-0.069 [-0.388; 0.250] 0.671
Carrier (N)	**32**	**24**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	29 22.89 (71.53)	23 15.88 (66.17)	1.39 [0.41; 4.68] 0.596	1.08 [0.75; 1.56] 0.674	0.054 [-0.194; 0.301] 0.671
SF-36 PCS 5-Point Response Week 52, N' n (%)	29 20.69 (64.66)	23 12.78 (53.25)	1.67 [0.55; 5.14] 0.368	1.21 [0.77; 1.92] 0.408	0.114 [-0.148; 0.376] 0.394

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

54.17 SF-36 PCS 2.5-Point Response / 5-Point Response by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 PCS 2.5-Point Response Week 52	N.E.				
SF-36 PCS 5-Point Response Week 52	p=0.373				
Non-carrier (N)	**25**	**32**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	23 18.89 (75.56)	28 19.95 (62.34)	1.78 [0.50; 6.30] 0.369	1.21 [0.85; 1.74] 0.292	0.132 [-0.111; 0.375] 0.286
SF-36 PCS 5-Point Response Week 52, N' n (%)	23 16.69 (66.76)	28 17.42 (54.44)	1.60 [0.51; 5.03] 0.421	1.23 [0.80; 1.89] 0.354	0.123 [-0.136; 0.382] 0.351
Carrier (N)	**26**	**12**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	25 18.00 (69.23)	9 11.57 (96.42)	N.E.	0.72 [0.53; 0.97] 0.031	-0.272 [-0.499; -0.044] 0.019
SF-36 PCS 5-Point Response Week 52, N' n (%)	25 15.00 (57.69)	9 8.32 (69.33)	0.66 [0.13; 3.21] 0.604	0.83 [0.49; 1.42] 0.503	-0.116 [-0.456; 0.223] 0.501

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

54.18 SF-36 PCS 2.5-Point Response / 5-Point Response by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test					
SF-36 PCS 2.5-Point Response Week 52	p=0.421				
SF-36 PCS 5-Point Response Week 52	p=0.585				
Non-carrier (N)	**39**	**35**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	36 26.89 (68.95)	28 23.52 (67.20)	1.25 [0.43; 3.64] 0.677	1.03 [0.74; 1.42] 0.873	0.017 [-0.201; 0.235] 0.875
SF-36 PCS 5-Point Response Week 52, N' n (%)	36 23.69 (60.74)	28 19.74 (56.40)	1.31 [0.49; 3.54] 0.592	1.08 [0.72; 1.61] 0.712	0.043 [-0.189; 0.276] 0.714
Carrier (N)	**11**	**9**			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	11 9.00 (81.82)	9 8.00 (88.89)	0.38 [0.03; 5.54] 0.480	0.92 [0.64; 1.32] 0.653	-0.071 [-0.377; 0.236] 0.651
SF-36 PCS 5-Point Response Week 52, N' n (%)	11 7.00 (63.64)	9 6.00 (66.67)	0.72 [0.11; 4.84] 0.733	0.95 [0.50; 1.82] 0.887	-0.030 [-0.449; 0.389] 0.887

N': Number of patients with available response value
N-N' is the number of values with MI.
n (%): Number and percentage of patients with event
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.
RR and RD calculated directly without adjustment within subgroups.

All results are combined over MI:
n and % are averages of all imputations.
P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

For parameter(s) SF-36 PCS 2.5-Point Response, SF-36 PCS 5-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.

55.0 WPAI-GH Percent Work Time Missed due to Health - Return Rates (FAS)

	Treatment Groups		
	SEC (N=47)	**ADA (N=40)**	**Total (N=87)**
Number of patients with valid data n (%)			
Baseline Returns	46 (97.9)	40 (100.0)	86 (98.9)
Week 4 Returns	42 (89.4)	32 (80.0)	74 (85.1)
Week 12 Returns	39 (83.0)	29 (72.5)	68 (78.2)
Week 16 Returns	43 (91.5)	30 (75.0)	73 (83.9)
Week 24 Returns	40 (85.1)	27 (67.5)	67 (77.0)
Week 32 Returns	38 (80.9)	27 (67.5)	65 (74.7)
Week 40 Returns	37 (78.7)	24 (60.0)	61 (70.1)
Week 52 Returns	40 (85.1)	22 (55.0)	62 (71.3)
Note: The table is based on all patients who were employed at baseline.			

55.1 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
N'	44	36		
Baseline Mean (SD)	19.48 (31.12)	12.51 (27.28)		
Week 52 Mean (SD)	16.16 (25.97)	24.08 (35.54)		
Week 4 Adjusted Mean Change (SE)	-4.91 (3.20)	-3.84 (3.65)		
Week 12 Adjusted Mean Change (SE)	-8.65 (3.01)	-6.26 (3.43)		
Week 16 Adjusted Mean Change (SE)	-6.71 (3.88)	4.76 (4.60)		
Week 24 Adjusted Mean Change (SE)	-6.88 (4.05)	1.80 (4.86)		
Week 32 Adjusted Mean Change (SE)	-3.63 (4.05)	-4.51 (4.77)		
Week 40 Adjusted Mean Change (SE)	-4.42 (4.04)	3.94 (4.95)		
Week 52 Adjusted Mean Change (SE)	0.25 (4.70)	6.92 (6.11)	-6.67 [-22.13; 8.78]	0.392

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

Note: The table is based on all patients who were employed at baseline.

55.2 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.323				
Male, N	32	23		
N'	30	21		
Baseline Mean (SD)	14.57 (26.14)	13.82 (29.80)		
Week 52 Mean (SD)	13.68 (25.70)	8.65 (19.34)		
Week 4 Adjusted Mean Change (SE)	-6.45 (4.00)	-7.05 (4.81)		
Week 12 Adjusted Mean Change (SE)	-6.95 (3.66)	-6.19 (4.79)		
Week 16 Adjusted Mean Change (SE)	-11.04 (4.72)	1.14 (5.82)		
Week 24 Adjusted Mean Change (SE)	-5.64 (4.81)	-5.41 (6.48)		
Week 32 Adjusted Mean Change (SE)	-6.22 (5.02)	-3.59 (6.73)		
Week 40 Adjusted Mean Change (SE)	-4.66 (5.09)	-0.01 (6.85)		
Week 52 Adjusted Mean Change (SE)	-1.48 (5.39)	-7.32 (7.96)	5.84 [-13.36; 25.05]	0.545
Female, N	15	17		
N'	14	15		
Baseline Mean (SD)	29.61 (38.53)	10.73 (24.24)		
Week 52 Mean (SD)	21.94 (26.80)	42.58 (42.33)		
Week 4 Adjusted Mean Change (SE)	-1.76 (5.69)	0.37 (5.72)		
Week 12 Adjusted Mean Change (SE)	-12.66 (5.52)	-6.04 (4.99)		
Week 16 Adjusted Mean Change (SE)	2.08 (6.83)	10.55 (7.35)		
Week 24 Adjusted Mean Change (SE)	-9.75 (7.36)	10.04 (7.24)		
Week 32 Adjusted Mean Change (SE)	1.52 (7.33)	-4.90 (6.97)		
Week 40 Adjusted Mean Change (SE)	-3.83 (7.03)	8.73 (7.41)		
Week 52 Adjusted Mean Change (SE)	4.27 (8.14)	24.97 (8.63)	-20.70 [-44.35; 2.95]	0.085

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

55.3 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.328				
PASDAS < 5.4, N	**13**	**11**		
N'	12	10		
Baseline Mean (SD)	3.59 (8.47)	4.38 (13.96)		
Week 52 Mean (SD)	12.12 (33.09)	13.89 (22.15)		
Week 4 Adjusted Mean Change (SE)	-8.03 (6.05)	-8.75 (6.70)		
Week 12 Adjusted Mean Change (SE)	5.33 (5.88)	-10.26 (6.02)		
Week 16 Adjusted Mean Change (SE)	-8.48 (7.79)	4.23 (8.62)		
Week 24 Adjusted Mean Change (SE)	-10.24 (8.50)	-10.93 (9.72)		
Week 32 Adjusted Mean Change (SE)	-11.00 (7.90)	-14.53 (9.48)		
Week 40 Adjusted Mean Change (SE)	0.60 (8.33)	2.80 (10.14)		
Week 52 Adjusted Mean Change (SE)	-1.57 (9.93)	0.30 (12.14)	-1.87 [-32.77; 29.03]	0.904
PASDAS ≥ 5.4, N	**34**	**29**		
N'	32	26		
Baseline Mean (SD)	25.73 (34.52)	15.59 (30.52)		
Week 52 Mean (SD)	17.33 (24.05)	27.90 (39.34)		
Week 4 Adjusted Mean Change (SE)	-3.64 (3.87)	-1.98 (4.39)		
Week 12 Adjusted Mean Change (SE)	-13.24 (3.39)	-4.22 (3.92)		
Week 16 Adjusted Mean Change (SE)	-6.05 (4.62)	4.82 (5.50)		
Week 24 Adjusted Mean Change (SE)	-5.59 (4.69)	6.36 (5.65)		
Week 32 Adjusted Mean Change (SE)	-0.76 (4.78)	-1.23 (5.50)		
Week 40 Adjusted Mean Change (SE)	-6.06 (4.80)	4.21 (5.77)		
Week 52 Adjusted Mean Change (SE)	1.16 (5.57)	9.13 (7.22)	-7.97 [-26.16; 10.21]	0.384

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

55.4 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.363				
Moderate/Severe Psoriasis (Def D): No, N	**18**	**20**		
N'	17	18		
Baseline Mean (SD)	16.29 (28.44)	7.43 (12.97)		
Week 52 Mean (SD)	18.65 (32.64)	16.67 (20.80)		
Week 4 Adjusted Mean Change (SE)	-0.20 (5.14)	-6.75 (5.19)		
Week 12 Adjusted Mean Change (SE)	-6.50 (4.70)	-10.89 (4.39)		
Week 16 Adjusted Mean Change (SE)	-9.04 (6.34)	8.23 (6.55)		
Week 24 Adjusted Mean Change (SE)	-8.25 (7.28)	-7.30 (7.09)		
Week 32 Adjusted Mean Change (SE)	-7.98 (6.28)	-12.55 (6.59)		
Week 40 Adjusted Mean Change (SE)	-6.07 (6.53)	8.44 (7.10)		
Week 52 Adjusted Mean Change (SE)	2.47 (8.10)	0.48 (9.16)	1.99 [-22.35; 26.33]	0.871
Moderate/Severe Psoriasis (Def D): Yes, N	**29**	**20**		
N'	27	18		
Baseline Mean (SD)	21.52 (33.07)	17.59 (36.13)		
Week 52 Mean (SD)	14.96 (22.70)	30.24 (44.33)		
Week 4 Adjusted Mean Change (SE)	-7.92 (4.11)	-0.49 (5.11)		
Week 12 Adjusted Mean Change (SE)	-9.95 (3.87)	1.11 (5.42)		
Week 16 Adjusted Mean Change (SE)	-5.22 (4.98)	1.14 (6.51)		
Week 24 Adjusted Mean Change (SE)	-6.03 (4.88)	10.06 (6.78)		
Week 32 Adjusted Mean Change (SE)	-0.49 (5.18)	3.63 (6.74)		
Week 40 Adjusted Mean Change (SE)	-3.35 (5.16)	-1.00 (6.95)		
Week 52 Adjusted Mean Change (SE)	-0.84 (5.88)	12.58 (8.38)	-13.42 [-33.80; 6.96]	0.193

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

55.5 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.463				
≤ Median, N	**31**	**18**		
N'	29	16		
Baseline Mean (SD)	18.24 (30.02)	8.10 (13.52)		
Week 52 Mean (SD)	15.01 (26.11)	13.73 (20.26)		
Week 4 Adjusted Mean Change (SE)	-8.26 (4.00)	-7.26 (5.53)		
Week 12 Adjusted Mean Change (SE)	-7.01 (3.65)	-10.10 (5.13)		
Week 16 Adjusted Mean Change (SE)	-3.96 (4.73)	9.02 (6.74)		
Week 24 Adjusted Mean Change (SE)	-8.76 (4.91)	-1.95 (7.43)		
Week 32 Adjusted Mean Change (SE)	-0.85 (5.06)	-0.96 (6.96)		
Week 40 Adjusted Mean Change (SE)	-2.89 (5.12)	1.37 (7.55)		
Week 52 Adjusted Mean Change (SE)	-0.33 (5.69)	-4.53 (9.17)	4.20 [-17.53; 25.93]	0.701
> Median, N	**16**	**22**		
N'	15	20		
Baseline Mean (SD)	21.79 (33.97)	16.11 (34.70)		
Week 52 Mean (SD)	18.83 (26.59)	32.70 (43.55)		
Week 4 Adjusted Mean Change (SE)	0.54 (5.30)	-0.91 (4.84)		
Week 12 Adjusted Mean Change (SE)	-12.16 (5.31)	-3.44 (4.61)		
Week 16 Adjusted Mean Change (SE)	-12.16 (6.72)	1.04 (6.24)		
Week 24 Adjusted Mean Change (SE)	-2.55 (7.35)	4.53 (6.63)		
Week 32 Adjusted Mean Change (SE)	-8.83 (6.89)	-7.82 (6.62)		
Week 40 Adjusted Mean Change (SE)	-6.85 (6.92)	5.96 (6.81)		
Week 52 Adjusted Mean Change (SE)	2.03 (8.38)	16.14 (8.27)	-14.11 [-37.60; 9.39]	0.235

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

55.6 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.919				
Enthesitis: No, N	25	18		
N'	23	16		
Baseline Mean (SD)	11.63 (22.44)	11.65 (25.62)		
Week 52 Mean (SD)	16.95 (28.67)	28.34 (40.87)		
Week 4 Adjusted Mean Change (SE)	-5.78 (4.45)	-2.05 (5.76)		
Week 12 Adjusted Mean Change (SE)	-2.98 (4.11)	-6.04 (5.07)		
Week 16 Adjusted Mean Change (SE)	-2.55 (5.43)	10.55 (6.53)		
Week 24 Adjusted Mean Change (SE)	-6.29 (5.90)	6.89 (6.88)		
Week 32 Adjusted Mean Change (SE)	-1.64 (5.76)	-4.56 (6.72)		
Week 40 Adjusted Mean Change (SE)	0.64 (5.84)	8.58 (7.00)		
Week 52 Adjusted Mean Change (SE)	1.84 (6.79)	12.54 (9.11)	-10.69 [-33.30; 11.91]	0.348
Enthesitis: Yes, N	22	22		
N'	21	20		
Baseline Mean (SD)	28.81 (37.50)	13.21 (29.15)		
Week 52 Mean (SD)	15.44 (23.97)	20.52 (31.84)		
Week 4 Adjusted Mean Change (SE)	-3.96 (4.84)	-5.15 (4.79)		
Week 12 Adjusted Mean Change (SE)	-15.42 (4.52)	-6.05 (4.57)		
Week 16 Adjusted Mean Change (SE)	-11.40 (5.77)	-0.39 (6.47)		
Week 24 Adjusted Mean Change (SE)	-7.65 (5.90)	-3.34 (7.18)		
Week 32 Adjusted Mean Change (SE)	-5.79 (5.98)	-4.03 (6.96)		
Week 40 Adjusted Mean Change (SE)	-9.35 (5.69)	-0.45 (6.98)		
Week 52 Adjusted Mean Change (SE)	-1.53 (6.89)	1.93 (8.45)	-3.46 [-25.37; 18.46]	0.754

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

55.7 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	**ADA (N=40)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.677				
Non-carrier, N	**20**	**17**		
N'	18	15		
Baseline Mean (SD)	18.72 (31.47)	11.02 (25.72)		
Week 52 Mean (SD)	15.24 (20.90)	24.89 (34.87)		
Week 4 Adjusted Mean Change (SE)	-4.88 (4.40)	-8.85 (5.51)		
Week 12 Adjusted Mean Change (SE)	-4.28 (4.80)	-6.59 (6.27)		
Week 16 Adjusted Mean Change (SE)	-6.11 (6.43)	4.55 (7.74)		
Week 24 Adjusted Mean Change (SE)	-1.74 (5.71)	1.37 (6.65)		
Week 32 Adjusted Mean Change (SE)	1.95 (6.56)	-4.38 (7.70)		
Week 40 Adjusted Mean Change (SE)	-7.47 (6.69)	4.23 (8.05)		
Week 52 Adjusted Mean Change (SE)	1.80 (7.68)	10.18 (10.21)	-8.38 [-34.12; 17.37]	0.517
Carrier, N	**14**	**14**		
N'	13	14		
Baseline Mean (SD)	14.64 (23.97)	16.78 (35.76)		
Week 52 Mean (SD)	17.42 (32.25)	23.52 (37.39)		
Week 4 Adjusted Mean Change (SE)	-7.48 (5.28)	5.66 (4.87)		
Week 12 Adjusted Mean Change (SE)	-6.19 (6.21)	0.20 (5.32)		
Week 16 Adjusted Mean Change (SE)	3.42 (7.37)	9.47 (7.35)		
Week 24 Adjusted Mean Change (SE)	-8.71 (6.51)	-1.40 (6.27)		
Week 32 Adjusted Mean Change (SE)	-3.92 (7.89)	0.33 (7.27)		
Week 40 Adjusted Mean Change (SE)	4.60 (8.28)	7.26 (7.51)		
Week 52 Adjusted Mean Change (SE)	3.63 (8.88)	8.86 (8.58)	-5.22 [-30.03; 19.58]	0.674

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

55.8 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.586				
Non-carrier, N	**21**	**12**		
N'	18	11		
Baseline Mean (SD)	20.76 (32.50)	10.84 (28.59)		
Week 52 Mean (SD)	12.12 (18.59)	35.71 (47.56)		
Week 4 Adjusted Mean Change (SE)	-11.33 (4.12)	-0.31 (5.45)		
Week 12 Adjusted Mean Change (SE)	-3.45 (5.04)	-4.50 (6.87)		
Week 16 Adjusted Mean Change (SE)	0.23 (6.47)	3.09 (8.58)		
Week 24 Adjusted Mean Change (SE)	-6.92 (3.93)	-0.62 (5.56)		
Week 32 Adjusted Mean Change (SE)	0.95 (6.43)	-3.05 (8.88)		
Week 40 Adjusted Mean Change (SE)	-6.09 (6.85)	2.78 (8.95)		
Week 52 Adjusted Mean Change (SE)	-2.05 (7.70)	16.66 (11.76)	-18.71 [-47.03; 9.61]	0.190
Carrier, N	**12**	**13**		
N'	12	13		
Baseline Mean (SD)	12.13 (20.23)	16.50 (37.20)		
Week 52 Mean (SD)	25.00 (35.36)	20.21 (32.94)		
Week 4 Adjusted Mean Change (SE)	-2.75 (5.38)	-1.33 (5.27)		
Week 12 Adjusted Mean Change (SE)	-8.85 (6.78)	-1.06 (6.26)		
Week 16 Adjusted Mean Change (SE)	-6.76 (8.23)	11.12 (8.56)		
Week 24 Adjusted Mean Change (SE)	-3.69 (5.20)	-14.94 (4.82)		
Week 32 Adjusted Mean Change (SE)	-2.93 (8.84)	-3.91 (7.99)		
Week 40 Adjusted Mean Change (SE)	-0.74 (8.46)	-1.98 (8.10)		
Week 52 Adjusted Mean Change (SE)	9.11 (9.95)	4.50 (9.89)	4.61 [-23.69; 32.92]	0.744

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

55.9 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.974				
Non-carrier, N	**14**	**14**		
N'	13	14		
Baseline Mean (SD)	23.91 (34.97)	9.36 (26.58)		
Week 52 Mean (SD)	16.82 (21.99)	35.00 (47.43)		
Week 4 Adjusted Mean Change (SE)	-6.92 (5.41)	-1.01 (5.23)		
Week 12 Adjusted Mean Change (SE)	-9.14 (5.91)	-3.33 (5.69)		
Week 16 Adjusted Mean Change (SE)	-7.05 (7.34)	-4.06 (7.00)		
Week 24 Adjusted Mean Change (SE)	-1.78 (7.40)	-2.20 (7.00)		
Week 32 Adjusted Mean Change (SE)	1.67 (7.89)	-3.86 (7.57)		
Week 40 Adjusted Mean Change (SE)	-10.79 (8.83)	2.51 (7.84)		
Week 52 Adjusted Mean Change (SE)	2.07 (9.05)	19.42 (9.34)	-17.35 [-43.52; 8.82]	0.189
Carrier, N	**19**	**17**		
N'	18	15		
Baseline Mean (SD)	12.56 (21.99)	17.14 (33.37)		
Week 52 Mean (SD)	15.72 (28.30)	14.97 (19.27)		
Week 4 Adjusted Mean Change (SE)	-5.28 (4.57)	0.27 (5.37)		
Week 12 Adjusted Mean Change (SE)	-1.93 (4.92)	-3.00 (5.65)		
Week 16 Adjusted Mean Change (SE)	1.40 (5.97)	19.43 (7.25)		
Week 24 Adjusted Mean Change (SE)	-6.31 (5.35)	1.24 (6.08)		
Week 32 Adjusted Mean Change (SE)	-1.97 (6.52)	0.06 (7.24)		
Week 40 Adjusted Mean Change (SE)	1.46 (6.51)	9.65 (7.67)		
Week 52 Adjusted Mean Change (SE)	2.75 (7.25)	-0.01 (8.56)	2.77 [-19.78; 25.31]	0.806

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

55.10 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.475				
Non-carrier, N	**18**	**23**		
N'	17	22		
Baseline Mean (SD)	14.88 (29.27)	14.02 (29.16)		
Week 52 Mean (SD)	18.84 (28.94)	30.93 (37.91)		
Week 4 Adjusted Mean Change (SE)	-8.24 (4.52)	-1.06 (4.27)		
Week 12 Adjusted Mean Change (SE)	-0.75 (5.02)	-4.70 (4.70)		
Week 16 Adjusted Mean Change (SE)	-5.22 (6.63)	8.47 (6.08)		
Week 24 Adjusted Mean Change (SE)	-2.56 (5.63)	4.62 (5.24)		
Week 32 Adjusted Mean Change (SE)	4.64 (6.92)	-3.51 (6.12)		
Week 40 Adjusted Mean Change (SE)	-3.85 (6.85)	11.23 (6.41)		
Week 52 Adjusted Mean Change (SE)	5.72 (7.57)	15.81 (7.12)	-10.09 [-31.05; 10.86]	0.337
Carrier, N	**16**	**8**		
N'	14	7		
Baseline Mean (SD)	19.23 (27.77)	12.50 (35.36)		
Week 52 Mean (SD)	12.82 (21.68)	0.77 (1.72)		
Week 4 Adjusted Mean Change (SE)	-2.53 (5.32)	0.20 (7.48)		
Week 12 Adjusted Mean Change (SE)	-9.81 (5.61)	0.29 (7.41)		
Week 16 Adjusted Mean Change (SE)	1.74 (7.08)	3.04 (10.69)		
Week 24 Adjusted Mean Change (SE)	-7.69 (6.25)	-13.61 (8.28)		
Week 32 Adjusted Mean Change (SE)	-6.18 (7.15)	1.34 (9.76)		
Week 40 Adjusted Mean Change (SE)	-1.31 (7.87)	-7.29 (10.09)		
Week 52 Adjusted Mean Change (SE)	-1.19 (8.12)	-12.41 (12.98)	11.22 [-19.52; 41.96]	0.467

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

55.11 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.451				
Non-carrier, N	**24**	**23**		
N'	21	22		
Baseline Mean (SD)	14.67 (27.05)	11.49 (28.52)		
Week 52 Mean (SD)	19.33 (28.75)	20.73 (29.99)		
Week 4 Adjusted Mean Change (SE)	-2.31 (3.95)	-1.01 (4.05)		
Week 12 Adjusted Mean Change (SE)	-1.34 (4.37)	-4.81 (4.38)		
Week 16 Adjusted Mean Change (SE)	1.70 (5.96)	5.08 (6.11)		
Week 24 Adjusted Mean Change (SE)	-3.16 (4.88)	0.17 (5.02)		
Week 32 Adjusted Mean Change (SE)	3.87 (5.65)	-7.38 (5.66)		
Week 40 Adjusted Mean Change (SE)	4.26 (5.58)	8.80 (5.75)		
Week 52 Adjusted Mean Change (SE)	8.11 (6.80)	7.03 (7.67)	1.08 [-19.58; 21.73]	0.917
Carrier, N	**9**	**7**		
N'	9	6		
Baseline Mean (SD)	22.59 (33.38)	8.31 (17.37)		
Week 52 Mean (SD)	10.18 (16.95)	19.79 (39.72)		
Week 4 Adjusted Mean Change (SE)	-9.40 (6.34)	-3.71 (7.95)		
Week 12 Adjusted Mean Change (SE)	-5.94 (6.70)	-3.94 (8.38)		
Week 16 Adjusted Mean Change (SE)	-4.88 (9.09)	11.49 (11.94)		
Week 24 Adjusted Mean Change (SE)	-1.26 (8.19)	-5.88 (9.55)		
Week 32 Adjusted Mean Change (SE)	-1.83 (8.51)	7.98 (9.87)		
Week 40 Adjusted Mean Change (SE)	-9.20 (8.60)	-9.12 (9.86)		
Week 52 Adjusted Mean Change (SE)	-1.75 (10.69)	8.21 (12.21)	-9.96 [-43.11; 23.20]	0.548

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

55.12 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.402				
Non-carrier, N	**24**	**25**		
N'	22	24		
Baseline Mean (SD)	16.52 (27.55)	15.46 (33.34)		
Week 52 Mean (SD)	12.33 (19.67)	21.24 (34.24)		
Week 4 Adjusted Mean Change (SE)	-10.10 (4.05)	-2.52 (4.03)		
Week 12 Adjusted Mean Change (SE)	-10.68 (4.15)	-0.88 (4.22)		
Week 16 Adjusted Mean Change (SE)	-3.04 (5.94)	7.78 (6.02)		
Week 24 Adjusted Mean Change (SE)	-5.46 (5.14)	-1.43 (5.24)		
Week 32 Adjusted Mean Change (SE)	-1.80 (5.94)	0.14 (5.81)		
Week 40 Adjusted Mean Change (SE)	-7.03 (6.16)	2.70 (6.00)		
Week 52 Adjusted Mean Change (SE)	-1.83 (6.80)	5.53 (7.29)	-7.36 [-27.43; 12.71]	0.464
Carrier, N	**8**	**6**		
N'	8	5		
Baseline Mean (SD)	9.71 (13.18)	5.98 (8.42)		
Week 52 Mean (SD)	29.87 (38.38)	33.70 (42.32)		
Week 4 Adjusted Mean Change (SE)	4.53 (6.43)	8.16 (8.24)		
Week 12 Adjusted Mean Change (SE)	11.37 (6.96)	-10.65 (8.40)		
Week 16 Adjusted Mean Change (SE)	1.41 (9.60)	4.28 (12.22)		
Week 24 Adjusted Mean Change (SE)	-4.33 (9.23)	5.24 (10.40)		
Week 32 Adjusted Mean Change (SE)	3.24 (9.17)	-10.90 (11.69)		
Week 40 Adjusted Mean Change (SE)	9.55 (10.04)	17.81 (11.97)		
Week 52 Adjusted Mean Change (SE)	16.24 (11.44)	21.03 (13.62)	-4.78 [-40.57; 31.00]	0.789

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

55.13 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.379				
Non-carrier, N	**27**	**26**		
N'	24	24		
Baseline Mean (SD)	16.29 (28.95)	15.76 (32.62)		
Week 52 Mean (SD)	16.14 (26.83)	25.49 (39.14)		
Week 4 Adjusted Mean Change (SE)	-6.34 (4.04)	0.98 (4.19)		
Week 12 Adjusted Mean Change (SE)	-4.86 (4.48)	-2.37 (4.52)		
Week 16 Adjusted Mean Change (SE)	-1.00 (5.40)	5.32 (5.64)		
Week 24 Adjusted Mean Change (SE)	-7.26 (3.99)	-5.92 (4.17)		
Week 32 Adjusted Mean Change (SE)	-3.61 (5.03)	-8.07 (5.05)		
Week 40 Adjusted Mean Change (SE)	-1.43 (5.89)	1.84 (5.94)		
Week 52 Adjusted Mean Change (SE)	2.42 (6.81)	8.96 (7.49)	-6.54 [-26.90; 13.82]	0.521
Carrier, N	**7**	**3**		
N'	7	3		
Baseline Mean (SD)	19.61 (27.15)	0.00 (0.00)		
Week 52 Mean (SD)	16.15 (23.61)	27.78 (25.46)		
Week 4 Adjusted Mean Change (SE)	-4.98 (7.26)	-6.89 (11.12)		
Week 12 Adjusted Mean Change (SE)	-5.55 (7.72)	-9.80 (13.97)		
Week 16 Adjusted Mean Change (SE)	-5.93 (9.84)	38.67 (18.02)		
Week 24 Adjusted Mean Change (SE)	1.97 (7.40)	8.17 (10.82)		
Week 32 Adjusted Mean Change (SE)	8.71 (8.60)	11.66 (13.20)		
Week 40 Adjusted Mean Change (SE)	-10.08 (10.76)	22.40 (15.56)		
Week 52 Adjusted Mean Change (SE)	1.81 (11.93)	15.83 (18.29)	-14.02 [-58.22; 30.17]	0.526

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

55.14 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.929				
Low score, N	**8**	**14**		
N'	6	14		
Baseline Mean (SD)	18.51 (33.65)	10.18 (26.47)		
Week 52 Mean (SD)	17.33 (20.47)	28.79 (43.48)		
Week 4 Adjusted Mean Change (SE)	-7.45 (7.69)	-1.91 (5.22)		
Week 12 Adjusted Mean Change (SE)	-6.75 (8.80)	-3.92 (5.73)		
Week 16 Adjusted Mean Change (SE)	-4.46 (11.77)	0.70 (7.30)		
Week 24 Adjusted Mean Change (SE)	-8.53 (9.92)	7.60 (6.94)		
Week 32 Adjusted Mean Change (SE)	11.58 (11.56)	-4.10 (7.79)		
Week 40 Adjusted Mean Change (SE)	-1.97 (14.61)	8.89 (8.38)		
Week 52 Adjusted Mean Change (SE)	4.42 (13.75)	11.55 (10.16)	-7.13 [-41.50; 27.25]	0.679
High score, N	**26**	**17**		
N'	25	15		
Baseline Mean (SD)	16.51 (26.99)	16.46 (33.59)		
Week 52 Mean (SD)	15.89 (27.01)	20.81 (30.36)		
Week 4 Adjusted Mean Change (SE)	-5.64 (3.91)	1.36 (5.37)		
Week 12 Adjusted Mean Change (SE)	-4.35 (4.24)	-2.48 (5.72)		
Week 16 Adjusted Mean Change (SE)	-1.46 (5.29)	13.83 (7.55)		
Week 24 Adjusted Mean Change (SE)	-4.00 (4.70)	-6.10 (5.90)		
Week 32 Adjusted Mean Change (SE)	-3.26 (5.48)	0.20 (6.89)		
Week 40 Adjusted Mean Change (SE)	-2.63 (5.60)	4.20 (7.19)		
Week 52 Adjusted Mean Change (SE)	2.17 (6.41)	7.68 (8.49)	-5.50 [-26.95; 15.95]	0.608

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

55.15 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	**ADA (N=40)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.511				
Non-carrier, N	**24**	**16**		
N'	21	14		
Baseline Mean (SD)	18.05 (31.04)	12.21 (26.50)		
Week 52 Mean (SD)	12.77 (19.49)	31.85 (41.09)		
Week 4 Adjusted Mean Change (SE)	-7.89 (4.04)	1.82 (5.14)		
Week 12 Adjusted Mean Change (SE)	-3.83 (4.43)	-5.31 (5.93)		
Week 16 Adjusted Mean Change (SE)	1.96 (5.75)	5.19 (7.27)		
Week 24 Adjusted Mean Change (SE)	-6.69 (5.08)	6.88 (6.65)		
Week 32 Adjusted Mean Change (SE)	1.77 (5.83)	0.54 (7.52)		
Week 40 Adjusted Mean Change (SE)	-5.65 (6.20)	10.49 (7.68)		
Week 52 Adjusted Mean Change (SE)	-0.53 (6.78)	14.69 (9.52)	-15.21 [-38.70; 8.28]	0.199
Carrier, N	**10**	**15**		
N'	10	15		
Baseline Mean (SD)	14.55 (21.47)	15.13 (34.71)		
Week 52 Mean (SD)	25.00 (37.80)	17.60 (30.47)		
Week 4 Adjusted Mean Change (SE)	-0.60 (6.48)	-2.42 (5.29)		
Week 12 Adjusted Mean Change (SE)	-8.16 (7.40)	-1.07 (5.52)		
Week 16 Adjusted Mean Change (SE)	-11.48 (8.76)	9.02 (7.55)		
Week 24 Adjusted Mean Change (SE)	-1.40 (7.78)	-6.58 (6.15)		
Week 32 Adjusted Mean Change (SE)	-6.88 (9.88)	-3.89 (7.23)		
Week 40 Adjusted Mean Change (SE)	3.44 (9.30)	1.74 (7.58)		
Week 52 Adjusted Mean Change (SE)	9.43 (10.70)	4.18 (8.73)	5.25 [-22.57; 33.07]	0.706

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

55.16 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.974				
Non-carrier, N	**14**	**14**		
N'	13	14		
Baseline Mean (SD)	23.91 (34.97)	9.36 (26.58)		
Week 52 Mean (SD)	16.82 (21.99)	35.00 (47.43)		
Week 4 Adjusted Mean Change (SE)	-6.92 (5.41)	-1.01 (5.23)		
Week 12 Adjusted Mean Change (SE)	-9.14 (5.91)	-3.33 (5.69)		
Week 16 Adjusted Mean Change (SE)	-7.05 (7.34)	-4.06 (7.00)		
Week 24 Adjusted Mean Change (SE)	-1.78 (7.40)	-2.20 (7.00)		
Week 32 Adjusted Mean Change (SE)	1.67 (7.89)	-3.86 (7.57)		
Week 40 Adjusted Mean Change (SE)	-10.79 (8.83)	2.51 (7.84)		
Week 52 Adjusted Mean Change (SE)	2.07 (9.05)	19.42 (9.34)	-17.35 [-43.52; 8.82]	0.189
Carrier, N	**20**	**17**		
N'	18	15		
Baseline Mean (SD)	11.90 (21.57)	17.14 (33.37)		
Week 52 Mean (SD)	15.72 (28.30)	14.97 (19.27)		
Week 4 Adjusted Mean Change (SE)	-5.28 (4.57)	0.27 (5.37)		
Week 12 Adjusted Mean Change (SE)	-1.93 (4.92)	-3.00 (5.65)		
Week 16 Adjusted Mean Change (SE)	1.40 (5.97)	19.43 (7.25)		
Week 24 Adjusted Mean Change (SE)	-6.31 (5.35)	1.24 (6.08)		
Week 32 Adjusted Mean Change (SE)	-1.97 (6.52)	0.06 (7.24)		
Week 40 Adjusted Mean Change (SE)	1.46 (6.51)	9.65 (7.67)		
Week 52 Adjusted Mean Change (SE)	2.75 (7.25)	-0.01 (8.56)	2.77 [-19.78; 25.31]	0.806

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

55.17 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.475				
Non-carrier, N	**18**	**23**		
N'	17	22		
Baseline Mean (SD)	14.88 (29.27)	14.02 (29.16)		
Week 52 Mean (SD)	18.84 (28.94)	30.93 (37.91)		
Week 4 Adjusted Mean Change (SE)	-8.24 (4.52)	-1.06 (4.27)		
Week 12 Adjusted Mean Change (SE)	-0.75 (5.02)	-4.70 (4.70)		
Week 16 Adjusted Mean Change (SE)	-5.22 (6.63)	8.47 (6.08)		
Week 24 Adjusted Mean Change (SE)	-2.56 (5.63)	4.62 (5.24)		
Week 32 Adjusted Mean Change (SE)	4.64 (6.92)	-3.51 (6.12)		
Week 40 Adjusted Mean Change (SE)	-3.85 (6.85)	11.23 (6.41)		
Week 52 Adjusted Mean Change (SE)	5.72 (7.57)	15.81 (7.12)	-10.09 [-31.05; 10.86]	0.337
Carrier, N	**16**	**8**		
N'	14	7		
Baseline Mean (SD)	19.23 (27.77)	12.50 (35.36)		
Week 52 Mean (SD)	12.82 (21.68)	0.77 (1.72)		
Week 4 Adjusted Mean Change (SE)	-2.53 (5.32)	0.20 (7.48)		
Week 12 Adjusted Mean Change (SE)	-9.81 (5.61)	0.29 (7.41)		
Week 16 Adjusted Mean Change (SE)	1.74 (7.08)	3.04 (10.69)		
Week 24 Adjusted Mean Change (SE)	-7.69 (6.25)	-13.61 (8.28)		
Week 32 Adjusted Mean Change (SE)	-6.18 (7.15)	1.34 (9.76)		
Week 40 Adjusted Mean Change (SE)	-1.31 (7.87)	-7.29 (10.09)		
Week 52 Adjusted Mean Change (SE)	-1.19 (8.12)	-12.41 (12.98)	11.22 [-19.52; 41.96]	0.467

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

55.18 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.861				
Non-carrier, N	**25**	**25**		
N'	22	24		
Baseline Mean (SD)	14.89 (26.48)	14.57 (32.67)		
Week 52 Mean (SD)	18.41 (28.34)	30.06 (38.47)		
Week 4 Adjusted Mean Change (SE)	-3.25 (3.82)	0.61 (3.80)		
Week 12 Adjusted Mean Change (SE)	-2.73 (4.27)	-2.22 (4.26)		
Week 16 Adjusted Mean Change (SE)	0.60 (5.66)	6.32 (5.63)		
Week 24 Adjusted Mean Change (SE)	-4.09 (5.09)	2.13 (5.25)		
Week 32 Adjusted Mean Change (SE)	2.05 (5.88)	-4.24 (5.74)		
Week 40 Adjusted Mean Change (SE)	3.15 (6.04)	11.00 (5.91)		
Week 52 Adjusted Mean Change (SE)	6.71 (6.72)	15.19 (7.27)	-8.48 [-28.38; 11.41]	0.395
Carrier, N	**8**	**6**		
N'	8	5		
Baseline Mean (SD)	12.91 (17.61)	9.70 (18.60)		
Week 52 Mean (SD)	10.30 (18.30)	3.75 (6.45)		
Week 4 Adjusted Mean Change (SE)	-4.97 (6.67)	-0.55 (8.76)		
Week 12 Adjusted Mean Change (SE)	-1.37 (7.04)	-0.77 (8.39)		
Week 16 Adjusted Mean Change (SE)	-0.70 (9.21)	17.73 (12.97)		
Week 24 Adjusted Mean Change (SE)	-5.20 (9.21)	-5.57 (10.30)		
Week 32 Adjusted Mean Change (SE)	-2.71 (9.10)	13.40 (11.54)		
Week 40 Adjusted Mean Change (SE)	-10.28 (9.85)	-7.19 (11.76)		
Week 52 Adjusted Mean Change (SE)	-2.36 (11.35)	-6.51 (13.56)	4.15 [-31.46; 39.76]	0.815

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

56.0 WPAI-GH Percent Impairment while Working due to Health - Return Rates (FAS)

	Treatment Groups		
	SEC (N=47)	ADA (N=40)	Total (N=87)
Number of patients with valid data n (%)			
Baseline Returns	43 (91.5)	37 (92.5)	80 (92.0)
Week 4 Returns	41 (87.2)	30 (75.0)	71 (81.6)
Week 12 Returns	39 (83.0)	27 (67.5)	66 (75.9)
Week 16 Returns	42 (89.4)	27 (67.5)	69 (79.3)
Week 24 Returns	39 (83.0)	24 (60.0)	63 (72.4)
Week 32 Returns	37 (78.7)	26 (65.0)	63 (72.4)
Week 40 Returns	36 (76.6)	23 (57.5)	59 (67.8)
Week 52 Returns	39 (83.0)	19 (47.5)	58 (66.7)
Note: The table is based on all patients who were employed at baseline.			

56.1 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	**ADA (N=40)**	**Mean Difference [95% CI]**	**p-value**
N'	42	33		
Baseline Mean (SD)	47.67 (23.28)	34.32 (26.09)		
Week 52 Mean (SD)	28.46 (24.66)	23.68 (22.41)		
Week 4 Adjusted Mean Change (SE)	-11.86 (3.27)	-15.66 (3.84)		
Week 12 Adjusted Mean Change (SE)	-16.99 (3.50)	-13.66 (4.06)		
Week 16 Adjusted Mean Change (SE)	-14.17 (3.73)	-19.19 (4.63)		
Week 24 Adjusted Mean Change (SE)	-14.36 (3.60)	-22.21 (4.47)		
Week 32 Adjusted Mean Change (SE)	-16.16 (3.73)	-16.25 (4.42)		
Week 40 Adjusted Mean Change (SE)	-15.54 (3.64)	-18.90 (4.42)		
Week 52 Adjusted Mean Change (SE)	-17.58 (3.79)	-17.04 (4.90)	-0.54 [-13.11; 12.03]	0.932

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

Note: The table is based on all patients who were employed at baseline.

56.2 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.861				
Male, N	**32**	**23**		
N'	29	19		
Baseline Mean (SD)	48.00 (23.84)	27.62 (24.68)		
Week 52 Mean (SD)	25.93 (23.74)	18.33 (21.67)		
Week 4 Adjusted Mean Change (SE)	-13.69 (3.98)	-14.58 (5.24)		
Week 12 Adjusted Mean Change (SE)	-18.07 (4.31)	-13.69 (5.89)		
Week 16 Adjusted Mean Change (SE)	-14.90 (4.51)	-19.54 (5.98)		
Week 24 Adjusted Mean Change (SE)	-15.19 (4.24)	-29.98 (6.14)		
Week 32 Adjusted Mean Change (SE)	-16.68 (4.68)	-16.28 (6.47)		
Week 40 Adjusted Mean Change (SE)	-14.36 (4.56)	-15.90 (6.39)		
Week 52 Adjusted Mean Change (SE)	-18.86 (4.67)	-17.09 (6.91)	-1.77 [-19.01; 15.47]	0.838
Female, N	**15**	**17**		
N'	13	14		
Baseline Mean (SD)	46.92 (22.87)	43.13 (26.00)		
Week 52 Mean (SD)	34.17 (26.78)	32.86 (22.15)		
Week 4 Adjusted Mean Change (SE)	-7.75 (6.02)	-17.32 (5.87)		
Week 12 Adjusted Mean Change (SE)	-14.57 (6.39)	-13.29 (5.95)		
Week 16 Adjusted Mean Change (SE)	-12.49 (6.83)	-20.04 (7.46)		
Week 24 Adjusted Mean Change (SE)	-11.28 (6.41)	-14.14 (6.39)		
Week 32 Adjusted Mean Change (SE)	-14.91 (6.59)	-16.35 (6.44)		
Week 40 Adjusted Mean Change (SE)	-17.52 (6.36)	-22.03 (6.50)		
Week 52 Adjusted Mean Change (SE)	-14.55 (6.88)	-16.06 (7.83)	1.52 [-19.23; 22.27]	0.884

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

56.3 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.984				
PASDAS < 5.4, N	**13**	**11**		
N'	12	10		
Baseline Mean (SD)	36.15 (22.19)	25.45 (28.41)		
Week 52 Mean (SD)	10.00 (5.35)	23.33 (28.75)		
Week 4 Adjusted Mean Change (SE)	-17.47 (5.90)	-20.95 (6.85)		
Week 12 Adjusted Mean Change (SE)	-20.80 (6.86)	-17.09 (7.57)		
Week 16 Adjusted Mean Change (SE)	-21.08 (6.89)	-27.58 (8.17)		
Week 24 Adjusted Mean Change (SE)	-13.91 (7.16)	-26.42 (8.26)		
Week 32 Adjusted Mean Change (SE)	-15.79 (7.04)	-27.13 (8.46)		
Week 40 Adjusted Mean Change (SE)	-17.64 (7.27)	-20.19 (8.53)		
Week 52 Adjusted Mean Change (SE)	-29.54 (7.56)	-16.96 (8.68)	-12.58 [-35.31; 10.15]	0.273
PASDAS ≥ 5.4, N	**34**	**29**		
N'	30	23		
Baseline Mean (SD)	52.67 (22.27)	38.08 (24.66)		
Week 52 Mean (SD)	33.23 (25.48)	23.85 (20.22)		
Week 4 Adjusted Mean Change (SE)	-9.22 (4.01)	-13.75 (4.56)		
Week 12 Adjusted Mean Change (SE)	-15.35 (4.20)	-12.65 (4.84)		
Week 16 Adjusted Mean Change (SE)	-10.94 (4.43)	-16.63 (5.34)		
Week 24 Adjusted Mean Change (SE)	-14.15 (4.32)	-20.75 (5.38)		
Week 32 Adjusted Mean Change (SE)	-16.10 (4.46)	-12.31 (5.15)		
Week 40 Adjusted Mean Change (SE)	-14.60 (4.36)	-18.60 (5.20)		
Week 52 Adjusted Mean Change (SE)	-13.40 (4.36)	-17.89 (5.77)	4.49 [-10.05; 19.03]	0.539

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

56.4 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	**ADA (N=40)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.271				
Moderate/Severe Psoriasis (Def D): No, N	**18**	**20**		
N'	17	18		
Baseline Mean (SD)	49.41 (20.45)	35.50 (28.56)		
Week 52 Mean (SD)	29.17 (23.14)	26.00 (23.19)		
Week 4 Adjusted Mean Change (SE)	-12.46 (5.31)	-15.83 (5.23)		
Week 12 Adjusted Mean Change (SE)	-9.76 (5.44)	-15.55 (5.13)		
Week 16 Adjusted Mean Change (SE)	-9.66 (5.84)	-22.46 (6.24)		
Week 24 Adjusted Mean Change (SE)	-5.88 (6.01)	-21.53 (5.71)		
Week 32 Adjusted Mean Change (SE)	-15.55 (5.80)	-22.54 (5.80)		
Week 40 Adjusted Mean Change (SE)	-12.57 (5.86)	-19.73 (5.90)		
Week 52 Adjusted Mean Change (SE)	-16.58 (6.37)	-17.76 (6.54)	1.18 [-17.18; 19.54]	0.898
Moderate/Severe Psoriasis (Def D): Yes, N	**29**	**20**		
N'	25	15		
Baseline Mean (SD)	46.54 (25.29)	32.94 (23.65)		
Week 52 Mean (SD)	28.15 (25.73)	21.11 (22.61)		
Week 4 Adjusted Mean Change (SE)	-11.75 (4.23)	-15.65 (5.60)		
Week 12 Adjusted Mean Change (SE)	-21.61 (4.47)	-11.13 (6.44)		
Week 16 Adjusted Mean Change (SE)	-16.98 (4.76)	-16.38 (6.52)		
Week 24 Adjusted Mean Change (SE)	-18.79 (4.38)	-24.65 (6.89)		
Week 32 Adjusted Mean Change (SE)	-16.45 (4.85)	-7.74 (6.73)		
Week 40 Adjusted Mean Change (SE)	-17.37 (4.67)	-18.15 (6.69)		
Week 52 Adjusted Mean Change (SE)	-18.60 (4.81)	-16.08 (7.53)	-2.51 [-20.54; 15.52]	0.781

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

56.5 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	**ADA (N=40)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.673				
≤ Median, N	**31**	**18**		
N'	28	16		
Baseline Mean (SD)	47.59 (21.82)	37.22 (27.40)		
Week 52 Mean (SD)	27.78 (24.39)	28.00 (22.51)		
Week 4 Adjusted Mean Change (SE)	-12.51 (4.04)	-13.71 (5.51)		
Week 12 Adjusted Mean Change (SE)	-14.65 (4.15)	-9.74 (5.60)		
Week 16 Adjusted Mean Change (SE)	-12.44 (4.56)	-21.22 (6.49)		
Week 24 Adjusted Mean Change (SE)	-15.04 (4.37)	-24.55 (6.14)		
Week 32 Adjusted Mean Change (SE)	-17.17 (4.55)	-8.35 (6.01)		
Week 40 Adjusted Mean Change (SE)	-16.77 (4.50)	-14.77 (6.20)		
Week 52 Adjusted Mean Change (SE)	-16.73 (4.63)	-15.16 (6.73)	-1.57 [-18.06; 14.92]	0.850
> Median, N	**16**	**22**		
N'	14	17		
Baseline Mean (SD)	47.86 (26.94)	31.58 (25.22)		
Week 52 Mean (SD)	30.00 (26.29)	18.89 (22.61)		
Week 4 Adjusted Mean Change (SE)	-10.27 (5.71)	-17.61 (5.33)		
Week 12 Adjusted Mean Change (SE)	-22.51 (6.13)	-17.47 (5.67)		
Week 16 Adjusted Mean Change (SE)	-17.80 (6.50)	-17.42 (6.37)		
Week 24 Adjusted Mean Change (SE)	-12.45 (6.53)	-18.79 (6.55)		
Week 32 Adjusted Mean Change (SE)	-15.28 (6.16)	-24.75 (6.20)		
Week 40 Adjusted Mean Change (SE)	-13.37 (6.18)	-23.09 (6.24)		
Week 52 Adjusted Mean Change (SE)	-19.28 (6.79)	-19.16 (7.22)	-0.12 [-20.05; 19.81]	0.991

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

56.6 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.452				
Enthesitis: No, N	**25**	**18**		
N'	23	15		
Baseline Mean (SD)	46.67 (22.20)	31.18 (28.04)		
Week 52 Mean (SD)	25.00 (23.83)	27.50 (26.05)		
Week 4 Adjusted Mean Change (SE)	-13.94 (4.38)	-18.81 (6.06)		
Week 12 Adjusted Mean Change (SE)	-17.57 (4.79)	-9.60 (6.18)		
Week 16 Adjusted Mean Change (SE)	-17.20 (5.14)	-19.07 (6.69)		
Week 24 Adjusted Mean Change (SE)	-17.64 (4.99)	-19.89 (6.36)		
Week 32 Adjusted Mean Change (SE)	-16.58 (5.29)	-14.32 (6.44)		
Week 40 Adjusted Mean Change (SE)	-15.71 (5.20)	-15.56 (6.45)		
Week 52 Adjusted Mean Change (SE)	-19.96 (5.35)	-16.54 (7.49)	-3.41 [-21.97; 15.15]	0.714
Enthesitis: Yes, N	**22**	**22**		
N'	19	18		
Baseline Mean (SD)	48.95 (25.14)	37.00 (24.73)		
Week 52 Mean (SD)	31.43 (25.55)	20.91 (20.23)		
Week 4 Adjusted Mean Change (SE)	-9.21 (4.99)	-14.09 (4.88)		
Week 12 Adjusted Mean Change (SE)	-16.42 (5.27)	-16.82 (5.49)		
Week 16 Adjusted Mean Change (SE)	-10.72 (5.43)	-19.46 (6.21)		
Week 24 Adjusted Mean Change (SE)	-10.98 (5.23)	-24.18 (6.42)		
Week 32 Adjusted Mean Change (SE)	-15.53 (5.48)	-17.72 (6.32)		
Week 40 Adjusted Mean Change (SE)	-15.00 (5.17)	-22.02 (6.13)		
Week 52 Adjusted Mean Change (SE)	-14.94 (5.56)	-17.52 (6.62)	2.58 [-14.70; 19.86]	0.766

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

56.7 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.329				
Non-carrier, N	**20**	**17**		
N'	17	14		
Baseline Mean (SD)	50.59 (20.15)	36.25 (25.53)		
Week 52 Mean (SD)	30.00 (22.91)	20.00 (23.90)		
Week 4 Adjusted Mean Change (SE)	-10.89 (4.79)	-25.29 (5.70)		
Week 12 Adjusted Mean Change (SE)	-17.64 (5.74)	-18.46 (6.50)		
Week 16 Adjusted Mean Change (SE)	-10.33 (6.16)	-21.26 (7.39)		
Week 24 Adjusted Mean Change (SE)	-12.90 (5.75)	-26.59 (6.79)		
Week 32 Adjusted Mean Change (SE)	-22.53 (5.90)	-17.22 (6.47)		
Week 40 Adjusted Mean Change (SE)	-20.05 (5.57)	-20.66 (6.20)		
Week 52 Adjusted Mean Change (SE)	-18.90 (6.05)	-23.16 (7.20)	4.26 [-14.83; 23.35]	0.655
Carrier, N	**14**	**14**		
N'	13	12		
Baseline Mean (SD)	44.29 (23.77)	35.83 (25.39)		
Week 52 Mean (SD)	24.55 (28.41)	26.36 (22.03)		
Week 4 Adjusted Mean Change (SE)	-15.93 (5.48)	-9.94 (5.55)		
Week 12 Adjusted Mean Change (SE)	-16.31 (6.59)	-9.45 (6.60)		
Week 16 Adjusted Mean Change (SE)	-15.23 (6.98)	-15.39 (7.34)		
Week 24 Adjusted Mean Change (SE)	-21.02 (6.23)	-19.55 (6.51)		
Week 32 Adjusted Mean Change (SE)	-18.03 (6.69)	-13.96 (6.79)		
Week 40 Adjusted Mean Change (SE)	-18.46 (6.46)	-17.15 (6.43)		
Week 52 Adjusted Mean Change (SE)	-17.27 (6.88)	-9.84 (7.12)	-7.43 [-27.47; 12.62]	0.459

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

56.8 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.692				
Non-carrier, N	**21**	**12**		
N'	17	10		
Baseline Mean (SD)	44.44 (21.48)	37.27 (22.84)		
Week 52 Mean (SD)	26.11 (23.04)	32.00 (23.87)		
Week 4 Adjusted Mean Change (SE)	-12.35 (4.78)	-15.05 (6.49)		
Week 12 Adjusted Mean Change (SE)	-18.22 (5.71)	-20.14 (7.68)		
Week 16 Adjusted Mean Change (SE)	-20.80 (5.72)	-13.56 (7.73)		
Week 24 Adjusted Mean Change (SE)	-17.35 (5.63)	-24.13 (8.05)		
Week 32 Adjusted Mean Change (SE)	-23.73 (5.76)	-21.54 (7.99)		
Week 40 Adjusted Mean Change (SE)	-23.91 (5.77)	-18.49 (7.76)		
Week 52 Adjusted Mean Change (SE)	-20.19 (6.33)	-20.05 (9.61)	-0.14 [-23.40; 23.13]	0.991
Carrier, N	**12**	**13**		
N'	12	11		
Baseline Mean (SD)	55.83 (18.81)	31.82 (24.42)		
Week 52 Mean (SD)	33.33 (29.58)	22.22 (23.33)		
Week 4 Adjusted Mean Change (SE)	-17.28 (6.24)	-17.67 (6.72)		
Week 12 Adjusted Mean Change (SE)	-15.34 (7.43)	-12.25 (7.37)		
Week 16 Adjusted Mean Change (SE)	-0.49 (7.37)	-24.65 (8.56)		
Week 24 Adjusted Mean Change (SE)	-15.65 (7.63)	-23.38 (7.56)		
Week 32 Adjusted Mean Change (SE)	-17.04 (7.84)	-10.56 (7.53)		
Week 40 Adjusted Mean Change (SE)	-11.62 (7.51)	-19.62 (7.36)		
Week 52 Adjusted Mean Change (SE)	-15.63 (8.51)	-12.30 (8.53)	-3.32 [-28.79; 22.14]	0.793

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

56.9 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.215				
Non-carrier, N	**14**	**14**		
N'	12	13		
Baseline Mean (SD)	43.33 (17.23)	31.54 (22.67)		
Week 52 Mean (SD)	29.09 (23.86)	14.29 (25.73)		
Week 4 Adjusted Mean Change (SE)	-7.97 (5.93)	-17.62 (5.81)		
Week 12 Adjusted Mean Change (SE)	-12.10 (6.69)	-19.07 (6.40)		
Week 16 Adjusted Mean Change (SE)	-2.98 (7.01)	-15.29 (7.05)		
Week 24 Adjusted Mean Change (SE)	-10.15 (7.17)	-24.39 (6.90)		
Week 32 Adjusted Mean Change (SE)	-18.75 (6.93)	-20.55 (6.69)		
Week 40 Adjusted Mean Change (SE)	-13.98 (6.89)	-19.37 (6.39)		
Week 52 Adjusted Mean Change (SE)	-18.04 (7.30)	-21.15 (7.68)	3.10 [-18.24; 24.45]	0.771
Carrier, N	**19**	**17**		
N'	18	13		
Baseline Mean (SD)	53.33 (21.42)	40.00 (26.99)		
Week 52 Mean (SD)	27.06 (26.16)	29.17 (19.29)		
Week 4 Adjusted Mean Change (SE)	-16.43 (4.91)	-16.51 (5.90)		
Week 12 Adjusted Mean Change (SE)	-20.68 (5.43)	-9.37 (6.32)		
Week 16 Adjusted Mean Change (SE)	-19.30 (5.91)	-20.31 (7.32)		
Week 24 Adjusted Mean Change (SE)	-21.29 (5.31)	-21.63 (6.41)		
Week 32 Adjusted Mean Change (SE)	-21.75 (5.64)	-11.09 (6.42)		
Week 40 Adjusted Mean Change (SE)	-22.45 (5.41)	-17.82 (6.30)		
Week 52 Adjusted Mean Change (SE)	-18.22 (5.89)	-11.68 (6.85)	-6.54 [-24.93; 11.85]	0.477

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

56.10 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	**ADA (N=40)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.196				
Non-carrier, N	**18**	**23**		
N'	16	20		
Baseline Mean (SD)	51.25 (18.21)	41.43 (26.13)		
Week 52 Mean (SD)	24.67 (21.67)	27.14 (23.67)		
Week 4 Adjusted Mean Change (SE)	-17.54 (4.99)	-15.97 (4.57)		
Week 12 Adjusted Mean Change (SE)	-18.34 (5.93)	-10.99 (5.22)		
Week 16 Adjusted Mean Change (SE)	-12.92 (6.19)	-14.01 (5.70)		
Week 24 Adjusted Mean Change (SE)	-17.56 (5.89)	-22.13 (5.49)		
Week 32 Adjusted Mean Change (SE)	-24.35 (6.20)	-17.17 (5.32)		
Week 40 Adjusted Mean Change (SE)	-22.25 (5.82)	-18.56 (5.05)		
Week 52 Adjusted Mean Change (SE)	-23.94 (6.34)	-14.50 (5.68)	-9.44 [-26.60; 7.72]	0.274
Carrier, N	**16**	**8**		
N'	14	6		
Baseline Mean (SD)	44.00 (25.01)	20.00 (11.55)		
Week 52 Mean (SD)	31.54 (28.53)	14.00 (16.73)		
Week 4 Adjusted Mean Change (SE)	-6.91 (5.55)	-20.76 (9.21)		
Week 12 Adjusted Mean Change (SE)	-15.16 (6.17)	-25.07 (9.81)		
Week 16 Adjusted Mean Change (SE)	-10.66 (6.51)	-35.49 (11.07)		
Week 24 Adjusted Mean Change (SE)	-15.60 (6.17)	-29.64 (9.65)		
Week 32 Adjusted Mean Change (SE)	-16.77 (6.20)	-12.57 (9.90)		
Week 40 Adjusted Mean Change (SE)	-16.29 (6.03)	-22.81 (9.46)		
Week 52 Adjusted Mean Change (SE)	-12.08 (6.38)	-21.93 (11.03)	9.85 [-16.10; 35.80]	0.449

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

56.11 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.490				
Non-carrier, N	**24**	**23**		
N'	21	20		
Baseline Mean (SD)	45.91 (23.02)	35.71 (24.20)		
Week 52 Mean (SD)	27.89 (26.16)	25.71 (24.09)		
Week 4 Adjusted Mean Change (SE)	-13.79 (4.52)	-17.34 (4.75)		
Week 12 Adjusted Mean Change (SE)	-17.43 (5.18)	-14.90 (5.30)		
Week 16 Adjusted Mean Change (SE)	-14.04 (5.56)	-17.50 (5.71)		
Week 24 Adjusted Mean Change (SE)	-21.09 (4.98)	-21.98 (5.40)		
Week 32 Adjusted Mean Change (SE)	-23.59 (5.09)	-21.64 (5.15)		
Week 40 Adjusted Mean Change (SE)	-20.69 (5.04)	-17.83 (5.19)		
Week 52 Adjusted Mean Change (SE)	-17.13 (5.46)	-13.46 (5.91)	-3.67 [-20.08; 12.74]	0.655
Carrier, N	**9**	**7**		
N'	8	6		
Baseline Mean (SD)	55.00 (17.73)	37.14 (29.28)		
Week 52 Mean (SD)	31.25 (22.32)	18.00 (17.89)		
Week 4 Adjusted Mean Change (SE)	-9.35 (7.70)	-17.94 (9.07)		
Week 12 Adjusted Mean Change (SE)	-15.80 (8.45)	-14.09 (9.59)		
Week 16 Adjusted Mean Change (SE)	-5.58 (8.66)	-25.60 (12.40)		
Week 24 Adjusted Mean Change (SE)	-4.62 (8.66)	-29.22 (9.49)		
Week 32 Adjusted Mean Change (SE)	-13.35 (7.88)	-0.43 (8.94)		
Week 40 Adjusted Mean Change (SE)	-13.93 (8.18)	-23.63 (9.01)		
Week 52 Adjusted Mean Change (SE)	-18.13 (8.89)	-22.87 (10.05)	4.74 [-22.76; 32.25]	0.730

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

56.12 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		**Comparison**	
	SEC (N=47)	**ADA (N=40)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.995				
Non-carrier, N	**24**	**25**		
N'	21	21		
Baseline Mean (SD)	48.18 (22.39)	34.09 (25.57)		
Week 52 Mean (SD)	30.48 (24.18)	24.00 (23.54)		
Week 4 Adjusted Mean Change (SE)	-11.18 (4.51)	-20.48 (4.74)		
Week 12 Adjusted Mean Change (SE)	-16.68 (5.13)	-13.17 (5.25)		
Week 16 Adjusted Mean Change (SE)	-13.05 (5.75)	-18.22 (6.31)		
Week 24 Adjusted Mean Change (SE)	-15.39 (4.92)	-27.78 (5.34)		
Week 32 Adjusted Mean Change (SE)	-23.17 (5.22)	-14.08 (5.26)		
Week 40 Adjusted Mean Change (SE)	-20.50 (4.99)	-17.67 (5.09)		
Week 52 Adjusted Mean Change (SE)	-17.05 (5.37)	-14.47 (5.78)	-2.58 [-18.89; 13.73]	0.751
Carrier, N	**8**	**6**		
N'	8	5		
Baseline Mean (SD)	45.00 (22.04)	43.33 (23.38)		
Week 52 Mean (SD)	23.33 (28.05)	22.50 (20.62)		
Week 4 Adjusted Mean Change (SE)	-14.06 (6.94)	-4.53 (8.91)		
Week 12 Adjusted Mean Change (SE)	-15.63 (8.15)	-16.52 (10.16)		
Week 16 Adjusted Mean Change (SE)	-8.96 (8.57)	-16.38 (10.96)		
Week 24 Adjusted Mean Change (SE)	-16.20 (8.19)	-8.17 (9.65)		
Week 32 Adjusted Mean Change (SE)	-12.71 (7.87)	-20.38 (10.09)		
Week 40 Adjusted Mean Change (SE)	-13.57 (8.14)	-22.47 (9.74)		
Week 52 Adjusted Mean Change (SE)	-18.05 (9.07)	-20.15 (11.01)	2.10 [-26.80; 31.00]	0.885

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

56.13 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.409				
Non-carrier, N	**27**	**26**		
N'	23	21		
Baseline Mean (SD)	45.83 (22.44)	35.22 (24.84)		
Week 52 Mean (SD)	28.57 (26.13)	20.00 (21.84)		
Week 4 Adjusted Mean Change (SE)	-19.02 (3.87)	-15.70 (4.28)		
Week 12 Adjusted Mean Change (SE)	-20.82 (5.07)	-13.39 (5.34)		
Week 16 Adjusted Mean Change (SE)	-14.64 (5.24)	-14.24 (5.79)		
Week 24 Adjusted Mean Change (SE)	-21.07 (4.67)	-20.39 (5.13)		
Week 32 Adjusted Mean Change (SE)	-21.49 (4.48)	-17.64 (4.73)		
Week 40 Adjusted Mean Change (SE)	-21.76 (4.86)	-18.77 (5.07)		
Week 52 Adjusted Mean Change (SE)	-16.95 (5.34)	-19.04 (5.86)	2.10 [-14.11; 18.31]	0.795
Carrier, N	**7**	**3**		
N'	7	3		
Baseline Mean (SD)	54.29 (19.02)	33.33 (23.09)		
Week 52 Mean (SD)	25.71 (22.25)	33.33 (32.15)		
Week 4 Adjusted Mean Change (SE)	4.98 (6.87)	-12.57 (10.37)		
Week 12 Adjusted Mean Change (SE)	-3.57 (8.96)	-17.17 (14.05)		
Week 16 Adjusted Mean Change (SE)	-7.31 (9.14)	-12.37 (16.43)		
Week 24 Adjusted Mean Change (SE)	-1.34 (8.59)	-31.02 (12.30)		
Week 32 Adjusted Mean Change (SE)	-20.47 (8.07)	-20.06 (11.85)		
Week 40 Adjusted Mean Change (SE)	-10.47 (8.56)	-20.42 (12.70)		
Week 52 Adjusted Mean Change (SE)	-19.92 (9.28)	-6.63 (14.01)	-13.29 [-47.54; 20.96]	0.437

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

56.14 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.882				
Low score, N	8	14		
N'	6	13		
Baseline Mean (SD)	31.43 (19.52)	37.69 (26.51)		
Week 52 Mean (SD)	30.00 (25.50)	24.29 (25.07)		
Week 4 Adjusted Mean Change (SE)	-9.51 (8.21)	-17.61 (5.75)		
Week 12 Adjusted Mean Change (SE)	-15.96 (9.90)	-15.03 (6.53)		
Week 16 Adjusted Mean Change (SE)	-24.48 (10.50)	-17.68 (6.88)		
Week 24 Adjusted Mean Change (SE)	-20.43 (9.63)	-26.23 (7.18)		
Week 32 Adjusted Mean Change (SE)	-26.72 (10.78)	-19.92 (6.86)		
Week 40 Adjusted Mean Change (SE)	-28.47 (10.54)	-15.96 (6.76)		
Week 52 Adjusted Mean Change (SE)	-12.09 (10.50)	-17.83 (7.57)	5.73 [-20.28; 31.75]	0.659
High score, N	26	17		
N'	24	13		
Baseline Mean (SD)	52.50 (20.27)	34.67 (24.46)		
Week 52 Mean (SD)	27.39 (25.27)	23.33 (21.88)		
Week 4 Adjusted Mean Change (SE)	-14.00 (4.34)	-16.32 (6.14)		
Week 12 Adjusted Mean Change (SE)	-17.68 (4.87)	-13.39 (6.56)		
Week 16 Adjusted Mean Change (SE)	-9.45 (5.16)	-19.63 (7.68)		
Week 24 Adjusted Mean Change (SE)	-15.82 (4.88)	-21.65 (6.44)		
Week 32 Adjusted Mean Change (SE)	-19.56 (4.90)	-12.61 (6.44)		
Week 40 Adjusted Mean Change (SE)	-18.06 (4.89)	-20.92 (6.42)		
Week 52 Adjusted Mean Change (SE)	-19.96 (5.15)	-14.60 (6.87)	-5.35 [-23.13; 12.43]	0.547

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

56.15 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.801				
Non-carrier, N	**24**	**16**		
N'	20	13		
Baseline Mean (SD)	42.86 (21.25)	38.67 (22.95)		
Week 52 Mean (SD)	26.19 (22.24)	27.50 (23.75)		
Week 4 Adjusted Mean Change (SE)	-12.77 (4.40)	-12.47 (5.66)		
Week 12 Adjusted Mean Change (SE)	-17.16 (5.09)	-18.06 (6.56)		
Week 16 Adjusted Mean Change (SE)	-14.86 (5.30)	-12.48 (6.74)		
Week 24 Adjusted Mean Change (SE)	-15.41 (5.10)	-24.11 (6.65)		
Week 32 Adjusted Mean Change (SE)	-21.31 (5.15)	-19.69 (6.68)		
Week 40 Adjusted Mean Change (SE)	-20.71 (5.04)	-19.03 (6.38)		
Week 52 Adjusted Mean Change (SE)	-18.76 (5.44)	-19.08 (7.48)	0.32 [-18.32; 18.95]	0.973
Carrier, N	**10**	**15**		
N'	10	13		
Baseline Mean (SD)	58.00 (19.89)	33.08 (27.80)		
Week 52 Mean (SD)	32.86 (33.02)	20.91 (22.12)		
Week 4 Adjusted Mean Change (SE)	-13.21 (6.97)	-22.84 (6.03)		
Week 12 Adjusted Mean Change (SE)	-17.97 (8.03)	-11.38 (6.46)		
Week 16 Adjusted Mean Change (SE)	-5.78 (8.17)	-27.42 (7.49)		
Week 24 Adjusted Mean Change (SE)	-20.32 (7.98)	-21.90 (6.87)		
Week 32 Adjusted Mean Change (SE)	-18.97 (8.54)	-12.61 (6.59)		
Week 40 Adjusted Mean Change (SE)	-14.47 (7.98)	-19.78 (6.44)		
Week 52 Adjusted Mean Change (SE)	-16.73 (8.88)	-13.78 (7.15)	-2.95 [-26.66; 20.75]	0.803

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

56.16 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.215				
Non-carrier, N	**14**	**14**		
N'	12	13		
Baseline Mean (SD)	43.33 (17.23)	31.54 (22.67)		
Week 52 Mean (SD)	29.09 (23.86)	14.29 (25.73)		
Week 4 Adjusted Mean Change (SE)	-7.97 (5.93)	-17.62 (5.81)		
Week 12 Adjusted Mean Change (SE)	-12.10 (6.69)	-19.07 (6.40)		
Week 16 Adjusted Mean Change (SE)	-2.98 (7.01)	-15.29 (7.05)		
Week 24 Adjusted Mean Change (SE)	-10.15 (7.17)	-24.39 (6.90)		
Week 32 Adjusted Mean Change (SE)	-18.75 (6.93)	-20.55 (6.69)		
Week 40 Adjusted Mean Change (SE)	-13.98 (6.89)	-19.37 (6.39)		
Week 52 Adjusted Mean Change (SE)	-18.04 (7.30)	-21.15 (7.68)	3.10 [-18.24; 24.45]	0.771
Carrier, N	**20**	**17**		
N'	18	13		
Baseline Mean (SD)	50.53 (24.15)	40.00 (26.99)		
Week 52 Mean (SD)	27.06 (26.16)	29.17 (19.29)		
Week 4 Adjusted Mean Change (SE)	-16.43 (4.91)	-16.51 (5.90)		
Week 12 Adjusted Mean Change (SE)	-20.68 (5.43)	-9.37 (6.32)		
Week 16 Adjusted Mean Change (SE)	-19.30 (5.91)	-20.31 (7.32)		
Week 24 Adjusted Mean Change (SE)	-21.29 (5.31)	-21.63 (6.41)		
Week 32 Adjusted Mean Change (SE)	-21.75 (5.64)	-11.09 (6.42)		
Week 40 Adjusted Mean Change (SE)	-22.45 (5.41)	-17.82 (6.30)		
Week 52 Adjusted Mean Change (SE)	-18.22 (5.89)	-11.68 (6.85)	-6.54 [-24.93; 11.85]	0.477

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

56.17 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	**ADA (N=40)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.196				
Non-carrier, N	**18**	**23**		
N'	16	20		
Baseline Mean (SD)	51.25 (18.21)	41.43 (26.13)		
Week 52 Mean (SD)	24.67 (21.67)	27.14 (23.67)		
Week 4 Adjusted Mean Change (SE)	-17.54 (4.99)	-15.97 (4.57)		
Week 12 Adjusted Mean Change (SE)	-18.34 (5.93)	-10.99 (5.22)		
Week 16 Adjusted Mean Change (SE)	-12.92 (6.19)	-14.01 (5.70)		
Week 24 Adjusted Mean Change (SE)	-17.56 (5.89)	-22.13 (5.49)		
Week 32 Adjusted Mean Change (SE)	-24.35 (6.20)	-17.17 (5.32)		
Week 40 Adjusted Mean Change (SE)	-22.25 (5.82)	-18.56 (5.05)		
Week 52 Adjusted Mean Change (SE)	-23.94 (6.34)	-14.50 (5.68)	-9.44 [-26.60; 7.72]	0.274
Carrier, N	**16**	**8**		
N'	14	6		
Baseline Mean (SD)	44.00 (25.01)	20.00 (11.55)		
Week 52 Mean (SD)	31.54 (28.53)	14.00 (16.73)		
Week 4 Adjusted Mean Change (SE)	-6.91 (5.55)	-20.76 (9.21)		
Week 12 Adjusted Mean Change (SE)	-15.16 (6.17)	-25.07 (9.81)		
Week 16 Adjusted Mean Change (SE)	-10.66 (6.51)	-35.49 (11.07)		
Week 24 Adjusted Mean Change (SE)	-15.60 (6.17)	-29.64 (9.65)		
Week 32 Adjusted Mean Change (SE)	-16.77 (6.20)	-12.57 (9.90)		
Week 40 Adjusted Mean Change (SE)	-16.29 (6.03)	-22.81 (9.46)		
Week 52 Adjusted Mean Change (SE)	-12.08 (6.38)	-21.93 (11.03)	9.85 [-16.10; 35.80]	0.449

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

56.18 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	**ADA (N=40)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.379				
Non-carrier, N	**25**	**25**		
N'	22	21		
Baseline Mean (SD)	45.22 (22.74)	35.45 (23.65)		
Week 52 Mean (SD)	26.50 (26.21)	25.71 (24.09)		
Week 4 Adjusted Mean Change (SE)	-14.37 (4.39)	-17.22 (4.62)		
Week 12 Adjusted Mean Change (SE)	-17.91 (4.99)	-14.37 (5.16)		
Week 16 Adjusted Mean Change (SE)	-14.66 (5.28)	-16.48 (5.45)		
Week 24 Adjusted Mean Change (SE)	-20.87 (4.80)	-21.53 (5.29)		
Week 32 Adjusted Mean Change (SE)	-23.76 (4.88)	-20.93 (4.96)		
Week 40 Adjusted Mean Change (SE)	-21.32 (4.90)	-17.30 (5.01)		
Week 52 Adjusted Mean Change (SE)	-18.24 (5.30)	-13.01 (5.81)	-5.24 [-21.22; 10.74]	0.513
Carrier, N	**8**	**6**		
N'	8	5		
Baseline Mean (SD)	55.00 (17.73)	38.33 (31.89)		
Week 52 Mean (SD)	25.71 (17.18)	18.00 (17.89)		
Week 4 Adjusted Mean Change (SE)	-9.16 (7.67)	-16.97 (10.02)		
Week 12 Adjusted Mean Change (SE)	-15.66 (8.37)	-15.27 (10.12)		
Week 16 Adjusted Mean Change (SE)	-5.28 (8.49)	-32.93 (13.96)		
Week 24 Adjusted Mean Change (SE)	-4.45 (8.57)	-30.16 (9.74)		
Week 32 Adjusted Mean Change (SE)	-13.11 (7.79)	2.12 (9.63)		
Week 40 Adjusted Mean Change (SE)	-13.80 (8.10)	-25.66 (9.73)		
Week 52 Adjusted Mean Change (SE)	-18.04 (8.87)	-23.62 (10.62)	5.58 [-22.72; 33.87]	0.693

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

57.0 WPAI-GH Percent Overall Work Impairment due to Health - Return Rates (FAS)

	Treatment Groups		
	SEC **(N=47)**	**ADA** **(N=40)**	**Total** **(N=87)**
Number of patients with valid data n (%)			
Baseline Returns	43 (91.5)	37 (92.5)	80 (92.0)
Week 4 Returns	41 (87.2)	30 (75.0)	71 (81.6)
Week 12 Returns	39 (83.0)	27 (67.5)	66 (75.9)
Week 16 Returns	42 (89.4)	27 (67.5)	69 (79.3)
Week 24 Returns	39 (83.0)	24 (60.0)	63 (72.4)
Week 32 Returns	37 (78.7)	26 (65.0)	63 (72.4)
Week 40 Returns	36 (76.6)	23 (57.5)	59 (67.8)
Week 52 Returns	39 (83.0)	19 (47.5)	58 (66.7)
Note: The table is based on all patients who were employed at baseline.			

57.1 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
N'	42	33		
Baseline Mean (SD)	52.03 (26.12)	36.32 (28.31)		
Week 52 Mean (SD)	36.49 (29.84)	32.28 (26.33)		
Week 4 Adjusted Mean Change (SE)	-12.21 (3.64)	-16.46 (4.27)		
Week 12 Adjusted Mean Change (SE)	-14.96 (3.95)	-16.67 (4.57)		
Week 16 Adjusted Mean Change (SE)	-14.32 (4.29)	-13.73 (5.33)		
Week 24 Adjusted Mean Change (SE)	-15.18 (3.98)	-21.74 (4.97)		
Week 32 Adjusted Mean Change (SE)	-14.92 (4.35)	-16.85 (5.17)		
Week 40 Adjusted Mean Change (SE)	-15.86 (4.03)	-9.53 (4.96)		
Week 52 Adjusted Mean Change (SE)	-14.89 (4.39)	-11.06 (5.85)	-3.83 [-18.75; 11.09]	0.610

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

Note: The table is based on all patients who were employed at baseline.

57.2 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	**ADA (N=40)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.710				
Male, N	**32**	**23**		
N'	29	19		
Baseline Mean (SD)	51.17 (26.14)	29.78 (27.72)		
Week 52 Mean (SD)	32.10 (28.26)	24.78 (27.38)		
Week 4 Adjusted Mean Change (SE)	-14.26 (4.42)	-17.15 (5.85)		
Week 12 Adjusted Mean Change (SE)	-15.24 (4.86)	-16.86 (6.69)		
Week 16 Adjusted Mean Change (SE)	-16.49 (5.13)	-14.57 (6.85)		
Week 24 Adjusted Mean Change (SE)	-16.13 (4.73)	-29.58 (6.88)		
Week 32 Adjusted Mean Change (SE)	-18.66 (5.37)	-16.23 (7.47)		
Week 40 Adjusted Mean Change (SE)	-17.58 (5.00)	-5.68 (7.10)		
Week 52 Adjusted Mean Change (SE)	-17.97 (5.33)	-16.38 (8.12)	-1.59 [-21.70; 18.51]	0.875
Female, N	**15**	**17**		
N'	13	14		
Baseline Mean (SD)	54.04 (27.04)	44.91 (27.56)		
Week 52 Mean (SD)	46.34 (32.16)	45.15 (19.99)		
Week 4 Adjusted Mean Change (SE)	-7.49 (6.72)	-15.65 (6.49)		
Week 12 Adjusted Mean Change (SE)	-14.39 (7.25)	-16.20 (6.64)		
Week 16 Adjusted Mean Change (SE)	-9.63 (7.81)	-15.52 (8.47)		
Week 24 Adjusted Mean Change (SE)	-11.66 (7.16)	-13.70 (7.14)		
Week 32 Adjusted Mean Change (SE)	-7.75 (7.62)	-17.53 (7.40)		
Week 40 Adjusted Mean Change (SE)	-12.81 (6.96)	-13.39 (7.23)		
Week 52 Adjusted Mean Change (SE)	-6.94 (7.87)	-3.37 (9.32)	-3.57 [-27.71; 20.56]	0.768

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

57.3 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.987				
PASDAS < 5.4, N	**13**	**11**		
N'	12	10		
Baseline Mean (SD)	37.32 (23.84)	27.17 (31.16)		
Week 52 Mean (SD)	11.02 (6.08)	30.00 (36.88)		
Week 4 Adjusted Mean Change (SE)	-18.58 (6.55)	-22.64 (7.64)		
Week 12 Adjusted Mean Change (SE)	-13.46 (7.75)	-21.23 (8.50)		
Week 16 Adjusted Mean Change (SE)	-21.72 (8.04)	-14.56 (9.53)		
Week 24 Adjusted Mean Change (SE)	-15.01 (7.88)	-29.68 (9.16)		
Week 32 Adjusted Mean Change (SE)	-17.16 (8.13)	-31.41 (9.87)		
Week 40 Adjusted Mean Change (SE)	-18.52 (8.12)	-12.23 (9.61)		
Week 52 Adjusted Mean Change (SE)	-31.07 (8.70)	-10.81 (10.19)	-20.26 [-46.64; 6.12]	0.130
PASDAS ≥ 5.4, N	**34**	**29**		
N'	30	23		
Baseline Mean (SD)	58.41 (24.78)	40.20 (26.70)		
Week 52 Mean (SD)	43.06 (30.03)	33.34 (21.67)		
Week 4 Adjusted Mean Change (SE)	-9.17 (4.48)	-14.29 (5.02)		
Week 12 Adjusted Mean Change (SE)	-15.26 (4.80)	-15.10 (5.47)		
Week 16 Adjusted Mean Change (SE)	-11.16 (5.21)	-14.20 (6.21)		
Week 24 Adjusted Mean Change (SE)	-14.73 (4.81)	-18.77 (5.94)		
Week 32 Adjusted Mean Change (SE)	-13.54 (5.23)	-11.80 (5.97)		
Week 40 Adjusted Mean Change (SE)	-14.62 (4.89)	-8.86 (5.83)		
Week 52 Adjusted Mean Change (SE)	-9.06 (5.05)	-12.73 (6.80)	3.67 [-13.44; 20.79]	0.669

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

57.4 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.590				
Moderate/Severe Psoriasis (Def D): No, N	**18**	**20**		
N'	17	18		
Baseline Mean (SD)	52.79 (22.98)	38.34 (31.27)		
Week 52 Mean (SD)	37.07 (28.10)	36.97 (27.85)		
Week 4 Adjusted Mean Change (SE)	-12.76 (5.87)	-16.76 (5.79)		
Week 12 Adjusted Mean Change (SE)	-8.29 (6.07)	-18.69 (5.71)		
Week 16 Adjusted Mean Change (SE)	-10.29 (6.76)	-12.62 (7.20)		
Week 24 Adjusted Mean Change (SE)	-6.22 (6.66)	-21.73 (6.37)		
Week 32 Adjusted Mean Change (SE)	-15.12 (6.64)	-24.53 (6.68)		
Week 40 Adjusted Mean Change (SE)	-16.79 (6.44)	-5.06 (6.58)		
Week 52 Adjusted Mean Change (SE)	-14.23 (7.44)	-8.69 (7.88)	-5.54 [-27.34; 16.27]	0.613
Moderate/Severe Psoriasis (Def D): Yes, N	**29**	**20**		
N'	25	15		
Baseline Mean (SD)	51.54 (28.42)	33.95 (25.10)		
Week 52 Mean (SD)	36.23 (31.10)	27.07 (25.10)		
Week 4 Adjusted Mean Change (SE)	-12.05 (4.73)	-16.57 (6.25)		
Week 12 Adjusted Mean Change (SE)	-19.29 (5.11)	-13.62 (7.45)		
Week 16 Adjusted Mean Change (SE)	-16.82 (5.54)	-15.21 (7.58)		
Week 24 Adjusted Mean Change (SE)	-19.73 (4.88)	-22.53 (7.68)		
Week 32 Adjusted Mean Change (SE)	-14.64 (5.58)	-6.21 (7.72)		
Week 40 Adjusted Mean Change (SE)	-15.06 (5.12)	-15.47 (7.37)		
Week 52 Adjusted Mean Change (SE)	-15.41 (5.52)	-13.63 (8.91)	-1.78 [-23.01; 19.45]	0.868

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

57.5 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	**ADA (N=40)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.509				
≤ Median, N	**31**	**18**		
N'	28	16		
Baseline Mean (SD)	52.34 (25.13)	40.34 (30.28)		
Week 52 Mean (SD)	35.01 (28.45)	37.70 (26.56)		
Week 4 Adjusted Mean Change (SE)	-13.28 (4.50)	-15.32 (6.08)		
Week 12 Adjusted Mean Change (SE)	-11.81 (4.66)	-11.55 (6.31)		
Week 16 Adjusted Mean Change (SE)	-11.45 (5.21)	-12.00 (7.39)		
Week 24 Adjusted Mean Change (SE)	-16.45 (4.82)	-20.95 (6.77)		
Week 32 Adjusted Mean Change (SE)	-14.52 (5.33)	-7.60 (7.02)		
Week 40 Adjusted Mean Change (SE)	-17.27 (5.04)	-6.33 (6.98)		
Week 52 Adjusted Mean Change (SE)	-15.58 (5.38)	-9.08 (8.01)	-6.50 [-26.07; 13.07]	0.509
> Median, N	**16**	**22**		
N'	14	17		
Baseline Mean (SD)	51.39 (29.05)	32.52 (26.56)		
Week 52 Mean (SD)	39.82 (33.84)	26.26 (26.26)		
Week 4 Adjusted Mean Change (SE)	-9.86 (6.31)	-17.63 (5.94)		
Week 12 Adjusted Mean Change (SE)	-22.08 (6.90)	-21.80 (6.35)		
Week 16 Adjusted Mean Change (SE)	-19.85 (7.42)	-16.23 (7.29)		
Week 24 Adjusted Mean Change (SE)	-11.85 (7.16)	-21.95 (7.27)		
Week 32 Adjusted Mean Change (SE)	-15.76 (7.14)	-26.81 (7.27)		
Week 40 Adjusted Mean Change (SE)	-12.91 (6.79)	-12.72 (7.01)		
Week 52 Adjusted Mean Change (SE)	-12.98 (7.84)	-12.86 (8.67)	-0.12 [-23.60; 23.37]	0.992

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

57.6 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.490				
Enthesitis: No, N	**25**	**18**		
N'	23	15		
Baseline Mean (SD)	49.72 (23.58)	33.37 (31.13)		
Week 52 Mean (SD)	32.56 (28.38)	33.71 (31.06)		
Week 4 Adjusted Mean Change (SE)	-14.72 (4.86)	-18.55 (6.69)		
Week 12 Adjusted Mean Change (SE)	-14.29 (5.34)	-14.64 (6.95)		
Week 16 Adjusted Mean Change (SE)	-18.09 (5.86)	-10.78 (7.65)		
Week 24 Adjusted Mean Change (SE)	-19.10 (5.49)	-19.62 (7.01)		
Week 32 Adjusted Mean Change (SE)	-16.46 (6.11)	-16.99 (7.46)		
Week 40 Adjusted Mean Change (SE)	-15.60 (5.79)	-7.73 (7.24)		
Week 52 Adjusted Mean Change (SE)	-17.75 (6.20)	-11.40 (8.94)	-6.35 [-28.32; 15.61]	0.565
Enthesitis: Yes, N	**22**	**22**		
N'	19	18		
Baseline Mean (SD)	54.95 (29.41)	38.83 (26.22)		
Week 52 Mean (SD)	39.85 (31.33)	31.24 (23.87)		
Week 4 Adjusted Mean Change (SE)	-8.86 (5.53)	-15.52 (5.44)		
Week 12 Adjusted Mean Change (SE)	-16.15 (5.98)	-18.19 (6.14)		
Week 16 Adjusted Mean Change (SE)	-10.00 (6.25)	-16.53 (7.12)		
Week 24 Adjusted Mean Change (SE)	-11.04 (5.78)	-23.76 (7.11)		
Week 32 Adjusted Mean Change (SE)	-12.95 (6.37)	-16.39 (7.37)		
Week 40 Adjusted Mean Change (SE)	-15.29 (5.72)	-11.38 (6.90)		
Week 52 Adjusted Mean Change (SE)	-11.56 (6.38)	-10.99 (7.93)	-0.57 [-20.98; 19.83]	0.955

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

57.7 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.490				
Non-carrier, N	**20**	**17**		
N'	17	14		
Baseline Mean (SD)	53.87 (20.96)	38.45 (27.60)		
Week 52 Mean (SD)	38.90 (27.26)	33.97 (25.49)		
Week 4 Adjusted Mean Change (SE)	-9.90 (5.44)	-28.03 (6.46)		
Week 12 Adjusted Mean Change (SE)	-13.26 (6.51)	-19.35 (7.63)		
Week 16 Adjusted Mean Change (SE)	-9.25 (6.94)	-19.65 (8.26)		
Week 24 Adjusted Mean Change (SE)	-13.00 (6.62)	-24.21 (7.85)		
Week 32 Adjusted Mean Change (SE)	-21.11 (6.87)	-14.70 (7.55)		
Week 40 Adjusted Mean Change (SE)	-20.47 (6.29)	-10.94 (7.15)		
Week 52 Adjusted Mean Change (SE)	-13.01 (6.86)	-12.49 (8.43)	-0.52 [-22.58; 21.55]	0.963
Carrier, N	**14**	**14**		
N'	13	12		
Baseline Mean (SD)	49.50 (28.32)	36.93 (26.60)		
Week 52 Mean (SD)	31.65 (31.56)	31.05 (28.10)		
Week 4 Adjusted Mean Change (SE)	-14.12 (6.29)	-8.95 (6.36)		
Week 12 Adjusted Mean Change (SE)	-14.20 (7.70)	-12.70 (7.49)		
Week 16 Adjusted Mean Change (SE)	-12.23 (7.90)	-8.50 (8.27)		
Week 24 Adjusted Mean Change (SE)	-20.49 (7.20)	-17.54 (7.53)		
Week 32 Adjusted Mean Change (SE)	-14.63 (7.84)	-15.95 (7.93)		
Week 40 Adjusted Mean Change (SE)	-15.11 (7.54)	-10.52 (7.39)		
Week 52 Adjusted Mean Change (SE)	-15.35 (7.91)	-10.05 (8.21)	-5.30 [-28.52; 17.93]	0.648

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

57.8 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.837				
Non-carrier, N	21	12		
N'	17	10		
Baseline Mean (SD)	49.43 (24.12)	38.84 (23.25)		
Week 52 Mean (SD)	34.69 (26.35)	38.00 (29.50)		
Week 4 Adjusted Mean Change (SE)	-14.15 (5.31)	-15.04 (7.15)		
Week 12 Adjusted Mean Change (SE)	-12.74 (6.34)	-24.76 (8.68)		
Week 16 Adjusted Mean Change (SE)	-17.04 (6.57)	-10.01 (8.84)		
Week 24 Adjusted Mean Change (SE)	-16.65 (6.18)	-27.33 (8.81)		
Week 32 Adjusted Mean Change (SE)	-21.10 (6.59)	-24.08 (9.18)		
Week 40 Adjusted Mean Change (SE)	-18.56 (6.33)	-15.22 (8.46)		
Week 52 Adjusted Mean Change (SE)	-15.04 (6.90)	-19.15 (11.13)	4.12 [-22.36; 30.59]	0.755
Carrier, N	12	13		
N'	12	11		
Baseline Mean (SD)	59.08 (21.80)	32.21 (25.11)		
Week 52 Mean (SD)	41.67 (34.28)	30.30 (26.12)		
Week 4 Adjusted Mean Change (SE)	-15.56 (6.82)	-19.42 (7.40)		
Week 12 Adjusted Mean Change (SE)	-14.54 (8.45)	-15.74 (8.35)		
Week 16 Adjusted Mean Change (SE)	-3.24 (8.32)	-19.35 (9.86)		
Week 24 Adjusted Mean Change (SE)	-16.05 (8.34)	-24.89 (8.37)		
Week 32 Adjusted Mean Change (SE)	-16.41 (9.08)	-10.38 (8.69)		
Week 40 Adjusted Mean Change (SE)	-21.69 (8.31)	-11.31 (8.14)		
Week 52 Adjusted Mean Change (SE)	-15.05 (9.49)	-4.83 (9.69)	-10.21 [-38.95; 18.52]	0.477

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

57.9 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.079				
Non-carrier, N	**14**	**14**		
N'	12	13		
Baseline Mean (SD)	48.28 (18.37)	32.90 (23.43)		
Week 52 Mean (SD)	38.88 (30.49)	21.43 (27.95)		
Week 4 Adjusted Mean Change (SE)	-6.23 (6.75)	-18.46 (6.65)		
Week 12 Adjusted Mean Change (SE)	-9.74 (7.71)	-23.78 (7.47)		
Week 16 Adjusted Mean Change (SE)	-2.14 (8.06)	-17.02 (8.05)		
Week 24 Adjusted Mean Change (SE)	-7.20 (8.13)	-25.66 (7.84)		
Week 32 Adjusted Mean Change (SE)	-19.46 (8.08)	-23.39 (7.80)		
Week 40 Adjusted Mean Change (SE)	-14.94 (7.85)	-17.23 (7.30)		
Week 52 Adjusted Mean Change (SE)	-11.27 (8.10)	-20.14 (8.97)	8.88 [-15.54; 33.29]	0.468
Carrier, N	**19**	**17**		
N'	18	13		
Baseline Mean (SD)	57.18 (24.90)	42.04 (29.35)		
Week 52 Mean (SD)	34.23 (28.24)	38.61 (24.29)		
Week 4 Adjusted Mean Change (SE)	-15.37 (5.64)	-17.31 (6.75)		
Week 12 Adjusted Mean Change (SE)	-16.16 (6.28)	-8.92 (7.32)		
Week 16 Adjusted Mean Change (SE)	-16.83 (6.76)	-9.67 (8.33)		
Week 24 Adjusted Mean Change (SE)	-22.02 (6.01)	-16.20 (7.30)		
Week 32 Adjusted Mean Change (SE)	-17.54 (6.57)	-7.98 (7.46)		
Week 40 Adjusted Mean Change (SE)	-21.22 (6.15)	-5.23 (7.12)		
Week 52 Adjusted Mean Change (SE)	-15.78 (6.58)	-2.88 (7.62)	-12.89 [-33.45; 7.66]	0.213

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

57.10 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.260				
Non-carrier, N	**18**	**23**		
N'	16	20		
Baseline Mean (SD)	54.49 (21.45)	43.73 (27.81)		
Week 52 Mean (SD)	35.52 (24.17)	38.65 (26.43)		
Week 4 Adjusted Mean Change (SE)	-17.10 (5.68)	-16.60 (5.21)		
Week 12 Adjusted Mean Change (SE)	-10.42 (6.74)	-12.17 (5.99)		
Week 16 Adjusted Mean Change (SE)	-10.27 (6.94)	-8.33 (6.38)		
Week 24 Adjusted Mean Change (SE)	-15.69 (6.77)	-19.85 (6.31)		
Week 32 Adjusted Mean Change (SE)	-19.85 (7.35)	-17.10 (6.28)		
Week 40 Adjusted Mean Change (SE)	-22.70 (6.64)	-8.66 (5.83)		
Week 52 Adjusted Mean Change (SE)	-16.81 (7.36)	-9.71 (6.65)	-7.10 [-27.16; 12.97]	0.480
Carrier, N	**16**	**8**		
N'	14	6		
Baseline Mean (SD)	49.12 (27.36)	20.00 (11.55)		
Week 52 Mean (SD)	36.67 (34.18)	14.46 (17.64)		
Week 4 Adjusted Mean Change (SE)	-4.04 (6.34)	-21.92 (10.52)		
Week 12 Adjusted Mean Change (SE)	-16.33 (7.04)	-30.73 (11.08)		
Week 16 Adjusted Mean Change (SE)	-10.30 (7.36)	-34.68 (12.41)		
Week 24 Adjusted Mean Change (SE)	-17.26 (7.12)	-29.12 (11.16)		
Week 32 Adjusted Mean Change (SE)	-17.49 (7.35)	-11.87 (11.71)		
Week 40 Adjusted Mean Change (SE)	-12.92 (6.94)	-19.48 (10.72)		
Week 52 Adjusted Mean Change (SE)	-10.97 (7.35)	-15.73 (13.09)	4.76 [-26.02; 35.55]	0.757

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

57.11 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	**ADA (N=40)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.443				
Non-carrier, N	**24**	**23**		
N'	21	20		
Baseline Mean (SD)	49.66 (25.99)	36.97 (25.16)		
Week 52 Mean (SD)	37.67 (29.72)	36.47 (27.51)		
Week 4 Adjusted Mean Change (SE)	-11.47 (5.16)	-17.12 (5.42)		
Week 12 Adjusted Mean Change (SE)	-13.72 (6.00)	-16.47 (6.14)		
Week 16 Adjusted Mean Change (SE)	-11.29 (6.31)	-11.44 (6.47)		
Week 24 Adjusted Mean Change (SE)	-19.98 (5.79)	-19.06 (6.28)		
Week 32 Adjusted Mean Change (SE)	-20.69 (6.14)	-20.99 (6.18)		
Week 40 Adjusted Mean Change (SE)	-17.74 (5.64)	-6.95 (5.85)		
Week 52 Adjusted Mean Change (SE)	-10.97 (6.07)	-6.76 (6.70)	-4.21 [-22.69; 14.26]	0.648
Carrier, N	**9**	**7**		
N'	8	6		
Baseline Mean (SD)	59.02 (20.16)	40.30 (32.94)		
Week 52 Mean (SD)	36.72 (26.60)	20.55 (20.70)		
Week 4 Adjusted Mean Change (SE)	-9.21 (8.72)	-21.36 (10.29)		
Week 12 Adjusted Mean Change (SE)	-11.35 (9.68)	-17.47 (11.23)		
Week 16 Adjusted Mean Change (SE)	-5.05 (9.82)	-25.45 (13.82)		
Week 24 Adjusted Mean Change (SE)	-6.31 (9.97)	-29.01 (11.01)		
Week 32 Adjusted Mean Change (SE)	-11.96 (9.37)	-0.46 (10.66)		
Week 40 Adjusted Mean Change (SE)	-16.37 (9.03)	-23.70 (9.93)		
Week 52 Adjusted Mean Change (SE)	-17.45 (9.76)	-21.36 (11.18)	3.92 [-26.53; 34.36]	0.797

	Treatment Groups		Comparison	
	SEC (N=47)	**ADA (N=40)**	**Mean Difference [95% CI]**	**p-value**
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup. Note: The table is based on all patients who were employed at baseline.				

57.12 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.949				
Non-carrier, N	**24**	**25**		
N'	21	21		
Baseline Mean (SD)	52.72 (24.94)	35.67 (27.20)		
Week 52 Mean (SD)	38.39 (27.91)	30.94 (28.17)		
Week 4 Adjusted Mean Change (SE)	-11.78 (5.06)	-23.35 (5.33)		
Week 12 Adjusted Mean Change (SE)	-17.11 (5.80)	-14.76 (6.00)		
Week 16 Adjusted Mean Change (SE)	-11.87 (6.56)	-14.11 (7.12)		
Week 24 Adjusted Mean Change (SE)	-14.76 (5.71)	-26.70 (6.18)		
Week 32 Adjusted Mean Change (SE)	-23.08 (6.09)	-12.71 (6.13)		
Week 40 Adjusted Mean Change (SE)	-17.41 (5.79)	-13.67 (5.94)		
Week 52 Adjusted Mean Change (SE)	-13.38 (6.11)	-9.47 (6.72)	-3.91 [-22.78; 14.97]	0.679
Carrier, N	**8**	**6**		
N'	8	5		
Baseline Mean (SD)	48.46 (24.91)	45.60 (25.41)		
Week 52 Mean (SD)	33.86 (32.17)	37.31 (20.35)		
Week 4 Adjusted Mean Change (SE)	-7.69 (7.74)	1.63 (9.94)		
Week 12 Adjusted Mean Change (SE)	-2.91 (9.16)	-19.69 (11.30)		
Week 16 Adjusted Mean Change (SE)	-5.29 (9.70)	-10.33 (12.39)		
Week 24 Adjusted Mean Change (SE)	-17.91 (9.38)	-3.17 (11.10)		
Week 32 Adjusted Mean Change (SE)	-6.19 (9.04)	-22.97 (11.56)		
Week 40 Adjusted Mean Change (SE)	-17.03 (9.45)	-0.60 (11.02)		
Week 52 Adjusted Mean Change (SE)	-12.37 (10.38)	-13.66 (12.57)	1.29 [-31.72; 34.31]	0.938

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

57.13 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.871				
Non-carrier, N	**27**	**26**		
N'	23	21		
Baseline Mean (SD)	49.32 (24.10)	37.21 (26.78)		
Week 52 Mean (SD)	35.08 (30.29)	27.12 (26.38)		
Week 4 Adjusted Mean Change (SE)	-17.65 (4.57)	-16.12 (5.08)		
Week 12 Adjusted Mean Change (SE)	-17.60 (5.72)	-17.62 (6.01)		
Week 16 Adjusted Mean Change (SE)	-15.12 (5.54)	-11.55 (6.16)		
Week 24 Adjusted Mean Change (SE)	-23.25 (5.32)	-19.74 (5.88)		
Week 32 Adjusted Mean Change (SE)	-19.87 (5.36)	-19.22 (5.67)		
Week 40 Adjusted Mean Change (SE)	-21.71 (5.42)	-11.71 (5.65)		
Week 52 Adjusted Mean Change (SE)	-14.99 (5.94)	-14.87 (6.78)	-0.11 [-18.56; 18.34]	0.990
Carrier, N	**7**	**3**		
N'	7	3		
Baseline Mean (SD)	60.71 (24.31)	33.33 (23.09)		
Week 52 Mean (SD)	38.98 (25.10)	51.67 (30.14)		
Week 4 Adjusted Mean Change (SE)	7.76 (8.17)	-15.05 (12.26)		
Week 12 Adjusted Mean Change (SE)	-0.33 (9.95)	-5.02 (16.42)		
Week 16 Adjusted Mean Change (SE)	-4.71 (9.71)	28.97 (17.39)		
Week 24 Adjusted Mean Change (SE)	4.81 (9.83)	-17.26 (14.02)		
Week 32 Adjusted Mean Change (SE)	-17.61 (9.69)	-5.61 (14.04)		
Week 40 Adjusted Mean Change (SE)	-8.09 (9.55)	8.01 (13.88)		
Week 52 Adjusted Mean Change (SE)	-12.39 (10.18)	11.06 (15.27)	-23.45 [-61.03; 14.12]	0.214

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

57.14 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.747				
Low score, N	**8**	**14**		
N'	6	13		
Baseline Mean (SD)	36.03 (20.03)	39.21 (27.11)		
Week 52 Mean (SD)	39.13 (33.35)	29.48 (30.38)		
Week 4 Adjusted Mean Change (SE)	-11.83 (9.37)	-18.43 (6.58)		
Week 12 Adjusted Mean Change (SE)	-17.10 (11.34)	-18.52 (7.55)		
Week 16 Adjusted Mean Change (SE)	-22.43 (11.91)	-15.43 (7.81)		
Week 24 Adjusted Mean Change (SE)	-21.67 (10.96)	-29.29 (8.19)		
Week 32 Adjusted Mean Change (SE)	-29.07 (12.54)	-22.70 (7.95)		
Week 40 Adjusted Mean Change (SE)	-23.16 (12.18)	-17.06 (7.71)		
Week 52 Adjusted Mean Change (SE)	-6.53 (11.58)	-19.79 (8.76)	13.26 [-15.92; 42.45]	0.365
High score, N	**26**	**17**		
N'	24	13		
Baseline Mean (SD)	56.52 (23.70)	36.57 (27.20)		
Week 52 Mean (SD)	35.38 (28.36)	33.92 (24.97)		
Week 4 Adjusted Mean Change (SE)	-11.66 (4.99)	-17.39 (7.06)		
Week 12 Adjusted Mean Change (SE)	-13.03 (5.63)	-14.13 (7.67)		
Week 16 Adjusted Mean Change (SE)	-8.09 (5.87)	-13.45 (8.67)		
Week 24 Adjusted Mean Change (SE)	-15.54 (5.56)	-16.05 (7.37)		
Week 32 Adjusted Mean Change (SE)	-16.43 (5.67)	-9.57 (7.43)		
Week 40 Adjusted Mean Change (SE)	-18.30 (5.47)	-6.37 (7.12)		
Week 52 Adjusted Mean Change (SE)	-16.51 (5.74)	-4.03 (7.72)	-12.48 [-32.46; 7.50]	0.215

	Treatment Groups		Comparison	
	SEC (N=47)	**ADA (N=40)**	**Mean Difference [95% CI]**	**p-value**
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup. Note: The table is based on all patients who were employed at baseline.				

57.15 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.987				
Non-carrier, N	**24**	**16**		
N'	20	13		
Baseline Mean (SD)	47.13 (23.90)	41.44 (25.29)		
Week 52 Mean (SD)	34.74 (26.70)	38.03 (28.45)		
Week 4 Adjusted Mean Change (SE)	-12.00 (5.03)	-11.62 (6.44)		
Week 12 Adjusted Mean Change (SE)	-13.00 (5.77)	-19.28 (7.62)		
Week 16 Adjusted Mean Change (SE)	-11.15 (6.07)	-6.91 (7.68)		
Week 24 Adjusted Mean Change (SE)	-15.48 (5.88)	-19.02 (7.67)		
Week 32 Adjusted Mean Change (SE)	-17.94 (6.05)	-17.92 (7.87)		
Week 40 Adjusted Mean Change (SE)	-16.54 (5.67)	-8.89 (7.14)		
Week 52 Adjusted Mean Change (SE)	-13.19 (6.13)	-15.51 (8.70)	2.32 [-19.14; 23.79]	0.829
Carrier, N	**10**	**15**		
N'	10	13		
Baseline Mean (SD)	61.90 (22.85)	33.60 (28.65)		
Week 52 Mean (SD)	40.00 (36.06)	28.10 (25.22)		
Week 4 Adjusted Mean Change (SE)	-10.05 (7.93)	-25.22 (6.90)		
Week 12 Adjusted Mean Change (SE)	-16.61 (9.47)	-14.17 (7.44)		
Week 16 Adjusted Mean Change (SE)	-9.22 (9.30)	-23.29 (8.55)		
Week 24 Adjusted Mean Change (SE)	-19.77 (9.18)	-23.00 (8.00)		
Week 32 Adjusted Mean Change (SE)	-20.15 (10.23)	-13.18 (7.80)		
Week 40 Adjusted Mean Change (SE)	-24.68 (9.14)	-13.23 (7.40)		
Week 52 Adjusted Mean Change (SE)	-17.52 (10.29)	-7.03 (8.27)	-10.48 [-38.09; 17.12]	0.448

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

57.16 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.079				
Non-carrier, N	**14**	**14**		
N'	12	13		
Baseline Mean (SD)	48.28 (18.37)	32.90 (23.43)		
Week 52 Mean (SD)	38.88 (30.49)	21.43 (27.95)		
Week 4 Adjusted Mean Change (SE)	-6.23 (6.75)	-18.46 (6.65)		
Week 12 Adjusted Mean Change (SE)	-9.74 (7.71)	-23.78 (7.47)		
Week 16 Adjusted Mean Change (SE)	-2.14 (8.06)	-17.02 (8.05)		
Week 24 Adjusted Mean Change (SE)	-7.20 (8.13)	-25.66 (7.84)		
Week 32 Adjusted Mean Change (SE)	-19.46 (8.08)	-23.39 (7.80)		
Week 40 Adjusted Mean Change (SE)	-14.94 (7.85)	-17.23 (7.30)		
Week 52 Adjusted Mean Change (SE)	-11.27 (8.10)	-20.14 (8.97)	8.88 [-15.54; 33.29]	0.468
Carrier, N	**20**	**17**		
N'	18	13		
Baseline Mean (SD)	54.17 (27.53)	42.04 (29.35)		
Week 52 Mean (SD)	34.23 (28.24)	38.61 (24.29)		
Week 4 Adjusted Mean Change (SE)	-15.37 (5.64)	-17.31 (6.75)		
Week 12 Adjusted Mean Change (SE)	-16.16 (6.28)	-8.92 (7.32)		
Week 16 Adjusted Mean Change (SE)	-16.83 (6.76)	-9.67 (8.33)		
Week 24 Adjusted Mean Change (SE)	-22.02 (6.01)	-16.20 (7.30)		
Week 32 Adjusted Mean Change (SE)	-17.54 (6.57)	-7.98 (7.46)		
Week 40 Adjusted Mean Change (SE)	-21.22 (6.15)	-5.23 (7.12)		
Week 52 Adjusted Mean Change (SE)	-15.78 (6.58)	-2.88 (7.62)	-12.89 [-33.45; 7.66]	0.213

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

57.17 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.260				
Non-carrier, N	18	23		
N'	16	20		
Baseline Mean (SD)	54.49 (21.45)	43.73 (27.81)		
Week 52 Mean (SD)	35.52 (24.17)	38.65 (26.43)		
Week 4 Adjusted Mean Change (SE)	-17.10 (5.68)	-16.60 (5.21)		
Week 12 Adjusted Mean Change (SE)	-10.42 (6.74)	-12.17 (5.99)		
Week 16 Adjusted Mean Change (SE)	-10.27 (6.94)	-8.33 (6.38)		
Week 24 Adjusted Mean Change (SE)	-15.69 (6.77)	-19.85 (6.31)		
Week 32 Adjusted Mean Change (SE)	-19.85 (7.35)	-17.10 (6.28)		
Week 40 Adjusted Mean Change (SE)	-22.70 (6.64)	-8.66 (5.83)		
Week 52 Adjusted Mean Change (SE)	-16.81 (7.36)	-9.71 (6.65)	-7.10 [-27.16; 12.97]	0.480
Carrier, N	16	8		
N'	14	6		
Baseline Mean (SD)	49.12 (27.36)	20.00 (11.55)		
Week 52 Mean (SD)	36.67 (34.18)	14.46 (17.64)		
Week 4 Adjusted Mean Change (SE)	-4.04 (6.34)	-21.92 (10.52)		
Week 12 Adjusted Mean Change (SE)	-16.33 (7.04)	-30.73 (11.08)		
Week 16 Adjusted Mean Change (SE)	-10.30 (7.36)	-34.68 (12.41)		
Week 24 Adjusted Mean Change (SE)	-17.26 (7.12)	-29.12 (11.16)		
Week 32 Adjusted Mean Change (SE)	-17.49 (7.35)	-11.87 (11.71)		
Week 40 Adjusted Mean Change (SE)	-12.92 (6.94)	-19.48 (10.72)		
Week 52 Adjusted Mean Change (SE)	-10.97 (7.35)	-15.73 (13.09)	4.76 [-26.02; 35.55]	0.757

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Note: The table is based on all patients who were employed at baseline.

57.18 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=47)	ADA (N=40)	Mean Difference [95% CI]	p-value
Interaction test: p=0.366				
Non-carrier, N	25	25		
N'	22	21		
Baseline Mean (SD)	49.41 (25.42)	36.65 (24.60)		
Week 52 Mean (SD)	35.78 (30.13)	36.47 (27.51)		
Week 4 Adjusted Mean Change (SE)	-12.57 (5.05)	-17.16 (5.30)		
Week 12 Adjusted Mean Change (SE)	-14.77 (5.82)	-16.26 (6.05)		
Week 16 Adjusted Mean Change (SE)	-12.48 (6.03)	-10.97 (6.21)		
Week 24 Adjusted Mean Change (SE)	-20.12 (5.59)	-18.98 (6.17)		
Week 32 Adjusted Mean Change (SE)	-21.34 (5.89)	-20.64 (5.95)		
Week 40 Adjusted Mean Change (SE)	-18.98 (5.57)	-7.14 (5.70)		
Week 52 Adjusted Mean Change (SE)	-12.80 (5.95)	-6.93 (6.66)	-5.87 [-24.09; 12.35]	0.520
Carrier, N	8	6		
N'	8	5		
Baseline Mean (SD)	59.02 (20.16)	42.02 (35.74)		
Week 52 Mean (SD)	31.57 (24.03)	20.55 (20.70)		
Week 4 Adjusted Mean Change (SE)	-9.28 (8.74)	-20.62 (11.42)		
Week 12 Adjusted Mean Change (SE)	-11.36 (9.65)	-17.08 (11.59)		
Week 16 Adjusted Mean Change (SE)	-4.91 (9.67)	-33.26 (15.51)		
Week 24 Adjusted Mean Change (SE)	-6.39 (9.88)	-29.45 (11.29)		
Week 32 Adjusted Mean Change (SE)	-11.92 (9.26)	2.31 (11.48)		
Week 40 Adjusted Mean Change (SE)	-16.45 (9.04)	-25.61 (10.83)		
Week 52 Adjusted Mean Change (SE)	-17.49 (9.84)	-21.91 (11.75)	4.43 [-26.96; 35.82]	0.777

	Treatment Groups		Comparison	
	SEC (N=47)	**ADA (N=40)**	**Mean Difference [95% CI]**	**p-value**
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un) Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup. Note: The table is based on all patients who were employed at baseline.				

58.0 WPAI-GH Percent Activity Impairment due to Health - Return Rates (FAS)

	Treatment Groups		
	SEC **(N=66)**	**ADA** **(N=62)**	**Total** **(N=128)**
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 4 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	57 (91.9)	122 (95.3)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	48 (77.4)	111 (86.7)

58.0 WPAI-GH Percent Activity Impairment due to Health - Return Rates (FAS)

58.1 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	60		
Baseline Mean (SD)	52.73 (26.46)	48.71 (28.43)		
Week 52 Mean (SD)	31.90 (25.14)	30.63 (24.36)		
Week 4 Adjusted Mean Change (SE)	-13.31 (2.65)	-9.66 (2.79)		
Week 12 Adjusted Mean Change (SE)	-16.35 (2.65)	-11.73 (2.77)		
Week 16 Adjusted Mean Change (SE)	-19.06 (2.82)	-13.10 (2.99)		
Week 24 Adjusted Mean Change (SE)	-17.80 (3.15)	-15.29 (3.41)		
Week 32 Adjusted Mean Change (SE)	-18.21 (3.01)	-16.81 (3.24)		
Week 40 Adjusted Mean Change (SE)	-17.31 (3.05)	-20.53 (3.36)		
Week 52 Adjusted Mean Change (SE)	-19.26 (3.01)	-18.03 (3.34)	-1.23 [-10.14; 7.68]	0.785

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: unstructured (un)

58.2 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.954				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	51.19 (27.60)	43.03 (31.07)		
Week 52 Mean (SD)	29.00 (25.60)	23.85 (22.99)		
Week 4 Adjusted Mean Change (SE)	-15.17 (3.35)	-11.78 (3.88)		
Week 12 Adjusted Mean Change (SE)	-21.28 (3.27)	-12.67 (3.75)		
Week 16 Adjusted Mean Change (SE)	-22.53 (3.52)	-16.65 (4.05)		
Week 24 Adjusted Mean Change (SE)	-21.72 (3.85)	-23.01 (4.58)		
Week 32 Adjusted Mean Change (SE)	-19.74 (3.80)	-21.14 (4.49)		
Week 40 Adjusted Mean Change (SE)	-18.46 (3.88)	-22.61 (4.64)		
Week 52 Adjusted Mean Change (SE)	-21.19 (3.75)	-23.41 (4.55)	2.22 [-9.43; 13.88]	0.706
Female, N	**24**	**29**		
N'	24	28		
Baseline Mean (SD)	55.42 (24.67)	55.17 (24.00)		
Week 52 Mean (SD)	36.96 (24.01)	38.64 (23.96)		
Week 4 Adjusted Mean Change (SE)	-10.02 (4.46)	-7.34 (4.10)		
Week 12 Adjusted Mean Change (SE)	-7.57 (4.36)	-10.82 (4.01)		
Week 16 Adjusted Mean Change (SE)	-12.91 (4.66)	-9.04 (4.41)		
Week 24 Adjusted Mean Change (SE)	-10.62 (5.18)	-6.44 (4.94)		
Week 32 Adjusted Mean Change (SE)	-15.32 (5.04)	-11.93 (4.75)		
Week 40 Adjusted Mean Change (SE)	-15.11 (5.09)	-18.22 (5.00)		
Week 52 Adjusted Mean Change (SE)	-15.74 (4.97)	-11.90 (4.88)	-3.85 [-17.58; 9.89]	0.580

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

58.3 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.946				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	34.38 (25.02)	26.15 (30.42)		
Week 52 Mean (SD)	20.63 (20.16)	26.67 (26.46)		
Week 4 Adjusted Mean Change (SE)	-25.49 (5.33)	-22.20 (6.04)		
Week 12 Adjusted Mean Change (SE)	-20.95 (5.56)	-18.47 (6.19)		
Week 16 Adjusted Mean Change (SE)	-28.18 (5.81)	-19.58 (6.58)		
Week 24 Adjusted Mean Change (SE)	-19.67 (6.65)	-20.57 (7.76)		
Week 32 Adjusted Mean Change (SE)	-21.15 (6.26)	-26.48 (7.50)		
Week 40 Adjusted Mean Change (SE)	-19.01 (6.44)	-26.12 (7.86)		
Week 52 Adjusted Mean Change (SE)	-26.28 (6.22)	-17.17 (7.75)	-9.12 [-28.29; 10.05]	0.348
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	47		
Baseline Mean (SD)	58.60 (24.33)	54.69 (24.93)		
Week 52 Mean (SD)	35.74 (25.69)	31.54 (24.12)		
Week 4 Adjusted Mean Change (SE)	-9.15 (2.99)	-6.55 (3.04)		
Week 12 Adjusted Mean Change (SE)	-14.73 (3.08)	-10.04 (3.13)		
Week 16 Adjusted Mean Change (SE)	-15.94 (3.28)	-11.53 (3.36)		
Week 24 Adjusted Mean Change (SE)	-17.04 (3.69)	-13.89 (3.87)		
Week 32 Adjusted Mean Change (SE)	-17.12 (3.51)	-14.44 (3.61)		
Week 40 Adjusted Mean Change (SE)	-16.59 (3.58)	-18.99 (3.77)		
Week 52 Adjusted Mean Change (SE)	-16.85 (3.54)	-18.04 (3.73)	1.19 [-8.95; 11.32]	0.817

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

58.4 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.481				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	31		
Baseline Mean (SD)	53.21 (24.65)	48.44 (28.30)		
Week 52 Mean (SD)	33.46 (22.79)	29.13 (23.53)		
Week 4 Adjusted Mean Change (SE)	-12.73 (4.10)	-10.08 (3.91)		
Week 12 Adjusted Mean Change (SE)	-10.23 (4.00)	-12.01 (3.81)		
Week 16 Adjusted Mean Change (SE)	-15.37 (4.33)	-13.54 (4.19)		
Week 24 Adjusted Mean Change (SE)	-10.68 (4.82)	-14.11 (4.69)		
Week 32 Adjusted Mean Change (SE)	-20.15 (4.65)	-16.66 (4.55)		
Week 40 Adjusted Mean Change (SE)	-14.44 (4.70)	-21.68 (4.79)		
Week 52 Adjusted Mean Change (SE)	-18.96 (4.71)	-17.59 (4.80)	-1.37 [-14.70; 11.97]	0.839
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	52.37 (28.04)	49.00 (29.05)		
Week 52 Mean (SD)	30.81 (26.91)	32.00 (25.50)		
Week 4 Adjusted Mean Change (SE)	-13.75 (3.52)	-9.21 (4.04)		
Week 12 Adjusted Mean Change (SE)	-20.97 (3.48)	-11.44 (3.97)		
Week 16 Adjusted Mean Change (SE)	-21.75 (3.74)	-12.67 (4.30)		
Week 24 Adjusted Mean Change (SE)	-22.86 (4.09)	-16.59 (4.90)		
Week 32 Adjusted Mean Change (SE)	-16.79 (3.99)	-16.90 (4.67)		
Week 40 Adjusted Mean Change (SE)	-19.46 (4.01)	-19.54 (4.74)		
Week 52 Adjusted Mean Change (SE)	-19.63 (3.99)	-18.42 (4.76)	-1.21 [-13.52; 11.10]	0.846

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

58.5 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.896				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	52.75 (24.70)	48.62 (30.20)		
Week 52 Mean (SD)	32.11 (24.62)	25.71 (23.15)		
Week 4 Adjusted Mean Change (SE)	-13.86 (3.43)	-7.70 (4.03)		
Week 12 Adjusted Mean Change (SE)	-19.19 (3.40)	-14.92 (3.95)		
Week 16 Adjusted Mean Change (SE)	-19.40 (3.59)	-19.93 (4.27)		
Week 24 Adjusted Mean Change (SE)	-21.92 (3.96)	-20.70 (4.89)		
Week 32 Adjusted Mean Change (SE)	-17.75 (3.91)	-14.11 (4.73)		
Week 40 Adjusted Mean Change (SE)	-18.65 (3.96)	-20.99 (4.97)		
Week 52 Adjusted Mean Change (SE)	-18.15 (3.90)	-20.24 (5.00)	2.09 [-10.49; 14.67]	0.743
> Median, N	**26**	**33**		
N'	26	31		
Baseline Mean (SD)	52.69 (29.47)	48.79 (27.24)		
Week 52 Mean (SD)	31.60 (26.41)	34.44 (25.01)		
Week 4 Adjusted Mean Change (SE)	-12.47 (4.25)	-11.50 (3.90)		
Week 12 Adjusted Mean Change (SE)	-12.10 (4.17)	-8.70 (3.86)		
Week 16 Adjusted Mean Change (SE)	-18.46 (4.43)	-6.88 (4.10)		
Week 24 Adjusted Mean Change (SE)	-11.19 (4.97)	-10.34 (4.64)		
Week 32 Adjusted Mean Change (SE)	-18.75 (4.76)	-18.97 (4.48)		
Week 40 Adjusted Mean Change (SE)	-15.23 (4.84)	-20.07 (4.62)		
Week 52 Adjusted Mean Change (SE)	-20.93 (4.82)	-16.05 (4.57)	-4.88 [-18.05; 8.29]	0.464

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

58.6 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.755				
Enthesitis: No, N	**34**	**22**		
N'	34	21		
Baseline Mean (SD)	50.00 (25.70)	44.09 (29.87)		
Week 52 Mean (SD)	29.69 (25.84)	28.33 (24.55)		
Week 4 Adjusted Mean Change (SE)	-17.01 (3.66)	-15.85 (4.71)		
Week 12 Adjusted Mean Change (SE)	-20.42 (3.67)	-15.41 (4.73)		
Week 16 Adjusted Mean Change (SE)	-22.36 (3.81)	-23.66 (4.95)		
Week 24 Adjusted Mean Change (SE)	-19.88 (4.41)	-19.46 (5.69)		
Week 32 Adjusted Mean Change (SE)	-21.46 (4.18)	-23.38 (5.32)		
Week 40 Adjusted Mean Change (SE)	-18.01 (4.30)	-22.59 (5.56)		
Week 52 Adjusted Mean Change (SE)	-21.45 (4.22)	-21.27 (5.54)	-0.18 [-13.94; 13.58]	0.979
Enthesitis: Yes, N	**32**	**40**		
N'	32	39		
Baseline Mean (SD)	55.63 (27.35)	51.25 (27.66)		
Week 52 Mean (SD)	34.19 (24.60)	32.00 (24.55)		
Week 4 Adjusted Mean Change (SE)	-9.32 (3.79)	-6.42 (3.42)		
Week 12 Adjusted Mean Change (SE)	-11.97 (3.79)	-9.76 (3.40)		
Week 16 Adjusted Mean Change (SE)	-15.46 (3.97)	-7.54 (3.60)		
Week 24 Adjusted Mean Change (SE)	-15.51 (4.53)	-13.18 (4.31)		
Week 32 Adjusted Mean Change (SE)	-14.60 (4.27)	-13.25 (4.06)		
Week 40 Adjusted Mean Change (SE)	-16.40 (4.38)	-19.67 (4.26)		
Week 52 Adjusted Mean Change (SE)	-16.87 (4.33)	-16.48 (4.22)	-0.39 [-12.34; 11.56]	0.949

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

58.7 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.619				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	57.59 (24.74)	45.20 (29.17)		
Week 52 Mean (SD)	35.36 (26.31)	25.24 (22.72)		
Week 4 Adjusted Mean Change (SE)	-11.83 (3.76)	-18.79 (4.03)		
Week 12 Adjusted Mean Change (SE)	-15.48 (4.10)	-16.78 (4.43)		
Week 16 Adjusted Mean Change (SE)	-19.74 (4.17)	-19.93 (4.57)		
Week 24 Adjusted Mean Change (SE)	-19.69 (4.56)	-19.70 (5.05)		
Week 32 Adjusted Mean Change (SE)	-20.53 (4.35)	-21.33 (4.78)		
Week 40 Adjusted Mean Change (SE)	-21.81 (4.45)	-27.04 (4.86)		
Week 52 Adjusted Mean Change (SE)	-18.52 (4.52)	-25.06 (5.04)	6.54 [-6.97; 20.05]	0.339
Carrier, N	**22**	**19**		
N'	22	18		
Baseline Mean (SD)	49.09 (24.28)	48.95 (28.46)		
Week 52 Mean (SD)	28.00 (25.26)	31.88 (27.13)		
Week 4 Adjusted Mean Change (SE)	-14.88 (4.28)	-7.86 (4.73)		
Week 12 Adjusted Mean Change (SE)	-16.14 (4.71)	-14.98 (5.16)		
Week 16 Adjusted Mean Change (SE)	-16.12 (4.80)	-15.10 (5.24)		
Week 24 Adjusted Mean Change (SE)	-19.62 (5.24)	-19.22 (5.83)		
Week 32 Adjusted Mean Change (SE)	-18.41 (5.14)	-18.24 (5.58)		
Week 40 Adjusted Mean Change (SE)	-17.90 (5.11)	-25.03 (5.81)		
Week 52 Adjusted Mean Change (SE)	-20.17 (5.23)	-16.65 (5.87)	-3.52 [-19.12; 12.09]	0.655

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

58.8 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.313				
Non-carrier, N	**28**	**19**		
N'	28	18		
Baseline Mean (SD)	52.50 (26.48)	47.37 (25.79)		
Week 52 Mean (SD)	31.85 (26.46)	33.08 (22.87)		
Week 4 Adjusted Mean Change (SE)	-12.40 (3.93)	-9.42 (4.93)		
Week 12 Adjusted Mean Change (SE)	-19.53 (4.13)	-19.51 (5.18)		
Week 16 Adjusted Mean Change (SE)	-22.02 (4.22)	-13.53 (5.37)		
Week 24 Adjusted Mean Change (SE)	-20.13 (4.51)	-15.66 (5.81)		
Week 32 Adjusted Mean Change (SE)	-21.05 (4.51)	-15.97 (5.80)		
Week 40 Adjusted Mean Change (SE)	-23.66 (4.48)	-19.26 (5.82)		
Week 52 Adjusted Mean Change (SE)	-19.61 (4.74)	-18.46 (6.43)	-1.15 [-17.05; 14.75]	0.886
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	57.73 (20.92)	45.79 (30.97)		
Week 52 Mean (SD)	34.00 (25.83)	27.78 (27.34)		
Week 4 Adjusted Mean Change (SE)	-14.22 (4.47)	-16.50 (4.80)		
Week 12 Adjusted Mean Change (SE)	-10.81 (4.74)	-13.39 (5.09)		
Week 16 Adjusted Mean Change (SE)	-14.16 (4.85)	-18.94 (5.21)		
Week 24 Adjusted Mean Change (SE)	-18.92 (5.18)	-24.58 (5.63)		
Week 32 Adjusted Mean Change (SE)	-18.68 (5.20)	-20.39 (5.55)		
Week 40 Adjusted Mean Change (SE)	-16.81 (5.06)	-28.81 (5.55)		
Week 52 Adjusted Mean Change (SE)	-19.47 (5.44)	-22.43 (5.83)	2.96 [-13.01; 18.92]	0.713

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

58.9 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.313				
Non-carrier, N	**19**	**21**		
N'	19	20		
Baseline Mean (SD)	56.84 (27.50)	48.57 (31.67)		
Week 52 Mean (SD)	34.74 (25.25)	29.33 (30.58)		
Week 4 Adjusted Mean Change (SE)	-11.79 (4.69)	-19.93 (4.56)		
Week 12 Adjusted Mean Change (SE)	-14.64 (4.98)	-22.83 (4.90)		
Week 16 Adjusted Mean Change (SE)	-15.90 (5.16)	-19.60 (5.09)		
Week 24 Adjusted Mean Change (SE)	-16.64 (5.68)	-23.05 (5.68)		
Week 32 Adjusted Mean Change (SE)	-18.82 (5.33)	-22.22 (5.36)		
Week 40 Adjusted Mean Change (SE)	-18.24 (5.41)	-23.33 (5.45)		
Week 52 Adjusted Mean Change (SE)	-18.43 (5.57)	-20.84 (5.86)	2.41 [-13.69; 18.51]	0.767
Carrier, N	**30**	**23**		
N'	30	23		
Baseline Mean (SD)	53.33 (21.55)	45.22 (26.09)		
Week 52 Mean (SD)	31.43 (26.77)	27.27 (20.28)		
Week 4 Adjusted Mean Change (SE)	-14.49 (3.71)	-9.51 (4.27)		
Week 12 Adjusted Mean Change (SE)	-17.41 (3.97)	-10.59 (4.54)		
Week 16 Adjusted Mean Change (SE)	-20.45 (4.08)	-16.77 (4.75)		
Week 24 Adjusted Mean Change (SE)	-22.67 (4.42)	-17.05 (5.15)		
Week 32 Adjusted Mean Change (SE)	-22.01 (4.33)	-18.50 (4.92)		
Week 40 Adjusted Mean Change (SE)	-23.68 (4.31)	-28.63 (5.00)		
Week 52 Adjusted Mean Change (SE)	-20.77 (4.49)	-22.27 (5.14)	1.50 [-12.09; 15.08]	0.827

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

58.10 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.566				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	57.20 (24.75)	46.25 (27.91)		
Week 52 Mean (SD)	32.17 (26.28)	32.50 (26.33)		
Week 4 Adjusted Mean Change (SE)	-15.31 (4.10)	-15.61 (3.61)		
Week 12 Adjusted Mean Change (SE)	-14.44 (4.42)	-13.82 (3.87)		
Week 16 Adjusted Mean Change (SE)	-18.37 (4.51)	-15.48 (3.96)		
Week 24 Adjusted Mean Change (SE)	-18.40 (4.85)	-16.63 (4.42)		
Week 32 Adjusted Mean Change (SE)	-15.28 (4.74)	-19.52 (4.21)		
Week 40 Adjusted Mean Change (SE)	-17.32 (4.77)	-24.66 (4.32)		
Week 52 Adjusted Mean Change (SE)	-20.22 (4.88)	-17.87 (4.38)	-2.35 [-15.43; 10.73]	0.722
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	50.77 (24.65)	48.33 (31.57)		
Week 52 Mean (SD)	32.40 (26.03)	14.44 (10.14)		
Week 4 Adjusted Mean Change (SE)	-11.16 (3.99)	-9.88 (6.13)		
Week 12 Adjusted Mean Change (SE)	-16.93 (4.26)	-22.54 (6.55)		
Week 16 Adjusted Mean Change (SE)	-18.08 (4.35)	-24.93 (6.85)		
Week 24 Adjusted Mean Change (SE)	-20.85 (4.76)	-27.57 (7.25)		
Week 32 Adjusted Mean Change (SE)	-23.73 (4.57)	-21.68 (6.95)		
Week 40 Adjusted Mean Change (SE)	-22.91 (4.68)	-30.62 (7.29)		
Week 52 Adjusted Mean Change (SE)	-18.33 (4.72)	-32.39 (7.56)	14.06 [-3.65; 31.77]	0.118

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

58.11 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.779				
Non-carrier, N	**38**	**33**		
N'	38	32		
Baseline Mean (SD)	53.42 (24.08)	46.67 (29.86)		
Week 52 Mean (SD)	33.43 (26.12)	25.38 (21.95)		
Week 4 Adjusted Mean Change (SE)	-11.97 (3.17)	-17.02 (3.45)		
Week 12 Adjusted Mean Change (SE)	-15.63 (3.44)	-16.57 (3.73)		
Week 16 Adjusted Mean Change (SE)	-17.94 (3.52)	-17.78 (3.84)		
Week 24 Adjusted Mean Change (SE)	-22.03 (3.75)	-21.28 (4.20)		
Week 32 Adjusted Mean Change (SE)	-20.70 (3.75)	-24.76 (4.13)		
Week 40 Adjusted Mean Change (SE)	-19.49 (3.70)	-29.60 (4.15)		
Week 52 Adjusted Mean Change (SE)	-18.15 (3.89)	-23.79 (4.43)	5.63 [-6.11; 17.37]	0.343
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	57.50 (27.34)	45.56 (25.55)		
Week 52 Mean (SD)	30.83 (26.44)	24.44 (22.42)		
Week 4 Adjusted Mean Change (SE)	-16.52 (5.70)	-14.67 (6.48)		
Week 12 Adjusted Mean Change (SE)	-15.02 (6.14)	-24.67 (7.20)		
Week 16 Adjusted Mean Change (SE)	-18.06 (6.27)	-28.94 (7.41)		
Week 24 Adjusted Mean Change (SE)	-11.29 (6.90)	-26.59 (7.89)		
Week 32 Adjusted Mean Change (SE)	-15.52 (6.60)	-13.25 (7.52)		
Week 40 Adjusted Mean Change (SE)	-21.16 (6.60)	-27.84 (7.52)		
Week 52 Adjusted Mean Change (SE)	-20.95 (6.84)	-24.68 (7.80)	3.73 [-16.95; 24.41]	0.721

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

58.12 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.182				
Non-carrier, N	**36**	**34**		
N'	36	33		
Baseline Mean (SD)	53.06 (26.28)	46.76 (30.52)		
Week 52 Mean (SD)	33.64 (26.08)	27.04 (24.93)		
Week 4 Adjusted Mean Change (SE)	-11.26 (3.24)	-18.73 (3.40)		
Week 12 Adjusted Mean Change (SE)	-15.22 (3.67)	-16.62 (3.88)		
Week 16 Adjusted Mean Change (SE)	-17.59 (3.75)	-19.97 (3.98)		
Week 24 Adjusted Mean Change (SE)	-17.24 (4.06)	-22.06 (4.38)		
Week 32 Adjusted Mean Change (SE)	-19.31 (3.91)	-22.20 (4.17)		
Week 40 Adjusted Mean Change (SE)	-20.06 (3.92)	-26.72 (4.22)		
Week 52 Adjusted Mean Change (SE)	-17.00 (4.03)	-22.20 (4.39)	5.20 [-6.68; 17.08]	0.386
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	53.08 (20.97)	47.00 (22.14)		
Week 52 Mean (SD)	28.46 (24.10)	31.00 (24.70)		
Week 4 Adjusted Mean Change (SE)	-16.84 (5.38)	1.85 (6.19)		
Week 12 Adjusted Mean Change (SE)	-16.14 (6.11)	-13.07 (7.01)		
Week 16 Adjusted Mean Change (SE)	-19.10 (6.20)	-10.20 (7.11)		
Week 24 Adjusted Mean Change (SE)	-23.61 (6.70)	-10.33 (7.68)		
Week 32 Adjusted Mean Change (SE)	-17.23 (6.42)	-11.59 (7.36)		
Week 40 Adjusted Mean Change (SE)	-20.20 (6.48)	-22.56 (7.55)		
Week 52 Adjusted Mean Change (SE)	-23.18 (6.57)	-16.82 (7.54)	-6.36 [-26.33; 13.61]	0.528

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

58.13 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.718				
Non-carrier, N	**42**	**36**		
N'	42	35		
Baseline Mean (SD)	51.67 (25.37)	46.39 (28.60)		
Week 52 Mean (SD)	33.08 (25.36)	28.62 (26.56)		
Week 4 Adjusted Mean Change (SE)	-15.45 (3.01)	-10.58 (3.31)		
Week 12 Adjusted Mean Change (SE)	-16.13 (3.35)	-17.06 (3.69)		
Week 16 Adjusted Mean Change (SE)	-19.03 (3.35)	-16.73 (3.73)		
Week 24 Adjusted Mean Change (SE)	-20.08 (3.63)	-18.70 (4.09)		
Week 32 Adjusted Mean Change (SE)	-18.65 (3.56)	-17.40 (3.96)		
Week 40 Adjusted Mean Change (SE)	-20.22 (3.65)	-22.72 (4.13)		
Week 52 Adjusted Mean Change (SE)	-17.66 (3.79)	-20.95 (4.32)	3.29 [-8.15; 14.73]	0.569
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	64.44 (18.78)	46.00 (33.62)		
Week 52 Mean (SD)	28.89 (29.34)	32.00 (16.43)		
Week 4 Adjusted Mean Change (SE)	-2.44 (6.59)	-28.15 (8.70)		
Week 12 Adjusted Mean Change (SE)	-14.03 (7.30)	0.01 (9.65)		
Week 16 Adjusted Mean Change (SE)	-14.67 (7.29)	-6.15 (9.64)		
Week 24 Adjusted Mean Change (SE)	-16.59 (7.92)	-26.62 (10.46)		
Week 32 Adjusted Mean Change (SE)	-24.32 (7.67)	-30.64 (10.14)		
Week 40 Adjusted Mean Change (SE)	-20.56 (7.96)	-34.78 (10.52)		
Week 52 Adjusted Mean Change (SE)	-25.59 (8.19)	-16.96 (10.81)	-8.63 [-35.70; 18.45]	0.528

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

58.14 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.362				
Low score, N	11	22		
N'	11	21		
Baseline Mean (SD)	43.64 (31.71)	47.73 (30.70)		
Week 52 Mean (SD)	39.00 (29.61)	30.67 (27.89)		
Week 4 Adjusted Mean Change (SE)	-9.00 (6.14)	-17.05 (4.46)		
Week 12 Adjusted Mean Change (SE)	-14.36 (6.53)	-21.28 (4.74)		
Week 16 Adjusted Mean Change (SE)	-15.53 (6.92)	-18.71 (4.96)		
Week 24 Adjusted Mean Change (SE)	-13.10 (7.22)	-14.63 (5.47)		
Week 32 Adjusted Mean Change (SE)	-14.62 (7.01)	-19.82 (5.33)		
Week 40 Adjusted Mean Change (SE)	-10.12 (7.02)	-22.17 (5.35)		
Week 52 Adjusted Mean Change (SE)	-6.97 (7.34)	-20.32 (5.73)	13.35 [-5.10; 31.80]	0.154
High score, N	40	22		
N'	40	22		
Baseline Mean (SD)	56.75 (22.00)	45.91 (27.02)		
Week 52 Mean (SD)	30.53 (24.93)	26.36 (22.58)		
Week 4 Adjusted Mean Change (SE)	-14.37 (3.24)	-11.34 (4.36)		
Week 12 Adjusted Mean Change (SE)	-16.10 (3.46)	-10.72 (4.67)		
Week 16 Adjusted Mean Change (SE)	-18.99 (3.56)	-17.05 (4.83)		
Week 24 Adjusted Mean Change (SE)	-21.53 (3.85)	-23.54 (5.17)		
Week 32 Adjusted Mean Change (SE)	-21.07 (3.77)	-19.80 (4.97)		
Week 40 Adjusted Mean Change (SE)	-23.08 (3.73)	-28.94 (5.01)		
Week 52 Adjusted Mean Change (SE)	-22.66 (3.84)	-22.26 (5.09)	-0.40 [-13.15; 12.35]	0.950

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

58.15 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.415				
Non-carrier, N	**31**	**23**		
N'	31	22		
Baseline Mean (SD)	51.94 (26.76)	48.26 (25.70)		
Week 52 Mean (SD)	32.00 (25.65)	30.00 (22.64)		
Week 4 Adjusted Mean Change (SE)	-13.30 (3.66)	-11.35 (4.35)		
Week 12 Adjusted Mean Change (SE)	-19.12 (3.88)	-17.66 (4.61)		
Week 16 Adjusted Mean Change (SE)	-19.41 (3.98)	-15.11 (4.79)		
Week 24 Adjusted Mean Change (SE)	-20.32 (4.36)	-18.31 (5.33)		
Week 32 Adjusted Mean Change (SE)	-19.98 (4.21)	-18.50 (5.11)		
Week 40 Adjusted Mean Change (SE)	-22.61 (4.25)	-22.23 (5.19)		
Week 52 Adjusted Mean Change (SE)	-19.09 (4.39)	-20.42 (5.54)	1.33 [-12.72; 15.38]	0.852
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	57.00 (21.30)	45.24 (32.03)		
Week 52 Mean (SD)	32.78 (26.97)	26.50 (26.61)		
Week 4 Adjusted Mean Change (SE)	-12.97 (4.59)	-17.15 (4.46)		
Week 12 Adjusted Mean Change (SE)	-10.26 (4.92)	-14.19 (4.78)		
Week 16 Adjusted Mean Change (SE)	-16.44 (5.05)	-20.85 (4.91)		
Week 24 Adjusted Mean Change (SE)	-18.65 (5.55)	-20.97 (5.46)		
Week 32 Adjusted Mean Change (SE)	-19.30 (5.36)	-21.68 (5.17)		
Week 40 Adjusted Mean Change (SE)	-16.38 (5.28)	-30.29 (5.25)		
Week 52 Adjusted Mean Change (SE)	-19.62 (5.56)	-22.96 (5.39)	3.34 [-12.14; 18.83]	0.669

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

58.16 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.282				
Non-carrier, N	**19**	**20**		
N'	19	19		
Baseline Mean (SD)	56.84 (27.50)	47.50 (32.10)		
Week 52 Mean (SD)	34.74 (25.25)	27.86 (31.18)		
Week 4 Adjusted Mean Change (SE)	-11.58 (4.66)	-19.11 (4.65)		
Week 12 Adjusted Mean Change (SE)	-14.37 (4.89)	-24.90 (4.93)		
Week 16 Adjusted Mean Change (SE)	-15.68 (5.09)	-22.53 (5.17)		
Week 24 Adjusted Mean Change (SE)	-16.43 (5.63)	-24.09 (5.80)		
Week 32 Adjusted Mean Change (SE)	-18.56 (5.36)	-20.86 (5.53)		
Week 40 Adjusted Mean Change (SE)	-17.94 (5.47)	-23.71 (5.67)		
Week 52 Adjusted Mean Change (SE)	-18.22 (5.58)	-21.18 (6.05)	2.96 [-13.44; 19.35]	0.721
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	52.19 (23.10)	46.25 (26.01)		
Week 52 Mean (SD)	30.69 (26.58)	28.26 (20.37)		
Week 4 Adjusted Mean Change (SE)	-14.11 (3.57)	-10.29 (4.14)		
Week 12 Adjusted Mean Change (SE)	-16.52 (3.77)	-9.34 (4.34)		
Week 16 Adjusted Mean Change (SE)	-19.71 (3.93)	-14.23 (4.57)		
Week 24 Adjusted Mean Change (SE)	-21.51 (4.25)	-16.17 (4.98)		
Week 32 Adjusted Mean Change (SE)	-20.27 (4.20)	-19.21 (4.82)		
Week 40 Adjusted Mean Change (SE)	-21.53 (4.22)	-27.56 (4.93)		
Week 52 Adjusted Mean Change (SE)	-19.70 (4.37)	-21.37 (5.02)	1.67 [-11.56; 14.90]	0.803

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

58.17 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.566				
Non-carrier, N	**25**	**32**		
N'	25	32		
Baseline Mean (SD)	57.20 (24.75)	46.25 (27.91)		
Week 52 Mean (SD)	32.17 (26.28)	32.50 (26.33)		
Week 4 Adjusted Mean Change (SE)	-15.31 (4.10)	-15.61 (3.61)		
Week 12 Adjusted Mean Change (SE)	-14.44 (4.42)	-13.82 (3.87)		
Week 16 Adjusted Mean Change (SE)	-18.37 (4.51)	-15.48 (3.96)		
Week 24 Adjusted Mean Change (SE)	-18.40 (4.85)	-16.63 (4.42)		
Week 32 Adjusted Mean Change (SE)	-15.28 (4.74)	-19.52 (4.21)		
Week 40 Adjusted Mean Change (SE)	-17.32 (4.77)	-24.66 (4.32)		
Week 52 Adjusted Mean Change (SE)	-20.22 (4.88)	-17.87 (4.38)	-2.35 [-15.43; 10.73]	0.722
Carrier, N	**26**	**12**		
N'	26	11		
Baseline Mean (SD)	50.77 (24.65)	48.33 (31.57)		
Week 52 Mean (SD)	32.40 (26.03)	14.44 (10.14)		
Week 4 Adjusted Mean Change (SE)	-11.16 (3.99)	-9.88 (6.13)		
Week 12 Adjusted Mean Change (SE)	-16.93 (4.26)	-22.54 (6.55)		
Week 16 Adjusted Mean Change (SE)	-18.08 (4.35)	-24.93 (6.85)		
Week 24 Adjusted Mean Change (SE)	-20.85 (4.76)	-27.57 (7.25)		
Week 32 Adjusted Mean Change (SE)	-23.73 (4.57)	-21.68 (6.95)		
Week 40 Adjusted Mean Change (SE)	-22.91 (4.68)	-30.62 (7.29)		
Week 52 Adjusted Mean Change (SE)	-18.33 (4.72)	-32.39 (7.56)	14.06 [-3.65; 31.77]	0.118

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

58.18 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.949				
Non-carrier, N	**39**	**35**		
N'	39	34		
Baseline Mean (SD)	52.82 (24.06)	46.86 (29.88)		
Week 52 Mean (SD)	32.78 (26.03)	28.57 (24.30)		
Week 4 Adjusted Mean Change (SE)	-11.93 (3.29)	-15.36 (3.51)		
Week 12 Adjusted Mean Change (SE)	-15.73 (3.56)	-15.14 (3.81)		
Week 16 Adjusted Mean Change (SE)	-18.00 (3.60)	-16.01 (3.86)		
Week 24 Adjusted Mean Change (SE)	-21.68 (3.88)	-18.82 (4.28)		
Week 32 Adjusted Mean Change (SE)	-20.59 (3.71)	-22.81 (4.00)		
Week 40 Adjusted Mean Change (SE)	-19.48 (3.88)	-26.60 (4.25)		
Week 52 Adjusted Mean Change (SE)	-18.18 (3.95)	-20.57 (4.37)	2.39 [-9.34; 14.11]	0.687
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	53.64 (25.01)	46.67 (24.49)		
Week 52 Mean (SD)	27.27 (24.53)	26.67 (26.93)		
Week 4 Adjusted Mean Change (SE)	-15.38 (6.23)	-8.12 (6.80)		
Week 12 Adjusted Mean Change (SE)	-14.52 (6.70)	-18.07 (7.33)		
Week 16 Adjusted Mean Change (SE)	-15.36 (6.77)	-23.32 (7.65)		
Week 24 Adjusted Mean Change (SE)	-11.70 (7.51)	-20.69 (8.03)		
Week 32 Adjusted Mean Change (SE)	-17.47 (6.90)	-8.77 (7.55)		
Week 40 Adjusted Mean Change (SE)	-21.13 (7.29)	-22.51 (8.14)		
Week 52 Adjusted Mean Change (SE)	-22.74 (7.33)	-22.29 (8.03)	-0.46 [-22.08; 21.17]	0.967

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: unstructured (un)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

59.0 Tender Dactylitis Count - Return Rates (FAS)

	Treatment Groups		
	SEC (N=66)	ADA (N=62)	Total (N=128)
Number of patients with valid data n (%)			
Baseline Returns	66 (100.0)	62 (100.0)	128 (100.0)
Week 2 Returns	65 (98.5)	61 (98.4)	126 (98.4)
Week 4 Returns	66 (100.0)	59 (95.2)	125 (97.7)
Week 8 Returns	66 (100.0)	60 (96.8)	126 (98.4)
Week 12 Returns	64 (97.0)	59 (95.2)	123 (96.1)
Week 16 Returns	65 (98.5)	55 (88.7)	120 (93.8)
Week 24 Returns	65 (98.5)	53 (85.5)	118 (92.2)
Week 32 Returns	61 (92.4)	53 (85.5)	114 (89.1)
Week 40 Returns	64 (97.0)	49 (79.0)	113 (88.3)
Week 52 Returns	63 (95.5)	49 (79.0)	112 (87.5)

59.1 Tender Dactylitis Count - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
N'	66	61		
Baseline Mean (SD)	0.36 (0.70)	0.36 (0.71)		
Week 52 Mean (SD)	0.01 (0.09)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.37 (0.03)	-0.36 (0.04)	-0.01 [-0.11; 0.10]	0.892

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, treatment x visit, baseline value x visit
Covariance structure: compound symmetry (cs)

59.2 Tender Dactylitis Count - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.321				
Male, N	**42**	**33**		
N'	42	32		
Baseline Mean (SD)	0.38 (0.68)	0.38 (0.68)		
Week 52 Mean (SD)	0.02 (0.11)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.36 (0.04)	-0.36 (0.05)	-0.01 [-0.14; 0.13]	0.895
Female, N	**24**	**29**		
N'	24	29		
Baseline Mean (SD)	0.33 (0.76)	0.34 (0.75)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.37 (0.06)	-0.36 (0.06)	-0.01 [-0.16; 0.15]	0.948

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

59.3 Tender Dactylitis Count - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.274				
PASDAS < 5.4, N	**16**	**13**		
N'	16	13		
Baseline Mean (SD)	0.09 (0.24)	0.11 (0.26)		
Week 52 Mean (SD)	0.04 (0.17)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.33 (0.07)	-0.34 (0.09)	0.01 [-0.22; 0.23]	0.953
PASDAS ≥ 5.4, N	**50**	**49**		
N'	50	48		
Baseline Mean (SD)	0.45 (0.78)	0.43 (0.77)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.38 (0.04)	-0.37 (0.04)	-0.01 [-0.13; 0.10]	0.839

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

59.4 Tender Dactylitis Count - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.879				
Moderate/Severe Psoriasis (Def D): No, N	**28**	**32**		
N'	28	32		
Baseline Mean (SD)	0.20 (0.46)	0.38 (0.73)		
Week 52 Mean (SD)	0.03 (0.14)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.36 (0.05)	-0.35 (0.06)	-0.01 [-0.16; 0.15]	0.928
Moderate/Severe Psoriasis (Def D): Yes, N	**38**	**30**		
N'	38	29		
Baseline Mean (SD)	0.48 (0.83)	0.34 (0.69)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.37 (0.05)	-0.37 (0.05)	-0.01 [-0.14; 0.13]	0.941

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

59.5 Tender Dactylitis Count - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.776				
≤ Median, N	**40**	**29**		
N'	40	29		
Baseline Mean (SD)	0.42 (0.77)	0.29 (0.59)		
Week 52 Mean (SD)	0.02 (0.11)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.36 (0.04)	-0.36 (0.06)	-0.00 [-0.15; 0.14]	0.957
> Median, N	**26**	**33**		
N'	26	32		
Baseline Mean (SD)	0.28 (0.60)	0.42 (0.80)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.37 (0.06)	-0.36 (0.05)	-0.01 [-0.16; 0.14]	0.898

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

59.6 Tender Dactylitis Count - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.236				
Enthesitis: No, N	34	22		
N'	34	22		
Baseline Mean (SD)	0.24 (0.50)	0.33 (0.69)		
Week 52 Mean (SD)	0.02 (0.12)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.36 (0.05)	-0.36 (0.06)	0.00 [-0.15; 0.16]	0.965
Enthesitis: Yes, N	32	40		
N'	32	39		
Baseline Mean (SD)	0.50 (0.85)	0.37 (0.72)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.37 (0.05)	-0.35 (0.05)	-0.02 [-0.16; 0.12]	0.792

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

59.7 Tender Dactylitis Count - Change from Baseline by HLA-DQA1*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.609				
Non-carrier, N	**29**	**25**		
N'	29	25		
Baseline Mean (SD)	0.18 (0.55)	0.40 (0.78)		
Week 52 Mean (SD)	0.02 (0.13)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.29 (0.05)	-0.30 (0.05)	0.01 [-0.13; 0.15]	0.870
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	0.42 (0.74)	0.25 (0.49)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.32 (0.06)	-0.31 (0.06)	-0.01 [-0.17; 0.15]	0.895

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

59.7 Tender Dactylitis Count - Change from Baseline by HLA-DQA1*05 (FAS)

59.8 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.983				
Non-carrier, N	**28**	**19**		
N'	28	19		
Baseline Mean (SD)	0.25 (0.57)	0.30 (0.75)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.33 (0.05)	-0.30 (0.07)	-0.03 [-0.19; 0.14]	0.733
Carrier, N	**22**	**19**		
N'	22	19		
Baseline Mean (SD)	0.34 (0.75)	0.39 (0.62)		
Week 52 Mean (SD)	0.03 (0.15)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.29 (0.06)	-0.32 (0.06)	0.03 [-0.13; 0.19]	0.711

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

59.9 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.064				
Non-carrier, N	19	21		
N'	19	21		
Baseline Mean (SD)	0.35 (0.72)	0.16 (0.39)		
Week 52 Mean (SD)	0.04 (0.16)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.28 (0.06)	-0.31 (0.06)	0.02 [-0.14; 0.19]	0.772
Carrier, N	30	23		
N'	30	23		
Baseline Mean (SD)	0.27 (0.62)	0.49 (0.83)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.32 (0.05)	-0.31 (0.05)	-0.01 [-0.15; 0.13]	0.886

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

59.10 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.536				
Non-carrier, N	25	32		
N'	25	32		
Baseline Mean (SD)	0.33 (0.69)	0.25 (0.57)		
Week 52 Mean (SD)	0.03 (0.14)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.28 (0.05)	-0.30 (0.05)	0.02 [-0.11; 0.16]	0.737
Carrier, N	26	12		
N'	26	12		
Baseline Mean (SD)	0.24 (0.62)	0.55 (0.87)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.33 (0.05)	-0.31 (0.08)	-0.01 [-0.20; 0.17]	0.886

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

59.11 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.793				
Non-carrier, N	**38**	**33**		
N'	38	33		
Baseline Mean (SD)	0.30 (0.65)	0.38 (0.73)		
Week 52 Mean (SD)	0.02 (0.12)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.30 (0.04)	-0.30 (0.05)	0.00 [-0.12; 0.12]	0.994
Carrier, N	**12**	**9**		
N'	12	9		
Baseline Mean (SD)	0.18 (0.63)	0.24 (0.48)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.30 (0.07)	-0.31 (0.08)	0.01 [-0.21; 0.22]	0.941

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

59.12 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.366				
Non-carrier, N	**36**	**34**		
N'	36	34		
Baseline Mean (SD)	0.30 (0.64)	0.32 (0.63)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.31 (0.04)	-0.30 (0.04)	-0.01 [-0.13; 0.11]	0.846
Carrier, N	**13**	**10**		
N'	13	10		
Baseline Mean (SD)	0.15 (0.54)	0.38 (0.83)		
Week 52 Mean (SD)	0.05 (0.19)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.25 (0.07)	-0.29 (0.08)	0.03 [-0.16; 0.23]	0.732

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

59.13 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.853				
Non-carrier, N	**42**	**36**		
N'	42	36		
Baseline Mean (SD)	0.24 (0.63)	0.24 (0.65)		
Week 52 Mean (SD)	0.02 (0.11)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.29 (0.04)	-0.29 (0.04)	0.00 [-0.12; 0.12]	0.977
Carrier, N	**9**	**5**		
N'	9	5		
Baseline Mean (SD)	0.49 (0.73)	0.74 (0.75)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.29 (0.08)	-0.29 (0.11)	0.00 [-0.27; 0.28]	0.985

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

59.14 Tender Dactylitis Count - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.040				
Low score, N	11	22		
N'	11	22		
Baseline Mean (SD)	0.28 (0.64)	0.20 (0.55)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.32 (0.08)	-0.30 (0.06)	-0.02 [-0.21; 0.17]	0.814
High score, N	40	22		
N'	40	22		
Baseline Mean (SD)	0.29 (0.65)	0.46 (0.76)		
Week 52 Mean (SD)	0.02 (0.11)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.30 (0.04)	-0.31 (0.05)	0.01 [-0.12; 0.14]	0.922

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

59.15 Tender Dactylitis Count - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.964				
Non-carrier, N	**31**	**23**		
N'	31	23		
Baseline Mean (SD)	0.30 (0.65)	0.32 (0.74)		
Week 52 Mean (SD)	0.02 (0.13)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.30 (0.05)	-0.30 (0.06)	-0.00 [-0.15; 0.14]	0.967
Carrier, N	**20**	**21**		
N'	20	21		
Baseline Mean (SD)	0.26 (0.65)	0.35 (0.60)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.31 (0.06)	-0.31 (0.06)	0.00 [-0.16; 0.16]	0.989

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

59.16 Tender Dactylitis Count - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	**ADA (N=62)**	**Mean Difference [95% CI]**	**p-value**
Interaction test: p=0.065				
Non-carrier, N	**19**	**20**		
N'	19	20		
Baseline Mean (SD)	0.35 (0.72)	0.16 (0.40)		
Week 52 Mean (SD)	0.04 (0.16)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.28 (0.06)	-0.30 (0.06)	0.02 [-0.14; 0.19]	0.787
Carrier, N	**32**	**24**		
N'	32	24		
Baseline Mean (SD)	0.25 (0.60)	0.47 (0.81)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.32 (0.05)	-0.31 (0.05)	-0.01 [-0.14; 0.13]	0.899

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

59.17 Tender Dactylitis Count - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.536				
Non-carrier, N	25	32		
N'	25	32		
Baseline Mean (SD)	0.33 (0.69)	0.25 (0.57)		
Week 52 Mean (SD)	0.03 (0.14)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.28 (0.05)	-0.30 (0.05)	0.02 [-0.11; 0.16]	0.737
Carrier, N	26	12		
N'	26	12		
Baseline Mean (SD)	0.24 (0.62)	0.55 (0.87)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.33 (0.05)	-0.31 (0.08)	-0.01 [-0.20; 0.17]	0.886

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

59.18 Tender Dactylitis Count - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=66)	ADA (N=62)	Mean Difference [95% CI]	p-value
Interaction test: p=0.623				
Non-carrier, N	**39**	**35**		
N'	39	35		
Baseline Mean (SD)	0.32 (0.65)	0.36 (0.71)		
Week 52 Mean (SD)	0.02 (0.12)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.31 (0.04)	-0.31 (0.05)	0.00 [-0.12; 0.12]	0.994
Carrier, N	**11**	**9**		
N'	11	9		
Baseline Mean (SD)	0.20 (0.66)	0.24 (0.48)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.31 (0.08)	-0.31 (0.08)	0.01 [-0.21; 0.23]	0.946

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.

Safety Analysis

S.1.1 Adverse Events, Binary Analysis (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	66	62			
Any AE, n (%)	46 (69.7)	45 (72.6)	0.87 [0.40; 1.87] 0.719	0.96 [0.77; 1.20] 0.719	-0.029 [-0.186; 0.128] 0.719
Any AE, disease specific events excluded, n (%)	46 (69.7)	42 (67.7)	1.10 [0.52; 2.31] 0.812	1.03 [0.81; 1.30] 0.812	0.020 [-0.141; 0.180] 0.812
Any SAE, n (%)	5 (7.6)	5 (8.1)	0.93 [0.26; 3.40] 0.918	0.94 [0.29; 3.09] 0.918	-0.005 [-0.098; 0.088] 0.918
Any SAE, disease specific events excluded, n (%)	5 (7.6)	4 (6.5)	1.19 [0.30; 4.64] 0.803	1.17 [0.33; 4.17] 0.804	0.011 [-0.077; 0.100] 0.803
Any severe AE, n (%)	2 (3.0)	1 (1.6)	1.91 [0.17; 21.57] 0.592	1.88 [0.17; 20.21] 0.603	0.014 [-0.038; 0.066] 0.592
Any severe AE, disease specific events excluded, n (%)	2 (3.0)	1 (1.6)	1.91 [0.17; 21.57] 0.592	1.88 [0.17; 20.21] 0.603	0.014 [-0.038; 0.066] 0.592
Any AE leading to study discontinuation, n (%)	0 (0.0)	3 (4.8)	N.E.	0.13 [0.01; 2.55] 0.181	-0.048 [-0.102; 0.005] 0.076
Any AE leading to study drug discontinuation, n (%)	0 (0.0)	3 (4.8)	N.E.	0.13 [0.01; 2.55] 0.181	-0.048 [-0.102; 0.005] 0.076

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with Wald CI) from logistic regression model with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value).

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

List of Excluded Disease-Specific SOC/Preferred Terms

Preferred Terms (grouped by disease-specific event category)
General disorders and administration site conditions
Fatigue
Malaise
Pain
Peripheral swelling
Investigations
Antinuclear antibody positive
DNA antibody positive
Double stranded DNA antibody
Double stranded DNA antibody positive
Musculoskeletal and connective tissue disorders
Arthralgia
Arthritis
Arthropathy
Back pain
Bone lesion
Bone pain
Bursitis
Chondritis
Chondropathy
Dactylitis
Fibromyalgia
Foot deformity
Groin pain
Joint effusion
Joint swelling
Muscular weakness
Musculoskeletal discomfort
Musculoskeletal pain
Musculoskeletal stiffness
Myalgia
Neck pain
Pain in extremity
Patellofemoral pain syndrome
Periarthritis
Plantar fasciitis

Preferred Terms (grouped by disease-specific event category)
Polyarthritis
Psoriatic arthropathy
Soft tissue swelling
Spinal pain
Synovitis
Tendon disorder
Tendon pain
Tendonitis
Tenosynovitis
Nervous system disorders
Lethargy
Psychiatric disorders
Mood altered
Sleep disorder
Stress
Skin and subcutaneous tissue disorders
Dry skin
Erythema
Pruritus
Pruritus generalised
Psoriasis
Skin discolouration
Skin disorder
Skin exfoliation
Skin induration
Skin irritation
Skin lesion

S.1.2 Adverse Events by SOC, PT and Severity, Binary Analysis (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	66	62			
Any adverse event, n (%)	**46 (69.7)**	**45 (72.6)**	**0.87 [0.40; 1.87] 0.719**	**0.96 [0.77; 1.20] 0.719**	**-0.029 [-0.186; 0.128] 0.719**
Mild, n (%)	45 (68.2)	40 (64.5)	1.18 [0.57; 2.46] 0.661	1.06 [0.83; 1.35] 0.662	0.037 [-0.127; 0.200] 0.661
Moderate, n (%)	14 (21.2)	23 (37.1)	0.46 [0.21; 1.00] 0.047	0.57 [0.32; 1.01] 0.053	-0.159 [-0.314; -0.003] 0.045
Severe, n (%)	2 (3.0)	1 (1.6)	1.91 [0.17; 21.57] 0.592	1.88 [0.17; 20.21] 0.603	0.014 [-0.038; 0.066] 0.592
Infections and infestations, n (%)	**40 (60.6)**	**30 (48.4)**	**1.64 [0.81; 3.31] 0.165**	**1.25 [0.91; 1.73] 0.171**	**0.122 [-0.049; 0.294] 0.162**
Mild, n (%)	36 (54.5)	23 (37.1)	2.03 [1.00; 4.13] 0.047	1.47 [0.99; 2.18] 0.054	0.174 [0.005; 0.344] 0.044
Moderate, n (%)	7 (10.6)	10 (16.1)	0.62 [0.22; 1.74] 0.357	0.66 [0.27; 1.62] 0.362	-0.055 [-0.173; 0.063] 0.359
Severe, n (%)	1 (1.5)	0 (0.0)	N.E.	2.82 [0.12; 67.98] 0.523	0.015 [-0.014; 0.045] 0.314
Nasopharyngitis, n (%)	**16 (24.2)**	**7 (11.3)**	**2.51 [0.96; 6.61] 0.053**	**2.15 [0.95; 4.86] 0.067**	**0.130 [-0.000; 0.260] 0.051**
Mild, n (%)	16 (24.2)	5 (8.1)	3.65 [1.25; 10.67] 0.011	3.01 [1.17; 7.71] 0.022	0.162 [0.038; 0.285] 0.010
Moderate, n (%)	1 (1.5)	2 (3.2)	0.46 [0.04; 5.22] 0.520	0.47 [0.04; 5.05] 0.533	-0.017 [-0.070; 0.036] 0.527
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Musculoskeletal and connective tissue disorders, n (%)	**10 (15.2)**	**15 (24.2)**	**0.56 [0.23; 1.36] 0.196**	**0.63 [0.30; 1.29] 0.203**	**-0.090 [-0.228; 0.047] 0.197**
Mild, n (%)	8 (12.1)	11 (17.7)	0.64 [0.24; 1.71] 0.371	0.68 [0.29; 1.59] 0.375	-0.056 [-0.180; 0.067] 0.372
Moderate, n (%)	3 (4.5)	5 (8.1)	0.54 [0.12; 2.37] 0.409	0.56 [0.14; 2.26] 0.418	-0.035 [-0.120; 0.049] 0.414

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Skin and subcutaneous tissue disorders, n (%)	**7 (10.6)**	**11 (17.7)**	**0.55 [0.20; 1.52] 0.245**	**0.60 [0.25; 1.44] 0.253**	**-0.071 [-0.192; 0.049] 0.246**
Mild, n (%)	4 (6.1)	9 (14.5)	0.38 [0.11; 1.30] 0.110	0.42 [0.14; 1.29] 0.128	-0.085 [-0.189; 0.020] 0.114
Moderate, n (%)	1 (1.5)	4 (6.5)	0.22 [0.02; 2.05] 0.138	0.23 [0.03; 2.04] 0.189	-0.049 [-0.117; 0.019] 0.154
Severe, n (%)	2 (3.0)	0 (0.0)	N.E.	4.70 [0.23; 96.04] 0.315	0.030 [-0.011; 0.072] 0.151
Gastrointestinal disorders, n (%)	**9 (13.6)**	**5 (8.1)**	**1.80 [0.57; 5.70] 0.309**	**1.69 [0.60; 4.77] 0.321**	**0.056 [-0.051; 0.163] 0.307**
Mild, n (%)	9 (13.6)	5 (8.1)	1.80 [0.57; 5.70] 0.309	1.69 [0.60; 4.77] 0.321	0.056 [-0.051; 0.163] 0.307
Moderate, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Nervous system disorders, n (%)	**6 (9.1)**	**9 (14.5)**	**0.59 [0.20; 1.76] 0.339**	**0.63 [0.24; 1.66] 0.346**	**-0.054 [-0.166; 0.058] 0.342**
Mild, n (%)	6 (9.1)	6 (9.7)	0.93 [0.28; 3.06] 0.909	0.94 [0.32; 2.76] 0.909	-0.006 [-0.107; 0.095] 0.909
Moderate, n (%)	0 (0.0)	5 (8.1)	N.E.	0.09 [0.00; 1.51] 0.094	-0.081 [-0.148; -0.013] 0.020
Severe, n (%)	0 (0.0)	1 (1.6)	N.E.	0.31 [0.01; 7.55] 0.475	-0.016 [-0.047; 0.015] 0.313
General disorders and administration site conditions, n (%)	**6 (9.1)**	**8 (12.9)**	**0.68 [0.22; 2.07] 0.490**	**0.70 [0.26; 1.92] 0.493**	**-0.038 [-0.147; 0.070] 0.491**
Mild, n (%)	5 (7.6)	7 (11.3)	0.64 [0.19; 2.15] 0.471	0.67 [0.22; 2.00] 0.475	-0.037 [-0.139; 0.064] 0.473
Moderate, n (%)	1 (1.5)	1 (1.6)	0.94 [0.06; 15.34] 0.964	0.94 [0.06; 14.70] 0.964	-0.001 [-0.044; 0.042] 0.964
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Investigations, n (%)	**5 (7.6)**	**7 (11.3)**	**0.64 [0.19; 2.15] 0.471**	**0.67 [0.22; 2.00] 0.475**	**-0.037 [-0.139; 0.064] 0.473**

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Mild, n (%)	5 (7.6)	6 (9.7)	0.77 [0.22; 2.65] 0.672	0.78 [0.25; 2.44] 0.672	-0.021 [-0.118; 0.076] 0.672
Moderate, n (%)	1 (1.5)	3 (4.8)	0.30 [0.03; 2.99] 0.271	0.31 [0.03; 2.93] 0.309	-0.033 [-0.094; 0.028] 0.286
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Respiratory, thoracic and mediastinal disorders, n (%)	**7 (10.6)**	**2 (3.2)**	**3.56 [0.71; 17.84] 0.093**	**3.29 [0.71; 15.23] 0.128**	**0.074 [-0.013; 0.160] 0.094**
Mild, n (%)	5 (7.6)	2 (3.2)	2.46 [0.46; 13.17] 0.271	2.35 [0.47; 11.66] 0.296	0.043 [-0.034; 0.121] 0.271
Moderate, n (%)	4 (6.1)	0 (0.0)	N.E.	8.46 [0.46; 154.03] 0.149	0.061 [0.003; 0.118] 0.039
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Vascular disorders, n (%)	**7 (10.6)**	**2 (3.2)**	**3.56 [0.71; 17.84] 0.093**	**3.29 [0.71; 15.23] 0.128**	**0.074 [-0.013; 0.160] 0.094**
Mild, n (%)	6 (9.1)	2 (3.2)	3.00 [0.58; 15.46] 0.161	2.82 [0.59; 13.44] 0.194	0.059 [-0.023; 0.141] 0.162
Moderate, n (%)	2 (3.0)	0 (0.0)	N.E.	4.70 [0.23; 96.04] 0.315	0.030 [-0.011; 0.072] 0.151
Severe, n (%)	1 (1.5)	0 (0.0)	N.E.	2.82 [0.12; 67.98] 0.523	0.015 [-0.014; 0.045] 0.314

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with Wald CI) from logistic regression model with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value).

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.1.3 Serious Adverse Events by SOC, PT and Severity, Binary Analysis (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	66	62			
Any SAE, n (%)	**5 (7.6)**	**5 (8.1)**	**0.93 [0.26; 3.40] 0.918**	**0.94 [0.29; 3.09] 0.918**	**-0.005 [-0.098; 0.088] 0.918**
Mild, n (%)	1 (1.5)	0 (0.0)	N.E.	2.82 [0.12; 67.98] 0.523	0.015 [-0.014; 0.045] 0.314
Moderate, n (%)	2 (3.0)	4 (6.5)	0.45 [0.08; 2.57] 0.357	0.47 [0.09; 2.47] 0.373	-0.034 [-0.108; 0.040] 0.364
Severe, n (%)	2 (3.0)	1 (1.6)	1.91 [0.17; 21.57] 0.592	1.88 [0.17; 20.21] 0.603	0.014 [-0.038; 0.066] 0.592

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with Wald CI) from logistic regression model with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value).

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.1.4 Any Adverse Event Leading to Study Discontinuation by SOC and PT, Frequencies (SAF)

	Treatment Groups	
	SEC (N=66)	ADA (N=62)
N'	66	62
Musculoskeletal and connective tissue disorders, n (%)	0 (0.0)	1 (1.6)
Intervertebral disc protrusion, n (%)	0 (0.0)	1 (1.6)
Nervous system disorders, n (%)	0 (0.0)	1 (1.6)
Paraesthesia, n (%)	0 (0.0)	1 (1.6)
Skin and subcutaneous tissue disorders, n (%)	0 (0.0)	1 (1.6)
Psoriasis, n (%)	0 (0.0)	1 (1.6)
N': Number of patients in the analysis		

S.1.5 Any Adverse Event Leading to Study Drug Discontinuation by SOC and PT, Frequencies (SAF)

	Treatment Groups	
	SEC (N=66)	ADA (N=62)
N'	66	62
Musculoskeletal and connective tissue disorders, n (%)	0 (0.0)	1 (1.6)
Intervertebral disc protrusion, n (%)	0 (0.0)	1 (1.6)
Nervous system disorders, n (%)	0 (0.0)	1 (1.6)
Paraesthesia, n (%)	0 (0.0)	1 (1.6)
Skin and subcutaneous tissue disorders, n (%)	0 (0.0)	1 (1.6)
Psoriasis, n (%)	0 (0.0)	1 (1.6)
N': Number of patients in the analysis		

S.1.6 Adverse Events of Special Interest by Severity, Binary Analysis (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	66	62			
Candida infections, n (%)	**2 (3.0)**	**1 (1.6)**	**1.91 [0.17; 21.57] 0.592**	**1.88 [0.17; 20.21] 0.603**	**0.014 [-0.038; 0.066] 0.592**
Mild, n (%)	2 (3.0)	1 (1.6)	1.91 [0.17; 21.57] 0.592	1.88 [0.17; 20.21] 0.603	0.014 [-0.038; 0.066] 0.592
Moderate, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Cardio-cerebrovascular-related events, n (%)	**2 (3.0)**	**2 (3.2)**	**0.94 [0.13; 6.87] 0.949**	**0.94 [0.14; 6.47] 0.949**	**-0.002 [-0.062; 0.058] 0.949**
Mild, n (%)	1 (1.5)	0 (0.0)	N.E.	2.82 [0.12; 67.98] 0.523	0.015 [-0.014; 0.045] 0.314
Moderate, n (%)	0 (0.0)	2 (3.2)	N.E.	0.19 [0.01; 3.84] 0.278	-0.032 [-0.076; 0.012] 0.151
Severe, n (%)	1 (1.5)	0 (0.0)	N.E.	2.82 [0.12; 67.98] 0.523	0.015 [-0.014; 0.045] 0.314
Serious, n (%)	1 (1.5)	1 (1.6)	0.94 [0.06; 15.34] 0.964	0.94 [0.06; 14.70] 0.964	-0.001 [-0.044; 0.042] 0.964
Inflammatory bowel disease, n (%)	**0 (0.0)**	**0 (0.0)**	**N.E.**	**N.E.**	**N.E.**
Mild, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections, n (%)	**0 (0.0)**	**0 (0.0)**	**N.E.**	**N.E.**	**N.E.**
Mild, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections, n (%)	**1 (1.5)**	**1 (1.6)**	**0.94 [0.06; 15.34] 0.964**	**0.94 [0.06; 14.70] 0.964**	**-0.001 [-0.044; 0.042] 0.964**

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Mild, n (%)	1 (1.5)	1 (1.6)	0.94 [0.06; 15.34] 0.964	0.94 [0.06; 14.70] 0.964	-0.001 [-0.044; 0.042] 0.964
Moderate, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Staphylococcal infections, n (%)	**0 (0.0)**	**0 (0.0)**	**N.E.**	**N.E.**	**N.E.**
Mild, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death), n (%)	**0 (0.0)**	**0 (0.0)**	**N.E.**	**N.E.**	**N.E.**
Mild, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ), n (%)	**1 (1.5)**	**0 (0.0)**	**N.E.**	**2.82 [0.12; 67.98] 0.523**	**0.015 [-0.014; 0.045] 0.314**
Mild, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate, n (%)	1 (1.5)	0 (0.0)	N.E.	2.82 [0.12; 67.98] 0.523	0.015 [-0.014; 0.045] 0.314
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ excl BCC and SCC), n (%)	**0 (0.0)**	**0 (0.0)**	**N.E.**	**N.E.**	**N.E.**
Mild, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections, n (%)	**26 (39.4)**	**18 (29.0)**	**1.59 [0.76; 3.32] 0.216**	**1.36 [0.83; 2.22] 0.223**	**0.104 [-0.060; 0.267] 0.214**
Mild, n (%)	24 (36.4)	15 (24.2)	1.79 [0.83; 3.86] 0.133	1.50 [0.87; 2.59] 0.142	0.122 [-0.036; 0.279] 0.130
Moderate, n (%)	3 (4.5)	3 (4.8)	0.94 [0.18; 4.82] 0.937	0.94 [0.20; 4.48] 0.937	-0.003 [-0.076; 0.070] 0.938

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with Wald CI) from logistic regression model with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value).

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.2.1 Adverse Events, Binary Analysis by Gender (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	66	62			
N' Male	42	33			
N' Female	24	29			
Any AE					
Interaction test	p=0.777				
Male, n (%)	29 (69.0)	23 (69.7)	0.97 [0.36; 2.61] 0.952	0.99 [0.73; 1.34] 0.952	-0.006 [-0.217; 0.204] 0.952
Female, n (%)	17 (70.8)	22 (75.9)	0.77 [0.23; 2.63] 0.680	0.93 [0.67; 1.30] 0.683	-0.050 [-0.290; 0.189] 0.681
Any SAE					
Interaction test	p=0.691				
Male, n (%)	4 (9.5)	3 (9.1)	1.05 [0.22; 5.07] 0.949	1.05 [0.25; 4.36] 0.949	0.004 [-0.128; 0.137] 0.949
Female, n (%)	1 (4.2)	2 (6.9)	0.59 [0.05; 6.90] 0.665	0.60 [0.06; 6.26] 0.673	-0.027 [-0.149; 0.095] 0.661
Any severe AE					
Interaction test	N.E.				
Male, n (%)	2 (4.8)	1 (3.0)	1.60 [0.14; 18.45] 0.701	1.57 [0.15; 16.59] 0.707	0.017 [-0.070; 0.104] 0.696
Female, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study discontinuation					
Interaction test	N.E.				
Male, n (%)	0 (0.0)	2 (6.1)	N.E.	0.16 [0.01; 3.19] 0.229	-0.061 [-0.142; 0.021] 0.145
Female, n (%)	0 (0.0)	1 (3.4)	N.E.	0.40 [0.02; 9.39] 0.569	-0.034 [-0.101; 0.032] 0.309
Any AE leading to study drug discontinuation					
Interaction test	N.E.				
Male, n (%)	0 (0.0)	2 (6.1)	N.E.	0.16 [0.01; 3.19] 0.229	-0.061 [-0.142; 0.021] 0.145

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Female, n (%)	0 (0.0)	1 (3.4)	N.E.	0.40 [0.02; 9.39] 0.569	-0.034 [-0.101; 0.032] 0.309

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.2.2 Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

There are no data meeting the display criteria for this table.

S.2.3 Serious Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

There are no data meeting the display criteria for this table.

S.2.3 Serious Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

S.2.4 Severe Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

There are no data meeting the display criteria for this table.

S.2.5 Adverse Events of Special Interest, Binary Analysis by Gender (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	66	62			
N' Male	42	33			
N' Female	24	29			
Candida infections					
Interaction test	N.E.				
Male, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Female, n (%)	2 (8.3)	1 (3.4)	2.55 [0.22; 29.93] 0.443	2.42 [0.23; 25.06] 0.460	0.049 [-0.080; 0.178] 0.458
Cardio-cerebrovascular-related events					
Interaction test	N.E.				
Male, n (%)	2 (4.8)	2 (6.1)	0.78 [0.10; 5.81] 0.804	0.79 [0.12; 5.29] 0.804	-0.013 [-0.117; 0.091] 0.806
Female, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Inflammatory bowel disease					
Interaction test	N.E.				
Male, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections					
Interaction test	N.E.				
Male, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections					
Interaction test	N.E.				
Male, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Female, n (%)	1 (4.2)	1 (3.4)	1.22 [0.07; 20.55] 0.892	1.21 [0.08; 18.32] 0.891	0.007 [-0.097; 0.111] 0.892
Staphylococcal infections					
Interaction test	N.E.				
Male, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death)					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Male, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)					
Interaction test	N.E.				
Male, n (%)	1 (2.4)	0 (0.0)	N.E.	2.37 [0.10; 56.41] 0.593	0.024 [-0.022; 0.070] 0.311
Female, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ excl BCC and SCC)					
Interaction test	N.E.				
Male, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections					
Interaction test	p=0.689				
Male, n (%)	17 (40.5)	9 (27.3)	1.81 [0.68; 4.85] 0.230	1.48 [0.76; 2.89] 0.246	0.132 [-0.080; 0.344] 0.223
Female, n (%)	9 (37.5)	9 (31.0)	1.33 [0.43; 4.17] 0.621	1.21 [0.57; 2.56] 0.620	0.065 [-0.192; 0.321] 0.621

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.3.1 Adverse Events, Binary Analysis by Disease Severity (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	66	62			
N' PASDAS < 5.4	16	13			
N' PASDAS ≥ 5.4	50	49			
Any AE					
Interaction test	p=0.183				
PASDAS < 5.4, n (%)	10 (62.5)	11 (84.6)	0.30 [0.05; 1.86] 0.176	0.74 [0.47; 1.15] 0.182	-0.221 [-0.529; 0.087] 0.159
PASDAS ≥ 5.4, n (%)	36 (72.0)	34 (69.4)	1.13 [0.48; 2.70] 0.775	1.04 [0.80; 1.34] 0.775	0.026 [-0.153; 0.205] 0.775
Any SAE					
Interaction test	p=0.218				
PASDAS < 5.4, n (%)	3 (18.8)	1 (7.7)	2.77 [0.25; 30.38] 0.378	2.44 [0.29; 20.75] 0.415	0.111 [-0.129; 0.350] 0.366
PASDAS ≥ 5.4, n (%)	2 (4.0)	4 (8.2)	0.47 [0.08; 2.69] 0.381	0.49 [0.09; 2.55] 0.397	-0.042 [-0.136; 0.052] 0.385
Any severe AE					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	1 (6.3)	1 (7.7)	0.80 [0.05; 14.16] 0.879	0.81 [0.06; 11.77] 0.879	-0.014 [-0.202; 0.173] 0.880
PASDAS ≥ 5.4, n (%)	1 (2.0)	0 (0.0)	N.E.	2.94 [0.12; 70.50] 0.506	0.020 [-0.019; 0.059] 0.312
Any AE leading to study discontinuation					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	0 (0.0)	2 (15.4)	N.E.	0.16 [0.01; 3.16] 0.231	-0.154 [-0.350; 0.042] 0.124
PASDAS ≥ 5.4, n (%)	0 (0.0)	1 (2.0)	N.E.	0.33 [0.01; 7.83] 0.490	-0.020 [-0.060; 0.019] 0.312
Any AE leading to study drug discontinuation					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASDAS < 5.4, n (%)	0 (0.0)	2 (15.4)	N.E.	0.16 [0.01; 3.16] 0.231	-0.154 [-0.350; 0.042] 0.124
PASDAS ≥ 5.4, n (%)	0 (0.0)	1 (2.0)	N.E.	0.33 [0.01; 7.83] 0.490	-0.020 [-0.060; 0.019] 0.312

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.3.2 Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

There are no data meeting the display criteria for this table.

S.3.3 Serious Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

There are no data meeting the display criteria for this table.

S.3.4 Severe Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

There are no data meeting the display criteria for this table.

S.3.5 Adverse Events of Special Interest, Binary Analysis by Disease Severity (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	66	62			
N' PASDAS < 5.4	16	13			
N' PASDAS ≥ 5.4	50	49			
Candida infections					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
PASDAS ≥ 5.4, n (%)	2 (4.0)	1 (2.0)	2.00 [0.18; 22.80] 0.566	1.96 [0.18; 20.92] 0.578	0.020 [-0.048; 0.087] 0.568
Cardio-cerebrovascular-related events					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	1 (6.3)	0 (0.0)	N.E.	2.47 [0.11; 56.04] 0.570	0.063 [-0.056; 0.181] 0.302
PASDAS ≥ 5.4, n (%)	1 (2.0)	2 (4.1)	0.48 [0.04; 5.47] 0.542	0.49 [0.05; 5.23] 0.555	-0.021 [-0.088; 0.047] 0.546
Inflammatory bowel disease					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
PASDAS ≥ 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
PASDAS ≥ 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
PASDAS ≥ 5.4, n (%)	1 (2.0)	1 (2.0)	0.98 [0.06; 16.11] 0.988	0.98 [0.06; 15.23] 0.988	-0.000 [-0.056; 0.055] 0.988
Staphylococcal infections					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
PASDAS ≥ 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
MACE (MI, Stroke, Cardiovascular death)					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
PASDAS ≥ 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	1 (6.3)	0 (0.0)	N.E.	2.47 [0.11; 56.04] 0.570	0.063 [-0.056; 0.181] 0.302
PASDAS ≥ 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ excl BCC and SCC)					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
PASDAS ≥ 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections					
Interaction test	p=0.460				
PASDAS < 5.4, n (%)	6 (37.5)	5 (38.5)	0.96 [0.21; 4.34] 0.958	0.98 [0.38; 2.48] 0.958	-0.010 [-0.365; 0.346] 0.958
PASDAS ≥ 5.4, n (%)	20 (40.0)	13 (26.5)	1.85 [0.79; 4.32] 0.154	1.51 [0.85; 2.68] 0.163	0.135 [-0.049; 0.318] 0.151

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.4.1 Adverse Events, Binary Analysis by Moderate/Severe PSO D (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	66	62			
N' Moderate/Severe Psoriasis (Def D): No	28	32			
N' Moderate/Severe Psoriasis (Def D): Yes	38	30			
Any AE					
Interaction test	p=0.210				
Moderate/Severe Psoriasis (Def D): No, n (%)	17 (60.7)	24 (75.0)	0.52 [0.17; 1.55] 0.235	0.81 [0.57; 1.16] 0.248	-0.143 [-0.378; 0.092] 0.234
Moderate/Severe Psoriasis (Def D): Yes, n (%)	29 (76.3)	21 (70.0)	1.38 [0.47; 4.07] 0.559	1.09 [0.81; 1.46] 0.564	0.063 [-0.149; 0.276] 0.560
Any SAE					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	2 (7.1)	0 (0.0)	N.E.	5.69 [0.28; 113.73] 0.255	0.071 [-0.024; 0.167] 0.142
Moderate/Severe Psoriasis (Def D): Yes, n (%)	3 (7.9)	5 (16.7)	0.43 [0.09; 1.96] 0.266	0.47 [0.12; 1.83] 0.278	-0.088 [-0.246; 0.071] 0.278
Any severe AE					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate/Severe Psoriasis (Def D): Yes, n (%)	2 (5.3)	1 (3.3)	1.61 [0.14; 18.67] 0.697	1.58 [0.15; 16.59] 0.704	0.019 [-0.076; 0.115] 0.693
Any AE leading to study discontinuation					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	0 (0.0)	2 (6.3)	N.E.	0.23 [0.01; 4.55] 0.333	-0.063 [-0.146; 0.021] 0.144
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	1 (3.3)	N.E.	0.26 [0.01; 6.28] 0.411	-0.033 [-0.098; 0.031] 0.309
Any AE leading to study drug discontinuation					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate/Severe Psoriasis (Def D): No, n (%)	0 (0.0)	2 (6.3)	N.E.	0.23 [0.01; 4.55] 0.333	-0.063 [-0.146; 0.021] 0.144
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	1 (3.3)	N.E.	0.26 [0.01; 6.28] 0.411	-0.033 [-0.098; 0.031] 0.309

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.4.2 Adverse Events by SOC and PT, Binary Analysis by Moderate/Severe PSO D (SAF)

There are no data meeting the display criteria for this table.

S.4.2 Adverse Events by SOC and PT, Binary Analysis by Moderate/Severe PSO D (SAF)

S.4.3 Serious Adverse Events by SOC and PT, Binary Analysis by Moderate/Severe PSO D (SAF)

There are no data meeting the display criteria for this table.

S.4.4 Severe Adverse Events by SOC and PT, Binary Analysis by Moderate/Severe PSO D (SAF)

There are no data meeting the display criteria for this table.

S.4.5 Adverse Events of Special Interest, Binary Analysis by Moderate/Severe PSO D (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	66	62			
N' Moderate/Severe Psoriasis (Def D): No	28	32			
N' Moderate/Severe Psoriasis (Def D): Yes	38	30			
Candida infections					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	2 (7.1)	0 (0.0)	N.E.	5.69 [0.28; 113.73] 0.255	0.071 [-0.024; 0.167] 0.142
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	1 (3.3)	N.E.	0.26 [0.01; 6.28] 0.411	-0.033 [-0.098; 0.031] 0.309
Cardio-cerebrovascular-related events					
Interaction test	p=0.851				
Moderate/Severe Psoriasis (Def D): No, n (%)	1 (3.6)	1 (3.1)	1.15 [0.07; 19.25] 0.924	1.14 [0.07; 17.44] 0.923	0.004 [-0.087; 0.096] 0.924
Moderate/Severe Psoriasis (Def D): Yes, n (%)	1 (2.6)	1 (3.3)	0.78 [0.05; 13.07] 0.865	0.79 [0.05; 12.11] 0.865	-0.007 [-0.089; 0.075] 0.867
Inflammatory bowel disease					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	1 (3.6)	1 (3.1)	1.15 [0.07; 19.25] 0.924	1.14 [0.07; 17.44] 0.923	0.004 [-0.087; 0.096] 0.924

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Staphylococcal infections					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death)					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	1 (3.6)	0 (0.0)	N.E.	3.41 [0.14; 80.59] 0.447	0.036 [-0.033; 0.104] 0.309
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ excl BCC and SCC)					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections					
Interaction test	p=0.078				
Moderate/Severe Psoriasis (Def D): No, n (%)	8 (28.6)	11 (34.4)	0.76 [0.25; 2.29] 0.629	0.83 [0.39; 1.77] 0.632	-0.058 [-0.293; 0.177] 0.628
Moderate/Severe Psoriasis (Def D): Yes, n (%)	18 (47.4)	7 (23.3)	2.96 [1.03; 8.53] 0.039	2.03 [0.98; 4.21] 0.057	0.240 [0.021; 0.460] 0.032

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.5.1 Adverse Events, Binary Analysis by Lymphocyte Count at BL (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	66	62			
N' ≤ Median	40	29			
N' > Median	26	33			
Any AE					
Interaction test	p=0.354				
≤ Median, n (%)	30 (75.0)	25 (86.2)	0.48 [0.13; 1.72] 0.245	0.87 [0.69; 1.10] 0.237	-0.112 [-0.296; 0.072] 0.232
> Median, n (%)	16 (61.5)	20 (60.6)	1.04 [0.36; 2.99] 0.942	1.02 [0.67; 1.53] 0.942	0.009 [-0.241; 0.260] 0.942
Any SAE					
Interaction test	p=0.839				
≤ Median, n (%)	3 (7.5)	2 (6.9)	1.09 [0.17; 7.01] 0.924	1.09 [0.19; 6.10] 0.924	0.006 [-0.117; 0.129] 0.923
> Median, n (%)	2 (7.7)	3 (9.1)	0.83 [0.13; 5.40] 0.848	0.85 [0.15; 4.70] 0.848	-0.014 [-0.156; 0.128] 0.847
Any severe AE					
Interaction test	N.E.				
≤ Median, n (%)	2 (5.0)	1 (3.4)	1.47 [0.13; 17.07] 0.752	1.45 [0.14; 15.24] 0.757	0.016 [-0.079; 0.110] 0.748
> Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study discontinuation					
Interaction test	N.E.				
≤ Median, n (%)	0 (0.0)	1 (3.4)	N.E.	0.24 [0.01; 5.78] 0.382	-0.034 [-0.101; 0.032] 0.309
> Median, n (%)	0 (0.0)	2 (6.1)	N.E.	0.25 [0.01; 5.03] 0.367	-0.061 [-0.142; 0.021] 0.145
Any AE leading to study drug discontinuation					
Interaction test	N.E.				
≤ Median, n (%)	0 (0.0)	1 (3.4)	N.E.	0.24 [0.01; 5.78] 0.382	-0.034 [-0.101; 0.032] 0.309

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
> Median, n (%)	0 (0.0)	2 (6.1)	N.E.	0.25 [0.01; 5.03] 0.367	-0.061 [-0.142; 0.021] 0.145

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.5.2 Adverse Events by SOC and PT, Binary Analysis by Lymphocyte Count at BL (SAF)

There are no data meeting the display criteria for this table.

S.5.2 Adverse Events by SOC and PT, Binary Analysis by Lymphocyte Count at BL (SAF)

S.5.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lymphocyte Count at BL (SAF)

There are no data meeting the display criteria for this table.

S.5.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lymphocyte Count at BL (SAF)

There are no data meeting the display criteria for this table.

S.5.5 Adverse Events of Special Interest, Binary Analysis by Lymphocyte Count at BL (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	66	62			
N' ≤ Median	40	29			
N' > Median	26	33			
Candida infections					
Interaction test	N.E.				
≤ Median, n (%)	1 (2.5)	1 (3.4)	0.72 [0.04; 11.97] 0.818	0.73 [0.05; 11.12] 0.817	-0.009 [-0.092; 0.073] 0.821
> Median, n (%)	1 (3.8)	0 (0.0)	N.E.	3.78 [0.16; 89.09] 0.410	0.038 [-0.035; 0.112] 0.308
Cardio-cerebrovascular-related events					
Interaction test	p=0.776				
≤ Median, n (%)	1 (2.5)	1 (3.4)	0.72 [0.04; 11.97] 0.818	0.73 [0.05; 11.12] 0.817	-0.009 [-0.092; 0.073] 0.821
> Median, n (%)	1 (3.8)	1 (3.0)	1.28 [0.08; 21.49] 0.864	1.27 [0.08; 19.34] 0.864	0.008 [-0.086; 0.102] 0.865
Inflammatory bowel disease					
Interaction test	N.E.				
≤ Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
> Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections					
Interaction test	N.E.				
≤ Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
> Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections					
Interaction test	N.E.				
≤ Median, n (%)	0 (0.0)	1 (3.4)	N.E.	0.24 [0.01; 5.78] 0.382	-0.034 [-0.101; 0.032] 0.309
> Median, n (%)	1 (3.8)	0 (0.0)	N.E.	3.78 [0.16; 89.09] 0.410	0.038 [-0.035; 0.112] 0.308
Staphylococcal infections					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
≤ Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
> Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death)					
Interaction test	N.E.				
≤ Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
> Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)					
Interaction test	N.E.				
≤ Median, n (%)	1 (2.5)	0 (0.0)	N.E.	2.20 [0.09; 52.04] 0.626	0.025 [-0.023; 0.073] 0.311
> Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ excl BCC and SCC)					
Interaction test	N.E.				
≤ Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
> Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections					
Interaction test	p=0.294				
≤ Median, n (%)	17 (42.5)	12 (41.4)	1.05 [0.40; 2.76] 0.926	1.03 [0.58; 1.80] 0.926	0.011 [-0.225; 0.247] 0.926
> Median, n (%)	9 (34.6)	6 (18.2)	2.38 [0.72; 7.89] 0.151	1.90 [0.78; 4.66] 0.159	0.164 [-0.061; 0.390] 0.153

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.6.1 Adverse Events, Binary Analysis by Enthesitis at BL According to LEI (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	66	62			
N' Enthesitis: No	34	22			
N' Enthesitis: Yes	32	40			
Any AE					
Interaction test	p=0.186				
Enthesitis: No, n (%)	24 (70.6)	19 (86.4)	0.38 [0.09; 1.57] 0.161	0.82 [0.62; 1.07] 0.148	-0.158 [-0.368; 0.052] 0.141
Enthesitis: Yes, n (%)	22 (68.8)	26 (65.0)	1.18 [0.44; 3.19] 0.737	1.06 [0.76; 1.47] 0.736	0.037 [-0.181; 0.256] 0.736
Any SAE					
Interaction test	p=0.903				
Enthesitis: No, n (%)	3 (8.8)	2 (9.1)	0.97 [0.15; 6.31] 0.973	0.97 [0.18; 5.35] 0.973	-0.003 [-0.156; 0.151] 0.973
Enthesitis: Yes, n (%)	2 (6.3)	3 (7.5)	0.82 [0.13; 5.24] 0.835	0.83 [0.15; 4.69] 0.836	-0.013 [-0.130; 0.105] 0.834
Any severe AE					
Interaction test	N.E.				
Enthesitis: No, n (%)	1 (2.9)	0 (0.0)	N.E.	1.97 [0.08; 46.33] 0.673	0.029 [-0.027; 0.086] 0.310
Enthesitis: Yes, n (%)	1 (3.1)	1 (2.5)	1.26 [0.08; 20.93] 0.873	1.25 [0.08; 19.22] 0.873	0.006 [-0.071; 0.084] 0.874
Any AE leading to study discontinuation					
Interaction test	N.E.				
Enthesitis: No, n (%)	0 (0.0)	2 (9.1)	N.E.	0.13 [0.01; 2.61] 0.184	-0.091 [-0.211; 0.029] 0.138
Enthesitis: Yes, n (%)	0 (0.0)	1 (2.5)	N.E.	0.41 [0.02; 9.84] 0.585	-0.025 [-0.073; 0.023] 0.311
Any AE leading to study drug discontinuation					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Enthesitis: No, n (%)	0 (0.0)	2 (9.1)	N.E.	0.13 [0.01; 2.61] 0.184	-0.091 [-0.211; 0.029] 0.138
Enthesitis: Yes, n (%)	0 (0.0)	1 (2.5)	N.E.	0.41 [0.02; 9.84] 0.585	-0.025 [-0.073; 0.023] 0.311

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.6.2 Adverse Events by SOC and PT, Binary Analysis by Enthesitis at BL According to LEI (SAF)

There are no data meeting the display criteria for this table.

S.6.2 Adverse Events by SOC and PT, Binary Analysis by Enthesitis at BL According to LEI (SAF)

S.6.3 Serious Adverse Events by SOC and PT, Binary Analysis by Enthesitis at BL According to LEI (SAF)

There are no data meeting the display criteria for this table.

S.6.4 Severe Adverse Events by SOC and PT, Binary Analysis by Enthesitis at BL According to LEI (SAF)

There are no data meeting the display criteria for this table.

S.6.5 Adverse Events of Special Interest, Binary Analysis by Enthesitis at BL According to LEI (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	66	62			
N' Enthesitis: No	34	22			
N' Enthesitis: Yes	32	40			
Candida infections					
Interaction test	N.E.				
Enthesitis: No, n (%)	1 (2.9)	0 (0.0)	N.E.	1.97 [0.08; 46.33] 0.673	0.029 [-0.027; 0.086] 0.310
Enthesitis: Yes, n (%)	1 (3.1)	1 (2.5)	1.26 [0.08; 20.93] 0.873	1.25 [0.08; 19.22] 0.873	0.006 [-0.071; 0.084] 0.874
Cardio-cerebrovascular-related events					
Interaction test	N.E.				
Enthesitis: No, n (%)	0 (0.0)	2 (9.1)	N.E.	0.13 [0.01; 2.61] 0.184	-0.091 [-0.211; 0.029] 0.138
Enthesitis: Yes, n (%)	2 (6.3)	0 (0.0)	N.E.	6.21 [0.31; 124.98] 0.233	0.063 [-0.021; 0.146] 0.144
Inflammatory bowel disease					
Interaction test	N.E.				
Enthesitis: No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Enthesitis: Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections					
Interaction test	N.E.				
Enthesitis: No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Enthesitis: Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections					
Interaction test	N.E.				
Enthesitis: No, n (%)	1 (2.9)	0 (0.0)	N.E.	1.97 [0.08; 46.33] 0.673	0.029 [-0.027; 0.086] 0.310
Enthesitis: Yes, n (%)	0 (0.0)	1 (2.5)	N.E.	0.41 [0.02; 9.84] 0.585	-0.025 [-0.073; 0.023] 0.311
Staphylococcal infections					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Enthesitis: No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Enthesitis: Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death)					
Interaction test	N.E.				
Enthesitis: No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Enthesitis: Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)					
Interaction test	N.E.				
Enthesitis: No, n (%)	1 (2.9)	0 (0.0)	N.E.	1.97 [0.08; 46.33] 0.673	0.029 [-0.027; 0.086] 0.310
Enthesitis: Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ excl BCC and SCC)					
Interaction test	N.E.				
Enthesitis: No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Enthesitis: Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections					
Interaction test	p=0.792				
Enthesitis: No, n (%)	15 (44.1)	7 (31.8)	1.69 [0.55; 5.21] 0.355	1.39 [0.68; 2.85] 0.373	0.123 [-0.133; 0.379] 0.347
Enthesitis: Yes, n (%)	11 (34.4)	11 (27.5)	1.38 [0.50; 3.78] 0.530	1.25 [0.62; 2.50] 0.529	0.069 [-0.146; 0.284] 0.531

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.7.1 Adverse Events, Binary Analysis by HLA-DQA1*05 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	51	44			
N' Non-carrier	29	25			
N' Carrier	22	19			
Any AE					
Interaction test	p=0.207				
Non-carrier, n (%)	20 (69.0)	18 (72.0)	0.86 [0.27; 2.80] 0.807	0.96 [0.68; 1.35] 0.807	-0.030 [-0.274; 0.213] 0.807
Carrier, n (%)	17 (77.3)	18 (94.7)	0.19 [0.02; 1.79] 0.099	0.82 [0.64; 1.05] 0.110	-0.175 [-0.377; 0.027] 0.090
Any SAE					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	3 (12.0)	N.E.	0.12 [0.01; 2.29] 0.160	-0.120 [-0.247; 0.007] 0.065
Carrier, n (%)	2 (9.1)	2 (10.5)	0.85 [0.11; 6.69] 0.877	0.86 [0.13; 5.56] 0.877	-0.014 [-0.197; 0.169] 0.878
Any severe AE					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (4.0)	N.E.	0.29 [0.01; 6.79] 0.441	-0.040 [-0.117; 0.037] 0.307
Carrier, n (%)	1 (4.5)	0 (0.0)	N.E.	2.61 [0.11; 60.52] 0.550	0.045 [-0.042; 0.132] 0.306
Any AE leading to study discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (4.0)	N.E.	0.29 [0.01; 6.79] 0.441	-0.040 [-0.117; 0.037] 0.307
Carrier, n (%)	0 (0.0)	1 (5.3)	N.E.	0.29 [0.01; 6.72] 0.440	-0.053 [-0.153; 0.048] 0.304
Any AE leading to study drug discontinuation					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Non-carrier, n (%)	0 (0.0)	1 (4.0)	N.E.	0.29 [0.01; 6.79] 0.441	-0.040 [-0.117; 0.037] 0.307
Carrier, n (%)	0 (0.0)	1 (5.3)	N.E.	0.29 [0.01; 6.72] 0.440	-0.053 [-0.153; 0.048] 0.304

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.7.2 Adverse Events by SOC and PT, Binary Analysis by HLA-DQA1*05 (SAF)

There are no data meeting the display criteria for this table.

S.7.2 Adverse Events by SOC and PT, Binary Analysis by HLA-DQA1*05 (SAF)

S.7.3 Serious Adverse Events by SOC and PT, Binary Analysis by HLA-DQA1*05 (SAF)

There are no data meeting the display criteria for this table.

S.7.4 Severe Adverse Events by SOC and PT, Binary Analysis by HLA-DQA1*05 (SAF)

There are no data meeting the display criteria for this table.

S.7.5 Adverse Events of Special Interest, Binary Analysis by HLA-DQA1*05 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	51	44			
N' Non-carrier	29	25			
N' Carrier	22	19			
Candida infections					
Interaction test	N.E.				
Non-carrier, n (%)	2 (6.9)	1 (4.0)	1.78 [0.15; 20.86] 0.639	1.72 [0.17; 17.90] 0.648	0.029 [-0.091; 0.149] 0.636
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Cardio-cerebrovascular-related events					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (8.0)	N.E.	0.17 [0.01; 3.45] 0.251	-0.080 [-0.186; 0.026] 0.140
Carrier, n (%)	1 (4.5)	0 (0.0)	N.E.	2.61 [0.11; 60.52] 0.550	0.045 [-0.042; 0.132] 0.306
Inflammatory bowel disease					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections					
Interaction test	N.E.				
Non-carrier, n (%)	1 (3.4)	0 (0.0)	N.E.	2.60 [0.11; 61.12] 0.553	0.034 [-0.032; 0.101] 0.309
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Staphylococcal infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
MACE (MI, Stroke, Cardiovascular death)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)					
Interaction test	N.E.				
Non-carrier, n (%)	1 (3.4)	0 (0.0)	N.E.	2.60 [0.11; 61.12] 0.553	0.034 [-0.032; 0.101] 0.309
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ excl BCC and SCC)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections					
Interaction test	p=0.950				
Non-carrier, n (%)	11 (37.9)	9 (36.0)	1.09 [0.36; 3.29] 0.883	1.05 [0.52; 2.12] 0.884	0.019 [-0.239; 0.277] 0.883
Carrier, n (%)	10 (45.5)	8 (42.1)	1.15 [0.33; 3.95] 0.829	1.08 [0.54; 2.17] 0.830	0.033 [-0.271; 0.338] 0.829

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.8.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs10555659 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	50	38			
N' Non-carrier	28	19			
N' Carrier	22	19			
Any AE					
Interaction test	p=0.862				
Non-carrier, n (%)	22 (78.6)	16 (84.2)	0.69 [0.15; 3.17] 0.627	0.93 [0.71; 1.23] 0.621	-0.056 [-0.280; 0.167] 0.621
Carrier, n (%)	15 (68.2)	15 (78.9)	0.57 [0.14; 2.37] 0.435	0.86 [0.60; 1.25] 0.435	-0.108 [-0.375; 0.160] 0.430
Any SAE					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	3 (15.8)	N.E.	0.10 [0.01; 1.80] 0.118	-0.158 [-0.322; 0.006] 0.059
Carrier, n (%)	2 (9.1)	2 (10.5)	0.85 [0.11; 6.69] 0.877	0.86 [0.13; 5.56] 0.877	-0.014 [-0.197; 0.169] 0.878
Any severe AE					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (5.3)	N.E.	0.23 [0.01; 5.36] 0.360	-0.053 [-0.153; 0.048] 0.304
Carrier, n (%)	1 (4.5)	0 (0.0)	N.E.	2.61 [0.11; 60.52] 0.550	0.045 [-0.042; 0.132] 0.306
Any AE leading to study discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (10.5)	N.E.	0.14 [0.01; 2.72] 0.193	-0.105 [-0.243; 0.033] 0.135
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (10.5)	N.E.	0.14 [0.01; 2.72] 0.193	-0.105 [-0.243; 0.033] 0.135

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.8.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10555659 (SAF)

There are no data meeting the display criteria for this table.

S.8.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10555659 (SAF)

There are no data meeting the display criteria for this table.

S.8.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10555659 (SAF)

There are no data meeting the display criteria for this table.

S.8.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs10555659 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	50	38			
N' Non-carrier	28	19			
N' Carrier	22	19			
Candida infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (5.3)	N.E.	0.23 [0.01; 5.36] 0.360	-0.053 [-0.153; 0.048] 0.304
Carrier, n (%)	2 (9.1)	0 (0.0)	N.E.	4.35 [0.22; 85.32] 0.333	0.091 [-0.029; 0.211] 0.138
Cardio-cerebrovascular-related events					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (5.3)	N.E.	0.23 [0.01; 5.36] 0.360	-0.053 [-0.153; 0.048] 0.304
Carrier, n (%)	1 (4.5)	1 (5.3)	0.86 [0.05; 14.71] 0.915	0.86 [0.06; 12.89] 0.915	-0.007 [-0.140; 0.126] 0.916
Inflammatory bowel disease					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	1 (4.5)	0 (0.0)	N.E.	2.61 [0.11; 60.52] 0.550	0.045 [-0.042; 0.132] 0.306
Staphylococcal infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	1 (4.5)	0 (0.0)	N.E.	2.61 [0.11; 60.52] 0.550	0.045 [-0.042; 0.132] 0.306
Malignant or unspecified tumours (SMQ excl BCC and SCC)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections					
Interaction test	p=0.108				
Non-carrier, n (%)	14 (50.0)	6 (31.6)	2.17 [0.64; 7.33] 0.207	1.58 [0.74; 3.38] 0.235	0.184 [-0.095; 0.463] 0.196
Carrier, n (%)	7 (31.8)	9 (47.4)	0.52 [0.15; 1.85] 0.308	0.67 [0.31; 1.46] 0.314	-0.156 [-0.453; 0.142] 0.305

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.9.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs111937633 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	49	44			
N' Non-carrier	19	21			
N' Carrier	30	23			
Any AE					
Interaction test	p=0.173				
Non-carrier, n (%)	13 (68.4)	19 (90.5)	0.23 [0.04; 1.31] 0.077	0.76 [0.54; 1.06] 0.103	-0.221 [-0.464; 0.023] 0.076
Carrier, n (%)	22 (73.3)	17 (73.9)	0.97 [0.28; 3.33] 0.962	0.99 [0.72; 1.37] 0.962	-0.006 [-0.245; 0.233] 0.962
Any SAE					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	3 (14.3)	N.E.	0.16 [0.01; 2.86] 0.211	-0.143 [-0.293; 0.007] 0.061
Carrier, n (%)	1 (3.3)	2 (8.7)	0.36 [0.03; 4.26] 0.403	0.38 [0.04; 3.97] 0.422	-0.054 [-0.185; 0.078] 0.425
Any severe AE					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	1 (4.3)	N.E.	0.26 [0.01; 6.06] 0.400	-0.043 [-0.127; 0.040] 0.307
Any AE leading to study discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (4.8)	N.E.	0.37 [0.02; 8.50] 0.532	-0.048 [-0.139; 0.043] 0.306
Carrier, n (%)	0 (0.0)	1 (4.3)	N.E.	0.26 [0.01; 6.06] 0.400	-0.043 [-0.127; 0.040] 0.307
Any AE leading to study drug discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (4.8)	N.E.	0.37 [0.02; 8.50] 0.532	-0.048 [-0.139; 0.043] 0.306

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	0 (0.0)	1 (4.3)	N.E.	0.26 [0.01; 6.06] 0.400	-0.043 [-0.127; 0.040] 0.307

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.9.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs111937633 (SAF)

There are no data meeting the display criteria for this table.

S.9.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs111937633 (SAF)

There are no data meeting the display criteria for this table.

S.9.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs111937633 (SAF)

There are no data meeting the display criteria for this table.

S.9.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs111937633 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	49	44			
N' Non-carrier	19	21			
N' Carrier	30	23			
Candida infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (4.8)	N.E.	0.37 [0.02; 8.50] 0.532	-0.048 [-0.139; 0.043] 0.306
Carrier, n (%)	2 (6.7)	0 (0.0)	N.E.	3.87 [0.19; 76.92] 0.375	0.067 [-0.023; 0.156] 0.143
Cardio-cerebrovascular-related events					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (9.5)	N.E.	0.22 [0.01; 4.31] 0.319	-0.095 [-0.221; 0.030] 0.137
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Inflammatory bowel disease					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	1 (3.3)	0 (0.0)	N.E.	2.32 [0.10; 54.53] 0.601	0.033 [-0.031; 0.098] 0.309
Staphylococcal infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
MACE (MI, Stroke, Cardiovascular death)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)					
Interaction test	N.E.				
Non-carrier, n (%)	1 (5.3)	0 (0.0)	N.E.	3.30 [0.14; 76.46] 0.457	0.053 [-0.048; 0.153] 0.304
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ excl BCC and SCC)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections					
Interaction test	p=0.768				
Non-carrier, n (%)	8 (42.1)	9 (42.9)	0.97 [0.28; 3.40] 0.962	0.98 [0.48; 2.02] 0.962	-0.008 [-0.314; 0.299] 0.962
Carrier, n (%)	12 (40.0)	8 (34.8)	1.25 [0.41; 3.86] 0.697	1.15 [0.56; 2.34] 0.700	0.052 [-0.210; 0.314] 0.696

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.10.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs11726476 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	51	44			
N' Non-carrier	25	32			
N' Carrier	26	12			
Any AE					
Interaction test	p=0.410				
Non-carrier, n (%)	20 (80.0)	26 (81.3)	0.92 [0.25; 3.46] 0.906	0.98 [0.76; 1.27] 0.906	-0.012 [-0.220; 0.195] 0.906
Carrier, n (%)	17 (65.4)	10 (83.3)	0.38 [0.07; 2.11] 0.241	0.78 [0.54; 1.14] 0.207	-0.179 [-0.459; 0.100] 0.208
Any SAE					
Interaction test	N.E.				
Non-carrier, n (%)	2 (8.0)	4 (12.5)	0.61 [0.10; 3.63] 0.578	0.64 [0.13; 3.22] 0.588	-0.045 [-0.201; 0.111] 0.573
Carrier, n (%)	0 (0.0)	1 (8.3)	N.E.	0.16 [0.01; 3.68] 0.252	-0.083 [-0.240; 0.073] 0.296
Any severe AE					
Interaction test	N.E.				
Non-carrier, n (%)	1 (4.0)	1 (3.1)	1.29 [0.08; 21.73] 0.859	1.28 [0.08; 19.47] 0.859	0.009 [-0.089; 0.106] 0.861
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (3.1)	N.E.	0.42 [0.02; 9.96] 0.594	-0.031 [-0.092; 0.029] 0.310
Carrier, n (%)	0 (0.0)	1 (8.3)	N.E.	0.16 [0.01; 3.68] 0.252	-0.083 [-0.240; 0.073] 0.296
Any AE leading to study drug discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (3.1)	N.E.	0.42 [0.02; 9.96] 0.594	-0.031 [-0.092; 0.029] 0.310

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	0 (0.0)	1 (8.3)	N.E.	0.16 [0.01; 3.68] 0.252	-0.083 [-0.240; 0.073] 0.296

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.10.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs11726476 (SAF)

There are no data meeting the display criteria for this table.

S.10.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs11726476 (SAF)

There are no data meeting the display criteria for this table.

S.10.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs11726476 (SAF)

There are no data meeting the display criteria for this table.

S.10.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs11726476 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	51	44			
N' Non-carrier	25	32			
N' Carrier	26	12			
Candida infections					
Interaction test	N.E.				
Non-carrier, n (%)	1 (4.0)	1 (3.1)	1.29 [0.08; 21.73] 0.859	1.28 [0.08; 19.47] 0.859	0.009 [-0.089; 0.106] 0.861
Carrier, n (%)	1 (3.8)	0 (0.0)	N.E.	1.44 [0.06; 33.09] 0.818	0.038 [-0.035; 0.112] 0.308
Cardio-cerebrovascular-related events					
Interaction test	N.E.				
Non-carrier, n (%)	1 (4.0)	1 (3.1)	1.29 [0.08; 21.73] 0.859	1.28 [0.08; 19.47] 0.859	0.009 [-0.089; 0.106] 0.861
Carrier, n (%)	0 (0.0)	1 (8.3)	N.E.	0.16 [0.01; 3.68] 0.252	-0.083 [-0.240; 0.073] 0.296
Inflammatory bowel disease					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections					
Interaction test	N.E.				
Non-carrier, n (%)	1 (4.0)	0 (0.0)	N.E.	3.81 [0.16; 89.67] 0.407	0.040 [-0.037; 0.117] 0.307
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Staphylococcal infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)					
Interaction test	N.E.				
Non-carrier, n (%)	1 (4.0)	0 (0.0)	N.E.	3.81 [0.16; 89.67] 0.407	0.040 [-0.037; 0.117] 0.307
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ excl BCC and SCC)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections					
Interaction test	p=0.791				
Non-carrier, n (%)	12 (48.0)	13 (40.6)	1.35 [0.47; 3.88] 0.578	1.18 [0.66; 2.12] 0.576	0.074 [-0.186; 0.333] 0.577
Carrier, n (%)	9 (34.6)	4 (33.3)	1.06 [0.25; 4.50] 0.938	1.04 [0.40; 2.71] 0.939	0.013 [-0.311; 0.336] 0.938

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.11.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs10609046 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	50	42			
N' Non-carrier	38	33			
N' Carrier	12	9			
Any AE					
Interaction test	p=0.673				
Non-carrier, n (%)	27 (71.1)	26 (78.8)	0.66 [0.22; 1.97] 0.453	0.90 [0.69; 1.18] 0.452	-0.077 [-0.278; 0.123] 0.450
Carrier, n (%)	9 (75.0)	8 (88.9)	0.38 [0.03; 4.37] 0.411	0.84 [0.57; 1.26] 0.405	-0.139 [-0.459; 0.181] 0.394
Any SAE					
Interaction test	N.E.				
Non-carrier, n (%)	2 (5.3)	4 (12.1)	0.40 [0.07; 2.36] 0.298	0.43 [0.08; 2.22] 0.316	-0.069 [-0.201; 0.063] 0.309
Carrier, n (%)	0 (0.0)	1 (11.1)	N.E.	0.26 [0.01; 5.65] 0.388	-0.111 [-0.316; 0.094] 0.289
Any severe AE					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.6)	1 (3.0)	0.86 [0.05; 14.39] 0.919	0.87 [0.06; 13.35] 0.919	-0.004 [-0.082; 0.074] 0.920
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (6.1)	N.E.	0.17 [0.01; 3.51] 0.254	-0.061 [-0.142; 0.021] 0.145
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (6.1)	N.E.	0.17 [0.01; 3.51] 0.254	-0.061 [-0.142; 0.021] 0.145
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.11.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10609046 (SAF)

There are no data meeting the display criteria for this table.

S.11.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10609046 (SAF)

S.11.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10609046 (SAF)

There are no data meeting the display criteria for this table.

S.11.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10609046 (SAF)

There are no data meeting the display criteria for this table.

S.11.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs10609046 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	50	42			
N' Non-carrier	38	33			
N' Carrier	12	9			
Candida infections					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.6)	0 (0.0)	N.E.	2.62 [0.11; 62.11] 0.552	0.026 [-0.025; 0.077] 0.311
Carrier, n (%)	1 (8.3)	1 (11.1)	0.73 [0.04; 13.45] 0.831	0.75 [0.05; 10.44] 0.830	-0.028 [-0.286; 0.230] 0.833
Cardio-cerebrovascular-related events					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.6)	1 (3.0)	0.86 [0.05; 14.39] 0.919	0.87 [0.06; 13.35] 0.919	-0.004 [-0.082; 0.074] 0.920
Carrier, n (%)	0 (0.0)	1 (11.1)	N.E.	0.26 [0.01; 5.65] 0.388	-0.111 [-0.316; 0.094] 0.289
Inflammatory bowel disease					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.6)	0 (0.0)	N.E.	2.62 [0.11; 62.11] 0.552	0.026 [-0.025; 0.077] 0.311
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Staphylococcal infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.6)	0 (0.0)	N.E.	2.62 [0.11; 62.11] 0.552	0.026 [-0.025; 0.077] 0.311
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ excl BCC and SCC)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections					
Interaction test	p=0.710				
Non-carrier, n (%)	14 (36.8)	11 (33.3)	1.17 [0.44; 3.11] 0.757	1.11 [0.58; 2.09] 0.758	0.035 [-0.187; 0.257] 0.757
Carrier, n (%)	6 (50.0)	5 (55.6)	0.80 [0.14; 4.53] 0.801	0.90 [0.40; 2.03] 0.800	-0.056 [-0.486; 0.375] 0.800

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.12.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs8007401 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	49	44			
N' Non-carrier	36	34			
N' Carrier	13	10			
Any AE					
Interaction test	p=0.095				
Non-carrier, n (%)	26 (72.2)	30 (88.2)	0.35 [0.10; 1.24] 0.089	0.82 [0.65; 1.04] 0.098	-0.160 [-0.342; 0.022] 0.085
Carrier, n (%)	10 (76.9)	6 (60.0)	2.22 [0.36; 13.54] 0.383	1.28 [0.71; 2.31] 0.407	0.169 [-0.211; 0.550] 0.383
Any SAE					
Interaction test	N.E.				
Non-carrier, n (%)	2 (5.6)	4 (11.8)	0.44 [0.08; 2.58] 0.350	0.47 [0.09; 2.41] 0.367	-0.062 [-0.194; 0.070] 0.355
Carrier, n (%)	0 (0.0)	1 (10.0)	N.E.	0.26 [0.01; 5.82] 0.397	-0.100 [-0.286; 0.086] 0.292
Any severe AE					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.8)	1 (2.9)	0.94 [0.06; 15.70] 0.967	0.94 [0.06; 14.51] 0.967	-0.002 [-0.080; 0.077] 0.967
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (5.9)	N.E.	0.19 [0.01; 3.80] 0.277	-0.059 [-0.138; 0.020] 0.145
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (5.9)	N.E.	0.19 [0.01; 3.80] 0.277	-0.059 [-0.138; 0.020] 0.145
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.12.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs8007401 (SAF)

There are no data meeting the display criteria for this table.

S.12.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs8007401 (SAF)

S.12.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs8007401 (SAF)

There are no data meeting the display criteria for this table.

S.12.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs8007401 (SAF)

There are no data meeting the display criteria for this table.

S.12.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs8007401 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	49	44			
N' Non-carrier	36	34			
N' Carrier	13	10			
Candida infections					
Interaction test	N.E.				
Non-carrier, n (%)	2 (5.6)	1 (2.9)	1.94 [0.17; 22.44] 0.585	1.89 [0.18; 19.89] 0.596	0.026 [-0.068; 0.120] 0.585
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Cardio-cerebrovascular-related events					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.8)	2 (5.9)	0.46 [0.04; 5.29] 0.518	0.47 [0.04; 4.97] 0.532	-0.031 [-0.127; 0.065] 0.524
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Inflammatory bowel disease					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.8)	0 (0.0)	N.E.	2.84 [0.12; 67.37] 0.519	0.028 [-0.026; 0.081] 0.310
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Staphylococcal infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death)					

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	1 (7.7)	0 (0.0)	N.E.	2.36 [0.11; 52.41] 0.588	0.077 [-0.068; 0.222] 0.298
Malignant or unspecified tumours (SMQ excl BCC and SCC)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections					
Interaction test	p=0.102				
Non-carrier, n (%)	18 (50.0)	13 (38.2)	1.62 [0.62; 4.18] 0.321	1.31 [0.76; 2.24] 0.328	0.118 [-0.113; 0.349] 0.318
Carrier, n (%)	2 (15.4)	4 (40.0)	0.27 [0.04; 1.95] 0.182	0.38 [0.09; 1.70] 0.207	-0.246 [-0.608; 0.115] 0.182

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.13.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs7349145 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	51	41			
N' Non-carrier	42	36			
N' Carrier	9	5			
Any AE					
Interaction test	p=0.828				
Non-carrier, n (%)	31 (73.8)	29 (80.6)	0.68 [0.23; 1.99] 0.479	0.92 [0.72; 1.17] 0.477	-0.067 [-0.253; 0.118] 0.476
Carrier, n (%)	6 (66.7)	4 (80.0)	0.50 [0.04; 6.68] 0.590	0.83 [0.44; 1.58] 0.575	-0.133 [-0.600; 0.333] 0.575
Any SAE					
Interaction test	N.E.				
Non-carrier, n (%)	2 (4.8)	5 (13.9)	0.31 [0.06; 1.71] 0.156	0.34 [0.07; 1.66] 0.184	-0.091 [-0.221; 0.039] 0.169
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any severe AE					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.4)	1 (2.8)	0.85 [0.05; 14.15] 0.912	0.86 [0.06; 13.22] 0.912	-0.004 [-0.075; 0.067] 0.912
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (5.6)	N.E.	0.17 [0.01; 3.47] 0.251	-0.056 [-0.130; 0.019] 0.146
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (5.6)	N.E.	0.17 [0.01; 3.47] 0.251	-0.056 [-0.130; 0.019] 0.146
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC **(N=66)**	**ADA** **(N=62)**	**OR** **[95% CI]** **p-value**	**RR** **[95% CI]** **p-value**	**RD** **[95% CI]** **p-value**

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.13.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs7349145 (SAF)

There are no data meeting the display criteria for this table.

S.13.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs7349145 (SAF)

S.13.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs7349145 (SAF)

There are no data meeting the display criteria for this table.

S.13.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs7349145 (SAF)

There are no data meeting the display criteria for this table.

S.13.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs7349145 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	51	41			
N' Non-carrier	42	36			
N' Carrier	9	5			
Candida infections					
Interaction test	N.E.				
Non-carrier, n (%)	2 (4.8)	1 (2.8)	1.75 [0.15; 20.14] 0.646	1.71 [0.16; 18.14] 0.654	0.020 [-0.064; 0.104] 0.643
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Cardio-cerebrovascular-related events					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.4)	2 (5.6)	0.41 [0.04; 4.77] 0.466	0.43 [0.04; 4.53] 0.481	-0.032 [-0.120; 0.056] 0.479
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Inflammatory bowel disease					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.4)	0 (0.0)	N.E.	2.58 [0.11; 61.48] 0.558	0.024 [-0.022; 0.070] 0.311
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Staphylococcal infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death)					

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.4)	0 (0.0)	N.E.	2.58 [0.11; 61.48] 0.558	0.024 [-0.022; 0.070] 0.311
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ excl BCC and SCC)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections					
Interaction test	p=0.587				
Non-carrier, n (%)	16 (38.1)	14 (38.9)	0.97 [0.39; 2.41] 0.943	0.98 [0.56; 1.72] 0.943	-0.008 [-0.225; 0.209] 0.943
Carrier, n (%)	5 (55.6)	2 (40.0)	1.87 [0.20; 17.27] 0.576	1.39 [0.41; 4.72] 0.598	0.156 [-0.383; 0.694] 0.571

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.14.1 Adverse Events, Binary Analysis by Lead Candidate Allele Score (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	51	44			
N' Low score	11	22			
N' High score	40	22			
Any AE					
Interaction test	p=0.258				
Low score, n (%)	8 (72.7)	20 (90.9)	0.27 [0.04; 1.91] 0.183	0.80 [0.54; 1.18] 0.256	-0.182 [-0.471; 0.107] 0.218
High score, n (%)	29 (72.5)	16 (72.7)	0.99 [0.31; 3.18] 0.985	1.00 [0.72; 1.37] 0.985	-0.002 [-0.234; 0.230] 0.985
Any SAE					
Interaction test	p=0.608				
Low score, n (%)	1 (9.1)	3 (13.6)	0.63 [0.06; 6.91] 0.700	0.67 [0.08; 5.69] 0.711	-0.045 [-0.268; 0.177] 0.689
High score, n (%)	1 (2.5)	2 (9.1)	0.26 [0.02; 3.00] 0.260	0.28 [0.03; 2.86] 0.280	-0.066 [-0.195; 0.064] 0.319
Any severe AE					
Interaction test	N.E.				
Low score, n (%)	1 (9.1)	1 (4.5)	2.10 [0.12; 37.12] 0.616	2.00 [0.14; 29.04] 0.612	0.045 [-0.145; 0.236] 0.641
High score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study discontinuation					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	2 (9.1)	N.E.	0.38 [0.02; 7.36] 0.525	-0.091 [-0.211; 0.029] 0.138
High score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	2 (9.1)	N.E.	0.38 [0.02; 7.36] 0.525	-0.091 [-0.211; 0.029] 0.138
High score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.14.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Allele Score (SAF)

There are no data meeting the display criteria for this table.

S.14.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Allele Score (SAF)

There are no data meeting the display criteria for this table.

S.14.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Allele Score (SAF)

There are no data meeting the display criteria for this table.

S.14.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Allele Score (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	51	44			
N' Low score	11	22			
N' High score	40	22			
Candida infections					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	1 (4.5)	N.E.	0.64 [0.03; 14.52] 0.779	-0.045 [-0.132; 0.042] 0.306
High score, n (%)	2 (5.0)	0 (0.0)	N.E.	2.80 [0.14; 55.95] 0.499	0.050 [-0.018; 0.118] 0.147
Cardio-cerebrovascular-related events					
Interaction test	N.E.				
Low score, n (%)	1 (9.1)	1 (4.5)	2.10 [0.12; 37.12] 0.616	2.00 [0.14; 29.04] 0.612	0.045 [-0.145; 0.236] 0.641
High score, n (%)	0 (0.0)	1 (4.5)	N.E.	0.19 [0.01; 4.41] 0.298	-0.045 [-0.132; 0.042] 0.306
Inflammatory bowel disease					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
High score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
High score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
High score, n (%)	1 (2.5)	0 (0.0)	N.E.	1.68 [0.07; 39.65] 0.747	0.025 [-0.023; 0.073] 0.311
Staphylococcal infections					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
High score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death)					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
High score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
High score, n (%)	1 (2.5)	0 (0.0)	N.E.	1.68 [0.07; 39.65] 0.747	0.025 [-0.023; 0.073] 0.311
Malignant or unspecified tumours (SMQ excl BCC and SCC)					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
High score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections					
Interaction test	p=0.944				
Low score, n (%)	4 (36.4)	8 (36.4)	1.00 [0.22; 4.50] 1.000	1.00 [0.38; 2.61] 1.000	0.000 [-0.348; 0.348] 1.000
High score, n (%)	17 (42.5)	9 (40.9)	1.07 [0.37; 3.07] 0.903	1.04 [0.56; 1.93] 0.904	0.016 [-0.240; 0.272] 0.903

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.15.1 Adverse Events, Binary Analysis by Linkage Variant rs10891185 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	51	44			
N' Non-carrier	31	23			
N' Carrier	20	21			
Any AE					
Interaction test	p=0.619				
Non-carrier, n (%)	24 (77.4)	19 (82.6)	0.72 [0.18; 2.83] 0.638	0.94 [0.72; 1.22] 0.634	-0.052 [-0.266; 0.162] 0.634
Carrier, n (%)	13 (65.0)	17 (81.0)	0.44 [0.11; 1.82] 0.247	0.80 [0.55; 1.18] 0.261	-0.160 [-0.428; 0.109] 0.244
Any SAE					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	3 (13.0)	N.E.	0.11 [0.01; 1.98] 0.133	-0.130 [-0.268; 0.007] 0.063
Carrier, n (%)	2 (10.0)	2 (9.5)	1.06 [0.13; 8.31] 0.959	1.05 [0.16; 6.76] 0.959	0.005 [-0.177; 0.187] 0.959
Any severe AE					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (4.3)	N.E.	0.25 [0.01; 5.87] 0.389	-0.043 [-0.127; 0.040] 0.307
Carrier, n (%)	1 (5.0)	0 (0.0)	N.E.	3.14 [0.14; 72.93] 0.475	0.050 [-0.046; 0.146] 0.305
Any AE leading to study discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (8.7)	N.E.	0.15 [0.01; 2.98] 0.214	-0.087 [-0.202; 0.028] 0.139
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (8.7)	N.E.	0.15 [0.01; 2.98] 0.214	-0.087 [-0.202; 0.028] 0.139

	Treatment Groups		Comparison		
	SEC (N=66)	**ADA (N=62)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.15.2 Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs10891185 (SAF)

There are no data meeting the display criteria for this table.

S.15.2 Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs10891185 (SAF)

S.15.3 Serious Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs10891185 (SAF)

There are no data meeting the display criteria for this table.

S.15.4 Severe Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs10891185 (SAF)

There are no data meeting the display criteria for this table.

S.15.5 Adverse Events of Special Interest, Binary Analysis by Linkage Variant rs10891185 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	51	44			
N' Non-carrier	31	23			
N' Carrier	20	21			
Candida infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (4.3)	N.E.	0.25 [0.01; 5.87] 0.389	-0.043 [-0.127; 0.040] 0.307
Carrier, n (%)	2 (10.0)	0 (0.0)	N.E.	5.24 [0.27; 102.81] 0.276	0.100 [-0.031; 0.231] 0.136
Cardio-cerebrovascular-related events					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (4.3)	N.E.	0.25 [0.01; 5.87] 0.389	-0.043 [-0.127; 0.040] 0.307
Carrier, n (%)	1 (5.0)	1 (4.8)	1.05 [0.06; 18.05] 0.972	1.05 [0.07; 15.68] 0.972	0.002 [-0.130; 0.134] 0.972
Inflammatory bowel disease					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	1 (5.0)	0 (0.0)	N.E.	3.14 [0.14; 72.93] 0.475	0.050 [-0.046; 0.146] 0.305
Staphylococcal infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)					
Interaction test	N.E.				
Non-carrier, n (%)	1 (3.2)	0 (0.0)	N.E.	2.25 [0.10; 52.85] 0.615	0.032 [-0.030; 0.094] 0.309
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ excl BCC and SCC)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections					
Interaction test	p=0.079				
Non-carrier, n (%)	15 (48.4)	7 (30.4)	2.14 [0.69; 6.66] 0.181	1.59 [0.78; 3.26] 0.205	0.180 [-0.078; 0.437] 0.172
Carrier, n (%)	6 (30.0)	10 (47.6)	0.47 [0.13; 1.70] 0.246	0.63 [0.28; 1.41] 0.261	-0.176 [-0.469; 0.117] 0.239

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.16.1 Adverse Events, Binary Analysis by Linkage Variant rs12065362 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	51	44			
N' Non-carrier	19	20			
N' Carrier	32	24			
Any AE					
Interaction test	p=0.179				
Non-carrier, n (%)	13 (68.4)	18 (90.0)	0.24 [0.04; 1.39] 0.090	0.76 [0.54; 1.07] 0.113	-0.216 [-0.463; 0.031] 0.087
Carrier, n (%)	24 (75.0)	18 (75.0)	1.00 [0.29; 3.39] 1.000	1.00 [0.74; 1.36] 1.000	0.000 [-0.229; 0.229] 1.000
Any SAE					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	3 (15.0)	N.E.	0.15 [0.01; 2.72] 0.200	-0.150 [-0.306; 0.006] 0.060
Carrier, n (%)	2 (6.3)	2 (8.3)	0.73 [0.10; 5.62] 0.766	0.75 [0.11; 4.95] 0.765	-0.021 [-0.160; 0.118] 0.769
Any severe AE					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	1 (3.1)	1 (4.2)	0.74 [0.04; 12.49] 0.836	0.75 [0.05; 11.40] 0.836	-0.010 [-0.111; 0.090] 0.838
Any AE leading to study discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (5.0)	N.E.	0.35 [0.02; 8.10] 0.512	-0.050 [-0.146; 0.046] 0.305
Carrier, n (%)	0 (0.0)	1 (4.2)	N.E.	0.25 [0.01; 5.94] 0.393	-0.042 [-0.122; 0.038] 0.307
Any AE leading to study drug discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (5.0)	N.E.	0.35 [0.02; 8.10] 0.512	-0.050 [-0.146; 0.046] 0.305

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	0 (0.0)	1 (4.2)	N.E.	0.25 [0.01; 5.94] 0.393	-0.042 [-0.122; 0.038] 0.307

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.16.2 Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs12065362 (SAF)

There are no data meeting the display criteria for this table.

S.16.2 Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs12065362 (SAF)

S.16.3 Serious Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs12065362 (SAF)

There are no data meeting the display criteria for this table.

S.16.4 Severe Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs12065362 (SAF)

There are no data meeting the display criteria for this table.

S.16.5 Adverse Events of Special Interest, Binary Analysis by Linkage Variant rs12065362 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	51	44			
N' Non-carrier	19	20			
N' Carrier	32	24			
Candida infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (5.0)	N.E.	0.35 [0.02; 8.10] 0.512	-0.050 [-0.146; 0.046] 0.305
Carrier, n (%)	2 (6.3)	0 (0.0)	N.E.	3.79 [0.19; 75.45] 0.383	0.063 [-0.021; 0.146] 0.144
Cardio-cerebrovascular-related events					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (10.0)	N.E.	0.21 [0.01; 4.11] 0.304	-0.100 [-0.231; 0.031] 0.136
Carrier, n (%)	1 (3.1)	0 (0.0)	N.E.	2.27 [0.10; 53.47] 0.610	0.031 [-0.029; 0.092] 0.310
Inflammatory bowel disease					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	1 (3.1)	0 (0.0)	N.E.	2.27 [0.10; 53.47] 0.610	0.031 [-0.029; 0.092] 0.310
Staphylococcal infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)					
Interaction test	N.E.				
Non-carrier, n (%)	1 (5.3)	0 (0.0)	N.E.	3.15 [0.14; 72.89] 0.474	0.053 [-0.048; 0.153] 0.304
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ excl BCC and SCC)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections					
Interaction test	p=0.614				
Non-carrier, n (%)	8 (42.1)	9 (45.0)	0.89 [0.25; 3.16] 0.855	0.94 [0.46; 1.91] 0.856	-0.029 [-0.340; 0.282] 0.855
Carrier, n (%)	13 (40.6)	8 (33.3)	1.37 [0.45; 4.13] 0.576	1.22 [0.60; 2.46] 0.582	0.073 [-0.181; 0.327] 0.574

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.17.1 Adverse Events, Binary Analysis by Linkage Variant rs11721988 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	51	44			
N' Non-carrier	25	32			
N' Carrier	26	12			
Any AE					
Interaction test	p=0.410				
Non-carrier, n (%)	20 (80.0)	26 (81.3)	0.92 [0.25; 3.46] 0.906	0.98 [0.76; 1.27] 0.906	-0.012 [-0.220; 0.195] 0.906
Carrier, n (%)	17 (65.4)	10 (83.3)	0.38 [0.07; 2.11] 0.241	0.78 [0.54; 1.14] 0.207	-0.179 [-0.459; 0.100] 0.208
Any SAE					
Interaction test	N.E.				
Non-carrier, n (%)	2 (8.0)	4 (12.5)	0.61 [0.10; 3.63] 0.578	0.64 [0.13; 3.22] 0.588	-0.045 [-0.201; 0.111] 0.573
Carrier, n (%)	0 (0.0)	1 (8.3)	N.E.	0.16 [0.01; 3.68] 0.252	-0.083 [-0.240; 0.073] 0.296
Any severe AE					
Interaction test	N.E.				
Non-carrier, n (%)	1 (4.0)	1 (3.1)	1.29 [0.08; 21.73] 0.859	1.28 [0.08; 19.47] 0.859	0.009 [-0.089; 0.106] 0.861
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (3.1)	N.E.	0.42 [0.02; 9.96] 0.594	-0.031 [-0.092; 0.029] 0.310
Carrier, n (%)	0 (0.0)	1 (8.3)	N.E.	0.16 [0.01; 3.68] 0.252	-0.083 [-0.240; 0.073] 0.296
Any AE leading to study drug discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (3.1)	N.E.	0.42 [0.02; 9.96] 0.594	-0.031 [-0.092; 0.029] 0.310

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	0 (0.0)	1 (8.3)	N.E.	0.16 [0.01; 3.68] 0.252	-0.083 [-0.240; 0.073] 0.296

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.17.2 Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs11721988 (SAF)

There are no data meeting the display criteria for this table.

S.17.2 Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs11721988 (SAF)

S.17.3 Serious Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs11721988 (SAF)

There are no data meeting the display criteria for this table.

S.17.4 Severe Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs11721988 (SAF)

There are no data meeting the display criteria for this table.

S.17.5 Adverse Events of Special Interest, Binary Analysis by Linkage Variant rs11721988 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	51	44			
N' Non-carrier	25	32			
N' Carrier	26	12			
Candida infections					
Interaction test	N.E.				
Non-carrier, n (%)	1 (4.0)	1 (3.1)	1.29 [0.08; 21.73] 0.859	1.28 [0.08; 19.47] 0.859	0.009 [-0.089; 0.106] 0.861
Carrier, n (%)	1 (3.8)	0 (0.0)	N.E.	1.44 [0.06; 33.09] 0.818	0.038 [-0.035; 0.112] 0.308
Cardio-cerebrovascular-related events					
Interaction test	N.E.				
Non-carrier, n (%)	1 (4.0)	1 (3.1)	1.29 [0.08; 21.73] 0.859	1.28 [0.08; 19.47] 0.859	0.009 [-0.089; 0.106] 0.861
Carrier, n (%)	0 (0.0)	1 (8.3)	N.E.	0.16 [0.01; 3.68] 0.252	-0.083 [-0.240; 0.073] 0.296
Inflammatory bowel disease					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections					
Interaction test	N.E.				
Non-carrier, n (%)	1 (4.0)	0 (0.0)	N.E.	3.81 [0.16; 89.67] 0.407	0.040 [-0.037; 0.117] 0.307
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Staphylococcal infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)					
Interaction test	N.E.				
Non-carrier, n (%)	1 (4.0)	0 (0.0)	N.E.	3.81 [0.16; 89.67] 0.407	0.040 [-0.037; 0.117] 0.307
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ excl BCC and SCC)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections					
Interaction test	p=0.791				
Non-carrier, n (%)	12 (48.0)	13 (40.6)	1.35 [0.47; 3.88] 0.578	1.18 [0.66; 2.12] 0.576	0.074 [-0.186; 0.333] 0.577
Carrier, n (%)	9 (34.6)	4 (33.3)	1.06 [0.25; 4.50] 0.938	1.04 [0.40; 2.71] 0.939	0.013 [-0.311; 0.336] 0.938

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.18.1 Adverse Events, Binary Analysis by Linkage Variant rs7787032 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	50	44			
N' Non-carrier	39	35			
N' Carrier	11	9			
Any AE					
Interaction test	p=0.630				
Non-carrier, n (%)	28 (71.8)	28 (80.0)	0.64 [0.22; 1.88] 0.410	0.90 [0.69; 1.16] 0.410	-0.082 [-0.276; 0.112] 0.406
Carrier, n (%)	8 (72.7)	8 (88.9)	0.33 [0.03; 3.93] 0.358	0.82 [0.53; 1.26] 0.360	-0.162 [-0.495; 0.172] 0.343
Any SAE					
Interaction test	N.E.				
Non-carrier, n (%)	2 (5.1)	5 (14.3)	0.32 [0.06; 1.79] 0.174	0.36 [0.07; 1.73] 0.202	-0.092 [-0.227; 0.043] 0.184
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any severe AE					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.6)	1 (2.9)	0.89 [0.05; 14.86] 0.938	0.90 [0.06; 13.82] 0.938	-0.003 [-0.077; 0.071] 0.938
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (5.7)	N.E.	0.18 [0.01; 3.63] 0.263	-0.057 [-0.134; 0.020] 0.145
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (5.7)	N.E.	0.18 [0.01; 3.63] 0.263	-0.057 [-0.134; 0.020] 0.145
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

S.18.2 Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs7787032 (SAF)

There are no data meeting the display criteria for this table.

S.18.2 Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs7787032 (SAF)

S.18.3 Serious Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs7787032 (SAF)

There are no data meeting the display criteria for this table.

S.18.3 Serious Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs7787032 (SAF)

S.18.4 Severe Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs7787032 (SAF)

There are no data meeting the display criteria for this table.

S.18.5 Adverse Events of Special Interest, Binary Analysis by Linkage Variant rs7787032 (SAF)

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	50	44			
N' Non-carrier	39	35			
N' Carrier	11	9			
Candida infections					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.6)	0 (0.0)	N.E.	2.70 [0.11; 64.21] 0.539	0.026 [-0.024; 0.075] 0.311
Carrier, n (%)	1 (9.1)	1 (11.1)	0.80 [0.04; 14.89] 0.881	0.82 [0.06; 11.33] 0.881	-0.020 [-0.287; 0.246] 0.882
Cardio-cerebrovascular-related events					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.6)	1 (2.9)	0.89 [0.05; 14.86] 0.938	0.90 [0.06; 13.82] 0.938	-0.003 [-0.077; 0.071] 0.938
Carrier, n (%)	0 (0.0)	1 (11.1)	N.E.	0.28 [0.01; 6.10] 0.416	-0.111 [-0.316; 0.094] 0.289
Inflammatory bowel disease					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Opportunistic infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Herpes viral infections					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.6)	0 (0.0)	N.E.	2.70 [0.11; 64.21] 0.539	0.026 [-0.024; 0.075] 0.311
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Staphylococcal infections					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=66)	ADA (N=62)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.6)	0 (0.0)	N.E.	2.70 [0.11; 64.21] 0.539	0.026 [-0.024; 0.075] 0.311
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ excl BCC and SCC)					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Upper respiratory tract infections					
Interaction test	p=0.254				
Non-carrier, n (%)	15 (38.5)	11 (31.4)	1.36 [0.52; 3.57] 0.526	1.22 [0.65; 2.30] 0.530	0.070 [-0.146; 0.287] 0.525
Carrier, n (%)	5 (45.5)	6 (66.7)	0.42 [0.07; 2.58] 0.340	0.68 [0.31; 1.51] 0.345	-0.212 [-0.638; 0.214] 0.329

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

Figures

Efficacy Analysis

6.1 HAQ-DI - Boxplot (FAS)

15.1 Patient's Assessment of PsA Pain (VAS) - Boxplot (FAS)

16.1 Patient's Global Assessment of PsA Disease Activity (VAS) - Boxplot (FAS)

17.1 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Boxplot (FAS)

38.1 DLQI - Boxplot (FAS)

40.1 EQ-5D VAS Score - Boxplot (FAS)

41.1 FACIT Fatigue - Boxplot (FAS)

43.1 SF-36 Bodily Pain - Boxplot (FAS)

44.1 SF-36 General Health - Boxplot (FAS)

44.10 SF-36 General Health - Boxplot by Lead Candidate Variant rs11726476 (FAS)

Non-carrier

Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

Carrier

Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

44.17 SF-36 General Health - Boxplot by Linkage Variant rs11721988 (FAS)

Non-carrier

Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

Carrier

Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

45.1 SF-36 Mental Health - Boxplot (FAS)

46.1 SF-36 Physical Functioning - Boxplot (FAS)

46.10 SF-36 Physical Functioning - Boxplot by Lead Candidate Variant rs11726476 (FAS)

Non-carrier

Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

Carrier

Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

46.17 SF-36 Physical Functioning - Boxplot by Linkage Variant rs11721988 (FAS)

Non-carrier

Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

Carrier

**Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.**

47.1 SF-36 Role Emotional - Boxplot (FAS)

47.1 SF-36 Role Emotional - Boxplot (FAS)

48.1 SF-36 Role Physical - Boxplot (FAS)

49.1 SF-36 Social Functioning - Boxplot (FAS)

49.6 SF-36 Social Functioning - Boxplot by Enthesitis at BL According to LEI (FAS)

Enthesitis: No

Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

Enthesitis: Yes

Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

50.1 SF-36 Vitality - Boxplot (FAS)

## 51.1 SF-36 MCS - Boxplot (FAS)

53.1 SF-36 PCS - Boxplot (FAS)

55.1 WPAI-GH Percent Work Time Missed due to Health - Boxplot (FAS)

56.1 WPAI-GH Percent Impairment while Working due to Health - Boxplot (FAS)

57.1 WPAI-GH Percent Overall Work Impairment due to Health - Boxplot (FAS)

58.1 WPAI-GH Percent Activity Impairment due to Health - Boxplot (FAS)